<SEC-DOCUMENT>0001628280-24-040187.txt : 20240912
<SEC-HEADER>0001628280-24-040187.hdr.sgml : 20240912
<ACCEPTANCE-DATETIME>20240912060746
ACCESSION NUMBER:		0001628280-24-040187
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240912
DATE AS OF CHANGE:		20240912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		241293821

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>inpha-20240630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b,d:932d298a79a740848b41d4e1133daf10-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:inpha="http://www.innate-pharma.com/20240630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>inpha-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4">Jun 30, 2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-5">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-7">0001598599</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-8">12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="inpha-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>inpha:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>inpha:employee</xbrli:measure></xbrli:unit><xbrli:unit id="share"><xbrli:measure>inpha:share</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:unit id="loan_agreement"><xbrli:measure>inpha:loan_agreement</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="loan"><xbrli:measure>inpha:loan</xbrli:measure></xbrli:unit><xbrli:unit id="target_option"><xbrli:measure>inpha:target_option</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>inpha:option</xbrli:measure></xbrli:unit><xbrli:unit id="preclinicalmolecule"><xbrli:measure>inpha:preclinicalMolecule</xbrli:measure></xbrli:unit><xbrli:unit id="licensing_agreement"><xbrli:measure>inpha:licensing_agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH6101WithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">inpha:IssuedCapitalFreeOfSubscriptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">inpha:ExerciseOfShareWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">inpha:DefinitiveAcquisitionOfFreeSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:FreeSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:FreeSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-10</xbrli:startDate><xbrli:endDate>2024-06-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:SICAVAndMutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:SICAVAndMutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH5201WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-05</xbrli:startDate><xbrli:endDate>2022-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-03</xbrli:startDate><xbrli:endDate>2017-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:OtherDisposalsOfAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:RetirementDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:RetirementDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:SeniorityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:SeniorityAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:The2016FreePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:The2017FreePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:CompanySavingPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:CompanySavingPlanEmployerTopUpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20161Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20162Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfEmployees20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfEmployees20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfManagement20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfManagement20181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20171Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20191Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus202012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus202012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:StockOptions20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:StockOptions20201Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Employees2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Employees2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Management2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Management2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20151Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20152Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20221Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-30</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:CollaborationAndLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:CollaborationAndLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH6101WithSanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH62Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH62Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH67Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH67Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AndAdvoralimabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AndAdvoralimabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2018AstraZenecaIPH5201AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2018AstraZenecaIPH5201AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-19</xbrli:startDate><xbrli:endDate>2023-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithGenzymeForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-25</xbrli:startDate><xbrli:endDate>2023-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:AdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:AdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:PreclinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">inpha:ChangesToCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:GrantsOfEmployeeEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">ifrs-full:TaxContingentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001598599</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">inpha:NovoNordiskASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-139 f-140" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="i932d298a79a740848b41d4e1133daf10_1"></div><div style="min-height:50pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:4.55pt"><span><br/></span></div><div style="margin-top:0.5pt"><span><br/></span></div><div style="margin-top:4.5pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:0.1pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.1pt;padding-left:199.2pt;padding-right:199.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:700;line-height:218%">Washington, D.C. 20549 FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="margin-top:0.5pt;padding-left:6.82pt;padding-right:6.82pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:0.35pt"><span><br/></span></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:240%">Date of report: September 12, 2024</span></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:240%">Commission File Number: 001-39084</span></div><div style="margin-top:0.05pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">Innate Pharma SA</ix:nonNumeric></span></div><div style="margin-top:0.45pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(Translation of registrant's name into English)</span></div><div style="margin-top:0.3pt"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma SA</span></div><div style="margin-top:0.4pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">117 Avenue de Luminy&#8212;BP 30191</span></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">13009 Marseille, France</span></div><div style="margin-top:0.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">+ 33 (0) 4 30 30 30</span></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">(Address of principal executive office)</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:56.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:240%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]&#160;&#160;&#160;&#160;Form 40-F [ ]</span></div><div style="padding-right:56.8pt"><span><br/></span></div><div style="padding-right:56.8pt"><span><br/></span></div><div style="padding-right:56.8pt"><span><br/></span></div><div style="padding-right:56.8pt"><span><br/></span></div><div style="padding-right:56.8pt"><span><br/></span></div><div style="padding-right:56.8pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report on Form&#160;6-K&#160;and Exhibit 99.2 to this Report on Form&#160;6-K&#160;(excluding the Statutory Auditors' Review Report on the Half-Yearly Financial Information on page 43 of Exhibit 99.2) shall be deemed to be incorporated by reference into the registration statement on Form&#160;F-3&#160;(File&#160;No.&#160;333-276164)&#160;and registration statement on Form S-8 (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i932d298a79a740848b41d4e1133daf10_7"></div><hr style="page-break-after:always"/><div style="min-height:49pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:3.45pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.7pt;padding-left:5.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit</span></div><div><span><br/></span></div><div style="margin-top:0.1pt"><span><br/></span></div><div style="margin-top:4.7pt;padding-left:22.5pt;text-indent:-20.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="inpha-20240630_d2.htm">99.2 H1 2024 Half-Year Financial Report, January 1 to June 30, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="inpha-20240630_d2.htm">2024</a></span></div><div style="margin-top:4.7pt;padding-left:7.75pt;text-indent:-20.25pt"><span><br/></span></div><div style="margin-top:0.55pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i932d298a79a740848b41d4e1133daf10_10"></div><hr style="page-break-after:always"/><div style="min-height:49pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3.55pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:0.3pt"><span><br/></span></div><div style="padding-left:5.55pt;padding-right:14.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:0.25pt"><span><br/></span></div><div style="padding-left:280.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">INNATE PHARMA S.A.</span></div><div><span><br/></span></div><div style="margin-top:0.3pt"><span><br/></span></div><div style="padding-left:280.1pt;padding-right:5.8pt;text-indent:-274.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%">Date: September 12, 2024&#160;&#160;&#160;&#160;By:&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%;text-decoration:underline">/s/ Herv&#233; Brailly&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:125%"> Name:&#160;&#160;&#160;&#160;Herv&#233; Brailly</span></div><div style="padding-left:280.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:106%">Title:&#160;&#160;&#160;&#160;Interim Chief Executive Officer</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>2
<FILENAME>inpha-20240630_d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b,d:634ed0333ee247d7904463c2d5fd1df7-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:inpha="http://www.innate-pharma.com/20240630" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>inpha-20240630_d2</title></head><body><div id="i634ed0333ee247d7904463c2d5fd1df7_4"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:133%">INNATE PHARMA SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:133%">HALF-YEAR FINANCIAL REPORT</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:133%">JUNE 30, 2024</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">INNATE PHARMA S.A.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">French </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:133%">soci&#233;t&#233; anonyme</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> governed by an Executive Board and a Supervisory Board</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">with a share capital of 4,049,171.60 euros composed of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">80,969,357 ordinary shares, and 14,075 preferred shares with a nominal value of 0.05 euros each</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Registered office: 117, Avenue de Luminy, F-13009 Marseille, France</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Registered with the Company and Trade Register of Marseille under number 424 365 336</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The following interim condensed consolidated financial statements have been approved by the Executive Board of the Company on September&#160;11, 2024, and have been subject to a limited review by our Statutory Auditors. They have been examined by the Supervisory Board of the Company on September&#160;11, 2024.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:400;line-height:120%">SUMMARY</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"/><td style="width:92.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_759">PRELIMINARY NOTE AND DISCLAIMER ON FORWARD-LOOKING INFORMATION AND RISK FACTORS</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">................................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_759">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_10">INNATE PHARMA </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_10">AT A GLANCE</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.............................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_10">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_13">HALF-YEAR MANAGEMENT REVIEW</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">......................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.7pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.7pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_16">Revenue and other income</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.....................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.05pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.05pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_19">Operating expenses</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_19">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.15pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.15pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_674">Net </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_674">f</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_674">inancial income (loss)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.....................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_674">11</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.33pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.33pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_22">Balance sheet items</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_22">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.6pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.6pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_25">Cash-flow items</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.......................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_25">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.89pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.89pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_28">Key events since January 1, 202</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4............................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_28">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.18pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.18pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_31">Nota</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.........................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_31">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.25pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.25pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_34">Main risks and uncertai</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_34">nties for the remaining si</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_34">x months of the fiscal year</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..........................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_34">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.97pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.97pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_37">Related party transactions</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">......................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_37">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:7pt;margin-top:7pt;padding-left:70.87pt;text-align:justify;text-indent:-70.87pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_40">INTERIM CONDENSED CONSOLIDATED </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_40">FINANCIAL STATEMENTS AS OF</a> JUNE 30, 2024</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">..........................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_40">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.7pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.7pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">Interim </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">Condensed Consolidated Statements of </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">Financi</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">al Position</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43"> (amounts in thousand</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">s of euro</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">....................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_43">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.05pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.05pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_46">Interim Condensed Consolidated Statements of Income (Loss) (amounts in thousands of euro, except share and per share amount</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_46">s)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">...........................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_46">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.15pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.15pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49">Interim Condensed Consolidated Statements of</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49"> Comprehensive</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49"> Income (Loss) (amounts in thousands of </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49">e</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49">uro</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49">)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..............................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_49">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.33pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.33pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52">Interim Condensed Consolidated Statements of </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52">C</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52">ash Flows</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52"> (amounts in thousands of euro</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52">)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">........................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_52">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.6pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.6pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">Interim</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55"> Consolidated Statements of </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">Changes in Shareholders</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">&#8217;</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55"> Equity</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55"> </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">(amounts in thousands of euro</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">, except share data</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">)</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">....................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_55">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.89pt;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.89pt;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_58">Interim Condensed Notes to the Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..............................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_58">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181">S</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181">TATUTORY AUDITORS</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181">&#8217;</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181"> REVIEW REPORT ON THE HALF-YEARLY FINA</a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181">NCIAL INFORMATION</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.......................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_181">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_184">DECLARATION BY THE PERSON RESPONSIBLE FOR THIS HALF-YEAR FINANCIAL REPORT</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">..................................................................................................................................................</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_184">44</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_759"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRELIMINARY NOTE AND DISCLAIMER ON FORWARD-LOOKING INFORMATION AND RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this interim financial report, unless stated otherwise, the terms the &#8220;Company,&#8221; &#8220;Innate,&#8221; &#8220;Innate Pharma&#8221; and &#8220;Group&#8221; refer to Innate Pharma SA and its subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This interim report contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. All statements other than those relating to present and historical facts and conditions contained in this interim report, including statements regarding the Company&#8217;s future results of operations and financial position, business strategy, plans and the Company&#8217;s objectives for research and development and future operations, are forward-looking statements. The use of certain words, including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s reliance on third parties to manufacture its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company&#8217;s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this interim report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:35.43pt;padding-right:35.43pt;text-align:center;text-indent:-70.87pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">INNATE PHARMA AT A GLANCE</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma SA (the &#8220;Company&#8221; and, with its subsidiary, referred to as the &#8220;Group&#8221;), is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET&#174; (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET&#174; multi-specific NK cell engagers to address multiple tumor types.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Since its creation, the Company has suffered losses due to its research and development ("R&amp;D") activities. The first half of 2024 generated a net loss of 24,764 thousand euros. As of June 30, 2024, shareholders' equity amounted to 28,796 thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its drug candidates in development.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company&#8217;s future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its R&amp;D; (ii)&#160;regulatory approval and market acceptance of the Company&#8217;s future drug candidates; (iii)&#160;the timely and successful completion of additional financing; and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments and debt financing.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The activity of the Company is not subject to seasonal effects. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma is based in Marseille, France and listed on Euronext in Paris and Nasdaq in the United States, and had 168 full time equivalent employees as of June 30, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Learn more about Innate Pharma at www.innate-pharma.com (please note the contents of the website are not incorporated into this report) .</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:35.43pt;padding-right:35.43pt;text-align:center;text-indent:-70.87pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">HALF-YEAR MANAGEMENT REVIEW</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The key elements of Innate Pharma&#8217;s financial results for the first half of 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Cash, cash equivalents and financial assets (current and non-current) amounting to &#8364;102.1m (million euros) as of June 30, 2024 (&#8364;102.3m as of December&#160;31, 2023). At the same date, the financial liabilities amounted to &#8364;35.5m, including &#8364;26.6m of non-current liabilities (&#8364;39.9m as of December&#160;31, 2023, including &#8364;31.0m of non-current financial liabilities).</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Revenue and other income amounting to &#8364;12.3m (&#8364;40.2m for the first half of 2023). This amount mainly results from collaboration and licensing revenue (&#8364;8.3m) and from research tax credit (&#8364;4.1m). Revenue from collaboration and licensing agreements mainly result from the agreements with AstraZeneca/Medimmune and Sanofi/Genzyme.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Operating expenses amounting to &#8364;38.7m (&#8364;40.6m for the first half of 2023), of which 75.2% are related to research and development. Research and development expenses amount to &#8364;29.1m compared to &#8364;31.5m for the first half of 2023 and decrease by &#8364;2.4m, mainly explained by lower personnel and other R&amp;D expenses by &#8364;2.2 millions (-15.4%). This decrease is due to an non-recurring amortization charge in the first half of 2023, related to the IPH5201 rights (full amortization of the additional &#8364;2.0 million invoice from Orega Biotech following the dosing of the first patient in the Phase 2 MATISSE clinical trial in June 2023). Additionally, direct R&amp;D expenses, which slightly decreased by &#8364;0.2 million, remained at &#8364;17.1 million, with an acceleration in preclinical spending related to the Antibody-Drug Conjugates (ADC) program offsetting the decrease in expenses related to certain more mature clinical-stage programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">General expenses amounting to &#8364;9.6 million (compared to &#8364;9.1 million in the first half of 2023), an increase of &#8364;0.4 million. This increase is due to a &#8364;0.4 million decrease in personnel expenses linked to a reduction of the  administrative staff (39 employees as of June 30, 2024, compared to 45 as of June 30, 2023), bringing personnel expenses to &#8364;4.0 million in the first half of 2024, more than offset by a &#8364;0.3 million increase in non-scientific and consulting fees, which amounts to &#8364;1.9 million in the first half of 2024, resulting from greater reliance on recruitment agencies, and (III) a &#8364;0.5 million increase in other expenses, mainly due to the derecognition of returned spaces in the first half of 2023 (as a reminder, on March 13, 2023, the Company signed an amendment to the lease of the 'Le Virage' building, aimed at reducing the area of leased premises) and the sale of related furniture during the same period, which led to an exceptional reduction in these charges in the first half of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">A net loss for the first half of 2024 amounting to &#8364;24.8m (compared to net income of &#8364;1.7m for the first half of 2023). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note on change of accounting standards during the period</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendements to IAS 1 : Classification of liabilities with covenants; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendements to IAS 7 and IFRS 7 : Supplier finance arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendements to IFRS 16 : Lease liability in a sale and leaseback. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Those amended standards have no impact on the interim condensed consolidated financial statements.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">A.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.41pt">Revenue and other income</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue and other income resulted from collaboration and licensing agreements and government financing for research expenditure. They decreased by &#8364;27.9 million, to &#8364;12.3 million for the six months ended June 30, 2024, as compared to revenue and other income of &#8364;40.2 million for the six months ended June 30, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:58.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,293</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35,344</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government funding for research expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,052</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,854</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue and other income</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,345</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">40,198</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:50.000%"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from collaboration and licensing agreements</span></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:50.000%"></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue from collaboration and licensing agreements decreased by &#8364;27.1 million, to &#8364;8.3 million for the six months ended June 30, 2024, as compared to revenue from collaboration and licensing agreements of &#8364;35.3 million for the six months ended June 30, 2023. As a reminder, these revenues mainly resulted from the spreading of proceeds received in connection with the agreements signed with AstraZeneca in April 2015 and October 2018 with Sanofi in 2016 and 2022 and with Takeda in 2023. These revenues are recognized when the entity's performance obligation is met. They are recognized at a point in time or spread over time according to the percentage of completion of the work that the Company is committed to carry out under these agreements. Revenue from collaboration and licensing agreements are set forth in the table below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:58.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,396</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,729</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which monalizumab agreement (AstraZeneca)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,994</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">9,503</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which 2016 Sanofi agreement</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,672</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of which Takeda agreement </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,553</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoicing of R&amp;D costs (IPH5201 agreement)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">897</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">616</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,293</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,344</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:50.000%"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from collaboration and licensing agreements</span></div></div><div style="display:inline-block;max-width:0.000%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:50.000%"><div style="text-align:justify"><span><br/></span></div></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For monalizumab, these amounts result from the partial recognition of the $250.0 million non-refundable upfront payment and the $100 million milestone regarding the exercise of the option received in June 2015 and October 2018 from AstraZeneca. The additional payment of $50.0&#160;million received from AstraZeneca in December 2020 triggered by the dosing of the first patient in the Phase 3 trial evaluating monalizumab was treated in full as a collaboration commitment ("collaboration liability" in the consolidated balance sheet) in view of the commitment linked to the agreement for the Phase 1/2 (co-financing) and Phase 3 studies (amendment signed in September 2020). Consequently, this additional payment has no impact on the transaction price. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">In addition to these amounts, AstraZeneca made an additional payment of $50.0 million in June 2022, triggered by the treatment of the first patient in a second Phase 3 trial evaluating monalizumab in April 2022. This additional </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">payment has been treated as a collaboration commitment ("collaboration liability" in the consolidated balance sheet) for an amount of $36.0 million in view to the contractual commitment linked to the Phase 1/2 studies (co-funding under the initial contract). The remaining $14.0 million was treated as a change in estimate of the transaction price, recognized in the income statement in line with the progress of the Phase 1/2 studies. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The amounts not yet recognized in revenue are classified as deferred revenue.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Proceeds related to monalizumab - AstraZeneca: </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to monalizumab decreased by &#8364;6.5 million, to &#8364;3.0 million for the six months ended June 30, 2024, as compared to &#8364;9.5 million for the six months ended June 30, 2023. This decrease is mainly due to the recognition of increased revenue in the first six months of 2023. Indeed, as of June 30, 2023, the Company had analyzed the cost base used to calculate the percentage of completion of Phase 1/2 trials in connection with their progress. This analysis led to a reduction in the cost base through a re-estimation of projected expenses. As a result, this adjustment on the cost base had a positive impact on the percentage of completion and led to the recognition of additional revenue of &#8364;5.9 million for the first half of 2023 which was not replicated in 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the deferred revenue related to monalizumab is &#8364;2.0 million entirely classified as &#8220;Deferred revenue&#8212;Current portion&#8221; in connection with the progress of Phase 1/2 trials.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Proceeds related to Sanofi licensing and collaboration agreement (2016) :   </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to the license and collaboration agreement signed with Sanofi in 2016 increased by &#8364;2.0 million, to &#8364;4.0 million for the six months ended June 30, 2024, as compared to &#8364;2.0 million for the six months ended June 30, 2023. On April 15, 2024, the Company announced the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 agreement, this trial progress triggered a milestone payment of &#8364;4.0 million fully recognized in revenue during the first quarter of 2024. This amount was received by the Company on May 17, 2024.As a reminder, the Company announced that, in June 2023, the first patient was dosed  in a Sanofi-sponsored Phase 1/2 clinical trial evaluating IPH6401/SAR'514 in relapsed or refractory Multiple Myeloma. As provided by the licensing agreement signed in 2016, Sanofi made a milestone payment of &#8364;2.0 million, fully recognized in revenue as of June 30, 2023. This amount was received by the Company on July 21, 2023. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Proceeds related to Sanofi research collaboration and licensing agreement (2022) :   </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, on December 19, 2022, the Company announced that it had entered into a research collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#8220;Sanofi&#8221;) pursuant to which the Company granted Sanofi an exclusive license on the Innate Pharma's B7-H3 ANKET&#174; program and options on two additional targets. On January 25, 2023, the Company announced the expiration of the waiting period under the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Hart-Scott-Rodino</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> (HSR) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Antitrust Improvements Act</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, the Company received an upfront payment of &#8364;25.0 million in March 2023, including &#8364;18.5 million for the exclusive license, &#8364;1.5 million for the research activities and &#8364;5.0 million for the option on two additional targets.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company considers that the license to the B7-H3 technology is a right to use the intellectual property granted exclusively to Sanofi from the effective date of the agreement. As such, the &#8364;18.5 million upfront payment relating to the exclusive license was fully recognized in revenue as of June 30, 2023. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company will perform collaborative research activities for an initial estimated three-year period from the effective date of the collaboration, i.e. January 24, 2023. During this period, Sanofi and Innate will collaborate and work on research activities as defined in the research program described in the agreement. Consequently, the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">corresponding upfront payment of &#8364;1.5 million is recognized on a straight-line basis over the duration of the research activities that the Company has agreed to carry out. As a result, a &#8364;0.2 million has been recognized in revenue as of June 30, 2024 and June 30, 2023. Amounts not recognized in revenue are classified as deferred revenue&#8212;current portion for &#8364;0.4 million and deferred revenue&#8212;non-current portion for &#8364;0.5 million. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As previously announced, on December 19, 2023, the Company announced that Sanofi had exercised an option for one of the two targets. As a consequence, the Company recognized related income of &#8364;2.5 million as of December 31, 2023. This option exercise also resulted in a milestone payment of &#8364;15.0 million, including &#8364;13.3 million in respect of the exclusive license, which was fully recognized in income as of December 31, 2023, and &#8364;1.7&#160;million in respect of research activities to be carried out by the Company, which will be recognized in income on a straight-line basis over the duration of the research work that the Company has agreed to carry out. Sanofi and Innate will collaborate and work on the research activities defined in the contractual research program. This work began during the first half of 2024. An amount of &#8364;0.2 million has been recognized in revenue as of June 30, 2024. Amounts not recognized in revenue are classified as deferred revenue&#8212;current portion for &#8364;0.4 million and deferred revenue&#8212;non-current portion for &#8364;1.1 million.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Proceeds related to Takeda licensing agreement (2023) :</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenues under the license agreement signed with Takeda in 2023 are nil for the first half of 2024, compared to &#8364;4.6 million for the first half of 2023. On April 3, 2023, the Company announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease. Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. As such, the Company considers that the license granted is a right to use the intellectual property, which is granted fully and perpetually to Takeda. The agreement does not stipulate that Innate's activities will significantly affect the intellectual property granted during the life of the agreement. Consequently, the $5.0 million (or &#8364;4.6 million) initial payment, received by the Company in May 2023, was fully recognized in revenue as of June 30, 2023. </span></div><div style="text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invoicing of research and development costs - AstraZeneca: </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Pursuant to our agreements with AstraZeneca, external research and development costs related to IPH5201 are equally shared between Innate Pharma and AstraZeneca, in accordance with the amendment signed in June 2022. These costs are invoiced back on a quarterly basis.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue from invoicing of research and development costs for the six months ended June 30, 2024  increased by &#8364;0.3 million as compared to the six months ended June 30, 2023. The change between the two periods is mainly explained by the increase in research and development costs incurred by the Company under these agreements during the first half of 2024 in line with the clinical trial progress.</span></div><div style="text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Government financing for research expenditures</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below details government financing for research expenditures for the six months ended June 30, 2024 and 2023.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:58.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,050</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,854 (1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grants</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government financing for research expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,052</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,854</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As of June 30, 2023, the amount is mainly composed of (i) the research tax credit calculated and recognized for the first half of 2023 for an amount of &#8364;5.0 million from which is subtracted (ii) a provision amounting to &#8364;0.2 million relating to the additional provision in connection with the tax inspection carried out in 2022 by the French tax authorities relating to the 2019 and 2020 financial years, as well as the research tax credit and the accuracy of its calculation for the 2018 to 2020 financial years. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Government financing for research expenditures decreased by &#8364;0.8 million, or 16.5%, to &#8364;4.1 million for the six months ended June 30, 2024 as compared to &#8364;4.9 million for the six months ended June 30, 2023. This change is mainly due to the &#8364;1.5 million decrease in the research tax credit, resulting from (i) the absence of depreciation for IPH5201 rights in the first half of 2024, compared with the depreciation recognized in the first half of 2023 following the additional payment of &#8364;2.0 million to Orega Biotech following the dosing of the first patient in the MATISSE Phase 2 clinical trial, (ii) a decrease in amortization expense for the monalizumab intangible asset, which is nearing the end of its amortization period, and (iii) a reduction in eligible R&amp;D personnel costs. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">However, these decreases were offset by a &#8364;0.5 million increase in Research tax credits (Cr&#233;dits d&#8217;imp&#244;t Recherches or &#8220;CIR&#8221;) from public and private R&amp;D subcontracting expenses over the period included in the calculation of the research tax credit, due to the inclusion, for the first half of 2024, of R&amp;D expenses incurred with a third party whose approval was under renewal as of June 30, 2023, and whose expenses had been excluded from eligible expenses for that period.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, the research tax credit is calculated as 30% of the amount of research and development expenses, net of grants received, eligible for the research tax credit for the fiscal year.</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_19"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">B.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.91pt">Operating expenses</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below presents our operating expenses for the six months periods ended June 30, 2024 and 2023:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(29,076)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(31,453)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,582)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,144)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(38,657)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(40,597)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:140%">Research and development expenses (R&amp;D)</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">R&amp;D expenses in the periods presented primarily relate to activities for the Company&#8217;s clinical and preclinical programs. Our research and development expenses are broken down as set forth in the table below :</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(69)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(604)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lacutamab</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5,224)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6,719)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPH65</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(844)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,225)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPH5201</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,725)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,236)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other programs</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(370)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(142)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Sub-total programs in clinical development</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,232)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(10,926)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Sub-total programs in preclinical development</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,838)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(6,339)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total direct research and development expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(17,070)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(17,265)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel expenses (including share-based payments)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8,760)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8,686)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(643)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,044)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,603)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,458)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Personnel and other expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(12,005)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(14,188)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total research and development expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(29,076)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31,453)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">R&amp;D expenses decreased by &#8364;2.4 million, or 7.6%, to &#8364;29.1 million for the six months ended June 30, 2024, as compared to R&amp;D of &#8364;31.5 million for the six months ended June 30, 2023. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">R&amp;D expenses represented a total of 75.2% and 77.5% of the total operating expenses for the six months ended June 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Direct R&amp;D expenses decreased by &#8364;0.2 million, or 1.1%, to &#8364;17.1 million for the six months ended June 30, 2024, as compared to an amount of &#8364;17.3 million for the six months ended June 30, 2023. This variation is mainly explained by a &#8364;2.5 million increase in expenses related to preclinical programs, particularly in the field of Antibody-Drug Conjugates (ADC), offset by a &#8364;2.7 million decrease in expenses related to clinical programs.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The variance relating to clinical programs is composed of the following items: (i) a &#8364;0.5 million increase related to recruitment costs for the Phase 2 MATISSE trial of the IPH5201 program, offset by (ii) a &#8364;1.4 million decrease in expenses for the IPH65 program, whose first patient was dosed in March 2024, (iii) a &#8364;1.5 million decrease in expenses for the lacutamab program, and (iv) a &#8364;0.5 million decrease in expenses related to the monalizumab program, decrease related to maturation of Phase I/II clinical trials under the collaboration with AstraZeneca.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Additionally, as of June 30, 2024, collaboration liabilities related to monalizumab and the agreements signed with AstraZeneca in April 2015, October 2018, and September 2020 amounted to &#8364;52.1 million, as compared to collaborations liabilities to &#8364;52.7 million as of December 31, 2023. This &#8364;0.5 million decrease mainly results from (i) net reimbursements of &#8364;2.4 million made to AstraZeneca in the first half of 2024 related to the co-funding of the monalizumab program, including the INTERLINK-1 Phase 3 trial launched in October 2020 and PACIFIC-9 launched in April 2022, and (ii) the increase in the collaboration commitment by &#8364;1.7 million due to exchange rate fluctuations observed during the period for the euro-dollar exchange rate.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Personnel and other expenses allocated to R&amp;D decreased by &#8364;2.2 million, or 15.4%, to &#8364;12.0 million for the six months ended June 30, 2024, as compared to an amount of &#8364;14.2 million for the six months ended June 30, 2023. This decrease is mainly explained by amortization charges related to the IPH5201 rights, following the full amortization of the additional &#8364;2.0 million invoice from Orega Biotech after the dosing of the first patient in the Phase 2 MATISSE clinical trial in June 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:140%">General and administrative expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%">:</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">General and administrative expenses increased by &#8364;0.4 million, or 4.8%, to &#8364;9.6 million for the six months ended June 30, 2024, as compared to general and administrative expenses of &#8364;9.1 million for the six months ended June 30, 2023. General and administrative expenses represent a total of 24.8% and 22.5% of the total operating expenses for the six months ended June 30, 2024 and 2023, respectively. The table below presents our general and administrative expenses by nature for the six months ended June 30, 2024 and 2023: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel expenses (including shared-based payments)</span></td><td colspan="3" style="background-color:#F2F2F2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,001)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,367)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non scientific advisory and consulting</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,934)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,662)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other expenses (1)</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,648)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,116)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total general and administrative expenses</span></td><td colspan="3" style="background-color:#F2F2F2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,582)</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,144)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Other expenses are related to intellectual property, maintenance costs for laboratory equipment and our premises, depreciation and amortization and other selling, general and administrative expenses.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Personnel expense includes the compensation paid to our employees. They amounted &#8364;4.0 million for the six months ended June 30, 2024, as compared to &#8364;4.4 million for the six months ended June 30, 2023. The decrease of &#8364;0.4 million is mainly due to a reduction of administrative workforce. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Non-scientific advisory and consulting expenses mostly consist of auditing, accounting, legal fees and hiring services. Non-scientific advisory and consulting expenses increased by &#8364;0.3 million, or 16.4%, to &#8364;1.9 million for the six months ended June 30, 2024 as compared to &#8364;1.7 million for the six months ended June 30, 2023. This increase is mainly due to greater reliance on recruitment agencies.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The rise in other expenses of  &#8364;0.5m mainly results from rent, maintenance, and upkeep costs (primarily related to property rentals; a exceptional effect related to the derecognition of returned spaces&#8212;as a reminder, on March 13, 2023, the Company signed an amendment to the lease of the "Le Virage" building, aimed at reducing the area of leased premises. The effective date of the lease amendment is March 15, 2023) as well as a &#8364;0.2 million increase in other net income and expenses (primarily related to the sale of office furniture following the reduction of leased spaces).</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_674"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">C.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:9.25pt">Net financial income (loss)</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">We recognized a net financial income of &#8364;1.5 million in the six months ended June 30, 2024 as compared to &#8364;2.1 million in the six months ended June 30, 2023. This variance mainly results from the unfavorable evolution of the dollar exchange rate and its impact on foreign exchange recorded during the first half of 2024, with a net foreign exchange loss of &#8364;0.9 million for the first half of 2024 as compared to a net foreign exchange gain of &#8364;0.4 million for the first half of 2023. The negative currency impact was offset by an increase in the fair value of certain financial instruments (net gain of &#8364;1.5 million for the six months ended June 30, 2024 as compared to a net gain of &#8364;1.0 million for the six months ended June 30, 2023) and by an increase in interest income of &#8364;1.3 million in first-half 2024 as compared to &#8364;1.0 million in first half of 2023. </span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below presents the components of our net financial income (loss) for the six months ended June 30, 2024 and 2023:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interests on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,269</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in valuation allowance on financial instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,471</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,073</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,613</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,083</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,763)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(642)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest on financial liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(300)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(324)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,064)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(966)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,549</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,116</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Our investment policy focuses on the absence of capital risk and, as far as possible, a guaranteed minimum performance.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For the six months ended June 30, 2024 and 2023, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the U.S. dollar on U.S. dollar-denominated cash and cash equivalents and financial assets. Unrealized losses on financial assets relate to unquoted instruments.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_22"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">D.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.14pt">Balance sheet items</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Cash, cash equivalents, short-term investments and non-current financial assets amounted to &#8364;102.1m as of June 30, 2024, as compared to &#8364;102.3m as of December&#160;31, 2023. Net cash as of June 30, 2024 amounted to </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8364;82.9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">m (</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8364;83.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">m as of December&#160;31, 2023). Net cash is equal to cash, cash equivalents and short-term investments less current financial liabilities. Net cash is a non-IFRS financial indicator that is reviewed by the Company&#8217;s management and that the Company believes provides useful information to investors with respect to measuring cash resources that are available for strategic investment. Net cash is not defined by IFRS and is not a substitute for &#8220;cash and cash equivalents&#8221; as reported under IFRS. Management recognizes that the term net cash may be interpreted differently by other companies and under different circumstances.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company has been primarily financed by revenue from its collaboration, licensing agreements since 2011 (&#8364;579.1m in total, or $656.1m), and by issuing new shares (&#8364;306.4m in total excluding share-based payments and the costs the costs associated with capital increases). The Company has also benefited from the research tax credit (CIR) and fundings received from BPI France (ex-Oseo) in repayable advances not bearing interest and PTZI loan (interest free loan for Innovation). As of June 30, 2023, the Company is not liable for any reimbursement in respect of these reimbursable advances and PTZI loan. The Company also has bank borrowings of &#8364;34.9m, including &#8364;25.2m of State Guaranteed Loans (&#8220;Pr&#234;ts Garantis par l&#8217;Etat&#8221;) as of June 30, 2024 and &#8364;9.6m loans subscribed with Soci&#233;t&#233; G&#233;n&#233;rale for the construction of its head office as well as &#8364;0.6m of lease liabilities.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The research tax credit (Cr&#233;dit d&#8217;Imp&#244;t Recherche) (the &#8220;Research Tax Credit&#8221; or &#8220;CIR&#8221;) granted by the French tax authorities in order to encourage companies to conduct technical and scientific research. Companies that can justify that these expenses meet the required criteria receive such grants in the form of a refundable tax credit that can be used for the payment of taxes due for the period in which the expense was incurred and for the next three years or refunded if necessary upon expiry of such a period. As a reminder, the Company has benefited from the early repayment of the Research Tax Credit (Cr&#233;dit Imp&#244;t Recherche - CIR) until December 31, 2019. As of December 31 2019 and December 31, 2023, the Company no longer met the eligibility criteria for this status (criteria not met after year-end analysis). As a result, the CIR for 2019 and 2020 represented a receivable from the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">French Treasury, which was refunded to the Company in January 2024 for &#8364;16.7 million and July 2024 for &#8364;12.8 million. The CIR calculated in respect of 2023 and the first half of 2024 is recognized as a non-current receivable. For fiscal years 2021 and 2022, the Company met the definition of an SME under European Union criteria and was therefore entitled to early repayment of the CIR in 2022 in respect of the 2021 tax year and in July 2023 in respect of the 2022 tax year. Since its creation and at the date of this report, the Company has benefited from CIR reimbursements for a net amount of &#8364;128.9m. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The other key balance sheet items as of June 30, 2024 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Deferred revenue of &#8364;6.9m (including &#8364;4.1m booked as &#8216;Deferred revenue &#8211; non-current portion&#8217;) and collaboration liabilities amounting to &#8364;52.1m (including &#8364;41.9m booked as &#8216;Collaboration liabilities - non-current portion&#8217;) relating to the remainder of the initial payment from AstraZeneca not yet recognized as revenue or used as part of the co-financing of the monalizumab program with AstraZeneca;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Receivables from the French government amounting to &#8364;26.6m in relation to the research tax credit for 2020, 2023 and the six-month period ended June 30, 2024;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Shareholders&#8217; equity of &#8364;28.8m including the net loss for the first half of 2024 of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8364;24.8m</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_25"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">E.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:9.71pt">Cash-flow items</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, cash and cash equivalents amounted to &#8364;70.0m, a decrease of &#8364;0.6m compared to December&#160;31, 2023.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The following table sets forth cash flow data for the six months ended June 30, 2024 and 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:58.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">in thousands of euro</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from / (used in) operating activities</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:2pt solid #B3B735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,036</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #B3B735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11,465)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from / (used in) investing activities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">932</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(246)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from / (used in) financing activities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,327)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,246)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effect of the exchange rate changes</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(257)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">145</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net increase / (decrease) in cash and cash equivalents:</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(615)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(12,811)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Cash flows from / (used in) operating activities:</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net cash flow from operating activities increased by &#8364;14.5 million to &#8364;3.0 million for the six months ended June 30, 2024 as compared to net cash flow used in operating activities of &#8364;11.5 million for the six months ended June 30, 2023. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net cash flow from operating activities for the first half of 2024 notably includes (i) the collection of &#8364;15.0 million in January 2024 following Sanofi's decision to exercise one of its two license option for an NK Cell Engager program in solid tumors, derived from the Company's ANKET&#174; (Antibody-based NK Cell Engager Therapeutics) platform, pursuant to the terms of the research collaboration and license agreement signed in December 2022, (ii) the collection in May 2024 of &#8364;4.8 million (including value-added tax) the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers and (iii) the repayment by the French Treasury of the research tax credit receivable relating to the 2019 financial year for an amount of &#8364;16.7 million during the first quarter of 2024, as well as the carry-back receivable for an amount of &#8364;0.3 million. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, for the first half of 2023, the net cash flow used in operating activities included (i) the &#8364;25.0 million upfront payment received from Sanofi in March 2023 following the effectiveness of the research collaboration and licensing agreement signed in December 2022 under which the Company granted Sanofi an exclusive license to Innate Pharma's B7-H3 ANKET&#174; program and options on two additional targets, but also (ii) the &#8364;4.6 million ($5.0 million) upfront payment received from Takeda following the signing of an exclusive licensing agreement which the Company grants Takeda exclusive worldwide rights for the research and development of certain antibody drug conjugates (ADCs) (please refer to Note 20.Events after the reporting date).</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Restated for these transactions linked to collaboration agreements and other non-recurring items such as the CIR refund, net cash flow used in operating activities for the first half of 2024 decreased by &#8364;7.3 million as compared to the first half of 2023. This change mainly results from lower net payments to suppliers and personnel costs. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Cash flows from / (used in) investing activities:</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net cash flow from investing activities  for the six months ended June 30, 2024 was &#8364;0.9 million and was mainly composed of a disposal of a current financial instrument which generated a net cash collection of &#8364;1.2 million partially offset by acquisitions of property, plant and equipment and intangible assets for a net amount &#8364;0.3 million. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net cash flow used in investing activities was &#8364;0.2 million for the six months ended June 30, 2023 and was mainly comprised of acquisitions of property, plant and equipment and intangible assets net of disposals. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has not made any other significant investments in tangible, intangible or significant current and non-current financial assets during the first half of 2024 and 2023. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#242021;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:133%">Cash flows from / (used in) financing activities: </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net cash flow used in financing activities for the six months ended June 30, 2024 was &#8364;4.3 million as compared to net cash flow used in financing activities of &#8364;1.2 million the six months ended June 30, 2023. These consumptions are mainly related to repayments of financial liabilities. Their increase over the period is related to the two State Guaranteed Loans, for which principal amortization began in the first quarter of 2024. As a reminder, the Company benefited from a one-year grace period in 2023, during which only interests and guarantee fees were paid.</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_28"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">F.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:10.03pt">Key events since January 1, 2024</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:12.53pt">On March 6, 2024, the Company announced the treatment of the first patient in the Phase 1/2 trial evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET&#174; platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On April 15, 2024, the Company announced the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 agreement, this trial progress triggered a milestone payment of &#8364;4.0 million fully recognized in revenue during the first quarter of 2024. This amount was received by the Company on May 17, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On June 10, 2024, the Executive Board carried out a capital increase of &#8364;5,342 following the creation of 106,844 ordinary shares in the context of a company savings plan benefiting to the employees, including 68,744 ordinary shares issued free of charge (subscription). The capital increase was undertaken as follows : a creation of 68,744 free shares with a nominal value of &#8364;0.05 issued free of charge by deduction from the share premium, with a creation of 38,100 ordinary shares with a nominal value of &#8364;0.05 and an issue price of &#8364;2.45 (i.e an increase in share premium of &#8364;91,440).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">G.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.07pt">Nota</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements for the six-month period ended June 30, 2024 were established in accordance with IAS 34 standard adopted by European Union and as issued by the International Accounting Standards Board (IASB). They have been subject to a limited review by our Statutory Auditors and were approved by the Executive Board of the Company on September&#160;11, 2024. They were reviewed by the Supervisory Board of the Company on September&#160;11, 2024 and will not be submitted for approval to the general meeting of shareholders.</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_34"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">H.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.14pt">Main risks and uncertainties for the remaining six months of the fiscal year</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Risk factors identified by the Company are presented in the item 3.D of the annual report filed with the SEC (20-F), on April 4, 2024 (SEC Accession No. 0001598599-24-000020). The main risks and uncertainties the Company may face in the six remaining months of the year are the same as the ones presented in the annual report available on the internet website of the Company.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Of note, the risks that are likely to arise during the remaining six months of the current financial year could also occur during subsequent years.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_37"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">I.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.14pt">Related party transactions</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Transactions with related parties during the periods under review are disclosed in Note 18 to the interim consolidated financial statements as of June 30,2024. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:35.43pt;padding-right:35.43pt;text-align:center;text-indent:-70.87pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_43"></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">A.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.91pt">Interim Condensed Consolidated Statements of Financial Position (amounts in thousands of euro) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:49.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.806%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-9">69,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-10">70,605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-11">21,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-12">21,851</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-13">19,795</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-14">55,557</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-15">111,594</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-16">148,012</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-17">119</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-18">416</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-19">5,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-20">6,322</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-21">10,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-22">9,796</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-23">85</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="3" id="f-24">87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others - non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-25">14,478</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-26">10,554</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-27">9,123</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-28">9,006</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-29">39,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-30">36,181</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-31">151,497</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-32">184,193</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-33">15,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-34">17,018</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration liabilities &#8211; current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CollaborationLiabilitiesCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-35">10,248</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CollaborationLiabilitiesCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-36">7,647</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities &#8211; current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-37">8,929</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-38">8,936</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue &#8211; current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-39">2,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-40">5,865</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions - current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-41">375</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-42">171</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-43">38,224</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-44">39,637</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration liabilities &#8211; non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CollaborationLiabilitiesNonCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-45">41,901</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CollaborationLiabilitiesNonCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-46">45,030</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities &#8211; non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-47">26,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-48">30,957</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Defined benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-49">2,470</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-50">2,441</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue &#8211; non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-51">4,116</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-52">4,618</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions - non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-53">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-54">603</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">9,123</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">9,006</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-57">84,478</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-58">92,656</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-59">4,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-60">4,044</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share premium</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-61">386,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-62">384,255</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-63">336,893</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-64">329,323</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherReserves" scale="3" id="f-65">354</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherReserves" scale="3" id="f-66">495</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-67">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" format="ixt:num-dot-decimal" scale="3" id="f-68">7,570</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-69">28,796</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-70">51,901</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">151,497</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">184,193</ix:nonFraction></span></td></tr></table></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="text-indent:31.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_46"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">B.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:8.91pt">Interim Condensed Consolidated Statements of Income (Loss) (amounts in thousands of euro, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-73">8,293</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-74">35,344</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government financing for research expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:GovernmentFinancingForResearchExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-75">4,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:GovernmentFinancingForResearchExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-76">4,854</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-77">12,345</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-78">40,198</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-79">29,076</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">31,453</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">9,582</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-82">9,144</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-83">38,657</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">40,597</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-85">26,313</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" id="f-86">398</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-87">3,613</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-88">3,083</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-89">2,064</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="f-90">966</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-91">1,549</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-92">2,116</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss) before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-93">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-94">1,718</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-95">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-97">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-98">1,718</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss) per share :</span></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of shares :</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-99"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-100">80,872,369</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-102">80,319,897</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in &#8364; per share)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- Basic income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-103">0.31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-104">0.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- Diluted income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-105">0.31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-106">0.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_49"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">C.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:9.25pt">Interim Condensed Consolidated Statements of Comprehensive Income (Loss) (amounts in thousands of euro)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss) for the period:</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">1,718</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Items which will not reclassified in the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains and (losses) related to defined benefit obligations</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-109">116</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-110">101</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Elements which will be reclassified in the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation gain (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-111">257</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-112">146</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-113">141</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-114">247</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-115">24,905</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-116">1,965</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">D.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:26.14pt">Interim Condensed Consolidated Statements of Cash Flows (amounts in thousands of euro)</span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-118">1,718</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization, net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6, 7</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">1,142</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">3,645</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Employee benefits costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-121">145</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="3" id="f-122">83</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in provision for charges</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="f-123">105</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="f-124">507</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-125">1,705</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-126">1,401</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFairValueGainsLosses" scale="3" id="f-127">992</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFairValueGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-128">1,044</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange (gains) losses on financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-129">524</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-130">288</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in accrued interests on financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" scale="3" id="f-131">212</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" scale="3" id="f-132">130</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposal of property and equipment (scrapping)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-133">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-134">591</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other profit or loss items with no cash effect</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-135">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="f-136">6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating cash flow before change in working capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-137">23,561</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-138">7,065</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in working capital (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-139">26,597</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-140">18,530</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash generated from / (used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-141">3,036</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-142">11,465</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisition of property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-143">283</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-144">309</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposal of other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-145">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="f-146">66</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-147">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" scale="3" id="f-148">3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposal of current financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-149">1,215</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-150">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Net cash generated from / (used in) investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-151">932</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-152">246</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the exercise / subscription of equity instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="f-153">93</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="f-154">348</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Repayment of borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-155">4,420</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-156">1,594</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net cash generated / (used in) from financing activities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-157">4,327</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-158">1,246</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Effect of the exchange rate changes</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-159">257</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-160">145</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net increase / (decrease) in cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="3" id="f-161">615</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-162">12,811</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at the beginning of the year:</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-163">70,605</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-164">84,225</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and cash equivalents at the end of the six-months period:</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-165">69,990</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-166">71,414</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">(1) Change in working capital are detailed below</ix:footnote>: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change in working capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#F2F2F2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-167">34,273</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-168">66,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-169">31,838</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue - current and non-current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-170">6,915</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-171">10,483</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-172">3,568</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others (excluding payables related to capital expenditures)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-173">15,873</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-174">17,018</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-175">1,145</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration liabilities - current and non-current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-176">52,149</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-177">52,677</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" scale="3" id="f-178">528</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total change in Working Capital</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#F2F2F2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ChangeInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-179">40,664</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:ChangeInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-180">14,067</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-181">26,597</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change in working capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-182">56,446</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-183">52,445</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-184">4,001</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue - current and non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-185">11,024</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:DeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-186">14,481</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-187">3,457</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-188">16,991</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-189">20,911</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-190">3,919</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collaboration liabilities - current and non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="inpha:CollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-191">56,058</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="inpha:CollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-192">63,211</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-193">7,153</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total change in working capital</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="inpha:ChangeInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-194">27,627</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="inpha:ChangeInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-195">46,158</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-196">18,530</ix:nonFraction>)</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">E.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:9.71pt">Interim Consolidated Statement of Changes in Shareholders&#8217; Equity (amounts in thousands of euro, except share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:21.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In thousands of euro, except for data share</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ordinary Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Preferred Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share premium</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Other <br/>comprehensive<br/>income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total attributable to equity holders of the Company</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-197">80,212,069</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-198">14,095</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-199">4,011</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-200">379,637</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-201">272,213</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-202">819</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-203">58,103</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-204">54,151</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">1,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-206">1,718</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial gains on defined benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-207">101</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-208">101</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-209">146</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-210">146</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive gain/(loss) for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-212">247</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-213">1,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-214">1,965</ix:nonFraction></span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-215">58,103</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-216">58,103</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise and subscription of equity instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares" format="ixt:num-dot-decimal" scale="0" id="f-218">304,553</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-219">15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-220">333</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-221">348</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shared-based payment </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-222">1,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-223">1,400</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-224">80,516,622</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-225">14,095</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-226">4,027</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-227">381,371</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-228">330,315</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-229">1,064</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-230">1,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-231">57,863</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-232">80,860,563</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-233">14,090</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-234">4,044</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-235">384,255</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-236">329,323</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-237">495</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-238">7,570</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-239">51,901</ix:nonFraction></span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-240">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">24,764</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial loss on defined benefit obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-242">116</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="f-243">116</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-244">257</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-245">257</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive gain/(loss) for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-246">141</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-247">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-248">24,905</ix:nonFraction>)</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of prior period income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-249">7,570</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-250">7,570</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise and subscription of equity instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares" format="ixt:num-dot-decimal" scale="0" id="f-252">106,844</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-253">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-254">88</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" scale="3" id="f-255">93</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shared-based payment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-256">1,706</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-257">1,706</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-258">80,967,407</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-259">14,090</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-260">4,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-261">386,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-262">336,893</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-263">354</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-264">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-265">28,796</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">F.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:10.03pt">Interim Condensed Notes to the Consolidated Financial Statements</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_61"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">1.</span><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" id="f-266" continuedAt="f-266-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">The Company and key events</span></ix:nonNumeric></div><div id="i634ed0333ee247d7904463c2d5fd1df7_64"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">1.1</span><ix:continuation id="f-266-1" continuedAt="f-266-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">The company</span></ix:continuation></div><ix:continuation id="f-266-2" continuedAt="f-266-3"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma SA (the &#8220;Company&#8221; and, with its subsidiary, referred to as the &#8220;Group&#8221;), is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET&#174; (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET&#174; multi-specific NK cell engagers to address multiple tumor types. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Since its creation, the Company has suffered losses due to its research and development ("R&amp;D") activities. The first half of 2024 generated a net loss of <ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">24,764</ix:nonFraction> thousand euros. As of June 30, 2024, shareholders' equity amounted to <ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-268">28,796</ix:nonFraction> thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its drug candidates in development.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company&#8217;s future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its R&amp;D; (ii)&#160;regulatory approval and market acceptance of the Company&#8217;s future drug candidates; (iii)&#160;the timely and successful completion of additional financing; and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments and debt financing.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The activity of the Company is not subject to seasonal effects.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company had <ix:nonFraction unitRef="subsidiary" contextRef="c-2" decimals="INF" name="inpha:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-269">one</ix:nonFraction> wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. The subsidiary is consolidated according global integration.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma is based in Marseille, France and listed on Euronext Paris and Nasdaq in the United States., and had <ix:nonFraction unitRef="employee" contextRef="c-2" decimals="2" name="ifrs-full:NumberOfEmployees" scale="0" id="f-270">168</ix:nonFraction> full time equivalent employees as of June 30, 2024.</span></div></ix:continuation><div id="i634ed0333ee247d7904463c2d5fd1df7_67"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">1.2</span><ix:continuation id="f-266-3" continuedAt="f-266-4"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Key events for the six-month period ended June 30, 2024</span></ix:continuation></div><ix:continuation id="f-266-4" continuedAt="f-266-5"><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On March 6, 2024, the Company announced the treatment of the first patient in the Phase 1/2 trial evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET&#174; platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On April 15, 2024, the Company announced the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 agreement, this trial progress triggered a milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-271">4</ix:nonFraction>&#160;million fully recognized in revenue during the first quarter of 2024. This amount was received by the Company on May 17, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On June 10, 2024, the Executive Board carried out a capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="0" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="f-272">5,342</ix:nonFraction> following the creation of <ix:nonFraction unitRef="share" contextRef="c-48" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-273">106,844</ix:nonFraction> ordinary shares benefiting the employees of the company, including <ix:nonFraction unitRef="share" contextRef="c-49" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-274">68,744</ix:nonFraction> ordinary shares issued free of charge (subscription). The capital increase carried out can be broken as follow : a creation of <ix:nonFraction unitRef="share" contextRef="c-50" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-275">68,744</ix:nonFraction> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-266-5"><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">free shares with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-51" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-276">0.05</ix:nonFraction> issued free of charge by deduction from the share premium, with a creation of <ix:nonFraction unitRef="share" contextRef="c-52" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-277">38,100</ix:nonFraction> ordinary shares with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-53" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-278">0.05</ix:nonFraction> and an issue price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-54" decimals="2" name="inpha:ShareIssuedPricePerShare" scale="0" id="f-279">2.45</ix:nonFraction> (i.e an increase in share premium of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-55" decimals="0" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="f-280">91,440</ix:nonFraction>).</span></div></ix:continuation><div style="text-indent:3.8pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_70"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">2.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-281" continuedAt="f-281-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Basis of presentation and statement of compliance</span></ix:nonNumeric></div><div id="i634ed0333ee247d7904463c2d5fd1df7_73"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">2.1</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-282" continuedAt="f-282-1" escape="true"><ix:continuation id="f-281-1" continuedAt="f-281-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Basis of preparation</span></ix:continuation></ix:nonNumeric></div><ix:continuation id="f-282-1"><ix:continuation id="f-281-2" continuedAt="f-281-3"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements as of June 30, 2024 and for the six-months period ended June 30, 2024 and 2023 and the related notes (together, the &#8220;interim condensed consolidated financial statements&#8221;) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company&#8217;s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board on September&#160;11, 2024 upon recommendation of the Audit Committee on September&#160;10, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">They have been prepared in accordance with IAS 34, &#8216;Interim Financial Reporting&#8217; as issued by the International Accounting Standard Board (&#8220;IASB&#8221;). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#8217;s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The results of the operations for the six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any year in the future.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_76"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">2.2</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-283" continuedAt="f-283-1" escape="true"><ix:continuation id="f-281-3" continuedAt="f-281-4"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Use of judgments and estimates </span></ix:continuation></ix:nonNumeric></div><ix:continuation id="f-283-1" continuedAt="f-283-2"><ix:continuation id="f-281-4" continuedAt="f-281-5"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-283-2"><ix:continuation id="f-281-5" continuedAt="f-281-6"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 2.w) of the appendix to the consolidated financial statements as of December 31, 2023 filed with SEC (20-F) on April 2, 2024. As of June 30, 2024, the Company has not identified any other significant estimates and judgments that could have an impact on the consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_79"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">2.3</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-284" continuedAt="f-284-1" escape="true"><ix:continuation id="f-281-6" continuedAt="f-281-7"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Recently issued accounting standards and interpretations </span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> </span></ix:continuation></ix:nonNumeric></div><ix:continuation id="f-284-1"><ix:continuation id="f-281-7" continuedAt="f-281-8"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 1 : Classification of liabilities with covenants; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 7 and IFRS 7 : Supplier finance arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IFRS 16 : Lease liability in a sale and leaseback. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Those amended standards have no impact on the interim condensed consolidated financial statements.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has not opted for the early application of any standards whose application would be mandatory from subsequent financial years.</span></div></ix:continuation></ix:continuation><div id="i634ed0333ee247d7904463c2d5fd1df7_82"></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%">2.4</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-285" continuedAt="f-285-1" escape="true"><ix:continuation id="f-281-8" continuedAt="f-281-9"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Translation of transactions denominated in foreign currency </span></ix:continuation></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" id="f-286" escape="true"><ix:continuation id="f-285-1"><ix:continuation id="f-281-9"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foreign currency transactions are translated into the functionnal currency using the following exchange rates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8364;1 equals to</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">USD</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-287">1.0806</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-288">1.0866</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-289">1.0813</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-290">1.1050</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-291">1.0813</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-2" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-292">1.0705</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_85"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">3.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" id="f-293" continuedAt="f-293-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Management of financial risks</span></ix:nonNumeric></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:continuation id="f-293-1">The Company did not identify other risks than the ones presented in the consolidated financial statements for the year ended December 31, 2023.</ix:continuation> </span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_88"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">4.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-294" continuedAt="f-294-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Cash, cash equivalents, short-term investments  and non-current financial assets</span></ix:nonNumeric></div><ix:continuation id="f-294-1" continuedAt="f-294-2"><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" id="f-295" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-296">69,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-297">70,605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-298">21,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-299">21,851</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CashCashEquivalentsAndShortTermInvestmentsAssets" format="ixt:num-dot-decimal" scale="3" id="f-300">91,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CashCashEquivalentsAndShortTermInvestmentsAssets" format="ixt:num-dot-decimal" scale="3" id="f-301">92,456</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-302">10,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-303">9,796</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash, cash equivalents and financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:TotalCashCashEquivalentsAndFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-304">102,149</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:TotalCashCashEquivalentsAndFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-305">102,252</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts and mutual funds units (with short-term maturities) held with various banking institutions. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company also holds shares in <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="inpha:NumberOfFinancialInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="f-306">three</ix:nonFraction> mutual funds. The risk profiles of these funds are rated from <ix:nonFraction unitRef="rate" contextRef="c-57" decimals="INF" name="inpha:RiskProfileRate" scale="0" id="f-307">1</ix:nonFraction> to <ix:nonFraction unitRef="rate" contextRef="c-58" decimals="INF" name="inpha:RiskProfileRate" scale="0" id="f-308">7</ix:nonFraction> by the financial institution that manages and markets these funds (1 being the lowest risk </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-294-2"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">profile).When the maturity of shares in mutual funds is longer than one year, they are classified as non-current financial instruments. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024 and December 31, 2023, the amount of cash, cash equivalents and financials assets denominated in US dollars amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-59" decimals="-3" name="inpha:TotalCashCashEquivalentsAndFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-309">18,221</ix:nonFraction> thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-60" decimals="-3" name="inpha:TotalCashCashEquivalentsAndFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-310">20,798</ix:nonFraction> thousand, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" id="f-311" continuedAt="f-311-1" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Changes in short-term investments and non-current financial assets for the six months ended June 30, 2023 and 2024 are the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions (2)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-312">21,851</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ShortTermInvestmentsAcquisitions" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:DecreaseThroughDerecognitionShortTermInvestment" format="ixt:num-dot-decimal" scale="3" id="f-314">1,215</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-315">438</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" scale="3" id="f-316">212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ShortTermInvestmentsForeignCurrencyEffect" scale="3" id="f-317">524</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-318">21,810</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-319">9,796</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:NonCurrentFinancialAssetsAcquisitions" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-322">553</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:NonCurrentFinancialAssetsForeignCurrencyEffect" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-325">10,350</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-326">31,647</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:TotalAcquisitions" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-328">1,215</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-329">991</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" scale="3" id="f-330">212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:TotalForeignCurrencyEffect" scale="3" id="f-331">524</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-332">32,160</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:CurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-333">17,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ShortTermInvestmentsAcquisitions" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:DecreaseThroughDerecognitionShortTermInvestment" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-336">271</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" scale="3" id="f-337">232</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="inpha:ShortTermInvestmentsForeignCurrencyEffect" scale="3" id="f-338">288</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:CurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-339">17,475</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-340">35,119</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:NonCurrentFinancialAssetsAcquisitions" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-343">772</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" scale="3" id="f-344">102</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:NonCurrentFinancialAssetsForeignCurrencyEffect" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:NoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-346">35,790</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-347">52,379</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:TotalAcquisitions" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-350">1,043</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" scale="3" id="f-351">130</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="inpha:TotalForeignCurrencyEffect" scale="3" id="f-352">288</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-353">53,265</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date. </span></div></ix:nonNumeric><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"><ix:continuation id="f-311-1">(2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date.</ix:continuation> </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For the six months ended June 30, 2024 , variance of fair value through the consolidated statement of income (loss) is made of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-354">553</ix:nonFraction> thousand of unrealized gains on non-current financial assets and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-355">438</ix:nonFraction> thousand of unrealized gains on short-term investments. For the six months ended June 30, 2023, variance of fair value through the consolidated statement of income (loss) was made of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-356">772</ix:nonFraction> thousand of unrealized gains on non-current financial assets and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" scale="3" id="f-357">271</ix:nonFraction> thousand of unrealized gains on short-term investments (see </span><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_148">note 1</a><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_148">5</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">).</span></div></ix:continuation><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">5.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory" id="f-358" continuedAt="f-358-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Trade receivables and others</span></ix:nonNumeric></div><ix:continuation id="f-358-1"><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock" id="f-359" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-360">97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-361">104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ResearchTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-362">12,755</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:ResearchTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-363">29,755</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other tax credits (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:OtherCurrentTaxCreditsReceivables" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:OtherCurrentTaxCreditsReceivables" scale="3" id="f-365">361</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-366">3,009</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-367">5,692</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VAT refund</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" scale="3" id="f-368">583</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-369">1,037</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade account receivables  (4)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="f-370">393</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-371">15,233</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepayments made to suppliers</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-372">2,957</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-373">3,374</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:TradeAndOtherCurrentReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-374">19,795</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:TradeAndOtherCurrentReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-375">55,557</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:NonCurrentResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-376">13,850</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:NonCurrentResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-377">9,800</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:NonCurrentPrepaidExpenses" scale="3" id="f-378">628</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:NonCurrentPrepaidExpenses" scale="3" id="f-379">754</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others - non-current</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-380">14,478</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-381">10,554</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade receivables and others </span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:TradeAndOtherReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-382">34,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:TradeAndOtherReceivablesExcludingRebates" format="ixt:num-dot-decimal" scale="3" id="f-383">66,111</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The Research tax credit (CIR) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:ResearchTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-384">29,755</ix:nonFraction> thousand recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the <ix:nonNumeric contextRef="c-61" name="inpha:IncomeFromResearchTaxCredit2019And2020Maturity" format="ixt-sec:durwordsen" id="f-385">three year</ix:nonNumeric> period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in January 2024 for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-61" decimals="-3" name="inpha:IncomeFromResearchTaxCredit2019" format="ixt:num-dot-decimal" scale="3" id="f-386">16,737</ix:nonFraction> thousand and to the CIR for the 2020 tax year of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-3" name="inpha:IncomeFromResearchTaxCredit2020" format="ixt:num-dot-decimal" scale="3" id="f-387">13,018</ix:nonFraction> thousand was collected in July 2024 for the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ResearchTaxCreditReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-388">12,755</ix:nonFraction> thousand following the offset of the restated amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:OffsetOfRestatedIncomeFromResearchTaxCredit2020" scale="3" id="f-389">263</ix:nonFraction> thousand (see note 8). The amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:NonCurrentResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-390">13,850</ix:nonFraction> thousand recognized as a non-current receivable as of June 30, 2024 corresponds to the CIR for the 2023 tax year for the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" name="inpha:IncomeFromResearchTaxCredit2023" format="ixt:num-dot-decimal" scale="3" id="f-391">9,800</ix:nonFraction> thousand and the amount of CIR calculated for the first half of 2024 for the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncomeFromResearchTaxCreditHalfYear2024" format="ixt:num-dot-decimal" scale="3" id="f-392">4,050</ix:nonFraction> thousand. Following the loss of SME status since December 31, 2023, the CIR for 2023 and 2024 represent non-current receivables from the French Treasury, which should in principle be offset against corporate income tax due for the following three years or refunded if necessary upon expiry of such a period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of December 31, 2023, this amount mainly included a carry-back tax receivable of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CarryBackTaxReceivable" scale="3" id="f-393">333</ix:nonFraction> thousand received in February 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(3)  As of June 30,2024, the prepaid expenses includes include an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-394">879</ix:nonFraction>&#160;thousand (<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-395">1,005</ix:nonFraction> thousand as of December 31, 2023) relating to the guarantee fees in line with the <ix:nonFraction unitRef="loan_agreement" contextRef="c-65" decimals="INF" name="inpha:BorrowingNumberOfLoanAgreement" format="ixt-sec:numwordsen" scale="0" id="f-396">two</ix:nonFraction> State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. Following the extension of these <ix:nonFraction unitRef="loan_agreement" contextRef="c-65" decimals="INF" name="inpha:BorrowingNumberOfLoanAgreement" format="ixt-sec:numwordsen" scale="0" id="f-397">two</ix:nonFraction> loans repayment for an additional period, the full amount of the guarantee fee over the additional <ix:nonNumeric contextRef="c-66" name="inpha:BorrowingMaturity" format="ixt-sec:durwordsen" id="f-398">five-year</ix:nonNumeric> period has been recognized as an operating expense in 2022. For each period-end, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(4) As of December 31, 2023, the amount is mainly comprised of invoice of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-67" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-399">15,000</ix:nonFraction>&#160;thousand issued in December 2023 following the exercise of the license option by Sanofi. This amount was collected by the Company in January 2024.</span></div></ix:nonNumeric><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value.  No valuation allowance was recognized on trade receivables and others as the credit risk of each debtor was considered as not significant.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">6.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-400" continuedAt="f-400-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Intangible assets</span></ix:nonNumeric></div><ix:continuation id="f-400-1" continuedAt="f-400-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="f-401" continuedAt="f-401-1" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:42.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased licenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-68" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-402">1,556</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-69" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-70" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-405">1,556</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-410">2,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-413">2,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-418">2,651</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-421">2,651</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-71" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-72" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-73" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-74" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-426">903</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-75" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-76" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-429">903</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-77" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-430">413</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-78" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-431">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-79" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-433">416</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-446">294</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-447">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-449">297</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-80" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-81" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-82" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-83" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-454">119</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-84" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-85" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-457">119</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) This amount corresponds to the additional invoice received from Orega Biotech for the rights relating to IPH5201 following the first patient dosed in the Phase 2 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">MATISSE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> clinical trial in June 2023, in accordance to the agreement signed in 2019. This additional invoice is fully amortized as of June 30, 2023 and paid on July 2023. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:continuation id="f-401-1">(2) As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-458">294</ix:nonFraction>&#160;thousand. As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-459">2,000</ix:nonFraction>&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-460">651</ix:nonFraction>&#160;thousand.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Since their acquisition, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. The Company has reassessed the anticipated residual duration of the Phase 2 trials as of June&#160;30, 2024 and estimated that it would be fully amortized by 2024, which is the same estimation as of December&#160;31, 2023, as a result of the completion of some trials and by modifying the estimated end dates relating to certain cohorts. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The net book values of the monalizumab rights were &#8364;<ix:nonFraction unitRef="eur" contextRef="c-89" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-461">119</ix:nonFraction> thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-90" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-462">416</ix:nonFraction> thousand as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">IPH5201 (Anti-CD39) rights acquired from Orega Biotech</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On January&#160;4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. The upfront payment paid by the Company to Orega Biotech has been recognized as an intangible asset in the consolidated financial statements for the year ended December&#160;31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was recognized as an intangible asset in addition to the initial payment. In June 2019, the Company also paid Orega Biotech &#8364;<ix:nonFraction unitRef="eur" contextRef="c-91" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-463">7.0</ix:nonFraction>&#160;million in relation to the anti-CD39 program as consideration following the collaboration and option agreement signed on October&#160;22, 2018 with AstraZeneca regarding IPH5201. Under this agreement, the Company also paid in April and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-400-2"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">June 2020, respectively &#8364;<ix:nonFraction unitRef="eur" contextRef="c-92" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-464">2.5</ix:nonFraction>  and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-93" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-465">0.2</ix:nonFraction>&#160;million to Orega Biotech following the first Phase 1 dosing relating to IPH5201. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, Orega Biotech claimed joint ownership of certain patents relating to IPH5201. The Company and Orega Biotech have resolved these claims in an arbitration proceeding, which decision was rendered in December 2021. As a result of this decision, the Company is required to pay a low-teen percentage of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201. Following this arbitration decision, the Company paid in January 2022 an additional amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-94" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-466">0.4</ix:nonFraction>&#160;million to Orega. The Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancer, of which the Company will be a sponsor. In accordance with the amendment signed on June 1, 2022, the Company was eligible for a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-467">5</ix:nonFraction>&#160;million by AstraZeneca, received in August 2022 by the Company. In October 2022, the Company therefore paid an additional &#8364;<ix:nonFraction unitRef="eur" contextRef="c-96" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-468">0.6</ix:nonFraction>&#160;million to Orega Biotech. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On June 26, 2023, the Company announced the treatment of the first patient in the Phase 2 MATISSE trial, conducted in collaboration with AstraZeneca and evaluating IPH5201 in early-stage lung cancer. As a consequence, the Company made an additional payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-97" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-469">2.0</ix:nonFraction>&#160;million to Orega Biotech in July 2023, in accordance with the agreement signed in 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">At the agreement inception, an upfront payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-98" decimals="-6" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-470">40</ix:nonFraction>&#160;million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-99" decimals="-5" name="inpha:PaymentsForMilestone" format="ixt:num-dot-decimal" scale="6" id="f-471">1.0</ix:nonFraction>&#160;million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase II trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of June 30, 2024, according to the uncertainty of these potential future payments, <ix:nonFraction unitRef="eur" contextRef="c-100" decimals="INF" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="0" id="f-472">no</ix:nonFraction> liability was recognized.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Development costs incurred by the Company are recognized as research and development expenses.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, during 2022 fourth quarter, the Company was informed by the sponsor of the Phase 2 clinical trial evaluating avdoralimab in inflammation in bullous pemphigoid ("BP") indication of its decision to discontinue said trial. Consequently, the Company decided in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022). </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Following that decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of avdoralimab's intangible assets, based on expected future cash flows, as of December 2022, date of the decision. Thus, on decision date to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, avdoralimab rights were fully written down to their net book value, i.e &#8364;<ix:nonFraction unitRef="eur" contextRef="c-101" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-473">41,000</ix:nonFraction>&#160;thousand.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">7.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-474" continuedAt="f-474-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Property and equipment</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-475" escape="true"><ix:continuation id="f-474-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-102" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-476">4,242</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-103" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-477">4,298</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-104" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-479">8,542</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-105" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-480">6,423</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-481">31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-482">279</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-484">310</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-485">79</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-486">513</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-487">78</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-488">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-489">591</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-490">513</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-491">323</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-492">670</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-494">993</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-495">428</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-106" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-107" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-108" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-498">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-499">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-109" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-110" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-501">3,437</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-111" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-502">3,829</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-112" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-504">7,268</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-113" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-505">5,561</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-114" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-506">2,958</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-115" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-507">3,378</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-116" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-509">6,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-117" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-510">5,055</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-511">15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-512">267</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-513">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-514">285</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-515">37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-517">18</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-518">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-519">18</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-520">18</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-521">352</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-522">493</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-523">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-524">845</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-525">392</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-118" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-119" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-120" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-121" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-122" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-531">2,621</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-123" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-532">3,134</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-124" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="f-533">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-534">5,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-125" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-535">4,682</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-126" decimals="-5" sign="-" name="ifrs-full:ChangesInPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-536">0.5</ix:nonFraction>&#160;million and a lease liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-5" sign="-" name="inpha:IncreaseDecreaseInFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-537">0.7</ix:nonFraction>&#160;million.</span></div></ix:continuation></ix:nonNumeric><div id="i634ed0333ee247d7904463c2d5fd1df7_100"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">8.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="f-538" continuedAt="f-538-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Trade payables and others</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfTradePayablesAndOthersTextBlock" id="f-539" escape="true"><ix:continuation id="f-538-1" continuedAt="f-538-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Suppliers (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-540">8,751</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-541">8,561</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax and employee-related payables (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-542">6,013</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-543">7,021</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other payables (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-544">1,109</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-545">1,436</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Trade payables and others (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-546">15,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-547">17,018</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables related to capital expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:CurrentPayablesRelatedToCapitalExpenditures" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:CurrentPayablesRelatedToCapitalExpenditures" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-550">15,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-551">17,018</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As of December 31, 2023, tax and employee related payables included a liability accrual of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-5" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-552">1.4</ix:nonFraction>&#160;million following the notification received as part of the tax inspection relating to accounting and research tax credits for the 2018 to 2020 financial years. The liability recognized as of June 30, 2024 in connection with notification is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-5" name="ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-553">0.4</ix:nonFraction>&#160;million following the payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-128" decimals="-5" name="inpha:PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-554">0.7</ix:nonFraction>&#160;million in February 2024 and the offset of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="inpha:OffsetAgainstIncomeFromResearchTaxCredit2020" format="ixt:num-dot-decimal" scale="6" id="f-555">0.3</ix:nonFraction>&#160;million against the 2020 research tax credit receivable initially recognized for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-5" name="inpha:IncomeFromResearchTaxCredit2020" format="ixt:num-dot-decimal" scale="6" id="f-556">13.0</ix:nonFraction>&#160;million and finally collected in July 2024 for &#8364;<ix:nonFraction unitRef="eur" contextRef="c-129" decimals="-5" name="inpha:IncomeFromResearchTaxCredit2020Receivable" format="ixt:num-dot-decimal" scale="6" id="f-557">12.7</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of June 30, 2024 an December 31, 2023, this amount includes mainly the liability related to the payment of the guarantee fees on the <ix:nonFraction unitRef="loan" contextRef="c-2" decimals="INF" name="inpha:NumberOfStateGuaranteedLoans" format="ixt-sec:numwordsen" scale="0" id="f-558"><ix:nonFraction unitRef="loan" contextRef="c-3" decimals="INF" name="inpha:NumberOfStateGuaranteedLoans" format="ixt-sec:numwordsen" scale="0" id="f-559">two</ix:nonFraction></ix:nonFraction> State Guaranteed Loans obtained from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas in 2021 (see note 9).</span></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-538-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book value of trade payables and others is considered to be a reasonable approximation of their fair value.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_103"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">9.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-560" continuedAt="f-560-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Financial liabilities</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" id="f-561" continuedAt="f-561-1" escape="true"><ix:continuation id="f-560-1" continuedAt="f-560-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.280%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-130" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-562">20,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-565">2,432</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-131" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-566">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-567">17,568</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-133" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-568">8,700</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-570">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-571">1,070</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-134" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-573">7,630</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-136" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-574">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-575">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-576">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-577">14</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-137" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-579">13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage" (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-139" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-580">375</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-582">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-583">121</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-140" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-585">254</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-142" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-586">246</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-589">47</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-143" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" scale="3" id="f-590">8</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-591">207</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-592">109</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-595">83</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-597">26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-598">85</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-600">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-601">17</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-602">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-603">87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-604">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-605">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-606">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-607">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-609">13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-610">99</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-612">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-613">28</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-615">71</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-616">10,247</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-618">17</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-619">630</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-621">9,634</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-622">39,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-623">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-624">49</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-625">4,446</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" scale="3" id="f-626">8</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-627">35,503</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-628">20,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-632">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-633">20,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-163" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-634">8,700</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-637">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-165" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-639">8,700</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-640">15</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-643">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-645">15</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-646">1,353</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" sign="-" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-648">736</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-649">130</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-651">487</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-652">345</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-653">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-655">50</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" scale="3" id="f-656">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-174" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-657">297</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-175" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-658">287</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-661">89</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-662">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-177" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-663">198</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-664">33</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-666">48</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-667">13</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-669">70</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-181" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-670">27</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-671">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-673">4</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-675">23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-676">154</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-679">27</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-3" name="ifrs-full:FinancialLiabilities" scale="3" id="f-681">127</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-682">11,338</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-683">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-685">602</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-686">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-687">10,736</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-688">42,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-689">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-690">689</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" scale="3" id="f-691">916</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" scale="3" id="f-692">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-693">40,658</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(1) As a reminder, on January 5, 2022, the Company announced that it had obtained &#8364;<ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-694">28.7</ix:nonFraction>&#160;million in non-dilutive financing in the form of <ix:nonFraction unitRef="loan_agreement" contextRef="c-190" decimals="INF" name="inpha:BorrowingNumberOfLoanAgreement" format="ixt-sec:numwordsen" scale="0" id="f-695">two</ix:nonFraction> State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-191" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-696">20.0</ix:nonFraction>&#160;million) and BNP Paribas (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-192" decimals="-5" name="ifrs-full:NotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-697">8.7</ix:nonFraction>&#160;million). The Company received the funds related to these <ix:nonFraction unitRef="loan_agreement" contextRef="c-190" decimals="INF" name="inpha:BorrowingNumberOfLoanAgreement" format="ixt-sec:numwordsen" scale="0" id="f-698">two</ix:nonFraction> loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of <ix:nonNumeric contextRef="c-193" name="inpha:BorrowingMaturity" format="ixt-sec:durwordsen" id="f-699">one year</ix:nonNumeric> with an option to extend to <ix:nonNumeric contextRef="c-193" name="inpha:BorrowingMaturityExtensionPeriodOption" format="ixt-sec:durwordsen" id="f-700">five years</ix:nonNumeric> usable from August, 2022. They are <ix:nonFraction unitRef="number" contextRef="c-190" decimals="2" name="inpha:BorrowingPercentageOfStateGuaranteedLoan" scale="-2" id="f-701">90</ix:nonFraction>% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has </span></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-560-2" continuedAt="f-560-3"><ix:continuation id="f-561-1"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">requested the extension of these <ix:nonFraction unitRef="loan" contextRef="c-194" decimals="INF" name="inpha:BorrowingNumberOfLoanAgreement" format="ixt-sec:numwordsen" scale="0" id="f-702">two</ix:nonFraction> loans repayment for an additional period of <ix:nonNumeric contextRef="c-195" name="inpha:BorrowingMaturity" format="ixt-sec:durwordsen" id="f-703">five years</ix:nonNumeric> starting in 2022 and including a <ix:nonNumeric contextRef="c-195" name="inpha:BorrowingGracePeriod" format="ixt-sec:durwordsen" id="f-704">one-year</ix:nonNumeric> grace period. Consequently, the Company has obtained agreements from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are <ix:nonFraction unitRef="number" contextRef="c-196" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-705">1.56</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-197" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-706">0.95</ix:nonFraction>% for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees. The amortization of the <ix:nonFraction unitRef="loan" contextRef="c-198" decimals="INF" name="inpha:NumberOfLoans" format="ixt-sec:numwordsen" scale="0" id="f-707">two</ix:nonFraction> loans began in 2024 for a period of <ix:nonNumeric contextRef="c-198" name="inpha:BorrowingMaturity" format="ixt-sec:durwordsen" id="f-708">four years</ix:nonNumeric>. The state guarantee fees amounts to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-709">877</ix:nonFraction>&#160;thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-710">379</ix:nonFraction>&#160;thousand for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans respectively. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(2) On July 3, 2017, the Company borrowed from the Bank &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; in order to finance the construction of its future headquarters. This loan amounting to a maximum of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-3" name="inpha:LoanAgreementMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-711">15,200</ix:nonFraction>&#160;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-712"><ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-713">1,300</ix:nonFraction></ix:nonFraction>&#160;thousand.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-3" name="inpha:LoanAgreementCollateral" format="ixt:num-dot-decimal" scale="3" id="f-714">15,200</ix:nonFraction>&#160;thousand loan granted, for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-715">13,900</ix:nonFraction>&#160;thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (<ix:nonNumeric contextRef="c-204" name="inpha:BorrowingsMaturityPeriod" format="ixt-sec:duryear" id="f-716">12</ix:nonNumeric> years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June&#160;30, 2024, the remaining capital of the loan amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-717">9,617</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">thousand. The Company authorized collateral over financial &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; instruments amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-3" name="inpha:LoanAgreementCollateral" format="ixt:num-dot-decimal" scale="3" id="f-718">15,200</ix:nonFraction>&#160;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" format="ixt:num-dot-decimal" scale="3" id="f-719">4,200</ix:nonFraction>&#160;thousand in July 2024, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" format="ixt:num-dot-decimal" scale="3" id="f-720">5,000</ix:nonFraction>&#160;thousand in August 2027 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" format="ixt:num-dot-decimal" scale="3" id="f-721">6,000</ix:nonFraction>&#160;thousand in August 2031. Following the release of the pledge on the &#8364;<ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-5" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsReleased" scale="6" id="f-722">4.2</ix:nonFraction>m financial instrument that had reached maturity, the company received this amount in July 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This loan bears a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="c-208" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-723">2.01</ix:nonFraction>%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(3) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-5" sign="-" name="ifrs-full:ChangesInPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-724">0.5</ix:nonFraction>&#160;million and a lease liability of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-127" decimals="-5" sign="-" name="inpha:IncreaseDecreaseInFinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-725">0.7</ix:nonFraction>&#160;million.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" id="f-726" continuedAt="f-726-1" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June&#160;30, 2024:</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-726-1"><ix:continuation id="f-560-3"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">From 2nd to 5th year included</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over 5 years</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-727">5,167</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-728">12,918</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-729">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-132" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-730">18,086</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-731">2,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-732">5,551</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-135" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-734">7,773</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-736">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-737">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-138" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-738">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-739">254</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-740">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-741">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-141" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-742">254</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-222" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-743">100</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-744">111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-144" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-746">211</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-747">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-748">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-750">26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-751">34</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-752">59</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-753">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-754">92</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-755">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-756">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-757">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-758">13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-759">57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-760">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-761">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" scale="3" id="f-762">71</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-763">1,545</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-764">5,587</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-765">3,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-766">10,342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-767">9,414</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-768">24,245</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-769">3,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:BankBorrowingsUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-770">36,869</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_106"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">10.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="f-771" continuedAt="f-771-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Employee benefit</span></ix:nonNumeric></div><ix:continuation id="f-771-1" continuedAt="f-771-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory" id="f-772" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Defined benefit obligation</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for retirement defined benefit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="f-773">2,118</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="f-774">2,064</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for seniority awards</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="3" id="f-775">352</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="3" id="f-776">377</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Defined benefit obligations</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="f-777">2,470</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:DefinedBenefitObligationAtPresentValue" format="ixt:num-dot-decimal" scale="3" id="f-778">2,441</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" id="f-779" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Amounts recognized in the statement of financial position are determined as follows (in thousand euros):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-5" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-780">2,550</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-781">312</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" scale="3" id="f-782">27</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-56" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="f-783">394</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-784">2,441</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" scale="3" id="f-785">166</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" scale="3" id="f-786">22</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="f-787">116</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="f-788">2,470</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Discount rates used by the Company to evaluate retirement benefits were based on iBoxx Corporate AA. It was <ix:nonFraction unitRef="number" contextRef="c-243" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-789">3.60</ix:nonFraction>% and  <ix:nonFraction unitRef="number" contextRef="c-244" decimals="4" name="ifrs-full:ActuarialAssumptionOfDiscountRates" scale="-2" id="f-790">3.20</ix:nonFraction>% as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div></ix:continuation><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:continuation id="f-771-2">In addition, the impact of the 2023 pension reform (including the raising of the retirement age) has been recognized as a plan amendment within the meaning of IAS 19, recognized in the income statement and balance sheet with no material impact at June 30, 2023.</ix:continuation> </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">11.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" id="f-791" continuedAt="f-791-1" escape="true">Capital</ix:nonNumeric> </span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_112"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.1</span><ix:continuation id="f-791-1" continuedAt="f-791-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Share capital </span></ix:continuation></div><div style="padding-left:36pt"><span><br/></span></div><ix:continuation id="f-791-2" continuedAt="f-791-3"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June&#160;30, 2024, the Company&#8217;s share capital amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-42" decimals="0" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="0" id="f-792">4,049,075</ix:nonFraction> divided into (i) <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-793">80,967,407</ix:nonFraction> ordinary shares, each with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-247" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-794">0.05</ix:nonFraction>; (ii) <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-795">6,509</ix:nonFraction> &#8220;2016&#8221; preferred shares, each with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-248" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-796">0.05</ix:nonFraction>, and (iii) <ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-797">7,581</ix:nonFraction> &#8220;2017&#8221; preferred shares, each with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-249" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-798">0.05</ix:nonFraction>, respectively, fully paid up. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On October 21, 2019 and December 30, 2019, the retention period for the &#8220;2016 free preferred shares&#8221; has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the achievement of the performance criteria. Holders of &#8220;2016&#8221; preferred shares&#8221; are entitled to vote at our shareholders&#8217; meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The &#8220;2017 preferred shares&#8221; will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends.</span></div></ix:continuation><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:continuation id="f-791-3" continuedAt="f-791-4">In the six months ended June&#160;30, 2024, a capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="0" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="f-799">5,342</ix:nonFraction> occurred as a result of the Executive Board decision on June 10, 2024, subsequent to the creation of <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares" format="ixt:num-dot-decimal" scale="0" id="f-800">106,844</ix:nonFraction> ordinary shares following the set-up of a company saving plan for the benefit of the Company&#8217;s employees, including <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares" format="ixt:num-dot-decimal" scale="0" id="f-801">68,744</ix:nonFraction> ordinary shares issued free of charge (top-up). This event led to a net capital increase of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-38" decimals="0" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="f-802">5,342</ix:nonFraction> and an increase in share premium of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="0" name="inpha:ExerciseAndSubscriptionOfEquityInstruments" format="ixt:num-dot-decimal" scale="0" id="f-803">88,003</ix:nonFraction>, broken down as a creation of <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="INF" name="inpha:NumberOfEquityInstrumentsConvertedInOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="f-804">38,100</ix:nonFraction> ordinary shares, with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-248" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-805">0.05</ix:nonFraction>, for an issue price of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-253" decimals="2" name="inpha:ShareIssuedPricePerShare" scale="0" id="f-806">2.45</ix:nonFraction>, (ii) a creation of  <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares" format="ixt:num-dot-decimal" scale="0" id="f-807">68,744</ix:nonFraction> ordinary shares, with a nominal value of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-248" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-808">0.05</ix:nonFraction></ix:continuation>.</span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_115"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.2</span><ix:continuation id="f-791-4" continuedAt="f-791-5"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Treasury shares</span></ix:continuation></div><ix:continuation id="f-791-5" continuedAt="f-791-6"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company held <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" format="ixt:num-dot-decimal" scale="0" id="f-809"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" format="ixt:num-dot-decimal" scale="0" id="f-810">18,575</ix:nonFraction></ix:nonFraction> of its own shares as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_118"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.3</span><ix:continuation id="f-791-6" continuedAt="f-791-7"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Share based payments </span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-811" continuedAt="f-811-1" escape="true"><ix:continuation id="f-791-7" continuedAt="f-791-8"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants issued as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants void as of  6/30/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants exercised as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants outstanding as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maximum number of shares to be issued  as of  6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price per share (in &#8364;)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Sept. 9, 2011 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-812">650,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-813">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-814">625,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-815">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-816">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-255" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-817">2.04</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;May 27, 2013 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2012 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-818">146,050</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-819">12,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-820">133,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-821">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-822">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-253" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-823">2.04</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2015 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-824">1,050,382</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-825">2,720</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-826">1,940</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-827">1,045,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-828">1,045,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-258" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-829">7.20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;October 21, 2016 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-830">2,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="f-831">550</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="f-832">250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-833">1,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-834">156,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-260" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-835">-</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-811-1" continuedAt="f-811-2"><ix:continuation id="f-791-8" continuedAt="f-791-9"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-836">2,486</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="f-837">251</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="f-838">172</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-839">2,063</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-840">268,190</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-262" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-841">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-842">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-843">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-844">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-845">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-846">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-264" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-847">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-2 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-848">3,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-849">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-850">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-851">3,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-852">333,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-266" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-853">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-854">250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-855">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-856">250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-857">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-858">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-268" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-859">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-860">5,725</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-861">5,725</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-862">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-863">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-864">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-270" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-865">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-866">2,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-867">2,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-868">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-869">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-870">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-272" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-871">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2017 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-872">114,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-873">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-874">110,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-875">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-876">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-274" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-877">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-878">67,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="f-879">469</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-275" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-880">66,559</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-881">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-882">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-276" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-883">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Employees 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-884">327,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-885">224,375</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-886">103,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-887">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-888">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-278" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-889">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Management 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-890">260,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-891">150,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-892">110,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-893">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-894">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-280" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-895">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2018 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-896">90,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-897">5,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-281" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-898">85,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-899">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-900">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-282" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-901">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New Members 2017-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-902">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-903">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-904">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-905">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-284" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-906">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-284" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-907">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-908">57,376</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-909">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-910">57,376</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-911">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-912">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-286" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-913">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 13, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2020-1 &amp; 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-914">79,861</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-915">17,885</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-287" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-916">61,976</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-917">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-918">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-288" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-919">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-920">766,650</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-921">681,420</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-922">85,230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-290" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-923">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-290" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-924">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-290" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-925">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-926">710,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-927">580,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-928">130,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-929">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-930">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-292" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-931">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-932">125,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-933">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-934">125,748</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-935">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-936">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-294" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-937">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-938">1,066,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-939">290,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-940">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-941">775,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-942">775,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-296" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-943">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-944">610,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-945">130,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-946">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-947">480,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-948">480,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-298" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-949">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-950">138,960</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-951">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-952">138,960</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-953">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-954">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-300" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-955">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-956">128,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-957">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-958">128,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-302" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-959">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-302" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-960">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-302" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-961">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-962">1,371,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-963">275,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-964">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-965">1,096,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-966">1,096,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-304" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-967">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-968">550,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-969">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-970">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-971">550,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-972">550,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-306" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-973">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-974">163,293</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-975">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-976">163,293</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-977">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-978">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-308" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-979">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-980">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-981">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-982">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-310" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-983">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-310" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-984">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-310" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-985">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-986">1,403,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-987">66,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-988">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-312" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-989">1,337,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-312" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-990">1,337,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-312" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-991">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-992">750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-993">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-994">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-995">750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-996">750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-314" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-997">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 15, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2024-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-998">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-999">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1000">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-316" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1001">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-316" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1002">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-316" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-1003">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1004">68,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1005">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1006">68,744</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1007">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1008">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-318" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-1009">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 21, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock Options 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1010">102,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1011">102,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-319" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1012">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1013">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1014">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-320" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-1015">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Employees 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1016">546,700</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1017">375,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1018">171,550</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1019">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1020">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-322" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-1021">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Management 2019 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1022">355,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1023">207,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-323" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1024">147,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1025">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1026">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-324" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-1027">-</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 29, 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2011-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1028">225,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1029">25,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-325" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1030">200,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-326" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1031">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-326" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1032">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-326" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1033">1.77</ix:nonFraction>   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 17, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1034">237,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1035">12,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1036">225,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1037">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1038">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-328" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1039">2.36</ix:nonFraction>   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 16, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1040">150,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1041">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1042">75,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1043">75,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-330" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1044">75,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-330" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1045">8.65</ix:nonFraction>   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 27, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1046">70,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1047">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1048">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1049">70,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1050">70,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-332" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1051">9.59</ix:nonFraction>   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1052">14,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1053">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1054">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1055">14,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1056">14,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-334" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1057">14.05</ix:nonFraction>   </span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-811-2"><ix:continuation id="f-791-9"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 20, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1058">37,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1059">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1060">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-336" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1061">37,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-336" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1062">37,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-336" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1063">11.00</ix:nonFraction>   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 16, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1064">40,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1065">31,740</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1066">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1067">8,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1068">8,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-338" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1069">2.31</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 15, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1070">50,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1071">12,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1072">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-340" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1073">38,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-340" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1074">38,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-340" decimals="INF" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1075">2.26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-1076">12,914,414</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1077">3,239,985</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1078">3,340,434</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1079">6,333,995</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1080">7,084,922</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:0 1pt"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_121"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">12.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-1081" continuedAt="f-1081-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Financial instruments recognized in the statement of financial position and related effect on the income statement</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="f-1082" escape="true"><ix:continuation id="f-1081-1" continuedAt="f-1081-2"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1083">10,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1084">10,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1085">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1086">10,350</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1087">34,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1088">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1089">34,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1090">34,273</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1091">21,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1092">21,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1093">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-349" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1094">21,809</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1095">69,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1096">69,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1097">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1098">69,990</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1099">136,422</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1100">102,149</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1101">34,273</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1102">136,422</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1103">26,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1104">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1105">26,574</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1106">26,574</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1107">8,929</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1108">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1109">8,929</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1110">8,929</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1111">15,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1112">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1113">15,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1114">15,873</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1115">51,376</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1116">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1117">51,376</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1118">51,376</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1119">9,796</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1120">9,796</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1121">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1122">9,796</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1123">66,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1124">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1125">66,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1126">66,111</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1127">21,851</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1128">21,851</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1129">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1130">21,851</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1131">70,605</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1132">70,605</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1133">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1134">70,605</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1135">168,363</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-380" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1136">102,252</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1137">66,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1138">168,363</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1139">30,957</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1140">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1141">30,957</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1142">30,957</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1143">8,936</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-386" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1144">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1145">8,936</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1146">8,936</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1147">17,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1148">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1149">17,018</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1150">17,018</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1151">56,911</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:fixed-zero" scale="3" id="f-1152">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-1153">56,911</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1154">56,911</ix:nonFraction></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.</span></div></ix:continuation></ix:nonNumeric><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1081-2"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IFRS 7 and IFRS 13, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: fair value determined based on quoted prices in active markets for assets or liabilities;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_124"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">13.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-1155" continuedAt="f-1155-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Revenue and other income</span></ix:nonNumeric></div><div id="i634ed0333ee247d7904463c2d5fd1df7_127"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.1</span><ix:continuation id="f-1155-1" continuedAt="f-1155-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Revenue from collaboration and licensing agreements</span></ix:continuation></div><ix:continuation id="f-1155-2" continuedAt="f-1155-3"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-1156" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca, Sanofi and Takeda :</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:58.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1157">7,396</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1158">34,728</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which monalizumab agreement (AstraZeneca)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1159">2,994</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1160">9,503</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which 2016 Sanofi agreement</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1161">4,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1162">2,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-1163">199</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1164">18,672</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-1165">203</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="f-1166">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Takeda agreement </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="f-1167">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1168">4,553</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoicing of R&amp;D costs (IPH5201 agreement)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-1169">897</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-1170">616</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1171">8,293</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1172">35,344</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">a)  Revenue recognition related to monalizumab AZ agreements and amendments</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="f-1173" continuedAt="f-1173-1" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Change in deferred revenue relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1174">14,481</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1175">9,503</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-3" sign="-" name="inpha:TransferToFromCollaborationLiabilities" scale="3" id="f-1176">283</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1177">4,695</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1178">5,156</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1179">2,994</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-3" sign="-" name="inpha:TransferToFromCollaborationLiabilities" scale="3" id="f-1180">172</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1181">1,990</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1155-3" continuedAt="f-1155-4"><ix:continuation id="f-1173-1" continuedAt="f-1173-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Change in collaboration liabilities relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1182">63,211</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-3" name="inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="3" id="f-1183">283</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-3" name="inpha:DecreaseThroughDeductionsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1184">7,436</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1185">56,058</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1186">52,677</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-3" name="inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1187">1,891</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-3" name="inpha:DecreaseThroughDeductionsContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1188">2,419</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1189">52,149</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">b)  Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to IPH5201 for the six months ended June 30, 2024 and June 30, 2023 are <ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="0" id="f-1190"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="0" id="f-1191">nil</ix:nonFraction></ix:nonFraction>. As a reminder, the Company signed on June 1, 2022  an amendment to the initial contract signed in October 2018. This amendment set the terms of the collaboration following AstraZeneca&#8217;s decision to advance IPH5201 to a Phase 2 study. The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial. Under the terms of this agreement, an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-3" name="inpha:ExternalCostsRelatedToTheClinicalTrial" scale="3" id="f-1192">897</ix:nonFraction> thousand was rebilled to AstraZeneca during the first half of 2024 (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-3" name="inpha:ExternalCostsRelatedToTheClinicalTrial" scale="3" id="f-1193">616</ix:nonFraction> thousand during the first half of 2023).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">c)  Revenue related to IPH6401 - Sanofi (2016)</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to IPH6401 under the collaboration and license agreement signed with Sanofi is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1194">4,000</ix:nonFraction>&#160;thousand for the six months ended June 30, 2024, as compared to a revenue of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-1195">2,000</ix:nonFraction>&#160;thousand as of June 30, 2023. During the period, the Company announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs. Under the terms of the 2016 research and licensing agreement with Sanofi, dosing of the first patient in the dose expansion part of the trial triggered a milestone payment to the Company of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-6" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-1196">4</ix:nonFraction>&#160;million recognized as revenue as of June 30, 2024. This amount was received by the Company on May 17, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, the Company announced that, in June 2023, the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial evaluating IPH6401/SAR'514 in relapsed or refractory Multiple Myeloma. Under the terms of the licensing agreement signed in 2016, Sanofi made a milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-3" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="3" id="f-1197">2,000</ix:nonFraction>&#160;thousand, fully recognized in revenue as of June 30, 2023. This amount was received by the Company on July 21, 2023. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d)  Revenue related to Sanofi research collaboration and licensing agreement (2022)</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On January 25, 2023, the Company announced the expiration of the waiting period under the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Hart-Scott-Rodino</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> (HSR) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Antitrust Improvements Act</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, under the terms of such agreement, the Company received an upfront payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived" format="ixt:num-dot-decimal" scale="3" id="f-1198">25,000</ix:nonFraction>&#160;thousand in March 2023, including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" format="ixt:num-dot-decimal" scale="3" id="f-1199">18,500</ix:nonFraction>&#160;thousand for the exclusive license, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" format="ixt:num-dot-decimal" scale="3" id="f-1200">1,500</ix:nonFraction>&#160;thousand for the research work and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" format="ixt:num-dot-decimal" scale="3" id="f-1201">5,000</ix:nonFraction>&#160;thousand for the <ix:nonFraction unitRef="target_option" contextRef="c-419" decimals="INF" name="inpha:NumberOfTargetOptions" format="ixt-sec:numwordsen" scale="0" id="f-1202">two</ix:nonFraction> additional targets options. On December 19, 2023, the Company announced that Sanofi had exercised an option for <ix:nonFraction unitRef="option" contextRef="c-420" decimals="INF" name="inpha:NumberOfOptionsExcercisedForLicenses" format="ixt-sec:numwordsen" scale="0" id="f-1203">one</ix:nonFraction> of the <ix:nonFraction unitRef="option" contextRef="c-421" decimals="INF" name="inpha:NumberOfExclusiveOptionsGranted" format="ixt-sec:numwordsen" scale="0" id="f-1204">two</ix:nonFraction> targets. This option exercise also resulted in a </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1155-4" continuedAt="f-1155-5"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">milestone payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-3" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" format="ixt:num-dot-decimal" scale="3" id="f-1205">15,000</ix:nonFraction>&#160;thousand, including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" format="ixt:num-dot-decimal" scale="3" id="f-1206">13,300</ix:nonFraction> thousand in respect of the exclusive license, which was fully recognized in income as of December 31, 2023, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" format="ixt:num-dot-decimal" scale="3" id="f-1207">1,700</ix:nonFraction>&#160;thousand for the research activities to be carried out by the Company. The Company considers that the license to the B7-H3 technology is a right to use the intellectual property granted exclusively to Sanofi from the effective date of the agreement. As such, all upfront payments relating to the licenses granted have been recognized in the income statement representing an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived" format="ixt:num-dot-decimal" scale="3" id="f-1208">31,800</ix:nonFraction>&#160;thousand, including &#8364;<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-5" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" format="ixt:num-dot-decimal" scale="6" id="f-1209">18.5</ix:nonFraction>&#160;million  relating to B7-H3 license and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-3" name="inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" format="ixt:num-dot-decimal" scale="3" id="f-1210">13,300</ix:nonFraction>&#160;thousand following the option exercised.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1173-2" continuedAt="f-1173-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in deferred revenue relating to the 2022 research collaboration and licensing agreement : </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1211">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-3" name="inpha:RevenueFromContractsWithCustomersMilestone" format="ixt:num-dot-decimal" scale="3" id="f-1212">6,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="3" id="f-1213">172</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1214">6,328</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1215">5,327</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-3" name="inpha:RevenueFromContractsWithCustomersMilestone" format="ixt:fixed-zero" scale="3" id="f-1216">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="3" id="f-1217">402</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1218">4,925</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:continuation id="f-1173-3">(1) The increase in deferred revenue relating to the 2022 research collaboration and licensing agreement with Sanofi between December 31, 2022 and June 30, 2023 mainly comprises (i) an upfront payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" format="ixt:num-dot-decimal" scale="3" id="f-1219">5,000</ix:nonFraction>&#160;thousand relating to the granting of <ix:nonFraction unitRef="target_option" contextRef="c-432" decimals="INF" name="inpha:NumberOfTargetOptions" format="ixt-sec:numwordsen" scale="0" id="f-1220">two</ix:nonFraction> options for exclusive licenses on Innate's intellectual property for the research, development, manufacturing and commercialization of NKCEs specifically targeting <ix:nonFraction unitRef="preclinicalmolecule" contextRef="c-433" decimals="INF" name="inpha:NumberOfPreclinicalMolecules" format="ixt-sec:numwordsen" scale="0" id="f-1221">two</ix:nonFraction> preclinical molecules. The Company will recognize the related revenues either at the reporting date or <ix:nonNumeric contextRef="c-431" name="inpha:RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" format="ixt-sec:durwordsen" id="f-1222">three years</ix:nonNumeric> after the effective date; as well as (ii) an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-3" name="inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" format="ixt:num-dot-decimal" scale="3" id="f-1223">1,500</ix:nonFraction>&#160;thousand relating to research activities to perform in collaboration with Sanofi. The Company will recognize the related revenues on a straight-line basis over the duration of the research work to which the Company has agreed.</ix:continuation> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e)  <ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfVarianceOfDeferredRevenueTableTextBlock" id="f-1224" continuedAt="f-1224-1" escape="true">Schedule of variance of deferred revenue </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1224-1"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-434" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1225">5,155</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1226">2,994</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1227">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-3" sign="-" name="inpha:TransferFromToCollaborationLiabilities" scale="3" id="f-1228">172</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-436" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1229">1,990</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-437" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1230">2,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1231">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1232">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-3" name="inpha:TransferFromToCollaborationLiabilities" format="ixt:fixed-zero" scale="3" id="f-1233">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1234">2,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1235">2,826</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="3" id="f-1236">402</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1237">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-3" name="inpha:TransferFromToCollaborationLiabilities" format="ixt:fixed-zero" scale="3" id="f-1238">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-442" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1239">2,424</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1240">10,481</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1241">3,396</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1242">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-3" sign="-" name="inpha:TransferFromToCollaborationLiabilities" scale="3" id="f-1243">172</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1244">6,915</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:24.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1245">14,481</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1246">9,503</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1247">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-3" sign="-" name="inpha:TransferFromToCollaborationLiabilities" scale="3" id="f-1248">283</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1249">4,696</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1250">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1251">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1252">5,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-3" name="inpha:TransferFromToCollaborationLiabilities" format="ixt:fixed-zero" scale="3" id="f-1253">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1254">5,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-452" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-1255">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" scale="3" id="f-1256">172</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1257">1,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-3" name="inpha:TransferFromToCollaborationLiabilities" format="ixt:fixed-zero" scale="3" id="f-1258">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-454" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1259">1,328</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1260">14,481</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1261">9,675</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-3" name="inpha:IncreaseThroughUpfrontPaymentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1262">5,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-3" sign="-" name="inpha:TransferFromToCollaborationLiabilities" scale="3" id="f-1263">283</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-457" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1264">11,024</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.2</span><ix:continuation id="f-1155-5" continuedAt="f-1155-6"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Government financing for research expenditures</span></ix:continuation></div><ix:continuation id="f-1155-6"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company receives grants from the European Commission, French government and state organizations in several different forms:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Research Tax Credits; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"> Investment and operating grants.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024 and 2023, an estimate of the research tax credit amount for the first half period is calculated on the basis of eligible expenses over the period. </span></div><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" id="f-1265" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-1266">4,050</ix:nonFraction> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:IncomeFromResearchTaxCredit" format="ixt:num-dot-decimal" scale="3" id="f-1267">4,854</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" scale="3" id="f-1268">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RevenueFromGovernmentGrants" format="ixt:fixed-zero" scale="3" id="f-1269">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government financing for research expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:GovernmentFinancingForResearchExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-1270">4,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:GovernmentFinancingForResearchExpenditures" format="ixt:num-dot-decimal" scale="3" id="f-1271">4,854</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_133"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">14.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="f-1273" continuedAt="f-1273-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfExpensesExplanatory" id="f-1272" continuedAt="f-1272-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Operating expenses</span></ix:nonNumeric></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="f-1273-1" continuedAt="f-1273-2"><ix:continuation id="f-1272-1" continuedAt="f-1272-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.476%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="9" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subcontracting costs(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1274">15,585</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:fixed-zero" scale="3" id="f-1275">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1276">15,585</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1277">15,857</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:fixed-zero" scale="3" id="f-1278">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:SubcontractingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1279">15,857</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of supplies and consumable materials</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1280">1,485</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="f-1281">153</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1282">1,638</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1283">1,410</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="f-1284">100</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:RawMaterialsAndConsumablesUsed" format="ixt:num-dot-decimal" scale="3" id="f-1285">1,510</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel expenses other than share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1286">7,532</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1287">3,470</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1288">11,002</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1289">7,781</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1290">3,871</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1291">11,652</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-1292">1,175</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="f-1293">531</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-1294">1,706</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="f-1295">905</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="f-1296">496</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-1297">1,401</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Personnel expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1298">8,707</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1299">4,001</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1300">12,708</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1301">8,686</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1302">4,367</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1303">13,053</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-scientific advisory and consulting(2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" scale="3" id="f-1304">124</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" format="ixt:num-dot-decimal" scale="3" id="f-1305">1,934</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" format="ixt:num-dot-decimal" scale="3" id="f-1306">2,058</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" scale="3" id="f-1307">532</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" format="ixt:num-dot-decimal" scale="3" id="f-1308">1,662</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:NonScientificAdvisoryAndConsulting" format="ixt:num-dot-decimal" scale="3" id="f-1309">2,194</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leasing and maintenance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:LeasingAndMaintenance" scale="3" id="f-1310">490</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:LeasingAndMaintenance" scale="3" id="f-1311">710</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:LeasingAndMaintenance" format="ixt:num-dot-decimal" scale="3" id="f-1312">1,200</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:LeasingAndMaintenance" scale="3" id="f-1313">470</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:LeasingAndMaintenance" scale="3" id="f-1314">445</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:LeasingAndMaintenance" scale="3" id="f-1315">915</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Travel expenses and meeting attendance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1316">272</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1317">151</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1318">423</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1319">180</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1320">143</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:TravelExpense" scale="3" id="f-1321">323</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing, communication and public relations</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1322">16</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1323">164</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1324">180</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1325">34</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1326">142</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="f-1327">176</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Scientific advisory and consulting(3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" scale="3" id="f-1328">933</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" format="ixt:fixed-zero" scale="3" id="f-1329">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" scale="3" id="f-1330">933</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" scale="3" id="f-1331">561</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" format="ixt:fixed-zero" scale="3" id="f-1332">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ScientificAdvisoryAndConsulting" scale="3" id="f-1333">561</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other purchases and external expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" scale="3" id="f-1334">10</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1335">1,125</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1336">1,135</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" scale="3" id="f-1337">13</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1338">1,153</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:OtherPurchasesAndExternalExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1339">1,166</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="f-1340">643</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="f-1341">503</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1342">1,146</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1343">3,044</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="f-1344">601</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:DepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1345">3,645</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intellectual property expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1346">568</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1347">128</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1348">696</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1349">570</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1350">68</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:IntellectualPropertyExpenses" scale="3" id="f-1351">638</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income and (expenses), net</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1352">242</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1353">714</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1354">956</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1355">98</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1356">464</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-1357">562</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1358">29,076</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1359">9,582</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1360">38,657</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1361">31,453</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1362">9,144</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1363">40,597</ix:nonFraction>)</span></td></tr></table></div><div style="text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26pt">The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. </span></div></ix:continuation></ix:continuation><div style="text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1273-2"><ix:continuation id="f-1272-2" continuedAt="f-1272-3"><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.</span></div></ix:continuation></ix:continuation><div id="i634ed0333ee247d7904463c2d5fd1df7_136"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.1</span><ix:continuation id="f-1272-3" continuedAt="f-1272-4"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Personnel expenses other than share-based compensation</span></ix:continuation></div><div style="padding-left:36pt"><span><br/></span></div><ix:continuation id="f-1272-4" continuedAt="f-1272-5"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The line item amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1364">11,002</ix:nonFraction>&#160;thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ShorttermEmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1365">11,652</ix:nonFraction>&#160;thousand for the six months ended June&#160;30, 2024 and 2023 respectively. The Company had <ix:nonFraction unitRef="employee" contextRef="c-2" decimals="2" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1366">168</ix:nonFraction> full time equivalent employees as of June&#160;30, 2024, compared to <ix:nonFraction unitRef="employee" contextRef="c-6" decimals="2" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1367">191</ix:nonFraction> as of June&#160;30, 2023. June 30, 2024, we had <ix:nonFraction unitRef="employee" contextRef="c-462" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1368">135</ix:nonFraction> employees, in research and development functions, compared to <ix:nonFraction unitRef="employee" contextRef="c-463" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1369">151</ix:nonFraction> employees as of June 30, 2023. Meanwhile, the administrative staff, totaled <ix:nonFraction unitRef="employee" contextRef="c-464" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1370">39</ix:nonFraction> people, compared to <ix:nonFraction unitRef="employee" contextRef="c-465" decimals="INF" name="ifrs-full:NumberOfEmployees" scale="0" id="f-1371">45</ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_139"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.2</span><ix:continuation id="f-1272-5" continuedAt="f-1272-6"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Depreciation and amortization</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1272-6" continuedAt="f-1272-7"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-87" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1372">2,000</ix:nonFraction>&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-88" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1373">651</ix:nonFraction>&#160;thousand. As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of  &#8364;<ix:nonFraction unitRef="eur" contextRef="c-86" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1374">294</ix:nonFraction>&#160;thousand .  (see Note 6).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_142"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.3</span><ix:continuation id="f-1272-7" continuedAt="f-1272-8"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Cost of suppliers and consumable materials</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1272-8"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company&#8217;s drug substance and/or drug product that is manufactured by third-parties, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_148"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">15.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="f-1375" continuedAt="f-1375-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Net financial income / (loss)</span></ix:nonNumeric></div><ix:continuation id="f-1375-1"><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock" id="f-1376" escape="true"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net financial income (loss) can be analyzed as follows :</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interests on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:InterestsAndGainsOnFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-1377">1,269</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:InterestsAndGainsOnFinancialAssets" scale="3" id="f-1378">965</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in valuation allowance on financial instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:ChangeInValuationAllowanceOfFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1379">1,471</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:ChangeInValuationAllowanceOfFinancialInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1380">1,044</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:NetForeignExchangeGain" scale="3" id="f-1381">873</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:NetForeignExchangeGain" format="ixt:num-dot-decimal" scale="3" id="f-1382">1,073</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-1383">3,613</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-1384">3,083</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1385">1,763</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:NetForeignExchangeLoss" scale="3" id="f-1386">642</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized losses on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:UnrealizedLossesOnFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1387">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:UnrealizedLossesOnFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-1388">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest on financial liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpense" scale="3" id="f-1389">300</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:InterestExpense" scale="3" id="f-1390">324</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1391">2,064</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceCosts" scale="3" id="f-1392">966</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-1393">1,549</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:FinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-1394">2,116</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For the six months ended June&#160;30, 2024 and 2023, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the US dollar on US dollars denominated cash and cash equivalent and financial assets accounts.   </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">16.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-1395" continuedAt="f-1395-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Income tax / (expense)</span></ix:nonNumeric></div><ix:continuation id="f-1395-1"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Due to the Company&#8217;s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. The main temporary differences are related to the application of the IFRS 15 standard for fiscal years beginning on or after January 1, 2018, finance leases, provisions for pension commitments and tax loss carryforwards.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company did <ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:fixed-zero" scale="0" id="f-1396">not</ix:nonFraction> recognize a current tax expense as of June&#160;30, 2024 regarding a projected tax rate of <ix:nonFraction unitRef="number" contextRef="c-466" decimals="2" name="ifrs-full:ApplicableTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1397">nil</ix:nonFraction> as of December 31, 2024.  As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma SA were &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:UnusedTaxLossesWithNoExpirationDate" format="ixt:num-dot-decimal" scale="3" id="f-1398"><ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:UnusedTaxLossesWithNoExpirationDate" format="ixt:num-dot-decimal" scale="3" id="f-1399">483,570</ix:nonFraction></ix:nonFraction> thousand with no expiration date (same amount as of December 31, 2023). As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma Inc was &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="inpha:UnusedTaxLossesSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-1400"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:UnusedTaxLossesSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-1401">15,181</ix:nonFraction></ix:nonFraction> thousand or $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="inpha:UnusedTaxLossesSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-1402"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="inpha:UnusedTaxLossesSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-1403">16,775</ix:nonFraction></ix:nonFraction> thousand (same amount as of December 31, 2023).</span></div></ix:continuation><div id="i634ed0333ee247d7904463c2d5fd1df7_154"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">17.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="f-1404" continuedAt="f-1404-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Commitments, contingencies and litigation</span></ix:nonNumeric></div><div id="i634ed0333ee247d7904463c2d5fd1df7_157"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.1</span><ix:continuation id="f-1404-1" continuedAt="f-1404-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Commitments</span></ix:continuation></div><ix:continuation id="f-1404-2" continuedAt="f-1404-3"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has identified the following changes in off-balance sheet commitments since December 31, 2023:</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt">non-cancellable purchase commitments as of June&#160;30, 2024 for a total of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:NonCancellableOffBalanceSheetPurchasedCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1405">6,612</ix:nonFraction> thousand with various CMOs. These commitments are comprised of non-cancellable purchase orders placed during the first half of 2024 with contract manufacturing organizations (CMOs) for the supply of various services in relation with preclinical work for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-3" name="inpha:NonCancellableOffBalanceSheetPurchasedCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1406">3,020</ix:nonFraction>&#160;thousand and clinical work for an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-3" name="inpha:NonCancellableOffBalanceSheetPurchasedCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1407">3,592</ix:nonFraction>&#160;thousand. The execution and billing of these services has not yet started at the date of this report.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt">financial commitments with Soci&#233;t&#233; G&#233;n&#233;rale in connection with the Company&#8217;s subscription of a loan in order to finance the construction of its future headquarters. As security for the loan, the Company pledged collateral in the form of financial instruments held at Soci&#233;t&#233; G&#233;n&#233;rale amounting to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-5" name="inpha:LoanAgreementCollateral" scale="6" id="f-1408">15.2</ix:nonFraction> million. The security interest on the pledged financial instruments will be released in accordance with the following schedule: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" format="ixt:num-dot-decimal" scale="3" id="f-1409">4,200</ix:nonFraction> thousand in July 2024, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" format="ixt:num-dot-decimal" scale="3" id="f-1410">5,000</ix:nonFraction> thousand in August 2027 and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" format="ixt:num-dot-decimal" scale="3" id="f-1411">6,000</ix:nonFraction> thousand in August 2031. At the date of this report, the first investment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-3" name="inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" format="ixt:num-dot-decimal" scale="3" id="f-1412">4,200</ix:nonFraction> thousand had matured and the Company obtained its restitution in July 2024 for a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-3" name="inpha:SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1413">4,427</ix:nonFraction> thousand, including interest. As of June 30, 2024, the remaining capital of this loan amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1414">9,617</ix:nonFraction> thousand.  Furthermore, under the loan, Innate is subject to a covenant that its total cash, cash equivalents and current and non-current financial assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. The Company was in compliance with this covenant as of December 31, 2023.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_160"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.2</span><ix:continuation id="f-1404-3" continuedAt="f-1404-4"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Contingencies and litigations</span></ix:continuation></div><ix:continuation id="f-1404-4" continuedAt="f-1404-5"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company is exposed to contingent liabilities happening in the ordinary course of its activities. Each pre-litigation, known litigation or procedure in course the Company is involved in is analyzed at each closing date after consultation of legal counsel. There is no acknowledged litigation as of June&#160;30, 2024.</span></div></ix:continuation><div><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_163"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.3</span><ix:continuation id="f-1404-5" continuedAt="f-1404-6"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Provisions</span></ix:continuation></div><ix:continuation id="f-1404-6" continuedAt="f-1404-7"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Provisions amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:Provisions" scale="3" id="f-1415">669</ix:nonFraction> thousand and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-3" decimals="-3" name="ifrs-full:Provisions" scale="3" id="f-1416">774</ix:nonFraction> thousand as of June&#160;30, 2024 and December 31, 2023, respectively. As of June&#160;30, 2024, they mainly consist of provision for charges amounting &#8364;<ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-3" name="ifrs-full:Provisions" scale="3" id="f-1417">586</ix:nonFraction> thousand relating to the employer contribution in respect of the grants of employee equity instruments. In accordance with French </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1404-7" continuedAt="f-1404-8"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">social legislation, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan.</span></div></ix:continuation><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"><ix:continuation id="f-1404-8">As a reminder, on March 16, 2022, the Company received a notice of a tax inspection by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2018 financial years 2020. On February 13, 2024, the Company was informed of the tax authorities conclusions regarding the tax inspection. A definitive amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-3" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-1418">1,367</ix:nonFraction>&#160;thousand was determined and classified as short-term tax liabilities as of December 31, 2023. During the first half of 2024, the Company made a payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:PaymentOfTaxesOtherThanIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-1419">693</ix:nonFraction>&#160;thousand.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_166"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">18.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-1420" continuedAt="f-1420-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Related party transactions</span></ix:nonNumeric></div><ix:continuation id="f-1420-1" continuedAt="f-1420-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">Members of the Executive Board and Other Executive Members </span></div><ix:nonNumeric contextRef="c-1" name="inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" id="f-1421" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel and other short-term employee benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1422">1,713</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1423">1,386</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Extra pension benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-1424">21</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="f-1425">11</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="f-1426">519</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="3" id="f-1427">408</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advisory fees </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="inpha:KeyManagementPersonnelCompensationAdvisoryFees" format="ixt:fixed-zero" scale="3" id="f-1428">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="inpha:KeyManagementPersonnelCompensationAdvisoryFees" scale="3" id="f-1429">318</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Executive Board Members and other Executive Members compensation</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1430">2,253</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1431">2,123</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Personnel and other short-term employee benefits correspond to amounts included in personnel expenses for the six-month periods ended June&#160;30, 2024 and 2023 respectively.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company has also recognized expenses totaling &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ProvisionForExpensesWithRelatedParties" scale="3" id="f-1432">184</ix:nonFraction> thousand with companies in which a mandate is held by the identified related parties.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Members of the Supervisory Board</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company recognized a provision of  &#8364;<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="inpha:ProvisionForAttendanceFees" scale="3" id="f-1433">163</ix:nonFraction> thousand for attendance fees (jetons de presence) relating to the six months ended June&#160;30, 2024. This amount includes the compensation for the Chairman of the Supervisory Board.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Related parties</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Novo Nordisk A/S is a shareholder, Supervisory Board member and is related to the Company by <ix:nonFraction unitRef="licensing_agreement" contextRef="c-472" decimals="INF" name="inpha:NumberOfLicensingAgreementsWithRelatedParties" format="ixt-sec:numwordsen" scale="0" id="f-1434">three</ix:nonFraction> licensing agreements related to the drug candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. As of June&#160;30, 2024, the Company has <ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="0" id="f-1435">no</ix:nonFraction> liability to Novo Nordisk A/S.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab and IPH5201). <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-1436" continuedAt="f-1436-1" escape="true">The payments between the two companies as well as the liabilities and receivables as of June&#160;30, 2024 are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-1420-2"><ix:continuation id="f-1436-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,2024</span></td></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets/Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collection (AstraZeneca to the Company) / Receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1437">1,657</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="f-1438">394</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (the Company to AstraZeneca) / Liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1439">3,342</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1440">3,926</ix:nonFraction>) </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" name="ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1441">1,685</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-2" decimals="-3" sign="-" name="inpha:NetAmountsReceivablePayableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="f-1442">3,532</ix:nonFraction>)</span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The business relationships between the Company and its subsidiary are governed by intra-group and commercial agreements, concluded at market standard conditions on an arm&#8217;s length basis.</span></div></ix:continuation><div id="i634ed0333ee247d7904463c2d5fd1df7_169"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">19.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-1443" continuedAt="f-1443-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Income / (loss) per share </span></ix:nonNumeric></div><div id="i634ed0333ee247d7904463c2d5fd1df7_172"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.1</span><ix:continuation id="f-1443-1" continuedAt="f-1443-2"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Basic income / (loss) per share</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-1444" continuedAt="f-1444-1" escape="true"><ix:continuation id="f-1443-2" continuedAt="f-1443-3"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"/><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1445">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1446">1,718</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1447">80,872,369</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1448">80,319,897</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Basic income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1449">0.31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1450">0.02</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_175"></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.2</span><ix:continuation id="f-1443-3" continuedAt="f-1443-4"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Diluted income / (loss) per share</span></ix:continuation></div><ix:continuation id="f-1444-1"><ix:continuation id="f-1443-4"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;In thousands of euro, except for data share</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss) for the period</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1451">24,764</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-4" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1452">1,718</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1453">80,872,369</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1454">80,319,897</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustment for share instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="f-1455">5,026,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" format="ixt:num-dot-decimal" scale="0" id="f-1456">3,461,439</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diluted income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1457">0.31</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-4" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1458">0.02</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i634ed0333ee247d7904463c2d5fd1df7_178"></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%">20.</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-1459" continuedAt="f-1459-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Events after the reporting date</span></ix:nonNumeric></div><ix:continuation id="f-1459-1"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On July 25, 2024, the Company received from Takeda a notice of termination of the Exclusive License agreement signed on March 31, 2023. This termination will be effective upon expiry of a 90-day notice period, i.e. on October 24, 2024.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_181"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:140%">STATUTORY AUDITORS' REVIEW REPORT ON THE HALF-YEARLY FINANCIAL INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">This is a free translation into English of the statutory auditors&#8217; review report on the half-yearly financial information issued in French and is provided solely for the convenience of English-speaking users. This report includes information relating to the specific verification of information given in the Group&#8217;s half-yearly management report. This report should be read in conjunction with, and construed in accordance with, French law and professional standards applicable in France.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders of INNATE PHARMA,</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In compliance with the assignment entrusted to us by your Annual General Meeting and in accordance with the requirements of article L.451-1-2 III of the French Monetary and Financial Code (&#8220;Code mon&#233;taire et financier&#8221;), we hereby report to you on:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:13.02pt">the review of the accompanying condensed half-yearly consolidated financial statements of Innate Pharma, for the period from January 1, 2024 to June 30, 2024;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:13.02pt">the verification of the information presented in the half-yearly management report.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These condensed half-yearly consolidated financial statements are the responsibility of the Executive Board. Our role is to express a conclusion on these financial statements based on our review. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conclusion on the financial statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our review in accordance with professional standards applicable in France. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34- standard of the IFRSs as adopted by the European Union applicable to interim financial information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Specific verification</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also verified the information presented in half-yearly</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">management report on the condensed half-yearly</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consolidated financial statements subject to our review. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have no matters to report as to its fair presentation and consistency with the condensed half-yearly</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Neuilly-sur-Seine and Paris-La D&#233;fense, September 11, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Statutory Auditors</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:150%">French original signed by</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">                          PricewaterhouseCoopers Audit&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                           Deloitte &amp; Associ&#233;s <br/>                       </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;          </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C&#233;dric Mazille&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                                           St&#233;phane MENARD</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i634ed0333ee247d7904463c2d5fd1df7_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:140%">DECLARATION BY THE PERSON RESPONSIBLE FOR THIS HALF-YEAR FINANCIAL REPORT </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">I hereby declare, to the best of my knowledge, that the condensed consolidated interim financial statements for the six months ended June 30, 2024 have been prepared in accordance with applicable accounting standards and give a true and fair view of the assets, liabilities, financial position and results of the Company and the subsidiaries included in the consolidation, and that the half year management reviews stated on page </span><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline" href="#i634ed0333ee247d7904463c2d5fd1df7_13">5</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> gives a fair description of the material events that occurred in the first six months of the financial year and their impact on the interim financial statements, as well as a description of the principal risks and uncertainties for the remaining six months of the year, along with the principal transactions with related parties.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Chairman of the Executive Board</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Mr Herv&#233; Brailly</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma</span><span style="color:#262626;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> |Half-year financial report June&#160;30, 2024 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">| </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>inpha-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:inpha="http://www.innate-pharma.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.innate-pharma.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inpha-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inpha-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inpha-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inpha-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.innate-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimCondensedConsolidatedStatementsofFinancialPosition" roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition">
        <link:definition>9952151 - Statement - Interim Condensed Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimCondensedConsolidatedStatementsofIncomeLoss" roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss">
        <link:definition>9952152 - Statement - Interim Condensed Consolidated Statements of Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>9952153 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimCondensedConsolidatedStatementsofCashFlows" roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952154 - Statement - Interim Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimConsolidatedStatementofChangesinShareholdersEquity" roleURI="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity">
        <link:definition>9952155 - Statement - Interim Consolidated Statement of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandkeyevents" roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyevents">
        <link:definition>9952156 - Disclosure - The Company and key events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandstatementofcompliance" roleURI="http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance">
        <link:definition>9952157 - Disclosure - Basis of presentation and statement of compliance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Managementoffinancialrisks" roleURI="http://www.innate-pharma.com/role/Managementoffinancialrisks">
        <link:definition>9952158 - Disclosure - Management of financial risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets" roleURI="http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets">
        <link:definition>9952159 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradereceivablesandothers" roleURI="http://www.innate-pharma.com/role/Tradereceivablesandothers">
        <link:definition>9952160 - Disclosure - Trade receivables and others</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://www.innate-pharma.com/role/Intangibleassets">
        <link:definition>9952161 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyandequipment" roleURI="http://www.innate-pharma.com/role/Propertyandequipment">
        <link:definition>9952162 - Disclosure - Property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tradepayablesandothers" roleURI="http://www.innate-pharma.com/role/Tradepayablesandothers">
        <link:definition>9952163 - Disclosure - Trade payables and others</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialliabilities" roleURI="http://www.innate-pharma.com/role/Financialliabilities">
        <link:definition>9952164 - Disclosure - Financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Employeebenefit" roleURI="http://www.innate-pharma.com/role/Employeebenefit">
        <link:definition>9952165 - Disclosure - Employee benefit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capital" roleURI="http://www.innate-pharma.com/role/Capital">
        <link:definition>9952166 - Disclosure - Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement" roleURI="http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement">
        <link:definition>9952167 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenueandotherincome" roleURI="http://www.innate-pharma.com/role/Revenueandotherincome">
        <link:definition>9952168 - Disclosure - Revenue and other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Operatingexpenses" roleURI="http://www.innate-pharma.com/role/Operatingexpenses">
        <link:definition>9952169 - Disclosure - Operating expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netfinancialincomeloss" roleURI="http://www.innate-pharma.com/role/Netfinancialincomeloss">
        <link:definition>9952170 - Disclosure - Net financial income / (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxexpense" roleURI="http://www.innate-pharma.com/role/Incometaxexpense">
        <link:definition>9952171 - Disclosure - Income tax / (expense)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentscontingenciesandlitigation" roleURI="http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation">
        <link:definition>9952172 - Disclosure - Commitments, contingencies and litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactions" roleURI="http://www.innate-pharma.com/role/Relatedpartytransactions">
        <link:definition>9952173 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incomelosspershare" roleURI="http://www.innate-pharma.com/role/Incomelosspershare">
        <link:definition>9952174 - Disclosure - Income / (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Eventsafterthereportingdate" roleURI="http://www.innate-pharma.com/role/Eventsafterthereportingdate">
        <link:definition>9952175 - Disclosure - Events after the reporting date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandstatementofcompliancePolicies" roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies">
        <link:definition>9954471 - Disclosure - Basis of presentation and statement of compliance (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandstatementofcomplianceTables" roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables">
        <link:definition>9954472 - Disclosure - Basis of presentation and statement of compliance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables" roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables">
        <link:definition>9954473 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothersTables" roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersTables">
        <link:definition>9954474 - Disclosure - Trade receivables and others (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://www.innate-pharma.com/role/IntangibleassetsTables">
        <link:definition>9954475 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentTables" roleURI="http://www.innate-pharma.com/role/PropertyandequipmentTables">
        <link:definition>9954476 - Disclosure - Property and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothersTables" roleURI="http://www.innate-pharma.com/role/TradepayablesandothersTables">
        <link:definition>9954477 - Disclosure - Trade payables and others (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesTables" roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesTables">
        <link:definition>9954478 - Disclosure - Financial liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeebenefitTables" roleURI="http://www.innate-pharma.com/role/EmployeebenefitTables">
        <link:definition>9954479 - Disclosure - Employee benefit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalTables" roleURI="http://www.innate-pharma.com/role/CapitalTables">
        <link:definition>9954480 - Disclosure - Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables" roleURI="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables">
        <link:definition>9954481 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeTables" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeTables">
        <link:definition>9954482 - Disclosure - Revenue and other income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesTables" roleURI="http://www.innate-pharma.com/role/OperatingexpensesTables">
        <link:definition>9954483 - Disclosure - Operating expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossTables" roleURI="http://www.innate-pharma.com/role/NetfinancialincomelossTables">
        <link:definition>9954484 - Disclosure - Net financial income / (loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsTables" roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsTables">
        <link:definition>9954485 - Disclosure - Related party transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomelosspershareTables" roleURI="http://www.innate-pharma.com/role/IncomelosspershareTables">
        <link:definition>9954486 - Disclosure - Income / (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandkeyeventsThecompanyDetails" roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails">
        <link:definition>9954487 - Disclosure - The Company and key events - The company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details" roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details">
        <link:definition>9954488 - Disclosure - The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails" roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails">
        <link:definition>9954489 - Disclosure - Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails">
        <link:definition>9954490 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails">
        <link:definition>9954491 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails">
        <link:definition>9954492 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails">
        <link:definition>9954493 - Disclosure - Trade receivables and others - Disclosure of trade receivables and others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails" roleURI="http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails">
        <link:definition>9954494 - Disclosure - Intangible assets - Disclosure of detailed information about intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails">
        <link:definition>9954495 - Disclosure - Intangible assets - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails" roleURI="http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails">
        <link:definition>9954496 - Disclosure - Property and equipment - Disclosure of detailed information about property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TradepayablesandothersDisclosureoftradepayablesandothersDetails" roleURI="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails">
        <link:definition>9954497 - Disclosure - Trade payables and others - Disclosure of trade payables and others (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails">
        <link:definition>9954498 - Disclosure - Financial liabilities - Disclosure of financial liabilities per maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails">
        <link:definition>9954499 - Disclosure - Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeebenefitDisclosureofdefinedbenefitplansDetails" roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails">
        <link:definition>9954500 - Disclosure - Employee benefit - Disclosure of defined benefit plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails">
        <link:definition>9954501 - Disclosure - Employee benefit - Disclosure of net defined benefit liability (asset) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeebenefitAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails">
        <link:definition>9954502 - Disclosure - Employee benefit - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalAdditionalInformationDetails" roleURI="http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails">
        <link:definition>9954503 - Disclosure - Capital - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" roleURI="http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails">
        <link:definition>9954504 - Disclosure - Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" roleURI="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails">
        <link:definition>9954505 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails">
        <link:definition>9954506 - Disclosure - Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails">
        <link:definition>9954507 - Disclosure - Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails">
        <link:definition>9954508 - Disclosure - Revenue and other income - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails">
        <link:definition>9954509 - Disclosure - Revenue and other income - Disclosure of variance of deferred revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails">
        <link:definition>9954510 - Disclosure - Revenue and other income - Disclosure of government financing for research expenditures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesDisclosureofexpensesbynatureDetails" roleURI="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails">
        <link:definition>9954511 - Disclosure - Operating expenses - Disclosure of expenses by nature (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpensesAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails">
        <link:definition>9954512 - Disclosure - Operating expenses - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" roleURI="http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails">
        <link:definition>9954513 - Disclosure - Net financial income / (loss) - Disclosure of net financial income (loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxexpenseDetails" roleURI="http://www.innate-pharma.com/role/IncometaxexpenseDetails">
        <link:definition>9954514 - Disclosure - Income tax / (expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentscontingenciesandlitigationDetails" roleURI="http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails">
        <link:definition>9954515 - Disclosure - Commitments, contingencies and litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails">
        <link:definition>9954516 - Disclosure - Related party transactions - Disclosure of key management personnel compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsAdditionalinformationDetails" roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails">
        <link:definition>9954517 - Disclosure - Related party transactions - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails">
        <link:definition>9954518 - Disclosure - Related party transactions - Disclosure of transactions between related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomelosspershareSummaryofincomelosspershareDetails" roleURI="http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails">
        <link:definition>9954519 - Disclosure - Income / (loss) per share - Summary of income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="inpha_CollaborationLiabilitiesCurrentPortion" abstract="false" name="CollaborationLiabilitiesCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CollaborationLiabilitiesNonCurrentPortion" abstract="false" name="CollaborationLiabilitiesNonCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_GovernmentFinancingForResearchExpenditures" abstract="false" name="GovernmentFinancingForResearchExpenditures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" abstract="false" name="ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SummaryOfChangesInWorkingCapitalAbstract" abstract="true" name="SummaryOfChangesInWorkingCapitalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_CollaborationLiabilities" abstract="false" name="CollaborationLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" abstract="false" name="AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ChangeInWorkingCapital" abstract="false" name="ChangeInWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" abstract="false" name="ExerciseAndSubscriptionOfEquityInstrumentsInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inpha_ExerciseAndSubscriptionOfEquityInstruments" abstract="false" name="ExerciseAndSubscriptionOfEquityInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CompanyInformationAbstract" abstract="true" name="CompanyInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" abstract="false" name="DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_SignificantAccountingPoliciesAbstract" abstract="true" name="SignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_ShareCapitalAndShareBasePaymentsAbstract" abstract="true" name="ShareCapitalAndShareBasePaymentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_CommitmentsContingenciesAndLitigationsAbstract" abstract="true" name="CommitmentsContingenciesAndLitigationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" abstract="false" name="DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" abstract="false" name="DisclosureOfTradeReceivablesAndOtherTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfTradePayablesAndOthersTextBlock" abstract="false" name="DisclosureOfTradePayablesAndOthersTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" abstract="false" name="DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" abstract="false" name="DisclosureOfVarianceOfDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" abstract="false" name="DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" abstract="false" name="DisclosureOfNetFinancialIncomeLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" abstract="false" name="DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="inpha_NumberOfClinicalProductCandidates" abstract="false" name="NumberOfClinicalProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_AgreementRelatedToIPH6101WithSanofiMember" abstract="true" name="AgreementRelatedToIPH6101WithSanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IssuedCapitalFreeOfSubscriptionMember" abstract="true" name="IssuedCapitalFreeOfSubscriptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" abstract="true" name="TypeOfExerciseAndSubscriptionOfSharesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" abstract="true" name="TypeOfExerciseAndSubscriptionOfSharesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_ExerciseOfShareWarrantsMember" abstract="true" name="ExerciseOfShareWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_DefinitiveAcquisitionOfFreeSharesMember" abstract="true" name="DefinitiveAcquisitionOfFreeSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_FreeSharesMember" abstract="true" name="FreeSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" abstract="false" name="RevenueFromContractsWithCustomersMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ShareIssuedPricePerShare" abstract="false" name="ShareIssuedPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TotalCashCashEquivalentsAndFinancialAssets" abstract="false" name="TotalCashCashEquivalentsAndFinancialAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SICAVMember" abstract="true" name="SICAVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SICAVAndMutualFundsMember" abstract="true" name="SICAVAndMutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" abstract="true" name="CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_NumberOfFinancialInstrumentsHeld" abstract="false" name="NumberOfFinancialInstrumentsHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inpha_RiskProfileRate" abstract="false" name="RiskProfileRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" abstract="false" name="NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" abstract="false" name="ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ShortTermInvestments1Abstract" abstract="true" name="ShortTermInvestments1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_ShortTermInvestmentsAcquisitions" abstract="false" name="ShortTermInvestmentsAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DecreaseThroughDerecognitionShortTermInvestment" abstract="false" name="DecreaseThroughDerecognitionShortTermInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" abstract="false" name="IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ShortTermInvestmentsForeignCurrencyEffect" abstract="false" name="ShortTermInvestmentsForeignCurrencyEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NonCurrentFinancialAssetsAbstract" abstract="true" name="NonCurrentFinancialAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_NonCurrentFinancialAssetsAcquisitions" abstract="false" name="NonCurrentFinancialAssetsAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" abstract="false" name="DecreaseThroughDerecognitionNonCurrentFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" abstract="false" name="IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" abstract="false" name="NonCurrentFinancialAssetsForeignCurrencyEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" abstract="true" name="TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" abstract="false" name="ShortTermInvestmentsAndNonCurrentFinancialAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TotalAcquisitions" abstract="false" name="TotalAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" abstract="false" name="DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" abstract="false" name="TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" abstract="false" name="IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TotalForeignCurrencyEffect" abstract="false" name="TotalForeignCurrencyEffect" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" abstract="true" name="PGELoanAgreementSocieteGeneraleAndBNPParibasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementWithSanofiMember" abstract="true" name="AgreementWithSanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ResearchTaxCreditReceivableCurrent" abstract="false" name="ResearchTaxCreditReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OtherCurrentTaxCreditsReceivables" abstract="false" name="OtherCurrentTaxCreditsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TradeAndOtherCurrentReceivablesExcludingRebates" abstract="false" name="TradeAndOtherCurrentReceivablesExcludingRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NonCurrentResearchTaxCredit" abstract="false" name="NonCurrentResearchTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NonCurrentPrepaidExpenses" abstract="false" name="NonCurrentPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" abstract="false" name="TradeAndOtherNonCurrentReceivablesExcludingRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TradeAndOtherReceivablesExcludingRebates" abstract="false" name="TradeAndOtherReceivablesExcludingRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit2019And2020Maturity" abstract="false" name="IncomeFromResearchTaxCredit2019And2020Maturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit2019" abstract="false" name="IncomeFromResearchTaxCredit2019" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit2020" abstract="false" name="IncomeFromResearchTaxCredit2020" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" abstract="false" name="OffsetOfRestatedIncomeFromResearchTaxCredit2020" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit2023" abstract="false" name="IncomeFromResearchTaxCredit2023" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCreditHalfYear2024" abstract="false" name="IncomeFromResearchTaxCreditHalfYear2024" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CarryBackTaxReceivable" abstract="false" name="CarryBackTaxReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_BorrowingNumberOfLoanAgreement" abstract="false" name="BorrowingNumberOfLoanAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_BorrowingMaturity" abstract="false" name="BorrowingMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_MonalizumabAgreementMember" abstract="true" name="MonalizumabAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementWithOregaBiotechMember" abstract="true" name="AgreementWithOregaBiotechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" abstract="true" name="MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" abstract="true" name="IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" abstract="true" name="AgreementRelatedToIPH5201WithAstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" abstract="true" name="IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_PaymentsForMilestone" abstract="false" name="PaymentsForMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_LaboratoryEquipmentAndOtherMember" abstract="true" name="LaboratoryEquipmentAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LeaseFinancingObligationsBuildingLeVirageMember" abstract="true" name="LeaseFinancingObligationsBuildingLeVirageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IncreaseDecreaseInFinancialLiabilities" abstract="false" name="IncreaseDecreaseInFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DisclosureOfTradePayablesAndOthersTable" abstract="true" name="DisclosureOfTradePayablesAndOthersTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="inpha_DisclosureOfTradePayablesAndOthersLineItems" abstract="true" name="DisclosureOfTradePayablesAndOthersLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" abstract="false" name="CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CurrentPayablesRelatedToCapitalExpenditures" abstract="false" name="CurrentPayablesRelatedToCapitalExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" abstract="false" name="PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" abstract="false" name="OffsetAgainstIncomeFromResearchTaxCredit2020" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit2020Receivable" abstract="false" name="IncomeFromResearchTaxCredit2020Receivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NumberOfStateGuaranteedLoans" abstract="false" name="NumberOfStateGuaranteedLoans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_PGELoanAgreementSocieteGeneraleMember" abstract="true" name="PGELoanAgreementSocieteGeneraleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_PGELoanAgreementBNPParibasMember" abstract="true" name="PGELoanAgreementBNPParibasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_PGELoanAgreementAccruedInterestMember" abstract="true" name="PGELoanAgreementAccruedInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LeaseFinancingObligationsInnateIncPremisesMember" abstract="true" name="LeaseFinancingObligationsInnateIncPremisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LeaseFinancingObligationsEquipmentMember" abstract="true" name="LeaseFinancingObligationsEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LeaseFinancingObligationsVehiclesMember" abstract="true" name="LeaseFinancingObligationsVehiclesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LeaseFinancingObligationsPrintersMember" abstract="true" name="LeaseFinancingObligationsPrintersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LoanEquipmentMember" abstract="true" name="LoanEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LoanBuildingMember" abstract="true" name="LoanBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_LoanAgreementWithSocitGnraleMember" abstract="true" name="LoanAgreementWithSocitGnraleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" abstract="false" name="ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" abstract="false" name="RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_BorrowingMaturityExtensionPeriodOption" abstract="false" name="BorrowingMaturityExtensionPeriodOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_BorrowingPercentageOfStateGuaranteedLoan" abstract="false" name="BorrowingPercentageOfStateGuaranteedLoan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="inpha_BorrowingGracePeriod" abstract="false" name="BorrowingGracePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_NumberOfLoans" abstract="false" name="NumberOfLoans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_LoanAgreementMaximumBorrowingCapacity" abstract="false" name="LoanAgreementMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_LoanAgreementCollateral" abstract="false" name="LoanAgreementCollateral" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_BorrowingsMaturityPeriod" abstract="false" name="BorrowingsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" abstract="false" name="SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" abstract="false" name="SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" abstract="false" name="SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" abstract="false" name="SecurityInterestOnPledgeOfFinancialInstrumentsReleased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_RetirementDefinedBenefitMember" abstract="true" name="RetirementDefinedBenefitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SeniorityAwardsMember" abstract="true" name="SeniorityAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_The2016FreePreferredSharesMember" abstract="true" name="The2016FreePreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_The2017FreePreferredSharesMember" abstract="true" name="The2017FreePreferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSAAR2012Member" abstract="true" name="BSAAR2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_CompanySavingPlanMember" abstract="true" name="CompanySavingPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_CompanySavingPlanEmployerTopUpMember" abstract="true" name="CompanySavingPlanEmployerTopUpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" abstract="false" name="NumberOfEquityInstrumentsConvertedInOrdinaryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="inpha_BSAAR2011Member" abstract="true" name="BSAAR2011Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSAAR2015Member" abstract="true" name="BSAAR2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPManagement20161Member" abstract="true" name="AGAPManagement20161Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPEmployees20161Member" abstract="true" name="AGAPEmployees20161Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAManagement20161Member" abstract="true" name="AGAManagement20161Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPManagement20162Member" abstract="true" name="AGAPManagement20162Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAManagement20162Member" abstract="true" name="AGAManagement20162Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPEmployees20171Member" abstract="true" name="AGAPEmployees20171Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPManagement20171Member" abstract="true" name="AGAPManagement20171Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAEmployees2017Member" abstract="true" name="AGAEmployees2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGABonus20181Member" abstract="true" name="AGABonus20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPPerfEmployees20181Member" abstract="true" name="AGAPPerfEmployees20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPPerfManagement20181Member" abstract="true" name="AGAPPerfManagement20181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAEmployees2018Member" abstract="true" name="AGAEmployees2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGANewMembers20171Member" abstract="true" name="AGANewMembers20171Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGABonus20191Member" abstract="true" name="AGABonus20191Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGABonus202012Member" abstract="true" name="AGABonus202012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPEmployees20201Member" abstract="true" name="AGAPEmployees20201Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPManagement20201Member" abstract="true" name="AGAPManagement20201Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGABonus20211Member" abstract="true" name="AGABonus20211Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPEmployees20211Member" abstract="true" name="AGAPEmployees20211Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPManagement20211Member" abstract="true" name="AGAPManagement20211Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPlanEpargneEntreprise2022Member" abstract="true" name="AGAPlanEpargneEntreprise2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGABonus20221Member" abstract="true" name="AGABonus20221Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPerfEmployees20221Member" abstract="true" name="AGAPerfEmployees20221Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPerfManagement20221Member" abstract="true" name="AGAPerfManagement20221Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAPlanEpargneEntreprise2023Member" abstract="true" name="AGAPlanEpargneEntreprise2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGANewMembers20231Member" abstract="true" name="AGANewMembers20231Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AGAPerfEmployees20231Member" abstract="true" name="AGAPerfEmployees20231Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AGAPerfManagement20231Member" abstract="true" name="AGAPerfManagement20231Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AGANewMembers20241Member" abstract="true" name="AGANewMembers20241Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AGAPlanEpargneEntreprise2024Member" abstract="true" name="AGAPlanEpargneEntreprise2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_StockOptions20201Member" abstract="true" name="StockOptions20201Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAP2019Employees2019Member" abstract="true" name="AGAP2019Employees2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AGAP2019Management2019Member" abstract="true" name="AGAP2019Management2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA20112Member" abstract="true" name="BSA20112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA2013Member" abstract="true" name="BSA2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA2014Member" abstract="true" name="BSA2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA20151Member" abstract="true" name="BSA20151Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA20152Member" abstract="true" name="BSA20152Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA2017Member" abstract="true" name="BSA2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA20221Member" abstract="true" name="BSA20221Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_BSA20231Member" abstract="true" name="BSA20231Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_NonCurrentFinancialAssetsMember" abstract="true" name="NonCurrentFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_TradeReceivablesAndOthersMember" abstract="true" name="TradeReceivablesAndOthersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_FinancialAssetsShortTermInvestmentsMember" abstract="true" name="FinancialAssetsShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_FinancialAssetsCashAndCashEquivalentsMember" abstract="true" name="FinancialAssetsCashAndCashEquivalentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_FinancialLiabilitiesNonCurrentPortionMember" abstract="true" name="FinancialLiabilitiesNonCurrentPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_FinancialLiabilitiesCurrentPortionMember" abstract="true" name="FinancialLiabilitiesCurrentPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_TradePayablesAndOthersMember" abstract="true" name="TradePayablesAndOthersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_FinancialLiabilitiesTradePayablesAndOthers" abstract="false" name="FinancialLiabilitiesTradePayablesAndOthers" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" abstract="false" name="FinancialLiabilitiesTradePayablesAndOthersAtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CollaborationAndLicensingAgreementsMember" abstract="true" name="CollaborationAndLicensingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementWithSanofi2022ANKETIPH62Member" abstract="true" name="AgreementWithSanofi2022ANKETIPH62Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementWithSanofi2022ANKETIPH67Member" abstract="true" name="AgreementWithSanofi2022ANKETIPH67Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AgreementWithTakedaMember" abstract="true" name="AgreementWithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IPH5201AndAdvoralimabAgreementsMember" abstract="true" name="IPH5201AndAdvoralimabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_DeferredRevenueMember" abstract="true" name="DeferredRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_CollaborationLiabilitiesMember" abstract="true" name="CollaborationLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_A2015AstraZenecaMonalizumabAgreementsMember" abstract="true" name="A2015AstraZenecaMonalizumabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SanofiResearchCollaborationAndLicensingAgreementMember" abstract="true" name="SanofiResearchCollaborationAndLicensingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementsWithSanofiForNKCellEngagesMember" abstract="true" name="AgreementsWithSanofiForNKCellEngagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_DeferredRevenueRollForwardAbstract" abstract="true" name="DeferredRevenueRollForwardAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersMilestone" abstract="false" name="RevenueFromContractsWithCustomersMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TransferToFromCollaborationLiabilities" abstract="false" name="TransferToFromCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_CollaborationLiabilitiesRollForwardAbstract" abstract="true" name="CollaborationLiabilitiesRollForwardAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" abstract="false" name="IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DecreaseThroughDeductionsContractLiabilities" abstract="false" name="DecreaseThroughDeductionsContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" abstract="false" name="RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NumberOfTargetOptions" abstract="false" name="NumberOfTargetOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_NumberOfPreclinicalMolecules" abstract="false" name="NumberOfPreclinicalMolecules" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" abstract="false" name="RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" abstract="false" name="RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_A2018AstraZenecaIPH5201AgreementMember" abstract="true" name="A2018AstraZenecaIPH5201AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_AgreementsWithGenzymeForNKCellEngagesMember" abstract="true" name="AgreementsWithGenzymeForNKCellEngagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ExternalCostsRelatedToTheClinicalTrial" abstract="false" name="ExternalCostsRelatedToTheClinicalTrial" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" abstract="false" name="RevenueFromContractsWithCustomersAdvancePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" abstract="false" name="RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NumberOfOptionsExcercisedForLicenses" abstract="false" name="NumberOfOptionsExcercisedForLicenses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_NumberOfExclusiveOptionsGranted" abstract="false" name="NumberOfExclusiveOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" abstract="false" name="RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_MonalizumabMember" abstract="true" name="MonalizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SanofiOptionsMember" abstract="true" name="SanofiOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SanofiServicesMember" abstract="true" name="SanofiServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_IncreaseThroughUpfrontPaymentContractLiabilities" abstract="false" name="IncreaseThroughUpfrontPaymentContractLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_TransferFromToCollaborationLiabilities" abstract="false" name="TransferFromToCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IncomeFromResearchTaxCredit" abstract="false" name="IncomeFromResearchTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_SubcontractingCosts" abstract="false" name="SubcontractingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NonScientificAdvisoryAndConsulting" abstract="false" name="NonScientificAdvisoryAndConsulting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_LeasingAndMaintenance" abstract="false" name="LeasingAndMaintenance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ScientificAdvisoryAndConsulting" abstract="false" name="ScientificAdvisoryAndConsulting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OtherPurchasesAndExternalExpenses" abstract="false" name="OtherPurchasesAndExternalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_IntellectualPropertyExpenses" abstract="false" name="IntellectualPropertyExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DisclosureOfOperatingExpensesTable" abstract="true" name="DisclosureOfOperatingExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="inpha_TypeOfEmployeeAxis" abstract="true" name="TypeOfEmployeeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="inpha_TypeOfEmployeeDomain" abstract="true" name="TypeOfEmployeeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_AdministrationMember" abstract="true" name="AdministrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_DisclosureOfOperatingExpensesLineItems" abstract="true" name="DisclosureOfOperatingExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_InterestsAndGainsOnFinancialAssets" abstract="false" name="InterestsAndGainsOnFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ChangeInValuationAllowanceOfFinancialInstruments" abstract="false" name="ChangeInValuationAllowanceOfFinancialInstruments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_UnrealizedLossesOnFinancialAssets" abstract="false" name="UnrealizedLossesOnFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OtherFinancialIncome" abstract="false" name="OtherFinancialIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_OtherFinancialExpenses" abstract="false" name="OtherFinancialExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_DisclosureOfIncomeTaxTable" abstract="true" name="DisclosureOfIncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="inpha_DisclosureOfIncomeTaxLineItems" abstract="true" name="DisclosureOfIncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="inpha_UnusedTaxLossesWithNoExpirationDate" abstract="false" name="UnusedTaxLossesWithNoExpirationDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_UnusedTaxLossesSubjectToExpiration" abstract="false" name="UnusedTaxLossesSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_PreclinicalServicesMember" abstract="true" name="PreclinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_GrantsOfEmployeeEquityInstrumentsMember" abstract="true" name="GrantsOfEmployeeEquityInstrumentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ChangesToCommitmentsMember" abstract="true" name="ChangesToCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="inpha_NonCancellableOffBalanceSheetPurchasedCommitments" abstract="false" name="NonCancellableOffBalanceSheetPurchasedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" abstract="false" name="SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_PaymentOfTaxesOtherThanIncomeTax" abstract="false" name="PaymentOfTaxesOtherThanIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_KeyManagementPersonnelCompensationAdvisoryFees" abstract="false" name="KeyManagementPersonnelCompensationAdvisoryFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NovoNordiskASMember" abstract="true" name="NovoNordiskASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="inpha_ProvisionForExpensesWithRelatedParties" abstract="false" name="ProvisionForExpensesWithRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_ProvisionForAttendanceFees" abstract="false" name="ProvisionForAttendanceFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="inpha_NumberOfLicensingAgreementsWithRelatedParties" abstract="false" name="NumberOfLicensingAgreementsWithRelatedParties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="inpha_NetAmountsReceivablePayableRelatedPartyTransactions" abstract="false" name="NetAmountsReceivablePayableRelatedPartyTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>inpha-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofFinancialPosition"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0ea4df4-2b79-4e47-9021-f00a4fdc10c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d0ea4df4-2b79-4e47-9021-f00a4fdc10c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_0d6705b3-6ad4-4d78-be9b-642ab811e896" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_0d6705b3-6ad4-4d78-be9b-642ab811e896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentReceivables_553ef39c-28dc-4cf7-9e37-647c2a6a077e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_NoncurrentReceivables_553ef39c-28dc-4cf7-9e37-647c2a6a077e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_a2da12fd-72b7-401e-9dd1-5e47bbc28531" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_a2da12fd-72b7-401e-9dd1-5e47bbc28531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_f8453431-0be6-476d-9c1d-2a5002a4d79a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_DeferredTaxAssets_f8453431-0be6-476d-9c1d-2a5002a4d79a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_a598a16e-64bb-429c-887d-d2c013f720dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_608bf759-1f7c-49b4-be0f-8c11a8526592" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_a598a16e-64bb-429c-887d-d2c013f720dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_11251a33-2466-4872-83ba-6c8be3ad1cf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_11251a33-2466-4872-83ba-6c8be3ad1cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesCurrentPortion_526fd710-1ec4-419a-b00d-7b16e7ae1826" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesCurrentPortion"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:to="loc_inpha_CollaborationLiabilitiesCurrentPortion_526fd710-1ec4-419a-b00d-7b16e7ae1826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_48cf47de-1617-4623-b644-84f744b39f5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_48cf47de-1617-4623-b644-84f744b39f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_d5ab9499-cfce-4c01-8ded-5db39f6c608c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:to="loc_ifrs-full_CurrentProvisions_d5ab9499-cfce-4c01-8ded-5db39f6c608c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_d3e78843-fbae-4c6f-bc14-5644ccba3308" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_53446c0e-a605-4685-b445-02d0c03a707b" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_d3e78843-fbae-4c6f-bc14-5644ccba3308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_b5f716cd-4eb3-4878-81f6-5ba58dd5f494" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4be851f9-feb7-4fd1-97a4-3323b228eaf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5f716cd-4eb3-4878-81f6-5ba58dd5f494" xlink:to="loc_ifrs-full_NoncurrentLiabilities_4be851f9-feb7-4fd1-97a4-3323b228eaf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_221c9473-d827-4b06-ba2f-5abff8251350" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5f716cd-4eb3-4878-81f6-5ba58dd5f494" xlink:to="loc_ifrs-full_CurrentLiabilities_221c9473-d827-4b06-ba2f-5abff8251350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_fed9b140-2187-45e7-b482-e2aa57c81264" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_b5f716cd-4eb3-4878-81f6-5ba58dd5f494" xlink:to="loc_ifrs-full_Equity_fed9b140-2187-45e7-b482-e2aa57c81264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_b438069c-0c47-4c22-9f9f-2c44b15763b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_0a69d458-14ba-4e71-80f4-f8bb739e07df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b438069c-0c47-4c22-9f9f-2c44b15763b5" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_0a69d458-14ba-4e71-80f4-f8bb739e07df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssets_04e47bfc-e0c7-4ab3-bef0-208421feda3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b438069c-0c47-4c22-9f9f-2c44b15763b5" xlink:to="loc_ifrs-full_CurrentFinancialAssets_04e47bfc-e0c7-4ab3-bef0-208421feda3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_9d1de3ac-923c-40f6-9b4a-4823cf4fcb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_b438069c-0c47-4c22-9f9f-2c44b15763b5" xlink:to="loc_ifrs-full_CashAndCashEquivalents_9d1de3ac-923c-40f6-9b4a-4823cf4fcb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_437ec207-eaff-4a5d-9e58-585a56d76e33" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:to="loc_ifrs-full_OtherReserves_437ec207-eaff-4a5d-9e58-585a56d76e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_a79d6566-9a5b-4224-9a1f-df0fe248ad4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_a79d6566-9a5b-4224-9a1f-df0fe248ad4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_7f81c29c-5dfe-4333-86e8-f1dd2183cd30" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:to="loc_ifrs-full_IssuedCapital_7f81c29c-5dfe-4333-86e8-f1dd2183cd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_62e75cb5-2533-42e2-a067-ea6e9a1704d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_62e75cb5-2533-42e2-a067-ea6e9a1704d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_bda9b5de-f34d-4925-aa85-a3b458927bda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_8d0d762f-527a-4aa9-918c-11b739b88a97" xlink:to="loc_ifrs-full_SharePremium_bda9b5de-f34d-4925-aa85-a3b458927bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_8fddbf67-f2b6-46c1-806f-0326e78d3b74" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_8fddbf67-f2b6-46c1-806f-0326e78d3b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_479d38ad-0cac-4770-951d-9c00b5e0f59c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_479d38ad-0cac-4770-951d-9c00b5e0f59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_9d84673b-4b14-4d3d-9ff3-7a344cfb6724" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_9d84673b-4b14-4d3d-9ff3-7a344cfb6724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesNonCurrentPortion_ac5f59a1-f2c3-4123-a8c0-bd820b41fec0" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesNonCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_inpha_CollaborationLiabilitiesNonCurrentPortion_ac5f59a1-f2c3-4123-a8c0-bd820b41fec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_9ed0b7ae-91ed-4980-81d3-8b17c482f009" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_ifrs-full_NoncurrentProvisions_9ed0b7ae-91ed-4980-81d3-8b17c482f009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_317cb0f7-302e-44bf-9bc3-d3f8676b0919" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_4a13e1f5-fefe-4c4f-a025-6db25c5d251c" xlink:to="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_317cb0f7-302e-44bf-9bc3-d3f8676b0919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_bd6f6edd-fb26-4b07-8e06-c133b224e191" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_4a5680ab-4ad4-43a2-b85f-1b44fe528429" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_bd6f6edd-fb26-4b07-8e06-c133b224e191" xlink:to="loc_ifrs-full_CurrentAssets_4a5680ab-4ad4-43a2-b85f-1b44fe528429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_68ccd88e-fb5c-4f59-a347-f805cf1fb31d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_bd6f6edd-fb26-4b07-8e06-c133b224e191" xlink:to="loc_ifrs-full_NoncurrentAssets_68ccd88e-fb5c-4f59-a347-f805cf1fb31d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_6e21305d-a8d1-4860-a157-5a21b555e546" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_f3a964a1-74f3-4d22-8c85-267fe53e8aff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_6e21305d-a8d1-4860-a157-5a21b555e546" xlink:to="loc_ifrs-full_FinanceIncomeCost_f3a964a1-74f3-4d22-8c85-267fe53e8aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_6be5340c-5d5d-4be2-9bfb-963c8aa9a703" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_6e21305d-a8d1-4860-a157-5a21b555e546" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_6be5340c-5d5d-4be2-9bfb-963c8aa9a703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_ae5dbfc0-ec06-4f12-b1e8-4825ed398d01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_b30f251b-cf44-425d-9f2b-871c2d75bcde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_ae5dbfc0-ec06-4f12-b1e8-4825ed398d01" xlink:to="loc_ifrs-full_FinanceCosts_b30f251b-cf44-425d-9f2b-871c2d75bcde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_57f0cad2-b389-4db9-9129-06628637439c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncomeCost_ae5dbfc0-ec06-4f12-b1e8-4825ed398d01" xlink:to="loc_ifrs-full_FinanceIncome_57f0cad2-b389-4db9-9129-06628637439c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3ae2e810-6acc-4c6f-89ab-255489283f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_d4ecb021-2506-45f9-96b3-c82df4cd41a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3ae2e810-6acc-4c6f-89ab-255489283f04" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_d4ecb021-2506-45f9-96b3-c82df4cd41a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_88d02546-b6ad-472d-af12-0e50b9efff4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_3ae2e810-6acc-4c6f-89ab-255489283f04" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_88d02546-b6ad-472d-af12-0e50b9efff4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_c01bd16f-d8a2-4421-aafa-387eb97520b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_821de7d3-88db-41e2-9344-86a7bf1ac047" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_c01bd16f-d8a2-4421-aafa-387eb97520b8" xlink:to="loc_ifrs-full_OperatingExpense_821de7d3-88db-41e2-9344-86a7bf1ac047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_282b073c-493d-4980-9a0e-1fae17a90c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_c01bd16f-d8a2-4421-aafa-387eb97520b8" xlink:to="loc_ifrs-full_Revenue_282b073c-493d-4980-9a0e-1fae17a90c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperations_1663a416-f153-4fcc-a4b8-1f692659252d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_d78ec6ae-a4d4-4f9b-be4c-4cdf7f71b0cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_1663a416-f153-4fcc-a4b8-1f692659252d" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_d78ec6ae-a4d4-4f9b-be4c-4cdf7f71b0cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_151654ac-2292-4ad5-a4bd-0f25cc41705d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperations_1663a416-f153-4fcc-a4b8-1f692659252d" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_151654ac-2292-4ad5-a4bd-0f25cc41705d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_2d27f762-5806-4fe7-8eed-ac0b502111aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_60d129ae-8589-4800-9564-98a6b12b8c7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_2d27f762-5806-4fe7-8eed-ac0b502111aa" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_60d129ae-8589-4800-9564-98a6b12b8c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GovernmentFinancingForResearchExpenditures_c3eb6e55-1186-4e73-b38c-1125c65321d2" xlink:href="inpha-20240630.xsd#inpha_GovernmentFinancingForResearchExpenditures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_2d27f762-5806-4fe7-8eed-ac0b502111aa" xlink:to="loc_inpha_GovernmentFinancingForResearchExpenditures_c3eb6e55-1186-4e73-b38c-1125c65321d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_84944ded-8c9a-4c43-896e-95a6ba5eddcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_96516004-fe1b-48bb-a48e-a0d39691e57a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_84944ded-8c9a-4c43-896e-95a6ba5eddcf" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_96516004-fe1b-48bb-a48e-a0d39691e57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_6644d7ed-71a4-4315-9272-6d492b2700a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_84944ded-8c9a-4c43-896e-95a6ba5eddcf" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_6644d7ed-71a4-4315-9272-6d492b2700a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_da78e975-ab35-4cb2-b344-3428682089e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_8ec1521e-3598-4cfd-8c21-3c6307827932" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_da78e975-ab35-4cb2-b344-3428682089e8" xlink:to="loc_ifrs-full_ProfitLoss_8ec1521e-3598-4cfd-8c21-3c6307827932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_2830de8e-6721-4d04-a72c-34595dc5e02a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_da78e975-ab35-4cb2-b344-3428682089e8" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_2830de8e-6721-4d04-a72c-34595dc5e02a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_b10904f8-4a41-4212-a5d8-318c0504a855" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_0b1fee5c-7be0-423c-a5d7-28253b9fb836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_b10904f8-4a41-4212-a5d8-318c0504a855" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_0b1fee5c-7be0-423c-a5d7-28253b9fb836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_7ee6adee-c50e-4199-b4b2-4165ee026834" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_b10904f8-4a41-4212-a5d8-318c0504a855" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_7ee6adee-c50e-4199-b4b2-4165ee026834" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3b870d88-a98d-4590-8c86-c2d8a66bcd14" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_a3da51d4-9dfc-47c2-97a0-848bedbbd6ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3b870d88-a98d-4590-8c86-c2d8a66bcd14" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_a3da51d4-9dfc-47c2-97a0-848bedbbd6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_091a79d7-0e70-49a8-9afd-b19fb49d00ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3b870d88-a98d-4590-8c86-c2d8a66bcd14" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_091a79d7-0e70-49a8-9afd-b19fb49d00ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_343ee75b-9b8f-4211-a13e-2f6979051682" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_343ee75b-9b8f-4211-a13e-2f6979051682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_5bdc2f60-6732-49ab-94f1-d3b8bcb5c2c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_5bdc2f60-6732-49ab-94f1-d3b8bcb5c2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7d07b1b7-875a-4225-b672-339703090fcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_ProfitLoss_7d07b1b7-875a-4225-b672-339703090fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_15777752-e282-43d1-a237-18d6ab8917e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_15777752-e282-43d1-a237-18d6ab8917e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_de9438c9-b1e9-4598-93d5-d26214702540" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_de9438c9-b1e9-4598-93d5-d26214702540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_362630df-94b1-440a-bbd2-3c29cf3a93a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_362630df-94b1-440a-bbd2-3c29cf3a93a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_727b29cc-3d00-4911-bb39-02eefab407b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_727b29cc-3d00-4911-bb39-02eefab407b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_3911d3ee-d348-4b3d-964c-6fd5ce8766ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_3911d3ee-d348-4b3d-964c-6fd5ce8766ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_13c9ad41-7171-45a9-bf05-91ce02afd3cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_13c9ad41-7171-45a9-bf05-91ce02afd3cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_f7a2e5de-1766-4e72-8523-a4ec57144466" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_85fda7fa-8507-451f-8278-78c5ef4d0400" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_f7a2e5de-1766-4e72-8523-a4ec57144466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInWorkingCapital_c42eb780-0eba-4871-8cff-d08226fe53c0" xlink:href="inpha-20240630.xsd#inpha_ChangeInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_dad349b4-69e2-4d02-954b-a3e0f24de379" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_ChangeInWorkingCapital_c42eb780-0eba-4871-8cff-d08226fe53c0" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_dad349b4-69e2-4d02-954b-a3e0f24de379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities_b704c06d-7f4e-4de4-b651-e7369cd3cba5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_ChangeInWorkingCapital_c42eb780-0eba-4871-8cff-d08226fe53c0" xlink:to="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities_b704c06d-7f4e-4de4-b651-e7369cd3cba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_e7617dff-39d8-4606-8494-15f2f54f697d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_ChangeInWorkingCapital_c42eb780-0eba-4871-8cff-d08226fe53c0" xlink:to="loc_ifrs-full_TradeAndOtherPayables_e7617dff-39d8-4606-8494-15f2f54f697d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilities_ef0e4dc1-f572-45f8-a223-f5a2a85f06fa" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_ChangeInWorkingCapital_c42eb780-0eba-4871-8cff-d08226fe53c0" xlink:to="loc_inpha_CollaborationLiabilities_ef0e4dc1-f572-45f8-a223-f5a2a85f06fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f64199fc-64ab-44db-b50c-e5c71e864817" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_e7eb1819-f086-4f3c-8083-a44644d0b4b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f64199fc-64ab-44db-b50c-e5c71e864817" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_e7eb1819-f086-4f3c-8083-a44644d0b4b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_27ce28f7-4c3f-42f9-a450-422876afc8c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f64199fc-64ab-44db-b50c-e5c71e864817" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_27ce28f7-4c3f-42f9-a450-422876afc8c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d29f6585-d6f8-4421-bc9b-b6e6a6e922c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f64199fc-64ab-44db-b50c-e5c71e864817" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d29f6585-d6f8-4421-bc9b-b6e6a6e922c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_58e79bd9-8545-40e4-bb9e-d8113950b656" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_f64199fc-64ab-44db-b50c-e5c71e864817" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_58e79bd9-8545-40e4-bb9e-d8113950b656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8a8a805d-a5c0-48d1-a8d1-2e46996f4f32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_fa266b9a-ea82-43b3-be1b-e1b7423ae479" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8a8a805d-a5c0-48d1-a8d1-2e46996f4f32" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_fa266b9a-ea82-43b3-be1b-e1b7423ae479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3d8e28a7-bbd1-4c70-af29-a9546e03e20a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_8a8a805d-a5c0-48d1-a8d1-2e46996f4f32" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3d8e28a7-bbd1-4c70-af29-a9546e03e20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_b4bcd551-0024-4a17-aeef-4a23b972716d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_d9d4478f-b588-4214-8084-c47b32aff49d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_b4bcd551-0024-4a17-aeef-4a23b972716d" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_d9d4478f-b588-4214-8084-c47b32aff49d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_e1ea27eb-4b88-4746-b803-d4f3a84d73d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_b4bcd551-0024-4a17-aeef-4a23b972716d" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_e1ea27eb-4b88-4746-b803-d4f3a84d73d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2ff61895-91e8-4a2f-a368-10d6f675e01b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_b4bcd551-0024-4a17-aeef-4a23b972716d" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_2ff61895-91e8-4a2f-a368-10d6f675e01b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_edf29e30-c1cf-4b37-967b-f74845d28b59" xlink:href="inpha-20240630.xsd#inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_b4bcd551-0024-4a17-aeef-4a23b972716d" xlink:to="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_edf29e30-c1cf-4b37-967b-f74845d28b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fc887059-4a7e-480b-82cb-b127ff4e69cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_55f14d88-5fcd-41c5-95c2-148af41b10bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fc887059-4a7e-480b-82cb-b127ff4e69cb" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_55f14d88-5fcd-41c5-95c2-148af41b10bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_34d39699-c0f3-418e-9af4-bf2d2f2b1831" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fc887059-4a7e-480b-82cb-b127ff4e69cb" xlink:to="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_34d39699-c0f3-418e-9af4-bf2d2f2b1831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_826e7dae-9ebe-42ee-a8ad-1759a64e4096" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fc887059-4a7e-480b-82cb-b127ff4e69cb" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_826e7dae-9ebe-42ee-a8ad-1759a64e4096" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_4b4651c9-5db5-4593-bf3d-9e40fe534c7d" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fc887059-4a7e-480b-82cb-b127ff4e69cb" xlink:to="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_4b4651c9-5db5-4593-bf3d-9e40fe534c7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimConsolidatedStatementofChangesinShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_8edec64e-6e01-4668-8520-55029a475069" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d9983d40-4d2e-48ee-aa81-00e7f4000fa8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_8edec64e-6e01-4668-8520-55029a475069" xlink:to="loc_ifrs-full_ProfitLoss_d9983d40-4d2e-48ee-aa81-00e7f4000fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_3475327a-2763-4856-a11e-e6b64a13c337" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_8edec64e-6e01-4668-8520-55029a475069" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_3475327a-2763-4856-a11e-e6b64a13c337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_f5f1a421-f371-4ce3-9d49-7d9424273032" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_8edec64e-6e01-4668-8520-55029a475069" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_f5f1a421-f371-4ce3-9d49-7d9424273032" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_0cc7079f-046e-4474-87da-cc3c78a759b8" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndShortTermInvestmentsAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3f1158f0-2a34-4211-a3fd-10563eb7cf64" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_0cc7079f-046e-4474-87da-cc3c78a759b8" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3f1158f0-2a34-4211-a3fd-10563eb7cf64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssets_62a476f7-fcad-4425-8cba-886bb30781f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_0cc7079f-046e-4474-87da-cc3c78a759b8" xlink:to="loc_ifrs-full_CurrentFinancialAssets_62a476f7-fcad-4425-8cba-886bb30781f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_946aa085-8f15-4944-b4fd-4805333935d1" xlink:href="inpha-20240630.xsd#inpha_TotalCashCashEquivalentsAndFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_e8e21c2a-6981-466d-9d4a-7a1d2a4e831f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_946aa085-8f15-4944-b4fd-4805333935d1" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_e8e21c2a-6981-466d-9d4a-7a1d2a4e831f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_7a12f31a-e30d-431c-a301-859ca74e8a12" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndShortTermInvestmentsAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_946aa085-8f15-4944-b4fd-4805333935d1" xlink:to="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_7a12f31a-e30d-431c-a301-859ca74e8a12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_2ace4d89-551f-433a-8daf-18e02052e8d1" xlink:href="inpha-20240630.xsd#inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_562c88cb-9a85-45fa-98a4-cb506c535643" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_2ace4d89-551f-433a-8daf-18e02052e8d1" xlink:to="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_562c88cb-9a85-45fa-98a4-cb506c535643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_fb5eb603-a57e-4744-af03-0a3c2be76b07" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_2ace4d89-551f-433a-8daf-18e02052e8d1" xlink:to="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_fb5eb603-a57e-4744-af03-0a3c2be76b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalAcquisitions_4ed12469-160e-4576-962d-80eb7e833b6d" xlink:href="inpha-20240630.xsd#inpha_TotalAcquisitions"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAcquisitions_940027d5-96ca-49fe-86e3-85180a8188a1" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAcquisitions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalAcquisitions_4ed12469-160e-4576-962d-80eb7e833b6d" xlink:to="loc_inpha_ShortTermInvestmentsAcquisitions_940027d5-96ca-49fe-86e3-85180a8188a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsAcquisitions_d243eb5b-a66f-4cea-b080-5cd718a319e5" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsAcquisitions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalAcquisitions_4ed12469-160e-4576-962d-80eb7e833b6d" xlink:to="loc_inpha_NonCurrentFinancialAssetsAcquisitions_d243eb5b-a66f-4cea-b080-5cd718a319e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalForeignCurrencyEffect_05935d9b-ecd2-4cd6-8f00-f1370a62c94d" xlink:href="inpha-20240630.xsd#inpha_TotalForeignCurrencyEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_1dc24f5c-2fd1-4192-8404-1df1f3ba4092" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsForeignCurrencyEffect"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalForeignCurrencyEffect_05935d9b-ecd2-4cd6-8f00-f1370a62c94d" xlink:to="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_1dc24f5c-2fd1-4192-8404-1df1f3ba4092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect_b9a5ad98-e22f-456a-8155-8db1af908ac1" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsForeignCurrencyEffect"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TotalForeignCurrencyEffect_05935d9b-ecd2-4cd6-8f00-f1370a62c94d" xlink:to="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect_b9a5ad98-e22f-456a-8155-8db1af908ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_019a7063-208d-48a7-b0a2-daf4fcba9059" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_0e1b9cdd-ff24-40b5-a228-ec3e6f109786" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_019a7063-208d-48a7-b0a2-daf4fcba9059" xlink:to="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_0e1b9cdd-ff24-40b5-a228-ec3e6f109786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_e2d05b8c-e08a-4498-b00f-d081a4dbf495" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_019a7063-208d-48a7-b0a2-daf4fcba9059" xlink:to="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_e2d05b8c-e08a-4498-b00f-d081a4dbf495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_31d4508d-4aef-4f9a-aa96-7e498b5dbc24" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_3cd09c10-3cc3-41d6-91f0-cc9e87a6b13a" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_31d4508d-4aef-4f9a-aa96-7e498b5dbc24" xlink:to="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_3cd09c10-3cc3-41d6-91f0-cc9e87a6b13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment_d54a53d9-0da4-4601-863a-35f207dd2e03" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_31d4508d-4aef-4f9a-aa96-7e498b5dbc24" xlink:to="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment_d54a53d9-0da4-4601-863a-35f207dd2e03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_5f9c6d1e-1dba-4c90-b6cd-33107d82b207" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentResearchTaxCredit_da812314-8815-4d62-ba11-c409a1cba42a" xlink:href="inpha-20240630.xsd#inpha_NonCurrentResearchTaxCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_5f9c6d1e-1dba-4c90-b6cd-33107d82b207" xlink:to="loc_inpha_NonCurrentResearchTaxCredit_da812314-8815-4d62-ba11-c409a1cba42a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentPrepaidExpenses_58931bff-2bd0-4b1a-8274-0e71b93bff81" xlink:href="inpha-20240630.xsd#inpha_NonCurrentPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_5f9c6d1e-1dba-4c90-b6cd-33107d82b207" xlink:to="loc_inpha_NonCurrentPrepaidExpenses_58931bff-2bd0-4b1a-8274-0e71b93bff81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherReceivablesExcludingRebates_9a37de02-41e3-47c4-9bc0-0dbab18cd77a" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherReceivablesExcludingRebates"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_f4e05ea0-a96a-40dd-99ef-de28f7a4075d" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherReceivablesExcludingRebates_9a37de02-41e3-47c4-9bc0-0dbab18cd77a" xlink:to="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_f4e05ea0-a96a-40dd-99ef-de28f7a4075d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_973d76ce-f361-493a-a6c6-56b7bc0a57f7" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherCurrentReceivablesExcludingRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherReceivablesExcludingRebates_9a37de02-41e3-47c4-9bc0-0dbab18cd77a" xlink:to="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_973d76ce-f361-493a-a6c6-56b7bc0a57f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherCurrentReceivablesExcludingRebates"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchTaxCreditReceivableCurrent_684c72eb-f398-47ba-bc4d-73155c565b2d" xlink:href="inpha-20240630.xsd#inpha_ResearchTaxCreditReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_inpha_ResearchTaxCreditReceivableCurrent_684c72eb-f398-47ba-bc4d-73155c565b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_bc333b47-9ced-4bf4-afdb-7ffb9c642c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_ifrs-full_CurrentTradeReceivables_bc333b47-9ced-4bf4-afdb-7ffb9c642c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_6e0d19d0-c4ac-420f-b4d6-168c134a6d46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_6e0d19d0-c4ac-420f-b4d6-168c134a6d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_e57eb43a-aa86-4d50-8897-cc213289dca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_e57eb43a-aa86-4d50-8897-cc213289dca8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_363d317f-4543-46e7-ab7d-8125c14311ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_ifrs-full_OtherCurrentReceivables_363d317f-4543-46e7-ab7d-8125c14311ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherCurrentTaxCreditsReceivables_8748c140-d3c6-47ab-875a-38a75cf61714" xlink:href="inpha-20240630.xsd#inpha_OtherCurrentTaxCreditsReceivables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_inpha_OtherCurrentTaxCreditsReceivables_8748c140-d3c6-47ab-875a-38a75cf61714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_70db869b-91db-44ee-aa91-e4feb9bbed39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_eb82b33d-c2ea-46a9-8e70-705ead076f06" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_70db869b-91db-44ee-aa91-e4feb9bbed39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradepayablesandothersDisclosureoftradepayablesandothersDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_62ec1de1-a8e3-4a1e-8662-d5df72d2b98d" xlink:href="inpha-20240630.xsd#inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_ea79d216-cc12-4862-8c50-5e71f32b8974" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_62ec1de1-a8e3-4a1e-8662-d5df72d2b98d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_ea79d216-cc12-4862-8c50-5e71f32b8974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c2bb2741-21c4-4a95-8640-354a767b59a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_62ec1de1-a8e3-4a1e-8662-d5df72d2b98d" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c2bb2741-21c4-4a95-8640-354a767b59a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_47670768-37a8-4e2e-8548-791fc5c12595" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_62ec1de1-a8e3-4a1e-8662-d5df72d2b98d" xlink:to="loc_ifrs-full_OtherCurrentPayables_47670768-37a8-4e2e-8548-791fc5c12595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1a1e9dc7-81e6-422f-a9e2-ce21d7aa886d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_6ab96428-4c02-4aaf-94d3-0ee413df3764" xlink:href="inpha-20240630.xsd#inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_1a1e9dc7-81e6-422f-a9e2-ce21d7aa886d" xlink:to="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_6ab96428-4c02-4aaf-94d3-0ee413df3764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_4d1e0394-fd09-43e2-b714-71c37b1f652f" xlink:href="inpha-20240630.xsd#inpha_CurrentPayablesRelatedToCapitalExpenditures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_1a1e9dc7-81e6-422f-a9e2-ce21d7aa886d" xlink:to="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_4d1e0394-fd09-43e2-b714-71c37b1f652f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GovernmentFinancingForResearchExpenditures_8b0d5b20-e53d-4022-897b-04a92dd035dc" xlink:href="inpha-20240630.xsd#inpha_GovernmentFinancingForResearchExpenditures"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit_249aa82f-ab55-4122-aba5-72cbbf11324d" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_GovernmentFinancingForResearchExpenditures_8b0d5b20-e53d-4022-897b-04a92dd035dc" xlink:to="loc_inpha_IncomeFromResearchTaxCredit_249aa82f-ab55-4122-aba5-72cbbf11324d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_0818cff1-3b1a-42c3-83cf-f379312af75a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_GovernmentFinancingForResearchExpenditures_8b0d5b20-e53d-4022-897b-04a92dd035dc" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_0818cff1-3b1a-42c3-83cf-f379312af75a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesDisclosureofexpensesbynatureDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SubcontractingCosts_d14dbe99-187e-48c8-9a73-3fc0143615fe" xlink:href="inpha-20240630.xsd#inpha_SubcontractingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_SubcontractingCosts_d14dbe99-187e-48c8-9a73-3fc0143615fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5ac7b3d8-9eb1-4f28-8673-a3651c50796a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5ac7b3d8-9eb1-4f28-8673-a3651c50796a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_7150eba0-6de5-436d-99a0-5cb00a00db58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_7150eba0-6de5-436d-99a0-5cb00a00db58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherPurchasesAndExternalExpenses_ae9c1f5e-24cd-400d-9b6d-66e1cfe991ec" xlink:href="inpha-20240630.xsd#inpha_OtherPurchasesAndExternalExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_OtherPurchasesAndExternalExpenses_ae9c1f5e-24cd-400d-9b6d-66e1cfe991ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IntellectualPropertyExpenses_ae26a2b3-aff2-4851-b11b-1b03218fa499" xlink:href="inpha-20240630.xsd#inpha_IntellectualPropertyExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_IntellectualPropertyExpenses_ae26a2b3-aff2-4851-b11b-1b03218fa499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeasingAndMaintenance_d12119dd-be0e-4e9a-8c7c-28c7b56a128b" xlink:href="inpha-20240630.xsd#inpha_LeasingAndMaintenance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_LeasingAndMaintenance_d12119dd-be0e-4e9a-8c7c-28c7b56a128b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_5123e62f-0486-442e-a4e6-36ec98d0fa3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_5123e62f-0486-442e-a4e6-36ec98d0fa3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TravelExpense_a8837227-f141-48aa-b708-ac8e784a33ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_TravelExpense_a8837227-f141-48aa-b708-ac8e784a33ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonScientificAdvisoryAndConsulting_c3fb67c1-f8e7-4cfc-ab62-30e8d5138d1c" xlink:href="inpha-20240630.xsd#inpha_NonScientificAdvisoryAndConsulting"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_NonScientificAdvisoryAndConsulting_c3fb67c1-f8e7-4cfc-ab62-30e8d5138d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ScientificAdvisoryAndConsulting_41972f96-57fc-4611-a64b-88e4ab9c82d9" xlink:href="inpha-20240630.xsd#inpha_ScientificAdvisoryAndConsulting"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_inpha_ScientificAdvisoryAndConsulting_41972f96-57fc-4611-a64b-88e4ab9c82d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_b7122830-841e-480d-98ea-88b77ef2aef6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_b7122830-841e-480d-98ea-88b77ef2aef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_f4bcd6ee-38e2-4776-8afc-f27a0b0cea27" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_5fe10987-80a3-4cb6-8e56-34c55d92f55a" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_f4bcd6ee-38e2-4776-8afc-f27a0b0cea27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_9e3aeb44-ac3a-4821-8445-02d21641e045" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_85f98321-3ea8-41c9-888d-c122f7da4695" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_9e3aeb44-ac3a-4821-8445-02d21641e045" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_85f98321-3ea8-41c9-888d-c122f7da4695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7cd81caf-c08f-411d-87f3-6f7efa137980" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_9e3aeb44-ac3a-4821-8445-02d21641e045" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_7cd81caf-c08f-411d-87f3-6f7efa137980" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_f12a680a-adb0-44c9-9c22-64aa895e6e6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments_88a85c0f-3267-44bc-8109-77fc1b9bd4df" xlink:href="inpha-20240630.xsd#inpha_ChangeInValuationAllowanceOfFinancialInstruments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_f12a680a-adb0-44c9-9c22-64aa895e6e6a" xlink:to="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments_88a85c0f-3267-44bc-8109-77fc1b9bd4df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_a1c7e887-8cb5-4f0e-9500-bff5abf86318" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_f12a680a-adb0-44c9-9c22-64aa895e6e6a" xlink:to="loc_ifrs-full_NetForeignExchangeGain_a1c7e887-8cb5-4f0e-9500-bff5abf86318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherFinancialIncome_39dda94c-3b76-47ab-a4a0-3a8c8a4a6d00" xlink:href="inpha-20240630.xsd#inpha_OtherFinancialIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_f12a680a-adb0-44c9-9c22-64aa895e6e6a" xlink:to="loc_inpha_OtherFinancialIncome_39dda94c-3b76-47ab-a4a0-3a8c8a4a6d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_InterestsAndGainsOnFinancialAssets_6583521e-af19-4d94-8700-6ecd4dcac71e" xlink:href="inpha-20240630.xsd#inpha_InterestsAndGainsOnFinancialAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_f12a680a-adb0-44c9-9c22-64aa895e6e6a" xlink:to="loc_inpha_InterestsAndGainsOnFinancialAssets_6583521e-af19-4d94-8700-6ecd4dcac71e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_d098eefa-2e07-4f6f-9984-4c8d0e521dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_b45de343-515e-4152-a923-1f5cad748a4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_d098eefa-2e07-4f6f-9984-4c8d0e521dfe" xlink:to="loc_ifrs-full_InterestExpense_b45de343-515e-4152-a923-1f5cad748a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnrealizedLossesOnFinancialAssets_d1d38230-e71b-4155-b6bd-4afe3d5be3ed" xlink:href="inpha-20240630.xsd#inpha_UnrealizedLossesOnFinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_d098eefa-2e07-4f6f-9984-4c8d0e521dfe" xlink:to="loc_inpha_UnrealizedLossesOnFinancialAssets_d1d38230-e71b-4155-b6bd-4afe3d5be3ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_dee93354-080e-4585-a8b8-f51b918a7a5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_d098eefa-2e07-4f6f-9984-4c8d0e521dfe" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_dee93354-080e-4585-a8b8-f51b918a7a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherFinancialExpenses_a70666f6-13da-416c-9af7-556884e7fcd3" xlink:href="inpha-20240630.xsd#inpha_OtherFinancialExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_d098eefa-2e07-4f6f-9984-4c8d0e521dfe" xlink:to="loc_inpha_OtherFinancialExpenses_a70666f6-13da-416c-9af7-556884e7fcd3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_37f8b223-3d46-4899-bc0d-32097a11faf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_259b6bda-15a5-47e4-9e89-9ca8fe39ebee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_37f8b223-3d46-4899-bc0d-32097a11faf8" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_259b6bda-15a5-47e4-9e89-9ca8fe39ebee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_812490e2-7154-425e-8ad7-07a343744372" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_37f8b223-3d46-4899-bc0d-32097a11faf8" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_812490e2-7154-425e-8ad7-07a343744372" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7165cc0a-ec60-4ef1-a2f6-ef91c646b85d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_37f8b223-3d46-4899-bc0d-32097a11faf8" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7165cc0a-ec60-4ef1-a2f6-ef91c646b85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees_d3e3a8a4-63f2-4028-a927-da048f092912" xlink:href="inpha-20240630.xsd#inpha_KeyManagementPersonnelCompensationAdvisoryFees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_37f8b223-3d46-4899-bc0d-32097a11faf8" xlink:to="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees_d3e3a8a4-63f2-4028-a927-da048f092912" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"/>
  <link:calculationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_8063e360-65b0-4088-b2fc-cd8d6d732269" xlink:href="inpha-20240630.xsd#inpha_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_93c13a0b-f94a-4120-af48-b046bfb825e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_8063e360-65b0-4088-b2fc-cd8d6d732269" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_93c13a0b-f94a-4120-af48-b046bfb825e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_b8c2dec5-14b7-4c29-8391-fb2f8c55227c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_8063e360-65b0-4088-b2fc-cd8d6d732269" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_b8c2dec5-14b7-4c29-8391-fb2f8c55227c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_e5640c7d-c0e7-4750-adce-194d6e73c954" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_c0e05bb1-4d46-4174-8bb1-27ff981f96b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_e5640c7d-c0e7-4750-adce-194d6e73c954" xlink:to="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_c0e05bb1-4d46-4174-8bb1-27ff981f96b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_81656639-b79e-497d-9d60-34cf5f089e23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_e5640c7d-c0e7-4750-adce-194d6e73c954" xlink:to="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_81656639-b79e-497d-9d60-34cf5f089e23" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>inpha-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimConsolidatedStatementofChangesinShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b6dffcc6-7b97-49cf-950e-2fd65bbfe243" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:to="loc_ifrs-full_OrdinarySharesMember_b6dffcc6-7b97-49cf-950e-2fd65bbfe243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember_8c3e85be-bb33-47b0-a89a-5f92d2e84cd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:to="loc_ifrs-full_PreferenceSharesMember_8c3e85be-bb33-47b0-a89a-5f92d2e84cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_d651fc27-6b51-4a83-ae81-69238f15ab38_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_d651fc27-6b51-4a83-ae81-69238f15ab38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_05a7558c-d416-4848-b0d4-a58dfe521fc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_IssuedCapitalMember_05a7558c-d416-4848-b0d4-a58dfe521fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_feeba92a-0eec-4a72-b63a-faf66d64dd24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_SharePremiumMember_feeba92a-0eec-4a72-b63a-faf66d64dd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_6f1d6ba3-515a-4170-90f1-5b5070f51bc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_6f1d6ba3-515a-4170-90f1-5b5070f51bc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c8588e29-d00a-4e6a-9feb-b9f4cf776a9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c8588e29-d00a-4e6a-9feb-b9f4cf776a9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_1534edd6-f892-4c24-881a-b973c59f64c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_1534edd6-f892-4c24-881a-b973c59f64c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_06079ea5-9060-420a-a0e0-0e2d3c9c87b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_NumberOfSharesIssued_06079ea5-9060-420a-a0e0-0e2d3c9c87b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_752a8a38-606a-4441-a240-1aae8364411d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_Equity_752a8a38-606a-4441-a240-1aae8364411d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7a1959c5-0155-4f1d-8750-bf4aaca680d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_ProfitLoss_7a1959c5-0155-4f1d-8750-bf4aaca680d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9551cdb8-3e5c-4eba-bc02-455c61f6f23d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9551cdb8-3e5c-4eba-bc02-455c61f6f23d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_23cb4a71-6514-4dcf-b0cb-181de3ea344a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_23cb4a71-6514-4dcf-b0cb-181de3ea344a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1fb5cef4-836a-4abe-80f0-1c5a1687ba0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_ComprehensiveIncome_1fb5cef4-836a-4abe-80f0-1c5a1687ba0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_4e5230d4-a9cd-4f58-a848-19a30cffd9ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_4e5230d4-a9cd-4f58-a848-19a30cffd9ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_26618dd1-8559-4b6b-b9a5-7d2dd1b9d2db" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_26618dd1-8559-4b6b-b9a5-7d2dd1b9d2db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_20717b66-0d4c-4d45-837d-19a1d2b86e67" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_20717b66-0d4c-4d45-837d-19a1d2b86e67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_fe787256-eec5-46bf-8632-57fd959b77a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_fe787256-eec5-46bf-8632-57fd959b77a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_bbde14cb-d0bc-456d-91dd-72d6130fe24b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f793a3e3-c6df-4e96-88fc-6513ee2b2614" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details" xlink:type="simple" xlink:href="inpha-20240630.xsd#TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_91610017-761c-4da1-9877-105bb26ce4a6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:to="loc_ifrs-full_TypesOfContractsDomain_91610017-761c-4da1-9877-105bb26ce4a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:to="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_07e5267c-3b3d-4d4d-9c54-ede80e8bf918" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_07e5267c-3b3d-4d4d-9c54-ede80e8bf918" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_55a5abae-5586-43ba-b976-9e48dddb3197_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_55a5abae-5586-43ba-b976-9e48dddb3197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IssuedCapitalFreeOfSubscriptionMember_dce1cb88-5ad0-40be-af1e-ef8a95878f07" xlink:href="inpha-20240630.xsd#inpha_IssuedCapitalFreeOfSubscriptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:to="loc_inpha_IssuedCapitalFreeOfSubscriptionMember_dce1cb88-5ad0-40be-af1e-ef8a95878f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_1f668aee-2634-4ac4-9bb7-0b9aa0e25c36" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:to="loc_ifrs-full_SharePremiumMember_1f668aee-2634-4ac4-9bb7-0b9aa0e25c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_426827f3-2c84-4413-950b-7bd5cc589983_default" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:to="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_426827f3-2c84-4413-950b-7bd5cc589983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:to="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseOfShareWarrantsMember_46f49e30-7a76-4ada-8dbf-399b9ccbd76e" xlink:href="inpha-20240630.xsd#inpha_ExerciseOfShareWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_inpha_ExerciseOfShareWarrantsMember_46f49e30-7a76-4ada-8dbf-399b9ccbd76e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember_f7a0e401-bf63-4036-a758-1445cf73ad3e" xlink:href="inpha-20240630.xsd#inpha_DefinitiveAcquisitionOfFreeSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember_f7a0e401-bf63-4036-a758-1445cf73ad3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_8c449a62-d37c-442e-9788-7543377f35a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_ifrs-full_OrdinarySharesMember_8c449a62-d37c-442e-9788-7543377f35a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_e096583a-3928-4233-b56f-f4cf28637858_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_e096583a-3928-4233-b56f-f4cf28637858_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_905b3ba2-88c2-442c-975e-97af1d3e5ffe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:to="loc_ifrs-full_OrdinarySharesMember_905b3ba2-88c2-442c-975e-97af1d3e5ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FreeSharesMember_434d61d1-2622-4aeb-a83e-980783d15b5a" xlink:href="inpha-20240630.xsd#inpha_FreeSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:to="loc_inpha_FreeSharesMember_434d61d1-2622-4aeb-a83e-980783d15b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_f2c937d4-6a52-4091-b159-b682fdbd76c6" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_f2c937d4-6a52-4091-b159-b682fdbd76c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_bdf55a07-8b12-4c33-b78a-d6749f69626b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_bdf55a07-8b12-4c33-b78a-d6749f69626b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_fd2693b3-1ccc-4ff0-b76b-0b1de4278987" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_ifrs-full_ParValuePerShare_fd2693b3-1ccc-4ff0-b76b-0b1de4278987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareIssuedPricePerShare_f8f0f019-cdef-42d1-ac0e-4e7a0ff7b479" xlink:href="inpha-20240630.xsd#inpha_ShareIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_ShareIssuedPricePerShare_f8f0f019-cdef-42d1-ac0e-4e7a0ff7b479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_b45aea3a-75f2-4551-99bf-159b64173f7f" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_b45aea3a-75f2-4551-99bf-159b64173f7f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_640d2098-1d3d-4022-bddc-8df7cc543685_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_640d2098-1d3d-4022-bddc-8df7cc543685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVMember_ccdc8626-fc7f-4ece-ab17-b1b2a302bdb0" xlink:href="inpha-20240630.xsd#inpha_SICAVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_SICAVMember_ccdc8626-fc7f-4ece-ab17-b1b2a302bdb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVAndMutualFundsMember_d6b97bc8-b334-4ac4-aa2e-8150049d1acc" xlink:href="inpha-20240630.xsd#inpha_SICAVAndMutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_SICAVAndMutualFundsMember_d6b97bc8-b334-4ac4-aa2e-8150049d1acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_bcacb93e-b7d2-4974-945e-548a4823ccbe" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_bcacb93e-b7d2-4974-945e-548a4823ccbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:to="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f698fff-1de4-4334-bfd1-83a5fbb7beef_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:to="loc_srt_RangeMember_3f698fff-1de4-4334-bfd1-83a5fbb7beef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:to="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22943afe-e1d7-43f4-ab47-7bc678a864f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:to="loc_srt_MinimumMember_22943afe-e1d7-43f4-ab47-7bc678a864f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36ca3799-880d-484d-bfa6-4b6f5a40f5d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:to="loc_srt_MaximumMember_36ca3799-880d-484d-bfa6-4b6f5a40f5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfFinancialInstrumentsHeld_0f8247ad-f823-4696-b062-d1b81d75b1e1" xlink:href="inpha-20240630.xsd#inpha_NumberOfFinancialInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_NumberOfFinancialInstrumentsHeld_0f8247ad-f823-4696-b062-d1b81d75b1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RiskProfileRate_b080b90d-dec0-4ab3-8b9e-47fcd0340dd1" xlink:href="inpha-20240630.xsd#inpha_RiskProfileRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_RiskProfileRate_b080b90d-dec0-4ab3-8b9e-47fcd0340dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_a1891540-e0c5-44fa-85ce-8359d9f74f29" xlink:href="inpha-20240630.xsd#inpha_TotalCashCashEquivalentsAndFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_a1891540-e0c5-44fa-85ce-8359d9f74f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_eb1b8483-3dc5-45cd-8e41-11a75ab93f91" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_eb1b8483-3dc5-45cd-8e41-11a75ab93f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_f79ce8c5-05a2-48a3-b1ec-aa28827d6a66" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_f79ce8c5-05a2-48a3-b1ec-aa28827d6a66" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_728e5f6f-9a67-4118-a34e-d0b8ef36e33f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_728e5f6f-9a67-4118-a34e-d0b8ef36e33f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GuaranteesMember_fe5925e3-197a-4d6b-a91b-c626f8d0ebcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GuaranteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:to="loc_ifrs-full_GuaranteesMember_fe5925e3-197a-4d6b-a91b-c626f8d0ebcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_15639bb6-59b0-4776-b39e-96e1f2b0b41d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_15639bb6-59b0-4776-b39e-96e1f2b0b41d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_06135630-caad-42ef-86ab-57552f187503" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_06135630-caad-42ef-86ab-57552f187503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_75f273fb-cc07-4ea0-9179-7e25cf8a9866_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:to="loc_ifrs-full_TypesOfContractsDomain_75f273fb-cc07-4ea0-9179-7e25cf8a9866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:to="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofiMember_e35655d1-8323-47a0-9b07-7bdf19931032" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:to="loc_inpha_AgreementWithSanofiMember_e35655d1-8323-47a0-9b07-7bdf19931032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_c520091a-76b7-442b-a3f1-eaf73f56f436" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_OtherCurrentReceivables_c520091a-76b7-442b-a3f1-eaf73f56f436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchTaxCreditReceivableCurrent_12f15ba1-1014-406f-8009-f4b3d37aa266" xlink:href="inpha-20240630.xsd#inpha_ResearchTaxCreditReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_ResearchTaxCreditReceivableCurrent_12f15ba1-1014-406f-8009-f4b3d37aa266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherCurrentTaxCreditsReceivables_c5e3b0e1-3cc4-4c18-9c04-a9603e3d2d3d" xlink:href="inpha-20240630.xsd#inpha_OtherCurrentTaxCreditsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_OtherCurrentTaxCreditsReceivables_c5e3b0e1-3cc4-4c18-9c04-a9603e3d2d3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_7a48283e-2295-4fdf-8907-97f796dbb366" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_7a48283e-2295-4fdf-8907-97f796dbb366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_ebb42a0d-762c-4cc1-888d-30de40c95ebe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_ebb42a0d-762c-4cc1-888d-30de40c95ebe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_2e9f609c-9759-4886-88a4-77281fefe4c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentTradeReceivables_2e9f609c-9759-4886-88a4-77281fefe4c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_7ece3c23-7ce8-4311-b49d-b786572ee46d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_7ece3c23-7ce8-4311-b49d-b786572ee46d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_89887f4e-cd7f-4f4e-867a-8dadf9777778" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherCurrentReceivablesExcludingRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_89887f4e-cd7f-4f4e-867a-8dadf9777778" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentResearchTaxCredit_67c89d81-66c7-4819-8967-b1914fd049a8" xlink:href="inpha-20240630.xsd#inpha_NonCurrentResearchTaxCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_NonCurrentResearchTaxCredit_67c89d81-66c7-4819-8967-b1914fd049a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentPrepaidExpenses_95db4882-1a70-4f07-9937-ab2fe21b5e6c" xlink:href="inpha-20240630.xsd#inpha_NonCurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_NonCurrentPrepaidExpenses_95db4882-1a70-4f07-9937-ab2fe21b5e6c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_b4b9ab56-1057-45d9-a5f6-18a33a801517" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_b4b9ab56-1057-45d9-a5f6-18a33a801517" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherReceivablesExcludingRebates_865e3e09-fd12-4afa-a659-592bf7f0549b" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherReceivablesExcludingRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherReceivablesExcludingRebates_865e3e09-fd12-4afa-a659-592bf7f0549b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_9249eb98-c24d-40ef-85e4-9b577a25cceb" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019And2020Maturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_9249eb98-c24d-40ef-85e4-9b577a25cceb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019_01df958b-7f42-4859-a86d-4a327ebb2b16" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2019_01df958b-7f42-4859-a86d-4a327ebb2b16" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020_5c946d40-47ea-48ba-81a7-7976487bd7d4" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020_5c946d40-47ea-48ba-81a7-7976487bd7d4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_a6b97c09-1008-4239-822f-530b6efa7bb7" xlink:href="inpha-20240630.xsd#inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_a6b97c09-1008-4239-822f-530b6efa7bb7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2023_30766576-5099-48a0-b331-387defd002ae" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2023"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2023_30766576-5099-48a0-b331-387defd002ae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024_12307211-481a-4995-92a9-8758eca66f32" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCreditHalfYear2024"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024_12307211-481a-4995-92a9-8758eca66f32" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CarryBackTaxReceivable_7427fad8-70f2-4ef1-a59a-76e803707b13" xlink:href="inpha-20240630.xsd#inpha_CarryBackTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_CarryBackTaxReceivable_7427fad8-70f2-4ef1-a59a-76e803707b13" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingNumberOfLoanAgreement_7aca2fa6-d1b4-4d51-b058-8a53d1c03e94" xlink:href="inpha-20240630.xsd#inpha_BorrowingNumberOfLoanAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_BorrowingNumberOfLoanAgreement_7aca2fa6-d1b4-4d51-b058-8a53d1c03e94" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturity_b4087b7b-504a-4ea0-9d4f-64b6067c040e" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_BorrowingMaturity_b4087b7b-504a-4ea0-9d4f-64b6067c040e" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_fde29346-e268-4d3d-b7e6-45e598846a91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_fde29346-e268-4d3d-b7e6-45e598846a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_ec90cbcd-f380-4702-b0aa-9b0cb6ac5d92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_LicencesMember_ec90cbcd-f380-4702-b0aa-9b0cb6ac5d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_2ac6b5f9-a97d-4fd8-8249-ad7df490807b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_2ac6b5f9-a97d-4fd8-8249-ad7df490807b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_6cc5cb17-69f7-41a8-9ef4-f0634c873443" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_6cc5cb17-69f7-41a8-9ef4-f0634c873443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2e97e380-1729-451a-b503-acb95136f745_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2e97e380-1729-451a-b503-acb95136f745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_c3d1f63a-ca45-407b-8a7d-b59b1956e5ee" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:to="loc_inpha_MonalizumabAgreementMember_c3d1f63a-ca45-407b-8a7d-b59b1956e5ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithOregaBiotechMember_b4623037-3193-4504-9a28-f01558f50e76" xlink:href="inpha-20240630.xsd#inpha_AgreementWithOregaBiotechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:to="loc_inpha_AgreementWithOregaBiotechMember_b4623037-3193-4504-9a28-f01558f50e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fe6f37eb-9020-4d72-bea8-dca74427036d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fe6f37eb-9020-4d72-bea8-dca74427036d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8593475c-c7e2-41f7-a1fb-ca74b170de25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8593475c-c7e2-41f7-a1fb-ca74b170de25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_febff1cd-6e86-4490-aa07-5561ba93dfa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_febff1cd-6e86-4490-aa07-5561ba93dfa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_9b7f8b5c-a361-4042-af0f-934ad6a03385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_9b7f8b5c-a361-4042-af0f-934ad6a03385" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3ba96e08-eda1-4c00-ab46-e4f928b9b9a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3ba96e08-eda1-4c00-ab46-e4f928b9b9a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_1743a060-1823-48fb-908e-c0cc6c893f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_1743a060-1823-48fb-908e-c0cc6c893f55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a30f19e2-78fa-4784-bf6b-a27b4018e730" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IntangibleassetsAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:to="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_6befc7ce-b66d-4e5c-8d5e-39ead12ec060_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:to="loc_ifrs-full_TypesOfContractsDomain_6befc7ce-b66d-4e5c-8d5e-39ead12ec060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:to="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_0a98f367-ad0e-4a12-a028-63fd03ba5de7" xlink:href="inpha-20240630.xsd#inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_0a98f367-ad0e-4a12-a028-63fd03ba5de7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_00031622-6636-4cf8-829d-1cd8ce189bae" xlink:href="inpha-20240630.xsd#inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_00031622-6636-4cf8-829d-1cd8ce189bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_e6e5e20c-6714-4d53-ae4a-201f113068d6" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH5201WithAstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_e6e5e20c-6714-4d53-ae4a-201f113068d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_e663481b-bd38-43a0-b7a8-4150360d0a44" xlink:href="inpha-20240630.xsd#inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_e663481b-bd38-43a0-b7a8-4150360d0a44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_f895f3ee-06d2-4e3c-b40d-ca4dc2c9f269" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_f895f3ee-06d2-4e3c-b40d-ca4dc2c9f269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_c86b1b19-a7d5-4757-9ab7-8c957791113b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_c86b1b19-a7d5-4757-9ab7-8c957791113b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_c90149d4-bec5-4619-a5d6-7b4fcd91fb41" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_c90149d4-bec5-4619-a5d6-7b4fcd91fb41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentsForMilestone_1e93063f-9ee4-4434-8e7e-9d3c7fa04a28" xlink:href="inpha-20240630.xsd#inpha_PaymentsForMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_inpha_PaymentsForMilestone_1e93063f-9ee4-4434-8e7e-9d3c7fa04a28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_9d4c7fc0-8c4d-49a7-b8e2-3192eecdb879" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_FinancialLiabilities_9d4c7fc0-8c4d-49a7-b8e2-3192eecdb879" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e95bd1c9-8889-4ef0-b018-f6f1eb999a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e95bd1c9-8889-4ef0-b018-f6f1eb999a09" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_c7e3b106-f331-4da8-b47f-31291dfffd5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_ifrs-full_LandAndBuildingsMember_c7e3b106-f331-4da8-b47f-31291dfffd5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LaboratoryEquipmentAndOtherMember_48390eaa-8d67-4fee-9127-21bbbf9a6233" xlink:href="inpha-20240630.xsd#inpha_LaboratoryEquipmentAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_inpha_LaboratoryEquipmentAndOtherMember_48390eaa-8d67-4fee-9127-21bbbf9a6233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_94ab75c7-7100-400d-98bf-d085690ade9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_ifrs-full_ConstructionInProgressMember_94ab75c7-7100-400d-98bf-d085690ade9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_48dabf4b-183d-4f88-b7c2-34e762cf228a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_48dabf4b-183d-4f88-b7c2-34e762cf228a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_f346c434-e8d0-42d1-9eed-c01f6a91a7ce" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_f346c434-e8d0-42d1-9eed-c01f6a91a7ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_01579f5d-8ec5-413f-aba5-bc8bca250d4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_01579f5d-8ec5-413f-aba5-bc8bca250d4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_d3a05d88-d372-471c-81ab-934abdf126e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:to="loc_ifrs-full_RightofuseAssetsMember_d3a05d88-d372-471c-81ab-934abdf126e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_e9412da1-2c96-44e6-8077-ffb05f54460c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_e9412da1-2c96-44e6-8077-ffb05f54460c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8cb1e5fa-f5ff-431a-9b81-716dfb9c5382" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8cb1e5fa-f5ff-431a-9b81-716dfb9c5382" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_bd415dfb-6f20-432d-ae5b-54a1c4aca4e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_bd415dfb-6f20-432d-ae5b-54a1c4aca4e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_536cc780-1382-4377-a243-6d0e5aa2173c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_536cc780-1382-4377-a243-6d0e5aa2173c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_b5c0333b-e2ef-4ecd-8678-e17a3a2ab8d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_b5c0333b-e2ef-4ecd-8678-e17a3a2ab8d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_5d15a60d-29e7-499f-a30a-2ac7b4b350dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_c31b8dfb-7d1b-4aff-9b5f-7e1f24b6e37e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_c31b8dfb-7d1b-4aff-9b5f-7e1f24b6e37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInFinancialLiabilities_55279af3-dd69-4623-aa7c-6d9fb69a1017" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_inpha_IncreaseDecreaseInFinancialLiabilities_55279af3-dd69-4623-aa7c-6d9fb69a1017" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradepayablesandothersDisclosureoftradepayablesandothersDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:to="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d5b92141-27d6-415b-88db-695f495c3023_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d5b92141-27d6-415b-88db-695f495c3023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:to="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a442488f-6044-4bd8-9ed8-112dd0f2b3ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:to="loc_srt_ScenarioForecastMember_a442488f-6044-4bd8-9ed8-112dd0f2b3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0f0cdf1f-12bc-4738-9a74-61d1cb3af13a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0f0cdf1f-12bc-4738-9a74-61d1cb3af13a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c10acb5d-728c-4f5e-a993-57e9c6817295" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c10acb5d-728c-4f5e-a993-57e9c6817295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_d54856eb-0080-4e8d-a3be-1f4b5c196485" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_OtherCurrentPayables_d54856eb-0080-4e8d-a3be-1f4b5c196485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_83f0bce8-8e1f-4bb1-90c9-ea892d820d28" xlink:href="inpha-20240630.xsd#inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_83f0bce8-8e1f-4bb1-90c9-ea892d820d28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_6a20bd5e-8862-4909-ab5a-3e7fd85fdf50" xlink:href="inpha-20240630.xsd#inpha_CurrentPayablesRelatedToCapitalExpenditures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_6a20bd5e-8862-4909-ab5a-3e7fd85fdf50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_76f124e2-9972-4f5a-9649-135389ad6ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_76f124e2-9972-4f5a-9649-135389ad6ac2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_f6cad113-40bc-4a1e-a7f2-5fab45e76d77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_f6cad113-40bc-4a1e-a7f2-5fab45e76d77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_aca26cea-706b-49ac-b170-75eefe152f74" xlink:href="inpha-20240630.xsd#inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_aca26cea-706b-49ac-b170-75eefe152f74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_b07c03bd-2cde-4d02-ada2-2a28433aa93c" xlink:href="inpha-20240630.xsd#inpha_OffsetAgainstIncomeFromResearchTaxCredit2020"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_b07c03bd-2cde-4d02-ada2-2a28433aa93c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020_1765dca7-a1a3-48f9-8beb-fb7bdb849c73" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020_1765dca7-a1a3-48f9-8beb-fb7bdb849c73" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020Receivable_2156c6b5-5486-4a96-b286-c6021f6f4b55" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020Receivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020Receivable_2156c6b5-5486-4a96-b286-c6021f6f4b55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfStateGuaranteedLoans_510c3d62-27f5-433c-9cd7-859a910d243d" xlink:href="inpha-20240630.xsd#inpha_NumberOfStateGuaranteedLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_NumberOfStateGuaranteedLoans_510c3d62-27f5-433c-9cd7-859a910d243d" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8c328f91-1d15-43bd-9fe8-00622e12aa41_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_8c328f91-1d15-43bd-9fe8-00622e12aa41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_c548d064-25a5-4cd9-8013-8c64b81a0020" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_c548d064-25a5-4cd9-8013-8c64b81a0020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_ce02ead3-7d45-4bea-9200-551880d7546a" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_ce02ead3-7d45-4bea-9200-551880d7546a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementAccruedInterestMember_a4316dd8-dc53-4e4b-8094-0e120dfb9498" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementAccruedInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementAccruedInterestMember_a4316dd8-dc53-4e4b-8094-0e120dfb9498" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_3ae1f4a8-8307-481d-b2b2-413925c71047" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_3ae1f4a8-8307-481d-b2b2-413925c71047" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_7f534cc0-9b5f-40be-8a50-5d02a1c023f8" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsInnateIncPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_7f534cc0-9b5f-40be-8a50-5d02a1c023f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsEquipmentMember_4295711a-3c5b-4893-9eb2-b3ce4fda0574" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsEquipmentMember_4295711a-3c5b-4893-9eb2-b3ce4fda0574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsVehiclesMember_355a4659-1358-4b18-803f-a7a313eca75f" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsVehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsVehiclesMember_355a4659-1358-4b18-803f-a7a313eca75f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsPrintersMember_cbccbcb9-84e7-4b38-9991-5e4c505e972d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsPrintersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsPrintersMember_cbccbcb9-84e7-4b38-9991-5e4c505e972d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanEquipmentMember_e1c79668-aa47-4d58-be7f-5c8fe632ba5e" xlink:href="inpha-20240630.xsd#inpha_LoanEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanEquipmentMember_e1c79668-aa47-4d58-be7f-5c8fe632ba5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanBuildingMember_8b3c1b0e-29ba-4f93-a470-2d30bae78a82" xlink:href="inpha-20240630.xsd#inpha_LoanBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanBuildingMember_8b3c1b0e-29ba-4f93-a470-2d30bae78a82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_2229c1d2-3b2f-4a4e-b766-3a8ef97a857f" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_2229c1d2-3b2f-4a4e-b766-3a8ef97a857f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementWithSocitGnraleMember_d4287a01-c8d4-4208-8852-62a5d93c647d" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementWithSocitGnraleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanAgreementWithSocitGnraleMember_d4287a01-c8d4-4208-8852-62a5d93c647d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_7613acf3-9643-449d-8e63-19ddff45d82a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_7613acf3-9643-449d-8e63-19ddff45d82a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_524a323a-fd02-4eee-b1c2-ff6e331ca480" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_524a323a-fd02-4eee-b1c2-ff6e331ca480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_ac8ef59f-0bd5-446b-b35b-97d2de862dfb" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_ac8ef59f-0bd5-446b-b35b-97d2de862dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_bee5a7e3-0200-47c8-b82f-e4f8510b0da2" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_bee5a7e3-0200-47c8-b82f-e4f8510b0da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_ea866e32-ee58-442a-a69d-e4ec60019333_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_ea866e32-ee58-442a-a69d-e4ec60019333_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GuaranteesMember_dffe8ecf-dee5-49a4-9f2d-915a27f5d2d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GuaranteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:to="loc_ifrs-full_GuaranteesMember_dffe8ecf-dee5-49a4-9f2d-915a27f5d2d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_5e3b25d6-b6c4-4955-8400-da10d23c890c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_5e3b25d6-b6c4-4955-8400-da10d23c890c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_f4016ff0-2714-40bd-984f-986bc77987a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:to="loc_ifrs-full_FixedInterestRateMember_f4016ff0-2714-40bd-984f-986bc77987a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_03649a43-686b-4b13-87a4-f360c12e896f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:to="loc_ifrs-full_RightofuseAssetsMember_03649a43-686b-4b13-87a4-f360c12e896f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_abc8d027-46dc-49b5-a65c-92dce1f883fb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_abc8d027-46dc-49b5-a65c-92dce1f883fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherDisposalsOfAssetsMember_98ff6c1a-432e-40ef-bf75-256e38b31385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherDisposalsOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:to="loc_ifrs-full_OtherDisposalsOfAssetsMember_98ff6c1a-432e-40ef-bf75-256e38b31385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_08b4002e-50a7-45d8-bfc8-4b057649a467" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_FinancialLiabilities_08b4002e-50a7-45d8-bfc8-4b057649a467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_04892a17-10b2-4049-8f00-f97b3d717d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_04892a17-10b2-4049-8f00-f97b3d717d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_9586b058-6c8d-4163-8f72-ddd4f07048bf" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_9586b058-6c8d-4163-8f72-ddd4f07048bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_643c5a83-2e59-4797-97e2-3fc73ea93204" xlink:href="inpha-20240630.xsd#inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_643c5a83-2e59-4797-97e2-3fc73ea93204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_a3accd3b-dcb7-4e17-8297-847cd1fede3d" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_a3accd3b-dcb7-4e17-8297-847cd1fede3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_2fdb5127-a8c4-47ad-b3c3-b48b8171445f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_NotionalAmount_2fdb5127-a8c4-47ad-b3c3-b48b8171445f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingNumberOfLoanAgreement_d774a4da-040a-43c2-ad64-aa42958d9864" xlink:href="inpha-20240630.xsd#inpha_BorrowingNumberOfLoanAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingNumberOfLoanAgreement_d774a4da-040a-43c2-ad64-aa42958d9864" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturity_b8829876-8efe-4bf1-b5ac-dea666631fee" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingMaturity_b8829876-8efe-4bf1-b5ac-dea666631fee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturityExtensionPeriodOption_c85cb1a6-17f9-4092-99f4-9a85f51cfca0" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturityExtensionPeriodOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingMaturityExtensionPeriodOption_c85cb1a6-17f9-4092-99f4-9a85f51cfca0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan_6b079798-5b67-4cd8-8de8-ad7a82ee6e99" xlink:href="inpha-20240630.xsd#inpha_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan_6b079798-5b67-4cd8-8de8-ad7a82ee6e99" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingGracePeriod_2939b391-8dbb-4f68-a011-54cd7b51cd75" xlink:href="inpha-20240630.xsd#inpha_BorrowingGracePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingGracePeriod_2939b391-8dbb-4f68-a011-54cd7b51cd75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_8ec2bcaf-0487-47d3-8e17-21a31cbb2969" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_BorrowingsInterestRate_8ec2bcaf-0487-47d3-8e17-21a31cbb2969" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLoans_7e5fc8d6-9c53-474b-9e44-2f22d812bcca" xlink:href="inpha-20240630.xsd#inpha_NumberOfLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_NumberOfLoans_7e5fc8d6-9c53-474b-9e44-2f22d812bcca" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_1b6e5c62-86a3-4a34-a938-6d1a9d05b116" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_1b6e5c62-86a3-4a34-a938-6d1a9d05b116" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementMaximumBorrowingCapacity_883d1f78-d5de-4d7f-8749-f9ea231594d4" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_LoanAgreementMaximumBorrowingCapacity_883d1f78-d5de-4d7f-8749-f9ea231594d4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementCollateral_cc2c5225-8f4b-4e09-bd3e-5970dce9f6e4" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementCollateral"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_LoanAgreementCollateral_cc2c5225-8f4b-4e09-bd3e-5970dce9f6e4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingsMaturityPeriod_130092be-9dea-400e-8a32-bb163a036871" xlink:href="inpha-20240630.xsd#inpha_BorrowingsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingsMaturityPeriod_130092be-9dea-400e-8a32-bb163a036871" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_6caf0170-ae70-4f71-9b22-93ff6899d00a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_6caf0170-ae70-4f71-9b22-93ff6899d00a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_303ec2b6-34a0-4ea2-b9e1-d6111db80e8a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_303ec2b6-34a0-4ea2-b9e1-d6111db80e8a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_49cee567-21f0-478a-9e66-f02ed1de75bd" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_49cee567-21f0-478a-9e66-f02ed1de75bd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_d683b3f3-0a08-4dec-8009-3d926ec8975a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_d683b3f3-0a08-4dec-8009-3d926ec8975a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_b0638121-3896-4616-9ff1-94b64200fc74" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_b0638121-3896-4616-9ff1-94b64200fc74" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInFinancialLiabilities_cd0edc2d-a2e9-494f-bc92-ed6bcd8d0932" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_IncreaseDecreaseInFinancialLiabilities_cd0edc2d-a2e9-494f-bc92-ed6bcd8d0932" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c1394e43-ed32-4412-83de-dca8a45753e6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c1394e43-ed32-4412-83de-dca8a45753e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_9fe2f40a-a181-4fb3-8230-e9affe3bfe78" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_9fe2f40a-a181-4fb3-8230-e9affe3bfe78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_21dae071-4fff-44bf-9a76-cf8207f2f0c9" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_21dae071-4fff-44bf-9a76-cf8207f2f0c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementAccruedInterestMember_b85939e3-81d5-4c4a-b223-487ca7bed0ed" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementAccruedInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementAccruedInterestMember_b85939e3-81d5-4c4a-b223-487ca7bed0ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_c2cc87f8-0381-4c55-91bb-eab2c6bbb027" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_c2cc87f8-0381-4c55-91bb-eab2c6bbb027" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_ed4d9b6e-b9de-42df-a981-d7df5459120d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsInnateIncPremisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_ed4d9b6e-b9de-42df-a981-d7df5459120d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsEquipmentMember_a6fca12a-4e12-45b3-9c4c-0edfa79e5b2d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsEquipmentMember_a6fca12a-4e12-45b3-9c4c-0edfa79e5b2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsVehiclesMember_f4bf78a9-c4fd-445c-ad7c-53a35860462b" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsVehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsVehiclesMember_f4bf78a9-c4fd-445c-ad7c-53a35860462b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsPrintersMember_6dc264ed-4373-49a8-886e-97f7ab05a1c9" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsPrintersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsPrintersMember_6dc264ed-4373-49a8-886e-97f7ab05a1c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanEquipmentMember_d06e3562-b0ae-4059-8a1e-9cca9eb9b03a" xlink:href="inpha-20240630.xsd#inpha_LoanEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LoanEquipmentMember_d06e3562-b0ae-4059-8a1e-9cca9eb9b03a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanBuildingMember_57b0c36f-f8d5-4a30-aa58-59ffa8169059" xlink:href="inpha-20240630.xsd#inpha_LoanBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LoanBuildingMember_57b0c36f-f8d5-4a30-aa58-59ffa8169059" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:to="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_4856d0ac-2387-475f-9fb1-f4f5d1639acb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:to="loc_ifrs-full_MaturityDomain_4856d0ac-2387-475f-9fb1-f4f5d1639acb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:to="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_a42e7447-c483-42cf-8763-c1be41086115" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_a42e7447-c483-42cf-8763-c1be41086115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_d8305dd7-dcf2-46d8-a1a1-f814a2ad832f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_d8305dd7-dcf2-46d8-a1a1-f814a2ad832f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_c4007626-8407-466b-b5eb-17e8d180ec2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_c4007626-8407-466b-b5eb-17e8d180ec2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_a2e86357-df91-4efd-bffb-29a6a8961f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_a2e86357-df91-4efd-bffb-29a6a8961f84" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitDisclosureofdefinedbenefitplansDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_2660018f-8264-45eb-941a-875e3bca4e90_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_2660018f-8264-45eb-941a-875e3bca4e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RetirementDefinedBenefitMember_ae3f82bb-7e39-4653-a05e-06dac8953a42" xlink:href="inpha-20240630.xsd#inpha_RetirementDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:to="loc_inpha_RetirementDefinedBenefitMember_ae3f82bb-7e39-4653-a05e-06dac8953a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SeniorityAwardsMember_bd86c91a-5bcb-43be-86c6-3fcb00acaf37" xlink:href="inpha-20240630.xsd#inpha_SeniorityAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:to="loc_inpha_SeniorityAwardsMember_bd86c91a-5bcb-43be-86c6-3fcb00acaf37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_ea386cc5-8925-4ccc-bea0-63ff3f75a275" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_ea386cc5-8925-4ccc-bea0-63ff3f75a275" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:to="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_8ddde843-3832-4679-89dc-c9e66bc6c27e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_8ddde843-3832-4679-89dc-c9e66bc6c27e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_564dca58-072e-4ab8-8fe4-0468a7c50221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_564dca58-072e-4ab8-8fe4-0468a7c50221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_914e5d40-a179-4885-be61-a8466d1b5984" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:to="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_914e5d40-a179-4885-be61-a8466d1b5984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_42323167-2b45-4983-8e41-8d14ac272c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_42323167-2b45-4983-8e41-8d14ac272c49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_2341b566-12da-4bad-9eee-d712858b90ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_2341b566-12da-4bad-9eee-d712858b90ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_c3e0bdcb-ef43-4d55-be10-4d41685123d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_c3e0bdcb-ef43-4d55-be10-4d41685123d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_7ccfe530-fd2d-4a16-969a-7608438ae465" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_7ccfe530-fd2d-4a16-969a-7608438ae465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c4007ec0-b1b4-4e4a-9548-2fdae7a36921" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_65040b03-2583-4c24-8000-a868c122dbe6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_65040b03-2583-4c24-8000-a868c122dbe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RetirementDefinedBenefitMember_5602de58-c2d5-4c5b-afd7-4eed377b85ca" xlink:href="inpha-20240630.xsd#inpha_RetirementDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:to="loc_inpha_RetirementDefinedBenefitMember_5602de58-c2d5-4c5b-afd7-4eed377b85ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_5120afba-c6d3-4a6d-bd5e-bdda3b503add" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_5120afba-c6d3-4a6d-bd5e-bdda3b503add" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CapitalAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_1a0a2cfe-1158-4a9f-b40a-772ec9498b77_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_1a0a2cfe-1158-4a9f-b40a-772ec9498b77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_10081e30-334d-4482-bc98-814639e3fdb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:to="loc_ifrs-full_IssuedCapitalMember_10081e30-334d-4482-bc98-814639e3fdb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a3ce7570-0389-4928-835e-5fb857b9a193" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:to="loc_ifrs-full_SharePremiumMember_a3ce7570-0389-4928-835e-5fb857b9a193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_26c8b3b3-08b6-47f3-818d-14f2e21209a2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_26c8b3b3-08b6-47f3-818d-14f2e21209a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f5cade63-5d36-492e-a6bb-6fa6c93bfafa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_ifrs-full_OrdinarySharesMember_f5cade63-5d36-492e-a6bb-6fa6c93bfafa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2016FreePreferredSharesMember_1e864b04-80d5-47ee-af9e-db2bd41a84b5" xlink:href="inpha-20240630.xsd#inpha_The2016FreePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_inpha_The2016FreePreferredSharesMember_1e864b04-80d5-47ee-af9e-db2bd41a84b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2017FreePreferredSharesMember_351d3dd0-3a13-474a-b9c4-c278e036b383" xlink:href="inpha-20240630.xsd#inpha_The2017FreePreferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_inpha_The2017FreePreferredSharesMember_351d3dd0-3a13-474a-b9c4-c278e036b383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ec7c4a3b-603c-4e91-9e0d-a068e1396380_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ec7c4a3b-603c-4e91-9e0d-a068e1396380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2012Member_ad06758d-fe20-4e07-b9db-d0be11a71894" xlink:href="inpha-20240630.xsd#inpha_BSAAR2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_BSAAR2012Member_ad06758d-fe20-4e07-b9db-d0be11a71894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanMember_59b548c0-823b-46ed-b731-ed1887c999b3" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_CompanySavingPlanMember_59b548c0-823b-46ed-b731-ed1887c999b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanEmployerTopUpMember_f0d89d2f-707c-4107-8f8f-7e113b959d2e" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanEmployerTopUpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_CompanySavingPlanEmployerTopUpMember_f0d89d2f-707c-4107-8f8f-7e113b959d2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_80145452-285d-41bf-bb7b-56d761dfd2c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_Equity_80145452-285d-41bf-bb7b-56d761dfd2c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_3fdf70c4-c37e-4343-a7ac-f4a11d69b04c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_3fdf70c4-c37e-4343-a7ac-f4a11d69b04c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_512ba7aa-f6f5-40b9-85fa-0856add9c7e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_ParValuePerShare_512ba7aa-f6f5-40b9-85fa-0856add9c7e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_64e5bc2e-68fb-4fd6-850e-3eaf7f0dbf40" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_NumberOfSharesIssued_64e5bc2e-68fb-4fd6-850e-3eaf7f0dbf40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_8898afca-bcea-4d1a-80bf-b5e0736cec32" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_8898afca-bcea-4d1a-80bf-b5e0736cec32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_a5a730e7-77ff-4333-9325-7e6431043be9" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_a5a730e7-77ff-4333-9325-7e6431043be9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_a3be49fc-5c89-487b-8a8f-a3c122798a05" xlink:href="inpha-20240630.xsd#inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_a3be49fc-5c89-487b-8a8f-a3c122798a05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareIssuedPricePerShare_46d73109-24fc-482c-b832-2b9f7cd31101" xlink:href="inpha-20240630.xsd#inpha_ShareIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ShareIssuedPricePerShare_46d73109-24fc-482c-b832-2b9f7cd31101" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_46bc5588-420e-40a8-a067-522658712865" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_46bc5588-420e-40a8-a067-522658712865" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_a0e34021-c6a9-44ab-90be-67248f06cb79_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_a0e34021-c6a9-44ab-90be-67248f06cb79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:to="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2011Member_2d230e22-78df-4c3b-8fb3-28be37ceac3e" xlink:href="inpha-20240630.xsd#inpha_BSAAR2011Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2011Member_2d230e22-78df-4c3b-8fb3-28be37ceac3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2012Member_4b16055f-12ad-4d96-ac54-5dac2e7f38f1" xlink:href="inpha-20240630.xsd#inpha_BSAAR2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2012Member_4b16055f-12ad-4d96-ac54-5dac2e7f38f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2015Member_12056254-44be-440e-8699-82fc62b7a80f" xlink:href="inpha-20240630.xsd#inpha_BSAAR2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2015Member_12056254-44be-440e-8699-82fc62b7a80f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20161Member_f37004cd-6e41-40a5-af9c-763df6e2a073" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20161Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20161Member_f37004cd-6e41-40a5-af9c-763df6e2a073" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20161Member_74873182-0fc4-409f-8725-5396f9d5a9e5" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20161Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20161Member_74873182-0fc4-409f-8725-5396f9d5a9e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20161Member_85b6db64-d4ec-49cb-9837-bbd10895cef0" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20161Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAManagement20161Member_85b6db64-d4ec-49cb-9837-bbd10895cef0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20162Member_a74862af-2462-4ac5-b270-c257ab758c82" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20162Member_a74862af-2462-4ac5-b270-c257ab758c82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20162Member_2621e85c-07da-4988-b0e6-175f0d0b8906" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20162Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAManagement20162Member_2621e85c-07da-4988-b0e6-175f0d0b8906" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20171Member_762bb475-5fba-41cb-9ff5-ab9554744d3e" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20171Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20171Member_762bb475-5fba-41cb-9ff5-ab9554744d3e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20171Member_eade75e4-2a42-41b7-9cb7-c26160bfbd86" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20171Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20171Member_eade75e4-2a42-41b7-9cb7-c26160bfbd86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2017Member_2b514cae-fbcc-44e5-a912-a488ee1174d7" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAEmployees2017Member_2b514cae-fbcc-44e5-a912-a488ee1174d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20181Member_5ed86492-7dde-4bc5-9201-1dc29c5908c4" xlink:href="inpha-20240630.xsd#inpha_AGABonus20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20181Member_5ed86492-7dde-4bc5-9201-1dc29c5908c4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfEmployees20181Member_2747f0c5-ad49-40b9-b373-cf23206f9a4f" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfEmployees20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPPerfEmployees20181Member_2747f0c5-ad49-40b9-b373-cf23206f9a4f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfManagement20181Member_5bf255d0-d238-4bcc-9240-53c5d84af19e" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfManagement20181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPPerfManagement20181Member_5bf255d0-d238-4bcc-9240-53c5d84af19e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2018Member_2930daa5-7f13-4d48-a0c8-c52a7e8f099d" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAEmployees2018Member_2930daa5-7f13-4d48-a0c8-c52a7e8f099d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20171Member_b720e988-a3b6-45dc-a883-0ebe1ba54341" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20171Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20171Member_b720e988-a3b6-45dc-a883-0ebe1ba54341" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20191Member_cad287aa-ebed-406c-a764-4815d866207c" xlink:href="inpha-20240630.xsd#inpha_AGABonus20191Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20191Member_cad287aa-ebed-406c-a764-4815d866207c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus202012Member_405f0d5e-1fa1-4636-94b6-1f5f45a03d0b" xlink:href="inpha-20240630.xsd#inpha_AGABonus202012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus202012Member_405f0d5e-1fa1-4636-94b6-1f5f45a03d0b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20201Member_af808d17-53ad-4411-b4c7-a08c57f50aab" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20201Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20201Member_af808d17-53ad-4411-b4c7-a08c57f50aab" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20201Member_09656a3a-63a3-4b01-84a8-3bf868601698" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20201Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20201Member_09656a3a-63a3-4b01-84a8-3bf868601698" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20211Member_80ba461c-0cd1-4cfc-b649-311d32b097f2" xlink:href="inpha-20240630.xsd#inpha_AGABonus20211Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20211Member_80ba461c-0cd1-4cfc-b649-311d32b097f2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20211Member_1fb16fa2-7ad1-4062-8018-c08c156544aa" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20211Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20211Member_1fb16fa2-7ad1-4062-8018-c08c156544aa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20211Member_0d382d5e-40d2-460e-a97d-31ca61e5a777" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20211Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20211Member_0d382d5e-40d2-460e-a97d-31ca61e5a777" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2022Member_49aab213-eda8-47cc-8476-d8cb99320c2d" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2022Member_49aab213-eda8-47cc-8476-d8cb99320c2d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20221Member_af798adc-dfd3-4e5f-ad58-35cb8af86664" xlink:href="inpha-20240630.xsd#inpha_AGABonus20221Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20221Member_af798adc-dfd3-4e5f-ad58-35cb8af86664" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20221Member_7155a5ae-934c-4a60-9e07-1ff23091dfd9" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20221Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfEmployees20221Member_7155a5ae-934c-4a60-9e07-1ff23091dfd9" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20221Member_0cb27b89-dcd6-4ec2-99fa-81d42a31cd99" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20221Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfManagement20221Member_0cb27b89-dcd6-4ec2-99fa-81d42a31cd99" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2023Member_0c50926e-b080-4e9c-916b-744f3a584e1c" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2023Member_0c50926e-b080-4e9c-916b-744f3a584e1c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20231Member_e687da2f-69af-47f0-bf43-a8f25e3497ec" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20231Member_e687da2f-69af-47f0-bf43-a8f25e3497ec" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20231Member_f88ae846-f28e-470f-8eb2-498fa90b9a3a" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfEmployees20231Member_f88ae846-f28e-470f-8eb2-498fa90b9a3a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20231Member_585ea6b1-15f2-46cb-80fe-f744df0be087" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfManagement20231Member_585ea6b1-15f2-46cb-80fe-f744df0be087" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20241Member_c0675369-0da0-4985-b851-0389e0c1eff5" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20241Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20241Member_c0675369-0da0-4985-b851-0389e0c1eff5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2024Member_37c4f02a-bd40-4294-81d3-7aa869f1b8aa" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2024Member_37c4f02a-bd40-4294-81d3-7aa869f1b8aa" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_StockOptions20201Member_d3f44d07-2d04-4080-8f59-97be193cc1f8" xlink:href="inpha-20240630.xsd#inpha_StockOptions20201Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_StockOptions20201Member_d3f44d07-2d04-4080-8f59-97be193cc1f8" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Employees2019Member_dc9e15c9-4800-430f-a1b9-3526efa04a87" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Employees2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAP2019Employees2019Member_dc9e15c9-4800-430f-a1b9-3526efa04a87" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Management2019Member_66bd50d2-5d68-4b93-85b8-c381e7ca931e" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Management2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAP2019Management2019Member_66bd50d2-5d68-4b93-85b8-c381e7ca931e" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20112Member_a70d086a-5d78-4a93-9053-2b7c973f62bd" xlink:href="inpha-20240630.xsd#inpha_BSA20112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20112Member_a70d086a-5d78-4a93-9053-2b7c973f62bd" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2013Member_880bd23d-730d-4fc4-9db3-9cb562e2f5ed" xlink:href="inpha-20240630.xsd#inpha_BSA2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2013Member_880bd23d-730d-4fc4-9db3-9cb562e2f5ed" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2014Member_b0681f02-efb0-4fbf-99d2-a914beb074ad" xlink:href="inpha-20240630.xsd#inpha_BSA2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2014Member_b0681f02-efb0-4fbf-99d2-a914beb074ad" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20151Member_879efd1f-9fc6-4af9-8700-3b40a6aeea26" xlink:href="inpha-20240630.xsd#inpha_BSA20151Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20151Member_879efd1f-9fc6-4af9-8700-3b40a6aeea26" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20152Member_6c3fa2c3-9e72-4f06-b2c5-0cd75a826098" xlink:href="inpha-20240630.xsd#inpha_BSA20152Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20152Member_6c3fa2c3-9e72-4f06-b2c5-0cd75a826098" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2017Member_441a194f-a320-4a27-8805-49dcc8148d11" xlink:href="inpha-20240630.xsd#inpha_BSA2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2017Member_441a194f-a320-4a27-8805-49dcc8148d11" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20221Member_6aa4ed39-ff66-4793-9667-610c6ad36098" xlink:href="inpha-20240630.xsd#inpha_BSA20221Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20221Member_6aa4ed39-ff66-4793-9667-610c6ad36098" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20231Member_95cf7b69-8b73-4363-bf2c-c0625d4e0629" xlink:href="inpha-20240630.xsd#inpha_BSA20231Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20231Member_95cf7b69-8b73-4363-bf2c-c0625d4e0629" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11b111cc-48ef-43dd-824f-99f31deb113d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11b111cc-48ef-43dd-824f-99f31deb113d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_8222b79c-0449-4e2e-9390-fc195dc64db3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_8222b79c-0449-4e2e-9390-fc195dc64db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6cf21874-1532-4309-848a-afc3873af961" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6cf21874-1532-4309-848a-afc3873af961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b8f6d3f8-97ea-419d-bacb-762309ee38c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b8f6d3f8-97ea-419d-bacb-762309ee38c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_12667532-7557-448e-ad71-2ba6effbc6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_12667532-7557-448e-ad71-2ba6effbc6e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_56d93cfe-fc7e-4867-af10-d04cd7f6d95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_56d93cfe-fc7e-4867-af10-d04cd7f6d95f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_23203491-2754-425c-bceb-a3ff9b5bc3ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_23203491-2754-425c-bceb-a3ff9b5bc3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsMember_498022a6-976c-426a-bdd7-c9b8d6c9e85f" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_NonCurrentFinancialAssetsMember_498022a6-976c-426a-bdd7-c9b8d6c9e85f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeReceivablesAndOthersMember_4ae923cf-500c-4c91-9b05-f00f79f9bb48" xlink:href="inpha-20240630.xsd#inpha_TradeReceivablesAndOthersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_TradeReceivablesAndOthersMember_4ae923cf-500c-4c91-9b05-f00f79f9bb48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsShortTermInvestmentsMember_9f0dfead-6d75-4c34-a223-34cec9d8353a" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_FinancialAssetsShortTermInvestmentsMember_9f0dfead-6d75-4c34-a223-34cec9d8353a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember_cc044d90-a580-43eb-b72e-88d3b670c0d3" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember_cc044d90-a580-43eb-b72e-88d3b670c0d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_fef4b9d8-968e-42b7-af94-2797695c82ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_fef4b9d8-968e-42b7-af94-2797695c82ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_012ff21d-fdc2-4908-988b-35ea228f1a11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_012ff21d-fdc2-4908-988b-35ea228f1a11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5f79112e-eb4a-4d54-9336-169f55061a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5f79112e-eb4a-4d54-9336-169f55061a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_d4bcbb5e-6f9e-412f-961e-2d02c518d143_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_d4bcbb5e-6f9e-412f-961e-2d02c518d143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember_3b1818d7-662a-43ad-9011-980f1318e693" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesNonCurrentPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember_3b1818d7-662a-43ad-9011-980f1318e693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesCurrentPortionMember_40b9838a-089a-4a25-92ef-9fc02597a400" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesCurrentPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_FinancialLiabilitiesCurrentPortionMember_40b9838a-089a-4a25-92ef-9fc02597a400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradePayablesAndOthersMember_e6182d1e-2327-4951-8981-5bd90e89cd59" xlink:href="inpha-20240630.xsd#inpha_TradePayablesAndOthersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_TradePayablesAndOthersMember_e6182d1e-2327-4951-8981-5bd90e89cd59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_11176399-9ef4-4b24-ac6e-508cc721ea2e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_11176399-9ef4-4b24-ac6e-508cc721ea2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_0001f58c-2d33-404c-8f2a-105eab2e2f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_0001f58c-2d33-404c-8f2a-105eab2e2f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_affd335e-db10-4269-b495-5fff2d834adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_affd335e-db10-4269-b495-5fff2d834adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_e0d445fa-7733-444f-bf16-0de64d1f491d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_ifrs-full_FinancialAssets_e0d445fa-7733-444f-bf16-0de64d1f491d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_5e878161-c0e1-448d-a348-e3244f99c655" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_5e878161-c0e1-448d-a348-e3244f99c655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers_a96d49e0-a9e0-4f83-ae19-b42ffe904542" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers_a96d49e0-a9e0-4f83-ae19-b42ffe904542" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_70b08891-270e-40d5-89a6-5ee3b344346a" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_70b08891-270e-40d5-89a6-5ee3b344346a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:to="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_f52d4237-a8b8-43b5-a7fb-526c96b463fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:to="loc_ifrs-full_TypesOfContractsDomain_f52d4237-a8b8-43b5-a7fb-526c96b463fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:to="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:href="inpha-20240630.xsd#inpha_CollaborationAndLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:to="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_8287cd7e-7421-4000-879e-802ed6ce2280" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_MonalizumabAgreementMember_8287cd7e-7421-4000-879e-802ed6ce2280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_7368077c-0668-48d9-bde7-a8c0e2e0cd4f" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_7368077c-0668-48d9-bde7-a8c0e2e0cd4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member_1ea5a0fa-45c8-46e3-95e9-ad487a82b915" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH62Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member_1ea5a0fa-45c8-46e3-95e9-ad487a82b915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member_4b8ab102-41b9-4c1c-b6d7-41c0b85a3456" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH67Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member_4b8ab102-41b9-4c1c-b6d7-41c0b85a3456" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithTakedaMember_443d161c-9263-45db-a2c5-a2340fc66199" xlink:href="inpha-20240630.xsd#inpha_AgreementWithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithTakedaMember_443d161c-9263-45db-a2c5-a2340fc66199" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AndAdvoralimabAgreementsMember_5ae1fd93-cde7-4b9e-9a38-f5742456c8b8" xlink:href="inpha-20240630.xsd#inpha_IPH5201AndAdvoralimabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:to="loc_inpha_IPH5201AndAdvoralimabAgreementsMember_5ae1fd93-cde7-4b9e-9a38-f5742456c8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_3a8572f8-228e-4462-978d-32e474ff60ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_3a8572f8-228e-4462-978d-32e474ff60ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_6b4dd50d-35db-42cb-83bc-0bde83d6468c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_6b4dd50d-35db-42cb-83bc-0bde83d6468c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueMember_62cca4a3-3374-408e-b555-d7a4899f9780" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:to="loc_inpha_DeferredRevenueMember_62cca4a3-3374-408e-b555-d7a4899f9780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesMember_88f735af-85c0-4eb5-803d-744b00a975a6" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:to="loc_inpha_CollaborationLiabilitiesMember_88f735af-85c0-4eb5-803d-744b00a975a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:to="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_752ccfe8-edc5-4973-805d-dee2697d6f05_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:to="loc_ifrs-full_TypesOfContractsDomain_752ccfe8-edc5-4973-805d-dee2697d6f05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:to="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember_6a864a00-adea-4803-9bdb-e6708ad8f07b" xlink:href="inpha-20240630.xsd#inpha_A2015AstraZenecaMonalizumabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember_6a864a00-adea-4803-9bdb-e6708ad8f07b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_3af3fcdb-7635-4e78-8311-c27d7bef4e2e" xlink:href="inpha-20240630.xsd#inpha_SanofiResearchCollaborationAndLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_3af3fcdb-7635-4e78-8311-c27d7bef4e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_419f0200-9a68-41b2-9534-00a21f49a2a4" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithSanofiForNKCellEngagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_419f0200-9a68-41b2-9534-00a21f49a2a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueRollForwardAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6c634406-3dca-4a17-a30a-77706b42e0ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_ifrs-full_ContractLiabilities_6c634406-3dca-4a17-a30a-77706b42e0ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestone_9c2ffb5b-1c85-42f1-a4a2-3683cde0143b" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestone_9c2ffb5b-1c85-42f1-a4a2-3683cde0143b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_62c3c1cb-4076-4d6f-983c-d40e131f5c34" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_62c3c1cb-4076-4d6f-983c-d40e131f5c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferToFromCollaborationLiabilities_87530cb2-35c9-4b9e-8362-0a41f1c866e0" xlink:href="inpha-20240630.xsd#inpha_TransferToFromCollaborationLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_inpha_TransferToFromCollaborationLiabilities_87530cb2-35c9-4b9e-8362-0a41f1c866e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_11d1f5b0-24b4-4ed1-84ee-07e9cf2b8c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesRollForwardAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_02f97ab0-6b50-41ef-96d2-3c7ed66c088a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_77ba699e-b381-44a3-9a66-8ec903e97162" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_77ba699e-b381-44a3-9a66-8ec903e97162" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDeductionsContractLiabilities_be0e9743-9f2c-4432-8489-cc9072bd237e" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDeductionsContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_inpha_DecreaseThroughDeductionsContractLiabilities_be0e9743-9f2c-4432-8489-cc9072bd237e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_56241e04-e1ab-4510-b208-9ea5e96f90e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_213114b7-3110-424c-af24-c574fd5c0470" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_213114b7-3110-424c-af24-c574fd5c0470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfTargetOptions_6216effc-2eac-4a3e-93ac-af1d07e2b615" xlink:href="inpha-20240630.xsd#inpha_NumberOfTargetOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_NumberOfTargetOptions_6216effc-2eac-4a3e-93ac-af1d07e2b615" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfPreclinicalMolecules_de427f22-c958-4eaa-b8e6-8b3f89734fe3" xlink:href="inpha-20240630.xsd#inpha_NumberOfPreclinicalMolecules"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_NumberOfPreclinicalMolecules_de427f22-c958-4eaa-b8e6-8b3f89734fe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_e548faf0-f233-4878-8630-3667a3de6eaa" xlink:href="inpha-20240630.xsd#inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_e548faf0-f233-4878-8630-3667a3de6eaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_fe6579ea-e611-40fa-b264-e1732567a200" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_fe6579ea-e611-40fa-b264-e1732567a200" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:to="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_d3d633e8-bffd-4e18-ab14-a41a2f644113_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:to="loc_ifrs-full_TypesOfContractsDomain_d3d633e8-bffd-4e18-ab14-a41a2f644113_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:to="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2018AstraZenecaIPH5201AgreementMember_12573c5b-e437-403c-95e2-efea2f493414" xlink:href="inpha-20240630.xsd#inpha_A2018AstraZenecaIPH5201AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_A2018AstraZenecaIPH5201AgreementMember_12573c5b-e437-403c-95e2-efea2f493414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_70301e34-47fb-4494-9829-1a9f6c07f4bb" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_70301e34-47fb-4494-9829-1a9f6c07f4bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_91db0d9a-2147-414a-9d1f-043cac2e663b" xlink:href="inpha-20240630.xsd#inpha_SanofiResearchCollaborationAndLicensingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_91db0d9a-2147-414a-9d1f-043cac2e663b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_6fdc9158-3e92-4a4e-8de1-909455a3fa8a" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithSanofiForNKCellEngagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_6fdc9158-3e92-4a4e-8de1-909455a3fa8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember_88f3f9e1-2816-4737-874a-b7f608f61292" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithGenzymeForNKCellEngagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember_88f3f9e1-2816-4737-874a-b7f608f61292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_fadcf6e6-a8d5-45ef-bb8c-b8d6d8e868ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_fadcf6e6-a8d5-45ef-bb8c-b8d6d8e868ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExternalCostsRelatedToTheClinicalTrial_8f8e31b1-ee98-4db9-a98f-7353b9d6b7c0" xlink:href="inpha-20240630.xsd#inpha_ExternalCostsRelatedToTheClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_ExternalCostsRelatedToTheClinicalTrial_8f8e31b1-ee98-4db9-a98f-7353b9d6b7c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_275761db-e4f0-4917-ad08-560057ab4992" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_275761db-e4f0-4917-ad08-560057ab4992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_1a852c2c-2d54-4e77-a6c2-443c1ad4ed31" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_1a852c2c-2d54-4e77-a6c2-443c1ad4ed31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_afc76962-1514-4bdc-b893-0f33935ac6a7" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_afc76962-1514-4bdc-b893-0f33935ac6a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_2c7ac8d0-5662-4fd7-a7c5-b086b177e424" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_2c7ac8d0-5662-4fd7-a7c5-b086b177e424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_98866885-5aa1-4d2b-abc7-34b65289a135" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_98866885-5aa1-4d2b-abc7-34b65289a135" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfTargetOptions_6fa8e0ab-fbea-4549-95fd-37ff4e0452a1" xlink:href="inpha-20240630.xsd#inpha_NumberOfTargetOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfTargetOptions_6fa8e0ab-fbea-4549-95fd-37ff4e0452a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfOptionsExcercisedForLicenses_9425d5f6-0b2e-4c3a-b911-9e4115c6ca74" xlink:href="inpha-20240630.xsd#inpha_NumberOfOptionsExcercisedForLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfOptionsExcercisedForLicenses_9425d5f6-0b2e-4c3a-b911-9e4115c6ca74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfExclusiveOptionsGranted_a5b2472e-949a-4ac2-a57c-81e64031f024" xlink:href="inpha-20240630.xsd#inpha_NumberOfExclusiveOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfExclusiveOptionsGranted_a5b2472e-949a-4ac2-a57c-81e64031f024" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_081f90e2-7be4-45b4-9bda-73162a502e82" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_081f90e2-7be4-45b4-9bda-73162a502e82" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_3f14b712-7c8b-4af5-bb54-82600c2c14d1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_3f14b712-7c8b-4af5-bb54-82600c2c14d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueMember_6c719b7f-5015-4298-98de-4b3b1401fb75" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:to="loc_inpha_DeferredRevenueMember_6c719b7f-5015-4298-98de-4b3b1401fb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_c73ba44d-7f29-4ccf-9a5f-87958796a3b3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_c73ba44d-7f29-4ccf-9a5f-87958796a3b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabMember_913f4549-457c-4bd7-9b9d-a9ada8cd7f38" xlink:href="inpha-20240630.xsd#inpha_MonalizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_MonalizumabMember_913f4549-457c-4bd7-9b9d-a9ada8cd7f38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiOptionsMember_eed6d980-84fc-4da8-9b47-2a09d3e4f21a" xlink:href="inpha-20240630.xsd#inpha_SanofiOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_SanofiOptionsMember_eed6d980-84fc-4da8-9b47-2a09d3e4f21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiServicesMember_7e74b163-132b-4d60-86d4-f5fe37b9210e" xlink:href="inpha-20240630.xsd#inpha_SanofiServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_SanofiServicesMember_7e74b163-132b-4d60-86d4-f5fe37b9210e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_f171d305-67bc-47c7-acfc-4f46048dacfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_ContractLiabilities_f171d305-67bc-47c7-acfc-4f46048dacfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_876d25bc-34d6-43c4-b0cb-4f68734bc543" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_876d25bc-34d6-43c4-b0cb-4f68734bc543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_d5293017-232c-4c12-84d3-6640e100d137" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughUpfrontPaymentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_d5293017-232c-4c12-84d3-6640e100d137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferFromToCollaborationLiabilities_9b6c5a4b-ccc4-427e-9397-65527d219929" xlink:href="inpha-20240630.xsd#inpha_TransferFromToCollaborationLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_inpha_TransferFromToCollaborationLiabilities_9b6c5a4b-ccc4-427e-9397-65527d219929" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_59108d73-eadf-4052-9275-16a3365c9279" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesDisclosureofexpensesbynatureDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchAndDevelopmentMember_75495962-d315-444b-93ab-3eca040068d0" xlink:href="inpha-20240630.xsd#inpha_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:to="loc_inpha_ResearchAndDevelopmentMember_75495962-d315-444b-93ab-3eca040068d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_629f8472-d2ba-48f4-822b-3d0829b497a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_629f8472-d2ba-48f4-822b-3d0829b497a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SubcontractingCosts_d2232886-5404-4e57-8925-e67540e87eba" xlink:href="inpha-20240630.xsd#inpha_SubcontractingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_SubcontractingCosts_d2232886-5404-4e57-8925-e67540e87eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5eb9ab81-8b27-4eff-ab7d-b1da22e26423" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5eb9ab81-8b27-4eff-ab7d-b1da22e26423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_c7724f2d-0db8-4d59-b55e-ec16eda14ac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_c7724f2d-0db8-4d59-b55e-ec16eda14ac7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_619e9a74-7e6c-4da4-ac4b-1651fd14dc6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_619e9a74-7e6c-4da4-ac4b-1651fd14dc6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_c3a82577-c99c-4173-87a4-ee709c637861" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_c3a82577-c99c-4173-87a4-ee709c637861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonScientificAdvisoryAndConsulting_91d01137-b88f-4293-8a51-4175a7ea8a58" xlink:href="inpha-20240630.xsd#inpha_NonScientificAdvisoryAndConsulting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_NonScientificAdvisoryAndConsulting_91d01137-b88f-4293-8a51-4175a7ea8a58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeasingAndMaintenance_e5e14400-9fce-43d1-9c7d-05b7b56cdd14" xlink:href="inpha-20240630.xsd#inpha_LeasingAndMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_LeasingAndMaintenance_e5e14400-9fce-43d1-9c7d-05b7b56cdd14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TravelExpense_f2e59966-22db-4f5d-9edd-26640eb22323" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_TravelExpense_f2e59966-22db-4f5d-9edd-26640eb22323" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_53743a0e-e43a-4e3c-a37d-50b9128d194a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_53743a0e-e43a-4e3c-a37d-50b9128d194a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ScientificAdvisoryAndConsulting_f125a84d-9492-4f2e-bbea-580d8bd5a4b1" xlink:href="inpha-20240630.xsd#inpha_ScientificAdvisoryAndConsulting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_ScientificAdvisoryAndConsulting_f125a84d-9492-4f2e-bbea-580d8bd5a4b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherPurchasesAndExternalExpenses_fd58f57b-371b-4f06-9ed6-8afc51005e87" xlink:href="inpha-20240630.xsd#inpha_OtherPurchasesAndExternalExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_OtherPurchasesAndExternalExpenses_fd58f57b-371b-4f06-9ed6-8afc51005e87" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_d6d60061-3763-476d-9627-79f6038310bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_d6d60061-3763-476d-9627-79f6038310bb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IntellectualPropertyExpenses_8a03001b-8b63-4e37-82d5-aaf248b63e33" xlink:href="inpha-20240630.xsd#inpha_IntellectualPropertyExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_IntellectualPropertyExpenses_8a03001b-8b63-4e37-82d5-aaf248b63e33" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_5a6811da-6b10-48e6-9ccf-a889a75e2adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_5a6811da-6b10-48e6-9ccf-a889a75e2adb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_7ef44933-9478-4821-bda9-8277320763ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_OperatingExpense_7ef44933-9478-4821-bda9-8277320763ed" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:to="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithOregaBiotechMember_d83609a1-6c1c-425d-8dc8-5de57a4ea389" xlink:href="inpha-20240630.xsd#inpha_AgreementWithOregaBiotechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:to="loc_inpha_AgreementWithOregaBiotechMember_d83609a1-6c1c-425d-8dc8-5de57a4ea389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_1f9f66c6-f942-4580-9fc7-2ad84f9866a5" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:to="loc_inpha_MonalizumabAgreementMember_1f9f66c6-f942-4580-9fc7-2ad84f9866a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:to="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeDomain_3722f254-5fa9-48e5-9391-f635b3b2a34a_default" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:to="loc_inpha_TypeOfEmployeeDomain_3722f254-5fa9-48e5-9391-f635b3b2a34a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:to="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchAndDevelopmentMember_1e726c1b-e9bc-4763-8a53-15ba39fbf5e5" xlink:href="inpha-20240630.xsd#inpha_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:to="loc_inpha_ResearchAndDevelopmentMember_1e726c1b-e9bc-4763-8a53-15ba39fbf5e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdministrationMember_e375b079-28c7-46e8-a9bf-77166eb4ccef" xlink:href="inpha-20240630.xsd#inpha_AdministrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:to="loc_inpha_AdministrationMember_e375b079-28c7-46e8-a9bf-77166eb4ccef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_7e0423a0-9726-4725-aefd-48c86f241fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_7e0423a0-9726-4725-aefd-48c86f241fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_e4a9059c-c8cc-41a1-ac75-f787e81af46b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_NumberOfEmployees_e4a9059c-c8cc-41a1-ac75-f787e81af46b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_cc47f29e-3f6b-484a-9075-89fc9e8c7a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_cc47f29e-3f6b-484a-9075-89fc9e8c7a09" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IncometaxexpenseDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IncometaxexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/IncometaxexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:to="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3a97a925-57f1-47bb-9b21-168c32a46d1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:to="loc_srt_ScenarioForecastMember_3a97a925-57f1-47bb-9b21-168c32a46d1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_1fd0e37c-1714-44b2-9616-8d85e78771d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_1fd0e37c-1714-44b2-9616-8d85e78771d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_c8df3e4e-df04-4584-b4ed-cceb487fde57" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_ifrs-full_ApplicableTaxRate_c8df3e4e-df04-4584-b4ed-cceb487fde57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesWithNoExpirationDate_c8ea3d3a-4e45-4158-8ec8-065d7bd9a6cf" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesWithNoExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_inpha_UnusedTaxLossesWithNoExpirationDate_c8ea3d3a-4e45-4158-8ec8-065d7bd9a6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesSubjectToExpiration_279fdb6d-6bc0-4aec-b08f-7eb79b7c1b45" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_inpha_UnusedTaxLossesSubjectToExpiration_279fdb6d-6bc0-4aec-b08f-7eb79b7c1b45" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CommitmentscontingenciesandlitigationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2a27b2bd-d4f5-437d-93fe-357b21807bca_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2a27b2bd-d4f5-437d-93fe-357b21807bca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:to="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PreclinicalServicesMember_16dfb7a4-ea15-4081-8651-3eec283e960a" xlink:href="inpha-20240630.xsd#inpha_PreclinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:to="loc_inpha_PreclinicalServicesMember_16dfb7a4-ea15-4081-8651-3eec283e960a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ClinicalServicesMember_00168ebd-d60e-46dc-b7b8-8cc669fa2edd" xlink:href="inpha-20240630.xsd#inpha_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:to="loc_inpha_ClinicalServicesMember_00168ebd-d60e-46dc-b7b8-8cc669fa2edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_11786a29-48fa-4b82-8b96-62cb4ae2c03c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_11786a29-48fa-4b82-8b96-62cb4ae2c03c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_4e8e1329-2a8f-40ca-92b6-17a2e535072e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_4e8e1329-2a8f-40ca-92b6-17a2e535072e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember_e6048169-a55b-4053-ac5b-6fcda4d34008" xlink:href="inpha-20240630.xsd#inpha_GrantsOfEmployeeEquityInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember_e6048169-a55b-4053-ac5b-6fcda4d34008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementWithSocitGnraleMember_df6a463e-c559-43f6-b97f-71686390c513" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementWithSocitGnraleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_inpha_LoanAgreementWithSocitGnraleMember_df6a463e-c559-43f6-b97f-71686390c513" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_ad31c32c-f17a-4397-b6b7-944a1ff62121_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_ad31c32c-f17a-4397-b6b7-944a1ff62121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxContingentLiabilityMember_14d95643-4f02-4b3a-8f42-7978d94faba4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxContingentLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:to="loc_ifrs-full_TaxContingentLiabilityMember_14d95643-4f02-4b3a-8f42-7978d94faba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_15f7ca7b-7b6d-4b6a-bc34-78f201e76231_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_15f7ca7b-7b6d-4b6a-bc34-78f201e76231_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangesToCommitmentsMember_a0862c50-9f8d-4717-96d6-88bc79516ba7" xlink:href="inpha-20240630.xsd#inpha_ChangesToCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:to="loc_inpha_ChangesToCommitmentsMember_a0862c50-9f8d-4717-96d6-88bc79516ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_37a1e892-2e8b-4e8a-b00a-502ee0ba13d8" xlink:href="inpha-20240630.xsd#inpha_NonCancellableOffBalanceSheetPurchasedCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_37a1e892-2e8b-4e8a-b00a-502ee0ba13d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_c92e6eb2-9ebe-4770-8950-df8bd7a017cc" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_c92e6eb2-9ebe-4770-8950-df8bd7a017cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_9b85e559-0765-4d00-8933-1bcebd9101d5" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_9b85e559-0765-4d00-8933-1bcebd9101d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_f437c03e-2a33-4160-8834-405a4fcd592a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_f437c03e-2a33-4160-8834-405a4fcd592a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_5494489a-fa60-42f5-8089-f514bd5db9ef" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_5494489a-fa60-42f5-8089-f514bd5db9ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_4c641340-5b7d-4b40-b3d5-1ee6f60819a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_ifrs-full_Provisions_4c641340-5b7d-4b40-b3d5-1ee6f60819a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_778a8dba-ad8b-4bfe-a056-78079678b00b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_778a8dba-ad8b-4bfe-a056-78079678b00b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOfTaxesOtherThanIncomeTax_099cc734-fdbf-45f1-ad2f-28bc812b7c3b" xlink:href="inpha-20240630.xsd#inpha_PaymentOfTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_PaymentOfTaxesOtherThanIncomeTax_099cc734-fdbf-45f1-ad2f-28bc812b7c3b" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_030c54d0-cd14-4ccc-b6c2-e48713c495d0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_030c54d0-cd14-4ccc-b6c2-e48713c495d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NovoNordiskASMember_8a69ab80-d938-4368-817f-264e4babbaa5" xlink:href="inpha-20240630.xsd#inpha_NovoNordiskASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:to="loc_inpha_NovoNordiskASMember_8a69ab80-d938-4368-817f-264e4babbaa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForExpensesWithRelatedParties_45dd3ae4-09d1-4498-bb11-739a8ce1342c" xlink:href="inpha-20240630.xsd#inpha_ProvisionForExpensesWithRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_ProvisionForExpensesWithRelatedParties_45dd3ae4-09d1-4498-bb11-739a8ce1342c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForAttendanceFees_cad73219-dd7e-48d4-9a75-967bd396aeec" xlink:href="inpha-20240630.xsd#inpha_ProvisionForAttendanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_ProvisionForAttendanceFees_cad73219-dd7e-48d4-9a75-967bd396aeec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties_11bfccb5-a733-4aa9-ac52-56c20d2ac5ff" xlink:href="inpha-20240630.xsd#inpha_NumberOfLicensingAgreementsWithRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties_11bfccb5-a733-4aa9-ac52-56c20d2ac5ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7294f4a9-dc82-4876-9342-670858ac1bbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7294f4a9-dc82-4876-9342-670858ac1bbf" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>inpha-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_inpha_LeaseFinancingObligationsEquipmentMember_e40cbaeb-865b-4ef7-87bb-bb0d10a8b2ff_terseLabel_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities &#8211; Laboratory equipment</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsEquipmentMember_label_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Equipment [Member]</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsEquipmentMember_documentation_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for lease finance obligations, equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsEquipmentMember" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeaseFinancingObligationsEquipmentMember" xlink:to="lab_inpha_LeaseFinancingObligationsEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_OtherCurrentTaxCreditsReceivables_4a648c11-bb87-448a-a118-1297849b3d49_verboseLabel_en-US" xlink:label="lab_inpha_OtherCurrentTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other tax credits</link:label>
    <link:label id="lab_inpha_OtherCurrentTaxCreditsReceivables_label_en-US" xlink:label="lab_inpha_OtherCurrentTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Tax Credits Receivables</link:label>
    <link:label id="lab_inpha_OtherCurrentTaxCreditsReceivables_documentation_en-US" xlink:label="lab_inpha_OtherCurrentTaxCreditsReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of other current tax credits receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherCurrentTaxCreditsReceivables" xlink:href="inpha-20240630.xsd#inpha_OtherCurrentTaxCreditsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_OtherCurrentTaxCreditsReceivables" xlink:to="lab_inpha_OtherCurrentTaxCreditsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_27c283c9-7f6c-4386-a8f9-8bd58bc91cc3_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">From 2nd to 5th year included</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_0dca5c73-ed47-4009-a78f-de637564a97f_totalLabel_en-US" xlink:label="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net receivables (liabilities)</link:label>
    <link:label id="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_label_en-US" xlink:label="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Amounts Receivable (Payable) Related Party Transactions</link:label>
    <link:label id="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_documentation_en-US" xlink:label="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net amounts of receivables (payable) resulting from related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:href="inpha-20240630.xsd#inpha_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:to="lab_inpha_NetAmountsReceivablePayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_974bb5ac-4f77-4877-bdff-6cad13ca5918_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingNumberOfLoanAgreement_cbc0b86e-c35f-4d50-b6fa-2c7ea7d2a30f_terseLabel_en-US" xlink:label="lab_inpha_BorrowingNumberOfLoanAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, number of loan agreement</link:label>
    <link:label id="lab_inpha_BorrowingNumberOfLoanAgreement_label_en-US" xlink:label="lab_inpha_BorrowingNumberOfLoanAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Number Of Loan Agreement</link:label>
    <link:label id="lab_inpha_BorrowingNumberOfLoanAgreement_documentation_en-US" xlink:label="lab_inpha_BorrowingNumberOfLoanAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Number Of Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingNumberOfLoanAgreement" xlink:href="inpha-20240630.xsd#inpha_BorrowingNumberOfLoanAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingNumberOfLoanAgreement" xlink:to="lab_inpha_BorrowingNumberOfLoanAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_537b7f65-4435-42fb-ab19-476ecd645d31_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income and (expenses), net</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4741f038-cbf5-4a4f-aa51-13e3d90b2bb3_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9f0fa25b-ea1a-473e-9b45-c911d36ac3b2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_c77b0484-f17c-43c8-8e9d-f317e549e728_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for research work</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received, Research</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:to="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_a075a0fe-246d-408e-851b-e3e72b99c16a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of change in deferred revenue and collaboration liabilities</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_4e42fa3e-5304-4fff-a278-5a8eab21af9f_negatedTerseLabel_en-US" xlink:label="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings/leases liabilities</link:label>
    <link:label id="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities</link:label>
    <link:label id="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:href="inpha-20240630.xsd#inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:to="lab_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationLiabilitiesCurrentPortion_f838cad9-3da5-464b-850b-4992e75e3bd1_terseLabel_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration liabilities &#8211; current portion</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesCurrentPortion_label_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities - Current Portion</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesCurrentPortion_documentation_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesCurrentPortion" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationLiabilitiesCurrentPortion" xlink:to="lab_inpha_CollaborationLiabilitiesCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_7c6f2e28-08b7-443a-815f-9930ec2d18a9_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share :</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_1bad5326-8e2f-4b06-902f-0b6ddfb3c5c1_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPEmployees20201Member_c4a4aeb2-ae45-448c-9171-5f3aba9809c4_terseLabel_en-US" xlink:label="lab_inpha_AGAPEmployees20201Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Employees 2020-1</link:label>
    <link:label id="lab_inpha_AGAPEmployees20201Member_label_en-US" xlink:label="lab_inpha_AGAPEmployees20201Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Employees 2020-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPEmployees20201Member_documentation_en-US" xlink:label="lab_inpha_AGAPEmployees20201Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGAP Employees 2020-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20201Member" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20201Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPEmployees20201Member" xlink:to="lab_inpha_AGAPEmployees20201Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_42e54f96-8b34-4a84-8fd2-f4bddbd21e7c_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in net defined benefit liability (asset) resulting from current service cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA2017Member_342d5d3a-872e-4706-ba18-fcfc2c4514ef_terseLabel_en-US" xlink:label="lab_inpha_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2017</link:label>
    <link:label id="lab_inpha_BSA2017Member_label_en-US" xlink:label="lab_inpha_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2017 [Member]</link:label>
    <link:label id="lab_inpha_BSA2017Member_documentation_en-US" xlink:label="lab_inpha_BSA2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSA 2017.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2017Member" xlink:href="inpha-20240630.xsd#inpha_BSA2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA2017Member" xlink:to="lab_inpha_BSA2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_b312b8e7-ae3c-499c-8f88-d31ab96a4e27_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income / (loss) per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_b651bcbe-809a-43d7-b5e0-ef7c99e432e3_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CarryBackTaxReceivable_cc914fe1-862f-4e2d-a662-d533190b7182_terseLabel_en-US" xlink:label="lab_inpha_CarryBackTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carry-back tax receivable</link:label>
    <link:label id="lab_inpha_CarryBackTaxReceivable_label_en-US" xlink:label="lab_inpha_CarryBackTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carry-Back Tax Receivable</link:label>
    <link:label id="lab_inpha_CarryBackTaxReceivable_documentation_en-US" xlink:label="lab_inpha_CarryBackTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carry-Back Tax Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CarryBackTaxReceivable" xlink:href="inpha-20240630.xsd#inpha_CarryBackTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CarryBackTaxReceivable" xlink:to="lab_inpha_CarryBackTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_01d22773-cda5-4a10-9824-c2880cc95883_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_cf3a2c61-dcb6-410f-b00c-ee5f59e7b753_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_6154f19a-0c52-4a24-984c-09c96109d10b_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IntellectualPropertyExpenses_3e444869-5579-4fee-a8ce-2924195c4393_negatedTerseLabel_en-US" xlink:label="lab_inpha_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property expenses</link:label>
    <link:label id="lab_inpha_IntellectualPropertyExpenses_label_en-US" xlink:label="lab_inpha_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Expenses</link:label>
    <link:label id="lab_inpha_IntellectualPropertyExpenses_documentation_en-US" xlink:label="lab_inpha_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of intellectual property expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IntellectualPropertyExpenses" xlink:href="inpha-20240630.xsd#inpha_IntellectualPropertyExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IntellectualPropertyExpenses" xlink:to="lab_inpha_IntellectualPropertyExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_d06e564d-2b7c-4ba2-963d-69b8374c4f26_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_66039319-97d7-45d1-8a08-194f4bd0e437_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for taxes other than income tax</link:label>
    <link:label id="lab_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_label_en-US" xlink:label="lab_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for taxes other than income tax [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember" xlink:to="lab_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_9c7c6bd4-29da-4805-9616-150470fa841a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_9b6d2158-244c-4f74-88e7-d9686b2be4b4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_c34a7b8c-9862-4dc9-bd10-f9ac60a681c7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RetirementDefinedBenefitMember_439ff756-08d8-42de-8ee9-120346d31127_terseLabel_en-US" xlink:label="lab_inpha_RetirementDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for retirement defined benefit</link:label>
    <link:label id="lab_inpha_RetirementDefinedBenefitMember_label_en-US" xlink:label="lab_inpha_RetirementDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Defined Benefit [Member]</link:label>
    <link:label id="lab_inpha_RetirementDefinedBenefitMember_documentation_en-US" xlink:label="lab_inpha_RetirementDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for retirement defined benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RetirementDefinedBenefitMember" xlink:href="inpha-20240630.xsd#inpha_RetirementDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RetirementDefinedBenefitMember" xlink:to="lab_inpha_RetirementDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_90fe0d86-7fdd-4997-9014-540f7400f5e9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LoanAgreementMaximumBorrowingCapacity_54063295-debc-47e3-9e50-828671e860ab_terseLabel_en-US" xlink:label="lab_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan agreement, maximum borrowing capacity</link:label>
    <link:label id="lab_inpha_LoanAgreementMaximumBorrowingCapacity_label_en-US" xlink:label="lab_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement Maximum Borrowing Capacity</link:label>
    <link:label id="lab_inpha_LoanAgreementMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity under the loan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:to="lab_inpha_LoanAgreementMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_965ccbcc-01d1-40bc-b069-6d0fd5605974_verboseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_ifrs-full_RevenueFromGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income from government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromGovernmentGrants" xlink:to="lab_ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShortTermInvestmentsAcquisitions_ca3aeab3-f6c2-495a-a0a3-5a211ba853d4_terseLabel_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, acquisitions</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsAcquisitions_label_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments, Acquisitions</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsAcquisitions_documentation_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in current investment resulting from origination or purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAcquisitions" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShortTermInvestmentsAcquisitions" xlink:to="lab_inpha_ShortTermInvestmentsAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock_5377eb90-d129-4963-b805-c903a1fada0c_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities per maturity</link:label>
    <link:label id="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Liabilities Per Maturity [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of financial liabilities per maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:to="lab_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesTable_5b7a5de5-ed4e-4243-a1fc-5dd2feeb315d_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesTable_label_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesTable_documentation_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesTable" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable" xlink:to="lab_inpha_DisclosureOfOperatingExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_4a3262eb-536f-4b0f-aed8-c957f5cf7031_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_309338e0-eb35-41c0-af1a-e7c66086d93f_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA20231Member_aa33bd37-9be8-46ab-b638-44c31c3bfbb8_terseLabel_en-US" xlink:label="lab_inpha_BSA20231Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2023-1</link:label>
    <link:label id="lab_inpha_BSA20231Member_label_en-US" xlink:label="lab_inpha_BSA20231Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2023-1 [Member]</link:label>
    <link:label id="lab_inpha_BSA20231Member_documentation_en-US" xlink:label="lab_inpha_BSA20231Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2023-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20231Member" xlink:href="inpha-20240630.xsd#inpha_BSA20231Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA20231Member" xlink:to="lab_inpha_BSA20231Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_04c4e49a-a25b-4269-a784-09a2bd5a3f8a_terseLabel_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax and employee-related payables</link:label>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_27ded690-1c4a-45e0-8853-a94e9262bd3d_terseLabel_en-US" xlink:label="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from contract liabilities, period</link:label>
    <link:label id="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_label_en-US" xlink:label="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Contract Liabilities, Recognition Period, Maximum</link:label>
    <link:label id="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_documentation_en-US" xlink:label="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues From Contract Liabilities, Recognition Period, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:href="inpha-20240630.xsd#inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:to="lab_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember_35b8b401-5e39-4b63-89a4-ab1ec2d85fe5_terseLabel_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities &#8211; Premises Innate Inc.</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember_label_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Innate Inc. Premises [Member]</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember_documentation_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the lease financing obligations for the Innate Inc. premises.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsInnateIncPremisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:to="lab_inpha_LeaseFinancingObligationsInnateIncPremisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PaymentOfTaxesOtherThanIncomeTax_5dce3f2e-09fe-4527-bddc-8b7ecdb2c691_terseLabel_en-US" xlink:label="lab_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of short term tax liability</link:label>
    <link:label id="lab_inpha_PaymentOfTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Taxes Other Than Income Tax</link:label>
    <link:label id="lab_inpha_PaymentOfTaxesOtherThanIncomeTax_documentation_en-US" xlink:label="lab_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Taxes Other Than Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:href="inpha-20240630.xsd#inpha_PaymentOfTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:to="lab_inpha_PaymentOfTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_41691860-341e-4f38-a912-cf8d9b4a0323_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory_293121b8-b008-44f1-b02c-c1d90322be49_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in short-term investments and non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ChangesToCommitmentsMember_5a220a9d-97e3-4379-9935-75fbf12c22ca_terseLabel_en-US" xlink:label="lab_inpha_ChangesToCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes to commitments</link:label>
    <link:label id="lab_inpha_ChangesToCommitmentsMember_label_en-US" xlink:label="lab_inpha_ChangesToCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes To Commitments [Member]</link:label>
    <link:label id="lab_inpha_ChangesToCommitmentsMember_documentation_en-US" xlink:label="lab_inpha_ChangesToCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes To Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangesToCommitmentsMember" xlink:href="inpha-20240630.xsd#inpha_ChangesToCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ChangesToCommitmentsMember" xlink:to="lab_inpha_ChangesToCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ExternalCostsRelatedToTheClinicalTrial_b2d268dc-cead-43b9-971c-cf5a2c96e215_terseLabel_en-US" xlink:label="lab_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External costs related to the clinical trial</link:label>
    <link:label id="lab_inpha_ExternalCostsRelatedToTheClinicalTrial_label_en-US" xlink:label="lab_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">External Costs Related To The Clinical Trial</link:label>
    <link:label id="lab_inpha_ExternalCostsRelatedToTheClinicalTrial_documentation_en-US" xlink:label="lab_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External Costs Related To The Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:href="inpha-20240630.xsd#inpha_ExternalCostsRelatedToTheClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:to="lab_inpha_ExternalCostsRelatedToTheClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementWithTakedaMember_0d8d36bd-312e-4941-88b5-5518472f576f_terseLabel_en-US" xlink:label="lab_inpha_AgreementWithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda agreement</link:label>
    <link:label id="lab_inpha_AgreementWithTakedaMember_label_en-US" xlink:label="lab_inpha_AgreementWithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Takeda [Member]</link:label>
    <link:label id="lab_inpha_AgreementWithTakedaMember_documentation_en-US" xlink:label="lab_inpha_AgreementWithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With Takeda</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithTakedaMember" xlink:href="inpha-20240630.xsd#inpha_AgreementWithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementWithTakedaMember" xlink:to="lab_inpha_AgreementWithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_inpha_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeLossPerShareAbstract" xlink:href="inpha-20240630.xsd#inpha_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeLossPerShareAbstract" xlink:to="lab_inpha_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_f379b870-5465-4527-8881-5c7832744d8c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue &#8211; current portion</link:label>
    <link:label id="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income including current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPEmployees20171Member_8c9940e1-d6c7-4aaf-bf22-5078a1db8c0d_terseLabel_en-US" xlink:label="lab_inpha_AGAPEmployees20171Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Employees 2017-1</link:label>
    <link:label id="lab_inpha_AGAPEmployees20171Member_label_en-US" xlink:label="lab_inpha_AGAPEmployees20171Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Employees 2017-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPEmployees20171Member_documentation_en-US" xlink:label="lab_inpha_AGAPEmployees20171Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20171Member" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20171Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPEmployees20171Member" xlink:to="lab_inpha_AGAPEmployees20171Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c8bb202d-8611-4c19-92e8-bd6120026aec_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ProvisionForAttendanceFees_d52fb52b-51c6-4f6d-a817-3eac5f212884_terseLabel_en-US" xlink:label="lab_inpha_ProvisionForAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for attendance fees</link:label>
    <link:label id="lab_inpha_ProvisionForAttendanceFees_label_en-US" xlink:label="lab_inpha_ProvisionForAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Attendance Fees</link:label>
    <link:label id="lab_inpha_ProvisionForAttendanceFees_documentation_en-US" xlink:label="lab_inpha_ProvisionForAttendanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of provision for attendance fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForAttendanceFees" xlink:href="inpha-20240630.xsd#inpha_ProvisionForAttendanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ProvisionForAttendanceFees" xlink:to="lab_inpha_ProvisionForAttendanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_85e5ba78-d663-4956-80b9-8e3a48819737_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_72be8af9-04b5-4a66-9107-af1c16a19954_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and others (excluding payables related to capital expenditures), variance</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_27342c6a-197e-4410-baa4-e5cae9ee11b2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfClinicalProductCandidates_1796e1b7-aa42-4b3f-9d27-d4cf7aa9609a_terseLabel_en-US" xlink:label="lab_inpha_NumberOfClinicalProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of clinical product candidates</link:label>
    <link:label id="lab_inpha_NumberOfClinicalProductCandidates_label_en-US" xlink:label="lab_inpha_NumberOfClinicalProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Clinical Product Candidates</link:label>
    <link:label id="lab_inpha_NumberOfClinicalProductCandidates_documentation_en-US" xlink:label="lab_inpha_NumberOfClinicalProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Clinical Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfClinicalProductCandidates" xlink:href="inpha-20240630.xsd#inpha_NumberOfClinicalProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfClinicalProductCandidates" xlink:to="lab_inpha_NumberOfClinicalProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_7302f389-d9ec-4a06-b1d1-7d8bef33b259_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPerfEmployees20221Member_489608d6-4e26-4c8c-b3ad-7771268a92b7_terseLabel_en-US" xlink:label="lab_inpha_AGAPerfEmployees20221Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2022-1</link:label>
    <link:label id="lab_inpha_AGAPerfEmployees20221Member_label_en-US" xlink:label="lab_inpha_AGAPerfEmployees20221Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2022-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPerfEmployees20221Member_documentation_en-US" xlink:label="lab_inpha_AGAPerfEmployees20221Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2022-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20221Member" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20221Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPerfEmployees20221Member" xlink:to="lab_inpha_AGAPerfEmployees20221Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_59f8a9c6-f0e8-4250-8ec8-402ae915545a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ExerciseOfShareWarrantsMember_d1335c69-26e3-4e9f-8d08-a4fbc358a856_terseLabel_en-US" xlink:label="lab_inpha_ExerciseOfShareWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Of Share Warrants</link:label>
    <link:label id="lab_inpha_ExerciseOfShareWarrantsMember_label_en-US" xlink:label="lab_inpha_ExerciseOfShareWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Share Warrants [Member]</link:label>
    <link:label id="lab_inpha_ExerciseOfShareWarrantsMember_documentation_en-US" xlink:label="lab_inpha_ExerciseOfShareWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Of Share Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseOfShareWarrantsMember" xlink:href="inpha-20240630.xsd#inpha_ExerciseOfShareWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ExerciseOfShareWarrantsMember" xlink:to="lab_inpha_ExerciseOfShareWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract_7a29b78b-d0ae-4245-96a7-9c37c56dd3e8_terseLabel_en-US" xlink:label="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in working capital</link:label>
    <link:label id="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract_label_en-US" xlink:label="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Changes In Working Capital [Abstract]</link:label>
    <link:label id="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract_documentation_en-US" xlink:label="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Changes In Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:href="inpha-20240630.xsd#inpha_SummaryOfChangesInWorkingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:to="lab_inpha_SummaryOfChangesInWorkingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_feb1902f-81f5-4f0b-bf76-fb8f37c38a0e_terseLabel_en-US" xlink:label="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cancellable off-balance sheet purchase commitments</link:label>
    <link:label id="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_label_en-US" xlink:label="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cancellable Off Balance Sheet Purchased Commitments</link:label>
    <link:label id="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_documentation_en-US" xlink:label="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:href="inpha-20240630.xsd#inpha_NonCancellableOffBalanceSheetPurchasedCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:to="lab_inpha_NonCancellableOffBalanceSheetPurchasedCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TransferToFromCollaborationLiabilities_291379e1-0565-4ff5-8a14-23af07da32b6_terseLabel_en-US" xlink:label="lab_inpha_TransferToFromCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer from / (to) collaboration liabilities</link:label>
    <link:label id="lab_inpha_TransferToFromCollaborationLiabilities_label_en-US" xlink:label="lab_inpha_TransferToFromCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer To (From) Collaboration Liabilities</link:label>
    <link:label id="lab_inpha_TransferToFromCollaborationLiabilities_documentation_en-US" xlink:label="lab_inpha_TransferToFromCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in contract liabilities resulting from transfer to collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferToFromCollaborationLiabilities" xlink:href="inpha-20240630.xsd#inpha_TransferToFromCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TransferToFromCollaborationLiabilities" xlink:to="lab_inpha_TransferToFromCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivables_c10750ce-cb16-4c36-a846-65140c5ba31a_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="lab_ifrs-full_TradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentResearchTaxCredit_2f1bad60-5900-419d-9a73-2628bdf891aa_verboseLabel_en-US" xlink:label="lab_inpha_NonCurrentResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit, non-current</link:label>
    <link:label id="lab_inpha_NonCurrentResearchTaxCredit_label_en-US" xlink:label="lab_inpha_NonCurrentResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Research Tax Credit</link:label>
    <link:label id="lab_inpha_NonCurrentResearchTaxCredit_documentation_en-US" xlink:label="lab_inpha_NonCurrentResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current research tax credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentResearchTaxCredit" xlink:href="inpha-20240630.xsd#inpha_NonCurrentResearchTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentResearchTaxCredit" xlink:to="lab_inpha_NonCurrentResearchTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DeferredRevenueMember_e6c77faa-29d6-44a2-9d4b-b3a3fd93ff54_terseLabel_en-US" xlink:label="lab_inpha_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_inpha_DeferredRevenueMember_label_en-US" xlink:label="lab_inpha_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_inpha_DeferredRevenueMember_documentation_en-US" xlink:label="lab_inpha_DeferredRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueMember" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DeferredRevenueMember" xlink:to="lab_inpha_DeferredRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member_6ae493e1-3bda-4fe3-a68f-38c4139044c2_terseLabel_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Sanofi, 2022 - ANKET IPH62</link:label>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member_label_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi 2022 - ANKET IPH62 [Member]</link:label>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member_documentation_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi 2022 - ANKET IPH62</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH62Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:to="lab_inpha_AgreementWithSanofi2022ANKETIPH62Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_b7563a17-c2ce-4438-bc22-86486785b207_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_796ddfb0-b7fb-43de-8140-897a865587b1_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_3a3c09bf-f1ca-40c2-b664-d190131b3de9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement Table [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_16fa3040-80a6-4a79-8fd3-88cebd122a99_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_0cd79341-fc34-4b92-b63b-4a165d370bc6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of other assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2024Member_17c7e83c-e1dc-444e-9de9-e335a8d0aa17_terseLabel_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2024</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2024Member_label_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2024 [Member]</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2024Member_documentation_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2024Member" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPlanEpargneEntreprise2024Member" xlink:to="lab_inpha_AGAPlanEpargneEntreprise2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_08245ed0-39c8-46e2-a439-52927d70f8da_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities at beginning of period</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_a5454117-2150-4b23-8ac7-012d271d1865_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities at end of period</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_d06993a0-3bfc-4e30-9e2b-6fe1d4e162ed_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, excluding profit (loss) for reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:to="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_ce11f6d1-b126-445b-987e-8ce57842b128_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and others</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInPropertyPlantAndEquipment_b67220f4-1623-48d4-8716-8ecdee60f01d_negatedLabel_en-US" xlink:label="lab_ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Write-off of right-of-use asset</link:label>
    <link:label id="lab_ifrs-full_ChangesInPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_ada75adf-7aaa-43b0-b55c-272eb4bb2af5_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization, net</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember_571e2edd-0607-4ce3-b442-5bdc724531d2_terseLabel_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities &#8211; Building "Le Virage"</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember_label_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Building, "Le Virage" [Member]</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember_documentation_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the finance lease obligations for the "Le Virage" building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:to="lab_inpha_LeaseFinancingObligationsBuildingLeVirageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsAxis_827e50d4-0c46-4f71-b4e6-fd759e2b619a_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_TypesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_OtherPurchasesAndExternalExpenses_26adf7fa-21ec-409e-abfb-ace574d2d3ec_negatedTerseLabel_en-US" xlink:label="lab_inpha_OtherPurchasesAndExternalExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other purchases and external expenses</link:label>
    <link:label id="lab_inpha_OtherPurchasesAndExternalExpenses_label_en-US" xlink:label="lab_inpha_OtherPurchasesAndExternalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Purchases And External Expenses</link:label>
    <link:label id="lab_inpha_OtherPurchasesAndExternalExpenses_documentation_en-US" xlink:label="lab_inpha_OtherPurchasesAndExternalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of other purchases and external expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherPurchasesAndExternalExpenses" xlink:href="inpha-20240630.xsd#inpha_OtherPurchasesAndExternalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_OtherPurchasesAndExternalExpenses" xlink:to="lab_inpha_OtherPurchasesAndExternalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock_6287553e-625f-48cf-abe4-d7133b2f5bf9_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Payables And Others [Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of trade payables and others.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:to="lab_inpha_DisclosureOfTradePayablesAndOthersTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_f737c745-3c26-4cf8-8c7c-9565d0132ca5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsMember_05a43bf5-77ea-412e-acdc-12a51c6f9519_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsMember_label_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current Financial Assets [Member]</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsMember_documentation_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for non-current financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsMember" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentFinancialAssetsMember" xlink:to="lab_inpha_NonCurrentFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_23d17ec1-8dbf-4fd6-930b-1296cc59abcc_terseLabel_en-US" xlink:label="lab_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opening balance after adjustment</link:label>
    <link:label id="lab_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_label_en-US" xlink:label="lab_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opening balance after adjustment, cumulative effect at date of initial application [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="lab_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_f2c0cf9f-4590-45dc-b188-d69b05e4d03c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_95b08893-de1e-46f0-8538-7f23326cd9da_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ScientificAdvisoryAndConsulting_dd4b69cf-c79b-4c34-af61-0e4bbbf242a2_negatedTerseLabel_en-US" xlink:label="lab_inpha_ScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Scientific advisory and consulting</link:label>
    <link:label id="lab_inpha_ScientificAdvisoryAndConsulting_label_en-US" xlink:label="lab_inpha_ScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scientific Advisory And Consulting</link:label>
    <link:label id="lab_inpha_ScientificAdvisoryAndConsulting_documentation_en-US" xlink:label="lab_inpha_ScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of Scientific advisory and consulting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ScientificAdvisoryAndConsulting" xlink:href="inpha-20240630.xsd#inpha_ScientificAdvisoryAndConsulting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ScientificAdvisoryAndConsulting" xlink:to="lab_inpha_ScientificAdvisoryAndConsulting" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_8739b512-4547-4ccd-8707-58186f4f15c1_terseLabel_en-US" xlink:label="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset of restated income from research tax credit</link:label>
    <link:label id="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_label_en-US" xlink:label="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offset Of Restated Income From Research Tax Credit 2020</link:label>
    <link:label id="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_documentation_en-US" xlink:label="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offset Of Restated Income From Research Tax Credit 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:href="inpha-20240630.xsd#inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:to="lab_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_e4d7ff97-cb3a-4f74-875c-bdf1cb11df91_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_d4a86a30-46da-4cb1-a9a8-22f8cd51bc45_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax / (expense)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TransferFromToCollaborationLiabilities_0a0bc176-9dfd-4815-bc2b-696b7f29bd22_terseLabel_en-US" xlink:label="lab_inpha_TransferFromToCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer from / (to) collaboration liabilities</link:label>
    <link:label id="lab_inpha_TransferFromToCollaborationLiabilities_label_en-US" xlink:label="lab_inpha_TransferFromToCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer From (To) Collaboration Liabilities</link:label>
    <link:label id="lab_inpha_TransferFromToCollaborationLiabilities_documentation_en-US" xlink:label="lab_inpha_TransferFromToCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in contract liabilities resulting from transfer to collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferFromToCollaborationLiabilities" xlink:href="inpha-20240630.xsd#inpha_TransferFromToCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TransferFromToCollaborationLiabilities" xlink:to="lab_inpha_TransferFromToCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_213cd3ae-6488-4f82-9dc4-103c5ae2ef34_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash generated from / (used in) investing activities:</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LeaseFinancingObligationsVehiclesMember_f121fb71-5fe6-41d2-90cf-db8674944973_terseLabel_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities &#8211; Vehicles</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsVehiclesMember_label_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Vehicles [Member]</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsVehiclesMember_documentation_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsVehiclesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the lease financing obligation for vehicles.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsVehiclesMember" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsVehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeaseFinancingObligationsVehiclesMember" xlink:to="lab_inpha_LeaseFinancingObligationsVehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember_8d09efdb-cf83-4b44-a8a6-a8d506e34ced_terseLabel_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Sanofi, 2016</link:label>
    <link:label id="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember_3a6d9b34-eb1a-4758-9e39-f87ddb168a99_verboseLabel_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Sanofi, 2016</link:label>
    <link:label id="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember_label_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Related To IPH6101 With Sanofi [Member]</link:label>
    <link:label id="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember_documentation_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Related To IPH6101 With Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:to="lab_inpha_AgreementRelatedToIPH6101WithSanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShareCapitalAndShareBasePaymentsAbstract_label_en-US" xlink:label="lab_inpha_ShareCapitalAndShareBasePaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital and Share Base Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract" xlink:href="inpha-20240630.xsd#inpha_ShareCapitalAndShareBasePaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract" xlink:to="lab_inpha_ShareCapitalAndShareBasePaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member_8b5a6649-a577-4d22-92db-f24cdd0b96a4_terseLabel_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi 2022 - ANKET IPH67</link:label>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member_label_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi 2022 - ANKET IPH67 [Member]</link:label>
    <link:label id="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member_documentation_en-US" xlink:label="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi 2022 - ANKET IPH67</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH67Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:to="lab_inpha_AgreementWithSanofi2022ANKETIPH67Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_8664cf36-ae83-436a-b4d1-ca25c66f5162_terseLabel_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">G&amp;A</link:label>
    <link:label id="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingGracePeriod_ebd31484-2418-4e8c-b0e9-53a5060430fe_terseLabel_en-US" xlink:label="lab_inpha_BorrowingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, grace period</link:label>
    <link:label id="lab_inpha_BorrowingGracePeriod_label_en-US" xlink:label="lab_inpha_BorrowingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Grace Period</link:label>
    <link:label id="lab_inpha_BorrowingGracePeriod_documentation_en-US" xlink:label="lab_inpha_BorrowingGracePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Grace Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingGracePeriod" xlink:href="inpha-20240630.xsd#inpha_BorrowingGracePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingGracePeriod" xlink:to="lab_inpha_BorrowingGracePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_9bdf88aa-fb44-4f8c-8dec-9a2feb58bc1b_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, variation of fair value through the consolidated statement of income (loss)</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_label_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_documentation_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gains (losses) on non-current financial assets at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:to="lab_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember_54dee4ec-7cd6-47e4-90d5-fb090ac07265_terseLabel_en-US" xlink:label="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definitive Acquisition Of Free Shares</link:label>
    <link:label id="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember_label_en-US" xlink:label="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Definitive Acquisition Of Free Shares [Member]</link:label>
    <link:label id="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember_documentation_en-US" xlink:label="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Definitive Acquisition Of Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:href="inpha-20240630.xsd#inpha_DefinitiveAcquisitionOfFreeSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:to="lab_inpha_DefinitiveAcquisitionOfFreeSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_193c1f00-8e58-4cbd-a309-c8f03ed58530_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPManagement20211Member_c3ede4a1-e9fa-408f-8f2f-840e09b64651_terseLabel_en-US" xlink:label="lab_inpha_AGAPManagement20211Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Management 2021-1</link:label>
    <link:label id="lab_inpha_AGAPManagement20211Member_label_en-US" xlink:label="lab_inpha_AGAPManagement20211Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Management 2021-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPManagement20211Member_documentation_en-US" xlink:label="lab_inpha_AGAPManagement20211Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGAP Management 2021-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20211Member" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20211Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPManagement20211Member" xlink:to="lab_inpha_AGAPManagement20211Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_03d97f82-8e59-4f34-bdb4-16ee60996c68_terseLabel_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security interest on pledge of financial instruments released</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_label_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Interest On Pledge Of Financial Instruments Released</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_documentation_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The values of security interest on the pledge of financial instruments will be released in 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:to="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_bad8f711-27a6-4c70-8124-93cbdded776a_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for target options</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received, Target Options</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received, Target Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:to="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2759d497-f0a9-4e63-9d2e-e7c6b23e8eeb_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3bce6c34-b9db-481a-ada6-6ac67f65dcca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TotalAcquisitions_423e0d2a-18ef-4ba6-a319-77025abecfdc_totalLabel_en-US" xlink:label="lab_inpha_TotalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, acquisitions</link:label>
    <link:label id="lab_inpha_TotalAcquisitions_label_en-US" xlink:label="lab_inpha_TotalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total, Acquisitions</link:label>
    <link:label id="lab_inpha_TotalAcquisitions_documentation_en-US" xlink:label="lab_inpha_TotalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in short-term investments and non-current financial assets resulting from origination or purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalAcquisitions" xlink:href="inpha-20240630.xsd#inpha_TotalAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TotalAcquisitions" xlink:to="lab_inpha_TotalAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_b1b63129-db6a-4f61-9df7-1e503e7cf20e_verboseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_1932dbdb-b417-4f86-a5b8-b378cd0c128e_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_e88b1735-7776-4435-abaa-081fc303f240_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan_3d88db33-36b8-4923-abae-4e5869cdd080_terseLabel_en-US" xlink:label="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, percentage of state-guaranteed loan</link:label>
    <link:label id="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan_label_en-US" xlink:label="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:label id="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan_documentation_en-US" xlink:label="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Percentage Of State-Guaranteed Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:href="inpha-20240630.xsd#inpha_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:to="lab_inpha_BorrowingPercentageOfStateGuaranteedLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LoanBuildingMember_5b8bb33a-e9ea-4871-9435-707b6f4172fc_terseLabel_en-US" xlink:label="lab_inpha_LoanBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing &#8211; Building (2)</link:label>
    <link:label id="lab_inpha_LoanBuildingMember_label_en-US" xlink:label="lab_inpha_LoanBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan, Building [Member]</link:label>
    <link:label id="lab_inpha_LoanBuildingMember_documentation_en-US" xlink:label="lab_inpha_LoanBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for loan, building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanBuildingMember" xlink:href="inpha-20240630.xsd#inpha_LoanBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LoanBuildingMember" xlink:to="lab_inpha_LoanBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_29ce72f2-b922-4ec6-8aa3-1dc9b4dcb49f_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net collection (payments)</link:label>
    <link:label id="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash repayments of advances and loans from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:to="lab_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_30bcbf02-46ae-4928-9913-14ec67afb409_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SanofiOptionsMember_27931cf9-e227-4afb-a69b-119a44032f8a_terseLabel_en-US" xlink:label="lab_inpha_SanofiOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi (2022) option</link:label>
    <link:label id="lab_inpha_SanofiOptionsMember_label_en-US" xlink:label="lab_inpha_SanofiOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi, Options [Member]</link:label>
    <link:label id="lab_inpha_SanofiOptionsMember_documentation_en-US" xlink:label="lab_inpha_SanofiOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi, Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiOptionsMember" xlink:href="inpha-20240630.xsd#inpha_SanofiOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SanofiOptionsMember" xlink:to="lab_inpha_SanofiOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredIncomeIncludingContractLiabilities_54e0226b-c44e-4204-a8f8-c28a577e31ac_negatedLabel_en-US" xlink:label="lab_ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue - current and non-current portion</link:label>
    <link:label id="lab_ifrs-full_DeferredIncomeIncludingContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income including contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:to="lab_ifrs-full_DeferredIncomeIncludingContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_f6e3d004-2c90-4dbe-8385-fdbfac542220_verboseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for share instruments (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of convertible instruments on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PGELoanAgreementAccruedInterestMember_e2e87005-1af0-4f88-99cd-7bf5f8ecfced_terseLabel_en-US" xlink:label="lab_inpha_PGELoanAgreementAccruedInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State guaranteed loans - accrued interest</link:label>
    <link:label id="lab_inpha_PGELoanAgreementAccruedInterestMember_label_en-US" xlink:label="lab_inpha_PGELoanAgreementAccruedInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Accrued Interest [Member]</link:label>
    <link:label id="lab_inpha_PGELoanAgreementAccruedInterestMember_documentation_en-US" xlink:label="lab_inpha_PGELoanAgreementAccruedInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementAccruedInterestMember" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementAccruedInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PGELoanAgreementAccruedInterestMember" xlink:to="lab_inpha_PGELoanAgreementAccruedInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationAndLicensingAgreementsMember_10100b35-47b9-4781-9e01-10be116fe2f6_terseLabel_en-US" xlink:label="lab_inpha_CollaborationAndLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaboration and licensing agreements</link:label>
    <link:label id="lab_inpha_CollaborationAndLicensingAgreementsMember_label_en-US" xlink:label="lab_inpha_CollaborationAndLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And Licensing Agreements [Member]</link:label>
    <link:label id="lab_inpha_CollaborationAndLicensingAgreementsMember_documentation_en-US" xlink:label="lab_inpha_CollaborationAndLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for collaboration and licensing agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationAndLicensingAgreementsMember" xlink:href="inpha-20240630.xsd#inpha_CollaborationAndLicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember" xlink:to="lab_inpha_CollaborationAndLicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_5e1dc3af-b0a9-45be-ae39-f719281f9881_terseLabel_en-US" xlink:label="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and others (excluding payables related to capital expenditures)</link:label>
    <link:label id="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_label_en-US" xlink:label="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Trade Payables And Others Excluding Payables Related To Capital Expenditures</link:label>
    <link:label id="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_documentation_en-US" xlink:label="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current Trade payables and others, excluding payables related to capital expenditures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:href="inpha-20240630.xsd#inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:to="lab_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_4d9d27f7-3158-4fd7-9494-561f94e22c9c_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of income (loss) per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CompanySavingPlanEmployerTopUpMember_b250d342-5f7f-4089-85cd-eef13b039e66_terseLabel_en-US" xlink:label="lab_inpha_CompanySavingPlanEmployerTopUpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company saving plan, employer top-up</link:label>
    <link:label id="lab_inpha_CompanySavingPlanEmployerTopUpMember_label_en-US" xlink:label="lab_inpha_CompanySavingPlanEmployerTopUpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Saving Plan, Employer Top Up [Member]</link:label>
    <link:label id="lab_inpha_CompanySavingPlanEmployerTopUpMember_documentation_en-US" xlink:label="lab_inpha_CompanySavingPlanEmployerTopUpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company Saving Plan, Employer Top Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanEmployerTopUpMember" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanEmployerTopUpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CompanySavingPlanEmployerTopUpMember" xlink:to="lab_inpha_CompanySavingPlanEmployerTopUpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfFinancialInstrumentsHeld_0df403d2-27c5-441d-a9ca-e4c8a853c2ff_terseLabel_en-US" xlink:label="lab_inpha_NumberOfFinancialInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of SICAV held (in units/shares)</link:label>
    <link:label id="lab_inpha_NumberOfFinancialInstrumentsHeld_label_en-US" xlink:label="lab_inpha_NumberOfFinancialInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Instruments Held</link:label>
    <link:label id="lab_inpha_NumberOfFinancialInstrumentsHeld_documentation_en-US" xlink:label="lab_inpha_NumberOfFinancialInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Financial Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfFinancialInstrumentsHeld" xlink:href="inpha-20240630.xsd#inpha_NumberOfFinancialInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfFinancialInstrumentsHeld" xlink:to="lab_inpha_NumberOfFinancialInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_2c4649b7-7b9a-4d1a-8d32-2bc9492c51e6_totalLabel_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_label_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Short-Term Investments, Assets</link:label>
    <link:label id="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_documentation_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents And Short-Term Investments, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndShortTermInvestmentsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:to="lab_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPerfEmployees20231Member_66627295-91a2-432b-8e59-7f6b26e5a874_terseLabel_en-US" xlink:label="lab_inpha_AGAPerfEmployees20231Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2023-1</link:label>
    <link:label id="lab_inpha_AGAPerfEmployees20231Member_label_en-US" xlink:label="lab_inpha_AGAPerfEmployees20231Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2023-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPerfEmployees20231Member_documentation_en-US" xlink:label="lab_inpha_AGAPerfEmployees20231Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Perf Employees 2023-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20231Member" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20231Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPerfEmployees20231Member" xlink:to="lab_inpha_AGAPerfEmployees20231Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSAAR2015Member_01e48374-3539-4e0f-a5ab-4df1b4ee20dc_terseLabel_en-US" xlink:label="lab_inpha_BSAAR2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSAAR 2015</link:label>
    <link:label id="lab_inpha_BSAAR2015Member_label_en-US" xlink:label="lab_inpha_BSAAR2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSAAR 2015 [Member]</link:label>
    <link:label id="lab_inpha_BSAAR2015Member_documentation_en-US" xlink:label="lab_inpha_BSAAR2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSAAR 2015.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2015Member" xlink:href="inpha-20240630.xsd#inpha_BSAAR2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSAAR2015Member" xlink:to="lab_inpha_BSAAR2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAbstract" xlink:to="lab_ifrs-full_ProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_1a1a67f0-ee58-4039-a40f-b77372ef35ee_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties_ffe7713f-71cc-4edf-bacb-e19ad678b197_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collection</link:label>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash advances and loans from related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:to="lab_ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_3f13aee6-5bbd-4148-83b1-99ffb6756f91_verboseLabel_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted cash flows</link:label>
    <link:label id="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank borrowings, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:to="lab_ifrs-full_BankBorrowingsUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_5dd738e5-ece4-4fe9-a7bd-fba9d7ce0c6d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_536eed92-04fa-4fa4-abb6-2fbba6006c36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_30670cc1-a804-48f8-99fd-30e59bff17a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and other income</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_a810e14c-5b61-4f0a-a9d0-296068267fb4_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LeaseFinancingObligationsPrintersMember_acf60d45-905d-4196-9b90-c7ee92370390_terseLabel_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsPrintersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities - Printers</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsPrintersMember_label_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsPrintersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Printers [Member]</link:label>
    <link:label id="lab_inpha_LeaseFinancingObligationsPrintersMember_documentation_en-US" xlink:label="lab_inpha_LeaseFinancingObligationsPrintersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Financing Obligations, Printers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsPrintersMember" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsPrintersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeaseFinancingObligationsPrintersMember" xlink:to="lab_inpha_LeaseFinancingObligationsPrintersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPerfManagement20221Member_20199bf5-de87-40bc-9be0-6cf039f503d1_terseLabel_en-US" xlink:label="lab_inpha_AGAPerfManagement20221Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2022-1</link:label>
    <link:label id="lab_inpha_AGAPerfManagement20221Member_label_en-US" xlink:label="lab_inpha_AGAPerfManagement20221Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2022-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPerfManagement20221Member_documentation_en-US" xlink:label="lab_inpha_AGAPerfManagement20221Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2022-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20221Member" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20221Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPerfManagement20221Member" xlink:to="lab_inpha_AGAPerfManagement20221Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_e6be0193-127f-4c98-b386-247f4088ab48_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_24c67f7d-2c45-45d9-9818-58354477b6c6_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_96048c0d-36be-425d-b82b-838ee6de32f2_verboseLabel_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit obligations</link:label>
    <link:label id="lab_ifrs-full_DefinedBenefitObligationAtPresentValue_label_en-US" xlink:label="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:to="lab_ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_fb55d538-80e3-4883-866c-7157da1478ab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management of financial risks</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_d6fbf28c-6077-415e-bf44-483bb60a0da2_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_The2016FreePreferredSharesMember_71759fdf-b683-4d2a-8065-1cde0bcbfba6_terseLabel_en-US" xlink:label="lab_inpha_The2016FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The 2016 free preferred shares</link:label>
    <link:label id="lab_inpha_The2016FreePreferredSharesMember_label_en-US" xlink:label="lab_inpha_The2016FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Free Preferred Shares [Member]</link:label>
    <link:label id="lab_inpha_The2016FreePreferredSharesMember_documentation_en-US" xlink:label="lab_inpha_The2016FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2016 free preferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2016FreePreferredSharesMember" xlink:href="inpha-20240630.xsd#inpha_The2016FreePreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_The2016FreePreferredSharesMember" xlink:to="lab_inpha_The2016FreePreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_2ea3f091-a64d-46aa-911d-46aa2ef9590e_terseLabel_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares [Axis]</link:label>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_label_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares [Axis]</link:label>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_documentation_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:to="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TradePayablesAndOthersMember_e4d7e9ed-a6da-4fb4-92bc-226a6e55553c_terseLabel_en-US" xlink:label="lab_inpha_TradePayablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and others</link:label>
    <link:label id="lab_inpha_TradePayablesAndOthersMember_label_en-US" xlink:label="lab_inpha_TradePayablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Payables And Others [Member]</link:label>
    <link:label id="lab_inpha_TradePayablesAndOthersMember_documentation_en-US" xlink:label="lab_inpha_TradePayablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for trade payables and others.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradePayablesAndOthersMember" xlink:href="inpha-20240630.xsd#inpha_TradePayablesAndOthersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TradePayablesAndOthersMember" xlink:to="lab_inpha_TradePayablesAndOthersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementWithOregaBiotechMember_53323b21-f4b6-4f69-a0cf-1e13c90612e3_terseLabel_en-US" xlink:label="lab_inpha_AgreementWithOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Orega Biotech</link:label>
    <link:label id="lab_inpha_AgreementWithOregaBiotechMember_label_en-US" xlink:label="lab_inpha_AgreementWithOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Orega Biotech [Member]</link:label>
    <link:label id="lab_inpha_AgreementWithOregaBiotechMember_documentation_en-US" xlink:label="lab_inpha_AgreementWithOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for agreement with Orega Biotech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithOregaBiotechMember" xlink:href="inpha-20240630.xsd#inpha_AgreementWithOregaBiotechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementWithOregaBiotechMember" xlink:to="lab_inpha_AgreementWithOregaBiotechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAbstract_3af232e8-5cae-48c7-8371-f3726ebf1cb3_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAbstract_label_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Financial Assets [Abstract]</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAbstract_documentation_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsAbstract" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract" xlink:to="lab_inpha_NonCurrentFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_95438fb2-0d27-49ac-bea8-86c24d3a5152_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shared-based payment</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0651295e-6f7a-43c3-9e17-27e52ca17848_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash generated from / (used in) operating activities:</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA2014Member_5f3d68a3-58a0-46ab-8fca-c5906c701c94_terseLabel_en-US" xlink:label="lab_inpha_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2014</link:label>
    <link:label id="lab_inpha_BSA2014Member_label_en-US" xlink:label="lab_inpha_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2014 [Member]</link:label>
    <link:label id="lab_inpha_BSA2014Member_documentation_en-US" xlink:label="lab_inpha_BSA2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSA 2014.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2014Member" xlink:href="inpha-20240630.xsd#inpha_BSA2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA2014Member" xlink:to="lab_inpha_BSA2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_23d16638-74e6-40b4-9c3c-806e965d0505_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_cedaeb03-73dc-42fc-a405-3f605ac0328d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_4e1c64f7-8619-40d5-8f57-6e55a5163633_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset) at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_9e4f85f2-cd1f-4649-bd36-3688c6fff3ca_terseLabel_en-US" xlink:label="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPH5201 (anti-CD39) rights acquired from Orega Biotech</link:label>
    <link:label id="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_label_en-US" xlink:label="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPH5201 (Anti-CD39) Rights Acquired From Orega Biotech [Member]</link:label>
    <link:label id="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_documentation_en-US" xlink:label="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for IPH5201 (Anti-CD39) rights acquired from Orega Biotech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:href="inpha-20240630.xsd#inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:to="lab_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_f4f9a9ee-0099-453b-8c73-22de45f388be_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade account receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_394bdd95-dd28-4431-9445-fa691807cd05_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PGELoanAgreementBNPParibasMember_72471f5e-ae89-4cb7-bc3b-b1d2551131d9_terseLabel_en-US" xlink:label="lab_inpha_PGELoanAgreementBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State guaranteed loan BNP Paribas (1)</link:label>
    <link:label id="lab_inpha_PGELoanAgreementBNPParibasMember_label_en-US" xlink:label="lab_inpha_PGELoanAgreementBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, BNP Paribas [Member]</link:label>
    <link:label id="lab_inpha_PGELoanAgreementBNPParibasMember_documentation_en-US" xlink:label="lab_inpha_PGELoanAgreementBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, BNP Paribas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PGELoanAgreementBNPParibasMember" xlink:to="lab_inpha_PGELoanAgreementBNPParibasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock_fcb5c9e3-29a1-4e3e-8d62-c43f82889c18_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables and others</link:label>
    <link:label id="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Trade Receivables And Other [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of trade receivables and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:to="lab_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LaboratoryEquipmentAndOtherMember_4a7845c6-bab1-4a13-a802-30b1411d58b1_terseLabel_en-US" xlink:label="lab_inpha_LaboratoryEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment and other</link:label>
    <link:label id="lab_inpha_LaboratoryEquipmentAndOtherMember_label_en-US" xlink:label="lab_inpha_LaboratoryEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment And Other [Member]</link:label>
    <link:label id="lab_inpha_LaboratoryEquipmentAndOtherMember_documentation_en-US" xlink:label="lab_inpha_LaboratoryEquipmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for laboratory equipment and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LaboratoryEquipmentAndOtherMember" xlink:href="inpha-20240630.xsd#inpha_LaboratoryEquipmentAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LaboratoryEquipmentAndOtherMember" xlink:to="lab_inpha_LaboratoryEquipmentAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterialsAndConsumablesUsed_a31a7501-3986-4f1e-a1c2-21bcff7b16d5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of supplies and consumable materials</link:label>
    <link:label id="lab_ifrs-full_RawMaterialsAndConsumablesUsed_label_en-US" xlink:label="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials and consumables used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="lab_ifrs-full_RawMaterialsAndConsumablesUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect_2df36e0b-b9db-4276-a2a3-3581cbfc3ca0_terseLabel_en-US" xlink:label="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, foreign currency effect</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect_label_en-US" xlink:label="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments, Foreign Currency Effect</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect_documentation_en-US" xlink:label="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in current financial assets resulting from foreign exchange and other movements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsForeignCurrencyEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:to="lab_inpha_ShortTermInvestmentsForeignCurrencyEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_9488e84a-b5f6-44c0-bd55-9b181e0a2e0b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments recognized in the statement of financial position and related effect on the income statement</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_613a11d5-cd9c-40b2-91e2-e7f7d5285080_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting standards and interpretations</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingMaturity_1b37f1bc-40ea-4797-99ce-7af90ac24c72_terseLabel_en-US" xlink:label="lab_inpha_BorrowingMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, maturity</link:label>
    <link:label id="lab_inpha_BorrowingMaturity_label_en-US" xlink:label="lab_inpha_BorrowingMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity</link:label>
    <link:label id="lab_inpha_BorrowingMaturity_documentation_en-US" xlink:label="lab_inpha_BorrowingMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturity" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingMaturity" xlink:to="lab_inpha_BorrowingMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_37ddcb64-9fde-4e15-9f39-287883d002e8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_89aa72a6-7a4d-4778-88cf-934960c22957_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_207d1734-ae02-4dcc-a530-f945e1ec2f85_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesExplanatory_11f63e6f-c642-45fc-812b-498212c4c6e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expenses [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_e7925f65-c0f0-4355-8a12-66a07b2441e2_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DeferredRevenueRollForwardAbstract_5d2ef15b-b694-499c-ba3a-5d58b0ec1402_terseLabel_en-US" xlink:label="lab_inpha_DeferredRevenueRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Roll Forward [Abstract]</link:label>
    <link:label id="lab_inpha_DeferredRevenueRollForwardAbstract_label_en-US" xlink:label="lab_inpha_DeferredRevenueRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Roll Forward [Abstract]</link:label>
    <link:label id="lab_inpha_DeferredRevenueRollForwardAbstract_documentation_en-US" xlink:label="lab_inpha_DeferredRevenueRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueRollForwardAbstract" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueRollForwardAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract" xlink:to="lab_inpha_DeferredRevenueRollForwardAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_3262342f-9ced-4329-9c5d-6708cc0e46c5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_e50c34fa-6d1b-4ce4-b2c7-c6b01734a218_terseLabel_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, variation of accrued interest</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income arising from interest for current financial assets that are not at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:to="lab_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_d3e45721-cccf-43f5-90ae-98a5118421f9_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_225a4eb0-4f3b-4942-92e3-035539687381_terseLabel_en-US" xlink:label="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment on social security and taxes other than income tax</link:label>
    <link:label id="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment On Social Security And Taxes Other Than Income Tax</link:label>
    <link:label id="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_documentation_en-US" xlink:label="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment On Social Security And Taxes Other Than Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="inpha-20240630.xsd#inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_ca73afc6-3e6d-419e-9103-8a23cfd11d68_terseLabel_en-US" xlink:label="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opening balance before adjustment, cumulative effect at date of initial application</link:label>
    <link:label id="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_label_en-US" xlink:label="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opening balance before adjustment, cumulative effect at date of initial application [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="lab_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_18cc5d2b-81ab-40de-a7f0-5bbe4c9ce20c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures_6ec5c533-24f9-42c5-ab50-771216db1734_terseLabel_en-US" xlink:label="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables related to capital expenditures</link:label>
    <link:label id="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures_label_en-US" xlink:label="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Payables Related To Capital Expenditures</link:label>
    <link:label id="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures_documentation_en-US" xlink:label="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current payables related to capital expenditures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:href="inpha-20240630.xsd#inpha_CurrentPayablesRelatedToCapitalExpenditures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:to="lab_inpha_CurrentPayablesRelatedToCapitalExpenditures" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_9060c55e-24a1-404c-b024-c502e4b258af_totalLabel_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total variance of accrued interest</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:to="lab_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_bee02d93-97cd-4e94-8413-a582c9cf4afc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, short-term investments and non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce927d7a-cc2b-4eb9-afc6-89cfbb31e09b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TradeReceivablesAndOthersMember_f0287e4d-6577-463a-9cb1-3369a4c2036a_terseLabel_en-US" xlink:label="lab_inpha_TradeReceivablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others</link:label>
    <link:label id="lab_inpha_TradeReceivablesAndOthersMember_label_en-US" xlink:label="lab_inpha_TradeReceivablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Receivables And Others [Member]</link:label>
    <link:label id="lab_inpha_TradeReceivablesAndOthersMember_documentation_en-US" xlink:label="lab_inpha_TradeReceivablesAndOthersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for trade receivables and others.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeReceivablesAndOthersMember" xlink:href="inpha-20240630.xsd#inpha_TradeReceivablesAndOthersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TradeReceivablesAndOthersMember" xlink:to="lab_inpha_TradeReceivablesAndOthersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGANewMembers20241Member_f66661f6-3997-47eb-8aa2-f96d5968c80d_terseLabel_en-US" xlink:label="lab_inpha_AGANewMembers20241Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA New members 2024-1</link:label>
    <link:label id="lab_inpha_AGANewMembers20241Member_label_en-US" xlink:label="lab_inpha_AGANewMembers20241Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA New Members 2024-1 [Member]</link:label>
    <link:label id="lab_inpha_AGANewMembers20241Member_documentation_en-US" xlink:label="lab_inpha_AGANewMembers20241Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA New Members 2024-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20241Member" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20241Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGANewMembers20241Member" xlink:to="lab_inpha_AGANewMembers20241Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LeasingAndMaintenance_4eea7c13-1d70-463a-80c0-a12f530492ec_negatedTerseLabel_en-US" xlink:label="lab_inpha_LeasingAndMaintenance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Leasing and maintenance</link:label>
    <link:label id="lab_inpha_LeasingAndMaintenance_label_en-US" xlink:label="lab_inpha_LeasingAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing And Maintenance</link:label>
    <link:label id="lab_inpha_LeasingAndMaintenance_documentation_en-US" xlink:label="lab_inpha_LeasingAndMaintenance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of leasing and maintenance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeasingAndMaintenance" xlink:href="inpha-20240630.xsd#inpha_LeasingAndMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LeasingAndMaintenance" xlink:to="lab_inpha_LeasingAndMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TradeAndOtherReceivablesExcludingRebates_a83c6cc9-cf7f-4737-98bb-6d55971e7511_totalLabel_en-US" xlink:label="lab_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others</link:label>
    <link:label id="lab_inpha_TradeAndOtherReceivablesExcludingRebates_label_en-US" xlink:label="lab_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Receivables Excluding Rebates</link:label>
    <link:label id="lab_inpha_TradeAndOtherReceivablesExcludingRebates_documentation_en-US" xlink:label="lab_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">he amount of trade receivables and other receivables, excluding rebates related to capital expenditures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherReceivablesExcludingRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:to="lab_inpha_TradeAndOtherReceivablesExcludingRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_2c52ffcf-6d24-4daa-9409-fe268a25dd2c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_99e1ea32-c429-4fdf-9758-4315d58264b5_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit obligations</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions for employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="lab_ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_60dfaa0a-cff3-4e49-bee0-96b5363b48c1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_3304ccd9-71bd-4372-a84d-fdafe2319330_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposal of property and equipment (scrapping)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on disposals of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_e8aeb7e8-abdb-4100-8ba5-bec8e1cca0d4_negatedLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Actuarial (gain) / loss</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_93f129b4-761e-4799-92b7-1041ba20828c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_3196a4df-cd2e-446d-862e-cb2b44a42b99_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_ab86be0d-853e-415b-be8d-a5fbcce2c894_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleMember_74a72771-f2a2-41cf-9223-501d10723e5e_terseLabel_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</link:label>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleMember_label_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Societe Generale [Member]</link:label>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleMember_documentation_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Societe Generale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:to="lab_inpha_PGELoanAgreementSocieteGeneraleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_a1c75cd1-54b0-44e1-bf80-e94c19d830b2_terseLabel_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed interest rate</link:label>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_68ae3588-3af2-41bd-9620-b6dc8fb61240_terseLabel_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares [Domain]</link:label>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_label_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares [Domain]</link:label>
    <link:label id="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_documentation_en-US" xlink:label="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type of Exercise And Subscription Of Shares [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:to="lab_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSAAR2012Member_17665ff1-c08a-4940-8de3-acfaa6ef3ddf_terseLabel_en-US" xlink:label="lab_inpha_BSAAR2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSAAR 2012</link:label>
    <link:label id="lab_inpha_BSAAR2012Member_label_en-US" xlink:label="lab_inpha_BSAAR2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSAAR 2012 [Member]</link:label>
    <link:label id="lab_inpha_BSAAR2012Member_documentation_en-US" xlink:label="lab_inpha_BSAAR2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSAAR 2012.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2012Member" xlink:href="inpha-20240630.xsd#inpha_BSAAR2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSAAR2012Member" xlink:to="lab_inpha_BSAAR2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_63b249d1-c720-4386-8d25-0ab6c7b186f7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_8627c995-31bf-4ed3-813e-9d7c59819868_terseLabel_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security interest on pledge of financial instruments released in 2024 including interest</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_label_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Interest On Pledged Financial Instruments Released, Including Interest</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_documentation_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Security Interest On Pledged Financial Instruments Released, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:to="lab_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5fceb077-171e-402d-9ef4-c75356bd35ec_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_8b15fc84-2063-473b-910b-f3a3b75d616e_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about defined benefit plans [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_c73b30da-55ba-418d-affa-44fd44a948d9_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_272305a1-b4e6-4a21-a4cf-144e3ab7db1f_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_545f63d3-7183-4417-bea7-a7c9c147b74d_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGABonus202012Member_ade302d0-b526-4dd1-a9b6-ca1966eeb8f4_terseLabel_en-US" xlink:label="lab_inpha_AGABonus202012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Bonus 2020-1 &amp; 2</link:label>
    <link:label id="lab_inpha_AGABonus202012Member_label_en-US" xlink:label="lab_inpha_AGABonus202012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Bonus 2020-1 &amp; 2 [Member]</link:label>
    <link:label id="lab_inpha_AGABonus202012Member_documentation_en-US" xlink:label="lab_inpha_AGABonus202012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Bonus 2020-1 &amp; 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus202012Member" xlink:href="inpha-20240630.xsd#inpha_AGABonus202012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGABonus202012Member" xlink:to="lab_inpha_AGABonus202012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ResearchTaxCreditReceivableCurrent_4f06e471-5c83-41ce-9c5a-c1b9ff9233c8_terseLabel_en-US" xlink:label="lab_inpha_ResearchTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_inpha_ResearchTaxCreditReceivableCurrent_label_en-US" xlink:label="lab_inpha_ResearchTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit, Receivable, Current</link:label>
    <link:label id="lab_inpha_ResearchTaxCreditReceivableCurrent_documentation_en-US" xlink:label="lab_inpha_ResearchTaxCreditReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Tax Credit, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchTaxCreditReceivableCurrent" xlink:href="inpha-20240630.xsd#inpha_ResearchTaxCreditReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ResearchTaxCreditReceivableCurrent" xlink:to="lab_inpha_ResearchTaxCreditReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_a7e4ea81-aa7a-4bde-ba68-9b0fb523a4ba_totalLabel_en-US" xlink:label="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, variation of fair value through the consolidated statement of income (loss)</link:label>
    <link:label id="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_label_en-US" xlink:label="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)</link:label>
    <link:label id="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_documentation_en-US" xlink:label="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:href="inpha-20240630.xsd#inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:to="lab_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingMaturityExtensionPeriodOption_ce04c163-588a-4b94-a186-6a867b66ae8a_terseLabel_en-US" xlink:label="lab_inpha_BorrowingMaturityExtensionPeriodOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing, maturity, extension period option</link:label>
    <link:label id="lab_inpha_BorrowingMaturityExtensionPeriodOption_label_en-US" xlink:label="lab_inpha_BorrowingMaturityExtensionPeriodOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity, Extension Period Option</link:label>
    <link:label id="lab_inpha_BorrowingMaturityExtensionPeriodOption_documentation_en-US" xlink:label="lab_inpha_BorrowingMaturityExtensionPeriodOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowing, Maturity, Extension Period Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturityExtensionPeriodOption" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturityExtensionPeriodOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingMaturityExtensionPeriodOption" xlink:to="lab_inpha_BorrowingMaturityExtensionPeriodOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_45546fe6-78d9-46f0-8e9a-6ac0b9147fe0_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, profit (loss) for reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:to="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_a8f2e3d4-725d-40ae-b5c4-963e6ac83bb6_negatedLabel_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestone_b6ab5f9b-6a39-44eb-bcf1-4d7b9b65cb42_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in deferred revenue/Additions</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestone_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestone_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestone" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersMilestone" xlink:to="lab_inpha_RevenueFromContractsWithCustomersMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TypeOfEmployeeDomain_1613a42f-cf97-45b2-b70e-f43734f59bb7_terseLabel_en-US" xlink:label="lab_inpha_TypeOfEmployeeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type Of Employee [Domain]</link:label>
    <link:label id="lab_inpha_TypeOfEmployeeDomain_label_en-US" xlink:label="lab_inpha_TypeOfEmployeeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type Of Employee [Domain]</link:label>
    <link:label id="lab_inpha_TypeOfEmployeeDomain_documentation_en-US" xlink:label="lab_inpha_TypeOfEmployeeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type Of Employee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeDomain" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TypeOfEmployeeDomain" xlink:to="lab_inpha_TypeOfEmployeeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ResearchAndDevelopmentMember_8be9d907-847d-4aa6-89a0-474df80f8895_terseLabel_en-US" xlink:label="lab_inpha_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_inpha_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_inpha_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_inpha_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_inpha_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchAndDevelopmentMember" xlink:href="inpha-20240630.xsd#inpha_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ResearchAndDevelopmentMember" xlink:to="lab_inpha_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGANewMembers20171Member_32691e4e-00e9-4857-aad4-94ca239b0615_terseLabel_en-US" xlink:label="lab_inpha_AGANewMembers20171Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA New Members 2017-1</link:label>
    <link:label id="lab_inpha_AGANewMembers20171Member_label_en-US" xlink:label="lab_inpha_AGANewMembers20171Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA New Members 2017-1 [Member]</link:label>
    <link:label id="lab_inpha_AGANewMembers20171Member_documentation_en-US" xlink:label="lab_inpha_AGANewMembers20171Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGA New Members 2017-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20171Member" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20171Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGANewMembers20171Member" xlink:to="lab_inpha_AGANewMembers20171Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_491b2142-4579-49e4-bc02-f53519fc78bd_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxTable_d785e624-4b78-407b-bace-24ff191ffd41_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxTable_label_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxTable_documentation_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxTable" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfIncomeTaxTable" xlink:to="lab_inpha_DisclosureOfIncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_2cac991d-df3e-464e-8859-86e85504ee5c_verboseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Extra pension benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_037ee223-b2a7-4f93-9003-0ff1eb6c73ad_negatedLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Revenue for the six months period/Deductions</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_6ad704d4-a74f-4016-b257-514e18d6b7d7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition in P&amp;L</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPManagement20201Member_b02c3b99-4763-42c3-b25b-a98629880784_terseLabel_en-US" xlink:label="lab_inpha_AGAPManagement20201Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Management 2020-1</link:label>
    <link:label id="lab_inpha_AGAPManagement20201Member_label_en-US" xlink:label="lab_inpha_AGAPManagement20201Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Management 2020-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPManagement20201Member_documentation_en-US" xlink:label="lab_inpha_AGAPManagement20201Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGAP Management 2020-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20201Member" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20201Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPManagement20201Member" xlink:to="lab_inpha_AGAPManagement20201Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LoanAgreementWithSocitGnraleMember_965cd0d9-8224-417f-9552-74fa6164baf5_terseLabel_en-US" xlink:label="lab_inpha_LoanAgreementWithSocitGnraleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale</link:label>
    <link:label id="lab_inpha_LoanAgreementWithSocitGnraleMember_label_en-US" xlink:label="lab_inpha_LoanAgreementWithSocitGnraleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement With Soci&#233;t&#233; G&#233;n&#233;rale [Member]</link:label>
    <link:label id="lab_inpha_LoanAgreementWithSocitGnraleMember_documentation_en-US" xlink:label="lab_inpha_LoanAgreementWithSocitGnraleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementWithSocitGnraleMember" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementWithSocitGnraleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LoanAgreementWithSocitGnraleMember" xlink:to="lab_inpha_LoanAgreementWithSocitGnraleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock_eb0df71b-3206-46c4-ba2f-9ad0f3158445_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of government financing for research expenditures</link:label>
    <link:label id="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Government Financing For Research Expenditures [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of government financing for research expenditures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:to="lab_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_0429800d-f68d-4aa6-addf-bd57d3077348_terseLabel_en-US" xlink:label="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Characteristics of defined benefit plans [axis]</link:label>
    <link:label id="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_label_en-US" xlink:label="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Characteristics of defined benefit plans [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:to="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LoanEquipmentMember_bc8763ba-1e4b-4c45-900b-28752c4e1b28_terseLabel_en-US" xlink:label="lab_inpha_LoanEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowing &#8211; Equipment</link:label>
    <link:label id="lab_inpha_LoanEquipmentMember_label_en-US" xlink:label="lab_inpha_LoanEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan, Equipment [Member]</link:label>
    <link:label id="lab_inpha_LoanEquipmentMember_documentation_en-US" xlink:label="lab_inpha_LoanEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for loan, equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanEquipmentMember" xlink:href="inpha-20240630.xsd#inpha_LoanEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LoanEquipmentMember" xlink:to="lab_inpha_LoanEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfStateGuaranteedLoans_5a76a66c-7981-4243-8026-4f208b8bdbda_terseLabel_en-US" xlink:label="lab_inpha_NumberOfStateGuaranteedLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of state guaranteed loans</link:label>
    <link:label id="lab_inpha_NumberOfStateGuaranteedLoans_label_en-US" xlink:label="lab_inpha_NumberOfStateGuaranteedLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of State Guaranteed Loans</link:label>
    <link:label id="lab_inpha_NumberOfStateGuaranteedLoans_documentation_en-US" xlink:label="lab_inpha_NumberOfStateGuaranteedLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of State Guaranteed Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfStateGuaranteedLoans" xlink:href="inpha-20240630.xsd#inpha_NumberOfStateGuaranteedLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfStateGuaranteedLoans" xlink:to="lab_inpha_NumberOfStateGuaranteedLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_1055965a-5be3-476a-b822-d46802ef236a_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, fair value</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxContingentLiabilityMember_65748bcf-2f08-4ed5-8bfd-2b8d9b5e07bc_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxContingentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax contingent liability</link:label>
    <link:label id="lab_ifrs-full_TaxContingentLiabilityMember_label_en-US" xlink:label="lab_ifrs-full_TaxContingentLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax contingent liability [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxContingentLiabilityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxContingentLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxContingentLiabilityMember" xlink:to="lab_ifrs-full_TaxContingentLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020Receivable_dd9e66fa-1e5e-4e4c-852c-65b26b75c2e4_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit 2020, receivable</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020Receivable_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2020, Receivable</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020Receivable_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2020, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020Receivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:to="lab_inpha_IncomeFromResearchTaxCredit2020Receivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_77f47f57-a01c-46b9-a7e8-5bd642b820bb_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [axis]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember_3dece9a0-ec73-424e-8858-e72292b4ca37_terseLabel_en-US" xlink:label="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements with Sanofi for NK Cell engages</link:label>
    <link:label id="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember_label_en-US" xlink:label="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements with Sanofi for NK Cell engages [Member]</link:label>
    <link:label id="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember_documentation_en-US" xlink:label="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements with Sanofi for NK Cell engages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithSanofiForNKCellEngagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:to="lab_inpha_AgreementsWithSanofiForNKCellEngagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_449dd787-3e37-440f-bf0a-8e50360fbf71_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_daa70ca1-1d75-455f-97ef-5742b2549729_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_b056bf4f-e79c-41c5-a64a-a6533ffd4e0c_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at beginning of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_0acf65f3-b853-4c96-bbe7-2ea1a7a759b4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill at end of period</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_3432bc7f-f8ff-47a2-bab2-e1f8c8940d38_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_9e64b391-0355-4704-9415-1f21c42540d6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_10044ca5-1f9a-4398-a4b7-2b3bea440efe_terseLabel_en-US" xlink:label="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_label_en-US" xlink:label="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Short-Term Investments And Non-Current Financial Assets [Abstract]</link:label>
    <link:label id="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_documentation_en-US" xlink:label="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Short-Term Investments And Non-Current Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:href="inpha-20240630.xsd#inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:to="lab_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_4026a851-25bb-4f07-8462-2eb034449e26_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_198aa162-a38d-440d-826b-a5cea91ab7b6_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_eca7257e-1b73-4ad0-964d-ec573c53cbdd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_0600c8a0-11af-456f-bc78-5d905d5b1b54_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional considerations</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationLiabilities_2a464571-46d6-4a22-b2e2-0b93382ff6a0_negatedLabel_en-US" xlink:label="lab_inpha_CollaborationLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Collaboration liabilities - current and non-current portion</link:label>
    <link:label id="lab_inpha_CollaborationLiabilities_label_en-US" xlink:label="lab_inpha_CollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities</link:label>
    <link:label id="lab_inpha_CollaborationLiabilities_documentation_en-US" xlink:label="lab_inpha_CollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilities" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationLiabilities" xlink:to="lab_inpha_CollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_ba20f9fc-22b8-4c6a-b6d2-92dd8f9e819a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA2013Member_3c3bdd88-20a0-41ff-8f2e-d99fff6f8700_terseLabel_en-US" xlink:label="lab_inpha_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2013</link:label>
    <link:label id="lab_inpha_BSA2013Member_label_en-US" xlink:label="lab_inpha_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2013 [Member]</link:label>
    <link:label id="lab_inpha_BSA2013Member_documentation_en-US" xlink:label="lab_inpha_BSA2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSA 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2013Member" xlink:href="inpha-20240630.xsd#inpha_BSA2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA2013Member" xlink:to="lab_inpha_BSA2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_f32ea867-6268-4821-b70f-cd49d2649194_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of transactions denominated in foreign currency</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_9077a080-072f-4168-9b53-bf79a72586c1_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_3ac52aeb-28cb-4460-a450-7f8d7ce103b2_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_3168980e-6269-4ed0-ae5b-a2532c539db7_verboseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_1a8455c1-80d9-43bf-86fc-2cb36e347cb1_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2022Member_b6cc2366-e331-4244-8bec-77eae2b7b2b1_terseLabel_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2022</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2022Member_label_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2022 [Member]</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2022Member_documentation_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2022Member" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPlanEpargneEntreprise2022Member" xlink:to="lab_inpha_AGAPlanEpargneEntreprise2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_d7af08d7-c2bb-4190-880d-6d40c9ac5c78_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments (benefits and contributions paid by the employer)</link:label>
    <link:label id="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_1bb1bb10-5b9d-4a61-833f-44a508ce00ef_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_18949f3e-eb22-44a2-bd60-d6d5093cf368_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGABonus20211Member_a0c5367e-796d-469f-aa2d-f4a6ae6ae9d8_terseLabel_en-US" xlink:label="lab_inpha_AGABonus20211Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Bonus 2021-1</link:label>
    <link:label id="lab_inpha_AGABonus20211Member_label_en-US" xlink:label="lab_inpha_AGABonus20211Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Bonus 2021-1 [Member]</link:label>
    <link:label id="lab_inpha_AGABonus20211Member_documentation_en-US" xlink:label="lab_inpha_AGABonus20211Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Bonus 2021-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20211Member" xlink:href="inpha-20240630.xsd#inpha_AGABonus20211Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGABonus20211Member" xlink:to="lab_inpha_AGABonus20211Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_dc8ec5b9-2297-4f54-9753-82802b27d2fd_terseLabel_en-US" xlink:label="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Sanofi, 2022</link:label>
    <link:label id="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_label_en-US" xlink:label="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Research Collaboration And Licensing Agreement [Member]</link:label>
    <link:label id="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_documentation_en-US" xlink:label="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi Research Collaboration And Licensing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:href="inpha-20240630.xsd#inpha_SanofiResearchCollaborationAndLicensingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:to="lab_inpha_SanofiResearchCollaborationAndLicensingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_2eae210b-7149-4c46-befc-ded12ef5de9b_terseLabel_en-US" xlink:label="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal of current financial instruments</link:label>
    <link:label id="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sales Of Current Financial Instruments, Classified As Investing Activities</link:label>
    <link:label id="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sales Of Current Financial Instruments, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_0a69f1cf-b1e8-48f7-8865-d37c58431c62_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares, diluted (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_77c32886-3d24-40e9-8b2e-994352c5f9b4_terseLabel_en-US" xlink:label="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Through Performance Obligation Being Satisfied, Contract Liabilities</link:label>
    <link:label id="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_documentation_en-US" xlink:label="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in contract liabilities resulting from additions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_e99a8e93-33a1-48c5-a240-d678f6642255_terseLabel_en-US" xlink:label="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate variation (non cash)</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_label_en-US" xlink:label="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Liabilities</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_documentation_en-US" xlink:label="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:to="lab_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementWithSanofiMember_1f0a0026-7a7a-4f11-8406-caddb842f9cc_terseLabel_en-US" xlink:label="lab_inpha_AgreementWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi</link:label>
    <link:label id="lab_inpha_AgreementWithSanofiMember_label_en-US" xlink:label="lab_inpha_AgreementWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi [Member]</link:label>
    <link:label id="lab_inpha_AgreementWithSanofiMember_documentation_en-US" xlink:label="lab_inpha_AgreementWithSanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement With Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofiMember" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementWithSanofiMember" xlink:to="lab_inpha_AgreementWithSanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_4e62ced3-f341-4076-aa57-c70f1fc33ec2_verboseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average rate (&#8364;1 equals to USD)</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_6a577729-def0-4692-85ff-45d9a7e2b90d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in accrued interests on financial assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in accrued income including contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_b0f22c72-adb7-4922-9b68-88944c1b8e15_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_5f2397e2-f686-4d58-9ec8-7a50acc0982a_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within 1 year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_588b98ba-70f8-44f7-88db-0b667623be34_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGANewMembers20231Member_3aacb55d-a8fa-4bb9-8975-84e86b3e2dda_terseLabel_en-US" xlink:label="lab_inpha_AGANewMembers20231Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA New members 2023-1</link:label>
    <link:label id="lab_inpha_AGANewMembers20231Member_label_en-US" xlink:label="lab_inpha_AGANewMembers20231Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA New Members 2023-1 [Member]</link:label>
    <link:label id="lab_inpha_AGANewMembers20231Member_documentation_en-US" xlink:label="lab_inpha_AGANewMembers20231Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA New Members 2023-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20231Member" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20231Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGANewMembers20231Member" xlink:to="lab_inpha_AGANewMembers20231Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments_bc78db79-8e30-42cd-9be8-f02371c34c04_terseLabel_en-US" xlink:label="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance on financial instruments</link:label>
    <link:label id="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments_label_en-US" xlink:label="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Valuation Allowance Of Financial Instruments</link:label>
    <link:label id="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments_documentation_en-US" xlink:label="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:href="inpha-20240630.xsd#inpha_ChangeInValuationAllowanceOfFinancialInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:to="lab_inpha_ChangeInValuationAllowanceOfFinancialInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TravelExpense_a9521168-00fe-4ae2-ba83-1787122a361a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TravelExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Travel expenses and meeting attendance</link:label>
    <link:label id="lab_ifrs-full_TravelExpense_label_en-US" xlink:label="lab_ifrs-full_TravelExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travel expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TravelExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TravelExpense" xlink:to="lab_ifrs-full_TravelExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_0d0bf722-79b5-48e0-87a8-9261dd1117eb_terseLabel_en-US" xlink:label="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Monalizumab (NKG2A) agreement with Novo Nordisk</link:label>
    <link:label id="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_label_en-US" xlink:label="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member]</link:label>
    <link:label id="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_documentation_en-US" xlink:label="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:href="inpha-20240630.xsd#inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:to="lab_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_7854fce8-99a2-4167-8d6d-cb024c33535f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise / subscription of equity instruments</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAManagement20161Member_c1ee4ee2-0b1c-46f8-b4cc-f3c9e754d780_terseLabel_en-US" xlink:label="lab_inpha_AGAManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Management 2016-1</link:label>
    <link:label id="lab_inpha_AGAManagement20161Member_label_en-US" xlink:label="lab_inpha_AGAManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Management 2016-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAManagement20161Member_documentation_en-US" xlink:label="lab_inpha_AGAManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGA Management 2016-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20161Member" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20161Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAManagement20161Member" xlink:to="lab_inpha_AGAManagement20161Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b8c15703-6936-40db-a24a-c40505b6c272_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_fd975361-ad05-4fc8-b03e-88712d45ad03_terseLabel_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, variation of accrued interest</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_documentation_en-US" xlink:label="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:to="lab_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ClinicalServicesMember_21f69e5e-5636-47d8-a700-2c26d318e4a4_terseLabel_en-US" xlink:label="lab_inpha_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Services</link:label>
    <link:label id="lab_inpha_ClinicalServicesMember_label_en-US" xlink:label="lab_inpha_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_inpha_ClinicalServicesMember_documentation_en-US" xlink:label="lab_inpha_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ClinicalServicesMember" xlink:href="inpha-20240630.xsd#inpha_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ClinicalServicesMember" xlink:to="lab_inpha_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_ce06ba63-d4b5-414c-8b31-5944e4d1b614_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RiskProfileRate_cc713c3e-3035-44ae-9b3f-1424eaba521f_terseLabel_en-US" xlink:label="lab_inpha_RiskProfileRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk profile rate</link:label>
    <link:label id="lab_inpha_RiskProfileRate_label_en-US" xlink:label="lab_inpha_RiskProfileRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Profile Rate</link:label>
    <link:label id="lab_inpha_RiskProfileRate_documentation_en-US" xlink:label="lab_inpha_RiskProfileRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Profile Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RiskProfileRate" xlink:href="inpha-20240630.xsd#inpha_RiskProfileRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RiskProfileRate" xlink:to="lab_inpha_RiskProfileRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_fd14e5b4-b3f6-4446-8800-30d814f1cd91_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_22e42a40-22e9-43ab-815b-b8afad56de47_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SICAVAndMutualFundsMember_ab1700d1-10a8-4ce6-a16d-76793331e315_terseLabel_en-US" xlink:label="lab_inpha_SICAVAndMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SICAV and mutual funds</link:label>
    <link:label id="lab_inpha_SICAVAndMutualFundsMember_label_en-US" xlink:label="lab_inpha_SICAVAndMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SICAV And Mutual Funds [Member]</link:label>
    <link:label id="lab_inpha_SICAVAndMutualFundsMember_documentation_en-US" xlink:label="lab_inpha_SICAVAndMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SICAV And Mutual Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVAndMutualFundsMember" xlink:href="inpha-20240630.xsd#inpha_SICAVAndMutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SICAVAndMutualFundsMember" xlink:to="lab_inpha_SICAVAndMutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_UnusedTaxLossesSubjectToExpiration_376c7d05-9cef-4187-be0b-fee577d39c17_terseLabel_en-US" xlink:label="lab_inpha_UnusedTaxLossesSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses subject to expiration</link:label>
    <link:label id="lab_inpha_UnusedTaxLossesSubjectToExpiration_label_en-US" xlink:label="lab_inpha_UnusedTaxLossesSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Tax Losses Subject To Expiration</link:label>
    <link:label id="lab_inpha_UnusedTaxLossesSubjectToExpiration_documentation_en-US" xlink:label="lab_inpha_UnusedTaxLossesSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of unused tax losses subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesSubjectToExpiration" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_UnusedTaxLossesSubjectToExpiration" xlink:to="lab_inpha_UnusedTaxLossesSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_5e7b9838-896b-4326-9019-004b1bfca42d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketing, communication and public relations</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_label_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense" xlink:to="lab_ifrs-full_SalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NovoNordiskASMember_5171efd1-28a8-4ee1-ad86-df1bd46cb09e_terseLabel_en-US" xlink:label="lab_inpha_NovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novo Nordisk A/S</link:label>
    <link:label id="lab_inpha_NovoNordiskASMember_label_en-US" xlink:label="lab_inpha_NovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novo Nordisk A/S [Member]</link:label>
    <link:label id="lab_inpha_NovoNordiskASMember_documentation_en-US" xlink:label="lab_inpha_NovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Novo Nordisk A/S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NovoNordiskASMember" xlink:href="inpha-20240630.xsd#inpha_NovoNordiskASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NovoNordiskASMember" xlink:to="lab_inpha_NovoNordiskASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_The2017FreePreferredSharesMember_6524ac93-fd1d-4577-ad54-3aecc4db28f7_terseLabel_en-US" xlink:label="lab_inpha_The2017FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The 2017 free preferred shares</link:label>
    <link:label id="lab_inpha_The2017FreePreferredSharesMember_label_en-US" xlink:label="lab_inpha_The2017FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Free Preferred Shares [Member]</link:label>
    <link:label id="lab_inpha_The2017FreePreferredSharesMember_documentation_en-US" xlink:label="lab_inpha_The2017FreePreferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2017 free preferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2017FreePreferredSharesMember" xlink:href="inpha-20240630.xsd#inpha_The2017FreePreferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_The2017FreePreferredSharesMember" xlink:to="lab_inpha_The2017FreePreferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_4d1be977-f6ee-482b-8a28-2bfbc69fd6de_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains and (losses) related to defined benefit obligations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_0fa7565b-993e-41b0-86e9-564f7d893179_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains on defined benefit obligations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ce0c2a39-4820-48cd-b39a-6d37cb5da7ea_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_c432d1f2-0175-48b3-a9cc-482a12d2f7ae_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Executive Board Members and other Executive Members compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_LoanAgreementCollateral_9435c9d6-c05c-4614-82c0-f18bc6a91eba_terseLabel_en-US" xlink:label="lab_inpha_LoanAgreementCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan agreement, collateral</link:label>
    <link:label id="lab_inpha_LoanAgreementCollateral_label_en-US" xlink:label="lab_inpha_LoanAgreementCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement Collateral</link:label>
    <link:label id="lab_inpha_LoanAgreementCollateral_documentation_en-US" xlink:label="lab_inpha_LoanAgreementCollateral" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of collateral in connection with the loan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementCollateral" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_LoanAgreementCollateral" xlink:to="lab_inpha_LoanAgreementCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember_7b506344-0d3e-47f7-a368-2dc8c098faee_terseLabel_en-US" xlink:label="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 monalizumab agreement, with AstraZeneca</link:label>
    <link:label id="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember_label_en-US" xlink:label="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 AstraZeneca Monalizumab Agreements [Member]</link:label>
    <link:label id="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember_documentation_en-US" xlink:label="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for 2015 AstraZeneca monalizumab agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:href="inpha-20240630.xsd#inpha_A2015AstraZenecaMonalizumabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:to="lab_inpha_A2015AstraZenecaMonalizumabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAManagement20162Member_470b286e-4666-4037-9801-144bebc54f6d_terseLabel_en-US" xlink:label="lab_inpha_AGAManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Management 2016-2</link:label>
    <link:label id="lab_inpha_AGAManagement20162Member_label_en-US" xlink:label="lab_inpha_AGAManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Management 2016-2 [Member]</link:label>
    <link:label id="lab_inpha_AGAManagement20162Member_documentation_en-US" xlink:label="lab_inpha_AGAManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGA Management 2016-2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20162Member" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20162Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAManagement20162Member" xlink:to="lab_inpha_AGAManagement20162Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024_f7235142-46bd-43ad-8d6f-41e291178914_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit HY 2024</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit Half Year 2024</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income related to research tax credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCreditHalfYear2024"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:to="lab_inpha_IncomeFromResearchTaxCreditHalfYear2024" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related party transactions [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract" xlink:to="lab_ifrs-full_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_3a62a398-0e56-41ba-8c64-e2caebe0735f_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic income (loss) per share (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_59922117-4d34-492e-afae-b46533b83bc7_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other profit or loss items with no cash effect</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentPrepaidExpenses_017b38d3-f9d7-452e-9c33-f2e2b68b28a2_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, non-current</link:label>
    <link:label id="lab_inpha_NonCurrentPrepaidExpenses_label_en-US" xlink:label="lab_inpha_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Prepaid Expenses</link:label>
    <link:label id="lab_inpha_NonCurrentPrepaidExpenses_documentation_en-US" xlink:label="lab_inpha_NonCurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentPrepaidExpenses" xlink:href="inpha-20240630.xsd#inpha_NonCurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentPrepaidExpenses" xlink:to="lab_inpha_NonCurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock_ccba4d92-9ab8-4fd4-8e2e-71f5f9aa4429_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and key events</link:label>
    <link:label id="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Company, Significant Agreements And Key Events [Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Company, Significant Agreements And Key Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:to="lab_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c66991cf-b1aa-45cb-b5a5-f4116c8cd166_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_dea06b2e-0965-481c-b8ce-c6acef8b615e_terseLabel_en-US" xlink:label="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, variation of fair value through the consolidated statement of income (loss)</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_label_en-US" xlink:label="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_documentation_en-US" xlink:label="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gains (losses) on current financial assets at fair value through profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:to="lab_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_3af7e0b7-ecfe-483d-b0d1-560e9a6f813c_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsDomain" xlink:to="lab_ifrs-full_TypesOfContractsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_61e142df-fb60-4b44-bed2-a9e584d19343_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_47626280-6b6b-4e22-a9e8-e79c839bf2d6_verboseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Closing rate (&#8364;1 equals to USD)</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_40064e6f-c518-4404-9ffa-9d9da2e8c633_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suppliers (excluding payables related to capital expenditures)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_23687161-502c-4d9c-bc77-9a29c90549aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_9bb01d5c-8cf1-4116-b77d-e7501b199c7a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShareIssuedPricePerShare_8d9cdbc4-ce0a-444d-a053-6e0c1e4c5261_terseLabel_en-US" xlink:label="lab_inpha_ShareIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issued, price per share (in EUR per share)</link:label>
    <link:label id="lab_inpha_ShareIssuedPricePerShare_label_en-US" xlink:label="lab_inpha_ShareIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issued Price Per Share</link:label>
    <link:label id="lab_inpha_ShareIssuedPricePerShare_documentation_en-US" xlink:label="lab_inpha_ShareIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit amount of equity securities issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareIssuedPricePerShare" xlink:href="inpha-20240630.xsd#inpha_ShareIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShareIssuedPricePerShare" xlink:to="lab_inpha_ShareIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_a8a8d62a-3056-4b11-8992-d771d0478e66_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_6ba34be0-1abe-451f-80c2-4cbedc41aa17_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) for the period:</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_55b9d8e1-ba70-4d73-a460-353057b436ce_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_7725becd-26ab-4bd2-b782-754f9dbb0e3e_netLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_0b55f07c-2eab-49b2-b766-7a0c37d22139_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain" xlink:to="lab_ifrs-full_TypesOfInterestRatesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfTargetOptions_1a8e552c-8fca-4740-925c-aa2a6a058aca_terseLabel_en-US" xlink:label="lab_inpha_NumberOfTargetOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of target options</link:label>
    <link:label id="lab_inpha_NumberOfTargetOptions_label_en-US" xlink:label="lab_inpha_NumberOfTargetOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Target Options</link:label>
    <link:label id="lab_inpha_NumberOfTargetOptions_documentation_en-US" xlink:label="lab_inpha_NumberOfTargetOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Target Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfTargetOptions" xlink:href="inpha-20240630.xsd#inpha_NumberOfTargetOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfTargetOptions" xlink:to="lab_inpha_NumberOfTargetOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_36e7eda8-770d-496d-9544-746a6712b828_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating cash flow before change in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_676b7717-fdf0-4fe4-b6dd-8e93521ca540_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_390545e0-0ae9-46b6-8112-c1c521a2ff9f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialLiabilitiesCurrentPortionMember_b2b123b8-6e73-46ed-ba2a-c42287b89e71_terseLabel_en-US" xlink:label="lab_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities&#8212;current portion</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesCurrentPortionMember_label_en-US" xlink:label="lab_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Current Portion [Member]</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesCurrentPortionMember_documentation_en-US" xlink:label="lab_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for financial liabilities&#8212;current portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesCurrentPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:to="lab_inpha_FinancialLiabilitiesCurrentPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d0b5eb28-fa55-4b6d-a274-5946850657c7_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation gain (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a813d15b-9d6f-43db-b922-f4f2b27eee46_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxLineItems_50006887-d672-46c3-9851-6f4997b38cec_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxLineItems_label_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfIncomeTaxLineItems_documentation_en-US" xlink:label="lab_inpha_DisclosureOfIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxLineItems" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems" xlink:to="lab_inpha_DisclosureOfIncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_9b0fa439-d217-416f-b8ce-6b79111aa8f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments, contingencies and litigation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_MonalizumabAgreementMember_796b05d3-66be-42fc-af27-2b2530311b61_terseLabel_en-US" xlink:label="lab_inpha_MonalizumabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monalizumab agreement</link:label>
    <link:label id="lab_inpha_MonalizumabAgreementMember_52da50c7-6a8f-4dfd-8f18-35a1ec2856f8_verboseLabel_en-US" xlink:label="lab_inpha_MonalizumabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Monalizumab agreement (AstraZeneca)</link:label>
    <link:label id="lab_inpha_MonalizumabAgreementMember_label_en-US" xlink:label="lab_inpha_MonalizumabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monalizumab Agreement [Member]</link:label>
    <link:label id="lab_inpha_MonalizumabAgreementMember_documentation_en-US" xlink:label="lab_inpha_MonalizumabAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for monalizumab agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_MonalizumabAgreementMember" xlink:to="lab_inpha_MonalizumabAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_6a71d1af-a138-4045-b828-582854cf07f9_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_fbb1f984-65dc-4b5a-a213-c9030863e273_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_289c530b-9b3b-429a-bb29-f136d4c77a90_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_b405358e-98de-45b3-bd3c-d87187840b7a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_0ae3113f-35c6-4639-94e6-e17b21087273_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems_8fbc2308-5744-4c3e-bc41-8586967048d6_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems_label_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems_documentation_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:to="lab_inpha_DisclosureOfTradePayablesAndOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit_16af6a34-46d0-4436-a43d-46d305f19a44_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income related to research tax credit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit" xlink:to="lab_inpha_IncomeFromResearchTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_b8d06e7c-ca8a-464e-9551-62c4b3b06fe1_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_12c59021-8b26-4a49-8d12-afbf3fd85f92_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Par value per share (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_d6ac28f6-09d2-4ad5-be32-f4e94109c1d5_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted income (loss) per share (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_e1e32fbf-a29b-4a55-b2cb-a26e94af743a_verboseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted income/(loss) per share (in EUR per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2023Member_eb3d7d10-d32c-4fb7-909f-b82d9bb8fed0_terseLabel_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2023</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2023Member_label_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2023 [Member]</link:label>
    <link:label id="lab_inpha_AGAPlanEpargneEntreprise2023Member_documentation_en-US" xlink:label="lab_inpha_AGAPlanEpargneEntreprise2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA "Plan Epargne Entreprise" 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2023Member" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPlanEpargneEntreprise2023Member" xlink:to="lab_inpha_AGAPlanEpargneEntreprise2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_b508fa1f-8dfe-4c9b-8e15-f53f6a209f29_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and statement of compliance</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_MonalizumabMember_238c2ebb-0024-4a83-a3b3-8bcf6c9935d2_terseLabel_en-US" xlink:label="lab_inpha_MonalizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monalizumab</link:label>
    <link:label id="lab_inpha_MonalizumabMember_label_en-US" xlink:label="lab_inpha_MonalizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monalizumab [Member]</link:label>
    <link:label id="lab_inpha_MonalizumabMember_documentation_en-US" xlink:label="lab_inpha_MonalizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Monalizumab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabMember" xlink:href="inpha-20240630.xsd#inpha_MonalizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_MonalizumabMember" xlink:to="lab_inpha_MonalizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_3f2b4806-4dcc-4728-914e-560248328fae_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement Line Items [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseDecreaseInFinancialLiabilities_dc07a515-0b8e-4bf7-836a-8c842fba541e_negatedTerseLabel_en-US" xlink:label="lab_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write-off of lease liability</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInFinancialLiabilities_label_en-US" xlink:label="lab_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Financial Liabilities</link:label>
    <link:label id="lab_inpha_IncreaseDecreaseInFinancialLiabilities_documentation_en-US" xlink:label="lab_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:to="lab_inpha_IncreaseDecreaseInFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_6d8cc7f0-f9d6-48d7-b38f-393aaa3f01f0_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Payment Received</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:to="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentProvisions_96d95718-d2d0-47b8-829b-eab756b0612a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions - current portion</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPPerfManagement20181Member_5c564a16-06e8-4044-ac12-0ed539b826ca_terseLabel_en-US" xlink:label="lab_inpha_AGAPPerfManagement20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Perf Management 2018-1</link:label>
    <link:label id="lab_inpha_AGAPPerfManagement20181Member_label_en-US" xlink:label="lab_inpha_AGAPPerfManagement20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Perf Management 2018-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPPerfManagement20181Member_documentation_en-US" xlink:label="lab_inpha_AGAPPerfManagement20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGA Perf Management 2018-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfManagement20181Member" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfManagement20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPPerfManagement20181Member" xlink:to="lab_inpha_AGAPPerfManagement20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_d8c7f5f9-8e0e-49d3-b145-e8c3b5c0b525_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions - non-current portion</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_a5dfdf9b-a296-4771-bd20-53ff1ac0b04a_terseLabel_en-US" xlink:label="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds</link:label>
    <link:label id="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_label_en-US" xlink:label="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Through Upfront Payment, Contract Liabilities</link:label>
    <link:label id="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_documentation_en-US" xlink:label="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in contract liabilities resulting from upfront payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughUpfrontPaymentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:to="lab_inpha_IncreaseThroughUpfrontPaymentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_70567b90-cc2a-4ea3-a3bd-47abe6ca7f92_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_6687b05c-3640-4839-9feb-d5dcc1251cab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement Line Items [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_a673d85e-3482-4750-a076-1e7996274120_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIntangibleAssetsMember" xlink:to="lab_ifrs-full_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments_cae99dac-c6d5-4e30-bd7b-50ba593ce7dd_terseLabel_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise and subscription of equity instruments</link:label>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments_label_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise And Subscription Of Equity Instruments</link:label>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments_documentation_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in equity resulting from exercise and subscription of equity instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:to="lab_inpha_ExerciseAndSubscriptionOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ChangeInWorkingCapital_9b1757fa-d309-448b-a4af-674ca51f3abc_negatedTotalLabel_en-US" xlink:label="lab_inpha_ChangeInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total change in working capital</link:label>
    <link:label id="lab_inpha_ChangeInWorkingCapital_label_en-US" xlink:label="lab_inpha_ChangeInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Working Capital</link:label>
    <link:label id="lab_inpha_ChangeInWorkingCapital_documentation_en-US" xlink:label="lab_inpha_ChangeInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of working capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInWorkingCapital" xlink:href="inpha-20240630.xsd#inpha_ChangeInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ChangeInWorkingCapital" xlink:to="lab_inpha_ChangeInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_e326d29e-8db7-4d2c-bf67-4c49e1624a2b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities &#8211; current portion</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_943a51fe-9388-40c3-b3ed-4329c97f2dd7_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cf195bbe-5afd-4c19-bc44-94be19aceb55_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_4398ec43-007e-419b-9b28-7c83d46905fb_negatedLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_4a17f8c5-145c-4c39-ba64-cb388cf97007_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_7114213f-4edc-4570-85dd-28fef540830c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_970ffa6d-2d3f-4a11-bf44-8ab3bdb6819f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpense_99f3d018-f586-4d60-91a3-1e7fd98020b4_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest on financial liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpense_label_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense" xlink:to="lab_ifrs-full_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSAAR2011Member_c04ea428-d902-41e9-823d-5aea397ba386_terseLabel_en-US" xlink:label="lab_inpha_BSAAR2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSAAR 2011</link:label>
    <link:label id="lab_inpha_BSAAR2011Member_label_en-US" xlink:label="lab_inpha_BSAAR2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSAAR 2011 [Member]</link:label>
    <link:label id="lab_inpha_BSAAR2011Member_documentation_en-US" xlink:label="lab_inpha_BSAAR2011Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSAAR 2011.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2011Member" xlink:href="inpha-20240630.xsd#inpha_BSAAR2011Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSAAR2011Member" xlink:to="lab_inpha_BSAAR2011Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8a1bd58b-9e74-4257-86a6-662f977a5dd8_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_8936887c-8d6b-457d-878a-f28804c0dae1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Personnel expenses other than share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_e1175937-2b9e-4efd-a0aa-5e36bf1442e5_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel expenses other than share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ShorttermEmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="lab_ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_fe2bdc40-cfb6-4d62-be05-0d0368a442a1_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash generated / (used in) from financing activities:</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_f320c9e9-7e4c-4eac-9a01-6cf6e9caced4_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_00e506db-6ecc-4a1e-a124-ce772cd1b75f_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_3b1b43d4-eb7b-4a0b-9460-55a60c287770_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_b5286ce9-23cb-4f85-b049-ea7f61076e31_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GuaranteesMember_878466ac-cd65-4283-b9e0-3f9f40185d9d_terseLabel_en-US" xlink:label="lab_ifrs-full_GuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_ifrs-full_GuaranteesMember_label_en-US" xlink:label="lab_ifrs-full_GuaranteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GuaranteesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GuaranteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GuaranteesMember" xlink:to="lab_ifrs-full_GuaranteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_9bd66b80-45e5-4597-8c0a-471d00f9c111_negatedLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade payables and others (excluding payables related to capital expenditures)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayables" xlink:to="lab_ifrs-full_TradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_6d8ac530-6b01-480e-8c05-f1c3fc6cf7a3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and others</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SubcontractingCosts_c2d7eade-d555-473c-8ab0-993419c6626e_negatedTerseLabel_en-US" xlink:label="lab_inpha_SubcontractingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Subcontracting costs</link:label>
    <link:label id="lab_inpha_SubcontractingCosts_label_en-US" xlink:label="lab_inpha_SubcontractingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subcontracting Costs</link:label>
    <link:label id="lab_inpha_SubcontractingCosts_documentation_en-US" xlink:label="lab_inpha_SubcontractingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of subcontracting costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SubcontractingCosts" xlink:href="inpha-20240630.xsd#inpha_SubcontractingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SubcontractingCosts" xlink:to="lab_inpha_SubcontractingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_6bf37d39-6b1c-4b33-846b-2f20656d8ca2_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IAS19 Restatement related to change in calculation method - IFRIC</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="lab_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_3d8955ae-7e81-44cb-9930-cd4301d22b34_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue &#8211; non-current portion</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current deferred income including non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_a4e8ebc4-c218-4a4b-a603-af2e7b38885f_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_320bc03d-c7e5-46b6-b460-fcaaa3e8ca6c_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_671b659b-f1fa-4f4e-8598-6c08b17a8016_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfContractsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfContractsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of contracts [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfContractsAxis" xlink:to="lab_ifrs-full_TypesOfContractsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_6ac2233a-d679-4bc8-bdf6-c84be377662c_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, excluding profit (loss) for reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:to="lab_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PreferenceSharesMember_18b95c50-9828-4334-9c6c-dd48f6baa8f8_terseLabel_en-US" xlink:label="lab_ifrs-full_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Shares</link:label>
    <link:label id="lab_ifrs-full_PreferenceSharesMember_label_en-US" xlink:label="lab_ifrs-full_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preference shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreferenceSharesMember" xlink:to="lab_ifrs-full_PreferenceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_768c9d1e-fb52-4713-870c-333f01a83641_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities &#8211; non-current portion</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA20112Member_debd4fee-7be8-48de-af3b-d73ed3046c20_terseLabel_en-US" xlink:label="lab_inpha_BSA20112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2011-2</link:label>
    <link:label id="lab_inpha_BSA20112Member_label_en-US" xlink:label="lab_inpha_BSA20112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2011-2 [Member]</link:label>
    <link:label id="lab_inpha_BSA20112Member_documentation_en-US" xlink:label="lab_inpha_BSA20112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20112Member" xlink:href="inpha-20240630.xsd#inpha_BSA20112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA20112Member" xlink:to="lab_inpha_BSA20112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_a99ab325-2448-4008-af35-cb7fde2698b7_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of free shares granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_StockOptions20201Member_96c9c9d6-a8e0-40b7-8633-6e27849bc337_terseLabel_en-US" xlink:label="lab_inpha_StockOptions20201Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options 2020-1</link:label>
    <link:label id="lab_inpha_StockOptions20201Member_label_en-US" xlink:label="lab_inpha_StockOptions20201Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options 2020-1 [Member]</link:label>
    <link:label id="lab_inpha_StockOptions20201Member_documentation_en-US" xlink:label="lab_inpha_StockOptions20201Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options 2020-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_StockOptions20201Member" xlink:href="inpha-20240630.xsd#inpha_StockOptions20201Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_StockOptions20201Member" xlink:to="lab_inpha_StockOptions20201Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_0281b306-382e-4e3b-b162-614c1b3457e9_terseLabel_en-US" xlink:label="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset against income from research tax credit 2020</link:label>
    <link:label id="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_label_en-US" xlink:label="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offset Against Income From Research Tax Credit 2020</link:label>
    <link:label id="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_documentation_en-US" xlink:label="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offset Against Income From Research Tax Credit 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:href="inpha-20240630.xsd#inpha_OffsetAgainstIncomeFromResearchTaxCredit2020"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:to="lab_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_a82c7711-99bf-4f2c-9a94-c5a58fb7247b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events after the reporting date</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_7feff19c-501f-4d8b-918f-39c03495765e_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and services</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesDomain_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesDomain" xlink:to="lab_ifrs-full_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_622e7206-aa49-4aac-9f05-433220fa6ef7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock_b32c17d6-0cdb-4409-acbb-be377f247d22_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of cash, cash equivalents and financial assets</link:label>
    <link:label id="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of cash, cash equivalents and financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:to="lab_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_014e8da7-7540-4f2b-a6db-232036c47e8c_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_d4c94cde-69b5-41a0-9de7-13fe5b906075_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_39e25d95-0d9d-448b-817a-3cf10d4fce94_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_InterestsAndGainsOnFinancialAssets_169ffe6c-3b22-40b5-a137-cff0b504c3cb_terseLabel_en-US" xlink:label="lab_inpha_InterestsAndGainsOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests on financial assets</link:label>
    <link:label id="lab_inpha_InterestsAndGainsOnFinancialAssets_label_en-US" xlink:label="lab_inpha_InterestsAndGainsOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interests And Gains On Financial Assets</link:label>
    <link:label id="lab_inpha_InterestsAndGainsOnFinancialAssets_documentation_en-US" xlink:label="lab_inpha_InterestsAndGainsOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of interests and gains on financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_InterestsAndGainsOnFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_InterestsAndGainsOnFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_InterestsAndGainsOnFinancialAssets" xlink:to="lab_inpha_InterestsAndGainsOnFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_72499af6-efcc-41d8-a60f-7b7df4399123_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_05056f36-cbab-4286-8fc1-5f918ef7fd03_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_50526776-d77a-40e7-b60e-a0e4670cc65e_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_857e0dda-84de-4785-bfbe-e8e25bbbccf6_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased licenses</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_b16fc782-970a-4bfc-a5c1-a84ba365ec84_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_730b9011-e6a0-45a9-8d5a-e0ee07daf11b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial income / (loss)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SICAVMember_091e1144-31c4-4d37-afe6-3303fc4c207b_terseLabel_en-US" xlink:label="lab_inpha_SICAVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SICAV</link:label>
    <link:label id="lab_inpha_SICAVMember_label_en-US" xlink:label="lab_inpha_SICAVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SICAV [Member]</link:label>
    <link:label id="lab_inpha_SICAVMember_documentation_en-US" xlink:label="lab_inpha_SICAVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SICAV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVMember" xlink:href="inpha-20240630.xsd#inpha_SICAVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SICAVMember" xlink:to="lab_inpha_SICAVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_e7f24e22-a77f-41bd-ad9b-59834578cdc3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_dc4c712f-3bed-4f0c-8b22-6c90efd62b9d_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance received - exclusive license</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received, Licenses</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for licenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:to="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPManagement20161Member_613e986c-16ef-4c25-9435-e6bcfb806049_terseLabel_en-US" xlink:label="lab_inpha_AGAPManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Management 2016-1</link:label>
    <link:label id="lab_inpha_AGAPManagement20161Member_label_en-US" xlink:label="lab_inpha_AGAPManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Management 2016-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPManagement20161Member_documentation_en-US" xlink:label="lab_inpha_AGAPManagement20161Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGAP Management 2016-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20161Member" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20161Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPManagement20161Member" xlink:to="lab_inpha_AGAPManagement20161Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_A2018AstraZenecaIPH5201AgreementMember_fb308257-85a2-4bb3-a0ea-cc8125fff91c_terseLabel_en-US" xlink:label="lab_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPH5201 agreement, with AstraZeneca</link:label>
    <link:label id="lab_inpha_A2018AstraZenecaIPH5201AgreementMember_label_en-US" xlink:label="lab_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 AstraZeneca IPH5201 Agreement [Member]</link:label>
    <link:label id="lab_inpha_A2018AstraZenecaIPH5201AgreementMember_documentation_en-US" xlink:label="lab_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Agreement related to IPH5201 with AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:href="inpha-20240630.xsd#inpha_A2018AstraZenecaIPH5201AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:to="lab_inpha_A2018AstraZenecaIPH5201AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_f0552cf4-1a95-4686-a732-f2cfbd5066b2_periodStartLabel_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, total</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_77816822-fcce-4303-8b1e-9aa5ce51c78c_periodEndLabel_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, total</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_label_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments And Non-current Financial Assets</link:label>
    <link:label id="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_documentation_en-US" xlink:label="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of short-term investments and non-current financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:to="lab_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember_be6eaf8d-d2c5-40ad-a4f8-2a88c73de177_terseLabel_en-US" xlink:label="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement with Sanofi, 2022</link:label>
    <link:label id="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember_label_en-US" xlink:label="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements with Genzyme for NK Cell engages [Member]</link:label>
    <link:label id="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember_documentation_en-US" xlink:label="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements with Genzyme for NK Cell engages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithGenzymeForNKCellEngagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:to="lab_inpha_AgreementsWithGenzymeForNKCellEngagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_bd651cb5-e1d6-4ce1-8fba-59dbd525091c_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_30c987f4-a01f-49e9-b8df-d2457d6d888b_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In progress</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets under development [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:to="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SeniorityAwardsMember_fd9e9735-c56d-4bf6-acc4-b2c7627f7cf8_terseLabel_en-US" xlink:label="lab_inpha_SeniorityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for seniority awards</link:label>
    <link:label id="lab_inpha_SeniorityAwardsMember_label_en-US" xlink:label="lab_inpha_SeniorityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seniority Awards [Member]</link:label>
    <link:label id="lab_inpha_SeniorityAwardsMember_documentation_en-US" xlink:label="lab_inpha_SeniorityAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for seniority awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SeniorityAwardsMember" xlink:href="inpha-20240630.xsd#inpha_SeniorityAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SeniorityAwardsMember" xlink:to="lab_inpha_SeniorityAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_41bfc96c-f00b-41cc-960a-65dbdeb914d3_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_404778e6-b7aa-4dbd-8e93-d3a86a7bd01d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfContingentLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_a6168508-53ac-4e63-bb27-49a65ff55ef2_terseLabel_en-US" xlink:label="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect at date of initial application [axis]</link:label>
    <link:label id="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_label_en-US" xlink:label="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative effect at date of initial application [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="lab_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_90b6b134-e6cc-4581-897c-26c93bf690b5_terseLabel_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and financial assets denominated in US dollars</link:label>
    <link:label id="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_label_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member]</link:label>
    <link:label id="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_documentation_en-US" xlink:label="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to cash, cash equivalents, and financial assets denominated in US dollars.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:to="lab_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_e512f6ae-247c-4a17-bb37-377a3fd86262_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TotalForeignCurrencyEffect_d79ad8c9-7c8d-4043-b899-ce19496b2772_totalLabel_en-US" xlink:label="lab_inpha_TotalForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, foreign currency effect</link:label>
    <link:label id="lab_inpha_TotalForeignCurrencyEffect_label_en-US" xlink:label="lab_inpha_TotalForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total, Foreign Currency Effect</link:label>
    <link:label id="lab_inpha_TotalForeignCurrencyEffect_documentation_en-US" xlink:label="lab_inpha_TotalForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalForeignCurrencyEffect" xlink:href="inpha-20240630.xsd#inpha_TotalForeignCurrencyEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TotalForeignCurrencyEffect" xlink:to="lab_inpha_TotalForeignCurrencyEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Provisions_046c9ca0-c7ed-4762-92a8-904ac3341c18_terseLabel_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total provisions</link:label>
    <link:label id="lab_ifrs-full_Provisions_label_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Provisions" xlink:to="lab_ifrs-full_Provisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentPayables_9c46af33-a5c8-4a7a-827a-70c2333064c9_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentPayables" xlink:to="lab_ifrs-full_OtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_6ba28d80-853c-441c-b39f-4ae2c2af63cf_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_abf53581-4e3e-45dc-af81-4628f9e1fc5a_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_dbcbf396-3f26-4740-8b26-7839a7e9fc07_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange (gains) losses on financial assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_bdb8256c-6d91-4160-9fad-068a6629a211_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance received</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Advance Payment Received</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of advance received by the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:to="lab_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_0f671700-e12a-4d65-9c61-ef83a5eca6c4_totalLabel_en-US" xlink:label="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Receivables and others</link:label>
    <link:label id="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_label_en-US" xlink:label="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Current Receivables Excluding Rebates</link:label>
    <link:label id="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_documentation_en-US" xlink:label="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of trade and other current receivables excluding rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherCurrentReceivablesExcludingRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:to="lab_inpha_TradeAndOtherCurrentReceivablesExcludingRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_d04913ec-3c7d-4232-b182-ee193c901f72_terseLabel_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise and subscription of equity instruments (in shares)</link:label>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_label_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise And Subscription Of Equity Instruments, In Shares</link:label>
    <link:label id="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_documentation_en-US" xlink:label="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:to="lab_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CompanySavingPlanMember_e2115e05-387b-44c0-8880-c8f02925f872_terseLabel_en-US" xlink:label="lab_inpha_CompanySavingPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company saving plan</link:label>
    <link:label id="lab_inpha_CompanySavingPlanMember_label_en-US" xlink:label="lab_inpha_CompanySavingPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Saving Plan [Member]</link:label>
    <link:label id="lab_inpha_CompanySavingPlanMember_documentation_en-US" xlink:label="lab_inpha_CompanySavingPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company Saving Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanMember" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CompanySavingPlanMember" xlink:to="lab_inpha_CompanySavingPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_f57abf91-fe40-4634-a039-161c4a79d46a_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_0fe094f7-f461-4412-804e-057e6f255e53_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_feb33fa8-827d-4560-8fb7-589317fc3cc5_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items which will not reclassified in the consolidated statement of income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_44691147-e9e6-457b-a66d-13903493ca83_terseLabel_en-US" xlink:label="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S</link:label>
    <link:label id="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_label_en-US" xlink:label="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPH5401 (Anti-C5aR) Rights Acquired From Novo Nordisk A/S [Member]</link:label>
    <link:label id="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_documentation_en-US" xlink:label="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:href="inpha-20240630.xsd#inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:to="lab_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_d8e92931-0b95-4ce1-a53c-e66e9d8dda68_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, current</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_3e8d9ffd-32f1-4f6f-b6ba-2bc6952180d2_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers_cb38159e-39e9-4e70-8ef9-ab20cbdb9dca_verboseLabel_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers_label_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Trade Payables And Others</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers_documentation_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of financial liabilities, trade payables and others.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:to="lab_inpha_FinancialLiabilitiesTradePayablesAndOthers" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PaymentsForMilestone_da76b518-719e-4ab9-9138-6d2a229d18cf_terseLabel_en-US" xlink:label="lab_inpha_PaymentsForMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for milestone</link:label>
    <link:label id="lab_inpha_PaymentsForMilestone_label_en-US" xlink:label="lab_inpha_PaymentsForMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Milestone</link:label>
    <link:label id="lab_inpha_PaymentsForMilestone_documentation_en-US" xlink:label="lab_inpha_PaymentsForMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents payments for milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentsForMilestone" xlink:href="inpha-20240630.xsd#inpha_PaymentsForMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PaymentsForMilestone" xlink:to="lab_inpha_PaymentsForMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfOptionsExcercisedForLicenses_522bb5c5-b513-4473-9291-681ab46ed87e_terseLabel_en-US" xlink:label="lab_inpha_NumberOfOptionsExcercisedForLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options excercised for licenses</link:label>
    <link:label id="lab_inpha_NumberOfOptionsExcercisedForLicenses_label_en-US" xlink:label="lab_inpha_NumberOfOptionsExcercisedForLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Options Excercised For Licenses</link:label>
    <link:label id="lab_inpha_NumberOfOptionsExcercisedForLicenses_documentation_en-US" xlink:label="lab_inpha_NumberOfOptionsExcercisedForLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Options Excercised For Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfOptionsExcercisedForLicenses" xlink:href="inpha-20240630.xsd#inpha_NumberOfOptionsExcercisedForLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfOptionsExcercisedForLicenses" xlink:to="lab_inpha_NumberOfOptionsExcercisedForLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_45005c26-c225-4591-8448-4f6a915cfa40_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssetsMember" xlink:to="lab_ifrs-full_RightofuseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_8541e4bf-d559-4a90-8ade-789701f4f392_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_3eff415d-5184-4c66-842b-ff59943c24c2_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of key management personnel compensation</link:label>
    <link:label id="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Key Management Personnel Compensation [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure for key management personnel compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:to="lab_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_fe465549-550f-46fd-abc7-0a5938653815_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_d605cbee-8a95-4b5e-872e-dd1effc8dc11_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of the year:</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_6c267f0e-4a01-4564-8417-8d6873768805_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the end of the six-months period:</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfWhollyOwnedSubsidiaries_71af26fe-4b78-448f-acb8-e286e8722ef4_terseLabel_en-US" xlink:label="lab_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of subsidiaries</link:label>
    <link:label id="lab_inpha_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_inpha_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Wholly Owned Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:href="inpha-20240630.xsd#inpha_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_inpha_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_c8641d59-8756-4402-ad71-e55e90d04640_terseLabel_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement related to IPH5201 with AstraZeneca</link:label>
    <link:label id="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_label_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Related To IPH5201 With AstraZeneca [Member]</link:label>
    <link:label id="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_documentation_en-US" xlink:label="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Agreement related to IPH5201 with AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH5201WithAstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:to="lab_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPPerfEmployees20181Member_5dfa76c7-4776-4eb4-84dc-e3f9c07a8dcc_terseLabel_en-US" xlink:label="lab_inpha_AGAPPerfEmployees20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Perf Employees 2018-1</link:label>
    <link:label id="lab_inpha_AGAPPerfEmployees20181Member_label_en-US" xlink:label="lab_inpha_AGAPPerfEmployees20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Perf Employees 2018-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPPerfEmployees20181Member_documentation_en-US" xlink:label="lab_inpha_AGAPPerfEmployees20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfEmployees20181Member" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfEmployees20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPPerfEmployees20181Member" xlink:to="lab_inpha_AGAPPerfEmployees20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_abb39fbd-53e9-475b-a44e-004b1555cca6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in provision for charges</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IssuedCapitalFreeOfSubscriptionMember_682bb3f5-675c-432a-a93b-95b50ae5b97c_terseLabel_en-US" xlink:label="lab_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued capital free of subscription</link:label>
    <link:label id="lab_inpha_IssuedCapitalFreeOfSubscriptionMember_label_en-US" xlink:label="lab_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued Capital Free Of Subscription [Member]</link:label>
    <link:label id="lab_inpha_IssuedCapitalFreeOfSubscriptionMember_documentation_en-US" xlink:label="lab_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issued Capital Free Of Subscription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:href="inpha-20240630.xsd#inpha_IssuedCapitalFreeOfSubscriptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:to="lab_inpha_IssuedCapitalFreeOfSubscriptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees_b49138af-fad3-4d3a-ae64-6239fadbbc39_terseLabel_en-US" xlink:label="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees_label_en-US" xlink:label="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Advisory Fees</link:label>
    <link:label id="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees_documentation_en-US" xlink:label="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:href="inpha-20240630.xsd#inpha_KeyManagementPersonnelCompensationAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:to="lab_inpha_KeyManagementPersonnelCompensationAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfPreclinicalMolecules_1a896ceb-9ded-47dd-a5ad-7619f6c61c5d_terseLabel_en-US" xlink:label="lab_inpha_NumberOfPreclinicalMolecules" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of preclinical molecules</link:label>
    <link:label id="lab_inpha_NumberOfPreclinicalMolecules_label_en-US" xlink:label="lab_inpha_NumberOfPreclinicalMolecules" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Preclinical Molecules</link:label>
    <link:label id="lab_inpha_NumberOfPreclinicalMolecules_documentation_en-US" xlink:label="lab_inpha_NumberOfPreclinicalMolecules" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Preclinical Molecules</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfPreclinicalMolecules" xlink:href="inpha-20240630.xsd#inpha_NumberOfPreclinicalMolecules"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfPreclinicalMolecules" xlink:to="lab_inpha_NumberOfPreclinicalMolecules" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_2d498fe3-146c-441d-8e06-398c3dcf12cd_negatedLabel_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, disposals</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_label_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Derecognition Non-current Financial Assets</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_documentation_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in non-current financial assets resulting from derecognition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:to="lab_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationLiabilitiesNonCurrentPortion_c5d4f67e-2e94-4697-8e41-b3d22b3f04b9_terseLabel_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration liabilities &#8211; non-current portion</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesNonCurrentPortion_label_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities - Non-current Portion</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesNonCurrentPortion_documentation_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesNonCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:to="lab_inpha_CollaborationLiabilitiesNonCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA20221Member_e8e54e1b-42fa-4fdb-b19f-c9dac28936b2_terseLabel_en-US" xlink:label="lab_inpha_BSA20221Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2022-1</link:label>
    <link:label id="lab_inpha_BSA20221Member_label_en-US" xlink:label="lab_inpha_BSA20221Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2022-1 [Member]</link:label>
    <link:label id="lab_inpha_BSA20221Member_documentation_en-US" xlink:label="lab_inpha_BSA20221Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BSA 2022-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20221Member" xlink:href="inpha-20240630.xsd#inpha_BSA20221Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA20221Member" xlink:to="lab_inpha_BSA20221Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesLineItems_e9a8dfef-8eef-4e53-9995-91f6391569ba_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesLineItems_label_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Line Items]</link:label>
    <link:label id="lab_inpha_DisclosureOfOperatingExpensesLineItems_documentation_en-US" xlink:label="lab_inpha_DisclosureOfOperatingExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of operating expenses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesLineItems" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems" xlink:to="lab_inpha_DisclosureOfOperatingExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_364aa97f-f5dc-4c47-a586-9fab0a68ab94_terseLabel_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lands and buildings</link:label>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_label_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember" xlink:to="lab_ifrs-full_LandAndBuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGABonus20191Member_4a9ce508-cc70-40f6-9731-d2c08688d886_terseLabel_en-US" xlink:label="lab_inpha_AGABonus20191Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Bonus 2019-1</link:label>
    <link:label id="lab_inpha_AGABonus20191Member_label_en-US" xlink:label="lab_inpha_AGABonus20191Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Bonus 2019-1 [Member]</link:label>
    <link:label id="lab_inpha_AGABonus20191Member_documentation_en-US" xlink:label="lab_inpha_AGABonus20191Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to AGA bonus 2019-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20191Member" xlink:href="inpha-20240630.xsd#inpha_AGABonus20191Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGABonus20191Member" xlink:to="lab_inpha_AGABonus20191Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_60341750-3319-4c46-bba7-c50f0c89d04b_totalLabel_en-US" xlink:label="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Receivables and others - non-current</link:label>
    <link:label id="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_label_en-US" xlink:label="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Non-current Receivables Excluding Rebates</link:label>
    <link:label id="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_documentation_en-US" xlink:label="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of trade and other non current receivables excluding rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:to="lab_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_2f2d330e-6af2-4b97-adf9-aa983eecec60_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_f9c2f43a-b081-4477-ae0f-5bd300e7dfd1_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGABonus20221Member_8c81ca69-9c30-4d23-b53b-938e84d48020_terseLabel_en-US" xlink:label="lab_inpha_AGABonus20221Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Bonus 2022-1</link:label>
    <link:label id="lab_inpha_AGABonus20221Member_label_en-US" xlink:label="lab_inpha_AGABonus20221Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Bonus 2022-1 [Member]</link:label>
    <link:label id="lab_inpha_AGABonus20221Member_documentation_en-US" xlink:label="lab_inpha_AGABonus20221Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Bonus 2022-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20221Member" xlink:href="inpha-20240630.xsd#inpha_AGABonus20221Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGABonus20221Member" xlink:to="lab_inpha_AGABonus20221Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_400721f6-aba3-4801-9c36-bfb28e36f5c9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAcquisitions_70a83e36-6628-4549-9b0f-72fe4807e816_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, acquisitions</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAcquisitions_label_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current Financial Assets, Acquisitions</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsAcquisitions_documentation_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in non-current financial assets resulting from origination or purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:to="lab_inpha_NonCurrentFinancialAssetsAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_inpha_SignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SignificantAccountingPoliciesAbstract" xlink:href="inpha-20240630.xsd#inpha_SignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract" xlink:to="lab_inpha_SignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_a36d9981-9a6d-4257-b7fd-be3f64207293_negatedLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock_df4df6a4-4637-449f-afc3-99a64fcd60c8_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of variance of deferred revenue</link:label>
    <link:label id="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Variance Of Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of variance of deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:to="lab_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_UnrealizedLossesOnFinancialAssets_e040b684-ce1f-4a53-a962-5b48e1dca026_negatedLabel_en-US" xlink:label="lab_inpha_UnrealizedLossesOnFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on financial assets</link:label>
    <link:label id="lab_inpha_UnrealizedLossesOnFinancialAssets_label_en-US" xlink:label="lab_inpha_UnrealizedLossesOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Losses On Financial Assets</link:label>
    <link:label id="lab_inpha_UnrealizedLossesOnFinancialAssets_documentation_en-US" xlink:label="lab_inpha_UnrealizedLossesOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of unrealized losses on financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnrealizedLossesOnFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_UnrealizedLossesOnFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_UnrealizedLossesOnFinancialAssets" xlink:to="lab_inpha_UnrealizedLossesOnFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_93adcada-cbd0-4b8c-98ae-a2b2b4ea7491_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets_8e34a9bb-c378-4247-a3ee-e850f4e86b25_totalLabel_en-US" xlink:label="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and financial assets</link:label>
    <link:label id="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets_4ccf88e1-d0d5-4ab4-a73b-bc31eee6377c_terseLabel_en-US" xlink:label="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and financial assets</link:label>
    <link:label id="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets_label_en-US" xlink:label="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Cash, Cash Equivalents And Financial Assets</link:label>
    <link:label id="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets_documentation_en-US" xlink:label="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash, cash equivalents and financial assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_TotalCashCashEquivalentsAndFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:to="lab_inpha_TotalCashCashEquivalentsAndFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_89f0564e-ef23-437b-8276-3a0f58c74dce_terseLabel_en-US" xlink:label="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration liabilities - current and non-current portion, variance</link:label>
    <link:label id="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_label_en-US" xlink:label="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Collaboration Liabilities</link:label>
    <link:label id="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_documentation_en-US" xlink:label="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:href="inpha-20240630.xsd#inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:to="lab_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPManagement20162Member_18da8f9a-156d-44f4-9012-4b2ae04e920c_terseLabel_en-US" xlink:label="lab_inpha_AGAPManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Management 2016-2</link:label>
    <link:label id="lab_inpha_AGAPManagement20162Member_label_en-US" xlink:label="lab_inpha_AGAPManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Management 2016-2 [Member]</link:label>
    <link:label id="lab_inpha_AGAPManagement20162Member_documentation_en-US" xlink:label="lab_inpha_AGAPManagement20162Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGAP Management 2016-2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20162Member" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20162Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPManagement20162Member" xlink:to="lab_inpha_AGAPManagement20162Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsDomain_7dcf52cf-8edb-4682-bcaa-a9ac98a11043_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of financial assets</link:label>
    <link:label id="lab_ifrs-full_TypesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_TypesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_af72b2dc-6c9b-4518-94b1-05d6d0071855_terseLabel_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security interest on pledge of financial instruments will be released in 2031</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_label_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Interest On Pledge Of Financial Instruments Will Be Released In 2031</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_documentation_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The values of Security interest on pledge of financial instruments will be released in 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:to="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPEmployees20211Member_cda47b0c-6d45-4007-8d3f-a2f892539259_terseLabel_en-US" xlink:label="lab_inpha_AGAPEmployees20211Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Employees 2021-1</link:label>
    <link:label id="lab_inpha_AGAPEmployees20211Member_label_en-US" xlink:label="lab_inpha_AGAPEmployees20211Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Employees 2021-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPEmployees20211Member_documentation_en-US" xlink:label="lab_inpha_AGAPEmployees20211Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGAP Employees 2021-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20211Member" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20211Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPEmployees20211Member" xlink:to="lab_inpha_AGAPEmployees20211Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_fa4bdbb2-1b5c-47db-8309-659e3f0e7aa9_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of the exchange rate changes</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_14783d31-da61-46e6-9db5-d21ed5af3f18_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_ff254c3c-074c-4f32-a325-1ec82bd3205d_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_d068ff49-fb4b-467c-a639-2a26dac05012_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_da59fad6-3612-432c-b355-c27577f68499_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_17cb5b62-6d04-47c3-8351-d47950b23b60_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_47aaecff-fc99-4268-9157-2380f20c361d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_f3ca3fd9-52f8-413f-a596-56ccd0fa179c_terseLabel_en-US" xlink:label="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity instruments converted in ordinary shares (in shares)</link:label>
    <link:label id="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_label_en-US" xlink:label="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equity Instruments Converted In Ordinary Shares</link:label>
    <link:label id="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_documentation_en-US" xlink:label="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Equity Instruments Converted In Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:href="inpha-20240630.xsd#inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:to="lab_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_555adb82-e243-418c-95f1-c4a38ff9d7da_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ca7005de-b6ce-49d3-af70-11f003df156b_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember_a1576f3c-51a2-454f-8ca0-1ab5b0637838_terseLabel_en-US" xlink:label="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets, Cash And Cash Equivalents [Member]</link:label>
    <link:label id="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember_documentation_en-US" xlink:label="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Assets, Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:to="lab_inpha_FinancialAssetsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAEmployees2017Member_0cdca856-8b0e-43e8-9ef0-b96fb079664f_terseLabel_en-US" xlink:label="lab_inpha_AGAEmployees2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Employees 2017</link:label>
    <link:label id="lab_inpha_AGAEmployees2017Member_label_en-US" xlink:label="lab_inpha_AGAEmployees2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Employees 2017 [Member]</link:label>
    <link:label id="lab_inpha_AGAEmployees2017Member_documentation_en-US" xlink:label="lab_inpha_AGAEmployees2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGA Employees 2017.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2017Member" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAEmployees2017Member" xlink:to="lab_inpha_AGAEmployees2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ShortTermInvestments1Abstract_c2583bcb-3579-4a54-bf2f-8c927b26ea87_terseLabel_en-US" xlink:label="lab_inpha_ShortTermInvestments1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_inpha_ShortTermInvestments1Abstract_label_en-US" xlink:label="lab_inpha_ShortTermInvestments1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Investments1 [Abstract]</link:label>
    <link:label id="lab_inpha_ShortTermInvestments1Abstract_documentation_en-US" xlink:label="lab_inpha_ShortTermInvestments1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Investments1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestments1Abstract" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestments1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ShortTermInvestments1Abstract" xlink:to="lab_inpha_ShortTermInvestments1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_a5c51fe6-1a04-4617-b8d5-31fc87f2fd6a_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_0864afbb-d1a3-4a0b-b8c9-b92a78af3a94_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Personnel expenses</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPerfManagement20231Member_1eba0419-7cb7-4d45-9362-3452d43f4e23_terseLabel_en-US" xlink:label="lab_inpha_AGAPerfManagement20231Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2023-1</link:label>
    <link:label id="lab_inpha_AGAPerfManagement20231Member_label_en-US" xlink:label="lab_inpha_AGAPerfManagement20231Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2023-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPerfManagement20231Member_documentation_en-US" xlink:label="lab_inpha_AGAPerfManagement20231Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGA Perf Management 2023-1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20231Member" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20231Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPerfManagement20231Member" xlink:to="lab_inpha_AGAPerfManagement20231Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_31d20b63-9b97-4b7c-92d4-599cc7f947ab_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net financial income (loss)</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost" xlink:to="lab_ifrs-full_FinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialAssets_5d6ca082-22c1-4e33-aa4f-00fd31135c49_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialAssets_96e71df4-a5a0-44a3-825d-c866ffb30ed8_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssets" xlink:to="lab_ifrs-full_CurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfExclusiveOptionsGranted_510579f7-47df-42e1-96f6-441ae7f58f3c_terseLabel_en-US" xlink:label="lab_inpha_NumberOfExclusiveOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of exclusive options granted</link:label>
    <link:label id="lab_inpha_NumberOfExclusiveOptionsGranted_label_en-US" xlink:label="lab_inpha_NumberOfExclusiveOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Exclusive Options Granted</link:label>
    <link:label id="lab_inpha_NumberOfExclusiveOptionsGranted_documentation_en-US" xlink:label="lab_inpha_NumberOfExclusiveOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Exclusive Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfExclusiveOptionsGranted" xlink:href="inpha-20240630.xsd#inpha_NumberOfExclusiveOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfExclusiveOptionsGranted" xlink:to="lab_inpha_NumberOfExclusiveOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_1719dd27-f19d-40e9-9fb7-e318b7376fef_terseLabel_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State guaranteed loan, Societe Generale and BNP Paribas</link:label>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_label_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Societe Generale And BNP Paribas [Member]</link:label>
    <link:label id="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_documentation_en-US" xlink:label="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PGE Loan Agreement, Societe Generale And BNP Paribas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:to="lab_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AdministrationMember_f3757f10-7159-4336-a196-619492b6b7cd_terseLabel_en-US" xlink:label="lab_inpha_AdministrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administration</link:label>
    <link:label id="lab_inpha_AdministrationMember_label_en-US" xlink:label="lab_inpha_AdministrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administration [Member]</link:label>
    <link:label id="lab_inpha_AdministrationMember_documentation_en-US" xlink:label="lab_inpha_AdministrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdministrationMember" xlink:href="inpha-20240630.xsd#inpha_AdministrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AdministrationMember" xlink:to="lab_inpha_AdministrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_7f873f43-6165-46a3-8812-0b6575dc6b59_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_88dd11c2-d2b2-4ca2-a8f9-4498c28ddb16_negatedTotalLabel_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, disposals</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_label_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Derecognition Short-term Investment And Non-current Financial Assets</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_documentation_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in short-term investment and non-current financial assets resulting from derecognition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:to="lab_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_6a02d2b0-473d-4fad-8d93-0d1874aefdb3_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_fb81fea9-57fa-42a5-b684-10fc853f5b3d_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings, profit (loss) for reporting period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:to="lab_ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_14208c53-2763-4957-9c5f-56eb13e97e5f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_aa0c6dfb-efd0-408d-bc7f-f31f8bc02bfb_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase / (decrease) in cash and cash equivalents:</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_f22edad4-345f-4c81-9486-2f4673ebbb3c_terseLabel_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security interest on pledge of financial instruments will be released in 2024</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_label_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Interest On Pledge Of Financial Instruments Will Be Released In 2024</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_documentation_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The values of security interest on the pledge of financial instruments will be released in 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:to="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_1b29e678-a88e-49c4-b8d6-62b9dd1116e8_terseLabel_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security interest on pledge of financial instruments will be released in 2027</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_label_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Interest On Pledge Of Financial Instruments Will Be Released In 2027</link:label>
    <link:label id="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_documentation_en-US" xlink:label="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The values of security interest on pledge of financial instruments will be released in 2027.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:to="lab_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAEmployees2018Member_84701d0b-e536-4eea-862d-ccf18efd463d_terseLabel_en-US" xlink:label="lab_inpha_AGAEmployees2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Employees 2018</link:label>
    <link:label id="lab_inpha_AGAEmployees2018Member_label_en-US" xlink:label="lab_inpha_AGAEmployees2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Employees 2018 [Member]</link:label>
    <link:label id="lab_inpha_AGAEmployees2018Member_documentation_en-US" xlink:label="lab_inpha_AGAEmployees2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2018Member" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAEmployees2018Member" xlink:to="lab_inpha_AGAEmployees2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BorrowingsMaturityPeriod_289eed80-5d6a-4d6a-ac0f-5d924b7e78be_terseLabel_en-US" xlink:label="lab_inpha_BorrowingsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity period</link:label>
    <link:label id="lab_inpha_BorrowingsMaturityPeriod_label_en-US" xlink:label="lab_inpha_BorrowingsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, Maturity Period</link:label>
    <link:label id="lab_inpha_BorrowingsMaturityPeriod_documentation_en-US" xlink:label="lab_inpha_BorrowingsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Borrowings, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingsMaturityPeriod" xlink:href="inpha-20240630.xsd#inpha_BorrowingsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BorrowingsMaturityPeriod" xlink:to="lab_inpha_BorrowingsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_221a0a86-5982-4d46-914c-e989a19646a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherDisposalsOfAssetsMember_2e762c30-2647-42e8-a76d-fafedbca76d0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherDisposalsOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other disposals of assets [member]</link:label>
    <link:label id="lab_ifrs-full_OtherDisposalsOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_OtherDisposalsOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other disposals of assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherDisposalsOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherDisposalsOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherDisposalsOfAssetsMember" xlink:to="lab_ifrs-full_OtherDisposalsOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CommitmentsContingenciesAndLitigationsAbstract_label_en-US" xlink:label="lab_inpha_CommitmentsContingenciesAndLitigationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Contingencies And Litigations [Abstract]</link:label>
    <link:label id="lab_inpha_CommitmentsContingenciesAndLitigationsAbstract_documentation_en-US" xlink:label="lab_inpha_CommitmentsContingenciesAndLitigationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments, Contingencies And Litigations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract" xlink:href="inpha-20240630.xsd#inpha_CommitmentsContingenciesAndLitigationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract" xlink:to="lab_inpha_CommitmentsContingenciesAndLitigationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_01d01bc0-e1af-4825-bc98-ffb42fa03f2b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal of other assets</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_6f6cf8e5-b787-4601-9f77-75007fca29b5_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_74d742d6-811c-4b7d-84eb-e22f99362256_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAP2019Employees2019Member_d50f6ac5-c9a3-44dc-87d0-2076036a65ce_terseLabel_en-US" xlink:label="lab_inpha_AGAP2019Employees2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP 2019 Employees 2019</link:label>
    <link:label id="lab_inpha_AGAP2019Employees2019Member_label_en-US" xlink:label="lab_inpha_AGAP2019Employees2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP 2019 Employees 2019 [Member]</link:label>
    <link:label id="lab_inpha_AGAP2019Employees2019Member_documentation_en-US" xlink:label="lab_inpha_AGAP2019Employees2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Employees2019Member" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Employees2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAP2019Employees2019Member" xlink:to="lab_inpha_AGAP2019Employees2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_acd3a45a-52a6-49d9-8ce5-289ff3c1f008_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_ec1d7114-3dc7-45ff-ad8c-ad60e66d070d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_63a777ba-2098-404c-b22a-02e0f403a724_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, non-current financial assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssets" xlink:to="lab_ifrs-full_NoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_1ede9d47-d1df-4ca2-b9ee-ae6bd3697749_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefit</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IPH5201AndAdvoralimabAgreementsMember_82fab8a6-0b86-4b29-bf37-5d6573f63b0b_terseLabel_en-US" xlink:label="lab_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Invoicing of R&amp;D costs (IPH5201 agreement)</link:label>
    <link:label id="lab_inpha_IPH5201AndAdvoralimabAgreementsMember_label_en-US" xlink:label="lab_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPH5201 And Advoralimab Agreements [Member]</link:label>
    <link:label id="lab_inpha_IPH5201AndAdvoralimabAgreementsMember_documentation_en-US" xlink:label="lab_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for IPH5201 and IPH5401 agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:href="inpha-20240630.xsd#inpha_IPH5201AndAdvoralimabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:to="lab_inpha_IPH5201AndAdvoralimabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_16ec2329-a7b0-4a4b-9958-c8995c42cc24_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in working capital</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_26be381e-0745-4578-8478-a521d0598ebb_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total change in working capital, variance</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_b9024e22-208e-4488-984d-46517e317631_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentInvestments_81c24651-426b-4628-801e-309306191153_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, current investments</link:label>
    <link:label id="lab_ifrs-full_CurrentInvestments_96394c86-8709-4c41-905f-213b4345f91d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, current investments</link:label>
    <link:label id="lab_ifrs-full_CurrentInvestments_label_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInvestments" xlink:to="lab_ifrs-full_CurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_08a4a460-3f8e-4d47-83c4-87bb3ea29408_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from collaboration and licensing agreements</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_9f8fd223-bba3-4e1d-8403-62705ce75b37_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities</link:label>
    <link:label id="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationLiabilitiesMember_9874607b-e18d-42e1-992b-905b2eb8c8e9_terseLabel_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration liabilities</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesMember_label_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities [Member]</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesMember_documentation_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for collaboration liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesMember" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationLiabilitiesMember" xlink:to="lab_inpha_CollaborationLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_d675b20b-9f55-44e0-9818-fae25a29ee97_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of judgments and estimates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_b95b8973-ea9f-4575-820c-42a3adcd6aea_terseLabel_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:label id="lab_ifrs-full_ActuarialAssumptionOfDiscountRates_label_en-US" xlink:label="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:to="lab_ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_872ce9be-4e56-4dd1-b5db-c5d9c3be0aa7_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepayments made to suppliers</link:label>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_label_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_c4b26707-6c96-49ac-bc39-823eb1fae934_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_361e79ab-df36-49e9-877a-db6e7aa43543_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares, basic (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_6a84422f-dba7-4d43-b0d5-a65fdc5b1625_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares in circulation (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_430f6b55-4660-4298-ba41-c8c8be2a224d_verboseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Personnel and other short-term employee benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_4a9e35a5-9d99-467e-9054-7afc53866437_negatedLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange losses</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_890963c6-064f-4b3e-a162-11d8693cbf8a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of prior period income (loss)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through appropriation of retained earnings, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAP2019Management2019Member_b7c9f1d9-3b50-4275-8d85-e58c3db43157_terseLabel_en-US" xlink:label="lab_inpha_AGAP2019Management2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP 2019 Management 2019</link:label>
    <link:label id="lab_inpha_AGAP2019Management2019Member_label_en-US" xlink:label="lab_inpha_AGAP2019Management2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP 2019 Management 2019 [Member]</link:label>
    <link:label id="lab_inpha_AGAP2019Management2019Member_documentation_en-US" xlink:label="lab_inpha_AGAP2019Management2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Management2019Member" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Management2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAP2019Management2019Member" xlink:to="lab_inpha_AGAP2019Management2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTable_5397a0ed-cf15-483a-b16e-995b0f0a3607_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTable_label_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Table]</link:label>
    <link:label id="lab_inpha_DisclosureOfTradePayablesAndOthersTable_documentation_en-US" xlink:label="lab_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of trade payables and others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:to="lab_inpha_DisclosureOfTradePayablesAndOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_0d9217c1-8496-4a41-bb2b-fce9e3d1aeb6_verboseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_a6ca73cc-0969-4617-927f-8d03999ef033_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember_d9b39b93-b397-4257-b5f9-77410c92e8ea_terseLabel_en-US" xlink:label="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants of employee equity instruments</link:label>
    <link:label id="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember_label_en-US" xlink:label="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grants Of Employee Equity Instruments [Member]</link:label>
    <link:label id="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember_documentation_en-US" xlink:label="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grants Of Employee Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:href="inpha-20240630.xsd#inpha_GrantsOfEmployeeEquityInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:to="lab_inpha_GrantsOfEmployeeEquityInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_b3bb2a52-f4f8-4609-ae9d-2f39e97a89f8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowing</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationAndAmortisationExpense_6493d359-f627-47d0-b5de-ddd249d3d1bc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_DepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_DepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_f6abb9fc-7366-416c-97ec-fdebac3a025a_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98744b76-8626-4866-9fa9-ac003febf33c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_e9d7668a-2659-4f8c-a31e-3f8bcac1be5d_terseLabel_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment received - option exercised</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_label_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised</link:label>
    <link:label id="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_documentation_en-US" xlink:label="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:to="lab_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_5bfc3b0f-16c5-4914-9848-755fb0139d62_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue - current and non-current portion, variance</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_bb3b2049-5639-4b9a-81e0-ac7f5d9cdc43_terseLabel_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, foreign currency effect</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_label_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current Financial Assets, Foreign Currency Effect</link:label>
    <link:label id="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_documentation_en-US" xlink:label="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsForeignCurrencyEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:to="lab_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ProvisionForExpensesWithRelatedParties_b90eb719-6577-4847-bae4-56f34fd8ed47_terseLabel_en-US" xlink:label="lab_inpha_ProvisionForExpensesWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for expenses with related parties</link:label>
    <link:label id="lab_inpha_ProvisionForExpensesWithRelatedParties_label_en-US" xlink:label="lab_inpha_ProvisionForExpensesWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision For Expenses With Related Parties</link:label>
    <link:label id="lab_inpha_ProvisionForExpensesWithRelatedParties_documentation_en-US" xlink:label="lab_inpha_ProvisionForExpensesWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provision For Expenses With Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForExpensesWithRelatedParties" xlink:href="inpha-20240630.xsd#inpha_ProvisionForExpensesWithRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ProvisionForExpensesWithRelatedParties" xlink:to="lab_inpha_ProvisionForExpensesWithRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_edd9ddfe-ec19-464b-95e1-6395dbb1df0a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialAssetsShortTermInvestmentsMember_cc3a592f-07d7-406a-a1be-f46d893a7195_terseLabel_en-US" xlink:label="lab_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_inpha_FinancialAssetsShortTermInvestmentsMember_label_en-US" xlink:label="lab_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets, Short-Term Investments [Member]</link:label>
    <link:label id="lab_inpha_FinancialAssetsShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Assets, Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:to="lab_inpha_FinancialAssetsShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember_3174f2fe-0625-450d-bdd3-a7974d0619b2_terseLabel_en-US" xlink:label="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities&#8212;non-current portion</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember_label_en-US" xlink:label="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Non-current Portion [Member]</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember_documentation_en-US" xlink:label="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for financial liabilities&#8212;non-current portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesNonCurrentPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:to="lab_inpha_FinancialLiabilitiesNonCurrentPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_a8d51d52-9bfd-45fb-ad82-3257dfae99ef_terseLabel_en-US" xlink:label="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Characteristics of defined benefit plans</link:label>
    <link:label id="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_label_en-US" xlink:label="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Characteristics of defined benefit plans [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain" xlink:to="lab_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FreeSharesMember_ef6fbc5f-bb0d-4397-97f8-c69144d0af65_terseLabel_en-US" xlink:label="lab_inpha_FreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Free Shares</link:label>
    <link:label id="lab_inpha_FreeSharesMember_label_en-US" xlink:label="lab_inpha_FreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Free Shares [Member]</link:label>
    <link:label id="lab_inpha_FreeSharesMember_documentation_en-US" xlink:label="lab_inpha_FreeSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FreeSharesMember" xlink:href="inpha-20240630.xsd#inpha_FreeSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FreeSharesMember" xlink:to="lab_inpha_FreeSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_20fa2337-a946-4f08-87cc-d4c44a6bd803_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaboration and licensing agreements</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DecreaseThroughDeductionsContractLiabilities_1323d278-1624-4045-8648-9e80ea5d20df_negatedLabel_en-US" xlink:label="lab_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_inpha_DecreaseThroughDeductionsContractLiabilities_label_en-US" xlink:label="lab_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Deductions, Contract Liabilities</link:label>
    <link:label id="lab_inpha_DecreaseThroughDeductionsContractLiabilities_documentation_en-US" xlink:label="lab_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in contract liabilities resulting from deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDeductionsContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:to="lab_inpha_DecreaseThroughDeductionsContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_UnusedTaxLossesWithNoExpirationDate_7621c433-2102-4fb4-90ea-c112c8e869ee_terseLabel_en-US" xlink:label="lab_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses with no expiration date</link:label>
    <link:label id="lab_inpha_UnusedTaxLossesWithNoExpirationDate_label_en-US" xlink:label="lab_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Tax Losses With No Expiration Date</link:label>
    <link:label id="lab_inpha_UnusedTaxLossesWithNoExpirationDate_documentation_en-US" xlink:label="lab_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of unused tax losses with no expiration date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesWithNoExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:to="lab_inpha_UnusedTaxLossesWithNoExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_SanofiServicesMember_a40b765e-45ca-4952-aec9-178782ccbb45_terseLabel_en-US" xlink:label="lab_inpha_SanofiServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi (2022) services</link:label>
    <link:label id="lab_inpha_SanofiServicesMember_label_en-US" xlink:label="lab_inpha_SanofiServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi, Services [Member]</link:label>
    <link:label id="lab_inpha_SanofiServicesMember_documentation_en-US" xlink:label="lab_inpha_SanofiServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi, Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiServicesMember" xlink:href="inpha-20240630.xsd#inpha_SanofiServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_SanofiServicesMember" xlink:to="lab_inpha_SanofiServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_cd63f9e6-73dd-412c-82a2-802f82594aae_terseLabel_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In progress</link:label>
    <link:label id="lab_ifrs-full_ConstructionInProgressMember_label_en-US" xlink:label="lab_ifrs-full_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConstructionInProgressMember" xlink:to="lab_ifrs-full_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_c277b41f-822f-451c-abc3-22f0ae72e113_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment_f26bb0c6-9ca7-4fbe-b605-8f0eb771030b_negatedLabel_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, disposals</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment_label_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease Through Derecognition Short-term Investment</link:label>
    <link:label id="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment_documentation_en-US" xlink:label="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in current investment resulting from derecognition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:to="lab_inpha_DecreaseThroughDerecognitionShortTermInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA20152Member_d34f6795-d201-4674-bc71-fb91d3e63226_terseLabel_en-US" xlink:label="lab_inpha_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2015-2</link:label>
    <link:label id="lab_inpha_BSA20152Member_label_en-US" xlink:label="lab_inpha_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2015-2 [Member]</link:label>
    <link:label id="lab_inpha_BSA20152Member_documentation_en-US" xlink:label="lab_inpha_BSA20152Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSA 2015-2.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20152Member" xlink:href="inpha-20240630.xsd#inpha_BSA20152Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA20152Member" xlink:to="lab_inpha_BSA20152Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_517f3a3d-cd03-4e8f-80fd-be81b86453ed_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:label id="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_76ac5389-7fe0-4266-9526-b7be5f30b2f2_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortizations</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_d11ad67d-6575-42af-83c6-8c4769287ffb_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_6fa19915-4746-4ff7-b0a6-291df3b0814c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other receivables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_e3e54302-d670-40f7-8603-567f6c0bf126_negatedLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_dd4f2467-b504-490f-8093-d1216dede1d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_74e0fb4e-0b55-44a4-b16b-69153438b252_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGABonus20181Member_8514512c-a543-45ee-80b0-bef1bd3d691a_terseLabel_en-US" xlink:label="lab_inpha_AGABonus20181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGA Bonus 2018-1</link:label>
    <link:label id="lab_inpha_AGABonus20181Member_label_en-US" xlink:label="lab_inpha_AGABonus20181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGA Bonus 2018-1 [Member]</link:label>
    <link:label id="lab_inpha_AGABonus20181Member_documentation_en-US" xlink:label="lab_inpha_AGABonus20181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20181Member" xlink:href="inpha-20240630.xsd#inpha_AGABonus20181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGABonus20181Member" xlink:to="lab_inpha_AGABonus20181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_5d5cb308-32e4-4b0d-8359-a24c74b28a59_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties_3b3e7a15-6887-4d94-b1e7-d0b86736a0f7_terseLabel_en-US" xlink:label="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of licensing agreements</link:label>
    <link:label id="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties_label_en-US" xlink:label="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Licensing Agreements With Related Parties</link:label>
    <link:label id="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties_documentation_en-US" xlink:label="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Licensing Agreements With Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:href="inpha-20240630.xsd#inpha_NumberOfLicensingAgreementsWithRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:to="lab_inpha_NumberOfLicensingAgreementsWithRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_89316040-d92d-4644-b6a3-b5a307e26b0c_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [domain]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment including right-of-use assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_aa88ae99-8ad0-435e-8b8c-eeaa832f6027_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment, net</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_494256b1-6962-4e84-b91f-1e6aeac81fc8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_033b75af-2a7e-4b8f-8732-687999607334_verboseLabel_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, fair value</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_label_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities, Trade Payables And Others, At Fair Value</link:label>
    <link:label id="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_documentation_en-US" xlink:label="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value of financial liabilities, trade payables and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:to="lab_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_18f1d802-bcb0-4d92-9a79-2bcc85b0e18c_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">VAT refund</link:label>
    <link:label id="lab_ifrs-full_CurrentValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="lab_ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock_8a28dd30-3b90-4850-8048-9267b163c416_terseLabel_en-US" xlink:label="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net financial income (loss)</link:label>
    <link:label id="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock_label_en-US" xlink:label="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Net Financial Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock_documentation_en-US" xlink:label="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of net financial income (loss).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:to="lab_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_85e7e4b5-2fd7-48d4-a5e3-97e28a74d01b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_2e91fd85-54d9-43c5-b64f-692b0196635e_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_label_en-US" xlink:label="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash advances and loans made to related parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="lab_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_d7b96790-910e-42a5-bca8-8e80e2ea42f0_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of own shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_label_en-US" xlink:label="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares in entity held by entity or by its subsidiaries or associates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="lab_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfEmployees_f9312fb5-d066-4e75-88e0-aafa2367d31c_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ifrs-full_NumberOfEmployees_label_en-US" xlink:label="lab_ifrs-full_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfEmployees" xlink:to="lab_ifrs-full_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CompanyInformationAbstract_label_en-US" xlink:label="lab_inpha_CompanyInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Information [Abstract]</link:label>
    <link:label id="lab_inpha_CompanyInformationAbstract_documentation_en-US" xlink:label="lab_inpha_CompanyInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Company Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanyInformationAbstract" xlink:href="inpha-20240630.xsd#inpha_CompanyInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CompanyInformationAbstract" xlink:to="lab_inpha_CompanyInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_60bfa58d-2e1c-4d7c-a2c1-f42568e40198_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elements which will be reclassified in the consolidated statement of income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_00a612ec-3f91-402e-840a-fe3486cb83d4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_d74601c9-4b96-4694-b040-ede4b1724e31_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit 2019 and 2020, maturity</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2019 And 2020, Maturity</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2019 And 2020, Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019And2020Maturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:to="lab_inpha_IncomeFromResearchTaxCredit2019And2020Maturity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_d6760a61-bf2c-490c-aa69-887edbec5bda_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_77148346-b73e-450d-af37-cc4e046ccfee_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of financial assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for fair value losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_6f17dbe8-2f08-42b7-aead-7ee353c902b8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_CollaborationLiabilitiesRollForwardAbstract_30a6d6f9-5b98-410a-8c68-ecbeb560f1ed_terseLabel_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities, Roll Forward [Abstract]</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesRollForwardAbstract_label_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities, Roll Forward [Abstract]</link:label>
    <link:label id="lab_inpha_CollaborationLiabilitiesRollForwardAbstract_documentation_en-US" xlink:label="lab_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Liabilities, Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesRollForwardAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:to="lab_inpha_CollaborationLiabilitiesRollForwardAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_GovernmentFinancingForResearchExpenditures_6740a873-b8fe-43b1-8066-9f4f05f11849_terseLabel_en-US" xlink:label="lab_inpha_GovernmentFinancingForResearchExpenditures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government financing for research expenditures</link:label>
    <link:label id="lab_inpha_GovernmentFinancingForResearchExpenditures_4ff0b97c-2c18-4131-be73-af669de81995_totalLabel_en-US" xlink:label="lab_inpha_GovernmentFinancingForResearchExpenditures" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Government financing for research expenditures</link:label>
    <link:label id="lab_inpha_GovernmentFinancingForResearchExpenditures_label_en-US" xlink:label="lab_inpha_GovernmentFinancingForResearchExpenditures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Financing For Research Expenditures</link:label>
    <link:label id="lab_inpha_GovernmentFinancingForResearchExpenditures_documentation_en-US" xlink:label="lab_inpha_GovernmentFinancingForResearchExpenditures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income recognised in relation to government financing for research expenditures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GovernmentFinancingForResearchExpenditures" xlink:href="inpha-20240630.xsd#inpha_GovernmentFinancingForResearchExpenditures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_GovernmentFinancingForResearchExpenditures" xlink:to="lab_inpha_GovernmentFinancingForResearchExpenditures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_1a298c52-70c6-4d8e-ad06-e3e5f80edf32_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of changes in the share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_33262eea-889a-4d10-a5a6-b99bfd09139f_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019_56664f11-1440-4165-883b-635f2c92c25c_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit 2019</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2019</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2019_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit2019" xlink:to="lab_inpha_IncomeFromResearchTaxCredit2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_d8003803-a581-408d-9fe9-1d7d123eab51_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_8fd6b805-c2da-48c2-b336-ce3b9f56dd54_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_c5125e2c-0fbc-4ab7-80e1-d6f8fbe51f4a_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_5e64a95e-8b99-48dd-bb62-33da682408cd_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_b189b4a0-3471-4afb-b9eb-f05f1e10a44b_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPEmployees20161Member_1da1bb3e-cc8f-4839-9b65-66ab93c2b964_terseLabel_en-US" xlink:label="lab_inpha_AGAPEmployees20161Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Employees 2016-1</link:label>
    <link:label id="lab_inpha_AGAPEmployees20161Member_label_en-US" xlink:label="lab_inpha_AGAPEmployees20161Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Employees 2016-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPEmployees20161Member_documentation_en-US" xlink:label="lab_inpha_AGAPEmployees20161Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for AGAP Employees 2016-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20161Member" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20161Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPEmployees20161Member" xlink:to="lab_inpha_AGAPEmployees20161Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_631f7791-7af3-4163-9b56-e274aee6f839_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentReceivables_493d966b-610e-4486-bcbd-50c80349fdc9_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and others - non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_NoncurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other non-current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentReceivables" xlink:to="lab_ifrs-full_NoncurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2023_d7a94484-24d8-4d2c-abe5-039f0c005395_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit 2023</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2023_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2023</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2023_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2023" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2023" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2023"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit2023" xlink:to="lab_inpha_IncomeFromResearchTaxCredit2023" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020_e46e469f-8a5d-4639-ab38-6243d10420cb_terseLabel_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from research tax credit 2020</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020_label_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2020</link:label>
    <link:label id="lab_inpha_IncomeFromResearchTaxCredit2020_documentation_en-US" xlink:label="lab_inpha_IncomeFromResearchTaxCredit2020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income From Research Tax Credit 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_IncomeFromResearchTaxCredit2020" xlink:to="lab_inpha_IncomeFromResearchTaxCredit2020" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_TypeOfEmployeeAxis_27696e92-bf12-4b2d-b54a-fdeb3577f705_terseLabel_en-US" xlink:label="lab_inpha_TypeOfEmployeeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type Of Employee [Axis]</link:label>
    <link:label id="lab_inpha_TypeOfEmployeeAxis_label_en-US" xlink:label="lab_inpha_TypeOfEmployeeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type Of Employee [Axis]</link:label>
    <link:label id="lab_inpha_TypeOfEmployeeAxis_documentation_en-US" xlink:label="lab_inpha_TypeOfEmployeeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Type Of Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeAxis" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_TypeOfEmployeeAxis" xlink:to="lab_inpha_TypeOfEmployeeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_5893edc3-95b4-43df-8b7f-e835608dde7c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_PreclinicalServicesMember_75f7b692-95f2-46ff-aecb-6129e39bcbd8_terseLabel_en-US" xlink:label="lab_inpha_PreclinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical Services</link:label>
    <link:label id="lab_inpha_PreclinicalServicesMember_label_en-US" xlink:label="lab_inpha_PreclinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preclinical Services [Member]</link:label>
    <link:label id="lab_inpha_PreclinicalServicesMember_documentation_en-US" xlink:label="lab_inpha_PreclinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PreclinicalServicesMember" xlink:href="inpha-20240630.xsd#inpha_PreclinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_PreclinicalServicesMember" xlink:to="lab_inpha_PreclinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_e358a41b-08c7-4d08-9c9f-e16044d80d44_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Revenue and other income</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_e48a96d8-c0f9-47b4-aec9-8a515b4afeb9_terseLabel_en-US" xlink:label="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from lease liabilities and other non cash effects</link:label>
    <link:label id="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Lease Liabilities, Classified As Financing Activities</link:label>
    <link:label id="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of proceeds from lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_BSA20151Member_6156a942-87f0-43c8-a77a-62f4da21b338_terseLabel_en-US" xlink:label="lab_inpha_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BSA 2015-1</link:label>
    <link:label id="lab_inpha_BSA20151Member_label_en-US" xlink:label="lab_inpha_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BSA 2015-1 [Member]</link:label>
    <link:label id="lab_inpha_BSA20151Member_documentation_en-US" xlink:label="lab_inpha_BSA20151Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for BSA 2015-1.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20151Member" xlink:href="inpha-20240630.xsd#inpha_BSA20151Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_BSA20151Member" xlink:to="lab_inpha_BSA20151Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_AGAPManagement20171Member_3857a3ff-1ce2-4fe8-9bee-83ffba0074ec_terseLabel_en-US" xlink:label="lab_inpha_AGAPManagement20171Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGAP Management 2017-1</link:label>
    <link:label id="lab_inpha_AGAPManagement20171Member_label_en-US" xlink:label="lab_inpha_AGAPManagement20171Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGAP Management 2017-1 [Member]</link:label>
    <link:label id="lab_inpha_AGAPManagement20171Member_documentation_en-US" xlink:label="lab_inpha_AGAPManagement20171Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20171Member" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20171Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_AGAPManagement20171Member" xlink:to="lab_inpha_AGAPManagement20171Member" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NonScientificAdvisoryAndConsulting_69636d5a-badd-4740-a5a5-69627d9aa454_negatedTerseLabel_en-US" xlink:label="lab_inpha_NonScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-scientific advisory and consulting</link:label>
    <link:label id="lab_inpha_NonScientificAdvisoryAndConsulting_label_en-US" xlink:label="lab_inpha_NonScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-scientific Advisory And Consulting</link:label>
    <link:label id="lab_inpha_NonScientificAdvisoryAndConsulting_documentation_en-US" xlink:label="lab_inpha_NonScientificAdvisoryAndConsulting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-scientific advisory and consulting.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonScientificAdvisoryAndConsulting" xlink:href="inpha-20240630.xsd#inpha_NonScientificAdvisoryAndConsulting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NonScientificAdvisoryAndConsulting" xlink:to="lab_inpha_NonScientificAdvisoryAndConsulting" xlink:type="arc" order="1"/>
    <link:label id="lab_inpha_NumberOfLoans_d3ed21d0-4a3b-4a17-8c80-a5044ca9077b_terseLabel_en-US" xlink:label="lab_inpha_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of loans</link:label>
    <link:label id="lab_inpha_NumberOfLoans_label_en-US" xlink:label="lab_inpha_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Loans</link:label>
    <link:label id="lab_inpha_NumberOfLoans_documentation_en-US" xlink:label="lab_inpha_NumberOfLoans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLoans" xlink:href="inpha-20240630.xsd#inpha_NumberOfLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_inpha_NumberOfLoans" xlink:to="lab_inpha_NumberOfLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotionalAmount_8f17fb04-8491-460e-8907-7ab5b6481c17_terseLabel_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_ifrs-full_NotionalAmount_label_en-US" xlink:label="lab_ifrs-full_NotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotionalAmount" xlink:to="lab_ifrs-full_NotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_e6d60048-6599-420e-b073-ffb583442a62_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0e651351-2cb3-4b23-ba06-2c51396a658a_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>inpha-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:e089b506-8190-44fa-9a88-6fafe9464f9f,g:d0409159-98ae-4c39-999f-222b7434e66b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Cover" xlink:type="simple" xlink:href="inpha-20240630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5a136138-ffae-4fa8-9123-6a76d896439d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_DocumentType_5a136138-ffae-4fa8-9123-6a76d896439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_821d330a-dbb9-4fff-84ad-201fdcf41da4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_EntityRegistrantName_821d330a-dbb9-4fff-84ad-201fdcf41da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3b51d915-2785-4a72-8cf4-830614583b58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_AmendmentFlag_3b51d915-2785-4a72-8cf4-830614583b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8465bc06-2d9a-452d-90ec-ca8a3b0fc010" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_DocumentPeriodEndDate_8465bc06-2d9a-452d-90ec-ca8a3b0fc010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4216db86-702f-4c52-81b6-1691765f70c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_DocumentFiscalYearFocus_4216db86-702f-4c52-81b6-1691765f70c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2b164119-6dfc-4e04-b39d-771759e5160e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2b164119-6dfc-4e04-b39d-771759e5160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3544e414-f293-4894-a185-17e804f7b43d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_EntityCentralIndexKey_3544e414-f293-4894-a185-17e804f7b43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_502822e5-d9aa-4bdf-b5fb-9aa02af59d2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1ed1102-2365-4dfd-a0d6-28298b912bc4" xlink:to="loc_dei_CurrentFiscalYearEndDate_502822e5-d9aa-4bdf-b5fb-9aa02af59d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofFinancialPosition"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_6ceba9c6-e7b1-4de2-a653-2599fa65f6a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_183ef617-e7d1-4582-b35f-f8367214c09b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_6ceba9c6-e7b1-4de2-a653-2599fa65f6a3" xlink:to="loc_ifrs-full_AssetsAbstract_183ef617-e7d1-4582-b35f-f8367214c09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_183ef617-e7d1-4582-b35f-f8367214c09b" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_28101df6-c054-46ea-b1f2-b6d6263424e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:to="loc_ifrs-full_CashAndCashEquivalents_28101df6-c054-46ea-b1f2-b6d6263424e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssets_3c78c06c-1f3f-49bf-8d0f-fb855a8fe982" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:to="loc_ifrs-full_CurrentFinancialAssets_3c78c06c-1f3f-49bf-8d0f-fb855a8fe982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_20bab992-d030-4b60-8615-ea4a7ef9395c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_20bab992-d030-4b60-8615-ea4a7ef9395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_2b0e5b1c-7f15-4098-b441-8ef36c994117" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ad50ba04-4afe-4e7e-87fa-b4e84998ffbc" xlink:to="loc_ifrs-full_CurrentAssets_2b0e5b1c-7f15-4098-b441-8ef36c994117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_183ef617-e7d1-4582-b35f-f8367214c09b" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a615623b-0e50-455d-a52e-ac445a71b14a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a615623b-0e50-455d-a52e-ac445a71b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_b04419e5-fcc3-48e8-8530-3ddcdfe15179" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_b04419e5-fcc3-48e8-8530-3ddcdfe15179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_672436c0-77f0-413e-b1d1-bd1159b8ef68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_672436c0-77f0-413e-b1d1-bd1159b8ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_57c6c7f5-3c95-4b98-9fbb-01211e837ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_57c6c7f5-3c95-4b98-9fbb-01211e837ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentReceivables_040f5a6b-3a27-4475-854b-eec7ec9a26be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_NoncurrentReceivables_040f5a6b-3a27-4475-854b-eec7ec9a26be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_7d299bd0-47d6-4ba3-9286-d0810ba82747" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_DeferredTaxAssets_7d299bd0-47d6-4ba3-9286-d0810ba82747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_27ede199-93a6-44e1-9df3-b23fe5a93b0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_e2cb4be4-1f66-418f-928a-97c0479db49b" xlink:to="loc_ifrs-full_NoncurrentAssets_27ede199-93a6-44e1-9df3-b23fe5a93b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_8be7ce0a-6344-4119-b510-6641062b9696" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_183ef617-e7d1-4582-b35f-f8367214c09b" xlink:to="loc_ifrs-full_Assets_8be7ce0a-6344-4119-b510-6641062b9696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_cbd58861-7b0c-42c4-98e3-d07659629453" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_6ceba9c6-e7b1-4de2-a653-2599fa65f6a3" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_cbd58861-7b0c-42c4-98e3-d07659629453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_cbd58861-7b0c-42c4-98e3-d07659629453" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_d93fac05-2328-40d7-9751-314a856393a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_d93fac05-2328-40d7-9751-314a856393a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesCurrentPortion_e9faca40-3a12-4821-8e02-90cbc990ec4f" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesCurrentPortion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_inpha_CollaborationLiabilitiesCurrentPortion_e9faca40-3a12-4821-8e02-90cbc990ec4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialLiabilities_aaf03052-2ddd-47b4-8aec-70b11ad4f5a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_ifrs-full_CurrentFinancialLiabilities_aaf03052-2ddd-47b4-8aec-70b11ad4f5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_22fe81a0-c870-4b02-8dc3-56c186c906fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities_22fe81a0-c870-4b02-8dc3-56c186c906fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_c7ebfc70-21fb-48aa-974f-9c4c2bcd28cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_ifrs-full_CurrentProvisions_c7ebfc70-21fb-48aa-974f-9c4c2bcd28cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_ee3d146d-8f23-4c57-ae44-1eb812d87ddd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_7c5300fe-ac93-452b-9036-511892d3b9fe" xlink:to="loc_ifrs-full_CurrentLiabilities_ee3d146d-8f23-4c57-ae44-1eb812d87ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_cbd58861-7b0c-42c4-98e3-d07659629453" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesNonCurrentPortion_65569555-6182-4953-924e-169fed77065e" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesNonCurrentPortion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_inpha_CollaborationLiabilitiesNonCurrentPortion_65569555-6182-4953-924e-169fed77065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialLiabilities_ff639eb5-951f-45a4-ba88-5e255966e742" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_NoncurrentFinancialLiabilities_ff639eb5-951f-45a4-ba88-5e255966e742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_8a1b670b-44b1-4fb5-8260-7b75984d693c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_NoncurrentProvisionsForEmployeeBenefits_8a1b670b-44b1-4fb5-8260-7b75984d693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_f419c1f2-d6c3-4673-922f-0038081cc177" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities_f419c1f2-d6c3-4673-922f-0038081cc177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_2ac90f2a-c994-44e0-a3b8-3fd9f743030e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_NoncurrentProvisions_2ac90f2a-c994-44e0-a3b8-3fd9f743030e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_6f535a81-b49a-482d-b9df-7fcc2bc939cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_6f535a81-b49a-482d-b9df-7fcc2bc939cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_922cf75e-48c4-4a1d-900e-f88ba19eb170" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_fc636298-71f6-4761-9aac-66e0b36f587e" xlink:to="loc_ifrs-full_NoncurrentLiabilities_922cf75e-48c4-4a1d-900e-f88ba19eb170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_6ceba9c6-e7b1-4de2-a653-2599fa65f6a3" xlink:to="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_8fe5ab1d-3307-4579-b76d-b6d9d57454f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_IssuedCapital_8fe5ab1d-3307-4579-b76d-b6d9d57454f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_b7c66742-d081-4e6e-aa90-44b15c4ca6f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_SharePremium_b7c66742-d081-4e6e-aa90-44b15c4ca6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_e40d0b7e-de30-494b-8f4b-f48c8524863b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_e40d0b7e-de30-494b-8f4b-f48c8524863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_040838fe-b719-482f-8f0a-eb1b436ae231" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_OtherReserves_040838fe-b719-482f-8f0a-eb1b436ae231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_3d2949b3-ccde-4fc5-aa74-05d6d53c5638" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriod_3d2949b3-ccde-4fc5-aa74-05d6d53c5638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8961485e-fbc8-4c22-b593-7a9fde88076e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_accdd77e-9139-48ec-b5a1-cf1774edacfd" xlink:to="loc_ifrs-full_Equity_8961485e-fbc8-4c22-b593-7a9fde88076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_dbfa5387-aba4-44c1-9277-9c364eaba32f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_6ceba9c6-e7b1-4de2-a653-2599fa65f6a3" xlink:to="loc_ifrs-full_EquityAndLiabilities_dbfa5387-aba4-44c1-9277-9c364eaba32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_f727b63f-c610-40a3-a06d-2de1ebeda88d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_f727b63f-c610-40a3-a06d-2de1ebeda88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GovernmentFinancingForResearchExpenditures_948c5049-1586-4e1e-bc07-f81b21ab7863" xlink:href="inpha-20240630.xsd#inpha_GovernmentFinancingForResearchExpenditures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_inpha_GovernmentFinancingForResearchExpenditures_948c5049-1586-4e1e-bc07-f81b21ab7863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_78c6a55a-2ab8-4df9-b430-dfafdd044dfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_Revenue_78c6a55a-2ab8-4df9-b430-dfafdd044dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_abb688e4-627e-4338-84a1-250c81df85d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_abb688e4-627e-4338-84a1-250c81df85d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_0f07a4ed-5b1c-42c6-92bd-cb09fde82177" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_0f07a4ed-5b1c-42c6-92bd-cb09fde82177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_62830ae4-8717-4f4b-8811-9ff918641e52" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_OperatingExpense_62830ae4-8717-4f4b-8811-9ff918641e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_6c2b79fd-9e73-4a4b-8cb6-0c6eda080b1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_6c2b79fd-9e73-4a4b-8cb6-0c6eda080b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_64a45b06-c10c-414d-a1da-5387a097b266" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_FinanceIncome_64a45b06-c10c-414d-a1da-5387a097b266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_828c437c-d55b-47fd-abb4-3139b8761138" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_FinanceCosts_828c437c-d55b-47fd-abb4-3139b8761138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_1fd06844-eddb-4e20-b4e3-da6f2408c041" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_FinanceIncomeCost_1fd06844-eddb-4e20-b4e3-da6f2408c041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_4821273e-5524-44fd-9419-39315fd4ff90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_4821273e-5524-44fd-9419-39315fd4ff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3c759d79-6d52-4a25-9106-475f045954dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3c759d79-6d52-4a25-9106-475f045954dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_66ff2f34-aaf9-4323-827d-317a540fcdb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_ProfitLoss_66ff2f34-aaf9-4323-827d-317a540fcdb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAbstract_1086c4ee-5e21-4ac4-8fe6-7186f7de2ef2" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_d2be230b-7865-40c6-8521-e3eefe909b80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:to="loc_ifrs-full_WeightedAverageShares_d2be230b-7865-40c6-8521-e3eefe909b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_e24b5dc3-ec55-4d31-b30e-dc43d6f0084f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_e24b5dc3-ec55-4d31-b30e-dc43d6f0084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_f5a31e85-d885-4ea2-afd5-01fe7cec5b72" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_f5a31e85-d885-4ea2-afd5-01fe7cec5b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_06abc857-fcab-49aa-af32-8360f3c0b18d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4238eb91-3ce3-4bc7-8c73-f0a5d95be3ea" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_06abc857-fcab-49aa-af32-8360f3c0b18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_cbe55fb5-1eca-4fbe-bcff-4b5e2be6d4b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:to="loc_ifrs-full_ProfitLoss_cbe55fb5-1eca-4fbe-bcff-4b5e2be6d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_7cfc1f22-850d-4ee4-88b5-2cc6f9072821" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_7cfc1f22-850d-4ee4-88b5-2cc6f9072821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_d6969cb6-941d-472f-8224-d5885f853e23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_7cfc1f22-850d-4ee4-88b5-2cc6f9072821" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_d6969cb6-941d-472f-8224-d5885f853e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4f9f7f27-4144-4455-8fa4-4c70d9da6c9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4f9f7f27-4144-4455-8fa4-4c70d9da6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_af5769ac-387f-4ec5-b40c-b822089d9d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4f9f7f27-4144-4455-8fa4-4c70d9da6c9a" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_af5769ac-387f-4ec5-b40c-b822089d9d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_525e9a9f-439b-4daa-abf9-59f4c70a37c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_525e9a9f-439b-4daa-abf9-59f4c70a37c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_f8ab6f25-623e-4487-95dc-cf45153cac26" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_008747ef-3312-45f9-a00a-30d485c04935" xlink:to="loc_ifrs-full_ComprehensiveIncome_f8ab6f25-623e-4487-95dc-cf45153cac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimCondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_c06f6972-f156-4037-bac2-3faca1cc66d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_ProfitLoss_c06f6972-f156-4037-bac2-3faca1cc66d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_dabfba2c-6111-42b3-8dd2-f801da73ea2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_dabfba2c-6111-42b3-8dd2-f801da73ea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_2a1851bd-e02b-4c60-82fe-af2f5efaca4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_2a1851bd-e02b-4c60-82fe-af2f5efaca4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_e370712b-c693-4903-bcf9-098f407df343" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_e370712b-c693-4903-bcf9-098f407df343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_3f6930da-f4e9-48a0-8bd1-9821f1a7efbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_3f6930da-f4e9-48a0-8bd1-9821f1a7efbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_3f413b21-7bf7-4e68-9eb6-2e43d49f49ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_3f413b21-7bf7-4e68-9eb6-2e43d49f49ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_676a8ccf-48d8-47d8-b42b-726ec9160619" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_676a8ccf-48d8-47d8-b42b-726ec9160619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_b1b77cb4-ff44-4d6e-ae1a-898d18a6d358" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets_b1b77cb4-ff44-4d6e-ae1a-898d18a6d358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_872c60bd-66d1-46ce-941a-85a6061d41b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_872c60bd-66d1-46ce-941a-85a6061d41b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_b45c9794-340d-481b-a88c-7359d5f6d819" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_b45c9794-340d-481b-a88c-7359d5f6d819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ec308f6d-a757-40b8-9480-4fd39c91bf21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_ec308f6d-a757-40b8-9480-4fd39c91bf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_96af0e8d-60b6-484b-a61c-e6746971e56f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_96af0e8d-60b6-484b-a61c-e6746971e56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_732c1a17-091e-4392-bc13-7faba3ce2474" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_732c1a17-091e-4392-bc13-7faba3ce2474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_63780192-fbd3-4e2d-9731-90de9c6f3d00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_63780192-fbd3-4e2d-9731-90de9c6f3d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_bfa37d98-37ea-4e11-8f7f-4d31451cc901" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_bfa37d98-37ea-4e11-8f7f-4d31451cc901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_7f2d2fab-b062-4dd0-af41-7f095499b7eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_7f2d2fab-b062-4dd0-af41-7f095499b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_a8c7591d-6ab9-4895-8fe2-e4f8deed2869" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities_a8c7591d-6ab9-4895-8fe2-e4f8deed2869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_6db80258-29de-4d92-a8b2-f2d0c4d2bb6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_6db80258-29de-4d92-a8b2-f2d0c4d2bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_7aa38c93-baed-44a9-a0d0-12bd40dc6dcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_7aa38c93-baed-44a9-a0d0-12bd40dc6dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_c5427f4b-f7fe-47f3-b84a-c2577942d489" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_c5427f4b-f7fe-47f3-b84a-c2577942d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_4792a53f-00b3-4e66-ba9c-b16b26595e1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_4792a53f-00b3-4e66-ba9c-b16b26595e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a94257a1-9534-4d5f-af2f-facbb57e338a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a94257a1-9534-4d5f-af2f-facbb57e338a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c74c5747-ea1f-48b6-b751-2a39736fe91d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c74c5747-ea1f-48b6-b751-2a39736fe91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1bec9677-a75b-4d0f-bd5a-f702825035d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1bec9677-a75b-4d0f-bd5a-f702825035d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_365a0049-7137-4b8d-a83c-fc25988616c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_ifrs-full_CashAndCashEquivalents_365a0049-7137-4b8d-a83c-fc25988616c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:href="inpha-20240630.xsd#inpha_SummaryOfChangesInWorkingCapitalAbstract"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_cd594cef-af78-47cd-b33d-0fe8749f3908" xlink:to="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_8181fb9d-8781-42b0-bbdd-6acaa767c686" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_8181fb9d-8781-42b0-bbdd-6acaa767c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_d1525acd-98d7-46f2-981b-f65bb99e3aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_d1525acd-98d7-46f2-981b-f65bb99e3aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities_aaab3fb4-be54-4156-87b8-75f99bed11a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredIncomeIncludingContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_DeferredIncomeIncludingContractLiabilities_aaab3fb4-be54-4156-87b8-75f99bed11a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_77d12014-b652-45f0-b305-1e29b3b7da23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_77d12014-b652-45f0-b305-1e29b3b7da23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_0e13aa57-f7b3-4c13-a2c3-c83384d7324a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_TradeAndOtherPayables_0e13aa57-f7b3-4c13-a2c3-c83384d7324a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b431eb74-983f-454a-a641-ffd68ffdba48" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b431eb74-983f-454a-a641-ffd68ffdba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilities_0fe4e949-edb5-4b9a-9dea-ae6e7494099f" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_inpha_CollaborationLiabilities_0fe4e949-edb5-4b9a-9dea-ae6e7494099f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_fba21a5d-367c-4574-8dde-d8a43b194b3c" xlink:href="inpha-20240630.xsd#inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities_fba21a5d-367c-4574-8dde-d8a43b194b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInWorkingCapital_929e2d3e-74eb-4f1f-8c32-e0fcf1ec214c" xlink:href="inpha-20240630.xsd#inpha_ChangeInWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_inpha_ChangeInWorkingCapital_929e2d3e-74eb-4f1f-8c32-e0fcf1ec214c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_379ea8e0-f338-4d37-a53e-8112b3a9cf9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SummaryOfChangesInWorkingCapitalAbstract_22134d94-0437-4f7d-b745-3209c0b2932e" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_379ea8e0-f338-4d37-a53e-8112b3a9cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="simple" xlink:href="inpha-20240630.xsd#InterimConsolidatedStatementofChangesinShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_df23188f-0aed-4b54-a434-e599b04b96d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_df23188f-0aed-4b54-a434-e599b04b96d0" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_36c5eb2f-64fd-47e0-9a04-2cea4b4c9e92" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_b6dffcc6-7b97-49cf-950e-2fd65bbfe243" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:to="loc_ifrs-full_OrdinarySharesMember_b6dffcc6-7b97-49cf-950e-2fd65bbfe243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember_8c3e85be-bb33-47b0-a89a-5f92d2e84cd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_ba6d1cdc-2a6d-4e68-a355-861f0ea32e5e" xlink:to="loc_ifrs-full_PreferenceSharesMember_8c3e85be-bb33-47b0-a89a-5f92d2e84cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d651fc27-6b51-4a83-ae81-69238f15ab38" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_05a7558c-d416-4848-b0d4-a58dfe521fc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_IssuedCapitalMember_05a7558c-d416-4848-b0d4-a58dfe521fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_feeba92a-0eec-4a72-b63a-faf66d64dd24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_SharePremiumMember_feeba92a-0eec-4a72-b63a-faf66d64dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_6f1d6ba3-515a-4170-90f1-5b5070f51bc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember_6f1d6ba3-515a-4170-90f1-5b5070f51bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c8588e29-d00a-4e6a-9feb-b9f4cf776a9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c8588e29-d00a-4e6a-9feb-b9f4cf776a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_1534edd6-f892-4c24-881a-b973c59f64c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_72d16e7f-9be9-4ca4-be00-a50fd877dfdf" xlink:to="loc_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_1534edd6-f892-4c24-881a-b973c59f64c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_0bf183ed-12d3-4a1b-8768-23615be20c25" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_06079ea5-9060-420a-a0e0-0e2d3c9c87b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_NumberOfSharesIssued_06079ea5-9060-420a-a0e0-0e2d3c9c87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_752a8a38-606a-4441-a240-1aae8364411d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_Equity_752a8a38-606a-4441-a240-1aae8364411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7a1959c5-0155-4f1d-8750-bf4aaca680d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_ProfitLoss_7a1959c5-0155-4f1d-8750-bf4aaca680d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9551cdb8-3e5c-4eba-bc02-455c61f6f23d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_9551cdb8-3e5c-4eba-bc02-455c61f6f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_23cb4a71-6514-4dcf-b0cb-181de3ea344a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_23cb4a71-6514-4dcf-b0cb-181de3ea344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1fb5cef4-836a-4abe-80f0-1c5a1687ba0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_ComprehensiveIncome_1fb5cef4-836a-4abe-80f0-1c5a1687ba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_4e5230d4-a9cd-4f58-a848-19a30cffd9ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_4e5230d4-a9cd-4f58-a848-19a30cffd9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_26618dd1-8559-4b6b-b9a5-7d2dd1b9d2db" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_26618dd1-8559-4b6b-b9a5-7d2dd1b9d2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_20717b66-0d4c-4d45-837d-19a1d2b86e67" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_20717b66-0d4c-4d45-837d-19a1d2b86e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_fe787256-eec5-46bf-8632-57fd959b77a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_fe787256-eec5-46bf-8632-57fd959b77a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_bbde14cb-d0bc-456d-91dd-72d6130fe24b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_NumberOfSharesIssued_bbde14cb-d0bc-456d-91dd-72d6130fe24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f793a3e3-c6df-4e96-88fc-6513ee2b2614" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_ba68a1f8-8b44-4538-a1ae-4adf29cd4b29" xlink:to="loc_ifrs-full_Equity_f793a3e3-c6df-4e96-88fc-6513ee2b2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyevents" xlink:type="simple" xlink:href="inpha-20240630.xsd#TheCompanyandkeyevents"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TheCompanyandkeyevents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanyInformationAbstract_0be665df-64d5-4aa0-bea4-19eb8870a376" xlink:href="inpha-20240630.xsd#inpha_CompanyInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock_eeaef86c-cd22-4557-8f04-b89fa9ee1f36" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_0be665df-64d5-4aa0-bea4-19eb8870a376" xlink:to="loc_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock_eeaef86c-cd22-4557-8f04-b89fa9ee1f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance" xlink:type="simple" xlink:href="inpha-20240630.xsd#Basisofpresentationandstatementofcompliance"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SignificantAccountingPoliciesAbstract_2588893a-fb59-484b-9ca4-54b7cb2ac8b5" xlink:href="inpha-20240630.xsd#inpha_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_59fdd2ce-1c2c-4e15-bff3-e1345b78d40a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_2588893a-fb59-484b-9ca4-54b7cb2ac8b5" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_59fdd2ce-1c2c-4e15-bff3-e1345b78d40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Managementoffinancialrisks" xlink:type="simple" xlink:href="inpha-20240630.xsd#Managementoffinancialrisks"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Managementoffinancialrisks" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_55e61baf-7c91-454f-a8ed-e6ab23e03bc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_cc14f375-75e0-4a0b-b9fe-f78d64055fe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_55e61baf-7c91-454f-a8ed-e6ab23e03bc6" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_cc14f375-75e0-4a0b-b9fe-f78d64055fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets" xlink:type="simple" xlink:href="inpha-20240630.xsd#Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6d9ec72d-914f-498b-a148-a3bdb391308b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_ce1c181d-353a-44c1-ace3-4c75eda570f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6d9ec72d-914f-498b-a148-a3bdb391308b" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_ce1c181d-353a-44c1-ace3-4c75eda570f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Tradereceivablesandothers" xlink:type="simple" xlink:href="inpha-20240630.xsd#Tradereceivablesandothers"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Tradereceivablesandothers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_59421b43-6158-4520-9fa2-2edf3290bc5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_1077fe63-43a2-4836-925d-212331fe7f2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_59421b43-6158-4520-9fa2-2edf3290bc5c" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_1077fe63-43a2-4836-925d-212331fe7f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Intangibleassets" xlink:type="simple" xlink:href="inpha-20240630.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_4c90b3d1-5c73-4c07-996c-71b12e13d3bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_3105b80b-c76d-45db-bf6c-4bd514fbbdf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_4c90b3d1-5c73-4c07-996c-71b12e13d3bc" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_3105b80b-c76d-45db-bf6c-4bd514fbbdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Propertyandequipment" xlink:type="simple" xlink:href="inpha-20240630.xsd#Propertyandequipment"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Propertyandequipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_f114ac16-c4d8-44d2-9543-e133432e974a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_d2b788fb-34a5-4042-ab1b-3e9aaa8f9db9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_f114ac16-c4d8-44d2-9543-e133432e974a" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_d2b788fb-34a5-4042-ab1b-3e9aaa8f9db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Tradepayablesandothers" xlink:type="simple" xlink:href="inpha-20240630.xsd#Tradepayablesandothers"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Tradepayablesandothers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fd019460-d627-46aa-b273-a5298d7c13be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_c43f5377-2ad8-4a7f-8e0e-72e22e2fca44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_fd019460-d627-46aa-b273-a5298d7c13be" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_c43f5377-2ad8-4a7f-8e0e-72e22e2fca44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Financialliabilities" xlink:type="simple" xlink:href="inpha-20240630.xsd#Financialliabilities"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Financialliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_deeee950-c369-46db-b5fe-aec542707a23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_c24c9636-c30f-44db-8e64-8ca1fea260e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_deeee950-c369-46db-b5fe-aec542707a23" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_c24c9636-c30f-44db-8e64-8ca1fea260e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Employeebenefit" xlink:type="simple" xlink:href="inpha-20240630.xsd#Employeebenefit"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Employeebenefit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_a6e8341f-fe9c-40cc-bb7a-dd3f6a6ff99a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_cde9db7f-3b73-4d99-9c52-2c99b5318174" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_a6e8341f-fe9c-40cc-bb7a-dd3f6a6ff99a" xlink:to="loc_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_cde9db7f-3b73-4d99-9c52-2c99b5318174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Capital" xlink:type="simple" xlink:href="inpha-20240630.xsd#Capital"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Capital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_d7a77faf-812b-4683-bfd4-b273042872b5" xlink:href="inpha-20240630.xsd#inpha_ShareCapitalAndShareBasePaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_c842d286-ecd5-4b20-8a55-e889efc6cd7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_d7a77faf-812b-4683-bfd4-b273042872b5" xlink:to="loc_ifrs-full_DisclosureOfIssuedCapitalExplanatory_c842d286-ecd5-4b20-8a55-e889efc6cd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement" xlink:type="simple" xlink:href="inpha-20240630.xsd#Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_83a3f860-266a-4190-a787-daab48838f74" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_50d0e355-e4ad-4aa1-8747-18e55d7fc2f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_83a3f860-266a-4190-a787-daab48838f74" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_50d0e355-e4ad-4aa1-8747-18e55d7fc2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Revenueandotherincome" xlink:type="simple" xlink:href="inpha-20240630.xsd#Revenueandotherincome"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Revenueandotherincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_12ef7142-7b58-41c8-8e3e-cb3a921f06c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_8299ef06-55c9-47aa-b136-692c527afa2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_12ef7142-7b58-41c8-8e3e-cb3a921f06c0" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_8299ef06-55c9-47aa-b136-692c527afa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Operatingexpenses" xlink:type="simple" xlink:href="inpha-20240630.xsd#Operatingexpenses"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Operatingexpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1667bb07-b419-449d-b240-8185085d2a6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesExplanatory_c0aaa820-68fa-40a8-ad89-27a7a9f0f5dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1667bb07-b419-449d-b240-8185085d2a6c" xlink:to="loc_ifrs-full_DisclosureOfExpensesExplanatory_c0aaa820-68fa-40a8-ad89-27a7a9f0f5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Netfinancialincomeloss" xlink:type="simple" xlink:href="inpha-20240630.xsd#Netfinancialincomeloss"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Netfinancialincomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b1901921-ff6c-4f1d-8457-7338673b6508" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_862f4563-9820-48c0-8d6e-73b997ea031d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_b1901921-ff6c-4f1d-8457-7338673b6508" xlink:to="loc_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_862f4563-9820-48c0-8d6e-73b997ea031d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Incometaxexpense" xlink:type="simple" xlink:href="inpha-20240630.xsd#Incometaxexpense"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Incometaxexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0124905e-8be8-4c33-9f1f-1fed179d3e75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_655f954c-4173-44d0-b35a-b057786a1ad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_0124905e-8be8-4c33-9f1f-1fed179d3e75" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_655f954c-4173-44d0-b35a-b057786a1ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation" xlink:type="simple" xlink:href="inpha-20240630.xsd#Commitmentscontingenciesandlitigation"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract_98aef10c-ac82-44df-91e7-3410e662fab7" xlink:href="inpha-20240630.xsd#inpha_CommitmentsContingenciesAndLitigationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_b2ac0f37-57d1-4abf-9a43-e41748b796a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract_98aef10c-ac82-44df-91e7-3410e662fab7" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_b2ac0f37-57d1-4abf-9a43-e41748b796a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Relatedpartytransactions" xlink:type="simple" xlink:href="inpha-20240630.xsd#Relatedpartytransactions"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Relatedpartytransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_809ee6e0-21d7-4509-b56d-75c3f5797ef3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_d31d63e6-447e-45d5-bd15-46402431eb14" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_809ee6e0-21d7-4509-b56d-75c3f5797ef3" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_d31d63e6-447e-45d5-bd15-46402431eb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Incomelosspershare" xlink:type="simple" xlink:href="inpha-20240630.xsd#Incomelosspershare"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Incomelosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeLossPerShareAbstract_742b5875-d69d-481d-84dc-ad76a03b0cc5" xlink:href="inpha-20240630.xsd#inpha_IncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_8e9277a2-bc0e-4fe6-a03d-b0b55a896fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_742b5875-d69d-481d-84dc-ad76a03b0cc5" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_8e9277a2-bc0e-4fe6-a03d-b0b55a896fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/Eventsafterthereportingdate" xlink:type="simple" xlink:href="inpha-20240630.xsd#Eventsafterthereportingdate"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/Eventsafterthereportingdate" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_bdc8dd24-47fd-4142-939e-6e04b162ed38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0d3049e6-e85d-4591-9aca-096505f957d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_bdc8dd24-47fd-4142-939e-6e04b162ed38" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0d3049e6-e85d-4591-9aca-096505f957d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" xlink:type="simple" xlink:href="inpha-20240630.xsd#BasisofpresentationandstatementofcompliancePolicies"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SignificantAccountingPoliciesAbstract_7280bfa1-e976-433b-b95e-55fec064300b" xlink:href="inpha-20240630.xsd#inpha_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_53606d4f-4211-4e84-b7aa-a3234a5f81c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_7280bfa1-e976-433b-b95e-55fec064300b" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_53606d4f-4211-4e84-b7aa-a3234a5f81c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_c2d58b8d-f27e-47da-a54c-2299d84840a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_7280bfa1-e976-433b-b95e-55fec064300b" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_c2d58b8d-f27e-47da-a54c-2299d84840a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_aabfebf7-d35f-449c-b5a2-2996a56d532b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_7280bfa1-e976-433b-b95e-55fec064300b" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_aabfebf7-d35f-449c-b5a2-2996a56d532b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_68d2f1b5-2fe1-4796-af84-03ab5b52c3ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_7280bfa1-e976-433b-b95e-55fec064300b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_68d2f1b5-2fe1-4796-af84-03ab5b52c3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#BasisofpresentationandstatementofcomplianceTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SignificantAccountingPoliciesAbstract_f47d053f-cd22-4e10-ab45-d32de847faa3" xlink:href="inpha-20240630.xsd#inpha_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_cac6be30-81be-4193-997e-98a0e8b7b0f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_f47d053f-cd22-4e10-ab45-d32de847faa3" xlink:to="loc_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_cac6be30-81be-4193-997e-98a0e8b7b0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dea60db3-8f75-43cc-9b2e-4de4ba4db7ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock_72239ad9-9fb2-4ada-8c67-651d85e40e18" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dea60db3-8f75-43cc-9b2e-4de4ba4db7ed" xlink:to="loc_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock_72239ad9-9fb2-4ada-8c67-651d85e40e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory_3c63ec69-919d-4720-809f-2adaa13cbd61" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_dea60db3-8f75-43cc-9b2e-4de4ba4db7ed" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory_3c63ec69-919d-4720-809f-2adaa13cbd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradereceivablesandothersTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TradereceivablesandothersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f6ac4ff1-38a9-439b-be09-9ee1a2fe12b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock_37013462-4ca7-4e45-9210-e15992ebf4de" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f6ac4ff1-38a9-439b-be09-9ee1a2fe12b7" xlink:to="loc_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock_37013462-4ca7-4e45-9210-e15992ebf4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_3de17d18-9936-4ffb-8c64-903f91a1cdfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_4e1437d9-8a11-47f4-ae99-70794d15a129" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_3de17d18-9936-4ffb-8c64-903f91a1cdfb" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_4e1437d9-8a11-47f4-ae99-70794d15a129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/PropertyandequipmentTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#PropertyandequipmentTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/PropertyandequipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_726d137b-d415-4615-ab83-b7f35487432a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_36961b72-4c67-4e3b-920e-d33ed07db748" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_726d137b-d415-4615-ab83-b7f35487432a" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_36961b72-4c67-4e3b-920e-d33ed07db748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradepayablesandothersTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradepayablesandothersTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TradepayablesandothersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f4e1786d-0998-4671-a817-d54f4241382f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersTextBlock_3e225017-3c97-4246-88e7-6123e77e28bf" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f4e1786d-0998-4671-a817-d54f4241382f" xlink:to="loc_inpha_DisclosureOfTradePayablesAndOthersTextBlock_3e225017-3c97-4246-88e7-6123e77e28bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/FinancialliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f25d9481-d2bd-4930-95f4-afaff25177a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock_87ec48dd-a463-49b0-85a6-590039244f79" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f25d9481-d2bd-4930-95f4-afaff25177a3" xlink:to="loc_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock_87ec48dd-a463-49b0-85a6-590039244f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1e11ed96-3e80-4ecb-8aa8-caade0b89d5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f25d9481-d2bd-4930-95f4-afaff25177a3" xlink:to="loc_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_1e11ed96-3e80-4ecb-8aa8-caade0b89d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_a0e47678-f4cb-464e-adc7-14e581901d07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_e01fb7cb-1106-4c8f-9898-ec615ce91217" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_a0e47678-f4cb-464e-adc7-14e581901d07" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory_e01fb7cb-1106-4c8f-9898-ec615ce91217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_32a62389-7080-469b-8ed9-5395f0615f68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_a0e47678-f4cb-464e-adc7-14e581901d07" xlink:to="loc_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_32a62389-7080-469b-8ed9-5395f0615f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CapitalTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#CapitalTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_feecff7d-1fcc-4de5-ab35-a12b893de989" xlink:href="inpha-20240630.xsd#inpha_ShareCapitalAndShareBasePaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_2f28cecd-6eb9-4bdf-b67a-7e1f6f2efb07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_feecff7d-1fcc-4de5-ab35-a12b893de989" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_2f28cecd-6eb9-4bdf-b67a-7e1f6f2efb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e2cf2e7a-be87-4ab4-80a9-9bb48acbd003" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_50853f03-9636-4b41-bb3e-139470c78c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e2cf2e7a-be87-4ab4-80a9-9bb48acbd003" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_50853f03-9636-4b41-bb3e-139470c78c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_0b314034-97c4-46a2-bf89-d1cbd03777eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_54bc3cfc-cd5d-46fc-9baf-45d5ff86b8a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_0b314034-97c4-46a2-bf89-d1cbd03777eb" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_54bc3cfc-cd5d-46fc-9baf-45d5ff86b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_a281995e-7f36-42ec-bd4d-c0a50a512ddc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_0b314034-97c4-46a2-bf89-d1cbd03777eb" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_a281995e-7f36-42ec-bd4d-c0a50a512ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock_25a6821c-e519-4073-b2c1-d6a65c0fec1a" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_0b314034-97c4-46a2-bf89-d1cbd03777eb" xlink:to="loc_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock_25a6821c-e519-4073-b2c1-d6a65c0fec1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock_db36db88-f696-4fc4-9468-356bdec235d9" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_0b314034-97c4-46a2-bf89-d1cbd03777eb" xlink:to="loc_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock_db36db88-f696-4fc4-9468-356bdec235d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cfc4f7da-91fb-4432-9f42-8a24624cf7bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_99653559-d041-4241-b11d-5f26e7a7e511" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cfc4f7da-91fb-4432-9f42-8a24624cf7bb" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_99653559-d041-4241-b11d-5f26e7a7e511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/NetfinancialincomelossTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#NetfinancialincomelossTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/NetfinancialincomelossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_379a785f-39d2-4524-9d10-aa5ea3ba0802" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock_0deef004-59cc-40b3-b6a7-67f817fe5aa1" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_379a785f-39d2-4524-9d10-aa5ea3ba0802" xlink:to="loc_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock_0deef004-59cc-40b3-b6a7-67f817fe5aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_be541b64-d3c6-4461-817c-80478086c05c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_d144437c-d170-4cbe-b20f-3a69a35a7cc0" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_be541b64-d3c6-4461-817c-80478086c05c" xlink:to="loc_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock_d144437c-d170-4cbe-b20f-3a69a35a7cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_b75af76a-347b-48fd-b1b4-f15396de8c8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_be541b64-d3c6-4461-817c-80478086c05c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_b75af76a-347b-48fd-b1b4-f15396de8c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IncomelosspershareTables" xlink:type="simple" xlink:href="inpha-20240630.xsd#IncomelosspershareTables"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IncomelosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeLossPerShareAbstract_03b82499-e4ea-460e-bdf4-10355c698b2b" xlink:href="inpha-20240630.xsd#inpha_IncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_c6e8fe26-a921-4ebf-b698-337acc782a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_03b82499-e4ea-460e-bdf4-10355c698b2b" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_c6e8fe26-a921-4ebf-b698-337acc782a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TheCompanyandkeyeventsThecompanyDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:href="inpha-20240630.xsd#inpha_CompanyInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfClinicalProductCandidates_19678fee-90c2-4002-ac39-a4c0745789f5" xlink:href="inpha-20240630.xsd#inpha_NumberOfClinicalProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:to="loc_inpha_NumberOfClinicalProductCandidates_19678fee-90c2-4002-ac39-a4c0745789f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_8ffe2214-c830-4f48-afd7-3f02605a436c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:to="loc_ifrs-full_ProfitLoss_8ffe2214-c830-4f48-afd7-3f02605a436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_aabf7cf8-e73b-45ee-b787-f97c5f7cddb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:to="loc_ifrs-full_Equity_aabf7cf8-e73b-45ee-b787-f97c5f7cddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfWhollyOwnedSubsidiaries_f2ac7e25-3d3f-476e-8368-6dac759d7d03" xlink:href="inpha-20240630.xsd#inpha_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:to="loc_inpha_NumberOfWhollyOwnedSubsidiaries_f2ac7e25-3d3f-476e-8368-6dac759d7d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_a6960e92-6569-4163-b723-19a2aa45d3dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_4b5c3c41-ab9b-4443-a10c-eff2379b7507" xlink:to="loc_ifrs-full_NumberOfEmployees_a6960e92-6569-4163-b723-19a2aa45d3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details" xlink:type="simple" xlink:href="inpha-20240630.xsd#TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanyInformationAbstract_f2c8e317-f43d-4b01-bf90-c42d01fbdc1c" xlink:href="inpha-20240630.xsd#inpha_CompanyInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CompanyInformationAbstract_f2c8e317-f43d-4b01-bf90-c42d01fbdc1c" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_91610017-761c-4da1-9877-105bb26ce4a6" xlink:to="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_07e5267c-3b3d-4d4d-9c54-ede80e8bf918" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_da8deabf-6b10-472a-ace8-ad06a5fb6b54" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_07e5267c-3b3d-4d4d-9c54-ede80e8bf918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_55a5abae-5586-43ba-b976-9e48dddb3197" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IssuedCapitalFreeOfSubscriptionMember_dce1cb88-5ad0-40be-af1e-ef8a95878f07" xlink:href="inpha-20240630.xsd#inpha_IssuedCapitalFreeOfSubscriptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:to="loc_inpha_IssuedCapitalFreeOfSubscriptionMember_dce1cb88-5ad0-40be-af1e-ef8a95878f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_1f668aee-2634-4ac4-9bb7-0b9aa0e25c36" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_132990f1-003d-4405-b698-54a523d6ca7e" xlink:to="loc_ifrs-full_SharePremiumMember_1f668aee-2634-4ac4-9bb7-0b9aa0e25c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:href="inpha-20240630.xsd#inpha_TypeOfExerciseAndSubscriptionOfSharesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis_426827f3-2c84-4413-950b-7bd5cc589983" xlink:to="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseOfShareWarrantsMember_46f49e30-7a76-4ada-8dbf-399b9ccbd76e" xlink:href="inpha-20240630.xsd#inpha_ExerciseOfShareWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_inpha_ExerciseOfShareWarrantsMember_46f49e30-7a76-4ada-8dbf-399b9ccbd76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember_f7a0e401-bf63-4036-a758-1445cf73ad3e" xlink:href="inpha-20240630.xsd#inpha_DefinitiveAcquisitionOfFreeSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_inpha_DefinitiveAcquisitionOfFreeSharesMember_f7a0e401-bf63-4036-a758-1445cf73ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_8c449a62-d37c-442e-9788-7543377f35a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfExerciseAndSubscriptionOfSharesDomain_3cc0de82-240d-498e-94d4-149c23638af9" xlink:to="loc_ifrs-full_OrdinarySharesMember_8c449a62-d37c-442e-9788-7543377f35a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_e096583a-3928-4233-b56f-f4cf28637858" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_905b3ba2-88c2-442c-975e-97af1d3e5ffe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:to="loc_ifrs-full_OrdinarySharesMember_905b3ba2-88c2-442c-975e-97af1d3e5ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FreeSharesMember_434d61d1-2622-4aeb-a83e-980783d15b5a" xlink:href="inpha-20240630.xsd#inpha_FreeSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_c733b9d7-eaff-471d-aad2-a519c89d1d9c" xlink:to="loc_inpha_FreeSharesMember_434d61d1-2622-4aeb-a83e-980783d15b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_081be20f-a21c-472a-af4b-5f92f652b868" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_f2c937d4-6a52-4091-b159-b682fdbd76c6" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_f2c937d4-6a52-4091-b159-b682fdbd76c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_bdf55a07-8b12-4c33-b78a-d6749f69626b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_bdf55a07-8b12-4c33-b78a-d6749f69626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_fd2693b3-1ccc-4ff0-b76b-0b1de4278987" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_ifrs-full_ParValuePerShare_fd2693b3-1ccc-4ff0-b76b-0b1de4278987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareIssuedPricePerShare_f8f0f019-cdef-42d1-ac0e-4e7a0ff7b479" xlink:href="inpha-20240630.xsd#inpha_ShareIssuedPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_ShareIssuedPricePerShare_f8f0f019-cdef-42d1-ac0e-4e7a0ff7b479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_b45aea3a-75f2-4551-99bf-159b64173f7f" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_89c0c256-ff5c-42b8-8889-2fd24a741944" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_b45aea3a-75f2-4551-99bf-159b64173f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SignificantAccountingPoliciesAbstract_3feca7d2-a245-4b16-9990-067b67c53c73" xlink:href="inpha-20240630.xsd#inpha_SignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_ee2be80a-7b7d-4c90-8753-f23208d08cfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_3feca7d2-a245-4b16-9990-067b67c53c73" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_ee2be80a-7b7d-4c90-8753-f23208d08cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_f081234e-9790-412a-b0e6-473e4dd8cf51" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_SignificantAccountingPoliciesAbstract_3feca7d2-a245-4b16-9990-067b67c53c73" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_f081234e-9790-412a-b0e6-473e4dd8cf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2491f185-b72f-4bea-a701-5f42c9fe2c9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2491f185-b72f-4bea-a701-5f42c9fe2c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssets_50387336-d6e7-452c-b528-c8b92f57c300" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:to="loc_ifrs-full_CurrentFinancialAssets_50387336-d6e7-452c-b528-c8b92f57c300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_80dc5432-eca2-499d-8d16-c8719134ad14" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndShortTermInvestmentsAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:to="loc_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets_80dc5432-eca2-499d-8d16-c8719134ad14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_35d36235-d703-4e9d-915d-9774edbc4013" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_35d36235-d703-4e9d-915d-9774edbc4013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_fdeceb28-0dd3-4d4f-b123-33b83b1be215" xlink:href="inpha-20240630.xsd#inpha_TotalCashCashEquivalentsAndFinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_ddfdcd46-c96b-4754-965f-031295ccb449" xlink:to="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_fdeceb28-0dd3-4d4f-b123-33b83b1be215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b180c17a-8a7c-4a98-9738-c830f25ad03a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_b180c17a-8a7c-4a98-9738-c830f25ad03a" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_640d2098-1d3d-4022-bddc-8df7cc543685" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVMember_ccdc8626-fc7f-4ece-ab17-b1b2a302bdb0" xlink:href="inpha-20240630.xsd#inpha_SICAVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_SICAVMember_ccdc8626-fc7f-4ece-ab17-b1b2a302bdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SICAVAndMutualFundsMember_d6b97bc8-b334-4ac4-aa2e-8150049d1acc" xlink:href="inpha-20240630.xsd#inpha_SICAVAndMutualFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_SICAVAndMutualFundsMember_d6b97bc8-b334-4ac4-aa2e-8150049d1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_bcacb93e-b7d2-4974-945e-548a4823ccbe" xlink:href="inpha-20240630.xsd#inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_a097d0db-999b-41bb-aa17-9dac49194bcf" xlink:to="loc_inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember_bcacb93e-b7d2-4974-945e-548a4823ccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:to="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f698fff-1de4-4334-bfd1-83a5fbb7beef" xlink:to="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22943afe-e1d7-43f4-ab47-7bc678a864f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:to="loc_srt_MinimumMember_22943afe-e1d7-43f4-ab47-7bc678a864f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_36ca3799-880d-484d-bfa6-4b6f5a40f5d4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2eb0d1df-f9ea-4830-a54e-4d84e15dfb16" xlink:to="loc_srt_MaximumMember_36ca3799-880d-484d-bfa6-4b6f5a40f5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_261c2d46-1091-4867-96ef-1668c75e8376" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfFinancialInstrumentsHeld_0f8247ad-f823-4696-b062-d1b81d75b1e1" xlink:href="inpha-20240630.xsd#inpha_NumberOfFinancialInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_NumberOfFinancialInstrumentsHeld_0f8247ad-f823-4696-b062-d1b81d75b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RiskProfileRate_b080b90d-dec0-4ab3-8b9e-47fcd0340dd1" xlink:href="inpha-20240630.xsd#inpha_RiskProfileRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_RiskProfileRate_b080b90d-dec0-4ab3-8b9e-47fcd0340dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_a1891540-e0c5-44fa-85ce-8359d9f74f29" xlink:href="inpha-20240630.xsd#inpha_TotalCashCashEquivalentsAndFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_TotalCashCashEquivalentsAndFinancialAssets_a1891540-e0c5-44fa-85ce-8359d9f74f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_eb1b8483-3dc5-45cd-8e41-11a75ab93f91" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_eb1b8483-3dc5-45cd-8e41-11a75ab93f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_f79ce8c5-05a2-48a3-b1ec-aa28827d6a66" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_041773ad-fe00-466d-b9a3-b4df00af4b71" xlink:to="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_f79ce8c5-05a2-48a3-b1ec-aa28827d6a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a7fadd6c-7eff-430e-a113-de1aec4f0e79" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestments1Abstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a7fadd6c-7eff-430e-a113-de1aec4f0e79" xlink:to="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments_f878256b-9a62-4516-a0e9-febf872424df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_ifrs-full_CurrentInvestments_f878256b-9a62-4516-a0e9-febf872424df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAcquisitions_a23d5422-23db-4909-8add-b13244a08b86" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_inpha_ShortTermInvestmentsAcquisitions_a23d5422-23db-4909-8add-b13244a08b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment_226690ac-5c8c-4f18-a5e9-06fedc5196e4" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_inpha_DecreaseThroughDerecognitionShortTermInvestment_226690ac-5c8c-4f18-a5e9-06fedc5196e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_358c26b0-581c-46e5-85f9-698d24c0d17a" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_358c26b0-581c-46e5-85f9-698d24c0d17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_284326f5-8226-4dd9-a8f5-389c0e76c296" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_284326f5-8226-4dd9-a8f5-389c0e76c296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect_b83b8f68-427d-412e-8897-fbc832d87e8a" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsForeignCurrencyEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_inpha_ShortTermInvestmentsForeignCurrencyEffect_b83b8f68-427d-412e-8897-fbc832d87e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments_17083bad-3369-484c-bb82-cfd77a1f7215" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShortTermInvestments1Abstract_87d71a1c-22f0-4e43-9f6a-b04a3a65e14d" xlink:to="loc_ifrs-full_CurrentInvestments_17083bad-3369-484c-bb82-cfd77a1f7215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a7fadd6c-7eff-430e-a113-de1aec4f0e79" xlink:to="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_68564e89-543b-4fd4-99ca-70f5081c5026" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_68564e89-543b-4fd4-99ca-70f5081c5026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsAcquisitions_162e29eb-ab17-4777-a823-55f9a6b3233f" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_inpha_NonCurrentFinancialAssetsAcquisitions_162e29eb-ab17-4777-a823-55f9a6b3233f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_43fac375-9a45-4d57-8d32-9fa7ff2676a0" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets_43fac375-9a45-4d57-8d32-9fa7ff2676a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_42c782a6-fb2d-4457-b7c7-3bd5bb31b76a" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_42c782a6-fb2d-4457-b7c7-3bd5bb31b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_9d6118e5-3a48-4e53-8957-8c1e8bf0796d" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_9d6118e5-3a48-4e53-8957-8c1e8bf0796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_ad984e77-aa1f-4c43-a3e6-bb2d9f7a7792" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsForeignCurrencyEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect_ad984e77-aa1f-4c43-a3e6-bb2d9f7a7792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssets_234c2ea1-71f4-4602-b5f0-93d929c8a4dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_NonCurrentFinancialAssetsAbstract_6235601d-f490-4a46-955f-b8c4f67934e0" xlink:to="loc_ifrs-full_NoncurrentFinancialAssets_234c2ea1-71f4-4602-b5f0-93d929c8a4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:href="inpha-20240630.xsd#inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a7fadd6c-7eff-430e-a113-de1aec4f0e79" xlink:to="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_36c9f196-34b5-4619-a21d-104504778bb6" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_36c9f196-34b5-4619-a21d-104504778bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalAcquisitions_758fc621-59f5-4ab8-b6c1-f77235bdf003" xlink:href="inpha-20240630.xsd#inpha_TotalAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_TotalAcquisitions_758fc621-59f5-4ab8-b6c1-f77235bdf003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_78b6e442-2029-464a-8ad0-0ca9d6d9315b" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets_78b6e442-2029-464a-8ad0-0ca9d6d9315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_7e583caa-a3d1-4027-a60c-3d3e47acef3a" xlink:href="inpha-20240630.xsd#inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss_7e583caa-a3d1-4027-a60c-3d3e47acef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_08fa6660-1735-4c8c-b088-9ea548ad04c7" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss_08fa6660-1735-4c8c-b088-9ea548ad04c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TotalForeignCurrencyEffect_7d24dd4b-11fd-4815-9d1f-e901b36c8bd2" xlink:href="inpha-20240630.xsd#inpha_TotalForeignCurrencyEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_TotalForeignCurrencyEffect_7d24dd4b-11fd-4815-9d1f-e901b36c8bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_5d86e8a3-4862-4753-a0fd-8c3e498f4f7a" xlink:href="inpha-20240630.xsd#inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract_7ce569b5-d99c-4cb7-98c9-cca82a2400e1" xlink:to="loc_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets_5d86e8a3-4862-4753-a0fd-8c3e498f4f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f1084de7-de2e-4334-8bcb-5b4d75b2da53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f1084de7-de2e-4334-8bcb-5b4d75b2da53" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_728e5f6f-9a67-4118-a34e-d0b8ef36e33f" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GuaranteesMember_fe5925e3-197a-4d6b-a91b-c626f8d0ebcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GuaranteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsDomain_7e60f27a-d023-49eb-8e25-67c5e957d2c6" xlink:to="loc_ifrs-full_GuaranteesMember_fe5925e3-197a-4d6b-a91b-c626f8d0ebcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_15639bb6-59b0-4776-b39e-96e1f2b0b41d" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_06135630-caad-42ef-86ab-57552f187503" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_66ee1bfb-f648-415b-bc21-53376d6a966d" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_06135630-caad-42ef-86ab-57552f187503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_75f273fb-cc07-4ea0-9179-7e25cf8a9866" xlink:to="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofiMember_e35655d1-8323-47a0-9b07-7bdf19931032" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_12e986af-400e-4509-9540-62774b09f49e" xlink:to="loc_inpha_AgreementWithSanofiMember_e35655d1-8323-47a0-9b07-7bdf19931032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_0af71db9-0921-4edc-9f9c-0f748fd310a9" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_c520091a-76b7-442b-a3f1-eaf73f56f436" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_OtherCurrentReceivables_c520091a-76b7-442b-a3f1-eaf73f56f436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchTaxCreditReceivableCurrent_12f15ba1-1014-406f-8009-f4b3d37aa266" xlink:href="inpha-20240630.xsd#inpha_ResearchTaxCreditReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_ResearchTaxCreditReceivableCurrent_12f15ba1-1014-406f-8009-f4b3d37aa266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherCurrentTaxCreditsReceivables_c5e3b0e1-3cc4-4c18-9c04-a9603e3d2d3d" xlink:href="inpha-20240630.xsd#inpha_OtherCurrentTaxCreditsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_OtherCurrentTaxCreditsReceivables_c5e3b0e1-3cc4-4c18-9c04-a9603e3d2d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_7a48283e-2295-4fdf-8907-97f796dbb366" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_7a48283e-2295-4fdf-8907-97f796dbb366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentValueAddedTaxReceivables_ebb42a0d-762c-4cc1-888d-30de40c95ebe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentValueAddedTaxReceivables"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentValueAddedTaxReceivables_ebb42a0d-762c-4cc1-888d-30de40c95ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_2e9f609c-9759-4886-88a4-77281fefe4c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentTradeReceivables_2e9f609c-9759-4886-88a4-77281fefe4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_7ece3c23-7ce8-4311-b49d-b786572ee46d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_7ece3c23-7ce8-4311-b49d-b786572ee46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_89887f4e-cd7f-4f4e-867a-8dadf9777778" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherCurrentReceivablesExcludingRebates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherCurrentReceivablesExcludingRebates_89887f4e-cd7f-4f4e-867a-8dadf9777778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentResearchTaxCredit_67c89d81-66c7-4819-8967-b1914fd049a8" xlink:href="inpha-20240630.xsd#inpha_NonCurrentResearchTaxCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_NonCurrentResearchTaxCredit_67c89d81-66c7-4819-8967-b1914fd049a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentPrepaidExpenses_95db4882-1a70-4f07-9937-ab2fe21b5e6c" xlink:href="inpha-20240630.xsd#inpha_NonCurrentPrepaidExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_NonCurrentPrepaidExpenses_95db4882-1a70-4f07-9937-ab2fe21b5e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_b4b9ab56-1057-45d9-a5f6-18a33a801517" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates_b4b9ab56-1057-45d9-a5f6-18a33a801517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeAndOtherReceivablesExcludingRebates_865e3e09-fd12-4afa-a659-592bf7f0549b" xlink:href="inpha-20240630.xsd#inpha_TradeAndOtherReceivablesExcludingRebates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_TradeAndOtherReceivablesExcludingRebates_865e3e09-fd12-4afa-a659-592bf7f0549b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_9249eb98-c24d-40ef-85e4-9b577a25cceb" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019And2020Maturity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2019And2020Maturity_9249eb98-c24d-40ef-85e4-9b577a25cceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2019_01df958b-7f42-4859-a86d-4a327ebb2b16" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2019"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2019_01df958b-7f42-4859-a86d-4a327ebb2b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020_5c946d40-47ea-48ba-81a7-7976487bd7d4" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020_5c946d40-47ea-48ba-81a7-7976487bd7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_a6b97c09-1008-4239-822f-530b6efa7bb7" xlink:href="inpha-20240630.xsd#inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020_a6b97c09-1008-4239-822f-530b6efa7bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2023_30766576-5099-48a0-b331-387defd002ae" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2023"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2023_30766576-5099-48a0-b331-387defd002ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024_12307211-481a-4995-92a9-8758eca66f32" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCreditHalfYear2024"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_IncomeFromResearchTaxCreditHalfYear2024_12307211-481a-4995-92a9-8758eca66f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CarryBackTaxReceivable_7427fad8-70f2-4ef1-a59a-76e803707b13" xlink:href="inpha-20240630.xsd#inpha_CarryBackTaxReceivable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_CarryBackTaxReceivable_7427fad8-70f2-4ef1-a59a-76e803707b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingNumberOfLoanAgreement_7aca2fa6-d1b4-4d51-b058-8a53d1c03e94" xlink:href="inpha-20240630.xsd#inpha_BorrowingNumberOfLoanAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_BorrowingNumberOfLoanAgreement_7aca2fa6-d1b4-4d51-b058-8a53d1c03e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturity_b4087b7b-504a-4ea0-9d4f-64b6067c040e" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_1ceb3790-5041-451e-965f-f5ff106f46d6" xlink:to="loc_inpha_BorrowingMaturity_b4087b7b-504a-4ea0-9d4f-64b6067c040e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_fadbeccc-f6fc-4dc7-9760-e228dfea9676" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_fadbeccc-f6fc-4dc7-9760-e228dfea9676" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_fde29346-e268-4d3d-b7e6-45e598846a91" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_ec90cbcd-f380-4702-b0aa-9b0cb6ac5d92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_LicencesMember_ec90cbcd-f380-4702-b0aa-9b0cb6ac5d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIntangibleAssetsMember_2ac6b5f9-a97d-4fd8-8249-ad7df490807b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_OtherIntangibleAssetsMember_2ac6b5f9-a97d-4fd8-8249-ad7df490807b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_6cc5cb17-69f7-41a8-9ef4-f0634c873443" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_3da4946d-b3b1-40f7-9fd2-2ad62c558052" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_6cc5cb17-69f7-41a8-9ef4-f0634c873443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2e97e380-1729-451a-b503-acb95136f745" xlink:to="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_c3d1f63a-ca45-407b-8a7d-b59b1956e5ee" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:to="loc_inpha_MonalizumabAgreementMember_c3d1f63a-ca45-407b-8a7d-b59b1956e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithOregaBiotechMember_b4623037-3193-4504-9a28-f01558f50e76" xlink:href="inpha-20240630.xsd#inpha_AgreementWithOregaBiotechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_2ab03d2f-1369-4ce1-9b53-842000ceca41" xlink:to="loc_inpha_AgreementWithOregaBiotechMember_b4623037-3193-4504-9a28-f01558f50e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d8f78127-6fdb-416b-86a6-7033c935b2b5" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_46a04627-902e-4cbb-a786-60dd7b114e9a" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fe6f37eb-9020-4d72-bea8-dca74427036d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fe6f37eb-9020-4d72-bea8-dca74427036d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8593475c-c7e2-41f7-a1fb-ca74b170de25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8593475c-c7e2-41f7-a1fb-ca74b170de25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_febff1cd-6e86-4490-aa07-5561ba93dfa1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_febff1cd-6e86-4490-aa07-5561ba93dfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_9b7f8b5c-a361-4042-af0f-934ad6a03385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_9b7f8b5c-a361-4042-af0f-934ad6a03385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3ba96e08-eda1-4c00-ab46-e4f928b9b9a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_3ba96e08-eda1-4c00-ab46-e4f928b9b9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_1743a060-1823-48fb-908e-c0cc6c893f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_1743a060-1823-48fb-908e-c0cc6c893f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a30f19e2-78fa-4784-bf6b-a27b4018e730" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_82ea7a48-54c7-4faf-a2a9-d8d31994b03e" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_a30f19e2-78fa-4784-bf6b-a27b4018e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IntangibleassetsAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_88166a1f-68eb-4632-b0be-d5443d4f4e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract_88166a1f-68eb-4632-b0be-d5443d4f4e87" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:to="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_6befc7ce-b66d-4e5c-8d5e-39ead12ec060" xlink:to="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_0a98f367-ad0e-4a12-a028-63fd03ba5de7" xlink:href="inpha-20240630.xsd#inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember_0a98f367-ad0e-4a12-a028-63fd03ba5de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_00031622-6636-4cf8-829d-1cd8ce189bae" xlink:href="inpha-20240630.xsd#inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember_00031622-6636-4cf8-829d-1cd8ce189bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_e6e5e20c-6714-4d53-ae4a-201f113068d6" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH5201WithAstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_AgreementRelatedToIPH5201WithAstraZenecaMember_e6e5e20c-6714-4d53-ae4a-201f113068d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_e663481b-bd38-43a0-b7a8-4150360d0a44" xlink:href="inpha-20240630.xsd#inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_bae875f1-a979-4790-bbc8-e8d9f4338da1" xlink:to="loc_inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember_e663481b-bd38-43a0-b7a8-4150360d0a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_28daef8a-33f6-42ec-be0a-749fe08066fd" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_f895f3ee-06d2-4e3c-b40d-ca4dc2c9f269" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_f895f3ee-06d2-4e3c-b40d-ca4dc2c9f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_c86b1b19-a7d5-4757-9ab7-8c957791113b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_c86b1b19-a7d5-4757-9ab7-8c957791113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_c90149d4-bec5-4619-a5d6-7b4fcd91fb41" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_c90149d4-bec5-4619-a5d6-7b4fcd91fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentsForMilestone_1e93063f-9ee4-4434-8e7e-9d3c7fa04a28" xlink:href="inpha-20240630.xsd#inpha_PaymentsForMilestone"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_inpha_PaymentsForMilestone_1e93063f-9ee4-4434-8e7e-9d3c7fa04a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_9d4c7fc0-8c4d-49a7-b8e2-3192eecdb879" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_FinancialLiabilities_9d4c7fc0-8c4d-49a7-b8e2-3192eecdb879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e95bd1c9-8889-4ef0-b018-f6f1eb999a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_a4ed3be6-868d-4df3-83eb-1ee0ed4d1eaf" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_e95bd1c9-8889-4ef0-b018-f6f1eb999a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_4eb2cc37-f211-4700-949c-929900b8b061" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_4eb2cc37-f211-4700-949c-929900b8b061" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_fa5858e0-2e1e-4fb1-81c1-18ce128a9fc9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_c7e3b106-f331-4da8-b47f-31291dfffd5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_ifrs-full_LandAndBuildingsMember_c7e3b106-f331-4da8-b47f-31291dfffd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LaboratoryEquipmentAndOtherMember_48390eaa-8d67-4fee-9127-21bbbf9a6233" xlink:href="inpha-20240630.xsd#inpha_LaboratoryEquipmentAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_inpha_LaboratoryEquipmentAndOtherMember_48390eaa-8d67-4fee-9127-21bbbf9a6233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConstructionInProgressMember_94ab75c7-7100-400d-98bf-d085690ade9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ConstructionInProgressMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_49dcbb83-a426-464c-9653-e5bfcfdcfac7" xlink:to="loc_ifrs-full_ConstructionInProgressMember_94ab75c7-7100-400d-98bf-d085690ade9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_48dabf4b-183d-4f88-b7c2-34e762cf228a" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_f346c434-e8d0-42d1-9eed-c01f6a91a7ce" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_05d36f85-42a2-4127-a019-81108dc6c091" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_f346c434-e8d0-42d1-9eed-c01f6a91a7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis_01579f5d-8ec5-413f-aba5-bc8bca250d4b" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_d3a05d88-d372-471c-81ab-934abdf126e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain_0de603a8-35c2-40e3-8e17-74683152ff83" xlink:to="loc_ifrs-full_RightofuseAssetsMember_d3a05d88-d372-471c-81ab-934abdf126e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f0e6107a-f42c-449e-a948-f91346235d41" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_e9412da1-2c96-44e6-8077-ffb05f54460c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_e9412da1-2c96-44e6-8077-ffb05f54460c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8cb1e5fa-f5ff-431a-9b81-716dfb9c5382" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8cb1e5fa-f5ff-431a-9b81-716dfb9c5382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_bd415dfb-6f20-432d-ae5b-54a1c4aca4e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_bd415dfb-6f20-432d-ae5b-54a1c4aca4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_536cc780-1382-4377-a243-6d0e5aa2173c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_536cc780-1382-4377-a243-6d0e5aa2173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_b5c0333b-e2ef-4ecd-8678-e17a3a2ab8d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_b5c0333b-e2ef-4ecd-8678-e17a3a2ab8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_5d15a60d-29e7-499f-a30a-2ac7b4b350dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e3301444-ed1e-4e12-b00e-c65828ba1e06" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_5d15a60d-29e7-499f-a30a-2ac7b4b350dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_c31b8dfb-7d1b-4aff-9b5f-7e1f24b6e37e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_c31b8dfb-7d1b-4aff-9b5f-7e1f24b6e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInFinancialLiabilities_55279af3-dd69-4623-aa7c-6d9fb69a1017" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInFinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80e4e2f3-d548-4c28-b571-f87206c43c07" xlink:to="loc_inpha_IncreaseDecreaseInFinancialLiabilities_55279af3-dd69-4623-aa7c-6d9fb69a1017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#TradepayablesandothersDisclosureoftradepayablesandothersDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_66e2b0db-f2be-424c-9e87-ad41cf4373a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_66e2b0db-f2be-424c-9e87-ad41cf4373a1" xlink:to="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:to="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d5b92141-27d6-415b-88db-695f495c3023" xlink:to="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a442488f-6044-4bd8-9ed8-112dd0f2b3ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_552a8307-eb1f-418e-9774-a2ab023a107b" xlink:to="loc_srt_ScenarioForecastMember_a442488f-6044-4bd8-9ed8-112dd0f2b3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfTradePayablesAndOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersTable_22d45268-c6e9-4b74-8bf8-7920124d8d08" xlink:to="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0f0cdf1f-12bc-4738-9a74-61d1cb3af13a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_0f0cdf1f-12bc-4738-9a74-61d1cb3af13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c10acb5d-728c-4f5e-a993-57e9c6817295" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_c10acb5d-728c-4f5e-a993-57e9c6817295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentPayables_d54856eb-0080-4e8d-a3be-1f4b5c196485" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_OtherCurrentPayables_d54856eb-0080-4e8d-a3be-1f4b5c196485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_83f0bce8-8e1f-4bb1-90c9-ea892d820d28" xlink:href="inpha-20240630.xsd#inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures_83f0bce8-8e1f-4bb1-90c9-ea892d820d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_6a20bd5e-8862-4909-ab5a-3e7fd85fdf50" xlink:href="inpha-20240630.xsd#inpha_CurrentPayablesRelatedToCapitalExpenditures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_CurrentPayablesRelatedToCapitalExpenditures_6a20bd5e-8862-4909-ab5a-3e7fd85fdf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_76f124e2-9972-4f5a-9649-135389ad6ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_76f124e2-9972-4f5a-9649-135389ad6ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_f6cad113-40bc-4a1e-a7f2-5fab45e76d77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_f6cad113-40bc-4a1e-a7f2-5fab45e76d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_aca26cea-706b-49ac-b170-75eefe152f74" xlink:href="inpha-20240630.xsd#inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax_aca26cea-706b-49ac-b170-75eefe152f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_b07c03bd-2cde-4d02-ada2-2a28433aa93c" xlink:href="inpha-20240630.xsd#inpha_OffsetAgainstIncomeFromResearchTaxCredit2020"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020_b07c03bd-2cde-4d02-ada2-2a28433aa93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020_1765dca7-a1a3-48f9-8beb-fb7bdb849c73" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020_1765dca7-a1a3-48f9-8beb-fb7bdb849c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit2020Receivable_2156c6b5-5486-4a96-b286-c6021f6f4b55" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit2020Receivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_IncomeFromResearchTaxCredit2020Receivable_2156c6b5-5486-4a96-b286-c6021f6f4b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfStateGuaranteedLoans_510c3d62-27f5-433c-9cd7-859a910d243d" xlink:href="inpha-20240630.xsd#inpha_NumberOfStateGuaranteedLoans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfTradePayablesAndOthersLineItems_396b365c-42dc-423f-a5ba-ac864eaa3bd7" xlink:to="loc_inpha_NumberOfStateGuaranteedLoans_510c3d62-27f5-433c-9cd7-859a910d243d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c869ccdb-dabc-48e3-b5c6-ec799a529d50" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_c869ccdb-dabc-48e3-b5c6-ec799a529d50" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_8c328f91-1d15-43bd-9fe8-00622e12aa41" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_c548d064-25a5-4cd9-8013-8c64b81a0020" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_c548d064-25a5-4cd9-8013-8c64b81a0020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_ce02ead3-7d45-4bea-9200-551880d7546a" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_ce02ead3-7d45-4bea-9200-551880d7546a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementAccruedInterestMember_a4316dd8-dc53-4e4b-8094-0e120dfb9498" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementAccruedInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementAccruedInterestMember_a4316dd8-dc53-4e4b-8094-0e120dfb9498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_3ae1f4a8-8307-481d-b2b2-413925c71047" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_3ae1f4a8-8307-481d-b2b2-413925c71047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_7f534cc0-9b5f-40be-8a50-5d02a1c023f8" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsInnateIncPremisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_7f534cc0-9b5f-40be-8a50-5d02a1c023f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsEquipmentMember_4295711a-3c5b-4893-9eb2-b3ce4fda0574" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsEquipmentMember_4295711a-3c5b-4893-9eb2-b3ce4fda0574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsVehiclesMember_355a4659-1358-4b18-803f-a7a313eca75f" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsVehiclesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsVehiclesMember_355a4659-1358-4b18-803f-a7a313eca75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsPrintersMember_cbccbcb9-84e7-4b38-9991-5e4c505e972d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsPrintersMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LeaseFinancingObligationsPrintersMember_cbccbcb9-84e7-4b38-9991-5e4c505e972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanEquipmentMember_e1c79668-aa47-4d58-be7f-5c8fe632ba5e" xlink:href="inpha-20240630.xsd#inpha_LoanEquipmentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanEquipmentMember_e1c79668-aa47-4d58-be7f-5c8fe632ba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanBuildingMember_8b3c1b0e-29ba-4f93-a470-2d30bae78a82" xlink:href="inpha-20240630.xsd#inpha_LoanBuildingMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanBuildingMember_8b3c1b0e-29ba-4f93-a470-2d30bae78a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_2229c1d2-3b2f-4a4e-b766-3a8ef97a857f" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_2229c1d2-3b2f-4a4e-b766-3a8ef97a857f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementWithSocitGnraleMember_d4287a01-c8d4-4208-8852-62a5d93c647d" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementWithSocitGnraleMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f3d47f52-4ac1-45df-9881-2901969a4c25" xlink:to="loc_inpha_LoanAgreementWithSocitGnraleMember_d4287a01-c8d4-4208-8852-62a5d93c647d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_7613acf3-9643-449d-8e63-19ddff45d82a" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_524a323a-fd02-4eee-b1c2-ff6e331ca480" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember_524a323a-fd02-4eee-b1c2-ff6e331ca480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_ac8ef59f-0bd5-446b-b35b-97d2de862dfb" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_ac8ef59f-0bd5-446b-b35b-97d2de862dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_bee5a7e3-0200-47c8-b82f-e4f8510b0da2" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_60359db9-ae97-4b84-a4da-0191fce884d6" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_bee5a7e3-0200-47c8-b82f-e4f8510b0da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsAxis_ea866e32-ee58-442a-a69d-e4ec60019333" xlink:to="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GuaranteesMember_dffe8ecf-dee5-49a4-9f2d-915a27f5d2d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GuaranteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfFinancialAssetsDomain_de7ca088-2732-4db3-9a2f-f11ad8a3d460" xlink:to="loc_ifrs-full_GuaranteesMember_dffe8ecf-dee5-49a4-9f2d-915a27f5d2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_5e3b25d6-b6c4-4955-8400-da10d23c890c" xlink:to="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_f4016ff0-2714-40bd-984f-986bc77987a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesDomain_763e7fc8-79d1-4884-ab66-c49c86a65b24" xlink:to="loc_ifrs-full_FixedInterestRateMember_f4016ff0-2714-40bd-984f-986bc77987a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_ff761b4d-1bd1-46bb-85a0-e7c3397c6dd2" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_03649a43-686b-4b13-87a4-f360c12e896f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_47227e64-eb44-41d8-8f56-ffd124e58652" xlink:to="loc_ifrs-full_RightofuseAssetsMember_03649a43-686b-4b13-87a4-f360c12e896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_abc8d027-46dc-49b5-a65c-92dce1f883fb" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherDisposalsOfAssetsMember_98ff6c1a-432e-40ef-bf75-256e38b31385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherDisposalsOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_73721d96-2ac2-49ec-83cd-e02beb2a266c" xlink:to="loc_ifrs-full_OtherDisposalsOfAssetsMember_98ff6c1a-432e-40ef-bf75-256e38b31385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_16405121-2ccc-4346-8170-5b529162a0a0" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_08b4002e-50a7-45d8-bfc8-4b057649a467" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_FinancialLiabilities_08b4002e-50a7-45d8-bfc8-4b057649a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_04892a17-10b2-4049-8f00-f97b3d717d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_04892a17-10b2-4049-8f00-f97b3d717d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_9586b058-6c8d-4163-8f72-ddd4f07048bf" xlink:href="inpha-20240630.xsd#inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities_9586b058-6c8d-4163-8f72-ddd4f07048bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_643c5a83-2e59-4797-97e2-3fc73ea93204" xlink:href="inpha-20240630.xsd#inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities_643c5a83-2e59-4797-97e2-3fc73ea93204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_a3accd3b-dcb7-4e17-8297-847cd1fede3d" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities_a3accd3b-dcb7-4e17-8297-847cd1fede3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotionalAmount_2fdb5127-a8c4-47ad-b3c3-b48b8171445f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_NotionalAmount_2fdb5127-a8c4-47ad-b3c3-b48b8171445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingNumberOfLoanAgreement_d774a4da-040a-43c2-ad64-aa42958d9864" xlink:href="inpha-20240630.xsd#inpha_BorrowingNumberOfLoanAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingNumberOfLoanAgreement_d774a4da-040a-43c2-ad64-aa42958d9864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturity_b8829876-8efe-4bf1-b5ac-dea666631fee" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingMaturity_b8829876-8efe-4bf1-b5ac-dea666631fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingMaturityExtensionPeriodOption_c85cb1a6-17f9-4092-99f4-9a85f51cfca0" xlink:href="inpha-20240630.xsd#inpha_BorrowingMaturityExtensionPeriodOption"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingMaturityExtensionPeriodOption_c85cb1a6-17f9-4092-99f4-9a85f51cfca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan_6b079798-5b67-4cd8-8de8-ad7a82ee6e99" xlink:href="inpha-20240630.xsd#inpha_BorrowingPercentageOfStateGuaranteedLoan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingPercentageOfStateGuaranteedLoan_6b079798-5b67-4cd8-8de8-ad7a82ee6e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingGracePeriod_2939b391-8dbb-4f68-a011-54cd7b51cd75" xlink:href="inpha-20240630.xsd#inpha_BorrowingGracePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingGracePeriod_2939b391-8dbb-4f68-a011-54cd7b51cd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_8ec2bcaf-0487-47d3-8e17-21a31cbb2969" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_BorrowingsInterestRate_8ec2bcaf-0487-47d3-8e17-21a31cbb2969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLoans_7e5fc8d6-9c53-474b-9e44-2f22d812bcca" xlink:href="inpha-20240630.xsd#inpha_NumberOfLoans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_NumberOfLoans_7e5fc8d6-9c53-474b-9e44-2f22d812bcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_1b6e5c62-86a3-4a34-a938-6d1a9d05b116" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_1b6e5c62-86a3-4a34-a938-6d1a9d05b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementMaximumBorrowingCapacity_883d1f78-d5de-4d7f-8749-f9ea231594d4" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementMaximumBorrowingCapacity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_LoanAgreementMaximumBorrowingCapacity_883d1f78-d5de-4d7f-8749-f9ea231594d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementCollateral_cc2c5225-8f4b-4e09-bd3e-5970dce9f6e4" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementCollateral"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_LoanAgreementCollateral_cc2c5225-8f4b-4e09-bd3e-5970dce9f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BorrowingsMaturityPeriod_130092be-9dea-400e-8a32-bb163a036871" xlink:href="inpha-20240630.xsd#inpha_BorrowingsMaturityPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_BorrowingsMaturityPeriod_130092be-9dea-400e-8a32-bb163a036871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_6caf0170-ae70-4f71-9b22-93ff6899d00a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_6caf0170-ae70-4f71-9b22-93ff6899d00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_303ec2b6-34a0-4ea2-b9e1-d6111db80e8a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_303ec2b6-34a0-4ea2-b9e1-d6111db80e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_49cee567-21f0-478a-9e66-f02ed1de75bd" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_49cee567-21f0-478a-9e66-f02ed1de75bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_d683b3f3-0a08-4dec-8009-3d926ec8975a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased_d683b3f3-0a08-4dec-8009-3d926ec8975a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_b0638121-3896-4616-9ff1-94b64200fc74" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_ifrs-full_ChangesInPropertyPlantAndEquipment_b0638121-3896-4616-9ff1-94b64200fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseDecreaseInFinancialLiabilities_cd0edc2d-a2e9-494f-bc92-ed6bcd8d0932" xlink:href="inpha-20240630.xsd#inpha_IncreaseDecreaseInFinancialLiabilities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_581c52e2-f996-4cae-a2ec-6fd50764a6cb" xlink:to="loc_inpha_IncreaseDecreaseInFinancialLiabilities_cd0edc2d-a2e9-494f-bc92-ed6bcd8d0932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bc1b4afc-213e-474e-a547-0ce4854d3b41" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bc1b4afc-213e-474e-a547-0ce4854d3b41" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_c1394e43-ed32-4412-83de-dca8a45753e6" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementSocieteGeneraleMember_9fe2f40a-a181-4fb3-8230-e9affe3bfe78" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementSocieteGeneraleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementSocieteGeneraleMember_9fe2f40a-a181-4fb3-8230-e9affe3bfe78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementBNPParibasMember_21dae071-4fff-44bf-9a76-cf8207f2f0c9" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementBNPParibasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementBNPParibasMember_21dae071-4fff-44bf-9a76-cf8207f2f0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PGELoanAgreementAccruedInterestMember_b85939e3-81d5-4c4a-b223-487ca7bed0ed" xlink:href="inpha-20240630.xsd#inpha_PGELoanAgreementAccruedInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_PGELoanAgreementAccruedInterestMember_b85939e3-81d5-4c4a-b223-487ca7bed0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_c2cc87f8-0381-4c55-91bb-eab2c6bbb027" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsBuildingLeVirageMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsBuildingLeVirageMember_c2cc87f8-0381-4c55-91bb-eab2c6bbb027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_ed4d9b6e-b9de-42df-a981-d7df5459120d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsInnateIncPremisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsInnateIncPremisesMember_ed4d9b6e-b9de-42df-a981-d7df5459120d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsEquipmentMember_a6fca12a-4e12-45b3-9c4c-0edfa79e5b2d" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsEquipmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsEquipmentMember_a6fca12a-4e12-45b3-9c4c-0edfa79e5b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsVehiclesMember_f4bf78a9-c4fd-445c-ad7c-53a35860462b" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsVehiclesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsVehiclesMember_f4bf78a9-c4fd-445c-ad7c-53a35860462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeaseFinancingObligationsPrintersMember_6dc264ed-4373-49a8-886e-97f7ab05a1c9" xlink:href="inpha-20240630.xsd#inpha_LeaseFinancingObligationsPrintersMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LeaseFinancingObligationsPrintersMember_6dc264ed-4373-49a8-886e-97f7ab05a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanEquipmentMember_d06e3562-b0ae-4059-8a1e-9cca9eb9b03a" xlink:href="inpha-20240630.xsd#inpha_LoanEquipmentMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LoanEquipmentMember_d06e3562-b0ae-4059-8a1e-9cca9eb9b03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanBuildingMember_57b0c36f-f8d5-4a30-aa58-59ffa8169059" xlink:href="inpha-20240630.xsd#inpha_LoanBuildingMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_cb496c5c-090c-4ab9-a473-dd9521400a7a" xlink:to="loc_inpha_LoanBuildingMember_57b0c36f-f8d5-4a30-aa58-59ffa8169059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:to="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_4856d0ac-2387-475f-9fb1-f4f5d1639acb" xlink:to="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_a42e7447-c483-42cf-8763-c1be41086115" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_a42e7447-c483-42cf-8763-c1be41086115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_d8305dd7-dcf2-46d8-a1a1-f814a2ad832f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_d8305dd7-dcf2-46d8-a1a1-f814a2ad832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_c4007626-8407-466b-b5eb-17e8d180ec2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_05ed23b5-29ca-4536-bb01-05a9089040e7" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_c4007626-8407-466b-b5eb-17e8d180ec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable_bf92d2a8-396f-4407-ad79-49a136789ba5" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_a2e86357-df91-4efd-bffb-29a6a8961f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BankBorrowingsUndiscountedCashFlows"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems_c8c43796-7534-4786-b401-c8c5c1dc6fe2" xlink:to="loc_ifrs-full_BankBorrowingsUndiscountedCashFlows_a2e86357-df91-4efd-bffb-29a6a8961f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitDisclosureofdefinedbenefitplansDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_1bd52aef-3baa-48a6-b67a-8a8ec822b2b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_1bd52aef-3baa-48a6-b67a-8a8ec822b2b7" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_2660018f-8264-45eb-941a-875e3bca4e90" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RetirementDefinedBenefitMember_ae3f82bb-7e39-4653-a05e-06dac8953a42" xlink:href="inpha-20240630.xsd#inpha_RetirementDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:to="loc_inpha_RetirementDefinedBenefitMember_ae3f82bb-7e39-4653-a05e-06dac8953a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SeniorityAwardsMember_bd86c91a-5bcb-43be-86c6-3fcb00acaf37" xlink:href="inpha-20240630.xsd#inpha_SeniorityAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_3e9f58ab-51c3-4fb2-99cf-26c28229f09a" xlink:to="loc_inpha_SeniorityAwardsMember_bd86c91a-5bcb-43be-86c6-3fcb00acaf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_400641be-1046-4e02-949f-a71c2e2eb1b9" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_ea386cc5-8925-4ccc-bea0-63ff3f75a275" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_0e0dd783-a805-4a80-963f-5f7ff1f83f80" xlink:to="loc_ifrs-full_DefinedBenefitObligationAtPresentValue_ea386cc5-8925-4ccc-bea0-63ff3f75a275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_6dbd34d0-4f48-4fe7-b21b-d410ff5c0712" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_6dbd34d0-4f48-4fe7-b21b-d410ff5c0712" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:to="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_8ddde843-3832-4679-89dc-c9e66bc6c27e" xlink:to="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_564dca58-072e-4ab8-8fe4-0468a7c50221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:to="loc_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_564dca58-072e-4ab8-8fe4-0468a7c50221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_914e5d40-a179-4885-be61-a8466d1b5984" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_bcddee20-f39c-42c6-b1c8-75bb8b639167" xlink:to="loc_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_914e5d40-a179-4885-be61-a8466d1b5984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_bb4993ae-dc62-4a79-8137-e0ec93e89dc9" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_42323167-2b45-4983-8e41-8d14ac272c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_42323167-2b45-4983-8e41-8d14ac272c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_2341b566-12da-4bad-9eee-d712858b90ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset_2341b566-12da-4bad-9eee-d712858b90ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_c3e0bdcb-ef43-4d55-be10-4d41685123d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_c3e0bdcb-ef43-4d55-be10-4d41685123d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_7ccfe530-fd2d-4a16-969a-7608438ae465" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_7ccfe530-fd2d-4a16-969a-7608438ae465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c4007ec0-b1b4-4e4a-9548-2fdae7a36921" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_b9f481f9-b1d1-4240-93e6-c4d84cca696a" xlink:to="loc_ifrs-full_LiabilityAssetOfDefinedBenefitPlans_c4007ec0-b1b4-4e4a-9548-2fdae7a36921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#EmployeebenefitAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_cd29e537-7e70-4571-9714-adeb12ce7906" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract_cd29e537-7e70-4571-9714-adeb12ce7906" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis_65040b03-2583-4c24-8000-a868c122dbe6" xlink:to="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RetirementDefinedBenefitMember_5602de58-c2d5-4c5b-afd7-4eed377b85ca" xlink:href="inpha-20240630.xsd#inpha_RetirementDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain_0635941f-8db1-425a-9578-e480ff92f862" xlink:to="loc_inpha_RetirementDefinedBenefitMember_5602de58-c2d5-4c5b-afd7-4eed377b85ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansTable_74a029ac-0965-473e-a1da-692aece40c77" xlink:to="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_5120afba-c6d3-4a6d-bd5e-bdda3b503add" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_eaace89f-b2d9-41d7-961a-47e1a505b473" xlink:to="loc_ifrs-full_ActuarialAssumptionOfDiscountRates_5120afba-c6d3-4a6d-bd5e-bdda3b503add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CapitalAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_3a6b6699-8f4c-435c-823a-ff6ea0128ca7" xlink:href="inpha-20240630.xsd#inpha_ShareCapitalAndShareBasePaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_3a6b6699-8f4c-435c-823a-ff6ea0128ca7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1a0a2cfe-1158-4a9f-b40a-772ec9498b77" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_10081e30-334d-4482-bc98-814639e3fdb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:to="loc_ifrs-full_IssuedCapitalMember_10081e30-334d-4482-bc98-814639e3fdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a3ce7570-0389-4928-835e-5fb857b9a193" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a596c4a8-cef8-47b7-b523-f200ea916573" xlink:to="loc_ifrs-full_SharePremiumMember_a3ce7570-0389-4928-835e-5fb857b9a193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_26c8b3b3-08b6-47f3-818d-14f2e21209a2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_f5cade63-5d36-492e-a6bb-6fa6c93bfafa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_ifrs-full_OrdinarySharesMember_f5cade63-5d36-492e-a6bb-6fa6c93bfafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2016FreePreferredSharesMember_1e864b04-80d5-47ee-af9e-db2bd41a84b5" xlink:href="inpha-20240630.xsd#inpha_The2016FreePreferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_inpha_The2016FreePreferredSharesMember_1e864b04-80d5-47ee-af9e-db2bd41a84b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_The2017FreePreferredSharesMember_351d3dd0-3a13-474a-b9c4-c278e036b383" xlink:href="inpha-20240630.xsd#inpha_The2017FreePreferredSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_f122cae8-5d3e-4bdd-bb07-2e234508dfc6" xlink:to="loc_inpha_The2017FreePreferredSharesMember_351d3dd0-3a13-474a-b9c4-c278e036b383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ec7c4a3b-603c-4e91-9e0d-a068e1396380" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2012Member_ad06758d-fe20-4e07-b9db-d0be11a71894" xlink:href="inpha-20240630.xsd#inpha_BSAAR2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_BSAAR2012Member_ad06758d-fe20-4e07-b9db-d0be11a71894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanMember_59b548c0-823b-46ed-b731-ed1887c999b3" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_CompanySavingPlanMember_59b548c0-823b-46ed-b731-ed1887c999b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CompanySavingPlanEmployerTopUpMember_f0d89d2f-707c-4107-8f8f-7e113b959d2e" xlink:href="inpha-20240630.xsd#inpha_CompanySavingPlanEmployerTopUpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b9eb8dd3-41cc-4817-ab19-1fbb6fe5b48a" xlink:to="loc_inpha_CompanySavingPlanEmployerTopUpMember_f0d89d2f-707c-4107-8f8f-7e113b959d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_2ce38c93-67c3-4f5f-bcf2-610568b4bfc7" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_80145452-285d-41bf-bb7b-56d761dfd2c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_Equity_80145452-285d-41bf-bb7b-56d761dfd2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_3fdf70c4-c37e-4343-a7ac-f4a11d69b04c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_3fdf70c4-c37e-4343-a7ac-f4a11d69b04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_512ba7aa-f6f5-40b9-85fa-0856add9c7e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_ParValuePerShare_512ba7aa-f6f5-40b9-85fa-0856add9c7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_64e5bc2e-68fb-4fd6-850e-3eaf7f0dbf40" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_NumberOfSharesIssued_64e5bc2e-68fb-4fd6-850e-3eaf7f0dbf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_8898afca-bcea-4d1a-80bf-b5e0736cec32" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstruments_8898afca-bcea-4d1a-80bf-b5e0736cec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_a5a730e7-77ff-4333-9325-7e6431043be9" xlink:href="inpha-20240630.xsd#inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares_a5a730e7-77ff-4333-9325-7e6431043be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_a3be49fc-5c89-487b-8a8f-a3c122798a05" xlink:href="inpha-20240630.xsd#inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares_a3be49fc-5c89-487b-8a8f-a3c122798a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareIssuedPricePerShare_46d73109-24fc-482c-b832-2b9f7cd31101" xlink:href="inpha-20240630.xsd#inpha_ShareIssuedPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_inpha_ShareIssuedPricePerShare_46d73109-24fc-482c-b832-2b9f7cd31101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_46bc5588-420e-40a8-a067-522658712865" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2750572d-58a6-41c0-baf2-8d5ddaf783c7" xlink:to="loc_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_46bc5588-420e-40a8-a067-522658712865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_406a910e-e372-45d5-8026-b4f7d9d5e767" xlink:href="inpha-20240630.xsd#inpha_ShareCapitalAndShareBasePaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_ShareCapitalAndShareBasePaymentsAbstract_406a910e-e372-45d5-8026-b4f7d9d5e767" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_a0e34021-c6a9-44ab-90be-67248f06cb79" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b5b1a4b9-2d95-4182-90ae-9987c797a60d" xlink:to="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2011Member_2d230e22-78df-4c3b-8fb3-28be37ceac3e" xlink:href="inpha-20240630.xsd#inpha_BSAAR2011Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2011Member_2d230e22-78df-4c3b-8fb3-28be37ceac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2012Member_4b16055f-12ad-4d96-ac54-5dac2e7f38f1" xlink:href="inpha-20240630.xsd#inpha_BSAAR2012Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2012Member_4b16055f-12ad-4d96-ac54-5dac2e7f38f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSAAR2015Member_12056254-44be-440e-8699-82fc62b7a80f" xlink:href="inpha-20240630.xsd#inpha_BSAAR2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSAAR2015Member_12056254-44be-440e-8699-82fc62b7a80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20161Member_f37004cd-6e41-40a5-af9c-763df6e2a073" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20161Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20161Member_f37004cd-6e41-40a5-af9c-763df6e2a073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20161Member_74873182-0fc4-409f-8725-5396f9d5a9e5" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20161Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20161Member_74873182-0fc4-409f-8725-5396f9d5a9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20161Member_85b6db64-d4ec-49cb-9837-bbd10895cef0" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20161Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAManagement20161Member_85b6db64-d4ec-49cb-9837-bbd10895cef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20162Member_a74862af-2462-4ac5-b270-c257ab758c82" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20162Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20162Member_a74862af-2462-4ac5-b270-c257ab758c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAManagement20162Member_2621e85c-07da-4988-b0e6-175f0d0b8906" xlink:href="inpha-20240630.xsd#inpha_AGAManagement20162Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAManagement20162Member_2621e85c-07da-4988-b0e6-175f0d0b8906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20171Member_762bb475-5fba-41cb-9ff5-ab9554744d3e" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20171Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20171Member_762bb475-5fba-41cb-9ff5-ab9554744d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20171Member_eade75e4-2a42-41b7-9cb7-c26160bfbd86" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20171Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20171Member_eade75e4-2a42-41b7-9cb7-c26160bfbd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2017Member_2b514cae-fbcc-44e5-a912-a488ee1174d7" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2017Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAEmployees2017Member_2b514cae-fbcc-44e5-a912-a488ee1174d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20181Member_5ed86492-7dde-4bc5-9201-1dc29c5908c4" xlink:href="inpha-20240630.xsd#inpha_AGABonus20181Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20181Member_5ed86492-7dde-4bc5-9201-1dc29c5908c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfEmployees20181Member_2747f0c5-ad49-40b9-b373-cf23206f9a4f" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfEmployees20181Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPPerfEmployees20181Member_2747f0c5-ad49-40b9-b373-cf23206f9a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPPerfManagement20181Member_5bf255d0-d238-4bcc-9240-53c5d84af19e" xlink:href="inpha-20240630.xsd#inpha_AGAPPerfManagement20181Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPPerfManagement20181Member_5bf255d0-d238-4bcc-9240-53c5d84af19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAEmployees2018Member_2930daa5-7f13-4d48-a0c8-c52a7e8f099d" xlink:href="inpha-20240630.xsd#inpha_AGAEmployees2018Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAEmployees2018Member_2930daa5-7f13-4d48-a0c8-c52a7e8f099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20171Member_b720e988-a3b6-45dc-a883-0ebe1ba54341" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20171Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20171Member_b720e988-a3b6-45dc-a883-0ebe1ba54341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20191Member_cad287aa-ebed-406c-a764-4815d866207c" xlink:href="inpha-20240630.xsd#inpha_AGABonus20191Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20191Member_cad287aa-ebed-406c-a764-4815d866207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus202012Member_405f0d5e-1fa1-4636-94b6-1f5f45a03d0b" xlink:href="inpha-20240630.xsd#inpha_AGABonus202012Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus202012Member_405f0d5e-1fa1-4636-94b6-1f5f45a03d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20201Member_af808d17-53ad-4411-b4c7-a08c57f50aab" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20201Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20201Member_af808d17-53ad-4411-b4c7-a08c57f50aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20201Member_09656a3a-63a3-4b01-84a8-3bf868601698" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20201Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20201Member_09656a3a-63a3-4b01-84a8-3bf868601698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20211Member_80ba461c-0cd1-4cfc-b649-311d32b097f2" xlink:href="inpha-20240630.xsd#inpha_AGABonus20211Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20211Member_80ba461c-0cd1-4cfc-b649-311d32b097f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPEmployees20211Member_1fb16fa2-7ad1-4062-8018-c08c156544aa" xlink:href="inpha-20240630.xsd#inpha_AGAPEmployees20211Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPEmployees20211Member_1fb16fa2-7ad1-4062-8018-c08c156544aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPManagement20211Member_0d382d5e-40d2-460e-a97d-31ca61e5a777" xlink:href="inpha-20240630.xsd#inpha_AGAPManagement20211Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPManagement20211Member_0d382d5e-40d2-460e-a97d-31ca61e5a777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2022Member_49aab213-eda8-47cc-8476-d8cb99320c2d" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2022Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2022Member_49aab213-eda8-47cc-8476-d8cb99320c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGABonus20221Member_af798adc-dfd3-4e5f-ad58-35cb8af86664" xlink:href="inpha-20240630.xsd#inpha_AGABonus20221Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGABonus20221Member_af798adc-dfd3-4e5f-ad58-35cb8af86664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20221Member_7155a5ae-934c-4a60-9e07-1ff23091dfd9" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20221Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfEmployees20221Member_7155a5ae-934c-4a60-9e07-1ff23091dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20221Member_0cb27b89-dcd6-4ec2-99fa-81d42a31cd99" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20221Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfManagement20221Member_0cb27b89-dcd6-4ec2-99fa-81d42a31cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2023Member_0c50926e-b080-4e9c-916b-744f3a584e1c" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2023Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2023Member_0c50926e-b080-4e9c-916b-744f3a584e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20231Member_e687da2f-69af-47f0-bf43-a8f25e3497ec" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20231Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20231Member_e687da2f-69af-47f0-bf43-a8f25e3497ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfEmployees20231Member_f88ae846-f28e-470f-8eb2-498fa90b9a3a" xlink:href="inpha-20240630.xsd#inpha_AGAPerfEmployees20231Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfEmployees20231Member_f88ae846-f28e-470f-8eb2-498fa90b9a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPerfManagement20231Member_585ea6b1-15f2-46cb-80fe-f744df0be087" xlink:href="inpha-20240630.xsd#inpha_AGAPerfManagement20231Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPerfManagement20231Member_585ea6b1-15f2-46cb-80fe-f744df0be087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGANewMembers20241Member_c0675369-0da0-4985-b851-0389e0c1eff5" xlink:href="inpha-20240630.xsd#inpha_AGANewMembers20241Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGANewMembers20241Member_c0675369-0da0-4985-b851-0389e0c1eff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAPlanEpargneEntreprise2024Member_37c4f02a-bd40-4294-81d3-7aa869f1b8aa" xlink:href="inpha-20240630.xsd#inpha_AGAPlanEpargneEntreprise2024Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAPlanEpargneEntreprise2024Member_37c4f02a-bd40-4294-81d3-7aa869f1b8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_StockOptions20201Member_d3f44d07-2d04-4080-8f59-97be193cc1f8" xlink:href="inpha-20240630.xsd#inpha_StockOptions20201Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_StockOptions20201Member_d3f44d07-2d04-4080-8f59-97be193cc1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Employees2019Member_dc9e15c9-4800-430f-a1b9-3526efa04a87" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Employees2019Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAP2019Employees2019Member_dc9e15c9-4800-430f-a1b9-3526efa04a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AGAP2019Management2019Member_66bd50d2-5d68-4b93-85b8-c381e7ca931e" xlink:href="inpha-20240630.xsd#inpha_AGAP2019Management2019Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_AGAP2019Management2019Member_66bd50d2-5d68-4b93-85b8-c381e7ca931e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20112Member_a70d086a-5d78-4a93-9053-2b7c973f62bd" xlink:href="inpha-20240630.xsd#inpha_BSA20112Member"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20112Member_a70d086a-5d78-4a93-9053-2b7c973f62bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2013Member_880bd23d-730d-4fc4-9db3-9cb562e2f5ed" xlink:href="inpha-20240630.xsd#inpha_BSA2013Member"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2013Member_880bd23d-730d-4fc4-9db3-9cb562e2f5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2014Member_b0681f02-efb0-4fbf-99d2-a914beb074ad" xlink:href="inpha-20240630.xsd#inpha_BSA2014Member"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2014Member_b0681f02-efb0-4fbf-99d2-a914beb074ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20151Member_879efd1f-9fc6-4af9-8700-3b40a6aeea26" xlink:href="inpha-20240630.xsd#inpha_BSA20151Member"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20151Member_879efd1f-9fc6-4af9-8700-3b40a6aeea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20152Member_6c3fa2c3-9e72-4f06-b2c5-0cd75a826098" xlink:href="inpha-20240630.xsd#inpha_BSA20152Member"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20152Member_6c3fa2c3-9e72-4f06-b2c5-0cd75a826098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA2017Member_441a194f-a320-4a27-8805-49dcc8148d11" xlink:href="inpha-20240630.xsd#inpha_BSA2017Member"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA2017Member_441a194f-a320-4a27-8805-49dcc8148d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20221Member_6aa4ed39-ff66-4793-9667-610c6ad36098" xlink:href="inpha-20240630.xsd#inpha_BSA20221Member"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20221Member_6aa4ed39-ff66-4793-9667-610c6ad36098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_BSA20231Member_95cf7b69-8b73-4363-bf2c-c0625d4e0629" xlink:href="inpha-20240630.xsd#inpha_BSA20231Member"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_WarrantsMember_c0705b54-d291-4c85-aa67-64436dc388bb" xlink:to="loc_inpha_BSA20231Member_95cf7b69-8b73-4363-bf2c-c0625d4e0629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_a383db82-968f-4dca-9ec2-b0c05affaaca" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11b111cc-48ef-43dd-824f-99f31deb113d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11b111cc-48ef-43dd-824f-99f31deb113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_8222b79c-0449-4e2e-9390-fc195dc64db3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_8222b79c-0449-4e2e-9390-fc195dc64db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6cf21874-1532-4309-848a-afc3873af961" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6cf21874-1532-4309-848a-afc3873af961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b8f6d3f8-97ea-419d-bacb-762309ee38c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b8f6d3f8-97ea-419d-bacb-762309ee38c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_12667532-7557-448e-ad71-2ba6effbc6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_12667532-7557-448e-ad71-2ba6effbc6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_56d93cfe-fc7e-4867-af10-d04cd7f6d95f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_426f2601-fcd8-4af3-8218-059e1fd16424" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_56d93cfe-fc7e-4867-af10-d04cd7f6d95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_7731ae79-07b4-4865-9363-b60bd0af4bc0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_7731ae79-07b4-4865-9363-b60bd0af4bc0" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_23203491-2754-425c-bceb-a3ff9b5bc3ec" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCurrentFinancialAssetsMember_498022a6-976c-426a-bdd7-c9b8d6c9e85f" xlink:href="inpha-20240630.xsd#inpha_NonCurrentFinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_NonCurrentFinancialAssetsMember_498022a6-976c-426a-bdd7-c9b8d6c9e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradeReceivablesAndOthersMember_4ae923cf-500c-4c91-9b05-f00f79f9bb48" xlink:href="inpha-20240630.xsd#inpha_TradeReceivablesAndOthersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_TradeReceivablesAndOthersMember_4ae923cf-500c-4c91-9b05-f00f79f9bb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsShortTermInvestmentsMember_9f0dfead-6d75-4c34-a223-34cec9d8353a" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_FinancialAssetsShortTermInvestmentsMember_9f0dfead-6d75-4c34-a223-34cec9d8353a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember_cc044d90-a580-43eb-b72e-88d3b670c0d3" xlink:href="inpha-20240630.xsd#inpha_FinancialAssetsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_daf54eed-fef6-401b-8602-5aa88ac9a226" xlink:to="loc_inpha_FinancialAssetsCashAndCashEquivalentsMember_cc044d90-a580-43eb-b72e-88d3b670c0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_fef4b9d8-968e-42b7-af94-2797695c82ec" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_012ff21d-fdc2-4908-988b-35ea228f1a11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_012ff21d-fdc2-4908-988b-35ea228f1a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5f79112e-eb4a-4d54-9336-169f55061a90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_77a36f77-5210-4ab0-83ab-b1d3bcb76318" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5f79112e-eb4a-4d54-9336-169f55061a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d4bcbb5e-6f9e-412f-961e-2d02c518d143" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember_3b1818d7-662a-43ad-9011-980f1318e693" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesNonCurrentPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_FinancialLiabilitiesNonCurrentPortionMember_3b1818d7-662a-43ad-9011-980f1318e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesCurrentPortionMember_40b9838a-089a-4a25-92ef-9fc02597a400" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesCurrentPortionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_FinancialLiabilitiesCurrentPortionMember_40b9838a-089a-4a25-92ef-9fc02597a400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TradePayablesAndOthersMember_e6182d1e-2327-4951-8981-5bd90e89cd59" xlink:href="inpha-20240630.xsd#inpha_TradePayablesAndOthersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_ff28a1c2-6ce9-4c8d-a116-1572bd2760c3" xlink:to="loc_inpha_TradePayablesAndOthersMember_e6182d1e-2327-4951-8981-5bd90e89cd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_11176399-9ef4-4b24-ac6e-508cc721ea2e" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_0001f58c-2d33-404c-8f2a-105eab2e2f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_0001f58c-2d33-404c-8f2a-105eab2e2f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_affd335e-db10-4269-b495-5fff2d834adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eb341560-d3e6-4363-99ec-06bcc135c19b" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_affd335e-db10-4269-b495-5fff2d834adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_88d21bdd-0be1-4213-b022-18e3402555dd" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_e0d445fa-7733-444f-bf16-0de64d1f491d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_ifrs-full_FinancialAssets_e0d445fa-7733-444f-bf16-0de64d1f491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_5e878161-c0e1-448d-a348-e3244f99c655" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_5e878161-c0e1-448d-a348-e3244f99c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers_a96d49e0-a9e0-4f83-ae19-b42ffe904542" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_inpha_FinancialLiabilitiesTradePayablesAndOthers_a96d49e0-a9e0-4f83-ae19-b42ffe904542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_70b08891-270e-40d5-89a6-5ee3b344346a" xlink:href="inpha-20240630.xsd#inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_39855116-3bdb-4ca9-b6d7-7356c73c0a2c" xlink:to="loc_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue_70b08891-270e-40d5-89a6-5ee3b344346a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_edd4ace1-35ab-40b8-8f93-b399e18517b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_edd4ace1-35ab-40b8-8f93-b399e18517b3" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:to="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_f52d4237-a8b8-43b5-a7fb-526c96b463fd" xlink:to="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:href="inpha-20240630.xsd#inpha_CollaborationAndLicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:to="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_8287cd7e-7421-4000-879e-802ed6ce2280" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_MonalizumabAgreementMember_8287cd7e-7421-4000-879e-802ed6ce2280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_7368077c-0668-48d9-bde7-a8c0e2e0cd4f" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_7368077c-0668-48d9-bde7-a8c0e2e0cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member_1ea5a0fa-45c8-46e3-95e9-ad487a82b915" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH62Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithSanofi2022ANKETIPH62Member_1ea5a0fa-45c8-46e3-95e9-ad487a82b915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member_4b8ab102-41b9-4c1c-b6d7-41c0b85a3456" xlink:href="inpha-20240630.xsd#inpha_AgreementWithSanofi2022ANKETIPH67Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithSanofi2022ANKETIPH67Member_4b8ab102-41b9-4c1c-b6d7-41c0b85a3456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithTakedaMember_443d161c-9263-45db-a2c5-a2340fc66199" xlink:href="inpha-20240630.xsd#inpha_AgreementWithTakedaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationAndLicensingAgreementsMember_7f50de2c-e594-4bff-9977-385494bf51d2" xlink:to="loc_inpha_AgreementWithTakedaMember_443d161c-9263-45db-a2c5-a2340fc66199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IPH5201AndAdvoralimabAgreementsMember_5ae1fd93-cde7-4b9e-9a38-f5742456c8b8" xlink:href="inpha-20240630.xsd#inpha_IPH5201AndAdvoralimabAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_420db765-c13b-48c0-8f16-34e5bbec3d9c" xlink:to="loc_inpha_IPH5201AndAdvoralimabAgreementsMember_5ae1fd93-cde7-4b9e-9a38-f5742456c8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_fefada37-ef07-4186-ac01-4cc35959e2b6" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_3a8572f8-228e-4462-978d-32e474ff60ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_0079b077-f972-4c54-bb70-5778931a7a8a" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_3a8572f8-228e-4462-978d-32e474ff60ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_799d98da-7043-4fb0-bf43-3eeaad0a461b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_799d98da-7043-4fb0-bf43-3eeaad0a461b" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b4dd50d-35db-42cb-83bc-0bde83d6468c" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueMember_62cca4a3-3374-408e-b555-d7a4899f9780" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:to="loc_inpha_DeferredRevenueMember_62cca4a3-3374-408e-b555-d7a4899f9780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesMember_88f735af-85c0-4eb5-803d-744b00a975a6" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_81027117-2928-48c1-ada8-6c5b28a8e3e7" xlink:to="loc_inpha_CollaborationLiabilitiesMember_88f735af-85c0-4eb5-803d-744b00a975a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:to="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_752ccfe8-edc5-4973-805d-dee2697d6f05" xlink:to="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember_6a864a00-adea-4803-9bdb-e6708ad8f07b" xlink:href="inpha-20240630.xsd#inpha_A2015AstraZenecaMonalizumabAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_A2015AstraZenecaMonalizumabAgreementsMember_6a864a00-adea-4803-9bdb-e6708ad8f07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_3af3fcdb-7635-4e78-8311-c27d7bef4e2e" xlink:href="inpha-20240630.xsd#inpha_SanofiResearchCollaborationAndLicensingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_3af3fcdb-7635-4e78-8311-c27d7bef4e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_419f0200-9a68-41b2-9534-00a21f49a2a4" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithSanofiForNKCellEngagesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_c20cf373-d969-46c2-ac8b-de2cb099ef6c" xlink:to="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_419f0200-9a68-41b2-9534-00a21f49a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_61754d9e-602b-4f92-9505-c90d7042769f" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueRollForwardAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6c634406-3dca-4a17-a30a-77706b42e0ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_ifrs-full_ContractLiabilities_6c634406-3dca-4a17-a30a-77706b42e0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestone_9c2ffb5b-1c85-42f1-a4a2-3683cde0143b" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestone_9c2ffb5b-1c85-42f1-a4a2-3683cde0143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_62c3c1cb-4076-4d6f-983c-d40e131f5c34" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_62c3c1cb-4076-4d6f-983c-d40e131f5c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferToFromCollaborationLiabilities_87530cb2-35c9-4b9e-8362-0a41f1c866e0" xlink:href="inpha-20240630.xsd#inpha_TransferToFromCollaborationLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_inpha_TransferToFromCollaborationLiabilities_87530cb2-35c9-4b9e-8362-0a41f1c866e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_11d1f5b0-24b4-4ed1-84ee-07e9cf2b8c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DeferredRevenueRollForwardAbstract_543e1e10-ca2a-42aa-afcb-e731a4ded167" xlink:to="loc_ifrs-full_ContractLiabilities_11d1f5b0-24b4-4ed1-84ee-07e9cf2b8c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:href="inpha-20240630.xsd#inpha_CollaborationLiabilitiesRollForwardAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_02f97ab0-6b50-41ef-96d2-3c7ed66c088a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_ifrs-full_ContractLiabilities_02f97ab0-6b50-41ef-96d2-3c7ed66c088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_77ba699e-b381-44a3-9a66-8ec903e97162" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_77ba699e-b381-44a3-9a66-8ec903e97162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DecreaseThroughDeductionsContractLiabilities_be0e9743-9f2c-4432-8489-cc9072bd237e" xlink:href="inpha-20240630.xsd#inpha_DecreaseThroughDeductionsContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_inpha_DecreaseThroughDeductionsContractLiabilities_be0e9743-9f2c-4432-8489-cc9072bd237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_56241e04-e1ab-4510-b208-9ea5e96f90e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CollaborationLiabilitiesRollForwardAbstract_547dc12e-10bc-4a2b-a919-8903963795a4" xlink:to="loc_ifrs-full_ContractLiabilities_56241e04-e1ab-4510-b208-9ea5e96f90e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_213114b7-3110-424c-af24-c574fd5c0470" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_213114b7-3110-424c-af24-c574fd5c0470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfTargetOptions_6216effc-2eac-4a3e-93ac-af1d07e2b615" xlink:href="inpha-20240630.xsd#inpha_NumberOfTargetOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_NumberOfTargetOptions_6216effc-2eac-4a3e-93ac-af1d07e2b615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfPreclinicalMolecules_de427f22-c958-4eaa-b8e6-8b3f89734fe3" xlink:href="inpha-20240630.xsd#inpha_NumberOfPreclinicalMolecules"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_NumberOfPreclinicalMolecules_de427f22-c958-4eaa-b8e6-8b3f89734fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_e548faf0-f233-4878-8630-3667a3de6eaa" xlink:href="inpha-20240630.xsd#inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum_e548faf0-f233-4878-8630-3667a3de6eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_fe6579ea-e611-40fa-b264-e1732567a200" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5066a3b9-e7fd-480e-810d-bb80b2a71067" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_fe6579ea-e611-40fa-b264-e1732567a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_cc9e810a-59f4-4518-a670-16c8218c7666" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_cc9e810a-59f4-4518-a670-16c8218c7666" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:to="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_d3d633e8-bffd-4e18-ab14-a41a2f644113" xlink:to="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_A2018AstraZenecaIPH5201AgreementMember_12573c5b-e437-403c-95e2-efea2f493414" xlink:href="inpha-20240630.xsd#inpha_A2018AstraZenecaIPH5201AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_A2018AstraZenecaIPH5201AgreementMember_12573c5b-e437-403c-95e2-efea2f493414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_70301e34-47fb-4494-9829-1a9f6c07f4bb" xlink:href="inpha-20240630.xsd#inpha_AgreementRelatedToIPH6101WithSanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementRelatedToIPH6101WithSanofiMember_70301e34-47fb-4494-9829-1a9f6c07f4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_91db0d9a-2147-414a-9d1f-043cac2e663b" xlink:href="inpha-20240630.xsd#inpha_SanofiResearchCollaborationAndLicensingAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_SanofiResearchCollaborationAndLicensingAgreementMember_91db0d9a-2147-414a-9d1f-043cac2e663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_6fdc9158-3e92-4a4e-8de1-909455a3fa8a" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithSanofiForNKCellEngagesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementsWithSanofiForNKCellEngagesMember_6fdc9158-3e92-4a4e-8de1-909455a3fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember_88f3f9e1-2816-4737-874a-b7f608f61292" xlink:href="inpha-20240630.xsd#inpha_AgreementsWithGenzymeForNKCellEngagesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_906012ea-5899-4954-9c2a-2302f4ca25d1" xlink:to="loc_inpha_AgreementsWithGenzymeForNKCellEngagesMember_88f3f9e1-2816-4737-874a-b7f608f61292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_40b879c9-8f5a-4c8e-98f8-16268b1b12ae" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_fadcf6e6-a8d5-45ef-bb8c-b8d6d8e868ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_fadcf6e6-a8d5-45ef-bb8c-b8d6d8e868ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ExternalCostsRelatedToTheClinicalTrial_8f8e31b1-ee98-4db9-a98f-7353b9d6b7c0" xlink:href="inpha-20240630.xsd#inpha_ExternalCostsRelatedToTheClinicalTrial"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_ExternalCostsRelatedToTheClinicalTrial_8f8e31b1-ee98-4db9-a98f-7353b9d6b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_275761db-e4f0-4917-ad08-560057ab4992" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived_275761db-e4f0-4917-ad08-560057ab4992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_1a852c2c-2d54-4e77-a6c2-443c1ad4ed31" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived_1a852c2c-2d54-4e77-a6c2-443c1ad4ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_afc76962-1514-4bdc-b893-0f33935ac6a7" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses_afc76962-1514-4bdc-b893-0f33935ac6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_2c7ac8d0-5662-4fd7-a7c5-b086b177e424" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch_2c7ac8d0-5662-4fd7-a7c5-b086b177e424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_98866885-5aa1-4d2b-abc7-34b65289a135" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions_98866885-5aa1-4d2b-abc7-34b65289a135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfTargetOptions_6fa8e0ab-fbea-4549-95fd-37ff4e0452a1" xlink:href="inpha-20240630.xsd#inpha_NumberOfTargetOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfTargetOptions_6fa8e0ab-fbea-4549-95fd-37ff4e0452a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfOptionsExcercisedForLicenses_9425d5f6-0b2e-4c3a-b911-9e4115c6ca74" xlink:href="inpha-20240630.xsd#inpha_NumberOfOptionsExcercisedForLicenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfOptionsExcercisedForLicenses_9425d5f6-0b2e-4c3a-b911-9e4115c6ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfExclusiveOptionsGranted_a5b2472e-949a-4ac2-a57c-81e64031f024" xlink:href="inpha-20240630.xsd#inpha_NumberOfExclusiveOptionsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_NumberOfExclusiveOptionsGranted_a5b2472e-949a-4ac2-a57c-81e64031f024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_081f90e2-7be4-45b4-9bda-73162a502e82" xlink:href="inpha-20240630.xsd#inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_45708194-1cc1-4c64-9bee-930f979d7499" xlink:to="loc_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised_081f90e2-7be4-45b4-9bda-73162a502e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_f199cfe0-1181-4dff-8467-939120a16636" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_f199cfe0-1181-4dff-8467-939120a16636" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3f14b712-7c8b-4af5-bb54-82600c2c14d1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DeferredRevenueMember_6c719b7f-5015-4298-98de-4b3b1401fb75" xlink:href="inpha-20240630.xsd#inpha_DeferredRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_cb7ce2ae-c2f1-4b4a-8526-5a5923cee848" xlink:to="loc_inpha_DeferredRevenueMember_6c719b7f-5015-4298-98de-4b3b1401fb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_c73ba44d-7f29-4ccf-9a5f-87958796a3b3" xlink:to="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabMember_913f4549-457c-4bd7-9b9d-a9ada8cd7f38" xlink:href="inpha-20240630.xsd#inpha_MonalizumabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_MonalizumabMember_913f4549-457c-4bd7-9b9d-a9ada8cd7f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiOptionsMember_eed6d980-84fc-4da8-9b47-2a09d3e4f21a" xlink:href="inpha-20240630.xsd#inpha_SanofiOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_SanofiOptionsMember_eed6d980-84fc-4da8-9b47-2a09d3e4f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SanofiServicesMember_7e74b163-132b-4d60-86d4-f5fe37b9210e" xlink:href="inpha-20240630.xsd#inpha_SanofiServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesDomain_8aed810f-eb78-4bbf-a7aa-8a6d07e2c302" xlink:to="loc_inpha_SanofiServicesMember_7e74b163-132b-4d60-86d4-f5fe37b9210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e884d55d-a6bc-46b4-a8ff-fd128cfd4fc8" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_f171d305-67bc-47c7-acfc-4f46048dacfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_ContractLiabilities_f171d305-67bc-47c7-acfc-4f46048dacfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_876d25bc-34d6-43c4-b0cb-4f68734bc543" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_876d25bc-34d6-43c4-b0cb-4f68734bc543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_d5293017-232c-4c12-84d3-6640e100d137" xlink:href="inpha-20240630.xsd#inpha_IncreaseThroughUpfrontPaymentContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_inpha_IncreaseThroughUpfrontPaymentContractLiabilities_d5293017-232c-4c12-84d3-6640e100d137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TransferFromToCollaborationLiabilities_9b6c5a4b-ccc4-427e-9397-65527d219929" xlink:href="inpha-20240630.xsd#inpha_TransferFromToCollaborationLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_inpha_TransferFromToCollaborationLiabilities_9b6c5a4b-ccc4-427e-9397-65527d219929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_59108d73-eadf-4052-9275-16a3365c9279" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_e8a2ba4c-c890-4d45-99b5-b4ffa24412a7" xlink:to="loc_ifrs-full_ContractLiabilities_59108d73-eadf-4052-9275-16a3365c9279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ba7a4cb2-b8b7-4568-a942-e30ea4353dc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeFromResearchTaxCredit_50b81752-8a2c-4bee-841f-c6a526d48a96" xlink:href="inpha-20240630.xsd#inpha_IncomeFromResearchTaxCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ba7a4cb2-b8b7-4568-a942-e30ea4353dc6" xlink:to="loc_inpha_IncomeFromResearchTaxCredit_50b81752-8a2c-4bee-841f-c6a526d48a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromGovernmentGrants_8808eb2b-8be8-4971-a8a6-7b0904de3cc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ba7a4cb2-b8b7-4568-a942-e30ea4353dc6" xlink:to="loc_ifrs-full_RevenueFromGovernmentGrants_8808eb2b-8be8-4971-a8a6-7b0904de3cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GovernmentFinancingForResearchExpenditures_ce1a43d2-f202-426b-b915-7b565cad7d52" xlink:href="inpha-20240630.xsd#inpha_GovernmentFinancingForResearchExpenditures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ba7a4cb2-b8b7-4568-a942-e30ea4353dc6" xlink:to="loc_inpha_GovernmentFinancingForResearchExpenditures_ce1a43d2-f202-426b-b915-7b565cad7d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesDisclosureofexpensesbynatureDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_494e0682-6a54-4eac-9cbe-8c2d54beddd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_494e0682-6a54-4eac-9cbe-8c2d54beddd4" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_a5b5ed82-a585-4cb1-9588-0ded9c3cf2ab" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchAndDevelopmentMember_75495962-d315-444b-93ab-3eca040068d0" xlink:href="inpha-20240630.xsd#inpha_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:to="loc_inpha_ResearchAndDevelopmentMember_75495962-d315-444b-93ab-3eca040068d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_629f8472-d2ba-48f4-822b-3d0829b497a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain_6c0bdf3a-bfcf-41f4-b384-6f4f5768b688" xlink:to="loc_ifrs-full_SellingGeneralAndAdministrativeExpenseMember_629f8472-d2ba-48f4-822b-3d0829b497a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_6a7a4bcf-c988-4143-81e0-9b7f0fddc022" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SubcontractingCosts_d2232886-5404-4e57-8925-e67540e87eba" xlink:href="inpha-20240630.xsd#inpha_SubcontractingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_SubcontractingCosts_d2232886-5404-4e57-8925-e67540e87eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5eb9ab81-8b27-4eff-ab7d-b1da22e26423" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterialsAndConsumablesUsed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_RawMaterialsAndConsumablesUsed_5eb9ab81-8b27-4eff-ab7d-b1da22e26423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_c7724f2d-0db8-4d59-b55e-ec16eda14ac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_c7724f2d-0db8-4d59-b55e-ec16eda14ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_619e9a74-7e6c-4da4-ac4b-1651fd14dc6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_619e9a74-7e6c-4da4-ac4b-1651fd14dc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_c3a82577-c99c-4173-87a4-ee709c637861" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_c3a82577-c99c-4173-87a4-ee709c637861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonScientificAdvisoryAndConsulting_91d01137-b88f-4293-8a51-4175a7ea8a58" xlink:href="inpha-20240630.xsd#inpha_NonScientificAdvisoryAndConsulting"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_NonScientificAdvisoryAndConsulting_91d01137-b88f-4293-8a51-4175a7ea8a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LeasingAndMaintenance_e5e14400-9fce-43d1-9c7d-05b7b56cdd14" xlink:href="inpha-20240630.xsd#inpha_LeasingAndMaintenance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_LeasingAndMaintenance_e5e14400-9fce-43d1-9c7d-05b7b56cdd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TravelExpense_f2e59966-22db-4f5d-9edd-26640eb22323" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TravelExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_TravelExpense_f2e59966-22db-4f5d-9edd-26640eb22323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_53743a0e-e43a-4e3c-a37d-50b9128d194a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_53743a0e-e43a-4e3c-a37d-50b9128d194a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ScientificAdvisoryAndConsulting_f125a84d-9492-4f2e-bbea-580d8bd5a4b1" xlink:href="inpha-20240630.xsd#inpha_ScientificAdvisoryAndConsulting"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_ScientificAdvisoryAndConsulting_f125a84d-9492-4f2e-bbea-580d8bd5a4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_OtherPurchasesAndExternalExpenses_fd58f57b-371b-4f06-9ed6-8afc51005e87" xlink:href="inpha-20240630.xsd#inpha_OtherPurchasesAndExternalExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_OtherPurchasesAndExternalExpenses_fd58f57b-371b-4f06-9ed6-8afc51005e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationAndAmortisationExpense_d6d60061-3763-476d-9627-79f6038310bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationAndAmortisationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_DepreciationAndAmortisationExpense_d6d60061-3763-476d-9627-79f6038310bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IntellectualPropertyExpenses_8a03001b-8b63-4e37-82d5-aaf248b63e33" xlink:href="inpha-20240630.xsd#inpha_IntellectualPropertyExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_inpha_IntellectualPropertyExpenses_8a03001b-8b63-4e37-82d5-aaf248b63e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_5a6811da-6b10-48e6-9ccf-a889a75e2adb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_5a6811da-6b10-48e6-9ccf-a889a75e2adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_7ef44933-9478-4821-bda9-8277320763ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsLineItems_a3c16c9b-2251-49e3-81a3-df2b7a23693b" xlink:to="loc_ifrs-full_OperatingExpense_7ef44933-9478-4821-bda9-8277320763ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#OperatingexpensesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2d8ab4f0-0d90-4a25-b0bd-ddf0e791c00f" xlink:to="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AgreementWithOregaBiotechMember_d83609a1-6c1c-425d-8dc8-5de57a4ea389" xlink:href="inpha-20240630.xsd#inpha_AgreementWithOregaBiotechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:to="loc_inpha_AgreementWithOregaBiotechMember_d83609a1-6c1c-425d-8dc8-5de57a4ea389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_MonalizumabAgreementMember_1f9f66c6-f942-4580-9fc7-2ad84f9866a5" xlink:href="inpha-20240630.xsd#inpha_MonalizumabAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_3c47b5eb-dbaf-45d7-ba83-717b93217354" xlink:to="loc_inpha_MonalizumabAgreementMember_1f9f66c6-f942-4580-9fc7-2ad84f9866a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:to="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:href="inpha-20240630.xsd#inpha_TypeOfEmployeeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfEmployeeAxis_3722f254-5fa9-48e5-9391-f635b3b2a34a" xlink:to="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ResearchAndDevelopmentMember_1e726c1b-e9bc-4763-8a53-15ba39fbf5e5" xlink:href="inpha-20240630.xsd#inpha_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:to="loc_inpha_ResearchAndDevelopmentMember_1e726c1b-e9bc-4763-8a53-15ba39fbf5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_AdministrationMember_e375b079-28c7-46e8-a9bf-77166eb4ccef" xlink:href="inpha-20240630.xsd#inpha_AdministrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_TypeOfEmployeeDomain_3383045d-5eb2-4e65-92a6-1dda9c731a72" xlink:to="loc_inpha_AdministrationMember_e375b079-28c7-46e8-a9bf-77166eb4ccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfOperatingExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesTable_662ea075-df18-41e1-b3b7-7aa3d0586fb9" xlink:to="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_7e0423a0-9726-4725-aefd-48c86f241fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_ShorttermEmployeeBenefitsExpense_7e0423a0-9726-4725-aefd-48c86f241fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfEmployees_e4a9059c-c8cc-41a1-ac75-f787e81af46b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_NumberOfEmployees_e4a9059c-c8cc-41a1-ac75-f787e81af46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_cc47f29e-3f6b-484a-9075-89fc9e8c7a09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfOperatingExpensesLineItems_fdbbbe18-33f9-45d3-a585-c661f2971680" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_cc47f29e-3f6b-484a-9075-89fc9e8c7a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_InterestsAndGainsOnFinancialAssets_48e5d5c6-c177-45cc-a336-5f17dc05cf7d" xlink:href="inpha-20240630.xsd#inpha_InterestsAndGainsOnFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_inpha_InterestsAndGainsOnFinancialAssets_48e5d5c6-c177-45cc-a336-5f17dc05cf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments_6e1d69ce-fc5a-480c-acd0-85537d7c060a" xlink:href="inpha-20240630.xsd#inpha_ChangeInValuationAllowanceOfFinancialInstruments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_inpha_ChangeInValuationAllowanceOfFinancialInstruments_6e1d69ce-fc5a-480c-acd0-85537d7c060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_5a647978-523b-478e-a246-3de7a6b4142f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_NetForeignExchangeGain_5a647978-523b-478e-a246-3de7a6b4142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_68151e16-3249-4380-a3c0-8e486ac33b09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_FinanceIncome_68151e16-3249-4380-a3c0-8e486ac33b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_a1191189-784c-4cfd-b1e8-166a034518f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_a1191189-784c-4cfd-b1e8-166a034518f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnrealizedLossesOnFinancialAssets_d288bd82-a3e0-4094-a864-d6811fffc784" xlink:href="inpha-20240630.xsd#inpha_UnrealizedLossesOnFinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_inpha_UnrealizedLossesOnFinancialAssets_d288bd82-a3e0-4094-a864-d6811fffc784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_7ddaf62f-1797-40ca-9767-e3627d098a3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_InterestExpense_7ddaf62f-1797-40ca-9767-e3627d098a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_bc02c4e1-f5ef-4416-b5db-b6910249137f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_FinanceCosts_bc02c4e1-f5ef-4416-b5db-b6910249137f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeCost_bfe7c1ca-4d69-4281-bfa0-b11438160665" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ffc4f408-f21b-4f04-8e3c-fe37b840aa2e" xlink:to="loc_ifrs-full_FinanceIncomeCost_bfe7c1ca-4d69-4281-bfa0-b11438160665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IncometaxexpenseDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IncometaxexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IncometaxexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_7456a023-a791-40f4-b2ef-32a41d9b4312" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundAbstract_7456a023-a791-40f4-b2ef-32a41d9b4312" xlink:to="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:to="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8dcfa2b3-b1f3-4e7e-893d-e1fc6a32eb5d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3a97a925-57f1-47bb-9b21-168c32a46d1b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_a2d8db5a-d8ed-443c-8f68-75b6f206dc81" xlink:to="loc_srt_ScenarioForecastMember_3a97a925-57f1-47bb-9b21-168c32a46d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:href="inpha-20240630.xsd#inpha_DisclosureOfIncomeTaxLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxTable_b3cc8fca-f132-44de-a0b3-c3ca393a118f" xlink:to="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_1fd0e37c-1714-44b2-9616-8d85e78771d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_1fd0e37c-1714-44b2-9616-8d85e78771d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_c8df3e4e-df04-4584-b4ed-cceb487fde57" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_ifrs-full_ApplicableTaxRate_c8df3e4e-df04-4584-b4ed-cceb487fde57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesWithNoExpirationDate_c8ea3d3a-4e45-4158-8ec8-065d7bd9a6cf" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesWithNoExpirationDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_inpha_UnusedTaxLossesWithNoExpirationDate_c8ea3d3a-4e45-4158-8ec8-065d7bd9a6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_UnusedTaxLossesSubjectToExpiration_279fdb6d-6bc0-4aec-b08f-7eb79b7c1b45" xlink:href="inpha-20240630.xsd#inpha_UnusedTaxLossesSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_DisclosureOfIncomeTaxLineItems_03ce0f3c-ead1-4c15-9c85-0eda0f3af036" xlink:to="loc_inpha_UnusedTaxLossesSubjectToExpiration_279fdb6d-6bc0-4aec-b08f-7eb79b7c1b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#CommitmentscontingenciesandlitigationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract_bbbf1c67-2da2-4d82-a461-b285ad5c432a" xlink:href="inpha-20240630.xsd#inpha_CommitmentsContingenciesAndLitigationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_CommitmentsContingenciesAndLitigationsAbstract_bbbf1c67-2da2-4d82-a461-b285ad5c432a" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfContractsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsAxis_2a27b2bd-d4f5-437d-93fe-357b21807bca" xlink:to="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PreclinicalServicesMember_16dfb7a4-ea15-4081-8651-3eec283e960a" xlink:href="inpha-20240630.xsd#inpha_PreclinicalServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:to="loc_inpha_PreclinicalServicesMember_16dfb7a4-ea15-4081-8651-3eec283e960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ClinicalServicesMember_00168ebd-d60e-46dc-b7b8-8cc669fa2edd" xlink:href="inpha-20240630.xsd#inpha_ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfContractsDomain_d2cb1958-c0c6-4591-b01c-17e32e406114" xlink:to="loc_inpha_ClinicalServicesMember_00168ebd-d60e-46dc-b7b8-8cc669fa2edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_11786a29-48fa-4b82-8b96-62cb4ae2c03c" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_4e8e1329-2a8f-40ca-92b6-17a2e535072e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember_4e8e1329-2a8f-40ca-92b6-17a2e535072e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember_e6048169-a55b-4053-ac5b-6fcda4d34008" xlink:href="inpha-20240630.xsd#inpha_GrantsOfEmployeeEquityInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_inpha_GrantsOfEmployeeEquityInstrumentsMember_e6048169-a55b-4053-ac5b-6fcda4d34008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_LoanAgreementWithSocitGnraleMember_df6a463e-c559-43f6-b97f-71686390c513" xlink:href="inpha-20240630.xsd#inpha_LoanAgreementWithSocitGnraleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_fe3aecea-be72-4f50-89a5-a0874bf783a4" xlink:to="loc_inpha_LoanAgreementWithSocitGnraleMember_df6a463e-c559-43f6-b97f-71686390c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfContingentLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesAxis_ad31c32c-f17a-4397-b6b7-944a1ff62121" xlink:to="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxContingentLiabilityMember_14d95643-4f02-4b3a-8f42-7978d94faba4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxContingentLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfContingentLiabilitiesDomain_b217638a-871a-4d7e-9368-531286ddd479" xlink:to="loc_ifrs-full_TaxContingentLiabilityMember_14d95643-4f02-4b3a-8f42-7978d94faba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_15f7ca7b-7b6d-4b6a-bc34-78f201e76231" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ChangesToCommitmentsMember_a0862c50-9f8d-4717-96d6-88bc79516ba7" xlink:href="inpha-20240630.xsd#inpha_ChangesToCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_f4537dab-82a7-43c5-a28e-d20b7693d668" xlink:to="loc_inpha_ChangesToCommitmentsMember_a0862c50-9f8d-4717-96d6-88bc79516ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_eff28546-caa8-4cbd-9ceb-3737ac969de9" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_37a1e892-2e8b-4e8a-b00a-502ee0ba13d8" xlink:href="inpha-20240630.xsd#inpha_NonCancellableOffBalanceSheetPurchasedCommitments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_NonCancellableOffBalanceSheetPurchasedCommitments_37a1e892-2e8b-4e8a-b00a-502ee0ba13d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_c92e6eb2-9ebe-4770-8950-df8bd7a017cc" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024_c92e6eb2-9ebe-4770-8950-df8bd7a017cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_9b85e559-0765-4d00-8933-1bcebd9101d5" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027_9b85e559-0765-4d00-8933-1bcebd9101d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_f437c03e-2a33-4160-8834-405a4fcd592a" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031_f437c03e-2a33-4160-8834-405a4fcd592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_5494489a-fa60-42f5-8089-f514bd5db9ef" xlink:href="inpha-20240630.xsd#inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest_5494489a-fa60-42f5-8089-f514bd5db9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_4c641340-5b7d-4b40-b3d5-1ee6f60819a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Provisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_ifrs-full_Provisions_4c641340-5b7d-4b40-b3d5-1ee6f60819a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_778a8dba-ad8b-4bfe-a056-78079678b00b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_778a8dba-ad8b-4bfe-a056-78079678b00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_PaymentOfTaxesOtherThanIncomeTax_099cc734-fdbf-45f1-ad2f-28bc812b7c3b" xlink:href="inpha-20240630.xsd#inpha_PaymentOfTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_4fd054be-0243-494b-810d-91c14a82de44" xlink:to="loc_inpha_PaymentOfTaxesOtherThanIncomeTax_099cc734-fdbf-45f1-ad2f-28bc812b7c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1aa38fd4-6c1c-4ea6-9fd3-d0a16b78a681" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_1aa38fd4-6c1c-4ea6-9fd3-d0a16b78a681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b7803292-c1be-4e06-a51f-ea24e689eced" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_b7803292-c1be-4e06-a51f-ea24e689eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ec94ed9e-da1a-42fa-889c-b7ac9c6f4a4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_ec94ed9e-da1a-42fa-889c-b7ac9c6f4a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees_111c3d41-e249-4c6c-9b26-a37510f2f3d4" xlink:href="inpha-20240630.xsd#inpha_KeyManagementPersonnelCompensationAdvisoryFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:to="loc_inpha_KeyManagementPersonnelCompensationAdvisoryFees_111c3d41-e249-4c6c-9b26-a37510f2f3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1d399b6e-806d-469a-b3a4-6128b5cb26db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e7e4dfec-3c91-486f-b3d6-556064d3bf63" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_1d399b6e-806d-469a-b3a4-6128b5cb26db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_28437e6c-6dd7-490a-863a-4c0b912f51a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_28437e6c-6dd7-490a-863a-4c0b912f51a4" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_030c54d0-cd14-4ccc-b6c2-e48713c495d0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NovoNordiskASMember_8a69ab80-d938-4368-817f-264e4babbaa5" xlink:href="inpha-20240630.xsd#inpha_NovoNordiskASMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesDomain_13268d86-dd46-47f1-b77a-cccacade09e9" xlink:to="loc_inpha_NovoNordiskASMember_8a69ab80-d938-4368-817f-264e4babbaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_6ec60266-58ac-40d7-a0f9-3b636a309bf0" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForExpensesWithRelatedParties_45dd3ae4-09d1-4498-bb11-739a8ce1342c" xlink:href="inpha-20240630.xsd#inpha_ProvisionForExpensesWithRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_ProvisionForExpensesWithRelatedParties_45dd3ae4-09d1-4498-bb11-739a8ce1342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_ProvisionForAttendanceFees_cad73219-dd7e-48d4-9a75-967bd396aeec" xlink:href="inpha-20240630.xsd#inpha_ProvisionForAttendanceFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_ProvisionForAttendanceFees_cad73219-dd7e-48d4-9a75-967bd396aeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties_11bfccb5-a733-4aa9-ac52-56c20d2ac5ff" xlink:href="inpha-20240630.xsd#inpha_NumberOfLicensingAgreementsWithRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_inpha_NumberOfLicensingAgreementsWithRelatedParties_11bfccb5-a733-4aa9-ac52-56c20d2ac5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7294f4a9-dc82-4876-9342-670858ac1bbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_fc6a3bbe-466d-462c-9b33-87c6f6d65436" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_7294f4a9-dc82-4876-9342-670858ac1bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_cc885ad1-12b0-49aa-abd6-0fc4ccbbb736" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_ifrs-full_CashAdvancesAndLoansFromRelatedParties_cc885ad1-12b0-49aa-abd6-0fc4ccbbb736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_3345a11a-6b69-46ac-8513-ee121752d259" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_3345a11a-6b69-46ac-8513-ee121752d259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_71eb54a3-ea5b-46ae-833b-45a4eb688f70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_71eb54a3-ea5b-46ae-833b-45a4eb688f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_8de755be-8b7c-4a5a-b295-216eb1c9e6d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_8de755be-8b7c-4a5a-b295-216eb1c9e6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_9e8a7472-da45-48f0-ba9e-315091aed677" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties_9e8a7472-da45-48f0-ba9e-315091aed677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_e8f650a0-bf54-409a-a43f-edddc6bac720" xlink:href="inpha-20240630.xsd#inpha_NetAmountsReceivablePayableRelatedPartyTransactions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartyTransactionsAbstract_e38a95c6-f691-4a8e-8287-3c4d60012798" xlink:to="loc_inpha_NetAmountsReceivablePayableRelatedPartyTransactions_e8f650a0-bf54-409a-a43f-edddc6bac720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails" xlink:type="simple" xlink:href="inpha-20240630.xsd#IncomelosspershareSummaryofincomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:href="inpha-20240630.xsd#inpha_IncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3fe29ade-2449-4a29-81a2-5c3535ec000c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:to="loc_ifrs-full_ProfitLoss_3fe29ade-2449-4a29-81a2-5c3535ec000c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_b861f19e-6a92-409a-9955-22c1b0da62b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:to="loc_ifrs-full_WeightedAverageShares_b861f19e-6a92-409a-9955-22c1b0da62b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_28373683-4865-41c3-88db-25695c06faa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_28373683-4865-41c3-88db-25695c06faa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_a493fc7f-2785-4d6e-bb3a-8c781ea88e63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:to="loc_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_a493fc7f-2785-4d6e-bb3a-8c781ea88e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_ad5ee893-ebf6-482e-b8d7-a21a22df9402" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_inpha_IncomeLossPerShareAbstract_64e7644d-8a7b-45c8-8504-48216713d6f8" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_ad5ee893-ebf6-482e-b8d7-a21a22df9402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058055586064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Innate Pharma SA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001598599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051643824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 69,990<span></span>
</td>
<td class="nump">&#8364; 70,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Short-term investments</a></td>
<td class="nump">21,809<span></span>
</td>
<td class="nump">21,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade receivables and others</a></td>
<td class="nump">19,795<span></span>
</td>
<td class="nump">55,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">111,594<span></span>
</td>
<td class="nump">148,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property and equipment</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivables', window );">Trade receivables and others - non-current</a></td>
<td class="nump">14,478<span></span>
</td>
<td class="nump">10,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">9,123<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">39,903<span></span>
</td>
<td class="nump">36,181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">151,497<span></span>
</td>
<td class="nump">184,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Payables and others</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesCurrentPortion', window );">Collaboration liabilities &#8211; current portion</a></td>
<td class="nump">10,248<span></span>
</td>
<td class="nump">7,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Financial liabilities &#8211; current portion</a></td>
<td class="nump">8,929<span></span>
</td>
<td class="nump">8,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities', window );">Deferred revenue &#8211; current portion</a></td>
<td class="nump">2,799<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions - current portion</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">38,224<span></span>
</td>
<td class="nump">39,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesNonCurrentPortion', window );">Collaboration liabilities &#8211; non-current portion</a></td>
<td class="nump">41,901<span></span>
</td>
<td class="nump">45,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Financial liabilities &#8211; non-current portion</a></td>
<td class="nump">26,574<span></span>
</td>
<td class="nump">30,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Defined benefit obligations</a></td>
<td class="nump">2,470<span></span>
</td>
<td class="nump">2,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities', window );">Deferred revenue &#8211; non-current portion</a></td>
<td class="nump">4,116<span></span>
</td>
<td class="nump">4,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions - non-current portion</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">9,123<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">84,478<span></span>
</td>
<td class="nump">92,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">4,049<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">386,049<span></span>
</td>
<td class="nump">384,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod', window );">Retained earnings</a></td>
<td class="num">(336,893)<span></span>
</td>
<td class="num">(329,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net income (loss)</a></td>
<td class="num">(24,764)<span></span>
</td>
<td class="num">(7,570)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">28,796<span></span>
</td>
<td class="nump">51,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">&#8364; 151,497<span></span>
</td>
<td class="nump">&#8364; 184,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CollaborationLiabilitiesCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CollaborationLiabilitiesCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CollaborationLiabilitiesNonCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CollaborationLiabilitiesNonCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056063184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Profit (loss) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">&#8364; 8,293<span></span>
</td>
<td class="nump">&#8364; 35,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_GovernmentFinancingForResearchExpenditures', window );">Government financing for research expenditures</a></td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">4,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue and other income</a></td>
<td class="nump">12,345<span></span>
</td>
<td class="nump">40,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(29,076)<span></span>
</td>
<td class="num">(31,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(9,582)<span></span>
</td>
<td class="num">(9,144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">(38,657)<span></span>
</td>
<td class="num">(40,597)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income (loss)</a></td>
<td class="num">(26,313)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">3,613<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(2,064)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income (loss)</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net income (loss) before tax</a></td>
<td class="num">(24,764)<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">&#8364; (24,764)<span></span>
</td>
<td class="nump">&#8364; 1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares, basic (in shares)</a></td>
<td class="nump">80,872,369<span></span>
</td>
<td class="nump">80,319,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares, diluted (in shares)</a></td>
<td class="nump">80,872,369<span></span>
</td>
<td class="nump">80,319,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic income (loss) per share (in EUR per share)</a></td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="nump">&#8364; 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted income (loss) per share (in EUR per share)</a></td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="nump">&#8364; 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_GovernmentFinancingForResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government financing for research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_GovernmentFinancingForResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056089216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Comprehensive Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss) for the period:</a></td>
<td class="num">&#8364; (24,764)<span></span>
</td>
<td class="nump">&#8364; 1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items which will not reclassified in the consolidated statement of income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains and (losses) related to defined benefit obligations</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Elements which will be reclassified in the consolidated statement of income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation gain (loss)</a></td>
<td class="num">(257)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="num">(141)<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="num">&#8364; (24,905)<span></span>
</td>
<td class="nump">&#8364; 1,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052125120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (24,764)<span></span>
</td>
<td class="nump">&#8364; 1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Employee benefits costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Change in provision for charges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(105)<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,705<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Change in fair value of financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(992)<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange (gains) losses on financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(524)<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets', window );">Change in accrued interests on financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment', window );">Disposal of property and equipment (scrapping)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other profit or loss items with no cash effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating cash flow before change in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,561)<span></span>
</td>
<td class="nump">7,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">26,597<span></span>
</td>
<td class="num">(18,530)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash generated from / (used in) operating activities:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,036<span></span>
</td>
<td class="num">(11,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Disposal of other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Purchase of other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities', window );">Disposal of current financial instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash generated from / (used in) investing activities:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">932<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the exercise / subscription of equity instruments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">93<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,420)<span></span>
</td>
<td class="num">(1,594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash generated / (used in) from financing activities:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,327)<span></span>
</td>
<td class="num">(1,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of the exchange rate changes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(257)<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase / (decrease) in cash and cash equivalents:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(12,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the year:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,605<span></span>
</td>
<td class="nump">84,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the six-months period:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,990<span></span>
</td>
<td class="nump">71,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SummaryOfChangesInWorkingCapitalAbstract', window );"><strong>Change in working capital</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">56,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,838<span></span>
</td>
<td class="num">(4,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred revenue - current and non-current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,915)<span></span>
</td>
<td class="num">(11,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Deferred revenue - current and non-current portion, variance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,568)<span></span>
</td>
<td class="num">(3,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables and others (excluding payables related to capital expenditures)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,873)<span></span>
</td>
<td class="num">(16,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables and others (excluding payables related to capital expenditures), variance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,145)<span></span>
</td>
<td class="num">(3,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilities', window );">Collaboration liabilities - current and non-current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,149)<span></span>
</td>
<td class="num">(56,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities', window );">Collaboration liabilities - current and non-current portion, variance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(7,153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ChangeInWorkingCapital', window );">Total change in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,664)<span></span>
</td>
<td class="num">(27,627)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Total change in working capital, variance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 26,597<span></span>
</td>
<td class="num">&#8364; (18,530)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Change in working capital are detailed below</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ChangeInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ChangeInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sales Of Current Financial Instruments, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SummaryOfChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Changes In Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SummaryOfChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051072688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Consolidated Statement of Changes in Shareholders&#8217; Equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Other comprehensive income</div></th>
<th class="th"><div>Net income (loss)</div></th>
<th class="th">
<div>Ordinary Shares </div>
<div>Share capital</div>
</th>
<th class="th">
<div>Preferred Shares </div>
<div>Share capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,212,069<span></span>
</td>
<td class="nump">14,095<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">&#8364; 54,151,000<span></span>
</td>
<td class="nump">&#8364; 4,011,000<span></span>
</td>
<td class="nump">&#8364; 379,637,000<span></span>
</td>
<td class="num">&#8364; (272,213,000)<span></span>
</td>
<td class="nump">&#8364; 819,000<span></span>
</td>
<td class="num">&#8364; (58,103,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains on defined benefit obligations</a></td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation loss</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="nump">1,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">247,000<span></span>
</td>
<td class="nump">1,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Allocation of prior period income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,103,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares', window );">Exercise and subscription of equity instruments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments</a></td>
<td class="nump">348,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Shared-based payment</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at end of period (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,516,622<span></span>
</td>
<td class="nump">14,095<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2023</a></td>
<td class="nump">57,863,000<span></span>
</td>
<td class="nump">4,027,000<span></span>
</td>
<td class="nump">381,371,000<span></span>
</td>
<td class="num">(330,315,000)<span></span>
</td>
<td class="nump">1,064,000<span></span>
</td>
<td class="nump">1,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,860,563<span></span>
</td>
<td class="nump">14,090<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2023</a></td>
<td class="nump">51,901,000<span></span>
</td>
<td class="nump">4,044,000<span></span>
</td>
<td class="nump">384,255,000<span></span>
</td>
<td class="num">(329,323,000)<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
<td class="num">(7,570,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(24,764,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,764,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains on defined benefit obligations</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation loss</a></td>
<td class="num">(257,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="num">(24,905,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,000)<span></span>
</td>
<td class="num">(24,764,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Allocation of prior period income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,570,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares', window );">Exercise and subscription of equity instruments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments</a></td>
<td class="nump">93,000<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">88,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Shared-based payment</a></td>
<td class="nump">1,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Balance at end of period (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,967,407<span></span>
</td>
<td class="nump">14,090<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2024</a></td>
<td class="nump">&#8364; 28,796,000<span></span>
</td>
<td class="nump">&#8364; 4,049,075<span></span>
</td>
<td class="nump">&#8364; 386,049,000<span></span>
</td>
<td class="num">&#8364; (336,893,000)<span></span>
</td>
<td class="nump">&#8364; 354,000<span></span>
</td>
<td class="num">&#8364; (24,764,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExerciseAndSubscriptionOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from exercise and subscription of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExerciseAndSubscriptionOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052237472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and key events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CompanyInformationAbstract', window );"><strong>Company Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock', window );">The Company and key events</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">The Company and key events</span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">The company</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma SA (the &#8220;Company&#8221; and, with its subsidiary, referred to as the &#8220;Group&#8221;), is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET&#174; (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET&#174; multi-specific NK cell engagers to address multiple tumor types. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Since its creation, the Company has suffered losses due to its research and development ("R&amp;D") activities. The first half of 2024 generated a net loss of 24,764 thousand euros. As of June 30, 2024, shareholders' equity amounted to 28,796 thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its drug candidates in development.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company&#8217;s future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its R&amp;D; (ii)&#160;regulatory approval and market acceptance of the Company&#8217;s future drug candidates; (iii)&#160;the timely and successful completion of additional financing; and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments and debt financing.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The activity of the Company is not subject to seasonal effects.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. The subsidiary is consolidated according global integration.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Innate Pharma is based in Marseille, France and listed on Euronext Paris and Nasdaq in the United States., and had 168 full time equivalent employees as of June 30, 2024.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Key events for the six-month period ended June 30, 2024</span><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On March 6, 2024, the Company announced the treatment of the first patient in the Phase 1/2 trial evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET&#174; platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On April 15, 2024, the Company announced the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 agreement, this trial progress triggered a milestone payment of &#8364;4&#160;million fully recognized in revenue during the first quarter of 2024. This amount was received by the Company on May 17, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt">On June 10, 2024, the Executive Board carried out a capital increase of &#8364;5,342 following the creation of 106,844 ordinary shares benefiting the employees of the company, including 68,744 ordinary shares issued free of charge (subscription). The capital increase carried out can be broken as follow : a creation of 68,744 </span></div><div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">free shares with a nominal value of &#8364;0.05 issued free of charge by deduction from the share premium, with a creation of 38,100 ordinary shares with a nominal value of &#8364;0.05 and an issue price of &#8364;2.45 (i.e an increase in share premium of &#8364;91,440).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CompanyInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CompanyInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Company, Significant Agreements And Key Events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051210416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and statement of compliance<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Basis of presentation and statement of compliance</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Basis of presentation and statement of compliance</span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Basis of preparation</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements as of June 30, 2024 and for the six-months period ended June 30, 2024 and 2023 and the related notes (together, the &#8220;interim condensed consolidated financial statements&#8221;) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company&#8217;s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board on September&#160;11, 2024 upon recommendation of the Audit Committee on September&#160;10, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">They have been prepared in accordance with IAS 34, &#8216;Interim Financial Reporting&#8217; as issued by the International Accounting Standard Board (&#8220;IASB&#8221;). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#8217;s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The results of the operations for the six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any year in the future.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Use of judgments and estimates </span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 2.w) of the appendix to the consolidated financial statements as of December 31, 2023 filed with SEC (20-F) on April 2, 2024. As of June 30, 2024, the Company has not identified any other significant estimates and judgments that could have an impact on the consolidated financial statements.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Recently issued accounting standards and interpretations </span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> </span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 1 : Classification of liabilities with covenants; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 7 and IFRS 7 : Supplier finance arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IFRS 16 : Lease liability in a sale and leaseback. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Those amended standards have no impact on the interim condensed consolidated financial statements.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has not opted for the early application of any standards whose application would be mandatory from subsequent financial years.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Translation of transactions denominated in foreign currency </span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foreign currency transactions are translated into the functionnal currency using the following exchange rates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8364;1 equals to</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">USD</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0806</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0866</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1050</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0705</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048921248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Management of financial risks<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory', window );">Management of financial risks</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Management of financial risks</span>The Company did not identify other risks than the ones presented in the consolidated financial statements for the year ended December 31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058057397568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, short-term investments and non-current financial assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Cash, cash equivalents, short-term investments and non-current financial assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Cash, cash equivalents, short-term investments  and non-current financial assets</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">91,799</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">92,456</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash, cash equivalents and financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,149</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,252</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts and mutual funds units (with short-term maturities) held with various banking institutions. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company also holds shares in three mutual funds. The risk profiles of these funds are rated from 1 to 7 by the financial institution that manages and markets these funds (1 being the lowest risk </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">profile).When the maturity of shares in mutual funds is longer than one year, they are classified as non-current financial instruments. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024 and December 31, 2023, the amount of cash, cash equivalents and financials assets denominated in US dollars amounted to &#8364;18,221 thousand and &#8364;20,798 thousand, respectively.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Changes in short-term investments and non-current financial assets for the six months ended June 30, 2023 and 2024 are the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions (2)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">438</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">524</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">21,810</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,350</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">31,647</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">991</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32,160</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,260</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">232</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(288)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,475</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35,119</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">772</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(102)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,790</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,379</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,043</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">130</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(288)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">53,265</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For the six months ended June 30, 2024 , variance of fair value through the consolidated statement of income (loss) is made of &#8364;553 thousand of unrealized gains on non-current financial assets and &#8364;438 thousand of unrealized gains on short-term investments. For the six months ended June 30, 2023, variance of fair value through the consolidated statement of income (loss) was made of &#8364;772 thousand of unrealized gains on non-current financial assets and &#8364;271 thousand of unrealized gains on short-term investments (see </span><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"><a href="#i634ed0333ee247d7904463c2d5fd1df7_148" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">note 1</a><a href="#i634ed0333ee247d7904463c2d5fd1df7_148" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline">5</a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050377472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and others<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade receivables and others</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Trade receivables and others</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,755</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,755</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other tax credits (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">361</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,009</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,692</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VAT refund</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">583</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade account receivables  (4)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">393</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,233</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepayments made to suppliers</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,957</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,374</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,795</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">55,557</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,850</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,800</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">628</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">754</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others - non-current</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,478</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,554</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade receivables and others </span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">66,111</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The Research tax credit (CIR) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of &#8364;29,755 thousand recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the three year period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in January 2024 for an amount of &#8364;16,737 thousand and to the CIR for the 2020 tax year of &#8364;13,018 thousand was collected in July 2024 for the amount of &#8364;12,755 thousand following the offset of the restated amount of &#8364;263 thousand (see note 8). The amount of &#8364;13,850 thousand recognized as a non-current receivable as of June 30, 2024 corresponds to the CIR for the 2023 tax year for the amount of &#8364;9,800 thousand and the amount of CIR calculated for the first half of 2024 for the amount of &#8364;4,050 thousand. Following the loss of SME status since December 31, 2023, the CIR for 2023 and 2024 represent non-current receivables from the French Treasury, which should in principle be offset against corporate income tax due for the following three years or refunded if necessary upon expiry of such a period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of December 31, 2023, this amount mainly included a carry-back tax receivable of &#8364;333 thousand received in February 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(3)  As of June 30,2024, the prepaid expenses includes include an amount of &#8364;879&#160;thousand (1,005 thousand as of December 31, 2023) relating to the guarantee fees in line with the two State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. For each period-end, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(4) As of December 31, 2023, the amount is mainly comprised of invoice of &#8364;15,000&#160;thousand issued in December 2023 following the exercise of the license option by Sanofi. This amount was collected by the Company in January 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value.  No valuation allowance was recognized on trade receivables and others as the credit risk of each debtor was considered as not significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056950576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Intangible assets</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:42.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased licenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,556</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,556</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,651)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,651)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">903</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">903</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">413</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">416</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(294)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(297)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) This amount corresponds to the additional invoice received from Orega Biotech for the rights relating to IPH5201 following the first patient dosed in the Phase 2 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">MATISSE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> clinical trial in June 2023, in accordance to the agreement signed in 2019. This additional invoice is fully amortized as of June 30, 2023 and paid on July 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(2) As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of &#8364;294&#160;thousand. As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#8364;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#8364;651&#160;thousand. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Since their acquisition, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. The Company has reassessed the anticipated residual duration of the Phase 2 trials as of June&#160;30, 2024 and estimated that it would be fully amortized by 2024, which is the same estimation as of December&#160;31, 2023, as a result of the completion of some trials and by modifying the estimated end dates relating to certain cohorts. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The net book values of the monalizumab rights were &#8364;119 thousand and &#8364;416 thousand as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">IPH5201 (Anti-CD39) rights acquired from Orega Biotech</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On January&#160;4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. The upfront payment paid by the Company to Orega Biotech has been recognized as an intangible asset in the consolidated financial statements for the year ended December&#160;31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was recognized as an intangible asset in addition to the initial payment. In June 2019, the Company also paid Orega Biotech &#8364;7.0&#160;million in relation to the anti-CD39 program as consideration following the collaboration and option agreement signed on October&#160;22, 2018 with AstraZeneca regarding IPH5201. Under this agreement, the Company also paid in April and </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">June 2020, respectively &#8364;2.5  and &#8364;0.2&#160;million to Orega Biotech following the first Phase 1 dosing relating to IPH5201. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, Orega Biotech claimed joint ownership of certain patents relating to IPH5201. The Company and Orega Biotech have resolved these claims in an arbitration proceeding, which decision was rendered in December 2021. As a result of this decision, the Company is required to pay a low-teen percentage of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201. Following this arbitration decision, the Company paid in January 2022 an additional amount of &#8364;0.4&#160;million to Orega. The Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancer, of which the Company will be a sponsor. In accordance with the amendment signed on June 1, 2022, the Company was eligible for a milestone payment of $5&#160;million by AstraZeneca, received in August 2022 by the Company. In October 2022, the Company therefore paid an additional &#8364;0.6&#160;million to Orega Biotech. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On June 26, 2023, the Company announced the treatment of the first patient in the Phase 2 MATISSE trial, conducted in collaboration with AstraZeneca and evaluating IPH5201 in early-stage lung cancer. As a consequence, the Company made an additional payment of &#8364;2.0&#160;million to Orega Biotech in July 2023, in accordance with the agreement signed in 2019. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">At the agreement inception, an upfront payment of &#8364;40&#160;million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of &#8364;1.0&#160;million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase II trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of June 30, 2024, according to the uncertainty of these potential future payments, no liability was recognized.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Development costs incurred by the Company are recognized as research and development expenses.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, during 2022 fourth quarter, the Company was informed by the sponsor of the Phase 2 clinical trial evaluating avdoralimab in inflammation in bullous pemphigoid ("BP") indication of its decision to discontinue said trial. Consequently, the Company decided in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022). </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Following that decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of avdoralimab's intangible assets, based on expected future cash flows, as of December 2022, date of the decision. Thus, on decision date to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, avdoralimab rights were fully written down to their net book value, i.e &#8364;41,000&#160;thousand.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051774144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Property and equipment</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,242</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,298</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,542</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">6,423</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">279</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">310</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">79</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(513)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(78)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(591)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(513)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(323)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(670)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(993)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(428)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,437</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,829</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,268</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">5,561</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,958</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,378</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,322</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">5,055</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">267</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(18)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(493)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(845)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(392)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,621</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,134</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,748</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">4,682</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;0.5&#160;million and a lease liability of &#8364;0.7&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050406560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and others<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade payables and others</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Trade payables and others</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Suppliers (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,751</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,561</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax and employee-related payables (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other payables (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,109</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,436</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Trade payables and others (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">17,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables related to capital expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,018</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As of December 31, 2023, tax and employee related payables included a liability accrual of &#8364;1.4&#160;million following the notification received as part of the tax inspection relating to accounting and research tax credits for the 2018 to 2020 financial years. The liability recognized as of June 30, 2024 in connection with notification is &#8364;0.4&#160;million following the payment of &#8364;0.7&#160;million in February 2024 and the offset of &#8364;0.3&#160;million against the 2020 research tax credit receivable initially recognized for &#8364;13.0&#160;million and finally collected in July 2024 for &#8364;12.7&#160;million.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of June 30, 2024 an December 31, 2023, this amount includes mainly the liability related to the payment of the guarantee fees on the two State Guaranteed Loans obtained from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas in 2021 (see note 9).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The book value of trade payables and others is considered to be a reasonable approximation of their fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050378208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt">Financial liabilities</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,432)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,568</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,070)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,630</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage" (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">375</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(83)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,247</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(630)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,634</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">39,893</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,446)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,503</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,353</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(736)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(130)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">345</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(50)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">297</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(89)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">198</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,338</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(602)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,736</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">42,251</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(689)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(916)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">40,658</span></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(1) As a reminder, on January 5, 2022, the Company announced that it had obtained &#8364;28.7&#160;million in non-dilutive financing in the form of two State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale (&#8364;20.0&#160;million) and BNP Paribas (&#8364;8.7&#160;million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees. The amortization of the two loans began in 2024 for a period of four years. The state guarantee fees amounts to &#8364;877&#160;thousand and &#8364;379&#160;thousand for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans respectively. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(2) On July 3, 2017, the Company borrowed from the Bank &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; in order to finance the construction of its future headquarters. This loan amounting to a maximum of &#8364;15,200&#160;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of &#8364;1,300&#160;thousand.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the &#8364;15,200&#160;thousand loan granted, for an amount of &#8364;13,900&#160;thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June&#160;30, 2024, the remaining capital of the loan amounted to &#8364;9,617</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">thousand. The Company authorized collateral over financial &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; instruments amounting to &#8364;15,200&#160;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#8364;4,200&#160;thousand in July 2024, &#8364;5,000&#160;thousand in August 2027 and &#8364;6,000&#160;thousand in August 2031. Following the release of the pledge on the &#8364;4.2m financial instrument that had reached maturity, the company received this amount in July 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(3) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;0.5&#160;million and a lease liability of &#8364;0.7&#160;million.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June&#160;30, 2024:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">From 2nd to 5th year included</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over 5 years</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,167</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,918</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,086</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,222</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,551</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,773</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">211</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,587</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,210</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,414</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">24,245</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,210</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">36,869</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051046096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract', window );"><strong>Disclosure of information about defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee benefit</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Employee benefit</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Defined benefit obligation</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for retirement defined benefit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,118</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,064</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for seniority awards</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">352</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">377</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Defined benefit obligations</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,470</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,441</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Amounts recognized in the statement of financial position are determined as follows (in thousand euros):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,550</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">312</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(27)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(394)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,441</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">166</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,470</span></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Discount rates used by the Company to evaluate retirement benefits were based on iBoxx Corporate AA. It was 3.60% and  3.20% as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div>In addition, the impact of the 2023 pension reform (including the raising of the retirement age) has been recognized as a plan amendment within the meaning of IAS 19, recognized in the income statement and balance sheet with no material impact at June 30, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050406560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShareCapitalAndShareBasePaymentsAbstract', window );"><strong>Share Capital and Share Base Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">Capital</a></td>
<td class="text">Capital<span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Share capital </span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June&#160;30, 2024, the Company&#8217;s share capital amounted to &#8364;4,049,075 divided into (i) 80,967,407 ordinary shares, each with a nominal value of &#8364;0.05; (ii) 6,509 &#8220;2016&#8221; preferred shares, each with a nominal value of &#8364;0.05, and (iii) 7,581 &#8220;2017&#8221; preferred shares, each with a nominal value of &#8364;0.05, respectively, fully paid up. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On October 21, 2019 and December 30, 2019, the retention period for the &#8220;2016 free preferred shares&#8221; has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the achievement of the performance criteria. Holders of &#8220;2016&#8221; preferred shares&#8221; are entitled to vote at our shareholders&#8217; meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The &#8220;2017 preferred shares&#8221; will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends.</span></div>In the six months ended June&#160;30, 2024, a capital increase of &#8364;5,342 occurred as a result of the Executive Board decision on June 10, 2024, subsequent to the creation of 106,844 ordinary shares following the set-up of a company saving plan for the benefit of the Company&#8217;s employees, including 68,744 ordinary shares issued free of charge (top-up). This event led to a net capital increase of &#8364;5,342 and an increase in share premium of &#8364;88,003, broken down as a creation of 38,100 ordinary shares, with a nominal value of &#8364;0.05, for an issue price of &#8364;2.45, (ii) a creation of  68,744 ordinary shares, with a nominal value of &#8364;0.05<span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Treasury shares</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company held 18,575 of its own shares as of June&#160;30, 2024 and December&#160;31, 2023, respectively.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Share based payments </span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants issued as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants void as of  6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants exercised as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants outstanding as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maximum number of shares to be issued  as of  6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price per share (in &#8364;)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Sept. 9, 2011 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">650,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">625,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;May 27, 2013 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2012 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">146,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">133,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2015 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,050,382</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,940</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,045,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,045,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;October 21, 2016 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,486</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">251</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">268,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-2 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,725</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,725</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2017 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">114,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">110,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67,028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Employees 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">327,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">224,375</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Management 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">260,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">110,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2018 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New Members 2017-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 13, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2020-1 &amp; 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79,861</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,885</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,976</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">766,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">681,420</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">710,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">580,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">130,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125,748</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125,748</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,066,600</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">610,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">130,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">138,960</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">138,960</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,371,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,096,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,096,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163,293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163,293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,403,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,337,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,337,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 15, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2024-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 21, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock Options 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Employees 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546,700</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">375,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">171,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Management 2019 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">355,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">147,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 29, 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2011-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.77   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 17, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">237,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.36   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 16, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.65   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 27, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.59   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.05   </span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 20, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.00   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 16, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,740</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 15, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,914,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,239,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,340,434</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,333,995</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,084,922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShareCapitalAndShareBasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShareCapitalAndShareBasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049319216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments recognized in the statement of financial position and related effect on the income statement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial instruments recognized in the statement of financial position and related effect on the income statement</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Financial instruments recognized in the statement of financial position and related effect on the income statement</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">136,422</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,149</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">136,422</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168,363</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,252</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168,363</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IFRS 7 and IFRS 13, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: fair value determined based on quoted prices in active markets for assets or liabilities;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051046096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue and other income</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Revenue and other income</span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Revenue from collaboration and licensing agreements</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca, Sanofi and Takeda :</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:58.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,396</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,728</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which monalizumab agreement (AstraZeneca)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,994</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">9,503</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which 2016 Sanofi agreement</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">18,672</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Takeda agreement </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,553</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoicing of R&amp;D costs (IPH5201 agreement)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">897</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">616</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,293</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,344</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">a)  Revenue recognition related to monalizumab AZ agreements and amendments</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Change in deferred revenue relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,481</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,503)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(283)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,695</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,156</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,994)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,990</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Change in collaboration liabilities relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">63,211</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">283</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,436)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,058</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,677</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,891</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,419)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,149</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">b)  Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to IPH5201 for the six months ended June 30, 2024 and June 30, 2023 are nil. As a reminder, the Company signed on June 1, 2022  an amendment to the initial contract signed in October 2018. This amendment set the terms of the collaboration following AstraZeneca&#8217;s decision to advance IPH5201 to a Phase 2 study. The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial. Under the terms of this agreement, an amount of &#8364;897 thousand was rebilled to AstraZeneca during the first half of 2024 (&#8364;616 thousand during the first half of 2023).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">c)  Revenue related to IPH6401 - Sanofi (2016)</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenue related to IPH6401 under the collaboration and license agreement signed with Sanofi is &#8364;4,000&#160;thousand for the six months ended June 30, 2024, as compared to a revenue of &#8364;2,000&#160;thousand as of June 30, 2023. During the period, the Company announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs. Under the terms of the 2016 research and licensing agreement with Sanofi, dosing of the first patient in the dose expansion part of the trial triggered a milestone payment to the Company of &#8364;4&#160;million recognized as revenue as of June 30, 2024. This amount was received by the Company on May 17, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As a reminder, the Company announced that, in June 2023, the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial evaluating IPH6401/SAR'514 in relapsed or refractory Multiple Myeloma. Under the terms of the licensing agreement signed in 2016, Sanofi made a milestone payment of &#8364;2,000&#160;thousand, fully recognized in revenue as of June 30, 2023. This amount was received by the Company on July 21, 2023. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d)  Revenue related to Sanofi research collaboration and licensing agreement (2022)</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On January 25, 2023, the Company announced the expiration of the waiting period under the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Hart-Scott-Rodino</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> (HSR) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Antitrust Improvements Act</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, under the terms of such agreement, the Company received an upfront payment of &#8364;25,000&#160;thousand in March 2023, including &#8364;18,500&#160;thousand for the exclusive license, &#8364;1,500&#160;thousand for the research work and &#8364;5,000&#160;thousand for the two additional targets options. On December 19, 2023, the Company announced that Sanofi had exercised an option for one of the two targets. This option exercise also resulted in a </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">milestone payment of &#8364;15,000&#160;thousand, including &#8364;13,300 thousand in respect of the exclusive license, which was fully recognized in income as of December 31, 2023, and &#8364;1,700&#160;thousand for the research activities to be carried out by the Company. The Company considers that the license to the B7-H3 technology is a right to use the intellectual property granted exclusively to Sanofi from the effective date of the agreement. As such, all upfront payments relating to the licenses granted have been recognized in the income statement representing an amount of &#8364;31,800&#160;thousand, including &#8364;18.5&#160;million  relating to B7-H3 license and &#8364;13,300&#160;thousand following the option exercised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in deferred revenue relating to the 2022 research collaboration and licensing agreement : </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,328</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,327</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(402)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,925</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(1) The increase in deferred revenue relating to the 2022 research collaboration and licensing agreement with Sanofi between December 31, 2022 and June 30, 2023 mainly comprises (i) an upfront payment of &#8364;5,000&#160;thousand relating to the granting of two options for exclusive licenses on Innate's intellectual property for the research, development, manufacturing and commercialization of NKCEs specifically targeting two preclinical molecules. The Company will recognize the related revenues either at the reporting date or three years after the effective date; as well as (ii) an amount of &#8364;1,500&#160;thousand relating to research activities to perform in collaboration with Sanofi. The Company will recognize the related revenues on a straight-line basis over the duration of the research work to which the Company has agreed. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e)  Schedule of variance of deferred revenue </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,155</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,994)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,990</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,826</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(402)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,424</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,481</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,396)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,915</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,481</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,503)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(283)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,696</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,328</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,481</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,675)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(283)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,024</span></td></tr></table></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Government financing for research expenditures</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company receives grants from the European Commission, French government and state organizations in several different forms:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Research Tax Credits; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"> Investment and operating grants.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024 and 2023, an estimate of the research tax credit amount for the first half period is calculated on the basis of eligible expenses over the period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,050 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,854</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government financing for research expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,052</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,854</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051046096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesExplanatory', window );">Operating expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Operating expenses</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="9" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subcontracting costs(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,585)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15,585)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,857)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15,857)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of supplies and consumable materials</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,485)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(153)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,638)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,410)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(100)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,510)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel expenses other than share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,532)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,470)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(11,002)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,781)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,871)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(11,652)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,175)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(531)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,706)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(905)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(496)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,401)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Personnel expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,707)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(4,001)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(12,708)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,686)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(4,367)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(13,053)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-scientific advisory and consulting(2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(124)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,934)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,058)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(532)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,662)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,194)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leasing and maintenance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(490)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(710)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,200)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(470)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(445)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(915)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Travel expenses and meeting attendance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(272)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(151)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(423)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(180)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(143)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(323)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing, communication and public relations</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(164)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(180)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(34)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(142)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(176)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Scientific advisory and consulting(3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(933)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(933)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(561)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(561)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other purchases and external expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,125)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,135)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,153)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,166)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(643)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(503)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,146)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,044)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(601)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,645)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intellectual property expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(568)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(128)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(696)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(570)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(68)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(638)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income and (expenses), net</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(242)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(956)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(98)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(464)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(562)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(29,076)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,582)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(38,657)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31,453)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,144)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(40,597)</span></td></tr></table></div><div style="text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26pt">The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Personnel expenses other than share-based compensation</span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The line item amounted to &#8364;11,002&#160;thousand and &#8364;11,652&#160;thousand for the six months ended June&#160;30, 2024 and 2023 respectively. The Company had 168 full time equivalent employees as of June&#160;30, 2024, compared to 191 as of June&#160;30, 2023. June 30, 2024, we had 135 employees, in research and development functions, compared to 151 employees as of June 30, 2023. Meanwhile, the administrative staff, totaled 39 people, compared to 45.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Depreciation and amortization</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#8364;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#8364;651&#160;thousand. As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of  &#8364;294&#160;thousand .  (see Note 6).</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Cost of suppliers and consumable materials</span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company&#8217;s drug substance and/or drug product that is manufactured by third-parties, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058057440880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income / (loss)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Net financial income / (loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Net financial income / (loss)</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net financial income (loss) can be analyzed as follows :</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interests on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,269</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in valuation allowance on financial instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,471</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,073</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,613</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,083</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,763)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(642)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized losses on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest on financial liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(300)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(324)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,064)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(966)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,549</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,116</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">For the six months ended June&#160;30, 2024 and 2023, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the US dollar on US dollars denominated cash and cash equivalent and financial assets accounts.   </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax / (expense)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundAbstract', window );"><strong>Income taxes paid (refund) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax / (expense)</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Income tax / (expense)</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Due to the Company&#8217;s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. The main temporary differences are related to the application of the IFRS 15 standard for fiscal years beginning on or after January 1, 2018, finance leases, provisions for pension commitments and tax loss carryforwards.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company did not recognize a current tax expense as of June&#160;30, 2024 regarding a projected tax rate of nil as of December 31, 2024.  As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma SA were &#8364;483,570 thousand with no expiration date (same amount as of December 31, 2023). As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma Inc was &#8364;15,181 thousand or $16,775 thousand (same amount as of December 31, 2023).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048959904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, contingencies and litigation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CommitmentsContingenciesAndLitigationsAbstract', window );"><strong>Commitments, Contingencies And Litigations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments, contingencies and litigation</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Commitments, contingencies and litigation</span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Commitments</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has identified the following changes in off-balance sheet commitments since December 31, 2023:</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt">non-cancellable purchase commitments as of June&#160;30, 2024 for a total of &#8364;6,612 thousand with various CMOs. These commitments are comprised of non-cancellable purchase orders placed during the first half of 2024 with contract manufacturing organizations (CMOs) for the supply of various services in relation with preclinical work for an amount of &#8364;3,020&#160;thousand and clinical work for an amount of &#8364;3,592&#160;thousand. The execution and billing of these services has not yet started at the date of this report.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt">financial commitments with Soci&#233;t&#233; G&#233;n&#233;rale in connection with the Company&#8217;s subscription of a loan in order to finance the construction of its future headquarters. As security for the loan, the Company pledged collateral in the form of financial instruments held at Soci&#233;t&#233; G&#233;n&#233;rale amounting to &#8364;15.2 million. The security interest on the pledged financial instruments will be released in accordance with the following schedule: &#8364;4,200 thousand in July 2024, &#8364;5,000 thousand in August 2027 and &#8364;6,000 thousand in August 2031. At the date of this report, the first investment of &#8364;4,200 thousand had matured and the Company obtained its restitution in July 2024 for a total amount of &#8364;4,427 thousand, including interest. As of June 30, 2024, the remaining capital of this loan amounted to &#8364;9,617 thousand.  Furthermore, under the loan, Innate is subject to a covenant that its total cash, cash equivalents and current and non-current financial assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. The Company was in compliance with this covenant as of December 31, 2023.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Contingencies and litigations</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company is exposed to contingent liabilities happening in the ordinary course of its activities. Each pre-litigation, known litigation or procedure in course the Company is involved in is analyzed at each closing date after consultation of legal counsel. There is no acknowledged litigation as of June&#160;30, 2024.</span></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Provisions</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Provisions amounted to &#8364;669 thousand and &#8364;774 thousand as of June&#160;30, 2024 and December 31, 2023, respectively. As of June&#160;30, 2024, they mainly consist of provision for charges amounting &#8364;586 thousand relating to the employer contribution in respect of the grants of employee equity instruments. In accordance with French </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">social legislation, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan.</span></div>As a reminder, on March 16, 2022, the Company received a notice of a tax inspection by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2018 financial years 2020. On February 13, 2024, the Company was informed of the tax authorities conclusions regarding the tax inspection. A definitive amount of &#8364;1,367&#160;thousand was determined and classified as short-term tax liabilities as of December 31, 2023. During the first half of 2024, the Company made a payment of &#8364;693&#160;thousand.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CommitmentsContingenciesAndLitigationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments, Contingencies And Litigations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CommitmentsContingenciesAndLitigationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party transactions</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Related party transactions</span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline">Members of the Executive Board and Other Executive Members </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel and other short-term employee benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,713</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,386</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Extra pension benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">519</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">408</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advisory fees </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">318</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Executive Board Members and other Executive Members compensation</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,253</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,123</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Personnel and other short-term employee benefits correspond to amounts included in personnel expenses for the six-month periods ended June&#160;30, 2024 and 2023 respectively.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">As of June 30, 2024, the Company has also recognized expenses totaling &#8364;184 thousand with companies in which a mandate is held by the identified related parties.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Members of the Supervisory Board</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company recognized a provision of  &#8364;163 thousand for attendance fees (jetons de presence) relating to the six months ended June&#160;30, 2024. This amount includes the compensation for the Chairman of the Supervisory Board.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Related parties</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Novo Nordisk A/S is a shareholder, Supervisory Board member and is related to the Company by three licensing agreements related to the drug candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. As of June&#160;30, 2024, the Company has no liability to Novo Nordisk A/S.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab and IPH5201). The payments between the two companies as well as the liabilities and receivables as of June&#160;30, 2024 are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,2024</span></td></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets/Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collection (AstraZeneca to the Company) / Receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,657</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">394</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (the Company to AstraZeneca) / Liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,342)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,926) </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,685)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,532)</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The business relationships between the Company and its subsidiary are governed by intra-group and commercial agreements, concluded at market standard conditions on an arm&#8217;s length basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047849984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income / (loss) per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeLossPerShareAbstract', window );"><strong>Income (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Income / (loss) per share</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Income / (loss) per share </span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Basic income / (loss) per share</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,764)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,718</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,872,369</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,319,897</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Basic income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.31)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td></tr></table></div><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt">Diluted income / (loss) per share</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;In thousands of euro, except for data share</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss) for the period</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,764)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,718</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,872,369</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,319,897</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustment for share instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,026,389</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,461,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diluted income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.31)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050378208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the reporting date<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events after the reporting date</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Events after the reporting date</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">On July 25, 2024, the Company received from Takeda a notice of termination of the Exclusive License agreement signed on March 31, 2023. This termination will be effective upon expiry of a 90-day notice period, i.e. on October 24, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056263712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and statement of compliance (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Basis of preparation</span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements as of June 30, 2024 and for the six-months period ended June 30, 2024 and 2023 and the related notes (together, the &#8220;interim condensed consolidated financial statements&#8221;) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company&#8217;s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board on September&#160;11, 2024 upon recommendation of the Audit Committee on September&#160;10, 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">They have been prepared in accordance with IAS 34, &#8216;Interim Financial Reporting&#8217; as issued by the International Accounting Standard Board (&#8220;IASB&#8221;). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#8217;s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The results of the operations for the six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any year in the future.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of judgments and estimates</a></td>
<td class="text"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Use of judgments and estimates </span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 2.w) of the appendix to the consolidated financial statements as of December 31, 2023 filed with SEC (20-F) on April 2, 2024. As of June 30, 2024, the Company has not identified any other significant estimates and judgments that could have an impact on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Recently issued accounting standards and interpretations</a></td>
<td class="text"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Recently issued accounting standards and interpretations </span><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"> </span><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 1 : Classification of liabilities with covenants; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IAS 7 and IFRS 7 : Supplier finance arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt">Amendments to IFRS 16 : Lease liability in a sale and leaseback. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Those amended standards have no impact on the interim condensed consolidated financial statements.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The Company has not opted for the early application of any standards whose application would be mandatory from subsequent financial years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Translation of transactions denominated in foreign currency</a></td>
<td class="text"><span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt">Translation of transactions denominated in foreign currency </span><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foreign currency transactions are translated into the functionnal currency using the following exchange rates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8364;1 equals to</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">USD</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0806</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0866</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1050</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0705</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048502992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and statement of compliance (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Disclosure of effect of changes in foreign exchange rates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Foreign currency transactions are translated into the functionnal currency using the following exchange rates:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8364;1 equals to</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Average rate</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Closing rate</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">USD</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0806</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0866</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1050</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0813</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.0705</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058057441664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, short-term investments and non-current financial assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock', window );">Disclosure of cash, cash equivalents and financial assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cash, cash equivalents and short-term investments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">91,799</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">92,456</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash, cash equivalents and financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,149</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,252</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory', window );">Disclosure of reconciliation of changes in short-term investments and non-current financial assets</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Changes in short-term investments and non-current financial assets for the six months ended June 30, 2023 and 2024 are the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions (2)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">438</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">524</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">21,810</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">553</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,350</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">31,647</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">991</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">212</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">524</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">32,160</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variance of fair value through the consolidated statement of income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Variation of accrued interests</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign currency effect</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,260</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">271</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">232</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(288)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,475</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">35,119</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">772</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(102)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,790</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,379</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,043</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">130</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(288)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">53,265</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date. </span></div>(2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash, cash equivalents and financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050378208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and others (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock', window );">Disclosure of trade receivables and others</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,755</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,755</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other tax credits (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">361</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,009</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,692</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VAT refund</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">583</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,037</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade account receivables  (4)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">393</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,233</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepayments made to suppliers</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,957</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,374</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">19,795</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">55,557</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13,850</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,800</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses (3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">628</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">754</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Receivables and others - non-current</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,478</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,554</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade receivables and others </span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">66,111</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) The Research tax credit (CIR) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of &#8364;29,755 thousand recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the three year period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in January 2024 for an amount of &#8364;16,737 thousand and to the CIR for the 2020 tax year of &#8364;13,018 thousand was collected in July 2024 for the amount of &#8364;12,755 thousand following the offset of the restated amount of &#8364;263 thousand (see note 8). The amount of &#8364;13,850 thousand recognized as a non-current receivable as of June 30, 2024 corresponds to the CIR for the 2023 tax year for the amount of &#8364;9,800 thousand and the amount of CIR calculated for the first half of 2024 for the amount of &#8364;4,050 thousand. Following the loss of SME status since December 31, 2023, the CIR for 2023 and 2024 represent non-current receivables from the French Treasury, which should in principle be offset against corporate income tax due for the following three years or refunded if necessary upon expiry of such a period. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of December 31, 2023, this amount mainly included a carry-back tax receivable of &#8364;333 thousand received in February 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(3)  As of June 30,2024, the prepaid expenses includes include an amount of &#8364;879&#160;thousand (1,005 thousand as of December 31, 2023) relating to the guarantee fees in line with the two State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. For each period-end, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(4) As of December 31, 2023, the amount is mainly comprised of invoice of &#8364;15,000&#160;thousand issued in December 2023 following the exercise of the license option by Sanofi. This amount was collected by the Company in January 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade receivables and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Disclosure of detailed information about intangible assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:42.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Purchased licenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,556</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,556</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,651)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,651)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">903</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">903</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">413</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">416</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional considerations</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortizations(2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(294)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(297)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">119</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) This amount corresponds to the additional invoice received from Orega Biotech for the rights relating to IPH5201 following the first patient dosed in the Phase 2 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">MATISSE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> clinical trial in June 2023, in accordance to the agreement signed in 2019. This additional invoice is fully amortized as of June 30, 2023 and paid on July 2023. </span></div>(2) As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of &#8364;294&#160;thousand. As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#8364;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#8364;651&#160;thousand.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Disclosure of detailed information about property, plant and equipment</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,242</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,298</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,542</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">6,423</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">279</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">310</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">79</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(513)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(78)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(591)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(513)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(323)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(670)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(993)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(428)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,437</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,829</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,268</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">5,561</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lands and buildings</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Laboratory equipment and other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In progress</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Of which right of use assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">January 1, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,958</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,378</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,322</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">5,055</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">267</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">285</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Disposals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(18)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(18)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(352)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(493)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(845)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(392)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,621</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,134</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,748</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">4,682</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;0.5&#160;million and a lease liability of &#8364;0.7&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051046096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and others (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfTradePayablesAndOthersTextBlock', window );">Disclosure of trade payables and others</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Suppliers (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,751</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,561</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax and employee-related payables (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,013</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other payables (2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,109</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,436</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Trade payables and others (excluding payables related to capital expenditures)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">17,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payables related to capital expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payables and others</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">17,018</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(1) As of December 31, 2023, tax and employee related payables included a liability accrual of &#8364;1.4&#160;million following the notification received as part of the tax inspection relating to accounting and research tax credits for the 2018 to 2020 financial years. The liability recognized as of June 30, 2024 in connection with notification is &#8364;0.4&#160;million following the payment of &#8364;0.7&#160;million in February 2024 and the offset of &#8364;0.3&#160;million against the 2020 research tax credit receivable initially recognized for &#8364;13.0&#160;million and finally collected in July 2024 for &#8364;12.7&#160;million.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%">(2) As of June 30, 2024 an December 31, 2023, this amount includes mainly the liability related to the payment of the guarantee fees on the two State Guaranteed Loans obtained from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas in 2021 (see note 9).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfTradePayablesAndOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade payables and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfTradePayablesAndOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056055808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock', window );">Disclosure of financial liabilities per maturity</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,432)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,568</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,070)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,630</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage" (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">375</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(121)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(47)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(83)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(17)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">87</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(28)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,247</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(630)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,634</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">39,893</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">49</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(4,446)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,503</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from borrowing</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds from lease liabilities and other non cash effects</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Repayments of borrowings/leases liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exchange rate variation (non cash)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,700</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,353</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(736)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(130)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">487</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">345</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(50)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">297</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(89)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">198</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">33</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">27</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">154</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(27)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">127</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11,338</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(602)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,736</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">42,251</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(689)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(916)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">40,658</span></td></tr></table></div><div style="margin-bottom:7pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(1) As a reminder, on January 5, 2022, the Company announced that it had obtained &#8364;28.7&#160;million in non-dilutive financing in the form of two State Guaranteed Loans from Soci&#233;t&#233; G&#233;n&#233;rale (&#8364;20.0&#160;million) and BNP Paribas (&#8364;8.7&#160;million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees. The amortization of the two loans began in 2024 for a period of four years. The state guarantee fees amounts to &#8364;877&#160;thousand and &#8364;379&#160;thousand for Soci&#233;t&#233; G&#233;n&#233;rale and BNP Paribas loans respectively. </span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(2) On July 3, 2017, the Company borrowed from the Bank &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; in order to finance the construction of its future headquarters. This loan amounting to a maximum of &#8364;15,200&#160;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of &#8364;1,300&#160;thousand.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the &#8364;15,200&#160;thousand loan granted, for an amount of &#8364;13,900&#160;thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June&#160;30, 2024, the remaining capital of the loan amounted to &#8364;9,617</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">thousand. The Company authorized collateral over financial &#8220;Soci&#233;t&#233; G&#233;n&#233;rale&#8221; instruments amounting to &#8364;15,200&#160;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#8364;4,200&#160;thousand in July 2024, &#8364;5,000&#160;thousand in August 2027 and &#8364;6,000&#160;thousand in August 2031. Following the release of the pledge on the &#8364;4.2m financial instrument that had reached maturity, the company received this amount in July 2024.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end.</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">(3) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#8364;0.5&#160;million and a lease liability of &#8364;0.7&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Disclosure of maturity analysis for non-derivative financial liabilities</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June&#160;30, 2024:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">From 2nd to 5th year included</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over 5 years</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,167</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,918</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,086</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loan BNP Paribas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,222</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,551</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,773</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">State guaranteed loans - accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Building "Le Virage"</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">254</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Premises Innate Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">211</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Laboratory equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities &#8211; Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lease liabilities - Printers</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">71</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Borrowing &#8211; Building </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,545</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,587</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,210</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">9,414</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">24,245</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,210</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">36,869</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities per maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051213568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract', window );"><strong>Disclosure of information about defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory', window );">Disclosure of defined benefit plans</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Defined benefit obligation</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for retirement defined benefit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,118</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,064</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allowance for seniority awards</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">352</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">377</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Defined benefit obligations</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,470</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,441</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory', window );">Disclosure of net defined benefit liability (asset)</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Amounts recognized in the statement of financial position are determined as follows (in thousand euros):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,550</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">312</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(27)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(394)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,441</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Service cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">166</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (benefits and contributions paid by the employer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(22)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Actuarial (gain) / loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(116)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,470</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047736544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShareCapitalAndShareBasePaymentsAbstract', window );"><strong>Share Capital and Share Base Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Disclosure of number and weighted average exercise prices of other equity instruments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Types</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants issued as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants void as of  6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants exercised as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of warrants outstanding as of 6/30/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maximum number of shares to be issued  as of  6/30/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise price per share (in &#8364;)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Sept. 9, 2011 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">650,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">625,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;May 27, 2013 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2012 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">146,050</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">133,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSAAR 2015 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,050,382</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,940</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,045,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,045,722</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;October 21, 2016 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">156,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,486</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">251</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">172</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,063</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">268,190</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 21, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP  Management 2016-2 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 30, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Management 2016-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">250,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,725</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,725</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2017-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,400</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 3,2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2017 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">114,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">110,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67,028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,559</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Employees 2018-1 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">327,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">224,375</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">103,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 20, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Perf Management 2018-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">260,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">110,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 14, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Employees 2018 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">90,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 29, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New Members 2017-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 3, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2019-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,376</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 13, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2020-1 &amp; 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79,861</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,885</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61,976</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">766,650</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">681,420</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">85,230</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">August 5, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">710,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">580,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">130,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125,748</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">125,748</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Employees 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,066,600</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">290,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">775,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP Management 2021-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">610,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">130,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">138,960</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">138,960</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">October 3, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Bonus 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">128,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,371,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">275,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,096,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,096,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 12, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">550,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 14, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163,293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">163,293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Employees 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,403,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,337,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,337,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 21, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA Perf Management 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">750,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">February 15, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA New members 2024-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 10, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGA "Plan Epargne Entreprise" 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">68,744</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 21, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock Options 2020-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">102,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Employees 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">546,700</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">375,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">171,550</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">November 4, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AGAP 2019 Management 2019 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">355,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">207,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">147,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 29, 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2011-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">200,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.77   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 17, 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">237,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.36   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 16, 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">150,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8.65   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">April 27, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.59   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">July 1, 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2015-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14.05   </span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">September 20, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">37,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11.00   </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 16, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2022-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">40,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31,740</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.31</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December 15, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BSA 2023-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">38,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">12,914,414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,239,985</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,340,434</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,333,995</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">7,084,922</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShareCapitalAndShareBasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShareCapitalAndShareBasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049443472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of detailed information about financial instruments</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10,350</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,273</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,809</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">69,990</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">136,422</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,149</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">34,273</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">136,422</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,574</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,929</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,873</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">51,376</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Book value on the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value through profit and loss (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized Cost (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-current financial assets </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,796</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade receivables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">66,111</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21,851</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">70,605</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168,363</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">102,252</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">66,111</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">168,363</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;non-current portion</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30,957</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial liabilities&#8212;current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,936</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade payables and others</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,018</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total financial liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,911</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049366896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Disclosure of revenue from collaboration and licensing agreements</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca, Sanofi and Takeda :</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:58.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7,396</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">34,728</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which monalizumab agreement (AstraZeneca)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,994</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">9,503</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which 2016 Sanofi agreement</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">199</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">18,672</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">203</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">of which Takeda agreement </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4,553</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Invoicing of R&amp;D costs (IPH5201 agreement)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">897</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">616</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Revenue from collaboration and licensing agreements</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">8,293</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">35,344</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Disclosure of change in deferred revenue and collaboration liabilities</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%">Change in deferred revenue relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,481</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,503)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(283)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,695</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,156</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue for the six months ended June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,994)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer from / (to)  collaboration liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,990</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Change in collaboration liabilities relating to monalizumab agreement:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">63,211</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">283</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,436)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">56,058</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,677</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,891</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,419)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">52,149</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in deferred revenue relating to the 2022 research collaboration and licensing agreement : </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions (1)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,328</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,327</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deductions</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(402)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,925</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>(1) The increase in deferred revenue relating to the 2022 research collaboration and licensing agreement with Sanofi between December 31, 2022 and June 30, 2023 mainly comprises (i) an upfront payment of &#8364;5,000&#160;thousand relating to the granting of two options for exclusive licenses on Innate's intellectual property for the research, development, manufacturing and commercialization of NKCEs specifically targeting two preclinical molecules. The Company will recognize the related revenues either at the reporting date or three years after the effective date; as well as (ii) an amount of &#8364;1,500&#160;thousand relating to research activities to perform in collaboration with Sanofi. The Company will recognize the related revenues on a straight-line basis over the duration of the research work to which the Company has agreed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock', window );">Disclosure of variance of deferred revenue</a></td>
<td class="text">Schedule of variance of deferred revenue <div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,155</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2,994)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,990</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,826</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(402)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,424</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10,481</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,396)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">6,915</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Recognition in P&amp;L</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Proceeds</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transfer from / (to) collaboration liabilities</span></td><td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Monalizumab</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14,481</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9,503)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(283)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,696</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sanofi (2022) services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(172)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,328</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">14,481</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,675)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(283)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">11,024</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock', window );">Disclosure of government financing for research expenditures</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research tax credit</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,050 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4,854</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Grant</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government financing for research expenditures</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,052</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,854</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of government financing for research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of variance of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050849808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Disclosure of expenses by nature</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt">Operating expenses</span><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="9" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">R&amp;D</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">G&amp;A</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Subcontracting costs(1)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,585)</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15,585)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15,857)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(15,857)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of supplies and consumable materials</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,485)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(153)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,638)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,410)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(100)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,510)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel expenses other than share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,532)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,470)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(11,002)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,781)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,871)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(11,652)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,175)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(531)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,706)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(905)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(496)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,401)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Personnel expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,707)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(4,001)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(12,708)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(8,686)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(4,367)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(13,053)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-scientific advisory and consulting(2)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(124)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,934)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,058)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(532)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,662)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,194)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leasing and maintenance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(490)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(710)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,200)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(470)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(445)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(915)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Travel expenses and meeting attendance</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(272)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(151)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(423)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(180)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(143)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(323)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing, communication and public relations</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(16)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(164)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(180)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(34)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(142)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(176)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Scientific advisory and consulting(3)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(933)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(933)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(561)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(561)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other purchases and external expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,125)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,135)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,153)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,166)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(643)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(503)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,146)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,044)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(601)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,645)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Intellectual property expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(568)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(128)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(696)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(570)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(68)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(638)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income and (expenses), net</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(242)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(714)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(956)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(98)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(464)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(562)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(29,076)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,582)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(38,657)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(31,453)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(9,144)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(40,597)</span></td></tr></table></div><div style="text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26pt">The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt">Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058055571952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income / (loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock', window );">Disclosure of net financial income (loss)</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Net financial income (loss) can be analyzed as follows :</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interests on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,269</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in valuation allowance on financial instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,471</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange gains</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">873</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,073</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial income</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,613</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,083</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign exchange losses</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1,763)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(642)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized losses on financial assets</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Interest on financial liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(300)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(324)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial expenses</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2,064)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(966)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net financial income (loss)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,549</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,116</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of net financial income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051944896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock', window );">Disclosure of key management personnel compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Personnel and other short-term employee benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,713</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,386</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Extra pension benefits</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">519</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">408</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advisory fees </span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">318</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Executive Board Members and other Executive Members compensation</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,253</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,123</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Disclosure of transactions between related parties</a></td>
<td class="text">The payments between the two companies as well as the liabilities and receivables as of June&#160;30, 2024 are as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30,2024</span></td></tr><tr><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands of euro)</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets/Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collection (AstraZeneca to the Company) / Receivables</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,657</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">394</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments (the Company to AstraZeneca) / Liabilities</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,342)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3,926) </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1,685)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(3,532)</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure for key management personnel compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056102368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income / (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeLossPerShareAbstract', window );"><strong>Income (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of income (loss) per share</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss)</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,764)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,718</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,872,369</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,319,897</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Basic income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.31)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%">Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;In thousands of euro, except for data share</span></td><td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net income/(loss) for the period</span></td><td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(24,764)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,718</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares in circulation</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,872,369</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,319,897</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustment for share instruments</span></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5,026,389</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,461,439</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diluted income/(loss) per share (&#8364; per share)</span></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(0.31)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">0.02</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052077712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and key events - The company (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>employee </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CompanyInformationAbstract', window );"><strong>Company Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (24,764)<span></span>
</td>
<td class="nump">&#8364; 1,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">&#8364; 28,796<span></span>
</td>
<td class="nump">&#8364; 57,863<span></span>
</td>
<td class="nump">&#8364; 51,901<span></span>
</td>
<td class="nump">&#8364; 54,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfWhollyOwnedSubsidiaries', window );">Number of subsidiaries | subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CompanyInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CompanyInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Wholly Owned Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049142032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 10, 2024 </div>
<div>EUR (&#8364;) </div>
<div>share </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share</a></td>
<td class="nump">106,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 93,000<span></span>
</td>
<td class="nump">&#8364; 348,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share</a></td>
<td class="nump">38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_FreeSharesMember', window );">Free Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShareIssuedPricePerShare', window );">Share issued, price per share (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_ExerciseOfShareWarrantsMember', window );">Exercise Of Share Warrants | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share</a></td>
<td class="nump">68,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_DefinitiveAcquisitionOfFreeSharesMember', window );">Definitive Acquisition Of Free Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=inpha_IssuedCapitalFreeOfSubscriptionMember', window );">Issued capital free of subscription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share</a></td>
<td class="nump">68,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 88,003<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium | Free Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments | &#8364;</a></td>
<td class="nump">&#8364; 91,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember', window );">Agreement with Sanofi, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived', window );">Milestone payment received | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,000,000<span></span>
</td>
<td class="nump">&#8364; 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExerciseAndSubscriptionOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from exercise and subscription of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExerciseAndSubscriptionOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_FreeSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=inpha_FreeSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_ExerciseOfShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_ExerciseOfShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_DefinitiveAcquisitionOfFreeSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=inpha_DefinitiveAcquisitionOfFreeSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TypeOfExerciseAndSubscriptionOfSharesAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=inpha_IssuedCapitalFreeOfSubscriptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=inpha_IssuedCapitalFreeOfSubscriptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056247488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate (&#8364;1 equals to USD)</a></td>
<td class="nump">1.0813<span></span>
</td>
<td class="nump">1.0806<span></span>
</td>
<td class="nump">1.0813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate (&#8364;1 equals to USD)</a></td>
<td class="nump">1.0705<span></span>
</td>
<td class="nump">1.0866<span></span>
</td>
<td class="nump">1.1050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051038544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 69,990<span></span>
</td>
<td class="nump">&#8364; 70,605<span></span>
</td>
<td class="nump">&#8364; 71,414<span></span>
</td>
<td class="nump">&#8364; 84,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Short-term investments</a></td>
<td class="nump">21,809<span></span>
</td>
<td class="nump">21,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">91,799<span></span>
</td>
<td class="nump">92,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
<td class="nump">&#8364; 35,790<span></span>
</td>
<td class="nump">&#8364; 35,119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalCashCashEquivalentsAndFinancialAssets', window );">Cash, cash equivalents and financial assets</a></td>
<td class="nump">&#8364; 102,149<span></span>
</td>
<td class="nump">&#8364; 102,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CashCashEquivalentsAndShortTermInvestmentsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Short-Term Investments, Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CashCashEquivalentsAndShortTermInvestmentsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalCashCashEquivalentsAndFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, cash equivalents and financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalCashCashEquivalentsAndFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050981408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>Rate </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfFinancialInstrumentsHeld', window );">Number of SICAV held (in units/shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalCashCashEquivalentsAndFinancialAssets', window );">Cash, cash equivalents and financial assets</a></td>
<td class="nump">&#8364; 102,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 102,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss', window );">Non-current financial assets, variation of fair value through the consolidated statement of income (loss)</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">&#8364; 772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss', window );">Short-term investments, variation of fair value through the consolidated statement of income (loss)</a></td>
<td class="nump">&#8364; 438<span></span>
</td>
<td class="nump">&#8364; 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_SICAVAndMutualFundsMember', window );">SICAV and mutual funds | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RiskProfileRate', window );">Risk profile rate | Rate</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_SICAVAndMutualFundsMember', window );">SICAV and mutual funds | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RiskProfileRate', window );">Risk profile rate | Rate</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember', window );">Cash, cash equivalents, and financial assets denominated in US dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalCashCashEquivalentsAndFinancialAssets', window );">Cash, cash equivalents and financial assets</a></td>
<td class="nump">&#8364; 18,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on non-current financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfFinancialInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financial Instruments Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfFinancialInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RiskProfileRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Profile Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RiskProfileRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on current financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalCashCashEquivalentsAndFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, cash equivalents and financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalCashCashEquivalentsAndFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_SICAVAndMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_SICAVAndMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049103264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestments1Abstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Beginning balance, current investments</a></td>
<td class="nump">&#8364; 21,851<span></span>
</td>
<td class="nump">&#8364; 17,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsAcquisitions', window );">Short-term investments, acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DecreaseThroughDerecognitionShortTermInvestment', window );">Short-term investments, disposals</a></td>
<td class="num">(1,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss', window );">Short-term investments, variation of fair value through the consolidated statement of income (loss)</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss', window );">Short-term investments, variation of accrued interest</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsForeignCurrencyEffect', window );">Short-term investments, foreign currency effect</a></td>
<td class="nump">524<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Ending balance, current investments</a></td>
<td class="nump">21,810<span></span>
</td>
<td class="nump">17,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentFinancialAssetsAbstract', window );"><strong>Non-current financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Beginning balance, non-current financial assets</a></td>
<td class="nump">9,796<span></span>
</td>
<td class="nump">35,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentFinancialAssetsAcquisitions', window );">Non-current financial assets, acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets', window );">Non-current financial assets, disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss', window );">Non-current financial assets, variation of fair value through the consolidated statement of income (loss)</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss', window );">Non-current financial assets, variation of accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect', window );">Non-current financial assets, foreign currency effect</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Ending balance, non-current financial assets</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">35,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets', window );">Beginning balance, total</a></td>
<td class="nump">31,647<span></span>
</td>
<td class="nump">52,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalAcquisitions', window );">Total, acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets', window );">Total, disposals</a></td>
<td class="num">(1,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss', window );">Total, variation of fair value through the consolidated statement of income (loss)</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss', window );">Total variance of accrued interest</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TotalForeignCurrencyEffect', window );">Total, foreign currency effect</a></td>
<td class="nump">524<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets', window );">Ending balance, total</a></td>
<td class="nump">&#8364; 32,160<span></span>
</td>
<td class="nump">&#8364; 53,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in non-current financial assets resulting from derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DecreaseThroughDerecognitionShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in current investment resulting from derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DecreaseThroughDerecognitionShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in short-term investment and non-current financial assets resulting from derecognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest for current financial assets that are not at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentFinancialAssetsAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in non-current financial assets resulting from origination or purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentFinancialAssetsAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentFinancialAssetsForeignCurrencyEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentFinancialAssetsForeignCurrencyEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on non-current financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestments1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Investments1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestments1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestmentsAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in current investment resulting from origination or purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestmentsAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term investments and non-current financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestmentsForeignCurrencyEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in current financial assets resulting from foreign exchange and other movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestmentsForeignCurrencyEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on current financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in short-term investments and non-current financial assets resulting from origination or purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalForeignCurrencyEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalForeignCurrencyEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Short-Term Investments And Non-Current Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048030896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables and others - Disclosure of trade receivables and others (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>loan</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>loan_agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 97<span></span>
</td>
<td class="nump">&#8364; 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ResearchTaxCreditReceivableCurrent', window );">Research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,755<span></span>
</td>
<td class="nump">29,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OtherCurrentTaxCreditsReceivables', window );">Other tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT refund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade account receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">15,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments made to suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TradeAndOtherCurrentReceivablesExcludingRebates', window );">Receivables and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,795<span></span>
</td>
<td class="nump">55,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentResearchTaxCredit', window );">Research tax credit, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,850<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCurrentPrepaidExpenses', window );">Prepaid expenses, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates', window );">Receivables and others - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,478<span></span>
</td>
<td class="nump">10,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TradeAndOtherReceivablesExcludingRebates', window );">Trade receivables and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">66,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2019And2020Maturity', window );">Income from research tax credit 2019 and 2020, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2019', window );">Income from research tax credit 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2020', window );">Income from research tax credit 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020', window );">Offset of restated income from research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2023', window );">Income from research tax credit 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCreditHalfYear2024', window );">Income from research tax credit HY 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CarryBackTaxReceivable', window );">Carry-back tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofiMember', window );">Agreement With Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade account receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember', window );">State guaranteed loan, Societe Generale and BNP Paribas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingNumberOfLoanAgreement', window );">Borrowing, number of loan agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingMaturity', window );">Borrowing, maturity</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember', window );">Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 879<span></span>
</td>
<td class="nump">&#8364; 1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingNumberOfLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Number Of Loan Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingNumberOfLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CarryBackTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carry-Back Tax Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CarryBackTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2019</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2019And2020Maturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2019 And 2020, Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2019And2020Maturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2020</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2023</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCreditHalfYear2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income related to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCreditHalfYear2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Current Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCurrentResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCurrentResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offset Of Restated Income From Research Tax Credit 2020</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_OtherCurrentTaxCreditsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other current tax credits receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_OtherCurrentTaxCreditsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ResearchTaxCreditReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Tax Credit, Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ResearchTaxCreditReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TradeAndOtherCurrentReceivablesExcludingRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade and other current receivables excluding rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TradeAndOtherCurrentReceivablesExcludingRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade and other non current receivables excluding rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TradeAndOtherReceivablesExcludingRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>he amount of trade receivables and other receivables, excluding rebates related to capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TradeAndOtherReceivablesExcludingRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047960832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Disclosure of detailed information about intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">&#8364; 416<span></span>
</td>
<td class="nump">&#8364; 1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="num">(297)<span></span>
</td>
<td class="num">(2,651)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember', window );">Monalizumab agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember', window );">Agreement with Orega Biotech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Purchased licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(2,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortizations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill at end of period</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052537648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Additional information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 119,000<span></span>
</td>
<td class="nump">&#8364; 903,000<span></span>
</td>
<td class="nump">&#8364; 1,556,000<span></span>
</td>
<td class="nump">&#8364; 416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,503,000<span></span>
</td>
<td class="nump">&#8364; 40,658,000<span></span>
</td>
<td class="nump">42,251,000<span></span>
</td>
<td class="nump">39,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember', window );">2014 Monalizumab (NKG2A) agreement with Novo Nordisk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember', window );">IPH5201 (anti-CD39) rights acquired from Orega Biotech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additional considerations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000,000<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="nump">&#8364; 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
<td class="nump">&#8364; 2,500,000<span></span>
</td>
<td class="nump">&#8364; 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH5201WithAstraZenecaMember', window );">Agreement related to IPH5201 with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived', window );">Milestone payment received | $</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember', window );">IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_PaymentsForMilestone', window );">Payments for milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_PaymentsForMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents payments for milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_PaymentsForMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH5201WithAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH5201WithAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052428112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment - Disclosure of detailed information about property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,322<span></span>
</td>
<td class="nump">&#8364; 8,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(845)<span></span>
</td>
<td class="num">(993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,748<span></span>
</td>
<td class="nump">7,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,055<span></span>
</td>
<td class="nump">6,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,682<span></span>
</td>
<td class="nump">5,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Write-off of right-of-use asset</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseInFinancialLiabilities', window );">Write-off of lease liability</a></td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Lands and buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">4,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=inpha_LaboratoryEquipmentAndOtherMember', window );">Laboratory equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,134<span></span>
</td>
<td class="nump">3,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">In progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment including right-of-use assets at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseInFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseInFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=inpha_LaboratoryEquipmentAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=inpha_LaboratoryEquipmentAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048113744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade payables and others - Disclosure of trade payables and others (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfTradePayablesAndOthersLineItems', window );"><strong>Disclosure of trade payables and others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Suppliers (excluding payables related to capital expenditures)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Tax and employee-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other current payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures', window );">Trade payables and others (excluding payables related to capital expenditures)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CurrentPayablesRelatedToCapitalExpenditures', window );">Payables related to capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Payables and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Current payables on social security and taxes other than income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Payment on social security and taxes other than income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020', window );">Offset against income from research tax credit 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2020', window );">Income from research tax credit 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfStateGuaranteedLoans', window );">Number of state guaranteed loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfTradePayablesAndOthersLineItems', window );"><strong>Disclosure of trade payables and others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit2020Receivable', window );">Income from research tax credit 2020, receivable</a></td>
<td class="nump">&#8364; 12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CurrentPayablesRelatedToCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables related to capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CurrentPayablesRelatedToCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current Trade payables and others, excluding payables related to capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfTradePayablesAndOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade payables and others [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfTradePayablesAndOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2020</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit2020Receivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income From Research Tax Credit 2020, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit2020Receivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfStateGuaranteedLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of State Guaranteed Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfStateGuaranteedLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_OffsetAgainstIncomeFromResearchTaxCredit2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offset Against Income From Research Tax Credit 2020</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_OffsetAgainstIncomeFromResearchTaxCredit2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment On Social Security And Taxes Other Than Income Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058043275456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of financial liabilities per maturity (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 15, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
<th class="th">
<div>Jan. 05, 2022 </div>
<div>EUR (&#8364;) </div>
<div>loan_agreement</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 03, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>loan_agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,503<span></span>
</td>
<td class="nump">&#8364; 40,658<span></span>
</td>
<td class="nump">&#8364; 39,893<span></span>
</td>
<td class="nump">&#8364; 42,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="num">(689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,446)<span></span>
</td>
<td class="num">(916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Write-off of right-of-use asset</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember', window );">Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember', window );">State guaranteed loan, Societe Generale and BNP Paribas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingNumberOfLoanAgreement', window );">Borrowing, number of loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingMaturity', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingGracePeriod', window );">Borrowing, grace period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingMaturity', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfLoans', window );">Number of loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1) | Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1) | Guarantees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 17,568<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,432)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,630<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember', window );">State guaranteed loans - accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage"</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseInFinancialLiabilities', window );">Write-off of lease liability</a></td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember', window );">Lease liabilities &#8211; Premises Innate Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember', window );">Lease liabilities &#8211; Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember', window );">Lease liabilities &#8211; Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember', window );">Lease liabilities - Printers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember', window );">Borrowing &#8211; Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember', window );">Borrowing &#8211; Building (2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,634<span></span>
</td>
<td class="nump">10,736<span></span>
</td>
<td class="nump">&#8364; 10,247<span></span>
</td>
<td class="nump">&#8364; 11,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Proceeds from lease liabilities and other non cash effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities', window );">Repayments of borrowings/leases liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(630)<span></span>
</td>
<td class="num">(602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities', window );">Exchange rate variation (non cash)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember', window );">State guaranteed loan, Societe Generale and BNP Paribas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingNumberOfLoanAgreement', window );">Borrowing, number of loan agreement | loan_agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingMaturity', window );">Borrowing, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingMaturityExtensionPeriodOption', window );">Borrowing, maturity, extension period option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingPercentageOfStateGuaranteedLoan', window );">Borrowing, percentage of state-guaranteed loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember', window );">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_LoanAgreementMaximumBorrowingCapacity', window );">Loan agreement, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_LoanAgreementCollateral', window );">Loan agreement, collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_BorrowingsMaturityPeriod', window );">Borrowings, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024', window );">Security interest on pledge of financial instruments will be released in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027', window );">Security interest on pledge of financial instruments will be released in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031', window );">Security interest on pledge of financial instruments will be released in 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember', window );">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale | Other disposals of assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased', window );">Security interest on pledge of financial instruments released</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember', window );">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale | Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingGracePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Grace Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingGracePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingMaturityExtensionPeriodOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Maturity, Extension Period Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingMaturityExtensionPeriodOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingNumberOfLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Number Of Loan Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingNumberOfLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingPercentageOfStateGuaranteedLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing, Percentage Of State-Guaranteed Loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingPercentageOfStateGuaranteedLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_BorrowingsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_BorrowingsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseInFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseInFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_LoanAgreementCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of collateral in connection with the loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_LoanAgreementCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_LoanAgreementMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_LoanAgreementMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Loans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of security interest on the pledge of financial instruments will be released in 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of security interest on the pledge of financial instruments will be released in 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of security interest on pledge of financial instruments will be released in 2027.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of Security interest on pledge of financial instruments will be released in 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=ifrs-full_GuaranteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementSocieteGeneraleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=inpha_PGELoanAgreementBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_OtherDisposalsOfAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_OtherDisposalsOfAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058042564992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">&#8364; 36,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">9,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember', window );">From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">24,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">3,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">18,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1) | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">5,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1) | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">12,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember', window );">State guaranteed loan Soci&#233;t&#233; G&#233;n&#233;rale (1) | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">7,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1) | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1) | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">5,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember', window );">State guaranteed loan BNP Paribas (1) | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember', window );">State guaranteed loans - accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember', window );">State guaranteed loans - accrued interest | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember', window );">State guaranteed loans - accrued interest | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember', window );">State guaranteed loans - accrued interest | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage"</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage" | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage" | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember', window );">Lease liabilities &#8211; Building "Le Virage" | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember', window );">Lease liabilities &#8211; Premises Innate Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember', window );">Lease liabilities &#8211; Premises Innate Inc. | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember', window );">Lease liabilities &#8211; Premises Innate Inc. | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember', window );">Lease liabilities &#8211; Premises Innate Inc. | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember', window );">Lease liabilities &#8211; Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember', window );">Lease liabilities &#8211; Laboratory equipment | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember', window );">Lease liabilities &#8211; Laboratory equipment | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember', window );">Lease liabilities &#8211; Laboratory equipment | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember', window );">Lease liabilities &#8211; Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember', window );">Lease liabilities &#8211; Vehicles | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember', window );">Lease liabilities &#8211; Vehicles | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember', window );">Lease liabilities &#8211; Vehicles | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember', window );">Lease liabilities - Printers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember', window );">Lease liabilities - Printers | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember', window );">Lease liabilities - Printers | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember', window );">Lease liabilities - Printers | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember', window );">Borrowing &#8211; Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember', window );">Borrowing &#8211; Equipment | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember', window );">Borrowing &#8211; Equipment | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember', window );">Borrowing &#8211; Equipment | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember', window );">Borrowing &#8211; Building (2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">10,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember', window );">Borrowing &#8211; Building (2) | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">1,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember', window );">Borrowing &#8211; Building (2) | From 2nd to 5th year included</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">5,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember', window );">Borrowing &#8211; Building (2) | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankBorrowingsUndiscountedCashFlows', window );">Undiscounted cash flows</a></td>
<td class="nump">&#8364; 3,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankBorrowingsUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankBorrowingsUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementSocieteGeneraleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementBNPParibasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_PGELoanAgreementAccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsBuildingLeVirageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsInnateIncPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LeaseFinancingObligationsPrintersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049540208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee benefit - Disclosure of defined benefit plans (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligations</a></td>
<td class="nump">&#8364; 2,470<span></span>
</td>
<td class="nump">&#8364; 2,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember', window );">Allowance for retirement defined benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligations</a></td>
<td class="nump">2,118<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_SeniorityAwardsMember', window );">Allowance for seniority awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligations</a></td>
<td class="nump">&#8364; 352<span></span>
</td>
<td class="nump">&#8364; 377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_SeniorityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_SeniorityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052230896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee benefit - Disclosure of net defined benefit liability (asset) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset) at beginning of period</a></td>
<td class="nump">&#8364; 2,441<span></span>
</td>
<td class="nump">&#8364; 2,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Service cost</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Payments (benefits and contributions paid by the employer)</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial (gain) / loss</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net defined benefit liability (asset) at end of period</a></td>
<td class="nump">&#8364; 2,470<span></span>
</td>
<td class="nump">&#8364; 2,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051724848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee benefit - Additional information (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember', window );">Allowance for retirement defined benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Actuarial assumption of discount rates</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis=inpha_RetirementDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049247760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital - Additional Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">&#8364; 28,796,000<span></span>
</td>
<td class="nump">&#8364; 57,863,000<span></span>
</td>
<td class="nump">&#8364; 51,901,000<span></span>
</td>
<td class="nump">&#8364; 54,151,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments</a></td>
<td class="nump">&#8364; 93,000<span></span>
</td>
<td class="nump">348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates', window );">Number of own shares (in shares)</a></td>
<td class="nump">18,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member', window );">BSAAR 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares', window );">Number of equity instruments converted in ordinary shares (in shares)</a></td>
<td class="nump">38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ShareIssuedPricePerShare', window );">Share issued, price per share (in EUR per share)</a></td>
<td class="nump">&#8364; 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanMember', window );">Company saving plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares', window );">Exercise and subscription of equity instruments (in shares)</a></td>
<td class="nump">106,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanEmployerTopUpMember', window );">Company saving plan, employer top-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares', window );">Exercise and subscription of equity instruments (in shares)</a></td>
<td class="nump">68,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="nump">80,967,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share)</a></td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_The2016FreePreferredSharesMember', window );">The 2016 free preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share)</a></td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued (in shares)</a></td>
<td class="nump">6,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_The2017FreePreferredSharesMember', window );">The 2017 free preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share (in EUR per share)</a></td>
<td class="nump">&#8364; 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued (in shares)</a></td>
<td class="nump">7,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">&#8364; 4,049,075<span></span>
</td>
<td class="nump">4,027,000<span></span>
</td>
<td class="nump">&#8364; 4,044,000<span></span>
</td>
<td class="nump">&#8364; 4,011,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments</a></td>
<td class="nump">&#8364; 5,342<span></span>
</td>
<td class="nump">&#8364; 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued (in shares)</a></td>
<td class="nump">80,967,407<span></span>
</td>
<td class="nump">80,516,622<span></span>
</td>
<td class="nump">80,860,563<span></span>
</td>
<td class="nump">80,212,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares', window );">Exercise and subscription of equity instruments (in shares)</a></td>
<td class="nump">106,844<span></span>
</td>
<td class="nump">304,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of changes in the share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">&#8364; 386,049,000<span></span>
</td>
<td class="nump">&#8364; 381,371,000<span></span>
</td>
<td class="nump">&#8364; 384,255,000<span></span>
</td>
<td class="nump">&#8364; 379,637,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExerciseAndSubscriptionOfEquityInstruments', window );">Exercise and subscription of equity instruments</a></td>
<td class="nump">&#8364; 88,003<span></span>
</td>
<td class="nump">&#8364; 333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExerciseAndSubscriptionOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from exercise and subscription of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExerciseAndSubscriptionOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Equity Instruments Converted In Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanEmployerTopUpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_CompanySavingPlanEmployerTopUpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_The2016FreePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=inpha_The2016FreePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=inpha_The2017FreePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=inpha_The2017FreePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047061968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 10, 2024 </div>
<div>share</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares) | share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">12,914,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">3,239,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">3,340,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">6,333,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">7,084,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2011Member', window );">BSAAR 2011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member', window );">BSAAR 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">146,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">133,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2015Member', window );">BSAAR 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">1,050,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,045,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,045,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20161Member', window );">AGAP Management 2016-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20161Member', window );">AGAP Employees 2016-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">2,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">268,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20161Member', window );">AGA Management 2016-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20162Member', window );">AGAP Management 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20162Member', window );">AGA Management 2016-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20171Member', window );">AGAP Employees 2017-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20171Member', window );">AGAP Management 2017-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2017Member', window );">AGA Employees 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">114,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">110,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20181Member', window );">AGA Bonus 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">67,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">66,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfEmployees20181Member', window );">AGAP Perf Employees 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">327,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">224,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">103,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfManagement20181Member', window );">AGAP Perf Management 2018-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2018Member', window );">AGA Employees 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">90,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">85,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20171Member', window );">AGA New Members 2017-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20191Member', window );">AGA Bonus 2019-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">57,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">57,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus202012Member', window );">AGA Bonus 2020-1 &amp; 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">79,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">17,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">61,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20201Member', window );">AGAP Employees 2020-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">766,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">681,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">85,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20201Member', window );">AGAP Management 2020-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20211Member', window );">AGA Bonus 2021-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">125,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">125,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20211Member', window );">AGAP Employees 2021-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">1,066,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">290,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">775,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">775,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20211Member', window );">AGAP Management 2021-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2022Member', window );">AGA "Plan Epargne Entreprise" 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">138,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">138,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20221Member', window );">AGA Bonus 2022-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">128,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">128,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20221Member', window );">AGA Perf Employees 2022-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">1,371,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,096,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,096,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20221Member', window );">AGA Perf Management 2022-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2023Member', window );">AGA "Plan Epargne Entreprise" 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">163,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">163,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20231Member', window );">AGA New members 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20231Member', window );">AGA Perf Employees 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">1,403,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">66,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,337,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">1,337,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20231Member', window );">AGA Perf Management 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20241Member', window );">AGA New members 2024-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2024Member', window );">AGA "Plan Epargne Entreprise" 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">68,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">68,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_StockOptions20201Member', window );">Stock Options 2020-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Employees2019Member', window );">AGAP 2019 Employees 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">546,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">375,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">171,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Management2019Member', window );">AGAP 2019 Management 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">207,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">147,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20112Member', window );">BSA 2011-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2013Member', window );">BSA 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">237,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2014Member', window );">BSA 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20151Member', window );">BSA 2015-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20152Member', window );">BSA 2015-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 14.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2017Member', window );">BSA 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20221Member', window );">BSA 2022-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">31,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">8,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">8,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20231Member', window );">BSA 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of free shares granted (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of other equity instruments forfeited in share-based payment arrangement (in shares)</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement (in shares)</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSAAR2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20161Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20161Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20162Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAManagement20162Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20171Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20171Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20171Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20171Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfEmployees20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfEmployees20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfManagement20181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPPerfManagement20181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAEmployees2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20171Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20171Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20191Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20191Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus202012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus202012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20211Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20211Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20211Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPEmployees20211Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20211Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPManagement20211Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20221Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGABonus20221Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20221Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20221Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20221Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20221Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfEmployees20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPerfManagement20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGANewMembers20241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAPlanEpargneEntreprise2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_StockOptions20201Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_StockOptions20201Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Employees2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Employees2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Management2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_AGAP2019Management2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20151Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20151Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20152Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20152Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20221Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20221Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=inpha_BSA20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058044979632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 136,422<span></span>
</td>
<td class="nump">&#8364; 168,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, fair value</a></td>
<td class="nump">136,422<span></span>
</td>
<td class="nump">168,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">51,376<span></span>
</td>
<td class="nump">56,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue', window );">Financial liabilities, fair value</a></td>
<td class="nump">51,376<span></span>
</td>
<td class="nump">56,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">51,376<span></span>
</td>
<td class="nump">56,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesNonCurrentPortionMember', window );">Financial liabilities&#8212;non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">26,574<span></span>
</td>
<td class="nump">30,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue', window );">Financial liabilities, fair value</a></td>
<td class="nump">26,574<span></span>
</td>
<td class="nump">30,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesNonCurrentPortionMember', window );">Financial liabilities&#8212;non-current portion | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesNonCurrentPortionMember', window );">Financial liabilities&#8212;non-current portion | Financial liabilities at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">26,574<span></span>
</td>
<td class="nump">30,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesCurrentPortionMember', window );">Financial liabilities&#8212;current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">8,929<span></span>
</td>
<td class="nump">8,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue', window );">Financial liabilities, fair value</a></td>
<td class="nump">8,929<span></span>
</td>
<td class="nump">8,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesCurrentPortionMember', window );">Financial liabilities&#8212;current portion | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesCurrentPortionMember', window );">Financial liabilities&#8212;current portion | Financial liabilities at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">8,929<span></span>
</td>
<td class="nump">8,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_TradePayablesAndOthersMember', window );">Trade payables and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue', window );">Financial liabilities, fair value</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_TradePayablesAndOthersMember', window );">Trade payables and others | Financial liabilities at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_TradePayablesAndOthersMember', window );">Trade payables and others | Financial liabilities at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_FinancialLiabilitiesTradePayablesAndOthers', window );">Financial liabilities</a></td>
<td class="nump">15,873<span></span>
</td>
<td class="nump">17,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">102,149<span></span>
</td>
<td class="nump">102,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">66,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_NonCurrentFinancialAssetsMember', window );">Non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, fair value</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_NonCurrentFinancialAssetsMember', window );">Non-current financial assets | Financial assets at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_NonCurrentFinancialAssetsMember', window );">Non-current financial assets | Financial assets at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_TradeReceivablesAndOthersMember', window );">Trade receivables and others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">66,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, fair value</a></td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">66,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_TradeReceivablesAndOthersMember', window );">Trade receivables and others | Financial assets at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_TradeReceivablesAndOthersMember', window );">Trade receivables and others | Financial assets at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">34,273<span></span>
</td>
<td class="nump">66,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">21,809<span></span>
</td>
<td class="nump">21,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, fair value</a></td>
<td class="nump">21,809<span></span>
</td>
<td class="nump">21,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsShortTermInvestmentsMember', window );">Short-term investments | Financial assets at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">21,809<span></span>
</td>
<td class="nump">21,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsShortTermInvestmentsMember', window );">Short-term investments | Financial assets at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsCashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">69,990<span></span>
</td>
<td class="nump">70,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, fair value</a></td>
<td class="nump">69,990<span></span>
</td>
<td class="nump">70,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Financial assets at fair value through profit or loss, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">69,990<span></span>
</td>
<td class="nump">70,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Financial assets at amortised cost, category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_FinancialLiabilitiesTradePayablesAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities, trade payables and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_FinancialLiabilitiesTradePayablesAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities, trade payables and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesNonCurrentPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesNonCurrentPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesCurrentPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_FinancialLiabilitiesCurrentPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_TradePayablesAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_TradePayablesAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_NonCurrentFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_NonCurrentFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_TradeReceivablesAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_TradeReceivablesAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=inpha_FinancialAssetsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051567664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">&#8364; 8,293<span></span>
</td>
<td class="nump">&#8364; 35,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_CollaborationAndLicensingAgreementsMember', window );">Proceeds from collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">7,396<span></span>
</td>
<td class="nump">34,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember', window );">Monalizumab agreement (AstraZeneca)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">9,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember', window );">Agreement with Sanofi, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH62Member', window );">Agreement with Sanofi, 2022 - ANKET IPH62</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">18,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH67Member', window );">Agreement With Sanofi 2022 - ANKET IPH67</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithTakedaMember', window );">Takeda agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5201AndAdvoralimabAgreementsMember', window );">Invoicing of R&amp;D costs (IPH5201 agreement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="nump">&#8364; 897<span></span>
</td>
<td class="nump">&#8364; 616<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_CollaborationAndLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_CollaborationAndLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH62Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH62Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH67Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithSanofi2022ANKETIPH67Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_IPH5201AndAdvoralimabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_IPH5201AndAdvoralimabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049284736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>target_option</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>preclinicalMolecule</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember', window );">Agreement with Sanofi, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions', window );">Payments for target options</a></td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfTargetOptions', window );">Number of target options | target_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch', window );">Payments for research work</a></td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember', window );">Agreements with Sanofi for NK Cell engages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions', window );">Payments for target options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfTargetOptions', window );">Number of target options | target_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfPreclinicalMolecules', window );">Number of preclinical molecules | preclinicalMolecule</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum', window );">Revenues from contract liabilities, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch', window );">Payments for research work</a></td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DeferredRevenueRollForwardAbstract', window );"><strong>Deferred Revenue, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,481<span></span>
</td>
<td class="nump">&#8364; 14,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue for the six months period/Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,396)<span></span>
</td>
<td class="num">(9,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,915<span></span>
</td>
<td class="nump">11,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,481<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,915<span></span>
</td>
<td class="nump">11,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Deferred revenue | 2015 monalizumab agreement, with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DeferredRevenueRollForwardAbstract', window );"><strong>Deferred Revenue, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue for the six months period/Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
<td class="num">(9,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TransferToFromCollaborationLiabilities', window );">Transfer from / (to) collaboration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Deferred revenue | Agreement with Sanofi, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DeferredRevenueRollForwardAbstract', window );"><strong>Deferred Revenue, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestone', window );">Increase in deferred revenue/Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue for the six months period/Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,925<span></span>
</td>
<td class="nump">6,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,925<span></span>
</td>
<td class="nump">6,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_CollaborationLiabilitiesMember', window );">Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DeferredRevenueRollForwardAbstract', window );"><strong>Deferred Revenue, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,677<span></span>
</td>
<td class="nump">63,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,149<span></span>
</td>
<td class="nump">56,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilitiesRollForwardAbstract', window );"><strong>Collaboration Liabilities, Roll Forward [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,677<span></span>
</td>
<td class="nump">63,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DecreaseThroughDeductionsContractLiabilities', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,419)<span></span>
</td>
<td class="num">(7,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 52,149<span></span>
</td>
<td class="nump">&#8364; 56,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CollaborationLiabilitiesRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Liabilities, Roll Forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CollaborationLiabilitiesRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DecreaseThroughDeductionsContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DecreaseThroughDeductionsContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DeferredRevenueRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Roll Forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DeferredRevenueRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in contract liabilities resulting from additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfPreclinicalMolecules">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Preclinical Molecules</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfPreclinicalMolecules</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfTargetOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Target Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfTargetOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Advance Payment Received, Research</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Advance Payment Received, Target Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues From Contract Liabilities, Recognition Period, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TransferToFromCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from transfer to collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TransferToFromCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_A2015AstraZenecaMonalizumabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_A2015AstraZenecaMonalizumabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_CollaborationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=inpha_CollaborationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058045982192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Additional information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 19, 2023 </div>
<div>option</div>
</th>
<th class="th">
<div>Jan. 25, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>target_option</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,293<span></span>
</td>
<td class="nump">&#8364; 35,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_A2018AstraZenecaIPH5201AgreementMember', window );">IPH5201 agreement, with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ExternalCostsRelatedToTheClinicalTrial', window );">External costs related to the clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember', window );">Agreement with Sanofi, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from collaboration and licensing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember', window );">Agreement with Sanofi, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived', window );">Advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses', window );">Advance received - exclusive license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch', window );">Payments for research work</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions', window );">Payments for target options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfTargetOptions', window );">Number of target options | target_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember', window );">Agreements with Sanofi for NK Cell engages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived', window );">Advance received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses', window );">Advance received - exclusive license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">&#8364; 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch', window );">Payments for research work</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,700<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions', window );">Payments for target options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfTargetOptions', window );">Number of target options | target_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfOptionsExcercisedForLicenses', window );">Number of options excercised for licenses | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfExclusiveOptionsGranted', window );">Number of exclusive options granted | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised', window );">Milestone payment received - option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithGenzymeForNKCellEngagesMember', window );">Agreement with Sanofi, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised', window );">Milestone payment received - option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ExternalCostsRelatedToTheClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>External Costs Related To The Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ExternalCostsRelatedToTheClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfExclusiveOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Exclusive Options Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfExclusiveOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfOptionsExcercisedForLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Options Excercised For Licenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfOptionsExcercisedForLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfTargetOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Target Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfTargetOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of advance received by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for licenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Advance Payment Received, Research</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Advance Payment Received, Target Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_A2018AstraZenecaIPH5201AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_A2018AstraZenecaIPH5201AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementRelatedToIPH6101WithSanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_SanofiResearchCollaborationAndLicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithSanofiForNKCellEngagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithGenzymeForNKCellEngagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementsWithGenzymeForNKCellEngagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052138832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Disclosure of variance of deferred revenue (Details) - Deferred revenue - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="nump">&#8364; 10,481<span></span>
</td>
<td class="nump">&#8364; 14,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognition in P&amp;L</a></td>
<td class="num">(3,396)<span></span>
</td>
<td class="num">(9,675)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseThroughUpfrontPaymentContractLiabilities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TransferFromToCollaborationLiabilities', window );">Transfer from / (to) collaboration liabilities</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="nump">6,915<span></span>
</td>
<td class="nump">11,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Monalizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="nump">5,155<span></span>
</td>
<td class="nump">14,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognition in P&amp;L</a></td>
<td class="num">(2,994)<span></span>
</td>
<td class="num">(9,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseThroughUpfrontPaymentContractLiabilities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TransferFromToCollaborationLiabilities', window );">Transfer from / (to) collaboration liabilities</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">4,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Sanofi (2022) option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognition in P&amp;L</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseThroughUpfrontPaymentContractLiabilities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TransferFromToCollaborationLiabilities', window );">Transfer from / (to) collaboration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember', window );">Sanofi (2022) services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at beginning of period</a></td>
<td class="nump">2,826<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Recognition in P&amp;L</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncreaseThroughUpfrontPaymentContractLiabilities', window );">Proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TransferFromToCollaborationLiabilities', window );">Transfer from / (to) collaboration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities at end of period</a></td>
<td class="nump">&#8364; 2,424<span></span>
</td>
<td class="nump">&#8364; 1,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncreaseThroughUpfrontPaymentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in contract liabilities resulting from upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncreaseThroughUpfrontPaymentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TransferFromToCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from transfer to collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TransferFromToCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=inpha_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=inpha_MonalizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=inpha_MonalizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=inpha_SanofiOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=inpha_SanofiOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=inpha_SanofiServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=inpha_SanofiServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058049366896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and other income - Disclosure of government financing for research expenditures (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeFromResearchTaxCredit', window );">Research tax credit</a></td>
<td class="nump">&#8364; 4,050<span></span>
</td>
<td class="nump">&#8364; 4,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Grant</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_GovernmentFinancingForResearchExpenditures', window );">Government financing for research expenditures</a></td>
<td class="nump">&#8364; 4,052<span></span>
</td>
<td class="nump">&#8364; 4,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_GovernmentFinancingForResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government financing for research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_GovernmentFinancingForResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeFromResearchTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income related to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeFromResearchTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058050668192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Disclosure of expenses by nature (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SubcontractingCosts', window );">Subcontracting costs</a></td>
<td class="num">&#8364; (15,585)<span></span>
</td>
<td class="num">&#8364; (15,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Cost of supplies and consumable materials</a></td>
<td class="num">(1,638)<span></span>
</td>
<td class="num">(1,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Personnel expenses other than share-based compensation</a></td>
<td class="num">(11,002)<span></span>
</td>
<td class="num">(11,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="num">(1,706)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">(12,708)<span></span>
</td>
<td class="num">(13,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonScientificAdvisoryAndConsulting', window );">Non-scientific advisory and consulting</a></td>
<td class="num">(2,058)<span></span>
</td>
<td class="num">(2,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_LeasingAndMaintenance', window );">Leasing and maintenance</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel expenses and meeting attendance</a></td>
<td class="num">(423)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing, communication and public relations</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ScientificAdvisoryAndConsulting', window );">Scientific advisory and consulting</a></td>
<td class="num">(933)<span></span>
</td>
<td class="num">(561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OtherPurchasesAndExternalExpenses', window );">Other purchases and external expenses</a></td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="num">(1,146)<span></span>
</td>
<td class="num">(3,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IntellectualPropertyExpenses', window );">Intellectual property expenses</a></td>
<td class="num">(696)<span></span>
</td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other income and (expenses), net</a></td>
<td class="num">(956)<span></span>
</td>
<td class="num">(562)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">(38,657)<span></span>
</td>
<td class="num">(40,597)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=inpha_ResearchAndDevelopmentMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SubcontractingCosts', window );">Subcontracting costs</a></td>
<td class="num">(15,585)<span></span>
</td>
<td class="num">(15,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Cost of supplies and consumable materials</a></td>
<td class="num">(1,485)<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Personnel expenses other than share-based compensation</a></td>
<td class="num">(7,532)<span></span>
</td>
<td class="num">(7,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="num">(1,175)<span></span>
</td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">(8,707)<span></span>
</td>
<td class="num">(8,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonScientificAdvisoryAndConsulting', window );">Non-scientific advisory and consulting</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_LeasingAndMaintenance', window );">Leasing and maintenance</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel expenses and meeting attendance</a></td>
<td class="num">(272)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing, communication and public relations</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ScientificAdvisoryAndConsulting', window );">Scientific advisory and consulting</a></td>
<td class="num">(933)<span></span>
</td>
<td class="num">(561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OtherPurchasesAndExternalExpenses', window );">Other purchases and external expenses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="num">(643)<span></span>
</td>
<td class="num">(3,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IntellectualPropertyExpenses', window );">Intellectual property expenses</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other income and (expenses), net</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">(29,076)<span></span>
</td>
<td class="num">(31,453)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">G&amp;A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SubcontractingCosts', window );">Subcontracting costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Cost of supplies and consumable materials</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Personnel expenses other than share-based compensation</a></td>
<td class="num">(3,470)<span></span>
</td>
<td class="num">(3,871)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation</a></td>
<td class="num">(531)<span></span>
</td>
<td class="num">(496)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel expenses</a></td>
<td class="num">(4,001)<span></span>
</td>
<td class="num">(4,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonScientificAdvisoryAndConsulting', window );">Non-scientific advisory and consulting</a></td>
<td class="num">(1,934)<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_LeasingAndMaintenance', window );">Leasing and maintenance</a></td>
<td class="num">(710)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TravelExpense', window );">Travel expenses and meeting attendance</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing, communication and public relations</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ScientificAdvisoryAndConsulting', window );">Scientific advisory and consulting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_OtherPurchasesAndExternalExpenses', window );">Other purchases and external expenses</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="num">(503)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IntellectualPropertyExpenses', window );">Intellectual property expenses</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other income and (expenses), net</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">&#8364; (9,582)<span></span>
</td>
<td class="num">&#8364; (9,144)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IntellectualPropertyExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intellectual property expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IntellectualPropertyExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_LeasingAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of leasing and maintenance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_LeasingAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonScientificAdvisoryAndConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-scientific advisory and consulting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonScientificAdvisoryAndConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_OtherPurchasesAndExternalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other purchases and external expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_OtherPurchasesAndExternalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ScientificAdvisoryAndConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Scientific advisory and consulting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ScientificAdvisoryAndConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SubcontractingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subcontracting costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SubcontractingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=inpha_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=inpha_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052029872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expenses - Additional information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure of operating expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Personnel expenses other than share-based compensation</a></td>
<td class="nump">&#8364; 11,002<span></span>
</td>
<td class="nump">&#8364; 11,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 297<span></span>
</td>
<td class="nump">&#8364; 2,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TypeOfEmployeeAxis=inpha_ResearchAndDevelopmentMember', window );">R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure of operating expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_TypeOfEmployeeAxis=inpha_AdministrationMember', window );">Administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure of operating expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember', window );">Agreement with Orega Biotech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure of operating expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember', window );">Monalizumab agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfOperatingExpensesLineItems', window );"><strong>Disclosure of operating expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">&#8364; 294<span></span>
</td>
<td class="nump">&#8364; 651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfOperatingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of operating expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfOperatingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TypeOfEmployeeAxis=inpha_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TypeOfEmployeeAxis=inpha_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_TypeOfEmployeeAxis=inpha_AdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_TypeOfEmployeeAxis=inpha_AdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_AgreementWithOregaBiotechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_MonalizumabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058062639216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net financial income / (loss) - Disclosure of net financial income (loss) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_InterestsAndGainsOnFinancialAssets', window );">Interests on financial assets</a></td>
<td class="nump">&#8364; 1,269<span></span>
</td>
<td class="nump">&#8364; 965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ChangeInValuationAllowanceOfFinancialInstruments', window );">Change in valuation allowance on financial instruments</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">3,613<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="num">(1,763)<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_UnrealizedLossesOnFinancialAssets', window );">Unrealized losses on financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest on financial liabilities</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(2,064)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income (loss)</a></td>
<td class="nump">&#8364; 1,549<span></span>
</td>
<td class="nump">&#8364; 2,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ChangeInValuationAllowanceOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ChangeInValuationAllowanceOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_InterestsAndGainsOnFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interests and gains on financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_InterestsAndGainsOnFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_UnrealizedLossesOnFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unrealized losses on financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_UnrealizedLossesOnFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058056288816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax / (expense) (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_UnusedTaxLossesWithNoExpirationDate', window );">Unused tax losses with no expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 483,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_UnusedTaxLossesSubjectToExpiration', window );">Unused tax losses subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,181<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
<td class="nump">&#8364; 15,181<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_DisclosureOfIncomeTaxLineItems', window );"><strong>Disclosure Of Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_DisclosureOfIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_DisclosureOfIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_UnusedTaxLossesSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_UnusedTaxLossesSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_UnusedTaxLossesWithNoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses with no expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_UnusedTaxLossesWithNoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058052299680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, contingencies and litigation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2017</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCancellableOffBalanceSheetPurchasedCommitments', window );">Non-cancellable off-balance sheet purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="nump">&#8364; 774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Tax and employee-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">7,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_PaymentOfTaxesOtherThanIncomeTax', window );">Payment of short term tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=ifrs-full_TaxContingentLiabilityMember', window );">Tax contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Tax and employee-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_GrantsOfEmployeeEquityInstrumentsMember', window );">Grants of employee equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember', window );">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024', window );">Security interest on pledge of financial instruments will be released in 2024</a></td>
<td class="nump">&#8364; 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027', window );">Security interest on pledge of financial instruments will be released in 2027</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031', window );">Security interest on pledge of financial instruments will be released in 2031</a></td>
<td class="nump">&#8364; 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember', window );">Loan agreement with Soci&#233;t&#233; G&#233;n&#233;rale | Changes to commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest', window );">Security interest on pledge of financial instruments released in 2024 including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_PreclinicalServicesMember', window );">Preclinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCancellableOffBalanceSheetPurchasedCommitments', window );">Non-cancellable off-balance sheet purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=inpha_ClinicalServicesMember', window );">Clinical Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NonCancellableOffBalanceSheetPurchasedCommitments', window );">Non-cancellable off-balance sheet purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NonCancellableOffBalanceSheetPurchasedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NonCancellableOffBalanceSheetPurchasedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_PaymentOfTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Taxes Other Than Income Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_PaymentOfTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of security interest on the pledge of financial instruments will be released in 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of security interest on pledge of financial instruments will be released in 2027.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The values of Security interest on pledge of financial instruments will be released in 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Security Interest On Pledged Financial Instruments Released, Including Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=ifrs-full_TaxContingentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=ifrs-full_TaxContingentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_GrantsOfEmployeeEquityInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_GrantsOfEmployeeEquityInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=inpha_LoanAgreementWithSocitGnraleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=inpha_ChangesToCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=inpha_ChangesToCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_PreclinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_PreclinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=inpha_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=inpha_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047789744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Disclosure of key management personnel compensation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Personnel and other short-term employee benefits</a></td>
<td class="nump">&#8364; 1,713<span></span>
</td>
<td class="nump">&#8364; 1,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Extra pension benefits</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_KeyManagementPersonnelCompensationAdvisoryFees', window );">Advisory fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Executive Board Members and other Executive Members compensation</a></td>
<td class="nump">&#8364; 2,253<span></span>
</td>
<td class="nump">&#8364; 2,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_KeyManagementPersonnelCompensationAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_KeyManagementPersonnelCompensationAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058051554896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related party transactions - Additional information (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>licensing_agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProvisionForExpensesWithRelatedParties', window );">Provision for expenses with related parties</a></td>
<td class="nump">&#8364; 184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ProvisionForAttendanceFees', window );">Provision for attendance fees</a></td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts payable, related party transactions</a></td>
<td class="nump">&#8364; 3,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=inpha_NovoNordiskASMember', window );">Novo Nordisk A/S</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NumberOfLicensingAgreementsWithRelatedParties', window );">Number of licensing agreements | licensing_agreement</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts payable, related party transactions</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NumberOfLicensingAgreementsWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Licensing Agreements With Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NumberOfLicensingAgreementsWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ProvisionForAttendanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for attendance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ProvisionForAttendanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ProvisionForExpensesWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Expenses With Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ProvisionForExpensesWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=inpha_NovoNordiskASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=inpha_NovoNordiskASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058055592528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions - Disclosure of transactions between related parties (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RelatedPartyTransactionsAbstract', window );"><strong>Related party transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties', window );">Collection</a></td>
<td class="nump">&#8364; 1,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Receivables</a></td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties', window );">Payments</a></td>
<td class="num">(3,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Liabilities</a></td>
<td class="num">(3,926)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties', window );">Net collection (payments)</a></td>
<td class="num">(1,685)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_NetAmountsReceivablePayableRelatedPartyTransactions', window );">Net receivables (liabilities)</a></td>
<td class="num">&#8364; (3,532)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_NetAmountsReceivablePayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amounts of receivables (payable) resulting from related party transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_NetAmountsReceivablePayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058048646288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income / (loss) per share - Summary of income (loss) per share (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_IncomeLossPerShareAbstract', window );"><strong>Income (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">&#8364; (24,764)<span></span>
</td>
<td class="nump">&#8364; 1,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares in circulation (in shares)</a></td>
<td class="nump">80,872,369<span></span>
</td>
<td class="nump">80,319,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic income (loss) per share (in EUR per share)</a></td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="nump">&#8364; 0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares', window );">Adjustment for share instruments (in shares)</a></td>
<td class="nump">5,026,389<span></span>
</td>
<td class="nump">3,461,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted income/(loss) per share (in EUR per share)</a></td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="nump">&#8364; 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140058047882656">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_TradeAndOtherPayables</td>
<td class="nump">&#8364; 17,018,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_TradeAndOtherPayables</td>
<td class="nump">20,911,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilities', window );">Collaboration Liabilities</a></td>
<td class="th" style="border-bottom: 0px;">inpha_CollaborationLiabilities</td>
<td class="nump">52,677,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_CollaborationLiabilities', window );">Collaboration Liabilities</a></td>
<td class="th" style="border-bottom: 0px;">inpha_CollaborationLiabilities</td>
<td class="nump">63,211,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_TradeAndOtherReceivables</td>
<td class="nump">66,111,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_TradeAndOtherReceivables</td>
<td class="nump">52,445,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ChangeInWorkingCapital', window );">Change In Working Capital</a></td>
<td class="th" style="border-bottom: 0px;">inpha_ChangeInWorkingCapital</td>
<td class="nump">14,067,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inpha_ChangeInWorkingCapital', window );">Change In Working Capital</a></td>
<td class="th" style="border-bottom: 0px;">inpha_ChangeInWorkingCapital</td>
<td class="nump">46,158,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income including contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
<td class="nump">10,483,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredIncomeIncludingContractLiabilities', window );">Deferred income including contract liabilities</a></td>
<td class="th" style="border-bottom: 0px;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
<td class="nump">&#8364; 14,481,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_ChangeInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_ChangeInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inpha_CollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of collaboration liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inpha_CollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inpha_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MYTR)UP;J^ZT0\N>-?A'8O?A=_@=02P,$%     @ ]# L62(,XI.\!   ^Q$
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M]<<;]B8D-P2&_,;*ZZQQ__6-[4=%.U7?E3?LKF]?S!$(#@$$WGW@2(?8KEJ
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MF'ECC^2PI!MN[N7N/Z@#&EJ\3'+MGF17VP8>R3;:R+)V1@8E$]6;_JP3T7)
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MY9Y#<U76 +[?2FF>/M@?.+X@LOH?4$L#!!0    ( /0P+%G5:$17R@<  -Q
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MZGS#44YP%>DW6 !*I0D3$T8JN2TCNSG2LM$6<V:UE@OK$O?+E2.*]_9S2(_
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M\1(K9TOXIP2S1@(@XXDB QU0HK%W182?U'2.DA",2*##UC2_$MNV=C>NN[I
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MC4QTD< Y+%(+)C'HWA'?1-1IE]4E#.'V24RST1E3S9XQ3Z=S8&HCX67D"H"
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M:W-H965T<R]S:&5E=#$P+GAM;,U8VV[;.!#]E8$+%#&@VKI8OJ2)@23=HKM
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MG,8G*#.-X'*X6$.FRJ4RF#LE-Y!F3-Y1!LU4Y3W%)=$A)J]FR#27BW:H@?&
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MW00:GRO"VC3<!NT'F^F_4$L#!!0    ( /0P+%G9NV5UJ@8  ) 0   9
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MH+8Z0U&ADN,\+M"YKBYT1R4M04X-0CN_FHC75L/)6G:@V)2]6"'F)B_)52?
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M MS?&M!T]8,.J-\.W_P;4$L#!!0    ( /0P+%F"U&2F!@0  )$)   9
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MWP;?3$P[ ,[72MF#X!887V'KOP!02P,$%     @ ]# L6>M!\"1-!   /0H
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M/'^8-Q=[WU/.G=PET^''E_-G]H&7Q F%=C;%3BD,?#J.B^*PA=SIW)A[,19
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M/>F<]23I*D3;8XUTY0 "K:S #?L-T_LC4)?:^!%JHJ?&0T*$ID1>\&.8^8/
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M884M.4BS /^7 HOI&6-@:/+7?P-02P,$%     @ ]# L6?I22ZN6"P  U2,
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MO5DX,ZH^7VD0Y*4\]..=1-PW=>B%.ZX!^Z5(6I@^8'0W+5->'DKL>E;GA^<
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MT>J* 'P%4]#WF70.V<.,G;K;]<,1$(<]Z6WD_O%6)WA.UYB"DM%03?A]84^
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M:#B99:,N;_N!-PU_;"Z-QT]7?MT %J^E#;B^,IB7?D *#O\^7/T-4$L#!!0
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M0[O'9//^738?7;XA>GH4/7V+_5]4Y[_PP&V@-0.^0K@Q=2/TX?V[Y3A;7#I
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MS!*PW077O7C3Q$ME:SQ=4?&QHF\"M&Q ^Z4Q_OF%'1R_,C9_ E!+ P04
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MBJ#;QCE-=G%Z'#EJ'S&IE.K2./B;G._=C)IF2^FP#LIGVW03@&=%/9>?07R
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M(N,%\'ZIM6L7WL'V.VS^+U!+ P04    " #T,"Q9QOV7X5(#  #@"   &0
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MFKZ8#,_$>#@^/Z)OTH1CPOHFK^B;ZY712YU(N#U+$EN:H,U*U"Z+?\T6/CA
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M$G.;B]_FXTVP!7\/7]@0;,Z7:QR%E*,%>+^TZ*35#6W0_(/D[K]02P,$%
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M*TM#WG_6=*M"[11HOU+*'@3G8+BGK?X&4$L#!!0    ( /0P+%F#5N,C+P0
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MB-VH*A4"8U:J*MBR4C!%ENN#Y[E %AUYNC(;B"J1J"G7&R96*^2M9A_%EN]
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M<E#N^M[],-767IDO*V.JPGZEIE@H&H#WJZHR[0]:H/L?BJO_ E!+ P04
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M#?=@M/X _U\9XPX+[Z#OZHN_ 5!+ P04    " #T,"Q9-U-0H+<&   '%
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M[KLS5)AG)].0/-=//1LN)4]U]<BB'2O4!!C?<R[KAMJ@>?M;_@M02P,$%
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M@^'I2^C+&^7*QKC> IE^"-7J46CI47K*WI<13P5>:>%KTSODA"F"WIHS@4&
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M@MH9T/E2*;M=. ?='VKV!U!+ P04    " #T,"Q9)6BWLJH#  !["   &0
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M.?T=H'8&M+Y5RK8#%Z#[WUC\#U!+ P04    " #T,"Q9H;56$F(#  "6"
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MS&)ET+ R<++RA2<L5R]]=+NO0ET[ ;J.%1(L @*SB!LVQ T/H'8.(;F'!(N
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M9"1+PYF N2*Z+ JJ?DV!R]W8"[W]P0-;K8T]\)/1AJ[@$<S39JYPYS<L2U:
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MPH!*Z@:>E[@E)I4S&9FQ&SX9L5I24L$-1Z(N2\Q_OP'*-F/'=QX';LE](?6
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M=E>K"\5WY0;E(U>*9^5I0O":B") _[_A7#U=%#=H]KB7_P%02P,$%     @
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M*Z3S;JBZBV^? =R^D6Q=/K-VQZ1DJ_+EDJHREA<!ZOLY8_+Y37& W9.8D_\
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M0+X_9TP\/BD'V-W#,_X/4$L#!!0    ( /0P+%D_O"(2'04  'D@   9
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M& R[PJ"E!$*@4XC3R5X"5Z7>IE7SPJ<\;R>-G_+5VUZO*.ZO0J!;2"#_A10
M"P%@X6SR7]B5_YKL6+(.- IQ&DW+^I@I 3Z@:T2!;B&!#AB2+ 0T5@+.MQ2P
MJP-RS_;9!_J$.'TF5\'D*0'N@&N$@6\A@5P84C L!(:%L\F%85<NY+;OA@B
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M"EXB8:PUFQE4VE1H'0UAYA;OE="[1.-4?)T7E#\#H"4P2(E"G]&"R(1RN1&
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MOG>N<G^2%G81;<LBM/M\D5A2GF$\8HBYJ0[[+,*^HY.A(K&1MF^[C>W?N-2
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MUS&@'#L?Y?X_C,--6I?J$!C' ./8J!C'2#&.2DW/%6 <(\(X]C3&H2'ZY0[
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M8EK8B@WGKDQVNV&878"M&(>MWGDW#&_A;JRK<0C>BH&WXE%Y*R;E+2HU/5?
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MX+95-P<MU'RS4CO8\A#*OPHWO_S\\ (>IQ]CV!NY$?OH:EI"ZS*A%9\?G<(
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ME;V*4[AAD_7:?6T"$JO9--[9-'[Z/93+,SE?%;1C,F;<NH7<4>L6LEZPKS=
M8C5O)CMO)D^; -+J#% X]?$7E-,>XLE2\:4QW:S:?6L6I%@ )%;SU-]YZK_
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M[I8M#R1;%;L['YA4@T'Q<T')E'*=0%V?,2:W!SJ#:L_RY#]02P,$%     @
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M+>16K'%,)H[R"$'XECC3BW<P].Y, IT)K"574,L5V-"GLTH!D%(\IRF5E B
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MZP!U?\&8?#G1#Z@_O4S_ U!+ P04    " #T,"Q9AZDON<X"  !K!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6RM56UOFS 0_BL6E:I6V@H%PJHV
M06K2[DVJ%*7K]F':!P<.L HVLTV2_?N=#6%)2J--VA>PS_<\?NY\/H_70CZK
M D"3355R-7$*K>MKUU5) 155%Z(&CBN9D!75.)6YJVH)-+6@JG1]SXO<BC+N
MQ&-KF\MX+!I=,@YS2513553^FD(IUA/GTMD:%BPOM#&X\;BF.3R"?JKG$F=N
MSY*R"KAB@A,)V<2YO;R>1<;?.GQEL%8[8V(B60KQ;":?THGC&4%00J(- \7?
M"F90EH8(9?SL.)U^2P/<'6_9W]O8,98E53 3Y3>6ZF+B7#DDA8PVI5Z(]4?H
MXAD9OD24RG[)NO/U')(T2HNJ Z."BO'V3S=='G8 R#,,\#N ?P@(7P$$'2"P
M@;;*;%AW5--X+,6:2..-;&9@<V/1& WCYA0?M<15AC@=+V %O %">4J$+D 2
MQA-1 7E+[IA*2J$:"41D)!<KD!S/3Y.,<<H3QG."581'J8#*I""PP=)*F4:
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MET+CI;'# E]#D,8!US,A]'9B-NC?U_@W4$L#!!0    ( /0P+%DS?H_S1P<
M #,H   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;+6:6V_;-AB&_XK@
M 44+-#6/DIPF!IJDVSJT:Y"TV\6P"\9F8J$Z>"2=PW[]*-DQ;>DC8SG93>/#
MR\\O69(/7TE'=Y7ZH6=2FNB^R$M]/)@9,S\<#O5D)@NAWU5S6=IOKBM5"&/?
MJINAGBLIIDVC(A\2A.)A(;)R,#YJ/CM7XZ-J8?*LE.<JTHNB$.KA1.;5W?$
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MN9QH1J+<ZRA/%,^*[8(55XK3XC !'($P ?K^ANM70W5B!JAWG,*?4$L#!!0
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M#6O51FLXPLQ'N5%"CQ(=IZ(%4*P@0046Z@$I@9G$=KTD>HUF24),&U-$6%T
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MIN]X$&:"'D\Y5X\=<^^T_QJB7U!+ P04    " #T,"Q93P&H3KT"  !+!P
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M#_:61%&2^!' _ ZB"$/@;<01S %XP) HJO;!G?TH7.]38?L?LM%O4$L#!!0
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MCGTR?UC9;'\:L?U9Q]M_ 5!+ P04    " #T,"Q9<WQX+%$"  #[+   &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(+CNJY)6
MG%%/,HVR >24'XIM$-!*LONVG(%]4 ]Z$G%&J$!<_@F?$/#X4@[-N&]/PV[?
M#8O/X^$TK*K=.':_ZGI8[\JQ&>[:KIS.1S9M?VS&\[+?UEVS?F^VI9;E,NK^
M=D;U]'@[<_'ZU97_F=AN-OMU^=VN_QS+:?S'X/JC[=^'72ECM7AM^FT95U7]
M>;CN'NK+)MV=)U>+Y[=5U3^_I:J>.T@@2.8/4@C2^8,,@FS^((<@GS\H("CF
M#\H0E.</NH>@^_F#'B#H8?Z@M$09EP1)$ZP)M$[(=2+P.B'8B4#LA&0G K,3
MHIT(U$[(=B)P.R'<B4#NA'0G KL3XIT(]!;46PCT%M1;"/26R<,V@=Z">@N!
MWH)Z"X'>@GH+@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WHIZ*X'>BGHK@=Z*>BN!
MWCIY64*@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ'>1J"WH=Y&
MH+>AWD:@MZ'>1J"W35YV$^AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H[:BW
M$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.V3CY4$>COJ[01Z.^KM!'H[ZNT$>COJ
M[01Z!^H=!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>@?J'01ZQ^1G$P*] _4. KT#
M]0X"O0/U#@*],^J="?3.J'<FT#NCWIE [XQZ9P*],^J="?3.J'<FT#NCWODG
M]1[&KT,9KCW?:[S^3U(]GL\MU\M?EM\[)_?X!>?ZMF)X^@M02P,$%     @
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ ]# L6=K8/3.X @  C0@  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /0P+%DG4:RY208   0>   8
M              " @?P*  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #T,"Q9(@SBD[P$  #[$0  &               @(%[$0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ]# L60=GY6*! P
M-PL  !@              ("!;18  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( /0P+%G-6"EZ @@  "PB   8              " @20:
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #T,"Q9U6A$
M5\H'  #<0   &               @(%<(@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ ]# L66181%O""   &A0  !@
M ("!7"H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /0P
M+%DAZ=6&O @  (,7   8              " @50S  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #T,"Q9/!*#!2$"  #[!   &
M        @(%&/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ ]# L65K<D;[V!0  O!$  !D              ("!G3X  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #T,"Q9V;ME=:H&  "0$
M&0              @('*1   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( /0P+%F'7\+2? H  "D>   9              " @:M+  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ]# L68+49*8&
M!   D0D  !D              ("!7E8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #T,"Q9ZT'P)$T$   ]"@  &0
M@(&;6@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /0P
M+%F(J9KO, L  (4@   9              " @1]?  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ ]# L6?<;MO)G P  Y <  !D
M         ("!AFH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #T,"Q9F[SO>:()  !M'   &0              @($D;@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /0P+%ES.0 '8@4  / /
M   9              " @?UW  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ ]# L6?I22ZN6"P  U2,  !D              ("!EGT
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #T,"Q9R,O,
MZK$&  ")$   &0              @(%CB0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( /0P+%E=3//ZBP,  #\(   9
M  " @4N0  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M]# L69X"(DC! P  <0@  !D              ("!#90  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #T,"Q9'%S'V+8&  !,$   &0
M            @($%F   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( /0P+%E^[&!DG 4  ),-   9              " @?*>  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ]# L6<;]E^%2 P
MX @  !D              ("!Q:0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #T,"Q9?"!"&:$"  #;!0  &0              @(%.
MJ   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /0P+%D1
M+QW-]@@  "P9   9              " @2:K  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ ]# L684Q#,*_ @  %@8  !D
M     ("!4[0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /0P+%F#5N,C+P0  ,H)   9              "
M@6O*  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ]# L
M6?C3_T%O"P  3R$  !D              ("!T<X  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #T,"Q9KV2"JSL#  #A!P  &0
M        @(%WV@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( /0P+%DW4U"@MP8   <4   9              " @>G=  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ]# L652]"VJH!   7PT
M !D              ("!U^0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #T,"Q9PF58^\,%  "O$@  &0              @(&VZ0
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /0P+%F&-* 1
M6 4  !(,   9              " @;#O  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ ]# L62:;7'?[ @  K08  !D
M ("!/_4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #T
M,"Q9)6BWLJH#  !["   &0              @(%Q^   >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( /0P+%FAM5828@,  )8(   9
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M970T-BYX;6Q02P$"% ,4    " #T,"Q9YR/A<G<$  !B%@  &0
M    @(%D$ $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M /0P+%GL@Z[C^P0  .\6   9              " @1(5 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ ]# L6<;0;0HU!P  E3D  !D
M             ("!1!H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #T,"Q9:\:US[ %  "I(P  &0              @(&P(0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /0P+%GZ$H#<P0<
M -A9   9              " @9<G 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ ]# L67,42_KD!@  SS,  !D              ("!
MCR\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #T,"Q9
M/[PB$AT%  !Y(   &0              @(&J-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( /0P+%D7(\==FQX  $LA @ 9
M      " @?X[ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ ]# L69RT*/"I"0  +EH  !D              ("!T%H! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #T,"Q92\KT?<L"  "O"@
M&0              @(&P9 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( /0P+%F)!4NR)@,   @)   9              " @;)G 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ]# L64@%V_];
M @  *08  !D              ("!#VL! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #T,"Q9M),JAS,'  "V/0  &0
M@(&A;0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /0P
M+%E"CU43P1L  !N/ 0 9              " @0MU 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ ]# L6;6)%.BF"   :58  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #T,"Q9Y$O
M _P$  "&&0  &0              @('LK0$ >&PO=V]R:W-H965T<R]S:&5E
M=#8U+GAM;%!+ 0(4 Q0    ( /0P+%F'J2^YS@(  &L'   9
M  " @1^S 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M]# L63-^C_-'!P  ,R@  !D              ("!)+8! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " #T,"Q9!< 39O0#  !]$@  &0
M            @(&BO0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( /0P+%E,ABE0@0,  $X+   9              " @<W! 0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ ]# L64:5MFV8 P
MFA$  !D              ("!A<4! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " #T,"Q9IO_#&MP%  ".+   &0              @(%4
MR0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( /0P+%G.
M-YH"& ,  +0(   9              " @6?/ 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ ]# L6;5S$F'6 @  00@  !D
M     ("!MM(! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M   N$P  #0              @ %#WP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( /0P+%F7BKL<P    !,"   +              "  :SB 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( /0P+%G; W;2K@4  %HR   /              "
M 97C 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #T,"Q9<WQX+%$"  #[
M+   &@              @ %PZ0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #T,"Q9SA7,7P\"  #J*P  $P              @ 'Y
LZP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5 !4  ,7   Y[@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>472</ContextCount>
  <ElementCount>317</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>141</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Interim Condensed Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition</Role>
      <ShortName>Interim Condensed Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Interim Condensed Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss</Role>
      <ShortName>Interim Condensed Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Interim Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Interim Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Interim Consolidated Statement of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity</Role>
      <ShortName>Interim Consolidated Statement of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - The Company and key events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TheCompanyandkeyevents</Role>
      <ShortName>The Company and key events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of presentation and statement of compliance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance</Role>
      <ShortName>Basis of presentation and statement of compliance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Management of financial risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Managementoffinancialrisks</Role>
      <ShortName>Management of financial risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets</Role>
      <ShortName>Cash, cash equivalents, short-term investments and non-current financial assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Trade receivables and others</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Tradereceivablesandothers</Role>
      <ShortName>Trade receivables and others</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Propertyandequipment</Role>
      <ShortName>Property and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Trade payables and others</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Tradepayablesandothers</Role>
      <ShortName>Trade payables and others</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Financialliabilities</Role>
      <ShortName>Financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Employee benefit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Employeebenefit</Role>
      <ShortName>Employee benefit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Capital</Role>
      <ShortName>Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement</Role>
      <ShortName>Financial instruments recognized in the statement of financial position and related effect on the income statement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Revenue and other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Revenueandotherincome</Role>
      <ShortName>Revenue and other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Operating expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Operatingexpenses</Role>
      <ShortName>Operating expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Net financial income / (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Netfinancialincomeloss</Role>
      <ShortName>Net financial income / (loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Income tax / (expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Incometaxexpense</Role>
      <ShortName>Income tax / (expense)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Commitments, contingencies and litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation</Role>
      <ShortName>Commitments, contingencies and litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Relatedpartytransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Income / (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Incomelosspershare</Role>
      <ShortName>Income / (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Events after the reporting date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/Eventsafterthereportingdate</Role>
      <ShortName>Events after the reporting date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of presentation and statement of compliance (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies</Role>
      <ShortName>Basis of presentation and statement of compliance (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Basis of presentation and statement of compliance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables</Role>
      <ShortName>Basis of presentation and statement of compliance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables</Role>
      <ShortName>Cash, cash equivalents, short-term investments and non-current financial assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Trade receivables and others (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TradereceivablesandothersTables</Role>
      <ShortName>Trade receivables and others (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Tradereceivablesandothers</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Intangibleassets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Property and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/PropertyandequipmentTables</Role>
      <ShortName>Property and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Propertyandequipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Trade payables and others (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TradepayablesandothersTables</Role>
      <ShortName>Trade payables and others (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Tradepayablesandothers</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Financial liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/FinancialliabilitiesTables</Role>
      <ShortName>Financial liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Financialliabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Employee benefit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/EmployeebenefitTables</Role>
      <ShortName>Employee benefit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Employeebenefit</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CapitalTables</Role>
      <ShortName>Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Capital</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables</Role>
      <ShortName>Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Revenue and other income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeTables</Role>
      <ShortName>Revenue and other income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Revenueandotherincome</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Operating expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/OperatingexpensesTables</Role>
      <ShortName>Operating expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Operatingexpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Net financial income / (loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/NetfinancialincomelossTables</Role>
      <ShortName>Net financial income / (loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Netfinancialincomeloss</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Related party transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RelatedpartytransactionsTables</Role>
      <ShortName>Related party transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Relatedpartytransactions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Income / (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IncomelosspershareTables</Role>
      <ShortName>Income / (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Incometaxexpense</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - The Company and key events - The company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails</Role>
      <ShortName>The Company and key events - The company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details</Role>
      <ShortName>The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails</Role>
      <ShortName>Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails</Role>
      <ShortName>Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails</Role>
      <ShortName>Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails</Role>
      <ShortName>Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Trade receivables and others - Disclosure of trade receivables and others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails</Role>
      <ShortName>Trade receivables and others - Disclosure of trade receivables and others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Intangible assets - Disclosure of detailed information about intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails</Role>
      <ShortName>Intangible assets - Disclosure of detailed information about intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Intangible assets - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails</Role>
      <ShortName>Intangible assets - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Property and equipment - Disclosure of detailed information about property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails</Role>
      <ShortName>Property and equipment - Disclosure of detailed information about property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Trade payables and others - Disclosure of trade payables and others (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails</Role>
      <ShortName>Trade payables and others - Disclosure of trade payables and others (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Financial liabilities - Disclosure of financial liabilities per maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails</Role>
      <ShortName>Financial liabilities - Disclosure of financial liabilities per maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails</Role>
      <ShortName>Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Employee benefit - Disclosure of defined benefit plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails</Role>
      <ShortName>Employee benefit - Disclosure of defined benefit plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Employee benefit - Disclosure of net defined benefit liability (asset) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails</Role>
      <ShortName>Employee benefit - Disclosure of net defined benefit liability (asset) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Employee benefit - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails</Role>
      <ShortName>Employee benefit - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Capital - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails</Role>
      <ShortName>Capital - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails</Role>
      <ShortName>Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails</Role>
      <ShortName>Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails</Role>
      <ShortName>Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails</Role>
      <ShortName>Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Revenue and other income - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails</Role>
      <ShortName>Revenue and other income - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Revenue and other income - Disclosure of variance of deferred revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails</Role>
      <ShortName>Revenue and other income - Disclosure of variance of deferred revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Revenue and other income - Disclosure of government financing for research expenditures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails</Role>
      <ShortName>Revenue and other income - Disclosure of government financing for research expenditures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Operating expenses - Disclosure of expenses by nature (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails</Role>
      <ShortName>Operating expenses - Disclosure of expenses by nature (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Operating expenses - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails</Role>
      <ShortName>Operating expenses - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Net financial income / (loss) - Disclosure of net financial income (loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails</Role>
      <ShortName>Net financial income / (loss) - Disclosure of net financial income (loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/NetfinancialincomelossTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income tax / (expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IncometaxexpenseDetails</Role>
      <ShortName>Income tax / (expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Incometaxexpense</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Commitments, contingencies and litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails</Role>
      <ShortName>Commitments, contingencies and litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Related party transactions - Disclosure of key management personnel compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails</Role>
      <ShortName>Related party transactions - Disclosure of key management personnel compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Related party transactions - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails</Role>
      <ShortName>Related party transactions - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Related party transactions - Disclosure of transactions between related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails</Role>
      <ShortName>Related party transactions - Disclosure of transactions between related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Income / (loss) per share - Summary of income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails</Role>
      <ShortName>Income / (loss) per share - Summary of income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.innate-pharma.com/role/IncomelosspershareTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="inpha-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - _IXDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - _IXDS</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="inpha-20240630.htm">inpha-20240630.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="inpha-20240630_d2.htm">inpha-20240630_d2.htm</File>
    <File>inpha-20240630.xsd</File>
    <File>inpha-20240630_cal.xml</File>
    <File>inpha-20240630_def.xml</File>
    <File>inpha-20240630_lab.xml</File>
    <File>inpha-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1085">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inpha-20240630.htm inpha-20240630_d2.htm": {
   "nsprefix": "inpha",
   "nsuri": "http://www.innate-pharma.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "inpha-20240630.htm",
      "inpha-20240630_d2.htm"
     ]
    },
    "schema": {
     "local": [
      "inpha-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "inpha-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inpha-20240630_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "inpha-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inpha-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 198,
   "keyCustom": 119,
   "axisStandard": 25,
   "axisCustom": 2,
   "memberStandard": 29,
   "memberCustom": 106,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 472,
   "entityCount": 1,
   "segmentCount": 141,
   "elementCount": 590,
   "unitCount": 15,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1085,
    "http://xbrl.sec.gov/dei/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://www.innate-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition",
     "longName": "9952151 - Statement - Interim Condensed Consolidated Statements of Financial Position",
     "shortName": "Interim Condensed Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
     "longName": "9952152 - Statement - Interim Condensed Consolidated Statements of Income (Loss)",
     "shortName": "Interim Condensed Consolidated Statements of Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:Revenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "longName": "9952153 - Statement - Interim Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Interim Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows",
     "longName": "9952154 - Statement - Interim Condensed Consolidated Statements of Cash Flows",
     "shortName": "Interim Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
     "longName": "9952155 - Statement - Interim Consolidated Statement of Changes in Shareholders\u2019 Equity",
     "shortName": "Interim Consolidated Statement of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.innate-pharma.com/role/TheCompanyandkeyevents",
     "longName": "9952156 - Disclosure - The Company and key events",
     "shortName": "The Company and key events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance",
     "longName": "9952157 - Disclosure - Basis of presentation and statement of compliance",
     "shortName": "Basis of presentation and statement of compliance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.innate-pharma.com/role/Managementoffinancialrisks",
     "longName": "9952158 - Disclosure - Management of financial risks",
     "shortName": "Management of financial risks",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets",
     "longName": "9952159 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets",
     "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.innate-pharma.com/role/Tradereceivablesandothers",
     "longName": "9952160 - Disclosure - Trade receivables and others",
     "shortName": "Trade receivables and others",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.innate-pharma.com/role/Intangibleassets",
     "longName": "9952161 - Disclosure - Intangible assets",
     "shortName": "Intangible assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.innate-pharma.com/role/Propertyandequipment",
     "longName": "9952162 - Disclosure - Property and equipment",
     "shortName": "Property and equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.innate-pharma.com/role/Tradepayablesandothers",
     "longName": "9952163 - Disclosure - Trade payables and others",
     "shortName": "Trade payables and others",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.innate-pharma.com/role/Financialliabilities",
     "longName": "9952164 - Disclosure - Financial liabilities",
     "shortName": "Financial liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.innate-pharma.com/role/Employeebenefit",
     "longName": "9952165 - Disclosure - Employee benefit",
     "shortName": "Employee benefit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.innate-pharma.com/role/Capital",
     "longName": "9952166 - Disclosure - Capital",
     "shortName": "Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement",
     "longName": "9952167 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement",
     "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.innate-pharma.com/role/Revenueandotherincome",
     "longName": "9952168 - Disclosure - Revenue and other income",
     "shortName": "Revenue and other income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.innate-pharma.com/role/Operatingexpenses",
     "longName": "9952169 - Disclosure - Operating expenses",
     "shortName": "Operating expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.innate-pharma.com/role/Netfinancialincomeloss",
     "longName": "9952170 - Disclosure - Net financial income / (loss)",
     "shortName": "Net financial income / (loss)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.innate-pharma.com/role/Incometaxexpense",
     "longName": "9952171 - Disclosure - Income tax / (expense)",
     "shortName": "Income tax / (expense)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation",
     "longName": "9952172 - Disclosure - Commitments, contingencies and litigation",
     "shortName": "Commitments, contingencies and litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.innate-pharma.com/role/Relatedpartytransactions",
     "longName": "9952173 - Disclosure - Related party transactions",
     "shortName": "Related party transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.innate-pharma.com/role/Incomelosspershare",
     "longName": "9952174 - Disclosure - Income / (loss) per share",
     "shortName": "Income / (loss) per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.innate-pharma.com/role/Eventsafterthereportingdate",
     "longName": "9952175 - Disclosure - Events after the reporting date",
     "shortName": "Events after the reporting date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies",
     "longName": "9954471 - Disclosure - Basis of presentation and statement of compliance (Policies)",
     "shortName": "Basis of presentation and statement of compliance (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables",
     "longName": "9954472 - Disclosure - Basis of presentation and statement of compliance (Tables)",
     "shortName": "Basis of presentation and statement of compliance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables",
     "longName": "9954473 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets (Tables)",
     "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.innate-pharma.com/role/TradereceivablesandothersTables",
     "longName": "9954474 - Disclosure - Trade receivables and others (Tables)",
     "shortName": "Trade receivables and others (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.innate-pharma.com/role/IntangibleassetsTables",
     "longName": "9954475 - Disclosure - Intangible assets (Tables)",
     "shortName": "Intangible assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.innate-pharma.com/role/PropertyandequipmentTables",
     "longName": "9954476 - Disclosure - Property and equipment (Tables)",
     "shortName": "Property and equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.innate-pharma.com/role/TradepayablesandothersTables",
     "longName": "9954477 - Disclosure - Trade payables and others (Tables)",
     "shortName": "Trade payables and others (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfTradePayablesAndOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.innate-pharma.com/role/FinancialliabilitiesTables",
     "longName": "9954478 - Disclosure - Financial liabilities (Tables)",
     "shortName": "Financial liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.innate-pharma.com/role/EmployeebenefitTables",
     "longName": "9954479 - Disclosure - Employee benefit (Tables)",
     "shortName": "Employee benefit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.innate-pharma.com/role/CapitalTables",
     "longName": "9954480 - Disclosure - Capital (Tables)",
     "shortName": "Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables",
     "longName": "9954481 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)",
     "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeTables",
     "longName": "9954482 - Disclosure - Revenue and other income (Tables)",
     "shortName": "Revenue and other income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.innate-pharma.com/role/OperatingexpensesTables",
     "longName": "9954483 - Disclosure - Operating expenses (Tables)",
     "shortName": "Operating expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.innate-pharma.com/role/NetfinancialincomelossTables",
     "longName": "9954484 - Disclosure - Net financial income / (loss) (Tables)",
     "shortName": "Net financial income / (loss) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsTables",
     "longName": "9954485 - Disclosure - Related party transactions (Tables)",
     "shortName": "Related party transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.innate-pharma.com/role/IncomelosspershareTables",
     "longName": "9954486 - Disclosure - Income / (loss) per share (Tables)",
     "shortName": "Income / (loss) per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails",
     "longName": "9954487 - Disclosure - The Company and key events - The company (Details)",
     "shortName": "The Company and key events - The company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "inpha:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details",
     "longName": "9954488 - Disclosure - The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)",
     "shortName": "The Company and key events - Key events for the six-month period ended June 30, 2024 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
      "unitRef": "share",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-52",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
      "unitRef": "share",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails",
     "longName": "9954489 - Disclosure - Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)",
     "shortName": "Basis of presentation and statement of compliance - Disclosure of effect of changes in foreign exchange rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails",
     "longName": "9954490 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)",
     "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of cash, cash equivalents and financial assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "inpha:CashCashEquivalentsAndShortTermInvestmentsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
     "longName": "9954491 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)",
     "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "inpha:NumberOfFinancialInstrumentsHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "inpha:NumberOfFinancialInstrumentsHeld",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails",
     "longName": "9954492 - Disclosure - Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)",
     "shortName": "Cash, cash equivalents, short-term investments and non-current financial assets - Disclosure of reconciliation of changes in short-term investments and non-current financial assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentInvestments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentInvestments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails",
     "longName": "9954493 - Disclosure - Trade receivables and others - Disclosure of trade receivables and others (Details)",
     "shortName": "Trade receivables and others - Disclosure of trade receivables and others (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:OtherCurrentReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:OtherCurrentReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
     "longName": "9954494 - Disclosure - Intangible assets - Disclosure of detailed information about intangible assets (Details)",
     "shortName": "Intangible assets - Disclosure of detailed information about intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
     "longName": "9954495 - Disclosure - Intangible assets - Additional information (Details)",
     "shortName": "Intangible assets - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails",
     "longName": "9954496 - Disclosure - Property and equipment - Disclosure of detailed information about property, plant and equipment (Details)",
     "shortName": "Property and equipment - Disclosure of detailed information about property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails",
     "longName": "9954497 - Disclosure - Trade payables and others - Disclosure of trade payables and others (Details)",
     "shortName": "Trade payables and others - Disclosure of trade payables and others (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "inpha:DisclosureOfTradePayablesAndOthersTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "inpha:DisclosureOfTradePayablesAndOthersTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
     "longName": "9954498 - Disclosure - Financial liabilities - Disclosure of financial liabilities per maturity (Details)",
     "shortName": "Financial liabilities - Disclosure of financial liabilities per maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails",
     "longName": "9954499 - Disclosure - Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)",
     "shortName": "Financial liabilities - Disclosure of maturity analysis for non-derivative financial liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:BankBorrowingsUndiscountedCashFlows",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails",
     "longName": "9954500 - Disclosure - Employee benefit - Disclosure of defined benefit plans (Details)",
     "shortName": "Employee benefit - Disclosure of defined benefit plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails",
     "longName": "9954501 - Disclosure - Employee benefit - Disclosure of net defined benefit liability (asset) (Details)",
     "shortName": "Employee benefit - Disclosure of net defined benefit liability (asset) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
     "longName": "9954502 - Disclosure - Employee benefit - Additional information (Details)",
     "shortName": "Employee benefit - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-243",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
     "longName": "9954503 - Disclosure - Capital - Additional Information (Details)",
     "shortName": "Capital - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails",
     "longName": "9954504 - Disclosure - Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)",
     "shortName": "Capital - Disclosure of number and weighted average exercise prices of other equity instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
      "unitRef": "share",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-341",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails",
     "longName": "9954505 - Disclosure - Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)",
     "shortName": "Financial instruments recognized in the statement of financial position and related effect on the income statement - Disclosure of detailed information about financial instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
     "longName": "9954506 - Disclosure - Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)",
     "shortName": "Revenue and other income - Disclosure of revenue from collaboration and licensing agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-393",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
     "longName": "9954507 - Disclosure - Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)",
     "shortName": "Revenue and other income - Disclosure of change in deferred revenue and collaboration liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-418",
      "name": "inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-433",
      "name": "inpha:NumberOfPreclinicalMolecules",
      "unitRef": "preclinicalmolecule",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
     "longName": "9954508 - Disclosure - Revenue and other income - Additional information (Details)",
     "shortName": "Revenue and other income - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-416",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails",
     "longName": "9954509 - Disclosure - Revenue and other income - Disclosure of variance of deferred revenue (Details)",
     "shortName": "Revenue and other income - Disclosure of variance of deferred revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-443",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-444",
      "name": "inpha:IncreaseThroughUpfrontPaymentContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails",
     "longName": "9954510 - Disclosure - Revenue and other income - Disclosure of government financing for research expenditures (Details)",
     "shortName": "Revenue and other income - Disclosure of government financing for research expenditures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:IncomeFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:IncomeFromResearchTaxCredit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails",
     "longName": "9954511 - Disclosure - Operating expenses - Disclosure of expenses by nature (Details)",
     "shortName": "Operating expenses - Disclosure of expenses by nature (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:SubcontractingCosts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:SubcontractingCosts",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
     "longName": "9954512 - Disclosure - Operating expenses - Additional information (Details)",
     "shortName": "Operating expenses - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ShorttermEmployeeBenefitsExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-462",
      "name": "ifrs-full:NumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails",
     "longName": "9954513 - Disclosure - Net financial income / (loss) - Disclosure of net financial income (loss) (Details)",
     "shortName": "Net financial income / (loss) - Disclosure of net financial income (loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "inpha:InterestsAndGainsOnFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "inpha:InterestsAndGainsOnFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.innate-pharma.com/role/IncometaxexpenseDetails",
     "longName": "9954514 - Disclosure - Income tax / (expense) (Details)",
     "shortName": "Income tax / (expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
     "longName": "9954515 - Disclosure - Commitments, contingencies and litigation (Details)",
     "shortName": "Commitments, contingencies and litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "inpha:NonCancellableOffBalanceSheetPurchasedCommitments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails",
     "longName": "9954516 - Disclosure - Related party transactions - Disclosure of key management personnel compensation (Details)",
     "shortName": "Related party transactions - Disclosure of key management personnel compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails",
     "longName": "9954517 - Disclosure - Related party transactions - Additional information (Details)",
     "shortName": "Related party transactions - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "inpha:ProvisionForExpensesWithRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "inpha:ProvisionForExpensesWithRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails",
     "longName": "9954518 - Disclosure - Related party transactions - Disclosure of transactions between related parties (Details)",
     "shortName": "Related party transactions - Disclosure of transactions between related parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CashAdvancesAndLoansFromRelatedParties",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails",
     "longName": "9954519 - Disclosure - Income / (loss) per share - Summary of income (loss) per share (Details)",
     "shortName": "Income / (loss) per share - Summary of income (loss) per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "unique": true
     }
    },
    "R9999": {
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "longName": "Uncategorized Items - _IXDS",
     "shortName": "Uncategorized Items - _IXDS",
     "isDefault": "false",
     "groupType": "",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inpha-20240630_d2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "inpha_A2015AstraZenecaMonalizumabAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "A2015AstraZenecaMonalizumabAgreementsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 monalizumab agreement, with AstraZeneca",
        "label": "2015 AstraZeneca Monalizumab Agreements [Member]",
        "documentation": "This member stands for 2015 AstraZeneca monalizumab agreements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_A2018AstraZenecaIPH5201AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "A2018AstraZenecaIPH5201AgreementMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPH5201 agreement, with AstraZeneca",
        "label": "2018 AstraZeneca IPH5201 Agreement [Member]",
        "documentation": "This member stands for Agreement related to IPH5201 with AstraZeneca."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGABonus20181Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGABonus20181Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Bonus 2018-1",
        "label": "AGA Bonus 2018-1 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGABonus20191Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGABonus20191Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Bonus 2019-1",
        "label": "AGA Bonus 2019-1 [Member]",
        "documentation": "Related to AGA bonus 2019-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGABonus202012Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGABonus202012Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Bonus 2020-1 &amp; 2",
        "label": "AGA Bonus 2020-1 &amp; 2 [Member]",
        "documentation": "AGA Bonus 2020-1 &amp; 2"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGABonus20211Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGABonus20211Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Bonus 2021-1",
        "label": "AGA Bonus 2021-1 [Member]",
        "documentation": "AGA Bonus 2021-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGABonus20221Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGABonus20221Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Bonus 2022-1",
        "label": "AGA Bonus 2022-1 [Member]",
        "documentation": "AGA Bonus 2022-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAEmployees2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAEmployees2017Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Employees 2017",
        "label": "AGA Employees 2017 [Member]",
        "documentation": "This member stands for AGA Employees 2017."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAEmployees2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAEmployees2018Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Employees 2018",
        "label": "AGA Employees 2018 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAManagement20161Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAManagement20161Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Management 2016-1",
        "label": "AGA Management 2016-1 [Member]",
        "documentation": "This member stands for AGA Management 2016-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAManagement20162Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAManagement20162Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Management 2016-2",
        "label": "AGA Management 2016-2 [Member]",
        "documentation": "This member stands for AGA Management 2016-2."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGANewMembers20171Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGANewMembers20171Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA New Members 2017-1",
        "label": "AGA New Members 2017-1 [Member]",
        "documentation": "This member stands for AGA New Members 2017-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGANewMembers20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGANewMembers20231Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA New members 2023-1",
        "label": "AGA New Members 2023-1 [Member]",
        "documentation": "AGA New Members 2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGANewMembers20241Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGANewMembers20241Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA New members 2024-1",
        "label": "AGA New Members 2024-1 [Member]",
        "documentation": "AGA New Members 2024-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAP2019Employees2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAP2019Employees2019Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP 2019 Employees 2019",
        "label": "AGAP 2019 Employees 2019 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAP2019Management2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAP2019Management2019Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP 2019 Management 2019",
        "label": "AGAP 2019 Management 2019 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPEmployees20161Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPEmployees20161Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Employees 2016-1",
        "label": "AGAP Employees 2016-1 [Member]",
        "documentation": "This member stands for AGAP Employees 2016-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPEmployees20171Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPEmployees20171Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Employees 2017-1",
        "label": "AGAP Employees 2017-1 [Member]",
        "documentation": "Related to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPEmployees20201Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPEmployees20201Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Employees 2020-1",
        "label": "AGAP Employees 2020-1 [Member]",
        "documentation": "AGAP Employees 2020-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPEmployees20211Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPEmployees20211Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Employees 2021-1",
        "label": "AGAP Employees 2021-1 [Member]",
        "documentation": "AGAP Employees 2021-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPManagement20161Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPManagement20161Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Management 2016-1",
        "label": "AGAP Management 2016-1 [Member]",
        "documentation": "This member stands for AGAP Management 2016-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPManagement20162Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPManagement20162Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Management 2016-2",
        "label": "AGAP Management 2016-2 [Member]",
        "documentation": "This member stands for AGAP Management 2016-2."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPManagement20171Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPManagement20171Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Management 2017-1",
        "label": "AGAP Management 2017-1 [Member]",
        "documentation": "Related to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPManagement20201Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPManagement20201Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Management 2020-1",
        "label": "AGAP Management 2020-1 [Member]",
        "documentation": "AGAP Management 2020-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPManagement20211Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPManagement20211Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Management 2021-1",
        "label": "AGAP Management 2021-1 [Member]",
        "documentation": "AGAP Management 2021-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPPerfEmployees20181Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPPerfEmployees20181Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Perf Employees 2018-1",
        "label": "AGAP Perf Employees 2018-1 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPPerfManagement20181Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPPerfManagement20181Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGAP Perf Management 2018-1",
        "label": "AGAP Perf Management 2018-1 [Member]",
        "documentation": "This member stands for AGA Perf Management 2018-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPerfEmployees20221Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPerfEmployees20221Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Perf Employees 2022-1",
        "label": "AGA Perf Employees 2022-1 [Member]",
        "documentation": "AGA Perf Employees 2022-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPerfEmployees20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPerfEmployees20231Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Perf Employees 2023-1",
        "label": "AGA Perf Employees 2023-1 [Member]",
        "documentation": "AGA Perf Employees 2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPerfManagement20221Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPerfManagement20221Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Perf Management 2022-1",
        "label": "AGA Perf Management 2022-1 [Member]",
        "documentation": "AGA Perf Management 2022-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPerfManagement20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPerfManagement20231Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA Perf Management 2023-1",
        "label": "AGA Perf Management 2023-1 [Member]",
        "documentation": "AGA Perf Management 2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPlanEpargneEntreprise2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPlanEpargneEntreprise2022Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA \"Plan Epargne Entreprise\" 2022",
        "label": "AGA \"Plan Epargne Entreprise\" 2022 [Member]",
        "documentation": "AGA \"Plan Epargne Entreprise\" 2022"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPlanEpargneEntreprise2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPlanEpargneEntreprise2023Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA \"Plan Epargne Entreprise\" 2023",
        "label": "AGA \"Plan Epargne Entreprise\" 2023 [Member]",
        "documentation": "AGA \"Plan Epargne Entreprise\" 2023"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AGAPlanEpargneEntreprise2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AGAPlanEpargneEntreprise2024Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGA \"Plan Epargne Entreprise\" 2024",
        "label": "AGA \"Plan Epargne Entreprise\" 2024 [Member]",
        "documentation": "AGA \"Plan Epargne Entreprise\" 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Accumulated other comprehensive income [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Acquisitions through business combinations, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ActuarialAssumptionOfDiscountRates",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial assumption of discount rates",
        "label": "Actuarial assumption of discount rates"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional considerations",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisitions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares, diluted (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in accrued interests on financial assets",
        "label": "Adjustments for decrease (increase) in accrued income including contract assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization, net",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of financial assets",
        "label": "Adjustments for fair value losses (gains)"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AdjustmentsForIncreaseDecreaseInCollaborationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AdjustmentsForIncreaseDecreaseInCollaborationLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration liabilities - current and non-current portion, variance",
        "label": "Adjustments For Increase (Decrease) In Collaboration Liabilities",
        "documentation": "Adjustments for increase (decrease) in collaboration liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue - current and non-current portion, variance",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits costs",
        "label": "Adjustments for increase (decrease) in employee benefit liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and others (excluding payables related to capital expenditures), variance",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in provision for charges",
        "label": "Adjustments for provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Adjustments for share-based payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange (gains) losses on financial assets",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AdministrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AdministrationMember",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administration",
        "label": "Administration [Member]",
        "documentation": "Administration"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementRelatedToIPH5201WithAstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementRelatedToIPH5201WithAstraZenecaMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement related to IPH5201 with AstraZeneca",
        "label": "Agreement Related To IPH5201 With AstraZeneca [Member]",
        "documentation": "This member stands for Agreement related to IPH5201 with AstraZeneca."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementRelatedToIPH6101WithSanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementRelatedToIPH6101WithSanofiMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Sanofi, 2016",
        "verboseLabel": "Agreement with Sanofi, 2016",
        "label": "Agreement Related To IPH6101 With Sanofi [Member]",
        "documentation": "Agreement Related To IPH6101 With Sanofi"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementWithOregaBiotechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementWithOregaBiotechMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Orega Biotech",
        "label": "Agreement With Orega Biotech [Member]",
        "documentation": "This member stands for agreement with Orega Biotech."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementWithSanofi2022ANKETIPH62Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementWithSanofi2022ANKETIPH62Member",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Sanofi, 2022 - ANKET IPH62",
        "label": "Agreement With Sanofi 2022 - ANKET IPH62 [Member]",
        "documentation": "Agreement With Sanofi 2022 - ANKET IPH62"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementWithSanofi2022ANKETIPH67Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementWithSanofi2022ANKETIPH67Member",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement With Sanofi 2022 - ANKET IPH67",
        "label": "Agreement With Sanofi 2022 - ANKET IPH67 [Member]",
        "documentation": "Agreement With Sanofi 2022 - ANKET IPH67"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementWithSanofiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementWithSanofiMember",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement With Sanofi",
        "label": "Agreement With Sanofi [Member]",
        "documentation": "Agreement With Sanofi"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementWithTakedaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementWithTakedaMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda agreement",
        "label": "Agreement With Takeda [Member]",
        "documentation": "Agreement With Takeda"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementsWithGenzymeForNKCellEngagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementsWithGenzymeForNKCellEngagesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Sanofi, 2022",
        "label": "Agreements with Genzyme for NK Cell engages [Member]",
        "documentation": "Agreements with Genzyme for NK Cell engages"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_AgreementsWithSanofiForNKCellEngagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "AgreementsWithSanofiForNKCellEngagesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements with Sanofi for NK Cell engages",
        "label": "Agreements with Sanofi for NK Cell engages [Member]",
        "documentation": "Agreements with Sanofi for NK Cell engages"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortizations",
        "terseLabel": "Amortisation, intangible assets other than goodwill",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable, related party transactions",
        "negatedLabel": "Liabilities",
        "label": "Amounts payable, related party transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": "inpha_NetAmountsReceivablePayableRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receivables",
        "label": "Amounts receivable, related party transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applicable tax rate",
        "label": "Applicable tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function",
        "label": "Attribution of expenses by nature to their function [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Average rate (\u20ac1 equals to USD)",
        "label": "Average foreign exchange rate"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA20112Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA20112Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2011-2",
        "label": "BSA 2011-2 [Member]",
        "documentation": "Related to the plan."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA2013Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2013",
        "label": "BSA 2013 [Member]",
        "documentation": "This member stands for BSA 2013."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA2014Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2014",
        "label": "BSA 2014 [Member]",
        "documentation": "This member stands for BSA 2014."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA20151Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA20151Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2015-1",
        "label": "BSA 2015-1 [Member]",
        "documentation": "This member stands for BSA 2015-1."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA20152Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA20152Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2015-2",
        "label": "BSA 2015-2 [Member]",
        "documentation": "This member stands for BSA 2015-2."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA2017Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2017",
        "label": "BSA 2017 [Member]",
        "documentation": "This member stands for BSA 2017."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA20221Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA20221Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2022-1",
        "label": "BSA 2022-1 [Member]",
        "documentation": "BSA 2022-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSA20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSA20231Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSA 2023-1",
        "label": "BSA 2023-1 [Member]",
        "documentation": "BSA 2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSAAR2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSAAR2011Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSAAR 2011",
        "label": "BSAAR 2011 [Member]",
        "documentation": "This member stands for BSAAR 2011."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSAAR2012Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSAAR2012Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSAAR 2012",
        "label": "BSAAR 2012 [Member]",
        "documentation": "This member stands for BSAAR 2012."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BSAAR2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BSAAR2015Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BSAAR 2015",
        "label": "BSAAR 2015 [Member]",
        "documentation": "This member stands for BSAAR 2015."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BankBorrowingsUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BankBorrowingsUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undiscounted cash flows",
        "label": "Bank borrowings, undiscounted cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic income (loss) per share (in EUR per share)",
        "label": "Basic earnings (loss) per share"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingGracePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingGracePeriod",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, grace period",
        "label": "Borrowing, Grace Period",
        "documentation": "Borrowing, Grace Period"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingMaturity",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, maturity",
        "label": "Borrowing, Maturity",
        "documentation": "Borrowing, Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingMaturityExtensionPeriodOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingMaturityExtensionPeriodOption",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, maturity, extension period option",
        "label": "Borrowing, Maturity, Extension Period Option",
        "documentation": "Borrowing, Maturity, Extension Period Option"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingNumberOfLoanAgreement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingNumberOfLoanAgreement",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, number of loan agreement",
        "label": "Borrowing, Number Of Loan Agreement",
        "documentation": "Borrowing, Number Of Loan Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingPercentageOfStateGuaranteedLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingPercentageOfStateGuaranteedLoan",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing, percentage of state-guaranteed loan",
        "label": "Borrowing, Percentage Of State-Guaranteed Loan",
        "documentation": "Borrowing, Percentage Of State-Guaranteed Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name",
        "label": "Borrowings by name [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_BorrowingsMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "BorrowingsMaturityPeriod",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, maturity period",
        "label": "Borrowings, Maturity Period",
        "documentation": "Borrowings, Maturity Period"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CarryBackTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CarryBackTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carry-back tax receivable",
        "label": "Carry-Back Tax Receivable",
        "documentation": "Carry-Back Tax Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansFromRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collection",
        "label": "Cash advances and loans from related parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAdvancesAndLoansMadeToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Cash advances and loans made to related parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": {
       "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year:",
        "periodEndLabel": "Cash and cash equivalents at the end of the six-months period:",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and financial assets denominated in US dollars",
        "label": "Cash, Cash Equivalents, And Financial Assets Denominated In US Dollars [Member]",
        "documentation": "Related to cash, cash equivalents, and financial assets denominated in US dollars."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": {
       "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, cash equivalents and short-term investments",
        "label": "Cash, Cash Equivalents And Short-Term Investments, Assets",
        "documentation": "Cash, Cash Equivalents And Short-Term Investments, Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash generated / (used in) from financing activities:",
        "label": "Cash flows from (used in) financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash generated from / (used in) investing activities:",
        "label": "Cash flows from (used in) investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash generated from / (used in) operating activities:",
        "label": "Cash flows from (used in) operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating cash flow before change in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashRepaymentsOfAdvancesAndLoansFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashRepaymentsOfAdvancesAndLoansFromRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net collection (payments)",
        "label": "Cash repayments of advances and loans from related parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets",
        "label": "Categories of financial assets [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities",
        "label": "Categories of financial liabilities [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties",
        "label": "Categories of related parties [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ChangeInValuationAllowanceOfFinancialInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ChangeInValuationAllowanceOfFinancialInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance on financial instruments",
        "label": "Change In Valuation Allowance Of Financial Instruments",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ChangeInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ChangeInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total change in working capital",
        "label": "Change In Working Capital",
        "documentation": "The amount of working capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ChangesInPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Write-off of right-of-use asset",
        "label": "Increase (decrease) in property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ChangesToCommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ChangesToCommitmentsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes to commitments",
        "label": "Changes To Commitments [Member]",
        "documentation": "Changes To Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CharacteristicsOfDefinedBenefitPlansAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Characteristics of defined benefit plans [axis]",
        "label": "Characteristics of defined benefit plans [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CharacteristicsOfDefinedBenefitPlansDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CharacteristicsOfDefinedBenefitPlansDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Characteristics of defined benefit plans",
        "label": "Characteristics of defined benefit plans [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets",
        "label": "Classes of assets [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of contingent liabilities [axis]",
        "label": "Classes of contingent liabilities [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfContingentLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfContingentLiabilitiesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of contingent liabilities",
        "label": "Classes of contingent liabilities [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets",
        "label": "Classes of financial assets [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities",
        "label": "Classes of financial liabilities [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities",
        "label": "Classes of liabilities [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital",
        "label": "Classes of share capital [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ClinicalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ClinicalServicesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Services",
        "label": "Clinical Services [Member]",
        "documentation": "Clinical Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceDisclosureofeffectofchangesinforeignexchangeratesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Closing rate (\u20ac1 equals to USD)",
        "label": "Closing foreign exchange rate"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationAndLicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationAndLicensingAgreementsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from collaboration and licensing agreements",
        "label": "Collaboration And Licensing Agreements [Member]",
        "documentation": "This member stands for collaboration and licensing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "inpha_ChangeInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Collaboration liabilities - current and non-current portion",
        "label": "Collaboration Liabilities",
        "documentation": "The amount of collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationLiabilitiesCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationLiabilitiesCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration liabilities \u2013 current portion",
        "label": "Collaboration Liabilities - Current Portion",
        "documentation": "The amount of current collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationLiabilitiesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration liabilities",
        "label": "Collaboration Liabilities [Member]",
        "documentation": "This member stands for collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationLiabilitiesNonCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationLiabilitiesNonCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration liabilities \u2013 non-current portion",
        "label": "Collaboration Liabilities - Non-current Portion",
        "documentation": "The amount of non-current collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CollaborationLiabilitiesRollForwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CollaborationLiabilitiesRollForwardAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Liabilities, Roll Forward [Abstract]",
        "label": "Collaboration Liabilities, Roll Forward [Abstract]",
        "documentation": "Collaboration Liabilities, Roll Forward"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CommitmentsContingenciesAndLitigationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CommitmentsContingenciesAndLitigationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments, Contingencies And Litigations [Abstract]",
        "documentation": "Commitments, Contingencies And Litigations"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CompanyInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CompanyInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Information [Abstract]",
        "documentation": "Company Information"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CompanySavingPlanEmployerTopUpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CompanySavingPlanEmployerTopUpMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company saving plan, employer top-up",
        "label": "Company Saving Plan, Employer Top Up [Member]",
        "documentation": "Company Saving Plan, Employer Top Up"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CompanySavingPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CompanySavingPlanMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company saving plan",
        "label": "Company Saving Plan [Member]",
        "documentation": "Company Saving Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity",
        "label": "Components of equity [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elements which will be reclassified in the consolidated statement of income (loss)",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items which will not reclassified in the consolidated statement of income (loss)",
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss)",
        "label": "Comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In progress",
        "label": "Construction in progress [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Contract liabilities at beginning of period",
        "periodEndLabel": "Contract liabilities at end of period",
        "label": "Contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments (benefits and contributions paid by the employer)",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CumulativeEffectAtDateOfInitialApplicationAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative effect at date of initial application [axis]",
        "label": "Cumulative effect at date of initial application [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepayments made to suppliers",
        "label": "Current advances to suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue \u2013 current portion",
        "label": "Current deferred income including current contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": {
       "parentTag": "inpha_CashCashEquivalentsAndShortTermInvestmentsAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments",
        "label": "Current financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities \u2013 current portion",
        "label": "Current financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, current investments",
        "periodEndLabel": "Ending balance, current investments",
        "label": "Current investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current payables on social security and taxes other than income tax",
        "label": "Current payables on social security and taxes other than income tax"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CurrentPayablesRelatedToCapitalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CurrentPayablesRelatedToCapitalExpenditures",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables related to capital expenditures",
        "label": "Current Payables Related To Capital Expenditures",
        "documentation": "The amount of current payables related to capital expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses, current",
        "terseLabel": "Current prepaid expenses",
        "label": "Current prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions - current portion",
        "label": "Current provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Service cost",
        "label": "Increase in net defined benefit liability (asset) resulting from current service cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense (income)",
        "label": "Current tax expense (income)"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and others (excluding payables related to capital expenditures)",
        "label": "Current Trade Payables And Others Excluding Payables Related To Capital Expenditures",
        "documentation": "The amount of current Trade payables and others, excluding payables related to capital expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade account receivables",
        "label": "Current trade receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "VAT refund",
        "label": "Current value added tax receivables"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DecreaseThroughDeductionsContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DecreaseThroughDeductionsContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deductions",
        "label": "Decrease Through Deductions, Contract Liabilities",
        "documentation": "The decrease in contract liabilities resulting from deductions."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DecreaseThroughDerecognitionNonCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DecreaseThroughDerecognitionNonCurrentFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-current financial assets, disposals",
        "label": "Decrease Through Derecognition Non-current Financial Assets",
        "documentation": "The decrease in non-current financial assets resulting from derecognition."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DecreaseThroughDerecognitionShortTermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DecreaseThroughDerecognitionShortTermInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Short-term investments, disposals",
        "label": "Decrease Through Derecognition Short-term Investment",
        "documentation": "The decrease in current investment resulting from derecognition."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total, disposals",
        "label": "Decrease Through Derecognition Short-term Investment And Non-current Financial Assets",
        "documentation": "The decrease in short-term investment and non-current financial assets resulting from derecognition."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revenue for the six months period/Deductions",
        "negatedTerseLabel": "Recognition in P&amp;L",
        "label": "Decrease through performance obligation being satisfied, contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredIncomeIncludingContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "inpha_ChangeInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue - current and non-current portion",
        "label": "Deferred income including contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DeferredRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DeferredRevenueMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue [Member]",
        "documentation": "This member stands for deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DeferredRevenueRollForwardAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DeferredRevenueRollForwardAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Revenue, Roll Forward [Abstract]",
        "label": "Deferred Revenue, Roll Forward [Abstract]",
        "documentation": "Deferred Revenue, Roll Forward"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DefinedBenefitObligationAtPresentValue",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Defined benefit obligations",
        "label": "Defined benefit obligation, at present value"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DefinitiveAcquisitionOfFreeSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DefinitiveAcquisitionOfFreeSharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definitive Acquisition Of Free Shares",
        "label": "Definitive Acquisition Of Free Shares [Member]",
        "documentation": "Definitive Acquisition Of Free Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation and amortization",
        "label": "Depreciation and amortisation expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation of transactions denominated in foreign currency",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting standards and interpretations",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted income (loss) per share (in EUR per share)",
        "verboseLabel": "Diluted income/(loss) per share (in EUR per share)",
        "label": "Diluted earnings (loss) per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustment for share instruments (in shares)",
        "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of judgments and estimates",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcompliancePolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of cash, cash equivalents and financial assets",
        "label": "Disclosure Of Cash, Cash Equivalents And Financial Assets [Text Block]",
        "documentation": "The disclosure of cash, cash equivalents and financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of changes in the share capital",
        "label": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [Table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Commitmentscontingenciesandlitigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments, contingencies and litigation",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyevents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company and key events",
        "label": "Disclosure Of Company, Significant Agreements And Key Events [Text Block]",
        "documentation": "Disclosure Of Company, Significant Agreements And Key Events"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities [table]",
        "label": "Disclosure of contingent liabilities [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities [table]",
        "label": "Disclosure of contingent liabilities [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans",
        "label": "Disclosure of defined benefit plans [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [line items]",
        "label": "Disclosure of defined benefit plans [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of defined benefit plans [table]",
        "label": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments",
        "label": "Disclosure of detailed information about financial instruments [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of revenue from collaboration and licensing agreements",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Incomelosspershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income / (loss) per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/BasisofpresentationandstatementofcomplianceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of effect of changes in foreign exchange rates",
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Employeebenefit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit",
        "label": "Disclosure of employee benefits [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Eventsafterthereportingdate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events after the reporting date",
        "label": "Disclosure of events after reporting period [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of expenses by nature",
        "label": "Disclosure of expenses by nature [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfExpensesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Operatingexpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Disclosure of expenses [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Netfinancialincomeloss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net financial income / (loss)",
        "label": "Disclosure of finance income (cost) [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Cashcashequivalentsshortterminvestmentsandnoncurrentfinancialassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, short-term investments and non-current financial assets",
        "label": "Disclosure of financial assets [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [Line Items]",
        "label": "Disclosure of financial assets [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [Table]",
        "label": "Disclosure of financial assets [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Financialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments recognized in the statement of financial position and related effect on the income statement",
        "label": "Disclosure of financial instruments [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Financialliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [Line Items]",
        "label": "Disclosure of financial liabilities [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities per maturity",
        "label": "Disclosure Of Financial Liabilities Per Maturity [Table Text Block]",
        "documentation": "The disclosure of financial liabilities per maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [Table]",
        "label": "Disclosure of financial liabilities [table]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of government financing for research expenditures",
        "label": "Disclosure Of Government Financing For Research Expenditures [Table Text Block]",
        "documentation": "The disclosure of government financing for research expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Incometaxexpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax / (expense)",
        "label": "Disclosure of income tax [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfIncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfIncomeTaxLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Income Tax [Line Items]",
        "label": "Disclosure Of Income Tax [Line Items]",
        "documentation": "Disclosure Of Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfIncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfIncomeTaxTable",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Income Tax [Table]",
        "label": "Disclosure Of Income Tax [Table]",
        "documentation": "Disclosure Of Income Tax [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of information about defined benefit plans [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Intangibleassets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disclosure of intangible assets [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Capital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital",
        "label": "Disclosure of issued capital [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfKeyManagementPersonnelCompensationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfKeyManagementPersonnelCompensationTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of key management personnel compensation",
        "label": "Disclosure Of Key Management Personnel Compensation [Table Text Block]",
        "documentation": "The disclosure for key management personnel compensation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Basisofpresentationandstatementofcompliance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation and statement of compliance",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Line Items [Line Items]",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Table [Table]",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Managementoffinancialrisks"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management of financial risks",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net defined benefit liability (asset)",
        "label": "Disclosure of net defined benefit liability (asset) [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfNetFinancialIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfNetFinancialIncomeLossTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of net financial income (loss)",
        "label": "Disclosure Of Net Financial Income (Loss) [Table Text Block]",
        "documentation": "The disclosure of net financial income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]",
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average exercise prices of other equity instruments",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfOperatingExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfOperatingExpensesLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating expenses [Line Items]",
        "label": "Disclosure of operating expenses [Line Items]",
        "documentation": "Disclosure of operating expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfOperatingExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfOperatingExpensesTable",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating expenses [Table]",
        "label": "Disclosure of operating expenses [Table]",
        "documentation": "Disclosure of operating expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Line Items [Line Items]",
        "label": "Disclosure of operating segments [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [Table]",
        "label": "Disclosure of operating segments [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Propertyandequipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [Line Items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in short-term investments and non-current financial assets",
        "label": "Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Relatedpartytransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions",
        "label": "Disclosure of related party [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Revenueandotherincome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and other income",
        "label": "Disclosure of revenue [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Line Items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [Table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Tradepayablesandothers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and others",
        "label": "Disclosure of trade and other payables [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/Tradereceivablesandothers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others",
        "label": "Disclosure of trade and other receivables [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfTradePayablesAndOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfTradePayablesAndOthersLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of trade payables and others [Line Items]",
        "label": "Disclosure of trade payables and others [Line Items]",
        "documentation": "Disclosure of trade payables and others [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfTradePayablesAndOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfTradePayablesAndOthersTable",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of trade payables and others [Table]",
        "label": "Disclosure of trade payables and others [Table]",
        "documentation": "Disclosure of trade payables and others [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfTradePayablesAndOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfTradePayablesAndOthersTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of trade payables and others",
        "label": "Disclosure Of Trade Payables And Others [Text Block]",
        "documentation": "The disclosure of trade payables and others."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfTradeReceivablesAndOtherTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfTradeReceivablesAndOtherTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of trade receivables and others",
        "label": "Disclosure Of Trade Receivables And Other [Table Text Block]",
        "documentation": "The disclosure of trade receivables and other."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [Line Items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [Table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_DisclosureOfVarianceOfDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "DisclosureOfVarianceOfDeferredRevenueTableTextBlock",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of variance of deferred revenue",
        "label": "Disclosure Of Variance Of Deferred Revenue [Table Text Block]",
        "documentation": "The disclosure of variance of deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "label": "Disposals, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share :",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of income (loss) per share",
        "label": "Earnings per share [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of the exchange rate changes",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Personnel expenses",
        "label": "Employee benefits expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.innate-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "terseLabel": "Total shareholders\u2019 equity",
        "label": "Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Equity and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ExerciseAndSubscriptionOfEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ExerciseAndSubscriptionOfEquityInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise and subscription of equity instruments",
        "label": "Exercise And Subscription Of Equity Instruments",
        "documentation": "The increase (decrease) in equity resulting from exercise and subscription of equity instruments."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ExerciseAndSubscriptionOfEquityInstrumentsInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ExerciseAndSubscriptionOfEquityInstrumentsInShares",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise and subscription of equity instruments (in shares)",
        "label": "Exercise And Subscription Of Equity Instruments, In Shares",
        "documentation": "The increase (decrease) in the number of shares issued resulting from exercise and subscription of equity instruments."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ExerciseOfShareWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ExerciseOfShareWarrantsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Of Share Warrants",
        "label": "Exercise Of Share Warrants [Member]",
        "documentation": "Exercise Of Share Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share-based compensation",
        "label": "Expense from share-based payment transactions with employees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of change in deferred revenue and collaboration liabilities",
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ExternalCostsRelatedToTheClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ExternalCostsRelatedToTheClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External costs related to the clinical trial",
        "label": "External Costs Related To The Clinical Trial",
        "documentation": "External Costs Related To The Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financial expenses",
        "negatedTotalLabel": "Financial expenses",
        "label": "Finance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial income",
        "totalLabel": "Financial income",
        "label": "Finance income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net financial income (loss)",
        "label": "Finance income (cost)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets",
        "label": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at amortised cost, category",
        "label": "Financial assets at amortised cost, category [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets, fair value",
        "label": "Financial assets, at fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value through profit or loss, category",
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialAssetsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialAssetsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Financial Assets, Cash And Cash Equivalents [Member]",
        "documentation": "Financial Assets, Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialAssetsShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialAssetsShortTermInvestmentsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Financial Assets, Short-Term Investments [Member]",
        "documentation": "Financial Assets, Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, category",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value through profit or loss, category",
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialLiabilitiesCurrentPortionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialLiabilitiesCurrentPortionMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities\u2014current portion",
        "label": "Financial Liabilities, Current Portion [Member]",
        "documentation": "This member stands for financial liabilities\u2014current portion."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialLiabilitiesNonCurrentPortionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialLiabilitiesNonCurrentPortionMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities\u2014non-current portion",
        "label": "Financial Liabilities, Non-current Portion [Member]",
        "documentation": "This member stands for financial liabilities\u2014non-current portion."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialLiabilitiesTradePayablesAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialLiabilitiesTradePayablesAndOthers",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities",
        "label": "Financial Liabilities, Trade Payables And Others",
        "documentation": "The amount of financial liabilities, trade payables and others."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FinancialLiabilitiesTradePayablesAndOthersAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FinancialLiabilitiesTradePayablesAndOthersAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities, fair value",
        "label": "Financial Liabilities, Trade Payables And Others, At Fair Value",
        "documentation": "The fair value of financial liabilities, trade payables and other."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate",
        "label": "Fixed interest rate [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_FreeSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "FreeSharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free Shares",
        "label": "Free Shares [Member]",
        "documentation": "Free Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Actuarial (gain) / loss",
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposal of property and equipment (scrapping)",
        "label": "Gains (losses) on disposals of property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_GovernmentFinancingForResearchExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "GovernmentFinancingForResearchExpenditures",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government financing for research expenditures",
        "totalLabel": "Government financing for research expenditures",
        "label": "Government Financing For Research Expenditures",
        "documentation": "The amount of income recognised in relation to government financing for research expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_GrantsOfEmployeeEquityInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "GrantsOfEmployeeEquityInstrumentsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants of employee equity instruments",
        "label": "Grants Of Employee Equity Instruments [Member]",
        "documentation": "Grants Of Employee Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GuaranteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GuaranteesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantees",
        "label": "Guarantees [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IPH5201AndAdvoralimabAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IPH5201AndAdvoralimabAgreementsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invoicing of R&amp;D costs (IPH5201 agreement)",
        "label": "IPH5201 And Advoralimab Agreements [Member]",
        "documentation": "This member stands for IPH5201 and IPH5401 agreements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPH5201 (anti-CD39) rights acquired from Orega Biotech",
        "label": "IPH5201 (Anti-CD39) Rights Acquired From Orega Biotech [Member]",
        "documentation": "This member stands for IPH5201 (Anti-CD39) rights acquired from Orega Biotech."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S",
        "label": "IPH5401 (Anti-C5aR) Rights Acquired From Novo Nordisk A/S [Member]",
        "documentation": "This member stands for PH5401 (anti-C5aR) rights acquired from Novo Nordisk A/S."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": {
       "parentTag": "inpha_GovernmentFinancingForResearchExpenditures",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit",
        "label": "Income From Research Tax Credit",
        "documentation": "The amount of income related to research tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit2019": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit2019",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit 2019",
        "label": "Income From Research Tax Credit 2019",
        "documentation": "Income From Research Tax Credit 2019"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit2019And2020Maturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit2019And2020Maturity",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit 2019 and 2020, maturity",
        "label": "Income From Research Tax Credit 2019 And 2020, Maturity",
        "documentation": "Income From Research Tax Credit 2019 And 2020, Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit2020": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit2020",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit 2020",
        "label": "Income From Research Tax Credit 2020",
        "documentation": "Income From Research Tax Credit 2020"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit2020Receivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit2020Receivable",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit 2020, receivable",
        "label": "Income From Research Tax Credit 2020, Receivable",
        "documentation": "Income From Research Tax Credit 2020, Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCredit2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCredit2023",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit 2023",
        "label": "Income From Research Tax Credit 2023",
        "documentation": "Income From Research Tax Credit 2023"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeFromResearchTaxCreditHalfYear2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeFromResearchTaxCreditHalfYear2024",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from research tax credit HY 2024",
        "label": "Income From Research Tax Credit Half Year 2024",
        "documentation": "The amount of income related to research tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncomeLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Tax expense (income)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IAS19 Restatement related to change in calculation method - IFRIC",
        "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, variation of accrued interest",
        "label": "Increase (Decrease) In Accrued Interest For Current Financial Assets Not At Fair Value Through Profit Or Loss",
        "documentation": "The amount of income arising from interest for current financial assets that are not at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets, variation of accrued interest",
        "label": "Increase (Decrease) In Accrued Interest For Non-current Financial Assets Not At Fair Value Through Profit Or Loss",
        "documentation": "The amount of income arising from interest for non-current financial assets that are not at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total variance of accrued interest",
        "label": "Increase (Decrease) In Accrued Interest For Short-term And Non-current Financial Assets Not At Fair Value Through Profit Or Loss",
        "documentation": "The amount of income arising from interest for short-term and non-current financial assets that are not at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase / (decrease) in cash and cash equivalents:",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseDecreaseInFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseDecreaseInFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write-off of lease liability",
        "label": "Increase (Decrease) In Financial Liabilities",
        "documentation": "Increase (Decrease) In Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in working capital",
        "negatedTotalLabel": "Total change in working capital, variance",
        "label": "Increase (decrease) in working capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of prior period income (loss)",
        "label": "Increase (decrease) through appropriation of retained earnings, equity"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseDecreaseThroughForeignExchangeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate variation (non cash)",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Liabilities",
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shared-based payment",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transfers",
        "label": "Increase (decrease) through transfers, property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase Through Performance Obligation Being Satisfied, Contract Liabilities",
        "documentation": "The increase in contract liabilities resulting from additions."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IncreaseThroughUpfrontPaymentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IncreaseThroughUpfrontPaymentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds",
        "label": "Increase Through Upfront Payment, Contract Liabilities",
        "documentation": "The increase in contract liabilities resulting from upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Intangible assets other than goodwill at beginning of period",
        "periodEndLabel": "Intangible assets other than goodwill at end of period",
        "verboseLabel": "Intangible assets other than goodwill",
        "label": "Intangible assets other than goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsUnderDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsUnderDevelopmentMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In progress",
        "label": "Intangible assets under development [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IntellectualPropertyExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IntellectualPropertyExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intellectual property expenses",
        "label": "Intellectual Property Expenses",
        "documentation": "The amount of intellectual property expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest on financial liabilities",
        "label": "Interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_InterestsAndGainsOnFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "InterestsAndGainsOnFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests on financial assets",
        "label": "Interests And Gains On Financial Assets",
        "documentation": "The amount of interests and gains on financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_IssuedCapitalFreeOfSubscriptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "IssuedCapitalFreeOfSubscriptionMember",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued capital free of subscription",
        "label": "Issued Capital Free Of Subscription [Member]",
        "documentation": "Issued Capital Free Of Subscription"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Executive Board Members and other Executive Members compensation",
        "label": "Key management personnel compensation"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_KeyManagementPersonnelCompensationAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "KeyManagementPersonnelCompensationAdvisoryFees",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisory fees",
        "label": "Key Management Personnel Compensation, Advisory Fees",
        "documentation": "Key Management Personnel Compensation, Advisory Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Extra pension benefits",
        "label": "Key management personnel compensation, post-employment benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Key management personnel compensation, share-based payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureofkeymanagementpersonnelcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Personnel and other short-term employee benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LaboratoryEquipmentAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LaboratoryEquipmentAndOtherMember",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment and other",
        "label": "Laboratory Equipment And Other [Member]",
        "documentation": "This member stands for laboratory equipment and other."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LandAndBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LandAndBuildingsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lands and buildings",
        "label": "Land and buildings [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over 5 years",
        "label": "Later than five years [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From 2nd to 5th year included",
        "label": "Later than two years and not later than five years [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeaseFinancingObligationsBuildingLeVirageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeaseFinancingObligationsBuildingLeVirageMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities \u2013 Building \"Le Virage\"",
        "label": "Lease Financing Obligations, Building, \"Le Virage\" [Member]",
        "documentation": "Related to the finance lease obligations for the \"Le Virage\" building."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeaseFinancingObligationsEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeaseFinancingObligationsEquipmentMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities \u2013 Laboratory equipment",
        "label": "Lease Financing Obligations, Equipment [Member]",
        "documentation": "This member stands for lease finance obligations, equipment."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeaseFinancingObligationsInnateIncPremisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeaseFinancingObligationsInnateIncPremisesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities \u2013 Premises Innate Inc.",
        "label": "Lease Financing Obligations, Innate Inc. Premises [Member]",
        "documentation": "Related to the lease financing obligations for the Innate Inc. premises."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeaseFinancingObligationsPrintersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeaseFinancingObligationsPrintersMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities - Printers",
        "label": "Lease Financing Obligations, Printers [Member]",
        "documentation": "Lease Financing Obligations, Printers"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeaseFinancingObligationsVehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeaseFinancingObligationsVehiclesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities \u2013 Vehicles",
        "label": "Lease Financing Obligations, Vehicles [Member]",
        "documentation": "Related to the lease financing obligation for vehicles."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LeasingAndMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LeasingAndMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Leasing and maintenance",
        "label": "Leasing And Maintenance",
        "documentation": "The amount of leasing and maintenance."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net defined benefit liability (asset) at beginning of period",
        "periodEndLabel": "Net defined benefit liability (asset) at end of period",
        "label": "Net defined benefit liability (asset)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased licenses",
        "label": "Licences [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LoanAgreementCollateral": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LoanAgreementCollateral",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement, collateral",
        "label": "Loan Agreement Collateral",
        "documentation": "The value of collateral in connection with the loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LoanAgreementMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LoanAgreementMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement, maximum borrowing capacity",
        "label": "Loan Agreement Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LoanAgreementWithSocitGnraleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LoanAgreementWithSocitGnraleMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale",
        "label": "Loan Agreement With Soci\u00e9t\u00e9 G\u00e9n\u00e9rale [Member]",
        "documentation": "This member stands for loan agreement with Soci\u00e9t\u00e9 G\u00e9n\u00e9rale."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LoanBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LoanBuildingMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing \u2013 Building (2)",
        "label": "Loan, Building [Member]",
        "documentation": "This member stands for loan, building."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_LoanEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "LoanEquipmentMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing \u2013 Equipment",
        "label": "Loan, Equipment [Member]",
        "documentation": "This member stands for loan, equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities",
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity",
        "label": "Maturity [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_MonalizumabAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "MonalizumabAgreementMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monalizumab agreement",
        "verboseLabel": "Monalizumab agreement (AstraZeneca)",
        "label": "Monalizumab Agreement [Member]",
        "documentation": "This member stands for monalizumab agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_MonalizumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "MonalizumabMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monalizumab",
        "label": "Monalizumab [Member]",
        "documentation": "This member stands for Monalizumab."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Monalizumab (NKG2A) agreement with Novo Nordisk",
        "label": "Monalizumab Rights Under The 2014 Monalizumab (NKG2A) Novo Nordisk Agreement [Member]",
        "documentation": "This member stands for Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NetAmountsReceivablePayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NetAmountsReceivablePayableRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsDisclosureoftransactionsbetweenrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net receivables (liabilities)",
        "label": "Net Amounts Receivable (Payable) Related Party Transactions",
        "documentation": "The net amounts of receivables (payable) resulting from related party transactions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange gains",
        "label": "Net foreign exchange gain"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange losses",
        "label": "Net foreign exchange loss"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCancellableOffBalanceSheetPurchasedCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCancellableOffBalanceSheetPurchasedCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancellable off-balance sheet purchase commitments",
        "label": "Non Cancellable Off Balance Sheet Purchased Commitments",
        "documentation": "Represents the amount of non-cancellable off-balance sheet purchase commitments as of the specified date."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentFinancialAssetsAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "label": "Non-Current Financial Assets [Abstract]",
        "documentation": "Non-Current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentFinancialAssetsAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentFinancialAssetsAcquisitions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalAcquisitions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets, acquisitions",
        "label": "Non-current Financial Assets, Acquisitions",
        "documentation": "The increase in non-current financial assets resulting from origination or purchase."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentFinancialAssetsForeignCurrencyEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentFinancialAssetsForeignCurrencyEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalForeignCurrencyEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets, foreign currency effect",
        "label": "Non-current Financial Assets, Foreign Currency Effect",
        "documentation": "The increase (decrease) in non-current financial assets resulting from foreign exchange and other movements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentFinancialAssetsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "label": "Non-current Financial Assets [Member]",
        "documentation": "This member stands for non-current financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets, variation of fair value through the consolidated statement of income (loss)",
        "label": "Non-current Financial Assets, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)",
        "documentation": "The gains (losses) on non-current financial assets at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses, non-current",
        "label": "Non-Current Prepaid Expenses",
        "documentation": "Non-Current Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonCurrentResearchTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonCurrentResearchTaxCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research tax credit, non-current",
        "label": "Non-Current Research Tax Credit",
        "documentation": "The amount of non-current research tax credit."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NonScientificAdvisoryAndConsulting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NonScientificAdvisoryAndConsulting",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-scientific advisory and consulting",
        "label": "Non-scientific Advisory And Consulting",
        "documentation": "The amount of non-scientific advisory and consulting."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue \u2013 non-current portion",
        "label": "Non-current deferred income including non-current contract liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": {
       "parentTag": "inpha_TotalCashCashEquivalentsAndFinancialAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails",
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "periodStartLabel": "Beginning balance, non-current financial assets",
        "periodEndLabel": "Ending balance, non-current financial assets",
        "label": "Non-current financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities \u2013 non-current portion",
        "label": "Non-current financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions - non-current portion",
        "label": "Non-current provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit obligations",
        "label": "Non-current provisions for employee benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others - non-current",
        "label": "Trade and other non-current receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year",
        "label": "Not later than one year [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Notional amount"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NovoNordiskASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NovoNordiskASMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novo Nordisk A/S",
        "label": "Novo Nordisk A/S [Member]",
        "documentation": "This member stands for Novo Nordisk A/S."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfClinicalProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfClinicalProductCandidates",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of clinical product candidates",
        "label": "Number Of Clinical Product Candidates",
        "documentation": "Number Of Clinical Product Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Number of employees"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfEquityInstrumentsConvertedInOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfEquityInstrumentsConvertedInOrdinaryShares",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity instruments converted in ordinary shares (in shares)",
        "label": "Number Of Equity Instruments Converted In Ordinary Shares",
        "documentation": "Number Of Equity Instruments Converted In Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfExclusiveOptionsGranted": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfExclusiveOptionsGranted",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of exclusive options granted",
        "label": "Number Of Exclusive Options Granted",
        "documentation": "Number Of Exclusive Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfFinancialInstrumentsHeld": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfFinancialInstrumentsHeld",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of SICAV held (in units/shares)",
        "label": "Number Of Financial Instruments Held",
        "documentation": "Number Of Financial Instruments Held"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of free shares granted (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfLicensingAgreementsWithRelatedParties": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfLicensingAgreementsWithRelatedParties",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of licensing agreements",
        "label": "Number Of Licensing Agreements With Related Parties",
        "documentation": "Number Of Licensing Agreements With Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfLoans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfLoans",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of loans",
        "label": "Number Of Loans",
        "documentation": "Number Of Loans"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfOptionsExcercisedForLicenses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfOptionsExcercisedForLicenses",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options excercised for licenses",
        "label": "Number of Options Excercised For Licenses",
        "documentation": "Number of Options Excercised For Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement (in shares)",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments forfeited in share-based payment arrangement (in shares)",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments outstanding in share-based payment arrangement (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfPreclinicalMolecules": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfPreclinicalMolecules",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of preclinical molecules",
        "label": "Number Of Preclinical Molecules",
        "documentation": "Number Of Preclinical Molecules"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "terseLabel": "Total number of shares issued (in shares)",
        "label": "Number of shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding (in shares)",
        "label": "Number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfStateGuaranteedLoans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfStateGuaranteedLoans",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of state guaranteed loans",
        "label": "Number Of State Guaranteed Loans",
        "documentation": "Number Of State Guaranteed Loans"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfTargetOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfTargetOptions",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of target options",
        "label": "Number Of Target Options",
        "documentation": "Number Of Target Options"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_NumberOfWhollyOwnedSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subsidiaries",
        "label": "Number Of Wholly Owned Subsidiaries",
        "documentation": "Number Of Wholly Owned Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_OffsetAgainstIncomeFromResearchTaxCredit2020": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OffsetAgainstIncomeFromResearchTaxCredit2020",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset against income from research tax credit 2020",
        "label": "Offset Against Income From Research Tax Credit 2020",
        "documentation": "Offset Against Income From Research Tax Credit 2020"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_OffsetOfRestatedIncomeFromResearchTaxCredit2020": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OffsetOfRestatedIncomeFromResearchTaxCredit2020",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset of restated income from research tax credit",
        "label": "Offset Of Restated Income From Research Tax Credit 2020",
        "documentation": "Offset Of Restated Income From Research Tax Credit 2020"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opening balance after adjustment",
        "label": "Opening balance after adjustment, cumulative effect at date of initial application [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofnetdefinedbenefitliabilityassetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opening balance before adjustment, cumulative effect at date of initial application",
        "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating expenses",
        "label": "Operating expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Ordinary shares [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other profit or loss items with no cash effect",
        "label": "Other adjustments for non-cash items"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation gain (loss)",
        "verboseLabel": "Foreign currency translation loss",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actuarial gains and (losses) related to defined benefit obligations",
        "verboseLabel": "Actuarial gains on defined benefit obligations",
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current payables",
        "label": "Other current payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_OtherCurrentTaxCreditsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OtherCurrentTaxCreditsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other tax credits",
        "label": "Other Current Tax Credits Receivables",
        "documentation": "The amount of other current tax credits receivables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherDisposalsOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherDisposalsOfAssetsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other disposals of assets [member]",
        "label": "Other disposals of assets [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_OtherFinancialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OtherFinancialExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "auth_ref": []
    },
    "inpha_OtherFinancialIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OtherFinancialIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "label": "Other intangible assets [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current non-financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income and (expenses), net",
        "label": "Other operating income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_OtherPurchasesAndExternalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "OtherPurchasesAndExternalExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other purchases and external expenses",
        "label": "Other Purchases And External Expenses",
        "documentation": "The amount of other purchases and external expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other reserves",
        "label": "Other reserves"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PGELoanAgreementAccruedInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PGELoanAgreementAccruedInterestMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State guaranteed loans - accrued interest",
        "label": "PGE Loan Agreement, Accrued Interest [Member]",
        "documentation": "PGE Loan Agreement, Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PGELoanAgreementBNPParibasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PGELoanAgreementBNPParibasMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State guaranteed loan BNP Paribas (1)",
        "label": "PGE Loan Agreement, BNP Paribas [Member]",
        "documentation": "PGE Loan Agreement, BNP Paribas"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PGELoanAgreementSocieteGeneraleAndBNPParibasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PGELoanAgreementSocieteGeneraleAndBNPParibasMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State guaranteed loan, Societe Generale and BNP Paribas",
        "label": "PGE Loan Agreement, Societe Generale And BNP Paribas [Member]",
        "documentation": "PGE Loan Agreement, Societe Generale And BNP Paribas"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PGELoanAgreementSocieteGeneraleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PGELoanAgreementSocieteGeneraleMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureofmaturityanalysisfornonderivativefinancialliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State guaranteed loan Soci\u00e9t\u00e9 G\u00e9n\u00e9rale (1)",
        "label": "PGE Loan Agreement, Societe Generale [Member]",
        "documentation": "PGE Loan Agreement, Societe Generale"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Par value per share (in EUR per share)",
        "label": "Par value per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax and employee-related payables",
        "label": "Payables on social security and taxes other than income tax"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PaymentOfTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PaymentOfTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of short term tax liability",
        "label": "Payment Of Taxes Other Than Income Tax",
        "documentation": "Payment Of Taxes Other Than Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment on social security and taxes other than income tax",
        "label": "Payment On Social Security And Taxes Other Than Income Tax",
        "documentation": "Payment On Social Security And Taxes Other Than Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PaymentsForMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PaymentsForMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for milestone",
        "label": "Payments For Milestone",
        "documentation": "Represents payments for milestone."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_PreclinicalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "PreclinicalServicesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical Services",
        "label": "Preclinical Services [Member]",
        "documentation": "Preclinical Services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Shares",
        "label": "Preference shares [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowing",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise / subscription of equity instruments",
        "label": "Proceeds from issuing shares"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from lease liabilities and other non cash effects",
        "label": "Proceeds From Lease Liabilities, Classified As Financing Activities",
        "documentation": "The amount of proceeds from lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of other assets",
        "label": "Proceeds from sales of other long-term assets, classified as investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal of current financial instruments",
        "label": "Proceeds From Sales Of Current Financial Instruments, Classified As Investing Activities",
        "documentation": "Proceeds From Sales Of Current Financial Instruments, Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services",
        "label": "Products and services [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsThecompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss) for the period:",
        "terseLabel": "Net income (loss)",
        "netLabel": "Net loss for the period",
        "label": "Profit (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) before tax",
        "label": "Profit (loss) before tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss)",
        "label": "Profit (loss) from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "periodStartLabel": "Property, plant and equipment including right-of-use assets at beginning of period",
        "periodEndLabel": "Property, plant and equipment including right-of-use assets at end of period",
        "label": "Property, plant and equipment including right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment including right-of-use assets [axis]",
        "label": "Property, plant and equipment including right-of-use assets [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment including right-of-use assets [domain]",
        "label": "Property, plant and equipment including right-of-use assets [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ProvisionForAttendanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ProvisionForAttendanceFees",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for attendance fees",
        "label": "Provision For Attendance Fees",
        "documentation": "The amount of provision for attendance fees."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ProvisionForExpensesWithRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ProvisionForExpensesWithRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RelatedpartytransactionsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for expenses with related parties",
        "label": "Provision For Expenses With Related Parties",
        "documentation": "Provision For Expenses With Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProvisionForTaxesOtherThanIncomeTaxMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for taxes other than income tax",
        "label": "Provision for taxes other than income tax [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Provisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Provisions",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total provisions",
        "label": "Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of other assets",
        "label": "Purchase of other long-term assets, classified as investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of property and equipment, net",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RawMaterialsAndConsumablesUsed",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of supplies and consumable materials",
        "label": "Raw materials and consumables used"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]",
        "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transactions [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of borrowings",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings/leases liabilities",
        "label": "Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities",
        "documentation": "Repayments Of Borrowings Net Of Exchange Rate Variation, Classified As Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Research And Development [Member]",
        "documentation": "Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ResearchTaxCreditReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ResearchTaxCreditReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherCurrentReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit",
        "label": "Research Tax Credit, Receivable, Current",
        "documentation": "Research Tax Credit, Receivable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained earnings, excluding profit (loss) for reporting period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained earnings, excluding profit (loss) for reporting period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss)",
        "label": "Retained earnings, profit (loss) for reporting period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriodMember",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss)",
        "label": "Retained earnings, profit (loss) for reporting period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RetirementDefinedBenefitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RetirementDefinedBenefitMember",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for retirement defined benefit",
        "label": "Retirement Defined Benefit [Member]",
        "documentation": "This member stands for retirement defined benefit."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue and other income",
        "label": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss",
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaboration and licensing agreements",
        "label": "Revenue from contracts with customers"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance received",
        "label": "Revenue From Contracts With Customers, Advance Payment Received",
        "documentation": "The amount of advance received by the company."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance received - exclusive license",
        "label": "Revenue From Contracts With Customers, Advance Payment Received, Licenses",
        "documentation": "The cash outflow for licenses."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for research work",
        "label": "Revenue From Contracts With Customers, Advance Payment Received, Research",
        "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Research"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for target options",
        "label": "Revenue From Contracts With Customers, Advance Payment Received, Target Options",
        "documentation": "Revenue From Contracts With Customers, Advance Payment Received, Target Options"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred revenue/Additions",
        "label": "Revenue From Contracts With Customers, Milestone",
        "documentation": "Revenue From Contracts With Customers, Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received",
        "label": "Revenue From Contracts With Customers, Milestone Payment Received",
        "documentation": "Revenue From Contracts With Customers, Milestone Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received - option exercised",
        "label": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised",
        "documentation": "Revenue From Contracts With Customers, Milestone Payment Received - Option Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails": {
       "parentTag": "inpha_GovernmentFinancingForResearchExpenditures",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofgovernmentfinancingforresearchexpendituresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Grant",
        "label": "Income from government grants"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RevenuesFromContractLiabilitiesRecognitionPeriodMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RevenuesFromContractLiabilitiesRecognitionPeriodMaximum",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from contract liabilities, period",
        "label": "Revenues From Contract Liabilities, Recognition Period, Maximum",
        "documentation": "Revenues From Contract Liabilities, Recognition Period, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/PropertyandequipmentDisclosureofdetailedinformationaboutpropertyplantandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_RiskProfileRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "RiskProfileRate",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk profile rate",
        "label": "Risk Profile Rate",
        "documentation": "Risk Profile Rate"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SICAVAndMutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SICAVAndMutualFundsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SICAV and mutual funds",
        "label": "SICAV And Mutual Funds [Member]",
        "documentation": "SICAV And Mutual Funds"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SICAVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SICAVMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SICAV",
        "label": "SICAV [Member]",
        "documentation": "SICAV"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Marketing, communication and public relations",
        "label": "Sales and marketing expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SanofiOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SanofiOptionsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi (2022) option",
        "label": "Sanofi, Options [Member]",
        "documentation": "Sanofi, Options"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SanofiResearchCollaborationAndLicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SanofiResearchCollaborationAndLicensingAgreementMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement with Sanofi, 2022",
        "label": "Sanofi Research Collaboration And Licensing Agreement [Member]",
        "documentation": "Sanofi Research Collaboration And Licensing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SanofiServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SanofiServicesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sanofi (2022) services",
        "label": "Sanofi, Services [Member]",
        "documentation": "Sanofi, Services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails",
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails",
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ScientificAdvisoryAndConsulting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ScientificAdvisoryAndConsulting",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Scientific advisory and consulting",
        "label": "Scientific Advisory And Consulting",
        "documentation": "The amount of Scientific advisory and consulting."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsReleased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsReleased",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security interest on pledge of financial instruments released",
        "label": "Security Interest On Pledge Of Financial Instruments Released",
        "documentation": "The values of security interest on the pledge of financial instruments will be released in 2024."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security interest on pledge of financial instruments will be released in 2024",
        "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2024",
        "documentation": "The values of security interest on the pledge of financial instruments will be released in 2024."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security interest on pledge of financial instruments will be released in 2027",
        "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2027",
        "documentation": "The values of security interest on pledge of financial instruments will be released in 2027."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security interest on pledge of financial instruments will be released in 2031",
        "label": "Security Interest On Pledge Of Financial Instruments Will Be Released In 2031",
        "documentation": "The values of Security interest on pledge of financial instruments will be released in 2024."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security interest on pledge of financial instruments released in 2024 including interest",
        "label": "Security Interest On Pledged Financial Instruments Released, Including Interest",
        "documentation": "Security Interest On Pledged Financial Instruments Released, Including Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "G&amp;A",
        "label": "Selling, general and administrative expense [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SeniorityAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SeniorityAwardsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/EmployeebenefitDisclosureofdefinedbenefitplansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for seniority awards",
        "label": "Seniority Awards [Member]",
        "documentation": "This member stands for seniority awards."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShareCapitalAndShareBasePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShareCapitalAndShareBasePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital and Share Base Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShareIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShareIssuedPricePerShare",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issued, price per share (in EUR per share)",
        "label": "Share Issued Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of own shares (in shares)",
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShortTermInvestments1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShortTermInvestments1Abstract",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short Term Investments1 [Abstract]",
        "documentation": "Short Term Investments1"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShortTermInvestmentsAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShortTermInvestmentsAcquisitions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalAcquisitions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, acquisitions",
        "label": "Short-term Investments, Acquisitions",
        "documentation": "The increase in current investment resulting from origination or purchase."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShortTermInvestmentsAndNonCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShortTermInvestmentsAndNonCurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, total",
        "periodEndLabel": "Ending balance, total",
        "label": "Short-term Investments And Non-current Financial Assets",
        "documentation": "The amount of short-term investments and non-current financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShortTermInvestmentsForeignCurrencyEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShortTermInvestmentsForeignCurrencyEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalForeignCurrencyEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, foreign currency effect",
        "label": "Short-term Investments, Foreign Currency Effect",
        "documentation": "The increase (decrease) in current financial assets resulting from foreign exchange and other movements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, variation of fair value through the consolidated statement of income (loss)",
        "label": "Short-term Investments, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)",
        "documentation": "The gains (losses) on current financial assets at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermEmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Personnel expenses other than share-based compensation",
        "terseLabel": "Personnel expenses other than share-based compensation",
        "label": "Short-term employee benefits expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimConsolidatedStatementofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails",
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_StockOptions20201Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "StockOptions20201Member",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options 2020-1",
        "label": "Stock Options 2020-1 [Member]",
        "documentation": "Stock Options 2020-1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SubcontractingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SubcontractingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Subcontracting costs",
        "label": "Subcontracting Costs",
        "documentation": "The amount of subcontracting costs."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_SummaryOfChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "SummaryOfChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in working capital",
        "label": "Summary Of Changes In Working Capital [Abstract]",
        "documentation": "Summary Of Changes In Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxContingentLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxContingentLiabilityMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax contingent liability",
        "label": "Tax contingent liability [member]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_The2016FreePreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "The2016FreePreferredSharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2016 free preferred shares",
        "label": "The 2016 Free Preferred Shares [Member]",
        "documentation": "Related to the 2016 free preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_The2017FreePreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "The2017FreePreferredSharesMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The 2017 free preferred shares",
        "label": "The 2017 Free Preferred Shares [Member]",
        "documentation": "Related to the 2017 free preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TotalAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TotalAcquisitions",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, acquisitions",
        "label": "Total, Acquisitions",
        "documentation": "The increase in short-term investments and non-current financial assets resulting from origination or purchase."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TotalCashCashEquivalentsAndFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TotalCashCashEquivalentsAndFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofcashcashequivalentsandfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, cash equivalents and financial assets",
        "terseLabel": "Cash, cash equivalents and financial assets",
        "label": "Total Cash, Cash Equivalents And Financial Assets",
        "documentation": "The amount of cash, cash equivalents and financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TotalForeignCurrencyEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TotalForeignCurrencyEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, foreign currency effect",
        "label": "Total, Foreign Currency Effect",
        "documentation": "The increase (decrease) in short-term and non-current financial assets resulting from foreign exchange and other movements."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TotalShortTermInvestmentsAndNonCurrentFinancialAssetsAbstract",
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Total Short-Term Investments And Non-Current Financial Assets [Abstract]",
        "documentation": "Total Short-Term Investments And Non-Current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/CashcashequivalentsshortterminvestmentsandnoncurrentfinancialassetsDisclosureofreconciliationofchangesinshortterminvestmentsandnoncurrentfinancialassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total, variation of fair value through the consolidated statement of income (loss)",
        "label": "Total, Variation Of Fair Value Through The Consolidated Statement Of Income (Loss)",
        "documentation": "The gains (losses) on short-term investment and non-current financial assets at fair value through profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition",
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and others",
        "label": "Trade and other current payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails": {
       "parentTag": "inpha_CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradepayablesandothersDisclosureoftradepayablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suppliers (excluding payables related to capital expenditures)",
        "label": "Current trade payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others",
        "label": "Trade and other current receivables"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TradeAndOtherCurrentReceivablesExcludingRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TradeAndOtherCurrentReceivablesExcludingRebates",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Receivables and others",
        "label": "Trade And Other Current Receivables Excluding Rebates",
        "documentation": "The amount of trade and other current receivables excluding rebates."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TradeAndOtherNonCurrentReceivablesExcludingRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TradeAndOtherNonCurrentReceivablesExcludingRebates",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": "inpha_TradeAndOtherReceivablesExcludingRebates",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Receivables and others - non-current",
        "label": "Trade And Other Non-current Receivables Excluding Rebates",
        "documentation": "The amount of trade and other non current receivables excluding rebates."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "inpha_ChangeInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade payables and others (excluding payables related to capital expenditures)",
        "label": "Trade and other payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "inpha_ChangeInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others - current and non-current portion (excluding receivables related to Property &amp; equipment)",
        "label": "Trade and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TradeAndOtherReceivablesExcludingRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TradeAndOtherReceivablesExcludingRebates",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Trade receivables and others",
        "label": "Trade And Other Receivables Excluding Rebates",
        "documentation": "he amount of trade receivables and other receivables, excluding rebates related to capital expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TradePayablesAndOthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TradePayablesAndOthersMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and others",
        "label": "Trade Payables And Others [Member]",
        "documentation": "This member stands for trade payables and others."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TradeReceivablesAndOthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TradeReceivablesAndOthersMember",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialinstrumentsrecognizedinthestatementoffinancialpositionandrelatedeffectontheincomestatementDisclosureofdetailedinformationaboutfinancialinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables and others",
        "label": "Trade Receivables And Others [Member]",
        "documentation": "This member stands for trade receivables and others."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TransferFromToCollaborationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TransferFromToCollaborationLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofvarianceofdeferredrevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer from / (to) collaboration liabilities",
        "label": "Transfer From (To) Collaboration Liabilities",
        "documentation": "The decrease in contract liabilities resulting from transfer to collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TransferToFromCollaborationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TransferToFromCollaborationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer from / (to) collaboration liabilities",
        "label": "Transfer To (From) Collaboration Liabilities",
        "documentation": "The decrease in contract liabilities resulting from transfer to collaboration liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TravelExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TravelExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesDisclosureofexpensesbynatureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Travel expenses and meeting attendance",
        "label": "Travel expense"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TypeOfEmployeeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TypeOfEmployeeAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type Of Employee [Axis]",
        "label": "Type Of Employee [Axis]",
        "documentation": "Type Of Employee"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TypeOfEmployeeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TypeOfEmployeeDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type Of Employee [Domain]",
        "label": "Type Of Employee [Domain]",
        "documentation": "Type Of Employee [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TypeOfExerciseAndSubscriptionOfSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TypeOfExerciseAndSubscriptionOfSharesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Exercise And Subscription Of Shares [Axis]",
        "label": "Type of Exercise And Subscription Of Shares [Axis]",
        "documentation": "Type of Exercise And Subscription Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_TypeOfExerciseAndSubscriptionOfSharesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "TypeOfExerciseAndSubscriptionOfSharesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Exercise And Subscription Of Shares [Domain]",
        "label": "Type of Exercise And Subscription Of Shares [Domain]",
        "documentation": "Type of Exercise And Subscription Of Shares [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfContractsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfContractsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts [axis]",
        "label": "Types of contracts [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfContractsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfContractsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CommitmentscontingenciesandlitigationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/IntangibleassetsDisclosureofdetailedinformationaboutintangibleassetsDetails",
      "http://www.innate-pharma.com/role/OperatingexpensesAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeAdditionalinformationDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofchangeindeferredrevenueandcollaborationliabilitiesDetails",
      "http://www.innate-pharma.com/role/RevenueandotherincomeDisclosureofrevenuefromcollaborationandlicensingagreementsDetails",
      "http://www.innate-pharma.com/role/TheCompanyandkeyeventsKeyeventsforthesixmonthperiodendedJune302024Details",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of contracts",
        "label": "Types of contracts [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of financial assets [axis]",
        "label": "Types of financial assets [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfFinancialAssetsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails",
      "http://www.innate-pharma.com/role/TradereceivablesandothersDisclosureoftradereceivablesandothersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of financial assets",
        "label": "Types of financial assets [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/FinancialliabilitiesDisclosureoffinancialliabilitiespermaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates",
        "label": "Types of interest rates [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalAdditionalInformationDetails",
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements",
        "label": "Types of share-based payment arrangements [domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inpha_UnrealizedLossesOnFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "UnrealizedLossesOnFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.innate-pharma.com/role/NetfinancialincomelossDisclosureofnetfinancialincomelossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses on financial assets",
        "label": "Unrealized Losses On Financial Assets",
        "documentation": "The amount of unrealized losses on financial assets."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_UnusedTaxLossesSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "UnusedTaxLossesSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses subject to expiration",
        "label": "Unused Tax Losses Subject To Expiration",
        "documentation": "The amount of unused tax losses subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "inpha_UnusedTaxLossesWithNoExpirationDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.innate-pharma.com/20240630",
     "localname": "UnusedTaxLossesWithNoExpirationDate",
     "crdr": "debit",
     "presentation": [
      "http://www.innate-pharma.com/role/IncometaxexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses with no expiration date",
        "label": "Unused Tax Losses With No Expiration Date",
        "documentation": "The amount of unused tax losses with no expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.innate-pharma.com/role/CapitalDisclosureofnumberandweightedaverageexercisepricesofotherequityinstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement (in EUR per share)",
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.innate-pharma.com/role/IncomelosspershareSummaryofincomelosspershareDetails",
      "http://www.innate-pharma.com/role/InterimCondensedConsolidatedStatementsofIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares, basic (in shares)",
        "verboseLabel": "Weighted average number of ordinary shares in circulation (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001628280-24-040187-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-040187-xbrl.zip
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M *#HC 7Q7%D'Z0"&:XEDO+(.NL"CL'2"@!EL)W![%$])I,X7G:RR#A)!D;B
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MH*#8J&3D4-A$5)8D][8@UA84U"*!QP[EOJIKVPJ*DDK&# 5-0V6U<F\#8FQ
M0642>(S(Y96V0FU 07%2R1"AG&4X*DN5>Q,08@(*:I'  T0N;P86:@,*BI!*
M!@CU+$-E17)O D),0$'%$4B R.U%S$+Q5E!5!!T,U+0"E67%/=POAEM!J1 .
MR>?R1FNA<"NH"D+G>/6,0&59<(_V"]$N*RCUO9SA 8VW@KJ:*(H%A(+*RI:"
MPPU8+CJ=((I<-K0DBHG+:/X,CTB O1,<L#_BGH^"#9;OXYC0]*&$S8;J@ %8
MN%$"#$?@&_7*@%65EX(QP $)4^:Z0=13B)T :QJ0,1#J!X"%AE4!,&!@X%,T
M(S'R[[U0C;*T']%YVD8AVP=<\3\U[JFQ7TVP;5K5<XIQC^(1IA1[JHT_X&)[
MQ_&OJ3S^%<#E[^)E?.F(#E&$O1Z:IP_#4HJ"<9KU;'#_:3B=H6 ^0-?\M8\L
M,HA'8?O]B;M^\' +LC>]E:T"N()^,V3MZ<P/YZS."V??9IKB![CV?BE^)X-6
MJ\\XT-84*L!U.R"H9,4FP(7Z:T??DN\HZ^.?FZ, +N,!027+40 7\(!H"H2C
M *[S7PM515.H $L#@*"2Q6F A8&7CG[K<ZOW%04HV\4E&TW3@*I&:D(NH$ER
MGJI&$@''8:$*X$AGW]%(%L@#,UFNHU')SV!X'V%'(Z$@#\QDN8Y&(L#]Z*]I
M05K52#O(!319SJ.1,'"/PW3U'8T4@CPPD^4ZFDD%ZYES3=.4K::94B ;,TFN
M4]-,*-B@,&U]1S.E0#IHLIQ'+ZE@@\(T]1R]A +)B,ER&[UD@I,P2#@ =5VC
MC5X"@4RX9#F,7M) KX?I:)VZM/4<O>2!7'"3Y4*:200<BHVT65<?JFNF$^0"
MG"0GJNLE%FQ0F:;>HY=2(!DQ66ZCETS0Q3=9CSK+TW6]A +IF,ER'3VE@H:N
M7J.G5" #+ED.HY=4L$! W\=!ZGI)!%+QDN4RFDD#:TDRPT%/MVEHI@K(QDR2
MZS3T$@0V)J+U]1V]- 'YH,ER'KUD@67HU_4)]X9>BH!,N&0YC%YBP$;0U]9K
M]%($I&,FRW7TD@4V8[ZVOJ.7-B ?-%G.HYE P-^R-D-T'.!V$%,\HR3";,CT
M5-@<4S.I(#_TY+B38^HE&BP3:5O/*.28>LD%,N&2Y3!Z"05;JPCU=1R]!(,\
M8)/E0)H)!UM+"/7U(,W$@SQPD^5"F@D(CV31CJ:.I)F2D!]ZLMQ)+TEA?7FA
M[6@:C2R]A 3IF$ER'4LO^6 [K=;6>_22$?* 398#Z2<G;&35VGJ0?GJ"=-QD
MN9!>@L)&*E#6U7WT$A.D8R;+==Z'D%#6U(G>AY @ 3U9[J21D#"(0_?[Y2QF
MW6C\[()C:Z0CY "9),>Q-9,1^&.*ZX_'-S1U'LUDA!Q@D^5 FLD(Z>"OOYA%
M5P_23$;( S=9+J21C' R:/%/)FJZB-362#R0AY0L-]%(,L@&7]-E!K9&ZH T
MH&0YB49"0#;VFDIHCD;EOS2@)#F)HU'1GXU]15.1S-&HSI>'E"PWT:BT7PR^
MIG6)HU$Q+P\I66ZB7?FNYU<_'$>[ZEV9CWTXCF[%N[9/VSBZ5>\J/5_CZ%:^
M:[L,LZQ;_:[2PLNR'@7\ZIC?$-\91YJZBAY%? YHR7(7P(7\J8^BB$-P3@(4
MN 3Y+?9[DY^Z87":4,JZWFJD#@* "W29"+SD,AB_C$-*'K^25=/MW?$Y(O17
MY"?X:D+#9#SIT7!$XDMZ$4;1HM^Y.K8"6$_0P%9:TY#&A#']:1C%ZAD'8 UC
M%^.XHLC#?>QB<HV&/HY:@7<93S!5B,H!*QDR$=A3^2ML!;"6HH&M*$[E@+6>
M78QC:]=@PL"XPG3:":YQ%*>5DS)85 "K.?E@L:?W5U@-8!E**ZM1F^@K@/6O
M5YC)*8HF+!'@_]/^(V&9@:\6U2LNAHE 8T_VK[ ;Q24\A>Q&<;J'K-_MO7D!
M$F0=[?VZCE+:V@5!0^*3F 'U(-&N[;_3Q'L<GS!0!Q+($M9#CG(?E?O>LMY&
M!*_MS>A9,X(L=@DQH]<P[]YNGK.;JE+"W L@414/R)+7>PL'JMH09#U,^UB@
MJM$H)=L]@D<ZG]I#<T67/E0A2V ZD[_J=J.:(J8LX:MN**JI<D40#""X(,MU
MA?DU('P@:W=@U_T[)<LN.988!"#+7NJOY2Z<347:2DTIJ4LY6\F?RH4:!V3=
M#>RZ?Z$(0%:MU%_+K1>5*R56*6<KBE,Y9!5-@77_0K& K$SIM();+WJ'+%/I
M9#6*$SUD>4R)=?]"T5!<#%-H_;9>9*^XA*>0W:A-]W7(^MW>FQ<@0=;1WJ_K
M**6M@5UX*Q02R!(6E*GXO1D]:T:0Q2ZMEOYH9C=*"7,PE]\*Q0.RY/7>PH&J
M-@19#],^%JAJ-$K)=G"6Y0K% +($IC/Y*VXW#=44,64)7W5#44V54V_=OU"X
M(,MUBJ[[%XH/8.UN\<&%4W;%%+F;4U6GH>^C84@1SU 9BUT0EW<0C%MCBK&D
ME47;7\BPV'^K?G+Z0D8#L$H&&S!G=\ <D8 !EJ>> FR%2Q_[[.:]J[#3^U*U
M3.LW$D\&*&!!25/  .M7.P%V!Q#_HEFK^TO[BD.7PP=-"R%$P%(19+B*\B[
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M?66O(4&&6BC7 ]:0WBO4(,@>L,[U7NU"%MOO%;/\:1>P8E;XF(/@/\!25^$
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M#:=3$O,SRA#YSTF  I<@_Q&1[2)$P<:GR@<AZ_ISP*J1'*2 W;F2-17$E37
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MT L?$5KZK4$A5=Y;'E+CP/%IL& (_@!$5HS) E06X+(B9!U2R*4=8/![629
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MI+O2PV13>I#9DVXA#WVDQLCF7ISBA'#!QP2"?'_(J+MPPH$-ELV?>Z]?""M
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M^V^__I[.\#S >+I8AFFJ"RS&?UJL?OGK+(7E:M>?I>O%HY^H/\'F8U!_!5R
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M%AX24_V]NKA/W6 U:0LX;7FQ<(QPFA8/?\'I)8Z$$Y'9^A3(RW6&T0>&P$M
M;H-G2?=9%[PB:JA*LQM$'"*)SO3G5GO/C9%!<0.%:TF>-AF,H*(CRHQ?-4_4
MXA1&]C%ZN_$TLG683$!BO2:#BH\04573F8LMED>6!N]IG.(.M FJ=O- ]A%1
MRW<XN_C,7'.C54@@A!<UH:@KMQGJ%41*BENF^X-/JPA'G,HN=P"HYE+LPEAG
M03@V K1;77E@36LB^=F)14T!&>>ASS>#6XSU$=QMY%HK3!;_&"_/7E\NEB22
M>6W@F[GP=+"=KM<SCM4"7:/J,"$3N8@NV?ZR3\^2.RQ-? AV'G52&LFH49WK
M+[,O.)^>WY1U3S^O'E MD+[Z;'6.\WAY.:\NFL1H4&O@W)G:.D/6J[[Z)H<.
MKM&2G/![%TR/%KKNONJP_-BC@-#E?K><'_,@NE)>J=H+TB4?:FT<Q5G>($&3
M4!DTYISZTQQ/A[Z'J<ZKO7\US3^3>">SU=2##?/>D+EB3$%!3J&EBY&LE2/W
MB&7IC>>H;9_FX@E2AZ4RCT+1-MW92D@-3\HO."4F)T33JWP^GHX7R\KR%]R0
M90QQ;(EERT.M?>,:O+ "3%9>1&$9"_UUPWJ&V&'IV<;H:2FHX=2FO9Z=7\SQ
MC#Y#K/14J/;8FKU7K>W$?+,2MBVKC7*@4-E;BEZBU 3)6#.?2H%4PADGF//8
M8P?BAP0V3:TZ3%P+CB"U=W7&5#V)@H-,A"#KA/6RO^3B8ZG54]N\8U'RU W-
M7A)H/4UP&V/"29:1C*RQ1(7*9'V#%8D8TU[GI)&)_ARCQZ@<EE5KCX\FTND#
M+9$SSU0AX 9%] @N(.CL0'*7F&8J.-V?*[0;6EKR_QLNWY=/X=LO83Q=U..,
MB_?3CV3+PH)"O95)>U]^QE([FJQ?O=8Y;(L1B[P@Z@0V(J-]DZGNFP7AA);1
ME^ADSZ,Z&W(W+.W=!+N[']%>(-'#T=[P\>9;.@O3S_CSN!2<XS15?C[-B>(K
MF8XLH@D9$9)F6$?6>(B*U)WB1B/I(^-D?UG28[D9EF$Y$72;BGQ <558G+V=
MS+YV'$E=K])_[+2=P7;1TN;[ZU7WWQ?U->SU9>>ME+^,SK+L' 3O,I!CPNK[
M"P-)9!>,B2GS'F?.[41SDY@J(>;5,K4#'GW]JEO58A1D#IIG!3Z7VD$EB3K6
M@?9$N8@YQFRP/X?Z43*'9;,[0-K6(*R!R)JF,B_"][6'\-?9?#[[6CO@O9Z$
MQ6)<QIA?+;9M O.\-MFTP-"2W^"# Q\HBHR<? ;E,V.AO_F6![$PL'1Z+^#K
M7M:->YC?VY&;Q/]5C<GKE<>P>#?]QVS^SSH%:MW_T^E"H7 )X#2KXRMX 2>L
M ^LH6"TU@&4]CI(YF(\&71GR_[E<+%<2?SN;KQ1-#$3"AS4,1E))1*LC^.A*
M]>DXU.85((KQUC/-C>OO*NXY:@=O+KK Y\-3W%2H+5N W*'K[],YALF8Z*(?
M2"+3C8-_%9ZN(M61CCD150R,E:*J%J)9%0Z9]%Q,42=QO]U5;_#;A?YA!6X#
M 61SP7?SOLMF9B./%IS5H?8(UU!;OX&4WC))D6XY2?GHL/KTG0Q2!PJJ]175
M7637-B2T(>]HTVKEH:7_TW4FEB,$RTQ*5D@+W&43HO/<8G]M@)XA=E@=_DX&
MJI8B[<QNO@WC^7^%R27>NLL=9?1*NN3K@UI?W7YRP676D(417-GZS.M4=G(;
MO<-J#C@0NWBT8#N#W,]X,<<TOI+0-+\ZKPTQ%ZL?-T4MT@@C62YDI2,'I5B
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M"[@NHFA5DY7]13U;21Q$,J8G37206#J>CS3"PE#EQ*%HLOA*%P=!D-DO.HA
MS@@S)>QJ;!]98Q"YD>8R;K>M;?NRW//XJBM* *S_JG'*ES!9%3 44\M["\7.
MJ@Y[4#E"U"P!ZF0Y.J,<[Z\_VJY4=UGQ=*<>"RU&[KB'PNI3_B(3..:J+ZSJ
MTU-6JZ('4-VT;[%=?Y4[G>!PR^R2]N+LMKSNW?0++NY1)VQ"X0H%>TG66J+B
MB3!=GXH(9TTHR:63@FT+S8-P]P8 MF/%V2W8ME6:9N&+T4Y#-O692>W;%U-M
M&F;0U.G:0J3^9A4<4L1_ZGJ=TX'M6'$V!-N;4C MWY=-W=G'L-Q<:+U_;#^T
M0^MC]N"TTJ!8#8RB1\B.<^DUHRBIOYO& Q@8A!?;-PR[%G0OQ>QW3HP+]/^K
MX2(ZD5*N$T968T8$*N.]*>0=#-NUZ[G0OP1A3/0!,*PJMJ*$6+OVT/^L$C*@
MZO%"LU6A_ZG=XPZPNH]SW%3HG4:O]^B2V9%O%6PMDN'D8%D&H0ARL+Q6!IE$
MP?I[<_<<M<-__M0><TTEV">R* 1,66L.K(I;!6XA()+_'H2,W@K+3:^]:O=
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M.E*8N5#& S=UBJFV!KP1&1S#:"E@D/'^4[ZG+<[M+V]O/NZ0[A5CPF9-!*=
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M #Q8$:,8"(759H#K].3^1W,TOOQP<H:.6ON9/'O\X#^P_2"$)SL#A"*9;4\
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M&DIB(FI'CKW*,_E2LD.R4FDJ-%&A,)@7@#(;>R E)&97PFO\L;@<= 58FO"
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M<&8X-H[E-/' QB&?(TY-9+DLS[4W;6BIEI@2_[FU![G%YY[06G(@^SS:%/J
M=S@-TOZFV!#/9_:H%_F! $>VAVC*IR/3HF+<"0#-&.$W0?Y]KS; @;IIE]%"
MADC#-,3\=X\W]Y]N[_ZHJ8(1="%O'#-R^T/.\BE6$ . E*_=Z]N/M]>U3NZR
M&)&:EG0*/9L:<CC-33B"5PC"U#10L\J*]Y=DWT4_6IJ=/G B'#C+T>KU@/J?
M\\-F15/+6.1@G5?-PA?[^2?M,_/.\X1)P-%>/Z:0V!XK/H),F&&-NI&WP[*-
M;LNTPXQ,F^R5[+!4'\PPP[+=:P'9_M.TOLBW%98G&O;BC.#\8^)>F&E'X((V
MP&(^*V?^?$-@*L)=MAGPI!$P,9XS,R1VSEC&JCR^*H\_QO)X5<FSQ-[7Q^^$
M)IJ955;<=66%_F!;HDA:UK*M5W=1W2\!TAD3KO,^1J/>SNGW3KVYJ7I_6F)I
MJ>)?V:<)>G^9S2=>O:Q/3\/M<A><]O8^/6EN"^%EP 1X<_&$RE9=R<5L#VW5
M8*-JL%$UV*@:;%0--G8K'6N)1%JKE$S:CQK^NT\D-"/5R9 515T*!@>P5;U9
MU/5QW[.ZBK=[![9@T$<?B#W 03;6LQUX_BM9-WW/%5.C-B'^O4"Z*G?TI3H;
M[,ENFLW5:FAC<]/U7#9[8OQZ5QTP]^3S>J<&BA\BI^ARTUBJFF]/=J.JY5:^
M'GBZXQ)'Z1(LI0/.Y5N^>?T1@**XP?U45N-2F8GO.&E7BR?M3N@#;+F<"7_9
M;L@<AV$ E7)<QH"#5YDB:2%S*1TFS4D1H5JTQ=A?D<USBBG>&&'#$S:R:>R;
M-:]4*A.?#.#-0!#R,@Q\&+'9>#"GF*\8B!CX"#\5\S5-F_""$&6CL>.],M@\
MNA)?TXR'9)KKQK'8Y$G&&M'7= !FQJ&;\3!/CXO-S@J%6R9P_>+YW^#M?;;7
M":9P>JDM/KVD##D"]J(QUVX H""P1!A71L8P^WTQ45J6'/8$+#)@R,/PJ*%-
M^0V8[6#WD416?6]Q>$#/Q_^;D_'_50<(SYI$G,WJ6"G>GV:03!+7$WP>TB10
MA^?Q\3F_26Z="6(&X+/7H@29SK=Y_LQ$D@<03B8G:528@^0#''+"G:?G1.-O
MC(V%H#^=' H@$E.Y:J!'F$YP";S,OO?96"1 L,& =TG()5: ,< '+<<<[[,P
M\C$S X &5$L3!;1+,S^7U(M3"U4].QE>3"&($\@HC03HA' KWN?$P@C_./G$
MI/^V?4#[B=2+;,?B+&6/\.:02Z)DN#/0#M[G<(Z(=1F7<GQO**$L3"X0C^?O
M2I< ]"A6W>"K/LO.4#<+,IUSV5 <FY@@!I]Z(T:(24]QA4@AIC$=6I(W&%"V
M"8#7%B&C;!)+3NZ*77(<G*T]5;79,@YWK.KUNX]5[=2U!F[[CH695!)!':>.
M%V0<P/LGR?[)LD/83:+\J5UF$L1R2=3KZYU,ANA2S\FE^Z-2*1*K^)3('9C/
M8!W3[.AG3)+*9(H591L2@^.@;QL6":*3*T( D9NY#B#D6_ELQJ(IVF)0MLMG
MI^2?@822L\^F-7A!2NEDSE[QLY],VYUA^\U\MC =73!G2*;2K&^W_QK#X872
M;I.:!7<J9W1@VC[@PXF(/OJ@E7 56=H!BS+BV;6GN.R)5:Y<\#0#&E./7=$:
M1P7A6@6;1.T,]!46<8&>I5Z";8U@.]?44J9NFD#("G+DW07'S*R*^"SEN7%B
M-1ZB"N4*EYXK9U54Z955>F657IE-KU2+TA7W.+VRRHZJLJ.VY6HN2H]:+U97
MY4=5^5&E@$1!@,R.HA_N6!]N-AP)R2T-@@/.DK@59ZR SMV))6D&<.[<:NLH
M()CM[ER5M69G$TK?^1UV)H;>'# 97W,_#)@2Z! 1 5;T^\8!D$*WR('3M]%:
M<W+,GM"WBGTJCX7"/Q;Y' ^HN5_QKMLM?9LD_!Y;!"INK63:5OF@:QTE/DXX
M/P^'=8KWJ\M-]8"89]8FE795-U.H']"U7]HTAOT\RN%<N>9FS8[W'P;-%4=V
M5>IEHX-T_K"1Z:YT./IF5KZ^<@3#'O3)Z<![R$W[H^H667(ESQS:=0D_JT^S
MK#0W&_V[_S#H-*M2H:4@M4P67=4-O>B8WC V<A<?/(0TK-?;2A_T;:58?8E\
M;%\'5AUE-H\!)?U7:>#U(THTYVEX9B]@Y&0>2'US;-/< 3OXAME25&8R,'W\
M,08.LP$0\)GT%)F^"?8BLR0L_!A%(^S-./#\$;JK]SDO_^.JG8)XV^ BUR9=
MQ ^Q^633--<T2485Z:7YO-(>"U\8XTBZB7PO:<+Z9_VA'J>B A(S?]8LYGJ
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M7?+)KDC;(L2[K O*MV-UU0=H"^ G^BO(].(=X0&%RQ90CVAQ ]$!A]MF+$:
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MXDGO&\#,P^<;<9Y%Q_R8P4=_NC28*-8A^$"$(!Z$&08()+1<0H?#<H8F11C
MQG$ATZ<!OE"T.4A6D3? 3:"K%]^@)3?4I0<Z,M(!$SLL)4W=Q!Z3ECAV["-8
M:!3@>B?&H-'1AEP%T[.AM#8<//:Z)Q@2*O=M?&.O<,2:<GH7GW=\.H#P1C[!
MLN-*FOG]-R>#$II:UY:)2XCK=F5")YT5FI?;]W/FH0=B2J. S0<V8&1CQVZ8
ME&";0*[9YNU)DSUU!"=K[QL7-72::EY./8<^AY-25A A5P'?B0/8F>CI-FL6
M(^<@,< T,QJQ<%$J+G9J5=<S'UZ;N[#LZ%1^6,(0)@H\(5M('F*K22'!2!YD
MIQRB$?W*P@FYG #9Y\<DDUP'B<3"B8?<!IL[\W!JZ.1EQ5.[Q%/WB;[--%82
M9L:3]\Q\EWOC"^A;:Z)?AG29DWC>9[D"^8E+$QZWQ$ ([.\U"M['!^R"$'Y%
M,3M%,0_H81YZ#DB80 @A"E^$K]G!JNUZ>S0Q[A0M#>J,-:<'%OS<Q7 ?3K$:
MO4>\;UD/Y]O0_H;I'(W#3>>X>?=TCDZ]A8TC*!^B-L"N7*NF<NR:Q5X8G)N3
M&36=N-%2Z@I.,R]ND@S**INZ,2--8X\!^#C,M2#E+908/^E1= \@2)0"!TBS
MO$YL.]# J=.I-]3.ROV;X)#;-,IJNM1NMLI[5*?JWU1-MUL,D*I[4S7=;F:?
MDEC<BX/=N71*YWC;/<L,7C6QR_;&18,96&DIK'[5?]T]\BD&EBXK>K,D!MI/
M")RJJFPT&T<S\6X>>_!4O_+88Q_PW]&U3>A_'[9XJADE5>[M.7VGCMOCH6\<
MZ*FU#K]J7)6/B<IO^ R4PJ(L_OOA$[;6.'RR5HUR^@L>0\EU,M< 1'[L"*.L
MZIF^M(L2;/_#+38^;:J-,EH>'#"$5$UNJ^HR,QSG.@WGQ1P6W3>9A&A@#LYZ
M3E9ZT@560MC]^;O7]34.VLMFE>RBBSDI?"(_,FVW:(N%D^Y4(S,%)G7:ZRN/
M5)PLPG1SBQ*P+UY7)L5IY9DTJPUMV5?,S0G.NAYR\VLZ2O/4/A.Y(#3/5"3=
MQ0!NY(?@3&0AQF&*!]/U!O9/ <9L[$"0!OO._#[.W/-<%M>(A"^>J*^"CV@&
MGBC.D>[^D*ZQ8N3&?3(QESQ./8&7<ED:1B//IRFI?EI[E$F8@[=W[_ZX>?SQ
M![5E7$JG73>T>Y[U*NJH)I__. 2XC5D$8C<XD\:.&6+-@2R-(S^(S'0T'I;B
M!;%MFB1%Y).(J/. V%52,Q;/VX,-) GT/.7QU)X&N8VS^UZ3^'F2^I1D;69S
MD&B(4PUT"K*.^9T_+,0DPVQV(T?^&)8HJIWPPZ]#-"HTR?)XD080(Q^?FB8%
M<636@K'G!AX5;  A4DU(Z%,3)=$R&18R"=2'[KUAZ(U6YURZ_?I[4U54WF+9
MM[THD'J.YZ'=XO:9SXNJ !("%&EN9KZ6)<Z2G<) )BTED^@_F4=%]0%IFCG/
M.N<$-YTOF<VDG1H<]A?0?<CSL9(B\KC$B7!I^C[26O];KO!@QKLR T/G"*2J
M**$J2CC*H@0]SQ)54<(V\C:RU6FSIQ#*21K8DM::,#2LQ-!(RU]3TR(:@SK'
MO%BA!/(5QEPC<1V)LI^R#_-S6I-9LRX+EE?7N2+O60I;5!ZD)8-QAGY<?2F6
M9[J\A#O FL;8'  ]E)-N8*7\VJK]KN=LE=C6H1'O9!7Q;E%@+.'!48P*#H%D
M&'9)Z44AKSM.#(G$7&BFYL+?,O ]6P#@1_,;L\P)D"(X1%YPP=;RH)L!G"!^
M<GKWB^<[%C ASF,&\DMMU019" 6+/3/'&\?F3#RLTA0VG63YT1,6K?XK>@+8
M@A';_7 -9MSIF)<7^Y@<CK"_\T(T NHWSSS=B"H,A;V!*=BP"2S$*)KENS>L
M>\^PHC*M@46J ^ '9I]3$MSQC9^Q)M@@[6Y A,<'*7MN#6@C\GF-/M58\$+6
M("F9X55*\BI"8,Z!)/9N94^9K<R\SHESXNS9J'8@O,6%LV9AB6).=-)1 9X6
M1..Q8\?F**P\\%R7.;RUPM)'14+4GCDUBL*C!^;4*-JBM*Q[XB7;NJ"3J[##
MKP2)T=Q4!"G5JF,FG!> J*:_ICOOI(W;A,!\ G7EFV$RR)DV4'P0SXP_Q\,:
M/,YYS<[[[?\5V=S<)_47SYV7\6@K.O&@LWB<].6QW1"8Q:9&%T&<89BO)5OI
ML+)O)!++JT(JR6%?6]'%5$0DOAU320F(0A3!K3&Y+2^H=A$KD[UIJ!N :3'J
MV,*5$EDB [MODA\C;7"%/@T!&CD+)B]_2\R("]O(S9T6GB31'K1:*,HJN-AG
M\BIF^J)MKJ$9C-EV2K%Q5/C>8BF_C"O[D:P];,83C<2Y 8M?$_N'UW;#:A+W
M&KUM1B\X>)KMIY%'+!S+M4T)LD\DER,<4(J;%_$3)%=R(/O@96-DLQ':W/_F
MYF>//='\]MD^MKD]4R9*HTWT,G,'#IP\^ME>+_S4*GB;+\ESR0,>CS)$SDYZ
M[$H#A@H O@)%:UL%)X,E*V?:AULY\_'=*V=4I:[HN.\_V*O$GC,]VN(0A3J1
M4+T9)A#(ZV#B#8K>)H&U<L7A.Q7B30!4JS<(@5]BKTZSJ)>?Z;JP4.S<MVJ,
M0SW7I@,6&)5H*"J6%]&M@+I:WP'U+UU_T)0:=[&0#<#@#(W=':C[E6N&D0]/
M^@:R&1LMHM^?\9B'+$JQL^Z<))@4:Y3<NNE-[#NV*B(ORJ\U>MX=6":_>];3
M-]O]*9 ^O8[&0V]D;M(>K10"/I;*6+VN:((<NZ"Q'$EME$N/.Q!SPY[CEE#J
MN;BFIJC-U!\D\Z8D_,WDFT2?*OSY!.^CLRH@ 5NSNKE^:XE-E$D%B!RR0Y*6
M!%1HSEL2+(JP"9>..(KR[CC"9YEO/(NN4HR=JBV.L(ICMLXQ9):JN6:L-]]9
M/T*'O/2K9_H6Q4=M/ *C\WJJ26F&?AJR;F@3KNBD@0Y<IBI-N6T8V-(0S%A0
M]**MJF V,(810<(%(R@D,)^I*2<>L6/+,1,E9J.QX[V"V9?MTMELRZVBUP1!
M1$8GXR,<AJ@RI%/137,L&I0^4D1X8H](PQ1+",UOS,VTJ)$N<*V9/8IWTTO$
M>ZD%![;YP'$##D\!R 64E<:,M0&WP-%!].I,LB;HL<#=8%Q'H*G$X[.+T-NR
MJBA3 %AF(=3GR.7K0?N_G[U"JQL-Z=2N,[HD!@[F>627E+FAH\J&H<SQT5=Q
M\BI.?I1Q<F-VG'SY@ZJNGAQV<'TOCM2_O?N1NEU76KCM.R\T]]CA]S@4K?+M
M$;4UQC"\13XR3"/D@=)$=%'D-.VDMVPW(^X>PKAKS[&#(3=LS7X?="5UJ",=
M>=M]D'0#7^%:: &9EC<6S9HGNAB2NDQ,"V'=TH!0UQ3!_RX\7#1O>A /#(1E
M=0HO^I7;'.A!?V:\^3U8)/\2\Q),R;%'Y"OCLQMH9$#DD^\N"CW0[5VP>6C4
M H4N<'/F&,<SI,N9M.?B%HJI#?[ 8'MI,PY5.&#$PNBADZ,C'B* \;,=X!)6
M?"Q?*9PS1%-YW"_L,8Z#\^7SR1GX0!YI<Z@=M4AJ"#(]D-;V\NG&X7KY?M\!
MD<3''7W&Y ^<DA:/MA )(3FW/>^91_,34K=Y<BY/.I#NL6B[QSEQ [-/G&I;
MO#?[]'E86-&B$;8X%V$JAZ37/\00,5TW2FVW@>W$<P"(+V^NI5--J7T\DY$%
MN4/$$(QWBM^"/$+W%7QYY]4EV*[:Z+0;G4Y-,VJX>TT1IZ#1/-3EFK_"$7Z
MGGL[C7VD*,VCDW=DA6W2A>:(Q>DIGDMS92;VGM]K.AM&1%E(6V"\YH7UX"3
M)H30/N<&?1F@>&3\2,ZQD,S(<>QOS'DE_8#1Z:Q#9AXK34=/"1N@GAR+IZ5Y
M?;@F?AP>C-E?$=Y!_7]G0_.-!M+IK<.5T+?O+J%538CH>Q$:1*_F:RX!;8_9
MYS&;1R>F4*7;M%DN98";B\+%$UM:R&@6*!_'$Q%@RDA4V[%=DK%4%]BG^4['
MW++:XO3'ZL'5@ZL'5P^N'KS.@RL/=>6A/DH/=:/(>;NJ"6\H1^6A;M0-/?,A
M\7'R:8;!^WC(]?.'D)92;[>V?PZY>[RYO_TL77^Y^W!S]W#S 7][^/+I]D/W
M$?[X>'O7O;N^[7Z2'A[A@\\W=X\/4O=!^O)1^L>?=S?3S2]7I0]]K2/>@@.=
MJM<;6X=D=Q=.=!UJ2GTKCB;7B1/].GM(>4B/)G N^9C(VJ]"5TFG/'5#1.8G
M.KZ>)>)HZTV&V_K*38:-3MUH%G< 7K4S<+O>T(N_6:?'L**7]ZCF3K4KCCER
M!SKC<)/A/3KS[A 0T&]1M6FNVC3_'4<X3<P#?==6S3O$(UTJ(WISVE 0!$)6
MK]G@N<R'K[-R0203QV/N0%^S\^&Z"]\4JJ6__PTZ?>X0CUS'Q7@;\TJ%N.WW
M(BYJ//E&;4O%Z78'=KZFMM^?[K,_V]\O7,_]Z/-0EQ2Y=GC/!K^<P$GM),ZH
MI@_Z->V$FKR-3"?XY:0& '#-$:S0'OA!#=/]+Y!.NJZ%/VY2(CFAD>YF"%=^
M#R_<:%2SO+ FG@10!  P@B>>^ >USLE5LR-W.LK/Y_FU7;T1M>TE+O2MX$)5
M3JY:BMQ4&O.1<=CB[V'H^6$-JV:R)>B5[*MD7Y;?N'&3.,/X@6!5?E-/KC15
M;BN=2OAM)/Q*08;&D=%0CUGX/?K8D,//C)E-.D8=O@AL5")P!1%(I (VQQ<D
M#L&"F?G$J[*??G*E=N169X'M4<G"K6+% *YHR(U&ZSB$8K$GX]'#ZL[^SODS
M=H.HBV'V%M;6>GJ] 8)%5>5&QSA@R;(Y$I:ULM9#0A-K&-NRHFI+"9+*77S
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MNTHP.N <E7G"MA*P6Q>PZ_$S>O<;JFQT%KB'*KGZ%M#7 /IM0U8["[3:$?>
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M111D(+A^K9=+0<N\-0^9=KV#UA9(&<"W/9*N/81&P"S\C70R"!]+>@CAQPC
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M_LH^"QT')VF+/!9['3W8'"W&UM&">5,-67^')/9=$9:_>; (%X5@[/0 P0A
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M.=/C=.[)<B:ZU><,6 [U+3T?S#XW,4'=&W,;=ORTBA@$[MPSL9PE,)$S%XO
M=K##D[XTP3!@XR%03P9QN26P!T_O@+N#I9FV[3Q3%,[I6,BA&W-.-Q?4E,!&
M;>*Q-9IL\_2YA/-6'E@2>(->MW+L=T@ [B_LW#<GSA1_%+4%;O_VZ[\^?0?<
MJ<GON*M;]OXJS 7[^B_.();%?;*?8&,N]SUYE/>&8Y4EQ ?*<4MP%M 5A773
MM=#[<NV=QR&TG8&Y<["*UPJF\,L6T:?9+[O.DZLO.$LW E]?Z)-^1"V"Q;^<
M/GU&ZDRILXNE%O@QFSB!QWUG"[16B^7<6>AL6U@VO,2E6KGW^]S"L4'>_AO
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ML$P,QC65X8W.Z[E>>XF9#.]=98^RYG[V $A<=\-6ZG'E1E*X42A_!?G50[%
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MQ#[5)_*PJSYIG4&M%9]L9^VH8^UASM[>'D\]G:KP6%#$R\W6YW=L/9:Z%$4
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M+TZ>&K3K+O=+M,,IA[\2VH5'QS#_]A=1DM[Y[#_<+^R_-ON/JR/0 4J^__K
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M%SO_*Z*[J,])\4D2U 'WP36!TJ:>4?9)/&!*X(@Y2P;X30NLA ,FF:I$,*%
M"^KC1@^/G@D+)'\&\!UKU8^ <8AOJ=>1>A*UQ14V'CD@T?+ -??-Q!L9<'>Q
M>RZ,UJ3+\AS&BRSE=U&2V>M3Y3BFB:F)NI5Z8VVPR5\!LEO4U;9#;B?D3.0[
M.@/ BDR9ZUJX"/2&I4^<\#T\P,Z2_74]!@*OW1N^$\N>*%+9&W(OIC\'UQ3
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MDP59SF24,&H[P$,XBW2;+I#4?$;J>$ RUX^2+Y&NINTMB1%^#*A*'^#0U,_
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MA2Z6IVLQV0I"[;Q>^&MZ2,YD18_-9Y?8QIQ[<@!<V2B['&B(I>[Z*"CX@27
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MF]W+K_=)IKL#:(+-"9:FKUM%J7.C@J+L44$1>OB(=1A<8&XJ2K8@%K4-R!)
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MWJ/R_[?WK4UN:L?:?X52WI-C5S$R=X2=4M7XMK?WV;Z4QTGJG"\I1EH:D8U
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MM-'4$'A-93YCA[C=;@RI(_8JBQIZ( %-1Y"3T72B,F70ABAT$4/'8!@Z_1&
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MGFP-([X(9@VN0NUHN)H[-,2AW-WX:XB*723]OOW!M]W=?E<46=4-[A45=%$
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MX>E]^-(X9N:[0X;OD:FJ2@9)P&'0*E38&D6Z%@9_TQDB_ ![2H*OM*1162#
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MX7]]HG=V;!NF>*Y$Y$J38,!]A=_3#N9IW \/0!\87"4)7P06"[X7UDYB*D(
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M\7!/"^)YT<=BA\A#M,B9^^!0;V*SQN?;>V,B,1[BH:&/QP5D!1;%])ZYN;6
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MQMIW0Z@7\F#Y=N1F/RT)Z+Y=]S1H<;K\TPT-Q9Q0;WVW )GJ1A^./OS[WMW
MQ3D<Z(V3\?#(?Y" #[N2(SN#Y3*XWOU!IWWT"?Q&^C9,:]BV.T/=LO (B;^%
M)CBPLNQ#B&#..?<QRB%@*I+F%X :[CQ\DK @8-(R3[BF- PUXI[XQ(-$;W_F
M_NE&H4I,A*B6A_F.R(S@)4]/,G11%H[).P@VG9[PR I#!8]'[GZF.[Q%C>I4
M:;]B!7PE%@9=)M9%K7#0U:3]MV!FUU&YC2ZV([%AI4,8&S#P7A@X9EEY21"-
M> 972*CZ<$H"Q.J)V)BUBM^_736.%Y]Y!"1@MX]U-MN 7_$<!Z#@A,PV40=
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M%3##SL9LGI98Q5#E6)0["EE+7I2L_>M':)ZU]QI>[MW>ZP+^A*N!(\C=T'C
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MK(TRG&51A6KMH2@R\JC%<,V^-R$\6I.EM3IZJ6QV%]6Z"G4#7(.;*9NQ'LI
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M*9!L-"4P""[7C!3/O-3TU^QRT8%[[N)@3'D Z N@35=JZF6#N8OK'^33SW[
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M.MQ4Z*T#!?12QOD*UZ<_IA77_&22;\+]D8[+Y??7EJU7W.3L6$Y%UI+ZGH$
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MH;,\T,^9R$F&9 +WJ6GN\H:/?^XZ;"6N#0IL>>-3MXCW."LWJ74%33KM"B=
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M0896U,9%A3X0::NQZ)0TM '9>;;CD5!>,N<&4=]C[ME!J[RO<E[^=*"?NO3
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M*Q,+D<QI[Q)=8MD:_;!-[$#]#+KOH6WOA[WKKN?O8+)<6LN,AT0N1W9T\I;
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MC[."*_=?$*[(B>J!-4C]52K:8F4F8N2P7VHG=&2BZI0P\W_K31E]NTW%6DW
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MXP)BG"!88IQ"2;(2%5'.N&OJT$[PR#[<?L,*UJBA?S1E!( UFH#?[P8/"KJ
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MW/UP<1CTG$\3[V"W=UXX.&IQE'.4)Q@2$<40<\8@29,(RA*G @D6R\*U*<=
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MK5[&Z#(W!K/<L2C QVAK@K(RZ@3+J!#I+_>KKZ_5]89?] _&R3/\<7G524C
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M/#;!'#PL*[J8W_M-;[*%TI931@#(C59VB]6>-BJ8E+9HE>AP"]KVP-'P\3O
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M1B*..ZYSH3D?93S8SHWHKMGZ69_S6H!7]TK'G\%K<XK#A]&\P'8AMM$ ]!P
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M]4_1:YM\%3$7SQ,+!S\7U$)@MK2UW&0O./DE*@0^/BD6%&'.*1@23Z_D8N6
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M\YO1C9A!TT*X5OL,F)Y7]4CJW!RJ?2;W\*7V/A;<I]:\.,#KM^--H24J=:Z
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M7U*TJV%W! ;<G\.'9O2#[F8=.T2/]T(W;75W6.MSV?K?=5UP5]9;*,)+FE-
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M*N-="@1RIH1 DD.J/?980^(F=C5MD3])M%$@>>HT&*K3#,'-Q0O%1,//)>V
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M^<C;%9CS V_G-T-_YZ_99B'>LG6UJ![J+(@/:EVG*M[G#-M, PI256";3<8
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M_L;6:V:6D8Z*EY%,9DP#EN44H!05P.8(@\+\OP()G1+M69AT+&!B5]X)\PU
M3U!P#2K#;?-S/)V<Y/?'6 R]0T9,'LR=B)TY0.LW^CSHNO!<S)+ VV^+S;WF
M/-,E10 74@#$"P88S'(@RC1/*<X5)+YTGA=$33P#+Q;$,2/;=8T<QLMUAL9
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M1!$_K6P-D/G:XJL9[:^JCW7YEUWB2JXA1S3% $EA-J$$4E!F2($"&ZQI#DT
MYME!.)IN4]^M[0*K7W:I+2&Y0A,,2F#$-0_4(P.P6DD3V39:UO[$5AON%>WG
M;D]^7]J16<1*0)H.P[ECM!$:OVS(-A[JP0@N@HC -*JU8AOUHVK^>5?UR;J7
M(B6L,!O:E%.SO^6: )IC!JB@"&K."I39MN4/-BOELT=BE8-LIPF_ZVM^HH'S
MY/_-P*_ 2NNZ_XW59C>EOWOF'+G@Z1(N1H0G-!.KEIN\ZC3X(;FKDMX&(!-
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MS6=,;W'!B,G=P*G<F>?W!;//)^ZE!T,2:UY_NKW]"-.L(V<0*5(,00IDF4*
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MW-A& UX-"7V@=-IQ3 .0Y['*3HD&G%:-.I)^]X_$:I*H1I6P_8<':%Z;D&G
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M,D!R\X\R%3F$,,5(N+6YN"DF\BM6BTRZK\)3*]3W1>O%Q_65&VNUW\OG:7#
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MH3Y\T(N+"U&.M=:/$O>&&G');Y,9ZD-Q8PT.[2?\9(_?K>E/O3=[,KZZ9=\
M,_5>.B,'W5+]E&UN_C*$5S[5>9CW^KY.T+-YVTWFGJVK_+@43;A1Y#GGA2B
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MYTBQ$M',[^#PJJS8&_F'@66UY&1]$)W\M*S:O_Z;;W!^'3O7 'P21#RW[6^
M,640/6A:]$#YN@8S!\.#4%P&O,.7!!5>V.0Z._;P;/3A727//UA$0<0HYT!
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MJ5PTV5Q?=VRSFQ6U<[GN>4GJ85G9)AH)9RL[3^K-S19RT\&)(2O+DML7F1*
M4B0 SW,&TERE&J7FO^:HA?-]Y=SM:T(P.ZG.4)H+7@%'5\=]$F3\OI]![V6
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M]:F!S78Y*'F4[[$ZJ!DZH]GKCKA2<&R<Q]!M.,31&'<,7+--EO92[I7F3X<
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MFR#T=&FZ_?NIV@"TO:/OGFS;W,URGX:[8\M*R?>M0[P@-*48"@Q2C#1 '"K
M3/@$LDP23*'@FG@>"88I$ON8<%4_S^WYEU%CO6GGM9J P7R95?*3?3F\0ZE
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MX Q.3Z\&]VM#2>2+VBISV7>S_,_J1:W6=75?][AKS#BG6H 28@Q0A@6@I1)
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M(YWC[5R[ >.[>3VPZFON7[L9/+"%[;A("&&__7J7IUF1=Q$Y1!J7M #2_"U
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M5D_%,]=M&:"6G@MG9)/K:I\2R(W?3;$E?S3V;[O;U+?U:->V(!0J*2"@!4?
M>$;&7^*E!HK  J=$2E5Z3IMPECWOQKK:L>6JKCX[M,EG?/U\.K]RK^5D.^JW
MX0_9-)\,U%'[XE'P'+DA[H3,K'O>MS5ZQ6UM)ZAN[UR[+1'B]GRVS<R7U5*P
MU5>U>5D*M6T/M,M"EQS;T>^%-MX/UAHP)>Q>=4X5I':CVJU%T6TYD:GI2&[2
M"?;Q#:[CX^((36*U'W?T&1R4Z7#=<A_G:!($PGPDKUOOZ2<-FC7@+EV_?D:O
M:="(4^=I^.>A/E1[$+=0L" ,91RD1)0 R90 *JCQD#*<(B1)*I%G8F^[LA?)
M^&?VME*.#G\&<L\'<'!U50*L\R.35L"43L29SM%=A$[>S [ F9F7G_?S'X1]
MO-="*;FU.R(?%3/?QD/+G'?[P0]WVWT_@3NQ6[[4_WFA$&$42P)$JBE I0E)
MS.>=VBW<S,0G3"ONT==FA";1'8!&LV9'=V5U2U8'Y4X/;!-AI_$JK95P+M0=
M?2?<'(E9\/5U-5IHZRW06JW39EH'S9*[[5%[EX-R<V'LY[+,@O44'5^>;C_<
MDV5P3@#)H$,4+F%6EVDT$.=.U?@%0SX=;[_>Y6E6=-G+."LPHR@'I-2IG39/
M "M+!G"ND61YQB'T"/9.%X],\$:835@N_!+8S^QWX>!PJ_QH]6!04-QV9ID/
M\X5;.&DV^@& R0BLW[(!3CJ[:$::Z5?WE#FN_":X977%5C^VR^V];D[9[BKY
MOFG=[#T'<'BI>"]/)_NH'YKU\-HNU)'F\;D;'+_W\K J<W=?=@:GI_^R^[6A
M15Z_L8H]U ,XS=M4=JP)25$RJ#7(A,H!THH RI4"Q/P=9VE:(N71X^2JG,B?
MQKJLYR#8DFKI7^?5CY#+%W,2NSW?_UZ3@TN]^FWWK?4:C4'8Y_6+;?W8C"AE
MR9/Y3Y-6=-TTRJ&DJ__ZF6NZ;AIQ6=1U^^<A%/1I77T52[.@\?/%G7Q9;M>;
M'X;FWJVK[?-J9QS^!:888EDPP)F4 )6H[H16 //W>2DI8ZA B\I6-2CYS962
MAN4Z/9^T>3XOI#L_H[9UV':O2,):3>J/MMCKXO/:.B#JPET3 13<3^T(E$YZ
M/47N72Q0?$AM6G"FV FIG)ZCR0C0'8 !)G18:$9*=#?KE!L]K@LBR6?+L_?Z
MXYI5VX6$2N:93 %BD)M_F \\$<228HJ08#0M2X]LXY.U(_MCC2S[N*ZL-*\7
M^ 0")P(+-<R3JQJ;[G7R<9Q-7OP3:EL8U;C:Z$LB?58,\<7)-7-20Y^R9RS0
M^Y/PDDE[C]CJKN;X!=%9J7F* $%VGCA.33!F7G50,EYPC$@FLM*W5O)80.Q7
MOQ76?K+\*R%/P'#=B0DWT==A<;,NJ,:QSX09BAM/Q,Y>U=AG=%\Y8^_OPO,P
MK(;+U;(MD&[&0FX_5!\,8U8/2[Y237_9>WM@^LW\UU_7:_G'<K7:[Q$J+'&:
M(@)P8;MNY>8UY6D)@=:\(!"AG&'/=O'CE8K\:I\J>-9*?KE7LIL9VQPV[\Q/
MDH=649=MR7BWS)5,YKT1?@0TSST(2G>9"K09,F5&JSI[DLU4X/;EYTRV=B@=
M[[-^C\Z$[W:&ZS<[.]WEW7J[>\=VZL'$6NW&9*IPD<$B [G@T%8L0<!9BLV_
MFK^FF.&">(X5]]8A,MGN]3E-XME9SZ-1R83[V]V;1+1:^1*J/^BN_!D52C^Z
M]$8Q^?UQ8 ,]@!N# 8E.A?Z:S<Q\P=!=$EWX4M=X[?@9^6C^]+_^1_<WYA]V
M?NK_^A__/U!+ P04    " #T,"Q92+Y8('VL   "WP< %@   &EN<&AA+3(P
M,C0P-C,P7W!R92YX;6SLO5MW6T>2)OH^O\*GSNN)<MXOO;I[EBS+;DW;EI:L
MJIHY+UQYB90P10(<@)2E^?4G$@#O!+D![+USTW-JN22*HI!Q^3(R(C(RXE__
MZ]>ST^^^X'(U6\S_[2_\K^POW^$\+?)L_NG?_O*WCS^!^\M__??_\E_^]?\"
M^.\_?/CENQ\7Z?(,YQ??O5YBN,#\W1^SB\_?77S&[_ZQ6/YS]B5\]_XT7)3%
M\@S@W]?_[/7B_-MR]NGSQ7>""77U8U=_N_P79,Y'S0PX[ADH50+XX!R8$@IZ
M953QY?_Y]"^9*>:Y]N!=0%!)TE?>%Q!"1*ND0F/B^D-/9_-__DO])885?D?L
MS5?K/_[;7SY?7)S_R_??__'''W_]&I>G?UTL/WTO&)/?7_WT7[8__O7!S_\A
MUS_-:<GOUW][_:.KV6,_2!_+O__OO_[R>_J,9P%F\]5%F*>ZP&KV+ZOU-W]9
MI'"QEOJS='VW\R?JG^#JQZ!^"[@ R?_Z=97_\N__Y;OO-N)8+D[Q Y;OZN]_
M^_#VSI*S^9P4">>?P_(L_#4MSKZO/_7]ZP6A@NA=__N+;^?X;W]9S<[.3_'J
M>Y^76/[M+[,Y_4.HFF5&LKKL_[WYE]_?K'Z^Q!5!9LWM+_2-[0?490ZD!+]>
MX#SCAL6K94X7Z<X/G58!+Z[_Y6F(>+K^[DG&V<GZ4U_%U<4RI(N3R#%SS@0(
M:32H7#($E@T()[R+GHN8U%W&*]TK(GRMCQ6FOWY:?/F>/OC[*HOZQ5HH:X$\
M6&XCG,/HOMJ '^EG3W3@TG#IH)2Z*4IP0+1*,,&:[+Q1TN>CR+Z]VEVJ;ROU
MU3)]MUAF7)(%N5HN+-,#!=_%[O8GOC\/2_H@2)]GI]?$EN7BK ]=72QZD-Q&
M+43N7[XCK@LNEYA_V6AE)W-KSB[(KN+Z)X_1^)OYQ>SBVP?\-*L"F%_\%L[P
MQ F>I60!<HR>Z"\%G J9M,=+3D7Q'(X#[&.K=D* F"X"CI9D8R2\(OCF"N&?
M3L.G$QDUSW0D@K".I!"L $?T@I/,<*4=_;T["@)WENND>SE=W1\NN\9*OS);
M[W$Y6^0W\_PC'9(G3AD=$WE-(OL 2HL,GF&"%%R0D97$..O%\M]9MA,(U'1!
M<+PL)P*&GV:K%$[_!X;E3_2=U8D2W.3H#%@F"GG'FO#,HP%N/+=&%\N2Z04.
M]Q;N! @]?4 <(\])06*#[ T3(G*C./=@<DF@D"F(Y-: M=QJCYH;ACV"XM;2
MG6!A7@HL#I7I)/S&U\3&,IR^I7#IZW_BMQ.IE4+%%13A)2CG%01.9R"WZ)@J
M-BIY7,CPZ+*= &&G"XCC9=D8#*\OE\L[=N[J\-.,>!>H@<X^.OQB+A!UB4!_
M8B(4[;-(QT6^.U;N! DW74CT(M'>4/&OWS^::CDJ!?1V3JO,SEXO"._S%6;Z
M8K4XG>6:]_N=UL!J(E>+\M-L'N9I1H9RL9K5E0]*&QV^6G^IIIXX/C(]-2O+
M%93+T].3ZS7?/5SR&L F80P^&4 ;.0$8!02C)0CM?:&OB@GRB1U<5UN#ZR)\
M7<P79]_6^Q@8?8#]?DU%_8F;KR MEB<W/[+6W7X4'VK';E9YM5KAQ>I: MQ)
M+(9;DD F"6@GZ%#6!8J3Q@JN$O-Q- G<I:U-TFQ !%V9P%Z4T?!0O*%_:\CO
ML1&R9C&0>Z="07+T+(*S)4!4Z)3WKI3XU+G8+Z8>);$UM([1^P,0':^$:6 I
MK#Z_FN?ZVYO_=3G[$D[K@7$B'&<\%P.):6+&(+' "PG(9".,5$+A4^%YSV!Z
ME,;6:.H!  ]!=;PVIH&J*U=S:\ W0CJ1R;K$3 )>9 'E8P&7&>VXZ+0.KJ!W
M8FP3=8_&-C<& Z/J>&U, E4?ER$C;8]W%Y]QN67J R:D?1)/D;8)R2AZ+R S
MR2B.,0R<X1HPJ&"Q>.GU>"?@,\2VN9T8%F=]ZF<2@+LCI!,1&>K($]A"1"OF
M'<E%<7!8I$G>*\YM&P>KS2W'*$;K -D?#IW%13CM"3J_+>;I4:F@2%%%5&1U
MC0'%70$O7 !O$U/6YZA&#/UV4=GZ%.S54^]%%9.P1V])"?-/,S*F&T[6AO;C
MYS#_>;'(?\SH)P+94R-D!-HN9&*USA"T0 A)*1TLCUR%T=#U++FM7?A^D/$
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MXDE(BJ,>+U2Y3UWK'%;OB#I*_,="Z&./)^2M+"[)[9JM5XGVQ[:4+(EH:1N
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M@.3EY")\RBJ*\9Z&=R"X];$^;.JE;XU- H:_7=;MLTV$KC;1V@DSK);9:/)
M# ,ER/P'AHQ<;));\LG9$4=6/49AZV"Y=R@\ -O1>IE0XXN-9$ZL%L$%$H-A
MY$HHI3@$H1CP$-!)0W\>L9W/[;*F*>:*^\+1 ;*?$')N#OX3&[C7/FE@7.M:
M@UI?N&L&L:@0$LF(Y?'.PANZIGOD]86@ W4PB=-M5X3S&Y*\/H:O=T8 ?B Y
MAM7E$K=]+'_$4IW0'W!.7US4H1>K$Z\U3SDZD*@3Q421/,S$ZL-'G0POI@@Y
MG@WKF[O6$>_P6&Z*AX-WQ!=<QL5H>^*J]^"/L[*]R299?%P2MZ=K+)P(F:(*
MEH/1O#8<3 4B2Q&XXQDE!JE&?"M[+#>M(^CVF.]5WQ/!^"/LGO 2=<*B@/P=
M<H'HGX%CA5R@I ,WY#H'-N[%\CT"&SV>'1&)QVIE$ITB[[]0^?AYN;C\]/G5
M^?ER<;Z<K17VKMS/8)THU$*N+SE)3.0Z:9)<O?CD/DB62LD^M'MIU(V'1F]S
M1P3H"+IM_G+RS5=<IMFJOE'__3*NTG)VOF%K(\I;TU;>SK<3!H0QW.7,P6GM
M0453[P""!IL%?3=Z^NW>X*>=KRKW7[W1<]WA43>&-EX0VLA:66ZC,4 [B5SI
MK#2="3;77<2SB,Z@L;VC;$KC[5NB:R_I3R*TWV&KUYLDTI_S^\U BK4G&])Z
M)O5)0>NLT 80DP9E8@%GI !MR4AK'ZT-(Q:!'<!!JS? [0_A_A0["?@^FM^/
M,2-7%%IE%FL+!I/!\YS!BFRX9/4%PG@3%@^_=_GS7;SLHYC6W:#OI_Z+]3)(
ME)!,+J#0&W"NI!K-2T01A>'C52KN<>TRUOCY0>]=]A%^K\ 9HE?!Q\]80_@P
M_Q;F^9_X#;^L7:@[Y'=L1+#CH_KK,M"%UF-;"&Q;.JU7>3LO"R)@C>&K9]TL
MHC$ZUP>0F0ZE$!A$#(I\*HS.61:D-1T]VMVK'.>?_SA;I=-%37+33MBL\?OL
MTWQ69JG.^/ZTQ$WVFSS(_\1O;]9"_$AR^X$^XI\GB &+,PE2%NN<MP57F(+H
M? D>D1?9E<&C"&G9[[LG_=]UW,=32V_.T! &YX>PFJT6Y?9GTFY>W70+H9\\
M/YV%><*#K- ^G]^?:3J8JU[LU6T<I;2XG*]+Z1:GLS3#FYD(0COG?"VCCS7)
MX%0$7XOXM(HV11&2B[KCSNZT8 ^]MV]MF5]#;3$33N^M=WN3OOEZ?AKF]5._
MG6A?<A8)@2=1+_&XAEB*!.12Z6A=5FR\"ZW#^6@Z]:!W5#W2F'L<#4_:(OY*
M''W:FHER-2%[.5O]\S W[(F/Z\_>=:6YMXY.MX'R6[B@W^F<?%,_G?S]#W7A
M5[0\8:9.@WQLSO@U8+5&PV,H8)/GM6]K@> P YH0A40F8QIOVDEO;/5K; \B
MY?;F3(FK(JT&JY&1F\363PP0"NU+HYC6!<=+RO7)6>LJU3;[X&G#/2I:)FW*
MZR"J1/_'FZECJ\^+Y06M?39;CY-?\TZNX7PQ3Y?+JO-K\UG;5QP8>O>Q;G^'
M0^]2Z*\OX&5,V_G5:<W=ZEUYM5[P5M?<"N2:Z;GMY9CL,5E14X2T3Y1W$0)7
MM8M(S%%Z+ID;+XM[*!?]GA'7FWJS])W]C#S52B*06M;*Y,0A)*R-_FF#YZ M
M*^-U0>I&<VN[/@HRGS;C/2ETT@9ZW<I_>3./BFS0HM;2'9CQW/EI/28]NU'<
MWD1JKP2/2H+AVI$_(1CX$@0(S$4*SV+2X[T(GH:)W#4%[?;6XLS:@H;VDB1A
M*2<->*$S""ZDY 5M$>,5D>U)_(LUFOM@]6FCV;>*)VT]W]('S3_-B+\C?-4'
M'])K&^HGZ.O-1-XLLP';6O<?/X?YSXM%_F-V>M,X727"DLP<=++UM&06O#<)
M+(]<()>9@JP1:U,ZDMVO$;R_[.V=(3G3T5&XEVSMRZ<S!7Z%Y*-BUN3.Q)C+
M> _ .A+=VN@-@[ZGK5Q?.IRT=7N_7)SC\J)>+M?(];P&J0=9N$<_J#\K]SR=
MO5FZJZ7JPZB+[4&Z7N\:8X5S%1(WD%2FDU1E 5ZK=19>*BG0VQ$?#CU+;K^6
M;>=RM[='%M$Z5R)(%30HI@2$R.F/Z$,(KO@<VYBX+M2WMG7]XN]I&]>[-B=M
M[-9^Z_EVEET/4?##C^HY!'Z&UO;Q;\F,>V489"/J9.L0( HZ=X,6==9UXC*.
MUUQ^@O'OU>#$.WDE)8N6UH((=?<&6\ A0[ "!?U74E C3LS>@_+6AG$4E.X1
M^1ZKW$G;RNO$Z.FMB8.'6,I'/Z@_._D\G>VM9$;ZG]<,DC2>\%>C!5T0 B:M
MA&5VS 'CT["2UVJ[M>B=?20HD#.27!S)2G5Q(NTCH\"EP L&81B.-R!G#\)?
MK(W<!Z,=KU1Z4.VD3>0;LG^+;XAQTTCC(.MX_S/Z,XQ/4C=(B=*=TN'%Y<4C
M?4:NX18,.JEX@8(^44R1$L1H ^0LBPFF%._;E"KNP42_%O%*7]N5[FZ9C!1D
MD2\A8TUJ9>_!)RU ).^CEMQQV\9E?(+HUI9P#&0^;0C[TNBDC>#53-?#*GAN
MS8/MJ0KG$6KZ*3>_/15LGM=__"&L</N(\]9!:H.U)9#?ST6D@]1)B"6K=<3!
ME'!6=*\X[[AFSW<7MR<=W,&L4R(+9P!3?082!0,7M 9TSF-))A'K;6SV#HJ;
M%I(/@9=G+BSZ4-RDC<VU:SF[J:E<8EI\FL_^-^;9G*+R6\]/KLOKSA>KV?9U
MRA+7'<.Q%$P7B_H/9NO^/=?_[+@8=T"Z!@B9QY+B(-[FDW6^3@99G&$@3.W&
MQ#V#8)V%'$)4SDE7&CE,XY6S/U=_K%EF6.?!H0JY/NKCX*RRP!UJG6U)HK1Y
M$O""BM%[PV#'B+H'54[:OG^HKYLO\>JZ8V-4#K+(CW]2?S:T Z6#6#WZ.GSZ
MM,1/USV\UG34!P>OR1!7X*W^,;OX_/IR=4$4+6_@R 46RY4 &VOY%T\.'$J$
M%&7P@A=FTGBSWWMAJ5][N5WV]KYRPI-_Q QHG3PH6^\-N#1U#!W%:C:4T*A,
M\2&M4[**XV#T:9-YI#8G;27?G>,RU*>B^/4<YZL#[V4>?DI_UO$9"GNSC*_F
MX?3;:K:J&9YJ@-?/L=8KWD#*&!LCLQ#I! :E?*;(2E$ Q)UF3F<1S(@SFYZE
MM^><XE;\=X)!5HLV* 0TKI!;PH*#D)TG8H,-OK"B<QNC]@BQK:U:S_AZ)EUX
MI+(F;;-^PYO7;AMGZ;0.'3C$<.WXJ/ZL5Q=:QS1AD4('3L<?E'6)Z7I:@=(6
MK)3.6!D- >U/:\(VL<^VR_)VI3NGNA%%:2/!UVVB7**MEPV2<*+W%@.3(PYC
MV8/P%V#:]L%=EP"V'R5.VLQM."0L;1V? Q^+W/N0/A^+/$5?CX]%ZC(?:9G5
M^S#+),3+>;YI)\6%\DPCN(CDY2=)>B^\ "^8N?59HAVU>>EN4OM^%+)=ZC;T
MC=;%Z]JJEM>+0)491*DI-&':6F<"#[E-TXC'J&UMM/K#U7-//X[4U*2-U.O%
MV=ELTXX@+=8]AW!>VQN%>:[5.INP_; +W4Z?W.-U[_Z<]-4K\6K=U[?7I4/T
ME^MU;](:W@4LG"4(R8F*G *>HP6I.$-#9U^X/X;PJ?Z)>ZS<K_VZM38M=[W\
MQ8XZK]H'BQ5I0=O,ZT0,XCK45PJT?Y2+UIO0YH)A/SX:]V0<"F=/&\ !53UI
MT_AA<[%)NKGX=G&[7?EA=Q [/JS/:X@N]/;FUVV7>U^7N]VV_.;.BWE$@PP$
MSQ:49AYB;3)M=9)%6_+E1VR"\ARU?=\?W*QVY_44Q2Y&HJ']:+$^%=40,Z^]
MW141+CG&$=M6=R"XM8_7*\:>NR0X7F63-F=OK[-7Y[1:+4$Z(B"]\S%]AZ2[
M:>S%8=LL4@<BOL?ENA;K&DY6B:B=U9"-SZ#<.LN1Z0S-U@0F(TNI:[W>[E5Z
M3NM?C9/?KG(GE8)>6!M$'=](V"V$8N(B4Y02M0[.FY+:M*%Z@NB6+E9/R'@F
MM=^3PB9M;#;=NT.AM6I)!)XOEM5KS/2SASV->.+S>GPFT97J8;JZ+N8A_\_+
M55UR0\FK2LF'*S+>KR<BW&1D<W(YTV93MA BZTVYEQZ!3D,5N1&8Y7@W 8?S
MT;,UW+G>[6W&LF3*T^9"IVO'#L\I1$D!F#>:U<2.S6T>E'4BO[53-A)FG[&B
MO2MZTO9TC_;Z5PW*#[*SAZS39(C XUR..$S "L=B"1S06PH.I*PM>S5"[=6;
MF%&2L:[S(QL,$UA+NK;\0-KUV]*LZ\K2ZT%"=PM+I6$FUQ:;@G-0Z!3$6C<5
MI*B]0(KCR38QFOOS,OVA ON@ZVE#.;"F)S%W[C:_-T+];Y?YT_5$F3=T1)T1
ML_=>'V?MHLM01(WM;28>ZZ6.$-YGIYQBH4U\M <3G;#<_]2Q)E@>2K?3 #'>
MGF7Z]1S3!>:W9^<DPGH).;NHC8G/Z?A+VUW\&_Y!^W>>PS*OWBW?SHD8HGZC
M^]5)"+%@+!:RU/5EO4\0=>WPZ;T)VF0MQ7@-N_OEK1/DY0N&?#LD3&\GW!^&
M\]-B2?\AJ>'UNG%^VB2&3Q^,QS$NB\*C!E&03C'K#83B*CY#U%&+)..(+U3[
M8*D3[M6?!/>CZ/W/$O-]7/>>&CKBVZ[2)-Y[C,,1H[U"#@33LFRG#R)G$*+2
M9%)%)O_8EG#?4YQ2M/=F_3;WUEC8[4YZ\S6MO_/A@?,4DHDH:^5ZQ/I<44*M
MO03O D,7;6PUOV)?3J8?Z>V#K&=28D-J>=*6LH=Y.T=8T/Y6G]0$HB$L[C5N
MCVA-%@S+48(K5I.'D1+X* B]&54,*D>+XY7XC]X^[^$<7=)Q_?^;&SW3>O<&
MV=P,T;5"2!^R!U^BJ$._ [AD;)W<G9U&Q9"[CL?8X52TOK\8!7M/C#X>3F73
MB-[N%-4D,B\DTFV@>GTTU3OV5Z>GBS^J;[=Y;K(^EN[^U,]+^K'78;G\1B?G
MJ[-ZA-8PX)D."#(9B<F0Q'B]JK>UPPWSI79A#8'+%+/A39R7%M)HE!YLM-DF
M(_:]0#AIWVKG^*TC/*;G/G.$X6'3]&Z*"4F5PD&ZX GT/D)$1B!"Y*'F,\3]
MQP%_:N]FK;U;,Z6NFFVOE7=S1$K+N%2&3L<4+(50%#UY07$4<NV]P%C(9AS@
MU71;_<5Z,_M@;;<W,X"*)FT.[T_8.L(*[OBHX::!#6KSND]EDAFYS=R!]](
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M GU$9VOK706.!0\^1N5"BIF W,0\CC?I<M<U\?-C$YV6A?CPII;Y1,4A1HG
MI5>6)>N2;--Z_T"&IA09]H;9PRH$^E3]I$^.1^=0'F'KG_J\@:=GCF9/#Y]/
MR*+DBDD%WB9%(5CMVEDH(LN\@E9::W'$!BO3FZ&Y-QEW]J2*2::2(.7:N,^4
M^OHGE'7_Y5*<B2Z\D &E$[7)X^#^&8,]%D(FD=F[\[KL5F^ ZX=F5SQO[IJV
MHQ;J-W8,6@C"<5^[J]A2SRV!"6)6&1(+FO[C(N?QIEGVS=V4LH&M]DI3Q+3<
M,P_N^?\>ENLN,.M\_YJ4K0[NW? +'8P3/ 'J.H"360E1) [9!*,3H^B-AV?=
MGH.7;]27; J8'45CDX+DSXLON)S78&(;7\P__;18?B"=$X&?UW,-\^R"?G1U
MC^,<I<G1.2C&UP<E)&2OC .I3<R8A-3YD+*A0^EIU%1LDJ =1:>3#B$?#.L^
M(GS<]5D#CA8?-&SL,"65_%%5:JM1STL$I:0 7Y0 %X0R0J5BXW@Q8:L!XS]\
M^ZV6,MT9;.&]T5)KVI!,\5J/S"%RGD$78= &2]:_34^.)XAN':[UC+=N \>/
M5=ZDK=OCP[R/,'%/?N#00\A;&SMI?;!.%Y ^"XJ[:;?Y7-O7!8U!QL <&V^*
MQH#&[H&;0.JXE5.^&AETSR5@&;$PID#[>D=*#@I$$RP86QRW!74(_  WK\O:
M+\!P[8.=W?Y:[XJ8M/7:-=_QJ S_DQ\Y_&S*06W8L],#(VK%HU&09:H#_@P'
M@D0"QY1US)G$]'@9M,$F5#[8-O^)WWZELWW30/\](7<QG^/IZ\59W:-K#=\/
M;[@BWX($D[EEH%)$"M(9;=Y@?) ZV)38 ;9L7SI:V[5>\;3;J@VJGDFDPN^]
M9+P6Y ]X\0?B_):<[\\6MCH4:P)(9<G?=263)QH5%*ZE-QE=<B/V=#^0B]:I
M[6%@/*YR)WU0/YQB>E27J!T?-N34U<&*7I^8L,ED=$)Y#Z@P@#*,K%@N"CBC
MV#,9[^+]@25-9J\^-;XS&70%A8'@11V<%&L-HG<@I0TI62>"'6^\\\N;L;H/
M AZY+>M),9,V+1\_8W4$PKPV)?HG?L/U&$3Z;MI\=U,#=6 KD(Z?W6-7D$.X
MZ<4.;9>]4RJV1:&*.LFD.(3H:TY-20B<)<!2!(6M=$K=KS'?:8=VKW*<,[^I
MFGY77M-?SU(X?;]<Y,MT\9JD.*O#:E<GW!M+B$?P+%%\S9B D*2'H!*S2EOG
M2]=!UL\NUM*:]*3'N\YXO^*=A,=-+-3W1&1U3UPA2RBX@N0D10M%.0@E6Y"%
M"<-T4-*,%_3>T-5RCEW?*#I6[/M#QF\@,\>+OJJ5UF\MUK/#;"H.T$IB7Q/D
MHW46BK=)T]_D/&)#X@U-+:>_#0:4 \3=O!KBRDS^X_/B]/3;NS_FF'^_C*M9
MGH5E[4U01$@6A0:990%E#8*3QH')]'WML\WW7R,\>P;M6*KE8+1!3Z ^1#N)
M\^>*H:OF":N38#PY^%Z T<:#XJ8V!102N \B!*6S'+%Z\0%YG1"E7P:B>E+"
M"XR+_O/J"Y)D?>0U^WI6'V^=K^?$KX.(_W8Y1\DJ+OJ/G Y9?>C8ZFB)#!U]
M%9$<2DY'GI(95&0<8O$,DA*Y]G+(B:>.A\8 T5<_56OK[-H)JU/7:IH^U/)'
M944@AU!%T,6+8K2(KE'+AL/XF6@4N ^>>GZML+^:)W%4?Z2?7%'P>\73JZ^S
MU8GGAK/:3]*:RD4.'+RS%CC3,0J34 4S&E@?H[#UW>#82'D U:/5-DGP_;@X
M"[/Y20XN(\5&8")G6]$DI @Z,Q-TB2;J\1+KC]/8&H#'Z_]92!V@C.9!ZBO:
MA^N+].V]X\?%V_?_04+A=0/^'N:+,OL5JUM\PBQJ86P"&>M)4=_%^*058$97
MQZ$6WWDV8N=%IP::0S2\&%[<DS!-U<E8S*OO3!'4.EVSWF):!QUBJ#/.71UY
M'@/$.OS<8VTUFJ/D?KP,V>,TMBXX:'XV]J"ZB4)PNV&Y%-ZSPH&6I<VDF-[<
M;VH5M)#9I&"Q(0BG<4+V@8(.T#I )<U/R;>KU27F;>NGG\B$ORLUWYB6L_.J
MGZW)S@EYJJ^<-!T$M9(6:1-R!"PN>.VL*YUO1CLM.#W '*+;Q;""GH1A6A=<
MO%_BV>SR;,L#+\:X@ C"2 4JU"=Q,5I@T8? 4.@DQXL8']+7^DSL%UM]*:*Y
M(:H.:7V,M.G^5IO0W=H=M%<J>YO01@GCA"VD[.2(+<4E>,TBV)AU2MIY[[K>
M+G5>]$4_\#["D1I0-2\#<=N]*5-B%)X(( C5!N\.P5/D ESY)*21+I2N3[?W
M6+9E9G4@I>\/K ,TT!Q:5RQM>?A'6"X#&?RM75:F*(^2@0WD;:J0 [@<ZXLH
M'WU*,5O3=6KQDPM-'CZ'J'8QC)R;0V;=_WE6QSV\2N05;!I0OBO54]P(:\M4
ML;7M]/HRHXXR8=) L-J1L)1.Q<J09>>1U]V6;%F?-0Z,AI#])+SS=\L\FX?E
MMSM<N*24#T9 KB^'E!(D)TLAA]5*2EO',XYXH_,8A2WKO 8'7'^ZF03"7M=Y
M.363?*>%='4+D'FCG0QD;H4#):2$J$VIS?*+<$9:I\>[Y=Y)YHMN@M-+AK07
M!4X7B]N]FJR4T6<+&$JMF^,90L@"@N8^.9]Y]N,5G3U!://,5S]PZ :S W0S
M": ]:KH]TU'&(,"Y^C) B42F6U?['0HGQT"7,EXF_N!C=6QH'0*!;D?I/OIH
M[OT_<#655-GPS$$80=0'C!"<).H=LTYFKN/]67X[W?R)^//#X>!X"4["JASE
M"OPRF^/;"SQ;G3B?6!+:0"F:W $Z_FD'. ^B9*&"5=RK\2IF^N&I44WV=)RT
M!M!H;A*?Y>O7V2G2E_.K*34?,"&%\+E6?GII*1 S0=<W>KYV+=,>HG'$:4W[
M)-/1=AY,1.O#M@5B%N.K;Q*&^^IUQ:Y119M<0GZW_#LQ7*=4K,^I&%:U&<::
M]U<U;[EI^W(2<]$Z, LN<F(_53_;N@#96.5KEU%AQNLDV2MKK1V/EGMB F"9
MQ%YY'Y9_#Z>7>-6KX82$9KR,$GBJ3=I*8<2!B< BSZB$==Z-5T5WG[H7?>W;
M%V*/4EES-V)-\J;X9CU2[H8+5UAAW$/*2*&&H$@A)(:@T 96BHW*[C5<\9$U
M7G1RL0\GH!?A-X?0SMN !^;[)"H=,,@ 5I?:W5)S\#X6(/\E&L6M++;L>;7[
M_*HO.CSJ V8#*6C2[UY_"*O9:E%N?V:8YUO3#&LGG=/U)(8;_2S*=I!A29M)
M(K/Z< YGG^;X=?.=9>UR<LR+V#'HZN^M[.A2[&> \,U$F%<I+2[GM1/^^\7I
M+,WPIIF?)!J#K<DSH32HR U!W3-@QD9CDY;)=JV3Z[3@\<[A=@3L3QMAOMD*
M\P,)\P111'2,]FVTF1Q=XL-9+:$(*9C+S*621W,3=]/9=(AO[ZAXZ OVI*&#
M+2LM'Q<]7A@N5IM)'P^X*<QQ(56]+B!&%!<!(D,#RDI4.1,S>KRQ!;OI;%F;
M,P;>>M)0CW@;XBQ_'5:?$_T?R5WY$DZKH[+ZO%A>D!]Q-IM_P=7%VGFADVF^
MF*?+9=7-]5B L!X!=OMT2@\_CO[I_7]PQ!G?DM[^SO[)2+VWMN?D_*:ZT'I7
MKEOOOBN;"7&WQL+5GOS5+;Z]27,N.65E('F*XY75"KS1A8P1%UZG%)7RHUF[
M0[GHX3P@]=59>O3;FQLMG@CE>>%.UPXY%*Q&#! LXZ"+$LD7I%_&ZSW].(VM
MKQM&0=XCQ\/Q"IM$5O3UQKI<C[38B.Y$,^FLE :R05MG922(6CA(+GI1M$V2
MC3<+]W$:6^?T6P'O>(6U]8$WW7-HW]S;.S6%4@_!CW0(OKTY!+?\.9:3KK.F
MR*<3H+S/X#)Y=,E9[KE4(7/5,:3<=^W6J?AQ@3:\>@ZW>XN+<-K7S>FU8W5_
M)TF=I1%20[9DC!02*YYK^L5:A3DFQ;@<S?3M)+-U@K^1]>M';<WS^A\KDA_?
M9/?Y*AD31K+D+&=9>Y84B!1]@I31R5A+>WC7KMK=5VV=UV]@\@9226_&;J+1
M_ZN<UV^6ZI# ZTYXC2/\)VF:5!3?77KM(_7('4O<!G"A/A *WI%ME6[=6[R(
MVC5"CA>+MHO4;U\YWC,,FWI+87@2U03Q6C^FG+%D@K  -\8EJ]%).]XCM^>H
M?;'1^SYH?+JJ]6@E3B..ORIMO\?.^@&-42P+1B+BN?;W8$) S#F1BUYLJGZ[
M<7HT2#Y%:6LX]HN+W4^1CE72I"&W?5 1F+>9Y5@O7<@5XS%"")SDE4-2GGL5
M4VD.NHD]?3L:%YTA=X"2FD=-O[]]_>KOVS<V*>7DC#!0DBT4[B6$$(EP<K]%
MD$S$'+N.![WUL5,%PB':6O0ANFGHG!R 7R\O+L/I3Y?S?/7**IOH;4P.HKSJ
M,16"0'!<,Z9\YB%U[=J^<Y'6.>9A\7"T6)NCHU.\_B/2\3&K(5Q^.__;[S\N
M3D_#\HK=F$**7M:9-W4HN+<*O-((6KF@G) IQ:Y-38XFIG6B>3"TC:NFAJA<
M+2]./M0ZD?7)+8OQKA3R#C/25JK[*9;,P<G:T#C:B/B4!U3"*JXII$]=.S_?
MX^G%JOYIC;XU\NXLV-I:#>(]'R[2*>!@"U^!D66>"Q1?IXS6:6Q!*P25G4*N
M<XG\J9S 7DAHZ<D<H:S[ZCY <HT5_NML/CN[;H$IA%<R% 3DV1+SA<[1J"S0
MV6JL"\ZH\M3KHJXJO[-H8Z4?HK)%'_)KK?CP]1;ATJ0@K??@7.W-Y%0FU <#
M*IJB@V)%YZ=>P7=6_.U%VUC^WA1_L/PFD0=YXMC[Y?J)"5/<UC9M4) Q4,80
M5SY(B"H7QNJ#?#M>56\7BEL[HP.GXGI76O-8Z.IY[S4WMQX?_0>>YA-6G%"V
M<D,.,W'C#416&[[QZ,C&ZLCQ'@2?G8VY:ZW6>93^M?OHJ,Q>1-T<.!]FJW^N
MAP:?;LK;(W,L>K*]&1/))40)+GHRX[:DS*1B.7?%R;V/GG" T@<LCA%D<Q3L
M4?\0N/-<*P;(D@:E2@"G4QT'JWWVQ:HB.K>D[K<DI<UYU =V!A)_<UC]MI@_
M7K'Z]["<;5_J_A1FFW?^'S\O%Y>?/J_'B,Y7B]/UY/O\^]6;R'?E[3PMSG ]
MVQPCV5+R,4'F*@6=,CA4'#@/5H?H9?&=3[.!:&Q=HS?T*3@%U38'^&-%L<<*
MH%B?T!'O3-=J6E?5P3'51+QSPF833-<V4@.0U[HX<&!8MU;HI-_^]_QR;8F)
M?FQVNA'NK5?M>W_H=-X4]L[3I"H6Q]->^XK'8$O(V22P6%N"2H80.)?DSO.
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MSD=>U-O5YL5IO5V%M#Y66R"L<SJDKH )+:0<4D9E13'#F8/'\3"VH3C8'3V
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M>4?<Z589U$HCU%948HCX3I=90:V.M)893>@I&>!H$VLX&!VC\U.-JD,4,'6
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M.<BA@#15D6)_..* CP-/D3DVM(8QLWI1TG3QMMF-52J5D0+8H@E,*J7- O#
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M_7KE!Y-QYU)6JEA0>Z J/!@9'& 6K5UXUC;:2"H-5TY\.C]3<JZ&P?KS?OX
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M%A"K,NWO2.N.9]ISZW0#T(7&\/N5\@1@LY/:^HS>B>LN-7IG(Z(+4A8$EZ0
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M?RAX.A'G!+F.&)M<+6^N/K JUNGI'S+-<3E;K'-=0\D5%5.<9&TEZYX@1%V
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M4$L! A0#%     @ ]# L65ID=[2<'@  F8<! !(              ( !M"0
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4!08     !P ' -,!  "JU0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>inpha-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:inpha="http://www.innate-pharma.com/20240630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inpha-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH6101WithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">inpha:IssuedCapitalFreeOfSubscriptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">inpha:ExerciseOfShareWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">inpha:DefinitiveAcquisitionOfFreeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-10</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfExerciseAndSubscriptionOfSharesAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-10</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:FreeSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-10</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:FreeSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-10</startDate>
            <endDate>2024-06-10</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:SICAVAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:SICAVAndMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH5201WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">inpha:LaboratoryEquipmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-05</startDate>
            <endDate>2022-01-05</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">ifrs-full:GuaranteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-03</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-03</startDate>
            <endDate>2017-07-03</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:OtherDisposalsOfAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementSocieteGeneraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementBNPParibasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:PGELoanAgreementAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsBuildingLeVirageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsInnateIncPremisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsVehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LeaseFinancingObligationsPrintersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:RetirementDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:RetirementDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:SeniorityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CharacteristicsOfDefinedBenefitPlansAxis">inpha:SeniorityAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:The2016FreePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">inpha:The2017FreePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:CompanySavingPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:CompanySavingPlanEmployerTopUpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSAAR2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20161Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAManagement20162Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfEmployees20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfEmployees20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfManagement20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPPerfManagement20181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAEmployees2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20171Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20191Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus202012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus202012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPEmployees20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPManagement20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGABonus20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfEmployees20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPerfManagement20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGANewMembers20241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAPlanEpargneEntreprise2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:StockOptions20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:StockOptions20201Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Employees2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Employees2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Management2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:AGAP2019Management2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20151Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20152Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20221Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">inpha:BSA20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:NonCurrentFinancialAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:TradeReceivablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">inpha:FinancialAssetsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesNonCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:FinancialLiabilitiesCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:TradePayablesAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:CollaborationAndLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:CollaborationAndLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementRelatedToIPH6101WithSanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH62Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH62Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH67Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithSanofi2022ANKETIPH67Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementWithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AndAdvoralimabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:IPH5201AndAdvoralimabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:CollaborationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2015AstraZenecaMonalizumabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2018AstraZenecaIPH5201AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:A2018AstraZenecaIPH5201AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-19</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-19</startDate>
            <endDate>2023-12-19</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithGenzymeForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-25</startDate>
            <endDate>2023-01-25</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:SanofiResearchCollaborationAndLicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:AgreementsWithSanofiForNKCellEngagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:MonalizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">inpha:SanofiServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">inpha:DeferredRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:AdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="inpha:TypeOfEmployeeAxis">inpha:AdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:PreclinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">inpha:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:LoanAgreementWithSocitGnraleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">inpha:ChangesToCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">inpha:GrantsOfEmployeeEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">ifrs-full:TaxContingentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598599</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">inpha:NovoNordiskASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>inpha:subsidiary</measure>
    </unit>
    <unit id="employee">
        <measure>inpha:employee</measure>
    </unit>
    <unit id="share">
        <measure>inpha:share</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <unit id="loan_agreement">
        <measure>inpha:loan_agreement</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="loan">
        <measure>inpha:loan</measure>
    </unit>
    <unit id="target_option">
        <measure>inpha:target_option</measure>
    </unit>
    <unit id="option">
        <measure>inpha:option</measure>
    </unit>
    <unit id="preclinicalmolecule">
        <measure>inpha:preclinicalMolecule</measure>
    </unit>
    <unit id="licensing_agreement">
        <measure>inpha:licensing_agreement</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-3">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-5">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-7">0001598599</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">Innate Pharma SA</dei:EntityRegistrantName>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-9" unitRef="eur">69990000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-10" unitRef="eur">70605000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-11" unitRef="eur">21809000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-12" unitRef="eur">21851000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-2" decimals="-3" id="f-13" unitRef="eur">19795000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-14" unitRef="eur">55557000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentAssets contextRef="c-2" decimals="-3" id="f-15" unitRef="eur">111594000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-16" unitRef="eur">148012000</ifrs-full:CurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-17" unitRef="eur">119000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-18" unitRef="eur">416000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-2" decimals="-3" id="f-19" unitRef="eur">5748000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-3" decimals="-3" id="f-20" unitRef="eur">6322000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-21" unitRef="eur">10350000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-22" unitRef="eur">9796000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-2" decimals="-3" id="f-23" unitRef="eur">85000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-3" decimals="-3" id="f-24" unitRef="eur">87000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:NoncurrentReceivables contextRef="c-2" decimals="-3" id="f-25" unitRef="eur">14478000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NoncurrentReceivables contextRef="c-3" decimals="-3" id="f-26" unitRef="eur">10554000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:DeferredTaxAssets contextRef="c-2" decimals="-3" id="f-27" unitRef="eur">9123000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-3" decimals="-3" id="f-28" unitRef="eur">9006000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-3" id="f-29" unitRef="eur">39903000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-3" id="f-30" unitRef="eur">36181000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c-2" decimals="-3" id="f-31" unitRef="eur">151497000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-32" unitRef="eur">184193000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-2" decimals="-3" id="f-33" unitRef="eur">15873000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-34" unitRef="eur">17018000</ifrs-full:TradeAndOtherCurrentPayables>
    <inpha:CollaborationLiabilitiesCurrentPortion contextRef="c-2" decimals="-3" id="f-35" unitRef="eur">10248000</inpha:CollaborationLiabilitiesCurrentPortion>
    <inpha:CollaborationLiabilitiesCurrentPortion contextRef="c-3" decimals="-3" id="f-36" unitRef="eur">7647000</inpha:CollaborationLiabilitiesCurrentPortion>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-37" unitRef="eur">8929000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-38" unitRef="eur">8936000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-39" unitRef="eur">2799000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-40" unitRef="eur">5865000</ifrs-full:CurrentDeferredIncomeIncludingCurrentContractLiabilities>
    <ifrs-full:CurrentProvisions contextRef="c-2" decimals="-3" id="f-41" unitRef="eur">375000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c-3" decimals="-3" id="f-42" unitRef="eur">171000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentLiabilities contextRef="c-2" decimals="-3" id="f-43" unitRef="eur">38224000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-44" unitRef="eur">39637000</ifrs-full:CurrentLiabilities>
    <inpha:CollaborationLiabilitiesNonCurrentPortion contextRef="c-2" decimals="-3" id="f-45" unitRef="eur">41901000</inpha:CollaborationLiabilitiesNonCurrentPortion>
    <inpha:CollaborationLiabilitiesNonCurrentPortion contextRef="c-3" decimals="-3" id="f-46" unitRef="eur">45030000</inpha:CollaborationLiabilitiesNonCurrentPortion>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-2" decimals="-3" id="f-47" unitRef="eur">26574000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities contextRef="c-3" decimals="-3" id="f-48" unitRef="eur">30957000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c-2" decimals="-3" id="f-49" unitRef="eur">2470000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits contextRef="c-3" decimals="-3" id="f-50" unitRef="eur">2441000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities contextRef="c-2" decimals="-3" id="f-51" unitRef="eur">4116000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-52" unitRef="eur">4618000</ifrs-full:NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentProvisions contextRef="c-2" decimals="-3" id="f-53" unitRef="eur">294000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-3" decimals="-3" id="f-54" unitRef="eur">603000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-2" decimals="-3" id="f-55" unitRef="eur">9123000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-3" decimals="-3" id="f-56" unitRef="eur">9006000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-2" decimals="-3" id="f-57" unitRef="eur">84478000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-3" id="f-58" unitRef="eur">92656000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="-3" id="f-59" unitRef="eur">4049000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-60" unitRef="eur">4044000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-2" decimals="-3" id="f-61" unitRef="eur">386049000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-62" unitRef="eur">384255000</ifrs-full:SharePremium>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod contextRef="c-2" decimals="-3" id="f-63" unitRef="eur">-336893000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod contextRef="c-3" decimals="-3" id="f-64" unitRef="eur">-329323000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:OtherReserves contextRef="c-2" decimals="-3" id="f-65" unitRef="eur">354000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-3" id="f-66" unitRef="eur">495000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-2" decimals="-3" id="f-67" unitRef="eur">-24764000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod contextRef="c-3" decimals="-3" id="f-68" unitRef="eur">-7570000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-69" unitRef="eur">28796000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-70" unitRef="eur">51901000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-3" id="f-71" unitRef="eur">151497000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-72" unitRef="eur">184193000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-73" unitRef="eur">8293000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-4" decimals="-3" id="f-74" unitRef="eur">35344000</ifrs-full:RevenueFromContractsWithCustomers>
    <inpha:GovernmentFinancingForResearchExpenditures contextRef="c-1" decimals="-3" id="f-75" unitRef="eur">4052000</inpha:GovernmentFinancingForResearchExpenditures>
    <inpha:GovernmentFinancingForResearchExpenditures contextRef="c-4" decimals="-3" id="f-76" unitRef="eur">4854000</inpha:GovernmentFinancingForResearchExpenditures>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-77" unitRef="eur">12345000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-4" decimals="-3" id="f-78" unitRef="eur">40198000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-79" unitRef="eur">29076000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-3" id="f-80" unitRef="eur">31453000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-81" unitRef="eur">9582000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-82" unitRef="eur">9144000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense contextRef="c-1" decimals="-3" id="f-83" unitRef="eur">38657000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-4" decimals="-3" id="f-84" unitRef="eur">40597000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-85" unitRef="eur">-26313000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-4" decimals="-3" id="f-86" unitRef="eur">-398000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-87" unitRef="eur">3613000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-3" id="f-88" unitRef="eur">3083000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-89" unitRef="eur">2064000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-3" id="f-90" unitRef="eur">966000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-3" id="f-91" unitRef="eur">1549000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-3" id="f-92" unitRef="eur">2116000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-93" unitRef="eur">-24764000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-4" decimals="-3" id="f-94" unitRef="eur">1718000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-95" unitRef="eur">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-4" decimals="-3" id="f-96" unitRef="eur">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-97" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-98" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-99" unitRef="shares">80872369</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-100" unitRef="shares">80872369</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-4" decimals="0" id="f-101" unitRef="shares">80319897</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="0" id="f-102" unitRef="shares">80319897</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-103"
      unitRef="eurPerShare">-0.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-104"
      unitRef="eurPerShare">0.02</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-105"
      unitRef="eurPerShare">-0.31</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-106"
      unitRef="eurPerShare">0.02</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-107" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-108" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-1" decimals="-3" id="f-109" unitRef="eur">116000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-4" decimals="-3" id="f-110" unitRef="eur">101000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-111" unitRef="eur">-257000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-4" decimals="-3" id="f-112" unitRef="eur">146000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-113" unitRef="eur">-141000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-4" decimals="-3" id="f-114" unitRef="eur">247000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-115" unitRef="eur">-24905000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-3" id="f-116" unitRef="eur">1965000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-117" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-118" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="eur">1142000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-4" decimals="-3" id="f-120" unitRef="eur">3645000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-1" decimals="-3" id="f-121" unitRef="eur">145000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c-4" decimals="-3" id="f-122" unitRef="eur">83000</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-1" decimals="-3" id="f-123" unitRef="eur">-105000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-4" decimals="-3" id="f-124" unitRef="eur">507000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-125" unitRef="eur">1705000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-4" decimals="-3" id="f-126" unitRef="eur">1401000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-1" decimals="-3" id="f-127" unitRef="eur">-992000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-4" decimals="-3" id="f-128" unitRef="eur">-1044000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-129" unitRef="eur">-524000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-4" decimals="-3" id="f-130" unitRef="eur">288000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets contextRef="c-1" decimals="-3" id="f-131" unitRef="eur">-212000</ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets contextRef="c-4" decimals="-3" id="f-132" unitRef="eur">-130000</ifrs-full:AdjustmentsForDecreaseIncreaseInAccruedIncomeIncludingContractAssets>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-133" unitRef="eur">-18000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-134" unitRef="eur">-591000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-1" decimals="-3" id="f-135" unitRef="eur">26000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-4" decimals="-3" id="f-136" unitRef="eur">6000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-137" unitRef="eur">-23561000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-4" decimals="-3" id="f-138" unitRef="eur">7065000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-139" unitRef="eur">-26597000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-4" decimals="-3" id="f-140" unitRef="eur">18530000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-141" unitRef="eur">3036000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-142" unitRef="eur">-11465000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-143" unitRef="eur">283000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-144" unitRef="eur">309000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-145" unitRef="eur">0</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-146" unitRef="eur">66000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-147" unitRef="eur">0</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-148" unitRef="eur">3000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-149" unitRef="eur">1215000</inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities>
    <inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-4" decimals="-3" id="f-150" unitRef="eur">0</inpha:ProceedsFromSalesOfCurrentFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-151" unitRef="eur">932000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-152" unitRef="eur">-246000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-3" id="f-153" unitRef="eur">93000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-4" decimals="-3" id="f-154" unitRef="eur">348000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-155" unitRef="eur">4420000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-156" unitRef="eur">1594000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-157" unitRef="eur">-4327000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-158" unitRef="eur">-1246000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-159" unitRef="eur">-257000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-160" unitRef="eur">145000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-161" unitRef="eur">-615000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-162" unitRef="eur">-12811000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-163" unitRef="eur">70605000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-164" unitRef="eur">84225000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-165" unitRef="eur">69990000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-6" decimals="-3" id="f-166" unitRef="eur">71414000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-2" decimals="-3" id="f-167" unitRef="eur">34273000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-3" decimals="-3" id="f-168" unitRef="eur">66111000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-1" decimals="-3" id="f-169" unitRef="eur">31838000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities contextRef="c-2" decimals="-3" id="f-170" unitRef="eur">6915000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities contextRef="c-3" decimals="-3" id="f-171" unitRef="eur">10483000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities contextRef="c-1" decimals="-3" id="f-172" unitRef="eur">-3568000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:TradeAndOtherPayables contextRef="c-2" decimals="-3" id="f-173" unitRef="eur">15873000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-3" decimals="-3" id="f-174" unitRef="eur">17018000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-175" unitRef="eur">-1145000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <inpha:CollaborationLiabilities contextRef="c-2" decimals="-3" id="f-176" unitRef="eur">52149000</inpha:CollaborationLiabilities>
    <inpha:CollaborationLiabilities contextRef="c-3" decimals="-3" id="f-177" unitRef="eur">52677000</inpha:CollaborationLiabilities>
    <inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities contextRef="c-1" decimals="-3" id="f-178" unitRef="eur">-528000</inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities>
    <inpha:ChangeInWorkingCapital contextRef="c-2" decimals="-3" id="f-179" unitRef="eur">40664000</inpha:ChangeInWorkingCapital>
    <inpha:ChangeInWorkingCapital contextRef="c-3" decimals="-3" id="f-180" unitRef="eur">14067000</inpha:ChangeInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-181" unitRef="eur">-26597000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-6" decimals="-3" id="f-182" unitRef="eur">56446000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-5" decimals="-3" id="f-183" unitRef="eur">52445000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-4" decimals="-3" id="f-184" unitRef="eur">-4001000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities contextRef="c-6" decimals="-3" id="f-185" unitRef="eur">11024000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:DeferredIncomeIncludingContractLiabilities contextRef="c-5" decimals="-3" id="f-186" unitRef="eur">14481000</ifrs-full:DeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities contextRef="c-4" decimals="-3" id="f-187" unitRef="eur">-3457000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:TradeAndOtherPayables contextRef="c-6" decimals="-3" id="f-188" unitRef="eur">16991000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-5" decimals="-3" id="f-189" unitRef="eur">20911000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-4" decimals="-3" id="f-190" unitRef="eur">-3919000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <inpha:CollaborationLiabilities contextRef="c-6" decimals="-3" id="f-191" unitRef="eur">56058000</inpha:CollaborationLiabilities>
    <inpha:CollaborationLiabilities contextRef="c-5" decimals="-3" id="f-192" unitRef="eur">63211000</inpha:CollaborationLiabilities>
    <inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities contextRef="c-4" decimals="-3" id="f-193" unitRef="eur">-7153000</inpha:AdjustmentsForIncreaseDecreaseInCollaborationLiabilities>
    <inpha:ChangeInWorkingCapital contextRef="c-6" decimals="-3" id="f-194" unitRef="eur">27627000</inpha:ChangeInWorkingCapital>
    <inpha:ChangeInWorkingCapital contextRef="c-5" decimals="-3" id="f-195" unitRef="eur">46158000</inpha:ChangeInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-4" decimals="-3" id="f-196" unitRef="eur">18530000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:NumberOfSharesIssued contextRef="c-7" decimals="INF" id="f-197" unitRef="shares">80212069</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c-8" decimals="INF" id="f-198" unitRef="shares">14095</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-199" unitRef="eur">4011000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-200" unitRef="eur">379637000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-201" unitRef="eur">-272213000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-202" unitRef="eur">819000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-3" id="f-203" unitRef="eur">-58103000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-204" unitRef="eur">54151000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-14" decimals="-3" id="f-205" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-206" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-15" decimals="-3" id="f-207" unitRef="eur">101000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-4" decimals="-3" id="f-208" unitRef="eur">101000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-15" decimals="-3" id="f-209" unitRef="eur">146000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-4" decimals="-3" id="f-210" unitRef="eur">146000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-3" id="f-211" unitRef="eur">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-3" id="f-212" unitRef="eur">247000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-14" decimals="-3" id="f-213" unitRef="eur">1718000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-4" decimals="-3" id="f-214" unitRef="eur">1965000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-16" decimals="-3" id="f-215" unitRef="eur">-58103000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-14" decimals="-3" id="f-216" unitRef="eur">58103000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-4" decimals="-3" id="f-217" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares
      contextRef="c-17"
      decimals="INF"
      id="f-218"
      unitRef="shares">304553</inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-18" decimals="-3" id="f-219" unitRef="eur">15000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-19" decimals="-3" id="f-220" unitRef="eur">333000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-4" decimals="-3" id="f-221" unitRef="eur">348000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-19" decimals="-3" id="f-222" unitRef="eur">1400000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-4" decimals="-3" id="f-223" unitRef="eur">1400000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-224"
      unitRef="shares">80516622</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-21"
      decimals="INF"
      id="f-225"
      unitRef="shares">14095</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-226" unitRef="eur">4027000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-227" unitRef="eur">381371000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-228" unitRef="eur">-330315000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-229" unitRef="eur">1064000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-230" unitRef="eur">1718000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-231" unitRef="eur">57863000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-232"
      unitRef="shares">80860563</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-28"
      decimals="INF"
      id="f-233"
      unitRef="shares">14090</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-29" decimals="-3" id="f-234" unitRef="eur">4044000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-3" id="f-235" unitRef="eur">384255000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-3" id="f-236" unitRef="eur">-329323000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-3" id="f-237" unitRef="eur">495000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-238" unitRef="eur">-7570000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-239" unitRef="eur">51901000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-34" decimals="-3" id="f-240" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-241" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-35" decimals="-3" id="f-242" unitRef="eur">116000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-1" decimals="-3" id="f-243" unitRef="eur">116000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-35" decimals="-3" id="f-244" unitRef="eur">-257000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-245" unitRef="eur">-257000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-35" decimals="-3" id="f-246" unitRef="eur">-141000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-34" decimals="-3" id="f-247" unitRef="eur">-24764000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-248" unitRef="eur">-24905000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-36" decimals="-3" id="f-249" unitRef="eur">-7570000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-34" decimals="-3" id="f-250" unitRef="eur">7570000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings contextRef="c-1" decimals="-3" id="f-251" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares
      contextRef="c-37"
      decimals="INF"
      id="f-252"
      unitRef="shares">106844</inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-38" decimals="-3" id="f-253" unitRef="eur">5000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-39" decimals="-3" id="f-254" unitRef="eur">88000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-1" decimals="-3" id="f-255" unitRef="eur">93000</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-39" decimals="-3" id="f-256" unitRef="eur">1706000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-257" unitRef="eur">1706000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-40"
      decimals="INF"
      id="f-258"
      unitRef="shares">80967407</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-41"
      decimals="INF"
      id="f-259"
      unitRef="shares">14090</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-42" decimals="-3" id="f-260" unitRef="eur">4049000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-3" id="f-261" unitRef="eur">386049000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-3" id="f-262" unitRef="eur">-336893000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-3" id="f-263" unitRef="eur">354000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-3" id="f-264" unitRef="eur">-24764000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-265" unitRef="eur">28796000</ifrs-full:Equity>
    <inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock contextRef="c-1" id="f-266">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;The Company and key events&lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;The company&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Innate Pharma SA (the &#x201c;Company&#x201d; and, with its subsidiary, referred to as the &#x201c;Group&#x201d;), is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET&#xae; (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate&#x2019;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET&#xae; multi-specific NK cell engagers to address multiple tumor types. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Since its creation, the Company has suffered losses due to its research and development ("R&amp;amp;D") activities. The first half of 2024 generated a net loss of 24,764 thousand euros. As of June 30, 2024, shareholders' equity amounted to 28,796 thousand euros. Subject to receiving new milestone payments related to its collaboration agreements, the Company expects to incur additional losses until, if necessary, it can generate significant revenues from its drug candidates in development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company&#x2019;s future operations are highly dependent on a combination of factors, including: (i)&#160;the success of its R&amp;amp;D; (ii)&#160;regulatory approval and market acceptance of the Company&#x2019;s future drug candidates; (iii)&#160;the timely and successful completion of additional financing; and (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments and debt financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The activity of the Company is not subject to seasonal effects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June 30, 2024, the Company had one wholly owned subsidiary: Innate Pharma, Inc., incorporated under the laws of Delaware in 2009. The subsidiary is consolidated according global integration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Innate Pharma is based in Marseille, France and listed on Euronext Paris and Nasdaq in the United States., and had 168 full time equivalent employees as of June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Key events for the six-month period ended June 30, 2024&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt"&gt;On March 6, 2024, the Company announced the treatment of the first patient in the Phase 1/2 trial evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET&#xae; platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt"&gt;On April 15, 2024, the Company announced the treatment of the first patient in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms of the 2016 agreement, this trial progress triggered a milestone payment of &#x20ac;4&#160;million fully recognized in revenue during the first quarter of 2024. This amount was received by the Company on May 17, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:13.02pt"&gt;On June 10, 2024, the Executive Board carried out a capital increase of &#x20ac;5,342 following the creation of 106,844 ordinary shares benefiting the employees of the company, including 68,744 ordinary shares issued free of charge (subscription). The capital increase carried out can be broken as follow : a creation of 68,744 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;free shares with a nominal value of &#x20ac;0.05 issued free of charge by deduction from the share premium, with a creation of 38,100 ordinary shares with a nominal value of &#x20ac;0.05 and an issue price of &#x20ac;2.45 (i.e an increase in share premium of &#x20ac;91,440).&lt;/span&gt;&lt;/div&gt;</inpha:DisclosureOfCompanySignificantAgreementsAndKeyEventsTextBlock>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-267" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-268" unitRef="eur">28796000</ifrs-full:Equity>
    <inpha:NumberOfWhollyOwnedSubsidiaries
      contextRef="c-2"
      decimals="INF"
      id="f-269"
      unitRef="subsidiary">1</inpha:NumberOfWhollyOwnedSubsidiaries>
    <ifrs-full:NumberOfEmployees contextRef="c-2" decimals="2" id="f-270" unitRef="employee">168</ifrs-full:NumberOfEmployees>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived contextRef="c-47" decimals="-6" id="f-271" unitRef="eur">4000000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-38" decimals="0" id="f-272" unitRef="eur">5342</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-48" decimals="INF" id="f-273" unitRef="share">106844</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-49" decimals="INF" id="f-274" unitRef="share">68744</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-50" decimals="INF" id="f-275" unitRef="share">68744</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="c-51"
      decimals="2"
      id="f-276"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-52" decimals="INF" id="f-277" unitRef="share">38100</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="c-53"
      decimals="2"
      id="f-278"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <inpha:ShareIssuedPricePerShare
      contextRef="c-54"
      decimals="2"
      id="f-279"
      unitRef="eurPerShare">2.45</inpha:ShareIssuedPricePerShare>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-55" decimals="0" id="f-280" unitRef="eur">91440</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-281">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Basis of presentation and statement of compliance&lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Basis of preparation&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The interim condensed consolidated financial statements as of June 30, 2024 and for the six-months period ended June 30, 2024 and 2023 and the related notes (together, the &#x201c;interim condensed consolidated financial statements&#x201d;) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company&#x2019;s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board on September&#160;11, 2024 upon recommendation of the Audit Committee on September&#160;10, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;They have been prepared in accordance with IAS 34, &#x2018;Interim Financial Reporting&#x2019; as issued by the International Accounting Standard Board (&#x201c;IASB&#x201d;). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#x2019;s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The results of the operations for the six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any year in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Use of judgments and estimates &lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 2.w) of the appendix to the consolidated financial statements as of December 31, 2023 filed with SEC (20-F) on April 2, 2024. As of June 30, 2024, the Company has not identified any other significant estimates and judgments that could have an impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Recently issued accounting standards and interpretations &lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IAS 1 : Classification of liabilities with covenants; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IAS 7 and IFRS 7 : Supplier finance arrangements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IFRS 16 : Lease liability in a sale and leaseback. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Those amended standards have no impact on the interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company has not opted for the early application of any standards whose application would be mandatory from subsequent financial years.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Translation of transactions denominated in foreign currency &lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Foreign currency transactions are translated into the functionnal currency using the following exchange rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x20ac;1 equals to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.1050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0705&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-282">&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Basis of preparation&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The interim condensed consolidated financial statements as of June 30, 2024 and for the six-months period ended June 30, 2024 and 2023 and the related notes (together, the &#x201c;interim condensed consolidated financial statements&#x201d;) have been prepared under the responsibility of the management of the Company in accordance with the underlying assumptions of going concern as the Company&#x2019;s loss-making situation is explained by the innovative nature of the products developed, therefore involving a multi-year research and development phase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The interim condensed consolidated financial statements were closed by the Executive Board, approved and authorized by the Supervisory Board on September&#160;11, 2024 upon recommendation of the Audit Committee on September&#160;10, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;They have been prepared in accordance with IAS 34, &#x2018;Interim Financial Reporting&#x2019; as issued by the International Accounting Standard Board (&#x201c;IASB&#x201d;). Due to the listing of ordinary shares of the Company on Euronext Paris and in accordance with the European Union&#x2019;s regulation No. 1606/2002 of July 19, 2002, the interim condensed consolidated financial statements are also prepared in accordance with IFRS, as adopted by the European Union (EU).For the presented periods, the differences between IFRS as issued by IASB and IFRS adopted by EU had no impact on the interim condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The general accounting conventions were applied in accordance with the underlying assumptions, namely (i) going concern, (ii) permanence of accounting methods from one year to the next and (iii) independence of financial years, and in conformity with the general rules for the preparation and presentation of consolidated financial statements in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;). The interim condensed consolidated financial statements do not include all disclosures required for annual financial statements and should therefore be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The results of the operations for the six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any year in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Except for number of shares and per share amounts, all amounts are expressed in thousands of euros, unless stated otherwise. Some amounts may be rounded for the calculation of financial information contained in the interim condensed consolidated financial statements. Accordingly, the totals in some tables may not be the exact sum of the preceding figures.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-283">&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Use of judgments and estimates &lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The preparation of financial statements in accordance with IFRS requires the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;These estimates can be revised where the circumstances on which they are based change. The actual results may therefore differ from the estimates initially formulated. The estimates and judgments which are mainly used by the Company are detailed in note 2.w) of the appendix to the consolidated financial statements as of December 31, 2023 filed with SEC (20-F) on April 2, 2024. As of June 30, 2024, the Company has not identified any other significant estimates and judgments that could have an impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-284">&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Recently issued accounting standards and interpretations &lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Application of the following amended standards is mandatory for the first time for the financial period beginning on January 1, 2024 and, as such, they have been adopted by the Company:   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IAS 1 : Classification of liabilities with covenants; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IAS 7 and IFRS 7 : Supplier finance arrangements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Amendments to IFRS 16 : Lease liability in a sale and leaseback. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Those amended standards have no impact on the interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company has not opted for the early application of any standards whose application would be mandatory from subsequent financial years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-285">&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:140%;padding-left:4.09pt"&gt;Translation of transactions denominated in foreign currency &lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Foreign currency transactions are translated into the functionnal currency using the following exchange rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x20ac;1 equals to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.1050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0705&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="c-1" id="f-286">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Foreign currency transactions are translated into the functionnal currency using the following exchange rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.880%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.325%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x20ac;1 equals to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0806&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.1050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.0705&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ifrs-full:AverageForeignExchangeRate contextRef="c-4" decimals="4" id="f-287" unitRef="number">1.0806</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-6" decimals="4" id="f-288" unitRef="number">1.0866</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c-56" decimals="4" id="f-289" unitRef="number">1.0813</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-3" decimals="4" id="f-290" unitRef="number">1.1050</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="c-1" decimals="4" id="f-291" unitRef="number">1.0813</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="c-2" decimals="4" id="f-292" unitRef="number">1.0705</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory contextRef="c-1" id="f-293">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Management of financial risks&lt;/span&gt;The Company did not identify other risks than the ones presented in the consolidated financial statements for the year ended December 31, 2023.</ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c-1" id="f-294">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Cash, cash equivalents, short-term investments  and non-current financial assets&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;91,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;92,456&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash, cash equivalents and financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Cash and cash equivalents are mainly composed of current bank accounts, interest-bearing accounts and fixed-term accounts and mutual funds units (with short-term maturities) held with various banking institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June 30, 2024, the Company also holds shares in three mutual funds. The risk profiles of these funds are rated from 1 to 7 by the financial institution that manages and markets these funds (1 being the lowest risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;profile).When the maturity of shares in mutual funds is longer than one year, they are classified as non-current financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Non-current financial assets generally include a guarantee of capital at the maturity date (which is always longer than one year). These instruments are defined by the Company as financial assets at fair value through profit or loss and classified as non-current due to their maturity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June 30, 2024 and December 31, 2023, the amount of cash, cash equivalents and financials assets denominated in US dollars amounted to &#x20ac;18,221 thousand and &#x20ac;20,798 thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Changes in short-term investments and non-current financial assets for the six months ended June 30, 2023 and 2024 are the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variance of fair value through the consolidated statement of income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variation of accrued interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign currency effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;21,810&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;31,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;32,160&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variance of fair value through the consolidated statement of income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variation of accrued interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign currency effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;17,475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;772&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,379&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;53,265&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;For the six months ended June 30, 2024 , variance of fair value through the consolidated statement of income (loss) is made of &#x20ac;553 thousand of unrealized gains on non-current financial assets and &#x20ac;438 thousand of unrealized gains on short-term investments. For the six months ended June 30, 2023, variance of fair value through the consolidated statement of income (loss) was made of &#x20ac;772 thousand of unrealized gains on non-current financial assets and &#x20ac;271 thousand of unrealized gains on short-term investments (see &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"&gt;&lt;a href="#i634ed0333ee247d7904463c2d5fd1df7_148" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"&gt;note 1&lt;/a&gt;&lt;a href="#i634ed0333ee247d7904463c2d5fd1df7_148" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;text-decoration:underline"&gt;5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock contextRef="c-1" id="f-295">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;91,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;92,456&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash, cash equivalents and financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,252&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inpha:DisclosureOfCashCashEquivalentsAndFinancialAssetsTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-296" unitRef="eur">69990000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-297" unitRef="eur">70605000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-298" unitRef="eur">21809000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-299" unitRef="eur">21851000</ifrs-full:CurrentFinancialAssets>
    <inpha:CashCashEquivalentsAndShortTermInvestmentsAssets contextRef="c-2" decimals="-3" id="f-300" unitRef="eur">91799000</inpha:CashCashEquivalentsAndShortTermInvestmentsAssets>
    <inpha:CashCashEquivalentsAndShortTermInvestmentsAssets contextRef="c-3" decimals="-3" id="f-301" unitRef="eur">92456000</inpha:CashCashEquivalentsAndShortTermInvestmentsAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-302" unitRef="eur">10350000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-303" unitRef="eur">9796000</ifrs-full:NoncurrentFinancialAssets>
    <inpha:TotalCashCashEquivalentsAndFinancialAssets contextRef="c-2" decimals="-3" id="f-304" unitRef="eur">102149000</inpha:TotalCashCashEquivalentsAndFinancialAssets>
    <inpha:TotalCashCashEquivalentsAndFinancialAssets contextRef="c-3" decimals="-3" id="f-305" unitRef="eur">102252000</inpha:TotalCashCashEquivalentsAndFinancialAssets>
    <inpha:NumberOfFinancialInstrumentsHeld contextRef="c-2" decimals="INF" id="f-306" unitRef="shares">3</inpha:NumberOfFinancialInstrumentsHeld>
    <inpha:RiskProfileRate contextRef="c-57" decimals="INF" id="f-307" unitRef="rate">1</inpha:RiskProfileRate>
    <inpha:RiskProfileRate contextRef="c-58" decimals="INF" id="f-308" unitRef="rate">7</inpha:RiskProfileRate>
    <inpha:TotalCashCashEquivalentsAndFinancialAssets contextRef="c-59" decimals="-3" id="f-309" unitRef="eur">18221000</inpha:TotalCashCashEquivalentsAndFinancialAssets>
    <inpha:TotalCashCashEquivalentsAndFinancialAssets contextRef="c-60" decimals="-3" id="f-310" unitRef="eur">20798000</inpha:TotalCashCashEquivalentsAndFinancialAssets>
    <ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory contextRef="c-1" id="f-311">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Changes in short-term investments and non-current financial assets for the six months ended June 30, 2023 and 2024 are the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variance of fair value through the consolidated statement of income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variation of accrued interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign currency effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;438&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;21,810&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;553&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;31,647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;524&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;32,160&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variance of fair value through the consolidated statement of income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Variation of accrued interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Foreign currency effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;17,475&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;35,119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;772&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,790&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,379&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;53,265&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) The additions correspond to both acquisitions and reclassifications of financial assets according to their maturity at the closing date. &lt;/span&gt;&lt;/div&gt;(2) The deductions correspond to both disposals and reclassifications of financial assets according to their maturity at the closing date.</ifrs-full:DisclosureOfReconciliationOfChangesInLossAllowanceAndExplanationOfChangesInGrossCarryingAmountForFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentInvestments contextRef="c-3" decimals="-3" id="f-312" unitRef="eur">21851000</ifrs-full:CurrentInvestments>
    <inpha:ShortTermInvestmentsAcquisitions contextRef="c-1" decimals="-3" id="f-313" unitRef="eur">0</inpha:ShortTermInvestmentsAcquisitions>
    <inpha:DecreaseThroughDerecognitionShortTermInvestment contextRef="c-1" decimals="-3" id="f-314" unitRef="eur">1215000</inpha:DecreaseThroughDerecognitionShortTermInvestment>
    <inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-1" decimals="-3" id="f-315" unitRef="eur">438000</inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-1" decimals="-3" id="f-316" unitRef="eur">212000</inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:ShortTermInvestmentsForeignCurrencyEffect contextRef="c-1" decimals="-3" id="f-317" unitRef="eur">524000</inpha:ShortTermInvestmentsForeignCurrencyEffect>
    <ifrs-full:CurrentInvestments contextRef="c-2" decimals="-3" id="f-318" unitRef="eur">21810000</ifrs-full:CurrentInvestments>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-319" unitRef="eur">9796000</ifrs-full:NoncurrentFinancialAssets>
    <inpha:NonCurrentFinancialAssetsAcquisitions contextRef="c-1" decimals="-3" id="f-320" unitRef="eur">0</inpha:NonCurrentFinancialAssetsAcquisitions>
    <inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets contextRef="c-1" decimals="-3" id="f-321" unitRef="eur">0</inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets>
    <inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-1" decimals="-3" id="f-322" unitRef="eur">553000</inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-1" decimals="-3" id="f-323" unitRef="eur">0</inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:NonCurrentFinancialAssetsForeignCurrencyEffect contextRef="c-1" decimals="-3" id="f-324" unitRef="eur">0</inpha:NonCurrentFinancialAssetsForeignCurrencyEffect>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-325" unitRef="eur">10350000</ifrs-full:NoncurrentFinancialAssets>
    <inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets contextRef="c-3" decimals="-3" id="f-326" unitRef="eur">31647000</inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets>
    <inpha:TotalAcquisitions contextRef="c-1" decimals="-3" id="f-327" unitRef="eur">0</inpha:TotalAcquisitions>
    <inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets contextRef="c-1" decimals="-3" id="f-328" unitRef="eur">1215000</inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets>
    <inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-1" decimals="-3" id="f-329" unitRef="eur">991000</inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-1" decimals="-3" id="f-330" unitRef="eur">212000</inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:TotalForeignCurrencyEffect contextRef="c-1" decimals="-3" id="f-331" unitRef="eur">524000</inpha:TotalForeignCurrencyEffect>
    <inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets contextRef="c-2" decimals="-3" id="f-332" unitRef="eur">32160000</inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets>
    <ifrs-full:CurrentInvestments contextRef="c-5" decimals="-3" id="f-333" unitRef="eur">17260000</ifrs-full:CurrentInvestments>
    <inpha:ShortTermInvestmentsAcquisitions contextRef="c-4" decimals="-3" id="f-334" unitRef="eur">0</inpha:ShortTermInvestmentsAcquisitions>
    <inpha:DecreaseThroughDerecognitionShortTermInvestment contextRef="c-4" decimals="-3" id="f-335" unitRef="eur">0</inpha:DecreaseThroughDerecognitionShortTermInvestment>
    <inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-4" decimals="-3" id="f-336" unitRef="eur">271000</inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-4" decimals="-3" id="f-337" unitRef="eur">232000</inpha:IncreaseDecreaseInAccruedInterestForCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:ShortTermInvestmentsForeignCurrencyEffect contextRef="c-4" decimals="-3" id="f-338" unitRef="eur">-288000</inpha:ShortTermInvestmentsForeignCurrencyEffect>
    <ifrs-full:CurrentInvestments contextRef="c-6" decimals="-3" id="f-339" unitRef="eur">17475000</ifrs-full:CurrentInvestments>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-5" decimals="-3" id="f-340" unitRef="eur">35119000</ifrs-full:NoncurrentFinancialAssets>
    <inpha:NonCurrentFinancialAssetsAcquisitions contextRef="c-4" decimals="-3" id="f-341" unitRef="eur">0</inpha:NonCurrentFinancialAssetsAcquisitions>
    <inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets contextRef="c-4" decimals="-3" id="f-342" unitRef="eur">0</inpha:DecreaseThroughDerecognitionNonCurrentFinancialAssets>
    <inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-4" decimals="-3" id="f-343" unitRef="eur">772000</inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-4" decimals="-3" id="f-344" unitRef="eur">-102000</inpha:IncreaseDecreaseInAccruedInterestForNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:NonCurrentFinancialAssetsForeignCurrencyEffect contextRef="c-4" decimals="-3" id="f-345" unitRef="eur">0</inpha:NonCurrentFinancialAssetsForeignCurrencyEffect>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c-6" decimals="-3" id="f-346" unitRef="eur">35790000</ifrs-full:NoncurrentFinancialAssets>
    <inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets contextRef="c-5" decimals="-3" id="f-347" unitRef="eur">52379000</inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets>
    <inpha:TotalAcquisitions contextRef="c-4" decimals="-3" id="f-348" unitRef="eur">0</inpha:TotalAcquisitions>
    <inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets contextRef="c-4" decimals="-3" id="f-349" unitRef="eur">0</inpha:DecreaseThroughDerecognitionShortTermInvestmentAndNonCurrentFinancialAssets>
    <inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-4" decimals="-3" id="f-350" unitRef="eur">1043000</inpha:TotalVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss contextRef="c-4" decimals="-3" id="f-351" unitRef="eur">130000</inpha:IncreaseDecreaseInAccruedInterestForShortTermAndNonCurrentFinancialAssetsNotAtFairValueThroughProfitOrLoss>
    <inpha:TotalForeignCurrencyEffect contextRef="c-4" decimals="-3" id="f-352" unitRef="eur">-288000</inpha:TotalForeignCurrencyEffect>
    <inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets contextRef="c-6" decimals="-3" id="f-353" unitRef="eur">53265000</inpha:ShortTermInvestmentsAndNonCurrentFinancialAssets>
    <inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-1" decimals="-3" id="f-354" unitRef="eur">553000</inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-1" decimals="-3" id="f-355" unitRef="eur">438000</inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-4" decimals="-3" id="f-356" unitRef="eur">772000</inpha:NonCurrentFinancialAssetsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss contextRef="c-4" decimals="-3" id="f-357" unitRef="eur">271000</inpha:ShortTermInvestmentsVariationOfFairValueThroughTheConsolidatedStatementOfIncomeLoss>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="c-1" id="f-358">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Trade receivables and others&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,755&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;29,755&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other tax credits (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepaid expenses (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,692&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VAT refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade account receivables  (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,233&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepayments made to suppliers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,374&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;19,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;55,557&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepaid expenses (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;628&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;754&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Receivables and others - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade receivables and others &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) The Research tax credit (CIR) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of &#x20ac;29,755 thousand recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the three year period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in January 2024 for an amount of &#x20ac;16,737 thousand and to the CIR for the 2020 tax year of &#x20ac;13,018 thousand was collected in July 2024 for the amount of &#x20ac;12,755 thousand following the offset of the restated amount of &#x20ac;263 thousand (see note 8). The amount of &#x20ac;13,850 thousand recognized as a non-current receivable as of June 30, 2024 corresponds to the CIR for the 2023 tax year for the amount of &#x20ac;9,800 thousand and the amount of CIR calculated for the first half of 2024 for the amount of &#x20ac;4,050 thousand. Following the loss of SME status since December 31, 2023, the CIR for 2023 and 2024 represent non-current receivables from the French Treasury, which should in principle be offset against corporate income tax due for the following three years or refunded if necessary upon expiry of such a period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(2) As of December 31, 2023, this amount mainly included a carry-back tax receivable of &#x20ac;333 thousand received in February 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(3)  As of June 30,2024, the prepaid expenses includes include an amount of &#x20ac;879&#160;thousand (1,005 thousand as of December 31, 2023) relating to the guarantee fees in line with the two State Guaranteed Loans from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. For each period-end, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(4) As of December 31, 2023, the amount is mainly comprised of invoice of &#x20ac;15,000&#160;thousand issued in December 2023 following the exercise of the license option by Sanofi. This amount was collected by the Company in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The net book value of the receivables is considered to be a reasonable approximation of their estimated fair value.  No valuation allowance was recognized on trade receivables and others as the credit risk of each debtor was considered as not significant.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock contextRef="c-1" id="f-359">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,755&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;29,755&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other tax credits (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepaid expenses (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,009&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,692&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VAT refund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;583&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,037&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade account receivables  (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,233&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepayments made to suppliers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,374&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;19,795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;55,557&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13,850&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prepaid expenses (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;628&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;754&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Receivables and others - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,478&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,554&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade receivables and others &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) The Research tax credit (CIR) is recognized as other operating income in the year to which the eligible research expenditure relates. The amount of &#x20ac;29,755 thousand recognized as current receivables as of December 31, 2023 comprises the research tax credit for the 2019 and 2020 tax years, for which the three year period has expired as of December 31, 2023. The CIR for 2019 was reimbursed in January 2024 for an amount of &#x20ac;16,737 thousand and to the CIR for the 2020 tax year of &#x20ac;13,018 thousand was collected in July 2024 for the amount of &#x20ac;12,755 thousand following the offset of the restated amount of &#x20ac;263 thousand (see note 8). The amount of &#x20ac;13,850 thousand recognized as a non-current receivable as of June 30, 2024 corresponds to the CIR for the 2023 tax year for the amount of &#x20ac;9,800 thousand and the amount of CIR calculated for the first half of 2024 for the amount of &#x20ac;4,050 thousand. Following the loss of SME status since December 31, 2023, the CIR for 2023 and 2024 represent non-current receivables from the French Treasury, which should in principle be offset against corporate income tax due for the following three years or refunded if necessary upon expiry of such a period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(2) As of December 31, 2023, this amount mainly included a carry-back tax receivable of &#x20ac;333 thousand received in February 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(3)  As of June 30,2024, the prepaid expenses includes include an amount of &#x20ac;879&#160;thousand (1,005 thousand as of December 31, 2023) relating to the guarantee fees in line with the two State Guaranteed Loans from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas. Following the extension of these two loans repayment for an additional period, the full amount of the guarantee fee over the additional five-year period has been recognized as an operating expense in 2022. For each period-end, an adjustment is made through the prepaid accounts to reflect the fact that the expenses are related to the fiscal year (see note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(4) As of December 31, 2023, the amount is mainly comprised of invoice of &#x20ac;15,000&#160;thousand issued in December 2023 following the exercise of the license option by Sanofi. This amount was collected by the Company in January 2024.&lt;/span&gt;&lt;/div&gt;</inpha:DisclosureOfTradeReceivablesAndOtherTableTextBlock>
    <ifrs-full:OtherCurrentReceivables contextRef="c-2" decimals="-3" id="f-360" unitRef="eur">97000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-361" unitRef="eur">104000</ifrs-full:OtherCurrentReceivables>
    <inpha:ResearchTaxCreditReceivableCurrent contextRef="c-2" decimals="-3" id="f-362" unitRef="eur">12755000</inpha:ResearchTaxCreditReceivableCurrent>
    <inpha:ResearchTaxCreditReceivableCurrent contextRef="c-3" decimals="-3" id="f-363" unitRef="eur">29755000</inpha:ResearchTaxCreditReceivableCurrent>
    <inpha:OtherCurrentTaxCreditsReceivables contextRef="c-2" decimals="-3" id="f-364" unitRef="eur">0</inpha:OtherCurrentTaxCreditsReceivables>
    <inpha:OtherCurrentTaxCreditsReceivables contextRef="c-3" decimals="-3" id="f-365" unitRef="eur">361000</inpha:OtherCurrentTaxCreditsReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-2" decimals="-3" id="f-366" unitRef="eur">3009000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-3" decimals="-3" id="f-367" unitRef="eur">5692000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-2" decimals="-3" id="f-368" unitRef="eur">583000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="c-3" decimals="-3" id="f-369" unitRef="eur">1037000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-2" decimals="-3" id="f-370" unitRef="eur">393000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-3" id="f-371" unitRef="eur">15233000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-2" decimals="-3" id="f-372" unitRef="eur">2957000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-3" decimals="-3" id="f-373" unitRef="eur">3374000</ifrs-full:CurrentAdvancesToSuppliers>
    <inpha:TradeAndOtherCurrentReceivablesExcludingRebates contextRef="c-2" decimals="-3" id="f-374" unitRef="eur">19795000</inpha:TradeAndOtherCurrentReceivablesExcludingRebates>
    <inpha:TradeAndOtherCurrentReceivablesExcludingRebates contextRef="c-3" decimals="-3" id="f-375" unitRef="eur">55557000</inpha:TradeAndOtherCurrentReceivablesExcludingRebates>
    <inpha:NonCurrentResearchTaxCredit contextRef="c-2" decimals="-3" id="f-376" unitRef="eur">13850000</inpha:NonCurrentResearchTaxCredit>
    <inpha:NonCurrentResearchTaxCredit contextRef="c-3" decimals="-3" id="f-377" unitRef="eur">9800000</inpha:NonCurrentResearchTaxCredit>
    <inpha:NonCurrentPrepaidExpenses contextRef="c-2" decimals="-3" id="f-378" unitRef="eur">628000</inpha:NonCurrentPrepaidExpenses>
    <inpha:NonCurrentPrepaidExpenses contextRef="c-3" decimals="-3" id="f-379" unitRef="eur">754000</inpha:NonCurrentPrepaidExpenses>
    <inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates contextRef="c-2" decimals="-3" id="f-380" unitRef="eur">14478000</inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates>
    <inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates contextRef="c-3" decimals="-3" id="f-381" unitRef="eur">10554000</inpha:TradeAndOtherNonCurrentReceivablesExcludingRebates>
    <inpha:TradeAndOtherReceivablesExcludingRebates contextRef="c-2" decimals="-3" id="f-382" unitRef="eur">34273000</inpha:TradeAndOtherReceivablesExcludingRebates>
    <inpha:TradeAndOtherReceivablesExcludingRebates contextRef="c-3" decimals="-3" id="f-383" unitRef="eur">66111000</inpha:TradeAndOtherReceivablesExcludingRebates>
    <inpha:ResearchTaxCreditReceivableCurrent contextRef="c-3" decimals="-3" id="f-384" unitRef="eur">29755000</inpha:ResearchTaxCreditReceivableCurrent>
    <inpha:IncomeFromResearchTaxCredit2019And2020Maturity contextRef="c-61" id="f-385">P3Y</inpha:IncomeFromResearchTaxCredit2019And2020Maturity>
    <inpha:IncomeFromResearchTaxCredit2019 contextRef="c-61" decimals="-3" id="f-386" unitRef="eur">16737000</inpha:IncomeFromResearchTaxCredit2019>
    <inpha:IncomeFromResearchTaxCredit2020 contextRef="c-62" decimals="-3" id="f-387" unitRef="eur">13018000</inpha:IncomeFromResearchTaxCredit2020>
    <inpha:ResearchTaxCreditReceivableCurrent contextRef="c-2" decimals="-3" id="f-388" unitRef="eur">12755000</inpha:ResearchTaxCreditReceivableCurrent>
    <inpha:OffsetOfRestatedIncomeFromResearchTaxCredit2020 contextRef="c-1" decimals="-3" id="f-389" unitRef="eur">263000</inpha:OffsetOfRestatedIncomeFromResearchTaxCredit2020>
    <inpha:NonCurrentResearchTaxCredit contextRef="c-2" decimals="-3" id="f-390" unitRef="eur">13850000</inpha:NonCurrentResearchTaxCredit>
    <inpha:IncomeFromResearchTaxCredit2023 contextRef="c-56" decimals="-3" id="f-391" unitRef="eur">9800000</inpha:IncomeFromResearchTaxCredit2023>
    <inpha:IncomeFromResearchTaxCreditHalfYear2024 contextRef="c-1" decimals="-3" id="f-392" unitRef="eur">4050000</inpha:IncomeFromResearchTaxCreditHalfYear2024>
    <inpha:CarryBackTaxReceivable contextRef="c-3" decimals="-3" id="f-393" unitRef="eur">333000</inpha:CarryBackTaxReceivable>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-63" decimals="-3" id="f-394" unitRef="eur">879000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-64" decimals="-3" id="f-395" unitRef="eur">1005000</ifrs-full:CurrentPrepaidExpenses>
    <inpha:BorrowingNumberOfLoanAgreement
      contextRef="c-65"
      decimals="INF"
      id="f-396"
      unitRef="loan_agreement">2</inpha:BorrowingNumberOfLoanAgreement>
    <inpha:BorrowingNumberOfLoanAgreement
      contextRef="c-65"
      decimals="INF"
      id="f-397"
      unitRef="loan_agreement">2</inpha:BorrowingNumberOfLoanAgreement>
    <inpha:BorrowingMaturity contextRef="c-66" id="f-398">P5Y</inpha:BorrowingMaturity>
    <ifrs-full:CurrentTradeReceivables contextRef="c-67" decimals="-3" id="f-399" unitRef="eur">15000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-400">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Intangible assets&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.118%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchased licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,556&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additional considerations(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortizations(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;413&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;416&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additional considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortizations(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) This amount corresponds to the additional invoice received from Orega Biotech for the rights relating to IPH5201 following the first patient dosed in the Phase 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;MATISSE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt; clinical trial in June 2023, in accordance to the agreement signed in 2019. This additional invoice is fully amortized as of June 30, 2023 and paid on July 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt;(2) As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of &#x20ac;294&#160;thousand. As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#x20ac;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#x20ac;651&#160;thousand. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Monalizumab rights under the 2014 monalizumab (NKG2A) Novo Nordisk agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Since their acquisition, monalizumab rights are amortized on a straight-line basis over the anticipated residual duration of the Phase II trials. The Company has reassessed the anticipated residual duration of the Phase 2 trials as of June&#160;30, 2024 and estimated that it would be fully amortized by 2024, which is the same estimation as of December&#160;31, 2023, as a result of the completion of some trials and by modifying the estimated end dates relating to certain cohorts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The net book values of the monalizumab rights were &#x20ac;119 thousand and &#x20ac;416 thousand as of June&#160;30, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;IPH5201 (Anti-CD39) rights acquired from Orega Biotech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;On January&#160;4, 2016, the Company and Orega Biotech entered into an exclusive licensing agreement by which Orega Biotech granted the Company full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. The upfront payment paid by the Company to Orega Biotech has been recognized as an intangible asset in the consolidated financial statements for the year ended December&#160;31, 2016. Criteria relating to the first development milestone were reached in December 2016. Consequently, the amount of this milestone was recognized as an intangible asset in addition to the initial payment. In June 2019, the Company also paid Orega Biotech &#x20ac;7.0&#160;million in relation to the anti-CD39 program as consideration following the collaboration and option agreement signed on October&#160;22, 2018 with AstraZeneca regarding IPH5201. Under this agreement, the Company also paid in April and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;June 2020, respectively &#x20ac;2.5  and &#x20ac;0.2&#160;million to Orega Biotech following the first Phase 1 dosing relating to IPH5201. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As a reminder, Orega Biotech claimed joint ownership of certain patents relating to IPH5201. The Company and Orega Biotech have resolved these claims in an arbitration proceeding, which decision was rendered in December 2021. As a result of this decision, the Company is required to pay a low-teen percentage of sub-licensing revenues received by the Company pursuant to its agreement with AstraZeneca regarding IPH5201. Following this arbitration decision, the Company paid in January 2022 an additional amount of &#x20ac;0.4&#160;million to Orega. The Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancer, of which the Company will be a sponsor. In accordance with the amendment signed on June 1, 2022, the Company was eligible for a milestone payment of $5&#160;million by AstraZeneca, received in August 2022 by the Company. In October 2022, the Company therefore paid an additional &#x20ac;0.6&#160;million to Orega Biotech. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;On June 26, 2023, the Company announced the treatment of the first patient in the Phase 2 MATISSE trial, conducted in collaboration with AstraZeneca and evaluating IPH5201 in early-stage lung cancer. As a consequence, the Company made an additional payment of &#x20ac;2.0&#160;million to Orega Biotech in July 2023, in accordance with the agreement signed in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;At the agreement inception, an upfront payment of &#x20ac;40&#160;million for acquired rights were recorded as intangible asset. As part of this agreement, an additional amount of &#x20ac;1.0&#160;million was paid in October 2020 to Novo Nordisk A / S following the launch of the first avdoralimab Phase II trial. As avdoralimab is still in clinical trial, the acquired rights are classified as intangible asset in progress. They were subject to annual impairment test. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of June 30, 2024, according to the uncertainty of these potential future payments, no liability was recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Development costs incurred by the Company are recognized as research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As a reminder, during 2022 fourth quarter, the Company was informed by the sponsor of the Phase 2 clinical trial evaluating avdoralimab in inflammation in bullous pemphigoid ("BP") indication of its decision to discontinue said trial. Consequently, the Company decided in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Following that decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of avdoralimab's intangible assets, based on expected future cash flows, as of December 2022, date of the decision. Thus, on decision date to stop the development of avdoralimab in bullous pemphigoid ("BP")  indication in inflammation, avdoralimab rights were fully written down to their net book value, i.e &#x20ac;41,000&#160;thousand.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c-1" id="f-401">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.118%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Purchased licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,556&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,556&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additional considerations(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortizations(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,651)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;413&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;416&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additional considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortizations(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(294)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(297)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) This amount corresponds to the additional invoice received from Orega Biotech for the rights relating to IPH5201 following the first patient dosed in the Phase 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;MATISSE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt; clinical trial in June 2023, in accordance to the agreement signed in 2019. This additional invoice is fully amortized as of June 30, 2023 and paid on July 2023. &lt;/span&gt;&lt;/div&gt;(2) As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of &#x20ac;294&#160;thousand. As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#x20ac;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#x20ac;651&#160;thousand.</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-68" decimals="-3" id="f-402" unitRef="eur">1556000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-69" decimals="-3" id="f-403" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-70" decimals="-3" id="f-404" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-5" decimals="-3" id="f-405" unitRef="eur">1556000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-71" decimals="-3" id="f-406" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-407" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-73" decimals="-3" id="f-408" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-409" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-71" decimals="-3" id="f-410" unitRef="eur">2000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-411" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-73" decimals="-3" id="f-412" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-413" unitRef="eur">2000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-71" decimals="-3" id="f-414" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-415" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-73" decimals="-3" id="f-416" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-417" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-71" decimals="-3" id="f-418" unitRef="eur">2651000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-419" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-73" decimals="-3" id="f-420" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-421" unitRef="eur">2651000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-71" decimals="-3" id="f-422" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-423" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-73" decimals="-3" id="f-424" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-425" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-74" decimals="-3" id="f-426" unitRef="eur">903000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-75" decimals="-3" id="f-427" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-76" decimals="-3" id="f-428" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-6" decimals="-3" id="f-429" unitRef="eur">903000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-77" decimals="-3" id="f-430" unitRef="eur">413000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-78" decimals="-3" id="f-431" unitRef="eur">3000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-79" decimals="-3" id="f-432" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-433" unitRef="eur">416000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-434" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-435" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-3" id="f-436" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-437" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-438" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-439" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-3" id="f-440" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-441" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-442" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-443" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-3" id="f-444" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-445" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-446" unitRef="eur">294000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-447" unitRef="eur">3000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-3" id="f-448" unitRef="eur">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-449" unitRef="eur">297000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-450" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-451" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-82" decimals="-3" id="f-452" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-453" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-83" decimals="-3" id="f-454" unitRef="eur">119000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-3" id="f-455" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-85" decimals="-3" id="f-456" unitRef="eur">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-457" unitRef="eur">119000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-3" id="f-458" unitRef="eur">294000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-3" id="f-459" unitRef="eur">2000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-3" id="f-460" unitRef="eur">651000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-3" id="f-461" unitRef="eur">119000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-3" id="f-462" unitRef="eur">416000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-5" id="f-463" unitRef="eur">7000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-5" id="f-464" unitRef="eur">2500000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-5" id="f-465" unitRef="eur">200000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-5" id="f-466" unitRef="eur">400000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived contextRef="c-95" decimals="-6" id="f-467" unitRef="usd">5000000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-5" id="f-468" unitRef="eur">600000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-5" id="f-469" unitRef="eur">2000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-6" id="f-470" unitRef="eur">40000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <inpha:PaymentsForMilestone contextRef="c-99" decimals="-5" id="f-471" unitRef="eur">1000000</inpha:PaymentsForMilestone>
    <ifrs-full:FinancialLiabilities contextRef="c-100" decimals="INF" id="f-472" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-3" id="f-473" unitRef="eur">41000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-474">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Property and equipment&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Lands and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Laboratory equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Of which right of use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,242&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;6,423&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(591)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(993)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;7,268&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;5,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Lands and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Laboratory equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Of which right of use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;5,055&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;285&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(845)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;4,682&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#x20ac;0.5&#160;million and a lease liability of &#x20ac;0.7&#160;million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-475">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.292%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Lands and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Laboratory equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Of which right of use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,242&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,298&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;6,423&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;279&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;79&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(591)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(993)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,437&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,829&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;7,268&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;5,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Lands and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Laboratory equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Of which right of use assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,378&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;5,055&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;285&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(845)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,134&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;4,682&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#x20ac;0.5&#160;million and a lease liability of &#x20ac;0.7&#160;million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-102" decimals="-3" id="f-476" unitRef="eur">4242000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-103" decimals="-3" id="f-477" unitRef="eur">4298000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-104" decimals="-3" id="f-478" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-5" decimals="-3" id="f-479" unitRef="eur">8542000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-105" decimals="-3" id="f-480" unitRef="eur">6423000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-481" unitRef="eur">31000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-482" unitRef="eur">279000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-483" unitRef="eur">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-484" unitRef="eur">310000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-485" unitRef="eur">79000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-486" unitRef="eur">513000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-487" unitRef="eur">78000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-488" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-489" unitRef="eur">591000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-490" unitRef="eur">513000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-491" unitRef="eur">323000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-492" unitRef="eur">670000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-493" unitRef="eur">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-494" unitRef="eur">993000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-495" unitRef="eur">428000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-496" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-497" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-498" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-499" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-500" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-110" decimals="-3" id="f-501" unitRef="eur">3437000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-111" decimals="-3" id="f-502" unitRef="eur">3829000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-112" decimals="-3" id="f-503" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-6" decimals="-3" id="f-504" unitRef="eur">7268000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-113" decimals="-3" id="f-505" unitRef="eur">5561000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-114" decimals="-3" id="f-506" unitRef="eur">2958000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-115" decimals="-3" id="f-507" unitRef="eur">3378000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-116" decimals="-3" id="f-508" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-3" decimals="-3" id="f-509" unitRef="eur">6322000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-117" decimals="-3" id="f-510" unitRef="eur">5055000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-118" decimals="-3" id="f-511" unitRef="eur">15000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-119" decimals="-3" id="f-512" unitRef="eur">267000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-120" decimals="-3" id="f-513" unitRef="eur">3000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-514" unitRef="eur">285000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-121" decimals="-3" id="f-515" unitRef="eur">37000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-118" decimals="-3" id="f-516" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-119" decimals="-3" id="f-517" unitRef="eur">18000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-120" decimals="-3" id="f-518" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-519" unitRef="eur">18000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-121" decimals="-3" id="f-520" unitRef="eur">18000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-118" decimals="-3" id="f-521" unitRef="eur">352000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-119" decimals="-3" id="f-522" unitRef="eur">493000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-120" decimals="-3" id="f-523" unitRef="eur">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-524" unitRef="eur">845000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-121" decimals="-3" id="f-525" unitRef="eur">392000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-118" decimals="-3" id="f-526" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-119" decimals="-3" id="f-527" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-120" decimals="-3" id="f-528" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-529" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment contextRef="c-121" decimals="-3" id="f-530" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-122" decimals="-3" id="f-531" unitRef="eur">2621000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-123" decimals="-3" id="f-532" unitRef="eur">3134000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-124" decimals="-3" id="f-533" unitRef="eur">3000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-2" decimals="-3" id="f-534" unitRef="eur">5748000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets contextRef="c-125" decimals="-3" id="f-535" unitRef="eur">4682000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="c-126" decimals="-5" id="f-536" unitRef="eur">-500000</ifrs-full:ChangesInPropertyPlantAndEquipment>
    <inpha:IncreaseDecreaseInFinancialLiabilities contextRef="c-127" decimals="-5" id="f-537" unitRef="eur">-700000</inpha:IncreaseDecreaseInFinancialLiabilities>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c-1" id="f-538">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Trade payables and others&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Suppliers (excluding payables related to capital expenditures)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Tax and employee-related payables (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other payables (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,436&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade payables and others (excluding payables related to capital expenditures)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payables related to capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) As of December 31, 2023, tax and employee related payables included a liability accrual of &#x20ac;1.4&#160;million following the notification received as part of the tax inspection relating to accounting and research tax credits for the 2018 to 2020 financial years. The liability recognized as of June 30, 2024 in connection with notification is &#x20ac;0.4&#160;million following the payment of &#x20ac;0.7&#160;million in February 2024 and the offset of &#x20ac;0.3&#160;million against the 2020 research tax credit receivable initially recognized for &#x20ac;13.0&#160;million and finally collected in July 2024 for &#x20ac;12.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(2) As of June 30, 2024 an December 31, 2023, this amount includes mainly the liability related to the payment of the guarantee fees on the two State Guaranteed Loans obtained from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas in 2021 (see note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The book value of trade payables and others is considered to be a reasonable approximation of their fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <inpha:DisclosureOfTradePayablesAndOthersTextBlock contextRef="c-1" id="f-539">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Suppliers (excluding payables related to capital expenditures)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,751&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Tax and employee-related payables (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other payables (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,436&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade payables and others (excluding payables related to capital expenditures)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payables related to capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(1) As of December 31, 2023, tax and employee related payables included a liability accrual of &#x20ac;1.4&#160;million following the notification received as part of the tax inspection relating to accounting and research tax credits for the 2018 to 2020 financial years. The liability recognized as of June 30, 2024 in connection with notification is &#x20ac;0.4&#160;million following the payment of &#x20ac;0.7&#160;million in February 2024 and the offset of &#x20ac;0.3&#160;million against the 2020 research tax credit receivable initially recognized for &#x20ac;13.0&#160;million and finally collected in July 2024 for &#x20ac;12.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt;(2) As of June 30, 2024 an December 31, 2023, this amount includes mainly the liability related to the payment of the guarantee fees on the two State Guaranteed Loans obtained from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas in 2021 (see note 9).&lt;/span&gt;&lt;/div&gt;</inpha:DisclosureOfTradePayablesAndOthersTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-2" decimals="-3" id="f-540" unitRef="eur">8751000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-3" id="f-541" unitRef="eur">8561000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-2" decimals="-3" id="f-542" unitRef="eur">6013000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-3" decimals="-3" id="f-543" unitRef="eur">7021000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:OtherCurrentPayables contextRef="c-2" decimals="-3" id="f-544" unitRef="eur">1109000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="c-3" decimals="-3" id="f-545" unitRef="eur">1436000</ifrs-full:OtherCurrentPayables>
    <inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures contextRef="c-2" decimals="-3" id="f-546" unitRef="eur">15873000</inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures>
    <inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures contextRef="c-3" decimals="-3" id="f-547" unitRef="eur">17018000</inpha:CurrentTradePayablesAndOthersExcludingPayablesRelatedToCapitalExpenditures>
    <inpha:CurrentPayablesRelatedToCapitalExpenditures contextRef="c-2" decimals="-3" id="f-548" unitRef="eur">0</inpha:CurrentPayablesRelatedToCapitalExpenditures>
    <inpha:CurrentPayablesRelatedToCapitalExpenditures contextRef="c-3" decimals="-3" id="f-549" unitRef="eur">0</inpha:CurrentPayablesRelatedToCapitalExpenditures>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-2" decimals="-3" id="f-550" unitRef="eur">15873000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-551" unitRef="eur">17018000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-3" decimals="-5" id="f-552" unitRef="eur">1400000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-2" decimals="-5" id="f-553" unitRef="eur">400000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <inpha:PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-128" decimals="-5" id="f-554" unitRef="eur">700000</inpha:PaymentOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <inpha:OffsetAgainstIncomeFromResearchTaxCredit2020 contextRef="c-1" decimals="-5" id="f-555" unitRef="eur">300000</inpha:OffsetAgainstIncomeFromResearchTaxCredit2020>
    <inpha:IncomeFromResearchTaxCredit2020 contextRef="c-62" decimals="-5" id="f-556" unitRef="eur">13000000</inpha:IncomeFromResearchTaxCredit2020>
    <inpha:IncomeFromResearchTaxCredit2020Receivable contextRef="c-129" decimals="-5" id="f-557" unitRef="eur">12700000</inpha:IncomeFromResearchTaxCredit2020Receivable>
    <inpha:NumberOfStateGuaranteedLoans contextRef="c-2" decimals="INF" id="f-558" unitRef="loan">2</inpha:NumberOfStateGuaranteedLoans>
    <inpha:NumberOfStateGuaranteedLoans contextRef="c-3" decimals="INF" id="f-559" unitRef="loan">2</inpha:NumberOfStateGuaranteedLoans>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-560">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:12.76pt"&gt;Financial liabilities&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from lease liabilities and other non cash effects &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Repayments of borrowings/leases liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exchange rate variation (non cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,568&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,070)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,630&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage" (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;207&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,634&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;39,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(4,446)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,503&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from lease liabilities and other non cash effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Repayments of borrowings/leases liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exchange rate variation (non cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage"&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;345&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(602)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;42,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(689)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;40,658&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(1) As a reminder, on January 5, 2022, the Company announced that it had obtained &#x20ac;28.7&#160;million in non-dilutive financing in the form of two State Guaranteed Loans from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (&#x20ac;20.0&#160;million) and BNP Paribas (&#x20ac;8.7&#160;million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees. The amortization of the two loans began in 2024 for a period of four years. The state guarantee fees amounts to &#x20ac;877&#160;thousand and &#x20ac;379&#160;thousand for Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas loans respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(2) On July 3, 2017, the Company borrowed from the Bank &#x201c;Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&#x201d; in order to finance the construction of its future headquarters. This loan amounting to a maximum of &#x20ac;15,200&#160;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of &#x20ac;1,300&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the &#x20ac;15,200&#160;thousand loan granted, for an amount of &#x20ac;13,900&#160;thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June&#160;30, 2024, the remaining capital of the loan amounted to &#x20ac;9,617&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;thousand. The Company authorized collateral over financial &#x201c;Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&#x201d; instruments amounting to &#x20ac;15,200&#160;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#x20ac;4,200&#160;thousand in July 2024, &#x20ac;5,000&#160;thousand in August 2027 and &#x20ac;6,000&#160;thousand in August 2031. Following the release of the pledge on the &#x20ac;4.2m financial instrument that had reached maturity, the company received this amount in July 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(3) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#x20ac;0.5&#160;million and a lease liability of &#x20ac;0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;From 2nd to 5th year included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,086&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,773&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage"&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;9,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;24,245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;36,869&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock contextRef="c-1" id="f-561">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from lease liabilities and other non cash effects &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Repayments of borrowings/leases liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exchange rate variation (non cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,432)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,568&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,070)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,630&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage" (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;207&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,247&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,634&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;39,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(4,446)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,503&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds from lease liabilities and other non cash effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Repayments of borrowings/leases liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exchange rate variation (non cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,700&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage"&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(736)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;487&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;345&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;297&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;198&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#F2F2F2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;127&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11,338&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(602)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;42,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(689)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;40,658&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(1) As a reminder, on January 5, 2022, the Company announced that it had obtained &#x20ac;28.7&#160;million in non-dilutive financing in the form of two State Guaranteed Loans from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale (&#x20ac;20.0&#160;million) and BNP Paribas (&#x20ac;8.7&#160;million). The Company received the funds related to these two loans on December 27 and 30, 2021 respectively. Both loans have an initial maturity of one year with an option to extend to five years usable from August, 2022. They are 90% guaranteed by the French government as part of the package of measures put in place by the French government to support companies during the COVID-19 pandemic. In August 2022, the Company has &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtained agreements from Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas. The effective interest rates applied to these contracts during the additional period are 1.56% and 0.95% for Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas loans, respectively, excluding insurance and guarantee fees, with an amortization exemption for the entire year 2023. During this grace period, the Company will only be liable for the payment of interest and the guarantee fees. The amortization of the two loans began in 2024 for a period of four years. The state guarantee fees amounts to &#x20ac;877&#160;thousand and &#x20ac;379&#160;thousand for Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale and BNP Paribas loans respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(2) On July 3, 2017, the Company borrowed from the Bank &#x201c;Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&#x201d; in order to finance the construction of its future headquarters. This loan amounting to a maximum of &#x20ac;15,200&#160;thousand will be raised during the period of the construction in order to pay the supplier payments as they become due. As of December 31, 2018 and 2019, the loan was raised at an amount of &#x20ac;1,300&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The loan release period was limited to August 30, 2019. On August 30, 2019, the Company drew down the remaining portion of the &#x20ac;15,200&#160;thousand loan granted, for an amount of &#x20ac;13,900&#160;thousand. The reimbursement of the capital has begun in August 30, 2019 and will proceed until August 30, 2031 (12 years). Given the development of its portfolio and in particular the refocusing of its activities on research and development, the Company has for the time being suspended the project to build its new head office on the land acquired in Luminy. In the meantime, the loan will be used to finance several structuring projects (improvement of the information system, development of a commercial platform, development of additional premises rented, etc.). As of June&#160;30, 2024, the remaining capital of the loan amounted to &#x20ac;9,617&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:140%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;thousand. The Company authorized collateral over financial &#x201c;Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&#x201d; instruments amounting to &#x20ac;15,200&#160;thousand. The security interest on the pledge financial instruments will be released in accordance with the following schedule: &#x20ac;4,200&#160;thousand in July 2024, &#x20ac;5,000&#160;thousand in August 2027 and &#x20ac;6,000&#160;thousand in August 2031. Following the release of the pledge on the &#x20ac;4.2m financial instrument that had reached maturity, the company received this amount in July 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;This loan bears a fixed interest rate of 2.01%. It is subject to a covenant based on the assumption that the total cash, cash equivalents and current and non-current financial assets are at least equal to principal as of financial year end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(3) As a reminder, on March 13, 2023, the Company signed an amendment to the lease for the "Le Virage" building, reducing the surface area of the leased premises. The effective date of the lease amendment is March 15, 2023. As a result, and in accordance with IFRS 16, the impact on the consolidated balance sheet at the effective date of the lease amendment is as follows: write-off of a right of use (asset) of &#x20ac;0.5&#160;million and a lease liability of &#x20ac;0.7&#160;million.&lt;/span&gt;&lt;/div&gt;</inpha:DisclosureOfFinancialLiabilitiesPerMaturityTableTextBlock>
    <ifrs-full:FinancialLiabilities contextRef="c-130" decimals="-3" id="f-562" unitRef="eur">20000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-131" decimals="-3" id="f-563" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-131" decimals="-3" id="f-564" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-131" decimals="-3" id="f-565" unitRef="eur">2432000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-131" decimals="-3" id="f-566" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-132" decimals="-3" id="f-567" unitRef="eur">17568000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-133" decimals="-3" id="f-568" unitRef="eur">8700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-134" decimals="-3" id="f-569" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-134" decimals="-3" id="f-570" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-134" decimals="-3" id="f-571" unitRef="eur">1070000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-134" decimals="-3" id="f-572" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-135" decimals="-3" id="f-573" unitRef="eur">7630000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-136" decimals="-3" id="f-574" unitRef="eur">14000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-137" decimals="-3" id="f-575" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-137" decimals="-3" id="f-576" unitRef="eur">13000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-137" decimals="-3" id="f-577" unitRef="eur">14000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-137" decimals="-3" id="f-578" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-138" decimals="-3" id="f-579" unitRef="eur">13000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-139" decimals="-3" id="f-580" unitRef="eur">375000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-140" decimals="-3" id="f-581" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-140" decimals="-3" id="f-582" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-140" decimals="-3" id="f-583" unitRef="eur">121000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-140" decimals="-3" id="f-584" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-141" decimals="-3" id="f-585" unitRef="eur">254000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-142" decimals="-3" id="f-586" unitRef="eur">246000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-143" decimals="-3" id="f-587" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-143" decimals="-3" id="f-588" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-143" decimals="-3" id="f-589" unitRef="eur">47000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-143" decimals="-3" id="f-590" unitRef="eur">8000</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-144" decimals="-3" id="f-591" unitRef="eur">207000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-145" decimals="-3" id="f-592" unitRef="eur">109000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-146" decimals="-3" id="f-593" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-146" decimals="-3" id="f-594" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-146" decimals="-3" id="f-595" unitRef="eur">83000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-146" decimals="-3" id="f-596" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-147" decimals="-3" id="f-597" unitRef="eur">26000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-148" decimals="-3" id="f-598" unitRef="eur">85000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-149" decimals="-3" id="f-599" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-149" decimals="-3" id="f-600" unitRef="eur">19000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-149" decimals="-3" id="f-601" unitRef="eur">17000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-149" decimals="-3" id="f-602" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-150" decimals="-3" id="f-603" unitRef="eur">87000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-151" decimals="-3" id="f-604" unitRef="eur">18000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-152" decimals="-3" id="f-605" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-152" decimals="-3" id="f-606" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-152" decimals="-3" id="f-607" unitRef="eur">4000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-152" decimals="-3" id="f-608" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-153" decimals="-3" id="f-609" unitRef="eur">13000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-154" decimals="-3" id="f-610" unitRef="eur">99000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-155" decimals="-3" id="f-611" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-155" decimals="-3" id="f-612" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-155" decimals="-3" id="f-613" unitRef="eur">28000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-155" decimals="-3" id="f-614" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-156" decimals="-3" id="f-615" unitRef="eur">71000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-157" decimals="-3" id="f-616" unitRef="eur">10247000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-158" decimals="-3" id="f-617" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-158" decimals="-3" id="f-618" unitRef="eur">17000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-158" decimals="-3" id="f-619" unitRef="eur">630000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-158" decimals="-3" id="f-620" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-159" decimals="-3" id="f-621" unitRef="eur">9634000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-3" decimals="-3" id="f-622" unitRef="eur">39893000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-623" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-624" unitRef="eur">49000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-625" unitRef="eur">4446000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-1" decimals="-3" id="f-626" unitRef="eur">8000</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-2" decimals="-3" id="f-627" unitRef="eur">35503000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-160" decimals="-3" id="f-628" unitRef="eur">20000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-161" decimals="-3" id="f-629" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-161" decimals="-3" id="f-630" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-161" decimals="-3" id="f-631" unitRef="eur">0</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-161" decimals="-3" id="f-632" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-162" decimals="-3" id="f-633" unitRef="eur">20000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-163" decimals="-3" id="f-634" unitRef="eur">8700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-164" decimals="-3" id="f-635" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-164" decimals="-3" id="f-636" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-164" decimals="-3" id="f-637" unitRef="eur">0</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-164" decimals="-3" id="f-638" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-165" decimals="-3" id="f-639" unitRef="eur">8700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-166" decimals="-3" id="f-640" unitRef="eur">15000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-167" decimals="-3" id="f-641" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-167" decimals="-3" id="f-642" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-167" decimals="-3" id="f-643" unitRef="eur">0</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-167" decimals="-3" id="f-644" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-168" decimals="-3" id="f-645" unitRef="eur">15000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-169" decimals="-3" id="f-646" unitRef="eur">1353000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-170" decimals="-3" id="f-647" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-170" decimals="-3" id="f-648" unitRef="eur">-736000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-170" decimals="-3" id="f-649" unitRef="eur">130000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-170" decimals="-3" id="f-650" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-171" decimals="-3" id="f-651" unitRef="eur">487000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-172" decimals="-3" id="f-652" unitRef="eur">345000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-173" decimals="-3" id="f-653" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-173" decimals="-3" id="f-654" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-173" decimals="-3" id="f-655" unitRef="eur">50000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-173" decimals="-3" id="f-656" unitRef="eur">2000</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-174" decimals="-3" id="f-657" unitRef="eur">297000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-175" decimals="-3" id="f-658" unitRef="eur">287000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-176" decimals="-3" id="f-659" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-176" decimals="-3" id="f-660" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-176" decimals="-3" id="f-661" unitRef="eur">89000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-176" decimals="-3" id="f-662" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-177" decimals="-3" id="f-663" unitRef="eur">198000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-178" decimals="-3" id="f-664" unitRef="eur">33000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-179" decimals="-3" id="f-665" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-179" decimals="-3" id="f-666" unitRef="eur">48000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-179" decimals="-3" id="f-667" unitRef="eur">13000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-179" decimals="-3" id="f-668" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-180" decimals="-3" id="f-669" unitRef="eur">70000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-181" decimals="-3" id="f-670" unitRef="eur">27000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-182" decimals="-3" id="f-671" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-182" decimals="-3" id="f-672" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-182" decimals="-3" id="f-673" unitRef="eur">4000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-182" decimals="-3" id="f-674" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-183" decimals="-3" id="f-675" unitRef="eur">23000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-184" decimals="-3" id="f-676" unitRef="eur">154000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-185" decimals="-3" id="f-677" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-185" decimals="-3" id="f-678" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-185" decimals="-3" id="f-679" unitRef="eur">27000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-185" decimals="-3" id="f-680" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-186" decimals="-3" id="f-681" unitRef="eur">127000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-187" decimals="-3" id="f-682" unitRef="eur">11338000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-188" decimals="-3" id="f-683" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-188" decimals="-3" id="f-684" unitRef="eur">0</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-188" decimals="-3" id="f-685" unitRef="eur">602000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-188" decimals="-3" id="f-686" unitRef="eur">0</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-189" decimals="-3" id="f-687" unitRef="eur">10736000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-5" decimals="-3" id="f-688" unitRef="eur">42251000</ifrs-full:FinancialLiabilities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-689" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-690" unitRef="eur">-689000</inpha:ProceedsFromLeaseLiabilitiesClassifiedAsFinancingActivities>
    <inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities contextRef="c-4" decimals="-3" id="f-691" unitRef="eur">916000</inpha:RepaymentsOfBorrowingsNetOfExchangeRateVariationClassifiedAsFinancingActivities>
    <inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-692" unitRef="eur">2000</inpha:IncreaseDecreaseThroughForeignExchangeFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-6" decimals="-3" id="f-693" unitRef="eur">40658000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NotionalAmount contextRef="c-190" decimals="-5" id="f-694" unitRef="eur">28700000</ifrs-full:NotionalAmount>
    <inpha:BorrowingNumberOfLoanAgreement
      contextRef="c-190"
      decimals="INF"
      id="f-695"
      unitRef="loan_agreement">2</inpha:BorrowingNumberOfLoanAgreement>
    <ifrs-full:NotionalAmount contextRef="c-191" decimals="-5" id="f-696" unitRef="eur">20000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount contextRef="c-192" decimals="-5" id="f-697" unitRef="eur">8700000</ifrs-full:NotionalAmount>
    <inpha:BorrowingNumberOfLoanAgreement
      contextRef="c-190"
      decimals="INF"
      id="f-698"
      unitRef="loan_agreement">2</inpha:BorrowingNumberOfLoanAgreement>
    <inpha:BorrowingMaturity contextRef="c-193" id="f-699">P1Y</inpha:BorrowingMaturity>
    <inpha:BorrowingMaturityExtensionPeriodOption contextRef="c-193" id="f-700">P5Y</inpha:BorrowingMaturityExtensionPeriodOption>
    <inpha:BorrowingPercentageOfStateGuaranteedLoan contextRef="c-190" decimals="2" id="f-701" unitRef="number">0.90</inpha:BorrowingPercentageOfStateGuaranteedLoan>
    <inpha:BorrowingNumberOfLoanAgreement contextRef="c-194" decimals="INF" id="f-702" unitRef="loan">2</inpha:BorrowingNumberOfLoanAgreement>
    <inpha:BorrowingMaturity contextRef="c-195" id="f-703">P5Y</inpha:BorrowingMaturity>
    <inpha:BorrowingGracePeriod contextRef="c-195" id="f-704">P1Y</inpha:BorrowingGracePeriod>
    <ifrs-full:BorrowingsInterestRate contextRef="c-196" decimals="4" id="f-705" unitRef="number">0.0156</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate contextRef="c-197" decimals="4" id="f-706" unitRef="number">0.0095</ifrs-full:BorrowingsInterestRate>
    <inpha:NumberOfLoans contextRef="c-198" decimals="INF" id="f-707" unitRef="loan">2</inpha:NumberOfLoans>
    <inpha:BorrowingMaturity contextRef="c-198" id="f-708">P4Y</inpha:BorrowingMaturity>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-199" decimals="-3" id="f-709" unitRef="eur">877000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-200" decimals="-3" id="f-710" unitRef="eur">379000</ifrs-full:CurrentPrepaidExpenses>
    <inpha:LoanAgreementMaximumBorrowingCapacity contextRef="c-201" decimals="-3" id="f-711" unitRef="eur">15200000</inpha:LoanAgreementMaximumBorrowingCapacity>
    <ifrs-full:FinancialLiabilities contextRef="c-202" decimals="-3" id="f-712" unitRef="eur">1300000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-203" decimals="-3" id="f-713" unitRef="eur">1300000</ifrs-full:FinancialLiabilities>
    <inpha:LoanAgreementCollateral contextRef="c-201" decimals="-3" id="f-714" unitRef="eur">15200000</inpha:LoanAgreementCollateral>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-204" decimals="-3" id="f-715" unitRef="eur">13900000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <inpha:BorrowingsMaturityPeriod contextRef="c-204" id="f-716">P12Y</inpha:BorrowingsMaturityPeriod>
    <ifrs-full:FinancialLiabilities contextRef="c-205" decimals="-3" id="f-717" unitRef="eur">9617000</ifrs-full:FinancialLiabilities>
    <inpha:LoanAgreementCollateral contextRef="c-201" decimals="-3" id="f-718" unitRef="eur">15200000</inpha:LoanAgreementCollateral>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024 contextRef="c-206" decimals="-3" id="f-719" unitRef="eur">4200000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027 contextRef="c-206" decimals="-3" id="f-720" unitRef="eur">5000000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031 contextRef="c-206" decimals="-3" id="f-721" unitRef="eur">6000000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsReleased contextRef="c-207" decimals="-5" id="f-722" unitRef="eur">4200000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsReleased>
    <ifrs-full:BorrowingsInterestRate contextRef="c-208" decimals="4" id="f-723" unitRef="number">0.0201</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ChangesInPropertyPlantAndEquipment contextRef="c-209" decimals="-5" id="f-724" unitRef="eur">-500000</ifrs-full:ChangesInPropertyPlantAndEquipment>
    <inpha:IncreaseDecreaseInFinancialLiabilities contextRef="c-127" decimals="-5" id="f-725" unitRef="eur">-700000</inpha:IncreaseDecreaseInFinancialLiabilities>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities contextRef="c-1" id="f-726">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The table below shows the schedule for the contractual repayment of financial liabilities (being principal and interest payments) as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;From 2nd to 5th year included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,167&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,918&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,086&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loan BNP Paribas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,773&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;State guaranteed loans - accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Building "Le Virage"&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Premises Innate Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities &#x2013; Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Lease liabilities - Printers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Borrowing &#x2013; Building &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,545&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,587&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;9,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;24,245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;36,869&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-210" decimals="-3" id="f-727" unitRef="eur">5167000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-211" decimals="-3" id="f-728" unitRef="eur">12918000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-212" decimals="-3" id="f-729" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-132" decimals="-3" id="f-730" unitRef="eur">18086000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-213" decimals="-3" id="f-731" unitRef="eur">2222000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-214" decimals="-3" id="f-732" unitRef="eur">5551000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-215" decimals="-3" id="f-733" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-135" decimals="-3" id="f-734" unitRef="eur">7773000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-216" decimals="-3" id="f-735" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-217" decimals="-3" id="f-736" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-218" decimals="-3" id="f-737" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-138" decimals="-3" id="f-738" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-219" decimals="-3" id="f-739" unitRef="eur">254000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-220" decimals="-3" id="f-740" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-221" decimals="-3" id="f-741" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-141" decimals="-3" id="f-742" unitRef="eur">254000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-222" decimals="-3" id="f-743" unitRef="eur">100000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-223" decimals="-3" id="f-744" unitRef="eur">111000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-224" decimals="-3" id="f-745" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-144" decimals="-3" id="f-746" unitRef="eur">211000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-225" decimals="-3" id="f-747" unitRef="eur">26000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-226" decimals="-3" id="f-748" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-227" decimals="-3" id="f-749" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-147" decimals="-3" id="f-750" unitRef="eur">26000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-228" decimals="-3" id="f-751" unitRef="eur">34000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-229" decimals="-3" id="f-752" unitRef="eur">59000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-230" decimals="-3" id="f-753" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-150" decimals="-3" id="f-754" unitRef="eur">92000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-231" decimals="-3" id="f-755" unitRef="eur">9000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-232" decimals="-3" id="f-756" unitRef="eur">4000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-233" decimals="-3" id="f-757" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-153" decimals="-3" id="f-758" unitRef="eur">13000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-234" decimals="-3" id="f-759" unitRef="eur">57000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-235" decimals="-3" id="f-760" unitRef="eur">14000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-236" decimals="-3" id="f-761" unitRef="eur">0</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-156" decimals="-3" id="f-762" unitRef="eur">71000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-237" decimals="-3" id="f-763" unitRef="eur">1545000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-238" decimals="-3" id="f-764" unitRef="eur">5587000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-239" decimals="-3" id="f-765" unitRef="eur">3210000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-159" decimals="-3" id="f-766" unitRef="eur">10342000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-240" decimals="-3" id="f-767" unitRef="eur">9414000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-241" decimals="-3" id="f-768" unitRef="eur">24245000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-242" decimals="-3" id="f-769" unitRef="eur">3210000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:BankBorrowingsUndiscountedCashFlows contextRef="c-2" decimals="-3" id="f-770" unitRef="eur">36869000</ifrs-full:BankBorrowingsUndiscountedCashFlows>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c-1" id="f-771">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Employee benefit&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%"&gt;Defined benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allowance for retirement defined benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,118&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,064&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allowance for seniority awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;352&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;377&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Defined benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Amounts recognized in the statement of financial position are determined as follows (in thousand euros):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;312&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (benefits and contributions paid by the employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;166&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (benefits and contributions paid by the employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,470&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Discount rates used by the Company to evaluate retirement benefits were based on iBoxx Corporate AA. It was 3.60% and  3.20% as of June&#160;30, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;In addition, the impact of the 2023 pension reform (including the raising of the retirement age) has been recognized as a plan amendment within the meaning of IAS 19, recognized in the income statement and balance sheet with no material impact at June 30, 2023.</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory contextRef="c-1" id="f-772">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:140%"&gt;Defined benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allowance for retirement defined benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,118&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,064&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allowance for seniority awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;352&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;377&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Defined benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,470&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-243" decimals="-3" id="f-773" unitRef="eur">2118000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-244" decimals="-3" id="f-774" unitRef="eur">2064000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-245" decimals="-3" id="f-775" unitRef="eur">352000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-246" decimals="-3" id="f-776" unitRef="eur">377000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-2" decimals="-3" id="f-777" unitRef="eur">2470000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue contextRef="c-3" decimals="-3" id="f-778" unitRef="eur">2441000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="c-1" id="f-779">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Amounts recognized in the statement of financial position are determined as follows (in thousand euros):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,550&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;312&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (benefits and contributions paid by the employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;166&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (benefits and contributions paid by the employer)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Actuarial (gain) / loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,470&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-5" decimals="-3" id="f-780" unitRef="eur">2550000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-56" decimals="-3" id="f-781" unitRef="eur">312000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="c-56" decimals="-3" id="f-782" unitRef="eur">27000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-56" decimals="-3" id="f-783" unitRef="eur">394000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-3" decimals="-3" id="f-784" unitRef="eur">2441000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-3" id="f-785" unitRef="eur">166000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-3" id="f-786" unitRef="eur">22000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset contextRef="c-1" decimals="-3" id="f-787" unitRef="eur">116000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans contextRef="c-2" decimals="-3" id="f-788" unitRef="eur">2470000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="c-243" decimals="4" id="f-789" unitRef="number">0.0360</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates contextRef="c-244" decimals="4" id="f-790" unitRef="number">0.0320</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="c-1" id="f-791">Capital&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Share capital &lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company manages its capital to ensure that the Company will be able to continue as a going concern while maximizing the return to shareholders through the optimization of the debt and equity balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June&#160;30, 2024, the Company&#x2019;s share capital amounted to &#x20ac;4,049,075 divided into (i) 80,967,407 ordinary shares, each with a nominal value of &#x20ac;0.05; (ii) 6,509 &#x201c;2016&#x201d; preferred shares, each with a nominal value of &#x20ac;0.05, and (iii) 7,581 &#x201c;2017&#x201d; preferred shares, each with a nominal value of &#x20ac;0.05, respectively, fully paid up. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Share capital does not include BSAs, BSAAR, AGAs and AGAPs that have been granted to certain investors or natural persons, both employees and non-employees of the Company, but not yet exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;On October 21, 2019 and December 30, 2019, the retention period for the &#x201c;2016 free preferred shares&#x201d; has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the achievement of the performance criteria. Holders of &#x201c;2016&#x201d; preferred shares&#x201d; are entitled to vote at our shareholders&#x2019; meetings, to dividends and to preferential subscription rights, on the basis of the number of ordinary shares to which they are entitled if they convert their preferred shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;In April 3, 2021, the retention period for the "2017 free preferred shares" has ended. The number of ordinary shares to which the conversion of one preferred share entitle has been determined according to the fulfillment of the performance criteria. According to these same performance criteria, the Executive Board of April 7, 2021 noted that the "2017 preferred shares" did not give right to any ordinary shares. The &#x201c;2017 preferred shares&#x201d; will not be redeemed by the Company and will remain incorporated into the capital, unless subsequently decided by the Executive Board. As the conversion is void, the "2017 preferred shares" no longer give the right to vote at our general meetings, nor to receive dividends.&lt;/span&gt;&lt;/div&gt;In the six months ended June&#160;30, 2024, a capital increase of &#x20ac;5,342 occurred as a result of the Executive Board decision on June 10, 2024, subsequent to the creation of 106,844 ordinary shares following the set-up of a company saving plan for the benefit of the Company&#x2019;s employees, including 68,744 ordinary shares issued free of charge (top-up). This event led to a net capital increase of &#x20ac;5,342 and an increase in share premium of &#x20ac;88,003, broken down as a creation of 38,100 ordinary shares, with a nominal value of &#x20ac;0.05, for an issue price of &#x20ac;2.45, (ii) a creation of  68,744 ordinary shares, with a nominal value of &#x20ac;0.05&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Treasury shares&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company held 18,575 of its own shares as of June&#160;30, 2024 and December&#160;31, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Share based payments &lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants issued as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants void as of  6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants exercised as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants outstanding as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maximum number of shares to be issued  as of  6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price per share (in &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;Sept. 9, 2011 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;650,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;625,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;May 27, 2013 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2012 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;146,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;133,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2015 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,050,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,940&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,045,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,045,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;October 21, 2016 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP  Management 2016-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;156,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 21, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;268,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 21, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Management 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 30, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP  Management 2016-2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;333,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 30, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Management 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2017-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2017-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Employees 2017 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;114,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;110,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 3, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2018-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;67,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 20, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Perf Employees 2018-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;327,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;224,375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;103,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 20, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Perf Management 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;260,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 14, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Employees 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;90,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New Members 2017-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 3, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 13, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2020-1 &amp;amp; 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79,861&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;61,976&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 5, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;766,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;681,420&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 5, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;710,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;580,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;125,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;125,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,066,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;290,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;138,960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;138,960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;128,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;128,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Employees 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,371,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;275,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,096,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,096,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Management 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;163,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;163,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New members 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Employees 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,403,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,337,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,337,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Management 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New members 2024-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 21, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Stock Options 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 4, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP 2019 Employees 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;546,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;375,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;171,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 4, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP 2019 Management 2019 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;355,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;207,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;147,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 29, 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2011-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.77   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 17, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;237,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.36   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.65   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 27, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9.59   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.05   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 20, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.00   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 16, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31,740&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12,914,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,239,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,340,434&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,333,995&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;7,084,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <ifrs-full:Equity contextRef="c-42" decimals="0" id="f-792" unitRef="eur">4049075</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-247"
      decimals="INF"
      id="f-793"
      unitRef="shares">80967407</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="c-247"
      decimals="INF"
      id="f-794"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-248"
      decimals="INF"
      id="f-795"
      unitRef="shares">6509</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-248"
      decimals="INF"
      id="f-796"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-249"
      decimals="INF"
      id="f-797"
      unitRef="shares">7581</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c-249"
      decimals="INF"
      id="f-798"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-38" decimals="0" id="f-799" unitRef="eur">5342</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares
      contextRef="c-250"
      decimals="INF"
      id="f-800"
      unitRef="shares">106844</inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares>
    <inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares
      contextRef="c-251"
      decimals="INF"
      id="f-801"
      unitRef="shares">68744</inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-38" decimals="0" id="f-802" unitRef="eur">5342</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:ExerciseAndSubscriptionOfEquityInstruments contextRef="c-39" decimals="0" id="f-803" unitRef="eur">88003</inpha:ExerciseAndSubscriptionOfEquityInstruments>
    <inpha:NumberOfEquityInstrumentsConvertedInOrdinaryShares
      contextRef="c-252"
      decimals="INF"
      id="f-804"
      unitRef="shares">38100</inpha:NumberOfEquityInstrumentsConvertedInOrdinaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-248"
      decimals="INF"
      id="f-805"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <inpha:ShareIssuedPricePerShare
      contextRef="c-253"
      decimals="2"
      id="f-806"
      unitRef="eurPerShare">2.45</inpha:ShareIssuedPricePerShare>
    <inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares
      contextRef="c-251"
      decimals="INF"
      id="f-807"
      unitRef="shares">68744</inpha:ExerciseAndSubscriptionOfEquityInstrumentsInShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-248"
      decimals="INF"
      id="f-808"
      unitRef="eurPerShare">0.05</ifrs-full:ParValuePerShare>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates contextRef="c-3" decimals="INF" id="f-809" unitRef="shares">18575</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates contextRef="c-2" decimals="INF" id="f-810" unitRef="shares">18575</ifrs-full:SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-1" id="f-811">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company has issued BSAs, BSAARs, AGAs and AGAPs as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants issued as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants void as of  6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants exercised as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of warrants outstanding as of 6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maximum number of shares to be issued  as of  6/30/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise price per share (in &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;Sept. 9, 2011 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;650,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;625,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;May 27, 2013 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2012 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;146,050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;133,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSAAR 2015 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,050,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,720&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,940&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,045,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,045,722&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;October 21, 2016 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP  Management 2016-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;156,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 21, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,486&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;172&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;268,190&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 21, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Management 2016-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 30, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP  Management 2016-2 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;333,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 30, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Management 2016-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;250,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2017-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,725&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2017-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 3,2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Employees 2017 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;114,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;110,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 3, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2018-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;67,028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,559&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 20, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Perf Employees 2018-1 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;327,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;224,375&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;103,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 20, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Perf Management 2018-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;260,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;110,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;January 14, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Employees 2018 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;90,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New Members 2017-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 3, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2019-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 13, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2020-1 &amp;amp; 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;79,861&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,885&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;61,976&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 5, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;766,650&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;681,420&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;85,230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;August 5, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;710,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;580,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;125,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;125,748&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Employees 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,066,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;290,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;775,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP Management 2021-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;610,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;130,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;138,960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;138,960&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;October 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Bonus 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;128,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;128,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Employees 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,371,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;275,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,096,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,096,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 12, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Management 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;550,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 14, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;163,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;163,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New members 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Employees 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,403,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,337,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,337,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA Perf Management 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;750,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;February 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA New members 2024-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;June 10, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGA "Plan Epargne Entreprise" 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;68,744&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 21, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Stock Options 2020-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;102,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 4, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP 2019 Employees 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;546,700&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;375,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;171,550&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;November 4, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;AGAP 2019 Management 2019 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;355,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;207,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;147,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 29, 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2011-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.77   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 17, 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2013&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;237,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.36   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 16, 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;75,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8.65   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;April 27, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9.59   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;July 1, 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2015-2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14.05   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.720%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.412%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;September 20, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;37,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11.00   &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 16, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2022-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;31,740&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December 15, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BSA 2023-1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;38,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;12,914,414&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,239,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,340,434&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,333,995&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;7,084,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-254"
      decimals="INF"
      id="f-812"
      unitRef="shares">650000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-254"
      decimals="INF"
      id="f-813"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-254"
      decimals="INF"
      id="f-814"
      unitRef="shares">625000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-255"
      decimals="INF"
      id="f-815"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-255"
      decimals="INF"
      id="f-816"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-255"
      decimals="INF"
      id="f-817"
      unitRef="eurPerShare">2.04</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-256"
      decimals="INF"
      id="f-818"
      unitRef="shares">146050</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-256"
      decimals="INF"
      id="f-819"
      unitRef="shares">12250</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-256"
      decimals="INF"
      id="f-820"
      unitRef="shares">133800</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-253"
      decimals="INF"
      id="f-821"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-253"
      decimals="INF"
      id="f-822"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-253"
      decimals="INF"
      id="f-823"
      unitRef="eurPerShare">2.04</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-257"
      decimals="INF"
      id="f-824"
      unitRef="shares">1050382</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-257"
      decimals="INF"
      id="f-825"
      unitRef="shares">2720</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-257"
      decimals="INF"
      id="f-826"
      unitRef="shares">1940</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-258"
      decimals="INF"
      id="f-827"
      unitRef="shares">1045722</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-258"
      decimals="INF"
      id="f-828"
      unitRef="shares">1045722</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-258"
      decimals="INF"
      id="f-829"
      unitRef="eurPerShare">7.20</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-259"
      decimals="INF"
      id="f-830"
      unitRef="shares">2000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-259"
      decimals="INF"
      id="f-831"
      unitRef="shares">550</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-259"
      decimals="INF"
      id="f-832"
      unitRef="shares">250</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-260"
      decimals="INF"
      id="f-833"
      unitRef="shares">1200</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-260"
      decimals="INF"
      id="f-834"
      unitRef="shares">156000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-260"
      decimals="INF"
      id="f-835"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-261"
      decimals="INF"
      id="f-836"
      unitRef="shares">2486</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-261"
      decimals="INF"
      id="f-837"
      unitRef="shares">251</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-261"
      decimals="INF"
      id="f-838"
      unitRef="shares">172</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-262"
      decimals="INF"
      id="f-839"
      unitRef="shares">2063</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-262"
      decimals="INF"
      id="f-840"
      unitRef="shares">268190</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-262"
      decimals="INF"
      id="f-841"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-263"
      decimals="INF"
      id="f-842"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-263"
      decimals="INF"
      id="f-843"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-263"
      decimals="INF"
      id="f-844"
      unitRef="shares">50000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-264"
      decimals="INF"
      id="f-845"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-264"
      decimals="INF"
      id="f-846"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-264"
      decimals="INF"
      id="f-847"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-265"
      decimals="INF"
      id="f-848"
      unitRef="shares">3000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-265"
      decimals="INF"
      id="f-849"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-265"
      decimals="INF"
      id="f-850"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-266"
      decimals="INF"
      id="f-851"
      unitRef="shares">3000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-266"
      decimals="INF"
      id="f-852"
      unitRef="shares">333000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-266"
      decimals="INF"
      id="f-853"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-267"
      decimals="INF"
      id="f-854"
      unitRef="shares">250000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-267"
      decimals="INF"
      id="f-855"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-267"
      decimals="INF"
      id="f-856"
      unitRef="shares">250000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-268"
      decimals="INF"
      id="f-857"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-268"
      decimals="INF"
      id="f-858"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-268"
      decimals="INF"
      id="f-859"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-269"
      decimals="INF"
      id="f-860"
      unitRef="shares">5725</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-269"
      decimals="INF"
      id="f-861"
      unitRef="shares">5725</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-269"
      decimals="INF"
      id="f-862"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-270"
      decimals="INF"
      id="f-863"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-270"
      decimals="INF"
      id="f-864"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-270"
      decimals="INF"
      id="f-865"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-271"
      decimals="INF"
      id="f-866"
      unitRef="shares">2400</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-271"
      decimals="INF"
      id="f-867"
      unitRef="shares">2400</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-271"
      decimals="INF"
      id="f-868"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-272"
      decimals="INF"
      id="f-869"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-272"
      decimals="INF"
      id="f-870"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-272"
      decimals="INF"
      id="f-871"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-273"
      decimals="INF"
      id="f-872"
      unitRef="shares">114500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-273"
      decimals="INF"
      id="f-873"
      unitRef="shares">4000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-273"
      decimals="INF"
      id="f-874"
      unitRef="shares">110500</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-274"
      decimals="INF"
      id="f-875"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-274"
      decimals="INF"
      id="f-876"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-274"
      decimals="INF"
      id="f-877"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-275"
      decimals="INF"
      id="f-878"
      unitRef="shares">67028</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-275"
      decimals="INF"
      id="f-879"
      unitRef="shares">469</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-275"
      decimals="INF"
      id="f-880"
      unitRef="shares">66559</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-276"
      decimals="INF"
      id="f-881"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-276"
      decimals="INF"
      id="f-882"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-276"
      decimals="INF"
      id="f-883"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-277"
      decimals="INF"
      id="f-884"
      unitRef="shares">327500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-277"
      decimals="INF"
      id="f-885"
      unitRef="shares">224375</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-277"
      decimals="INF"
      id="f-886"
      unitRef="shares">103125</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-278"
      decimals="INF"
      id="f-887"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-278"
      decimals="INF"
      id="f-888"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-278"
      decimals="INF"
      id="f-889"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-279"
      decimals="INF"
      id="f-890"
      unitRef="shares">260000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-279"
      decimals="INF"
      id="f-891"
      unitRef="shares">150000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-279"
      decimals="INF"
      id="f-892"
      unitRef="shares">110000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-280"
      decimals="INF"
      id="f-893"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-280"
      decimals="INF"
      id="f-894"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-280"
      decimals="INF"
      id="f-895"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-281"
      decimals="INF"
      id="f-896"
      unitRef="shares">90650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-281"
      decimals="INF"
      id="f-897"
      unitRef="shares">5000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-281"
      decimals="INF"
      id="f-898"
      unitRef="shares">85650</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-282"
      decimals="INF"
      id="f-899"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-282"
      decimals="INF"
      id="f-900"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-282"
      decimals="INF"
      id="f-901"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-283"
      decimals="INF"
      id="f-902"
      unitRef="shares">25000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-283"
      decimals="INF"
      id="f-903"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-283"
      decimals="INF"
      id="f-904"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-284"
      decimals="INF"
      id="f-905"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-284"
      decimals="INF"
      id="f-906"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-284"
      decimals="INF"
      id="f-907"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-285"
      decimals="INF"
      id="f-908"
      unitRef="shares">57376</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-285"
      decimals="INF"
      id="f-909"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-285"
      decimals="INF"
      id="f-910"
      unitRef="shares">57376</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-286"
      decimals="INF"
      id="f-911"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-286"
      decimals="INF"
      id="f-912"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-286"
      decimals="INF"
      id="f-913"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-287"
      decimals="INF"
      id="f-914"
      unitRef="shares">79861</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-287"
      decimals="INF"
      id="f-915"
      unitRef="shares">17885</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-287"
      decimals="INF"
      id="f-916"
      unitRef="shares">61976</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-288"
      decimals="INF"
      id="f-917"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-288"
      decimals="INF"
      id="f-918"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-288"
      decimals="INF"
      id="f-919"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-289"
      decimals="INF"
      id="f-920"
      unitRef="shares">766650</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-289"
      decimals="INF"
      id="f-921"
      unitRef="shares">681420</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-289"
      decimals="INF"
      id="f-922"
      unitRef="shares">85230</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-290"
      decimals="INF"
      id="f-923"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-290"
      decimals="INF"
      id="f-924"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-290"
      decimals="INF"
      id="f-925"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-291"
      decimals="INF"
      id="f-926"
      unitRef="shares">710000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-291"
      decimals="INF"
      id="f-927"
      unitRef="shares">580000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-291"
      decimals="INF"
      id="f-928"
      unitRef="shares">130000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-292"
      decimals="INF"
      id="f-929"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-292"
      decimals="INF"
      id="f-930"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-292"
      decimals="INF"
      id="f-931"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-293"
      decimals="INF"
      id="f-932"
      unitRef="shares">125748</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-293"
      decimals="INF"
      id="f-933"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-293"
      decimals="INF"
      id="f-934"
      unitRef="shares">125748</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-294"
      decimals="INF"
      id="f-935"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-294"
      decimals="INF"
      id="f-936"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-294"
      decimals="INF"
      id="f-937"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-295"
      decimals="INF"
      id="f-938"
      unitRef="shares">1066600</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-295"
      decimals="INF"
      id="f-939"
      unitRef="shares">290800</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-295"
      decimals="INF"
      id="f-940"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-296"
      decimals="INF"
      id="f-941"
      unitRef="shares">775800</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-296"
      decimals="INF"
      id="f-942"
      unitRef="shares">775800</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-296"
      decimals="INF"
      id="f-943"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-297"
      decimals="INF"
      id="f-944"
      unitRef="shares">610000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-297"
      decimals="INF"
      id="f-945"
      unitRef="shares">130000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-297"
      decimals="INF"
      id="f-946"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-298"
      decimals="INF"
      id="f-947"
      unitRef="shares">480000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-298"
      decimals="INF"
      id="f-948"
      unitRef="shares">480000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-298"
      decimals="INF"
      id="f-949"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-299"
      decimals="INF"
      id="f-950"
      unitRef="shares">138960</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-299"
      decimals="INF"
      id="f-951"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-299"
      decimals="INF"
      id="f-952"
      unitRef="shares">138960</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-300"
      decimals="INF"
      id="f-953"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-300"
      decimals="INF"
      id="f-954"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-300"
      decimals="INF"
      id="f-955"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-301"
      decimals="INF"
      id="f-956"
      unitRef="shares">128061</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-301"
      decimals="INF"
      id="f-957"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-301"
      decimals="INF"
      id="f-958"
      unitRef="shares">128061</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-302"
      decimals="INF"
      id="f-959"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-302"
      decimals="INF"
      id="f-960"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-302"
      decimals="INF"
      id="f-961"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-303"
      decimals="INF"
      id="f-962"
      unitRef="shares">1371500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-303"
      decimals="INF"
      id="f-963"
      unitRef="shares">275000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-303"
      decimals="INF"
      id="f-964"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-304"
      decimals="INF"
      id="f-965"
      unitRef="shares">1096500</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-304"
      decimals="INF"
      id="f-966"
      unitRef="shares">1096500</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-304"
      decimals="INF"
      id="f-967"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-305"
      decimals="INF"
      id="f-968"
      unitRef="shares">550000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-305"
      decimals="INF"
      id="f-969"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-305"
      decimals="INF"
      id="f-970"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-306"
      decimals="INF"
      id="f-971"
      unitRef="shares">550000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-306"
      decimals="INF"
      id="f-972"
      unitRef="shares">550000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-306"
      decimals="INF"
      id="f-973"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-307"
      decimals="INF"
      id="f-974"
      unitRef="shares">163293</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-307"
      decimals="INF"
      id="f-975"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-307"
      decimals="INF"
      id="f-976"
      unitRef="shares">163293</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-308"
      decimals="INF"
      id="f-977"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-308"
      decimals="INF"
      id="f-978"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-308"
      decimals="INF"
      id="f-979"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-309"
      decimals="INF"
      id="f-980"
      unitRef="shares">25000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-309"
      decimals="INF"
      id="f-981"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-309"
      decimals="INF"
      id="f-982"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-310"
      decimals="INF"
      id="f-983"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-310"
      decimals="INF"
      id="f-984"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-310"
      decimals="INF"
      id="f-985"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-311"
      decimals="INF"
      id="f-986"
      unitRef="shares">1403500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-311"
      decimals="INF"
      id="f-987"
      unitRef="shares">66250</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-311"
      decimals="INF"
      id="f-988"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-312"
      decimals="INF"
      id="f-989"
      unitRef="shares">1337250</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-312"
      decimals="INF"
      id="f-990"
      unitRef="shares">1337250</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-312"
      decimals="INF"
      id="f-991"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-313"
      decimals="INF"
      id="f-992"
      unitRef="shares">750000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-313"
      decimals="INF"
      id="f-993"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-313"
      decimals="INF"
      id="f-994"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-314"
      decimals="INF"
      id="f-995"
      unitRef="shares">750000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-314"
      decimals="INF"
      id="f-996"
      unitRef="shares">750000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-314"
      decimals="INF"
      id="f-997"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-315"
      decimals="INF"
      id="f-998"
      unitRef="shares">25000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-315"
      decimals="INF"
      id="f-999"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-315"
      decimals="INF"
      id="f-1000"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-316"
      decimals="INF"
      id="f-1001"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-316"
      decimals="INF"
      id="f-1002"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-316"
      decimals="INF"
      id="f-1003"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-317"
      decimals="INF"
      id="f-1004"
      unitRef="shares">68744</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-317"
      decimals="INF"
      id="f-1005"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-317"
      decimals="INF"
      id="f-1006"
      unitRef="shares">68744</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-318"
      decimals="INF"
      id="f-1007"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-318"
      decimals="INF"
      id="f-1008"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-318"
      decimals="INF"
      id="f-1009"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-319"
      decimals="INF"
      id="f-1010"
      unitRef="shares">102000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-319"
      decimals="INF"
      id="f-1011"
      unitRef="shares">102000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-319"
      decimals="INF"
      id="f-1012"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-320"
      decimals="INF"
      id="f-1013"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-320"
      decimals="INF"
      id="f-1014"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-320"
      decimals="INF"
      id="f-1015"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-321"
      decimals="INF"
      id="f-1016"
      unitRef="shares">546700</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-321"
      decimals="INF"
      id="f-1017"
      unitRef="shares">375150</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-321"
      decimals="INF"
      id="f-1018"
      unitRef="shares">171550</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-322"
      decimals="INF"
      id="f-1019"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-322"
      decimals="INF"
      id="f-1020"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-322"
      decimals="INF"
      id="f-1021"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-323"
      decimals="INF"
      id="f-1022"
      unitRef="shares">355000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-323"
      decimals="INF"
      id="f-1023"
      unitRef="shares">207500</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-323"
      decimals="INF"
      id="f-1024"
      unitRef="shares">147500</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-324"
      decimals="INF"
      id="f-1025"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-324"
      decimals="INF"
      id="f-1026"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-324"
      decimals="INF"
      id="f-1027"
      unitRef="eurPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-325"
      decimals="INF"
      id="f-1028"
      unitRef="shares">225000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-325"
      decimals="INF"
      id="f-1029"
      unitRef="shares">25000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-325"
      decimals="INF"
      id="f-1030"
      unitRef="shares">200000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-326"
      decimals="INF"
      id="f-1031"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-326"
      decimals="INF"
      id="f-1032"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-326"
      decimals="INF"
      id="f-1033"
      unitRef="eurPerShare">1.77</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-327"
      decimals="INF"
      id="f-1034"
      unitRef="shares">237500</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-327"
      decimals="INF"
      id="f-1035"
      unitRef="shares">12500</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-327"
      decimals="INF"
      id="f-1036"
      unitRef="shares">225000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-328"
      decimals="INF"
      id="f-1037"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-328"
      decimals="INF"
      id="f-1038"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-328"
      decimals="INF"
      id="f-1039"
      unitRef="eurPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-329"
      decimals="INF"
      id="f-1040"
      unitRef="shares">150000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-329"
      decimals="INF"
      id="f-1041"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-329"
      decimals="INF"
      id="f-1042"
      unitRef="shares">75000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-330"
      decimals="INF"
      id="f-1043"
      unitRef="shares">75000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-330"
      decimals="INF"
      id="f-1044"
      unitRef="shares">75000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-330"
      decimals="INF"
      id="f-1045"
      unitRef="eurPerShare">8.65</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-331"
      decimals="INF"
      id="f-1046"
      unitRef="shares">70000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-331"
      decimals="INF"
      id="f-1047"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-331"
      decimals="INF"
      id="f-1048"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-332"
      decimals="INF"
      id="f-1049"
      unitRef="shares">70000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-332"
      decimals="INF"
      id="f-1050"
      unitRef="shares">70000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-332"
      decimals="INF"
      id="f-1051"
      unitRef="eurPerShare">9.59</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-333"
      decimals="INF"
      id="f-1052"
      unitRef="shares">14200</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-333"
      decimals="INF"
      id="f-1053"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-333"
      decimals="INF"
      id="f-1054"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-334"
      decimals="INF"
      id="f-1055"
      unitRef="shares">14200</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-334"
      decimals="INF"
      id="f-1056"
      unitRef="shares">14200</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-334"
      decimals="INF"
      id="f-1057"
      unitRef="eurPerShare">14.05</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-335"
      decimals="INF"
      id="f-1058"
      unitRef="shares">37000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-335"
      decimals="INF"
      id="f-1059"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-335"
      decimals="INF"
      id="f-1060"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-336"
      decimals="INF"
      id="f-1061"
      unitRef="shares">37000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-336"
      decimals="INF"
      id="f-1062"
      unitRef="shares">37000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-336"
      decimals="INF"
      id="f-1063"
      unitRef="eurPerShare">11.00</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-337"
      decimals="INF"
      id="f-1064"
      unitRef="shares">40000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-337"
      decimals="INF"
      id="f-1065"
      unitRef="shares">31740</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-337"
      decimals="INF"
      id="f-1066"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-338"
      decimals="INF"
      id="f-1067"
      unitRef="shares">8260</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-338"
      decimals="INF"
      id="f-1068"
      unitRef="shares">8260</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-338"
      decimals="INF"
      id="f-1069"
      unitRef="eurPerShare">2.31</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-339"
      decimals="INF"
      id="f-1070"
      unitRef="shares">50000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-339"
      decimals="INF"
      id="f-1071"
      unitRef="shares">12000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-339"
      decimals="INF"
      id="f-1072"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-340"
      decimals="INF"
      id="f-1073"
      unitRef="shares">38000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-340"
      decimals="INF"
      id="f-1074"
      unitRef="shares">38000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-340"
      decimals="INF"
      id="f-1075"
      unitRef="eurPerShare">2.26</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-341"
      decimals="INF"
      id="f-1076"
      unitRef="shares">12914414</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-341"
      decimals="INF"
      id="f-1077"
      unitRef="shares">3239985</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-341"
      decimals="INF"
      id="f-1078"
      unitRef="shares">3340434</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-342"
      decimals="INF"
      id="f-1079"
      unitRef="shares">6333995</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="c-342"
      decimals="INF"
      id="f-1080"
      unitRef="shares">7084922</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-1081">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Financial instruments recognized in the statement of financial position and related effect on the income statement&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value through profit and loss (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized cost (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;136,422&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;136,422&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value through profit and loss (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;168,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;168,363&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt; The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt; The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 7 and IFRS 13, financial instruments are presented in three categories based on a hierarchy of methods used to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: fair value determined based on quoted prices in active markets for assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: fair value determined on the observable database for the asset or liability concerned either directly or indirectly;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: fair value determined on the basis of evaluation techniques based in whole or in part on unobservable data.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory contextRef="c-1" id="f-1082">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The following tables show the carrying amounts and fair values of financial assets and financial liabilities. The tables do not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value through profit and loss (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized cost (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;10,350&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,809&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;69,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;136,422&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,149&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;34,273&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;136,422&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,574&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,929&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;15,873&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;51,376&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Book value on the statement of financial position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value through profit and loss (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized Cost (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-current financial assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;9,796&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade receivables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21,851&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;70,605&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;168,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;102,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;66,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;168,363&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;30,957&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial liabilities&#x2014;current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;8,936&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Trade payables and others&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,911&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt; The fair value of financial assets classified as fair value through profit and loss corresponds to the market value of the assets, which are primarily determined using level 2 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:133%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt; The book amount of financial assets and liabilities measured at amortized cost was deemed to be a reasonable estimation of fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets contextRef="c-343" decimals="-3" id="f-1083" unitRef="eur">10350000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-344" decimals="-3" id="f-1084" unitRef="eur">10350000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-345" decimals="-3" id="f-1085" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-343" decimals="-3" id="f-1086" unitRef="eur">10350000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-346" decimals="-3" id="f-1087" unitRef="eur">34273000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-347" decimals="-3" id="f-1088" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-348" decimals="-3" id="f-1089" unitRef="eur">34273000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-346" decimals="-3" id="f-1090" unitRef="eur">34273000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-349" decimals="-3" id="f-1091" unitRef="eur">21809000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-350" decimals="-3" id="f-1092" unitRef="eur">21809000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-351" decimals="-3" id="f-1093" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-349" decimals="-3" id="f-1094" unitRef="eur">21809000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-352" decimals="-3" id="f-1095" unitRef="eur">69990000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-353" decimals="-3" id="f-1096" unitRef="eur">69990000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-354" decimals="-3" id="f-1097" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-352" decimals="-3" id="f-1098" unitRef="eur">69990000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-2" decimals="-3" id="f-1099" unitRef="eur">136422000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-355" decimals="-3" id="f-1100" unitRef="eur">102149000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-356" decimals="-3" id="f-1101" unitRef="eur">34273000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-2" decimals="-3" id="f-1102" unitRef="eur">136422000</ifrs-full:FinancialAssetsAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-357" decimals="-3" id="f-1103" unitRef="eur">26574000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-358" decimals="-3" id="f-1104" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-359" decimals="-3" id="f-1105" unitRef="eur">26574000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-357" decimals="-3" id="f-1106" unitRef="eur">26574000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-360" decimals="-3" id="f-1107" unitRef="eur">8929000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-361" decimals="-3" id="f-1108" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-362" decimals="-3" id="f-1109" unitRef="eur">8929000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-360" decimals="-3" id="f-1110" unitRef="eur">8929000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-363" decimals="-3" id="f-1111" unitRef="eur">15873000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-364" decimals="-3" id="f-1112" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-365" decimals="-3" id="f-1113" unitRef="eur">15873000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-363" decimals="-3" id="f-1114" unitRef="eur">15873000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-2" decimals="-3" id="f-1115" unitRef="eur">51376000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-366" decimals="-3" id="f-1116" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-367" decimals="-3" id="f-1117" unitRef="eur">51376000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-2" decimals="-3" id="f-1118" unitRef="eur">51376000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-368" decimals="-3" id="f-1119" unitRef="eur">9796000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-369" decimals="-3" id="f-1120" unitRef="eur">9796000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-370" decimals="-3" id="f-1121" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-368" decimals="-3" id="f-1122" unitRef="eur">9796000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-371" decimals="-3" id="f-1123" unitRef="eur">66111000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-372" decimals="-3" id="f-1124" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-373" decimals="-3" id="f-1125" unitRef="eur">66111000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-371" decimals="-3" id="f-1126" unitRef="eur">66111000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-374" decimals="-3" id="f-1127" unitRef="eur">21851000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-375" decimals="-3" id="f-1128" unitRef="eur">21851000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-376" decimals="-3" id="f-1129" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-374" decimals="-3" id="f-1130" unitRef="eur">21851000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-377" decimals="-3" id="f-1131" unitRef="eur">70605000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-378" decimals="-3" id="f-1132" unitRef="eur">70605000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-379" decimals="-3" id="f-1133" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-377" decimals="-3" id="f-1134" unitRef="eur">70605000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-3" decimals="-3" id="f-1135" unitRef="eur">168363000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-380" decimals="-3" id="f-1136" unitRef="eur">102252000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-381" decimals="-3" id="f-1137" unitRef="eur">66111000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-3" decimals="-3" id="f-1138" unitRef="eur">168363000</ifrs-full:FinancialAssetsAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-382" decimals="-3" id="f-1139" unitRef="eur">30957000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-383" decimals="-3" id="f-1140" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-384" decimals="-3" id="f-1141" unitRef="eur">30957000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-382" decimals="-3" id="f-1142" unitRef="eur">30957000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-385" decimals="-3" id="f-1143" unitRef="eur">8936000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-386" decimals="-3" id="f-1144" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-387" decimals="-3" id="f-1145" unitRef="eur">8936000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-385" decimals="-3" id="f-1146" unitRef="eur">8936000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-388" decimals="-3" id="f-1147" unitRef="eur">17018000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-389" decimals="-3" id="f-1148" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-390" decimals="-3" id="f-1149" unitRef="eur">17018000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-388" decimals="-3" id="f-1150" unitRef="eur">17018000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-3" decimals="-3" id="f-1151" unitRef="eur">56911000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-391" decimals="-3" id="f-1152" unitRef="eur">0</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthers contextRef="c-392" decimals="-3" id="f-1153" unitRef="eur">56911000</inpha:FinancialLiabilitiesTradePayablesAndOthers>
    <inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue contextRef="c-3" decimals="-3" id="f-1154" unitRef="eur">56911000</inpha:FinancialLiabilitiesTradePayablesAndOthersAtFairValue>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-1155">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Revenue and other income&lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Revenue from collaboration and licensing agreements&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca, Sanofi and Takeda :&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Proceeds from collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,396&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,728&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which monalizumab agreement (AstraZeneca)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;9,503&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which 2016 Sanofi agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,672&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Takeda agreement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4,553&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Invoicing of R&amp;amp;D costs (IPH5201 agreement)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;616&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue from collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,344&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;a)  Revenue recognition related to monalizumab AZ agreements and amendments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%"&gt;Change in deferred revenue relating to monalizumab agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue for the six months ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfer from / (to)  collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,695&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,156&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue for the six months ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,994)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfer from / (to)  collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%"&gt;Change in collaboration liabilities relating to monalizumab agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;63,211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,436)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,058&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,677&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,891&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,419)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;b)  Revenue recognition related to IPH5201 AstraZeneca collaboration and option agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Revenue related to IPH5201 for the six months ended June 30, 2024 and June 30, 2023 are nil. As a reminder, the Company signed on June 1, 2022  an amendment to the initial contract signed in October 2018. This amendment set the terms of the collaboration following AstraZeneca&#x2019;s decision to advance IPH5201 to a Phase 2 study. The Company will conduct the study. Both parties will share the external cost related to the study and incurred by the Company and AstraZeneca will provide products necessary to conduct the clinical trial. Under the terms of this agreement, an amount of &#x20ac;897 thousand was rebilled to AstraZeneca during the first half of 2024 (&#x20ac;616 thousand during the first half of 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;c)  Revenue related to IPH6401 - Sanofi (2016)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Revenue related to IPH6401 under the collaboration and license agreement signed with Sanofi is &#x20ac;4,000&#160;thousand for the six months ended June 30, 2024, as compared to a revenue of &#x20ac;2,000&#160;thousand as of June 30, 2023. During the period, the Company announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101, evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs. Under the terms of the 2016 research and licensing agreement with Sanofi, dosing of the first patient in the dose expansion part of the trial triggered a milestone payment to the Company of &#x20ac;4&#160;million recognized as revenue as of June 30, 2024. This amount was received by the Company on May 17, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As a reminder, the Company announced that, in June 2023, the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial evaluating IPH6401/SAR'514 in relapsed or refractory Multiple Myeloma. Under the terms of the licensing agreement signed in 2016, Sanofi made a milestone payment of &#x20ac;2,000&#160;thousand, fully recognized in revenue as of June 30, 2023. This amount was received by the Company on July 21, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d)  Revenue related to Sanofi research collaboration and licensing agreement (2022)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;On January 25, 2023, the Company announced the expiration of the waiting period under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%"&gt;Hart-Scott-Rodino&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt; (HSR) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%"&gt;Antitrust Improvements Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt; of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, under the terms of such agreement, the Company received an upfront payment of &#x20ac;25,000&#160;thousand in March 2023, including &#x20ac;18,500&#160;thousand for the exclusive license, &#x20ac;1,500&#160;thousand for the research work and &#x20ac;5,000&#160;thousand for the two additional targets options. On December 19, 2023, the Company announced that Sanofi had exercised an option for one of the two targets. This option exercise also resulted in a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;milestone payment of &#x20ac;15,000&#160;thousand, including &#x20ac;13,300 thousand in respect of the exclusive license, which was fully recognized in income as of December 31, 2023, and &#x20ac;1,700&#160;thousand for the research activities to be carried out by the Company. The Company considers that the license to the B7-H3 technology is a right to use the intellectual property granted exclusively to Sanofi from the effective date of the agreement. As such, all upfront payments relating to the licenses granted have been recognized in the income statement representing an amount of &#x20ac;31,800&#160;thousand, including &#x20ac;18.5&#160;million  relating to B7-H3 license and &#x20ac;13,300&#160;thousand following the option exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in deferred revenue relating to the 2022 research collaboration and licensing agreement : &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,328&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,327&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,925&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;(1) The increase in deferred revenue relating to the 2022 research collaboration and licensing agreement with Sanofi between December 31, 2022 and June 30, 2023 mainly comprises (i) an upfront payment of &#x20ac;5,000&#160;thousand relating to the granting of two options for exclusive licenses on Innate's intellectual property for the research, development, manufacturing and commercialization of NKCEs specifically targeting two preclinical molecules. The Company will recognize the related revenues either at the reporting date or three years after the effective date; as well as (ii) an amount of &#x20ac;1,500&#160;thousand relating to research activities to perform in collaboration with Sanofi. The Company will recognize the related revenues on a straight-line basis over the duration of the research work to which the Company has agreed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e)  Schedule of variance of deferred revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Recognition in P&amp;amp;L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transfer from / (to) collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Monalizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,994)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,424&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,396)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Recognition in P&amp;amp;L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transfer from / (to) collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Monalizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,696&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,328&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,675)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;11,024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Government financing for research expenditures&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company receives grants from the European Commission, French government and state organizations in several different forms:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt;Research Tax Credits; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:21.26pt;text-align:justify;text-indent:-21.26pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:16.28pt"&gt; Investment and operating grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June 30, 2024 and 2023, an estimate of the research tax credit amount for the first half period is calculated on the basis of eligible expenses over the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,050 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,854&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Government financing for research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,854&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-1156">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Revenues from collaboration and licensing agreements result from agreements signed with AstraZeneca, Sanofi and Takeda :&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.867%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Proceeds from collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7,396&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;34,728&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which monalizumab agreement (AstraZeneca)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,994&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;9,503&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which 2016 Sanofi agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;2,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;18,672&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment,  income related to the option exercise and income related to the completion of work in line with the joint research program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;203&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;of which Takeda agreement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;4,553&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Invoicing of R&amp;amp;D costs (IPH5201 agreement)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;897&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;616&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Revenue from collaboration and licensing agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;8,293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;35,344&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-393" decimals="-3" id="f-1157" unitRef="eur">7396000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-394" decimals="-3" id="f-1158" unitRef="eur">34728000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-86" decimals="-3" id="f-1159" unitRef="eur">2994000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-88" decimals="-3" id="f-1160" unitRef="eur">9503000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-47" decimals="-3" id="f-1161" unitRef="eur">4000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-395" decimals="-3" id="f-1162" unitRef="eur">2000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-396" decimals="-3" id="f-1163" unitRef="eur">199000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-397" decimals="-3" id="f-1164" unitRef="eur">18672000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-398" decimals="-3" id="f-1165" unitRef="eur">203000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-399" decimals="-3" id="f-1166" unitRef="eur">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-400" decimals="-3" id="f-1167" unitRef="eur">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-401" decimals="-3" id="f-1168" unitRef="eur">4553000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-402" decimals="-3" id="f-1169" unitRef="eur">897000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-403" decimals="-3" id="f-1170" unitRef="eur">616000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-1171" unitRef="eur">8293000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-4" decimals="-3" id="f-1172" unitRef="eur">35344000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="c-1" id="f-1173">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:140%"&gt;Change in deferred revenue relating to monalizumab agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.215%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue for the six months ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfer from / (to)  collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,695&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,156&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenue for the six months ended June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,994)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transfer from / (to)  collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%"&gt;Change in collaboration liabilities relating to monalizumab agreement:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;63,211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,436)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;56,058&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,677&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,891&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,419)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;52,149&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in deferred revenue relating to the 2022 research collaboration and licensing agreement : &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,328&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,327&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,925&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) The increase in deferred revenue relating to the 2022 research collaboration and licensing agreement with Sanofi between December 31, 2022 and June 30, 2023 mainly comprises (i) an upfront payment of &#x20ac;5,000&#160;thousand relating to the granting of two options for exclusive licenses on Innate's intellectual property for the research, development, manufacturing and commercialization of NKCEs specifically targeting two preclinical molecules. The Company will recognize the related revenues either at the reporting date or three years after the effective date; as well as (ii) an amount of &#x20ac;1,500&#160;thousand relating to research activities to perform in collaboration with Sanofi. The Company will recognize the related revenues on a straight-line basis over the duration of the research work to which the Company has agreed.</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:ContractLiabilities contextRef="c-404" decimals="-3" id="f-1174" unitRef="eur">14481000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-405" decimals="-3" id="f-1175" unitRef="eur">9503000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:TransferToFromCollaborationLiabilities contextRef="c-405" decimals="-3" id="f-1176" unitRef="eur">-283000</inpha:TransferToFromCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-406" decimals="-3" id="f-1177" unitRef="eur">4695000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-407" decimals="-3" id="f-1178" unitRef="eur">5156000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-408" decimals="-3" id="f-1179" unitRef="eur">2994000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:TransferToFromCollaborationLiabilities contextRef="c-408" decimals="-3" id="f-1180" unitRef="eur">-172000</inpha:TransferToFromCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-409" decimals="-3" id="f-1181" unitRef="eur">1990000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-410" decimals="-3" id="f-1182" unitRef="eur">63211000</ifrs-full:ContractLiabilities>
    <inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-411" decimals="-3" id="f-1183" unitRef="eur">283000</inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:DecreaseThroughDeductionsContractLiabilities contextRef="c-411" decimals="-3" id="f-1184" unitRef="eur">7436000</inpha:DecreaseThroughDeductionsContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-412" decimals="-3" id="f-1185" unitRef="eur">56058000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-413" decimals="-3" id="f-1186" unitRef="eur">52677000</ifrs-full:ContractLiabilities>
    <inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-414" decimals="-3" id="f-1187" unitRef="eur">1891000</inpha:IncreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:DecreaseThroughDeductionsContractLiabilities contextRef="c-414" decimals="-3" id="f-1188" unitRef="eur">2419000</inpha:DecreaseThroughDeductionsContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-415" decimals="-3" id="f-1189" unitRef="eur">52149000</ifrs-full:ContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-416" decimals="-3" id="f-1190" unitRef="eur">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-417" decimals="-3" id="f-1191" unitRef="eur">0</ifrs-full:RevenueFromContractsWithCustomers>
    <inpha:ExternalCostsRelatedToTheClinicalTrial contextRef="c-416" decimals="-3" id="f-1192" unitRef="eur">897000</inpha:ExternalCostsRelatedToTheClinicalTrial>
    <inpha:ExternalCostsRelatedToTheClinicalTrial contextRef="c-417" decimals="-3" id="f-1193" unitRef="eur">616000</inpha:ExternalCostsRelatedToTheClinicalTrial>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-47" decimals="-3" id="f-1194" unitRef="eur">4000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-395" decimals="-3" id="f-1195" unitRef="eur">2000000</ifrs-full:RevenueFromContractsWithCustomers>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived contextRef="c-47" decimals="-6" id="f-1196" unitRef="eur">4000000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived contextRef="c-395" decimals="-3" id="f-1197" unitRef="eur">2000000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceived>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived contextRef="c-418" decimals="-3" id="f-1198" unitRef="eur">25000000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses contextRef="c-418" decimals="-3" id="f-1199" unitRef="eur">18500000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch contextRef="c-418" decimals="-3" id="f-1200" unitRef="eur">1500000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions contextRef="c-418" decimals="-3" id="f-1201" unitRef="eur">5000000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions>
    <inpha:NumberOfTargetOptions
      contextRef="c-419"
      decimals="INF"
      id="f-1202"
      unitRef="target_option">2</inpha:NumberOfTargetOptions>
    <inpha:NumberOfOptionsExcercisedForLicenses
      contextRef="c-420"
      decimals="INF"
      id="f-1203"
      unitRef="option">1</inpha:NumberOfOptionsExcercisedForLicenses>
    <inpha:NumberOfExclusiveOptionsGranted
      contextRef="c-421"
      decimals="INF"
      id="f-1204"
      unitRef="option">2</inpha:NumberOfExclusiveOptionsGranted>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised contextRef="c-422" decimals="-3" id="f-1205" unitRef="eur">15000000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses contextRef="c-423" decimals="-3" id="f-1206" unitRef="eur">13300000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch contextRef="c-423" decimals="-3" id="f-1207" unitRef="eur">1700000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived contextRef="c-424" decimals="-3" id="f-1208" unitRef="eur">31800000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceived>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses contextRef="c-424" decimals="-5" id="f-1209" unitRef="eur">18500000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedLicenses>
    <inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised contextRef="c-424" decimals="-3" id="f-1210" unitRef="eur">13300000</inpha:RevenueFromContractsWithCustomersMilestonePaymentReceivedOptionExercised>
    <ifrs-full:ContractLiabilities contextRef="c-425" decimals="-3" id="f-1211" unitRef="eur">0</ifrs-full:ContractLiabilities>
    <inpha:RevenueFromContractsWithCustomersMilestone contextRef="c-426" decimals="-3" id="f-1212" unitRef="eur">6500000</inpha:RevenueFromContractsWithCustomersMilestone>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-426" decimals="-3" id="f-1213" unitRef="eur">172000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-427" decimals="-3" id="f-1214" unitRef="eur">6328000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-428" decimals="-3" id="f-1215" unitRef="eur">5327000</ifrs-full:ContractLiabilities>
    <inpha:RevenueFromContractsWithCustomersMilestone contextRef="c-429" decimals="-3" id="f-1216" unitRef="eur">0</inpha:RevenueFromContractsWithCustomersMilestone>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-429" decimals="-3" id="f-1217" unitRef="eur">402000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-430" decimals="-3" id="f-1218" unitRef="eur">4925000</ifrs-full:ContractLiabilities>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions contextRef="c-431" decimals="-3" id="f-1219" unitRef="eur">5000000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedTargetOptions>
    <inpha:NumberOfTargetOptions
      contextRef="c-432"
      decimals="INF"
      id="f-1220"
      unitRef="target_option">2</inpha:NumberOfTargetOptions>
    <inpha:NumberOfPreclinicalMolecules
      contextRef="c-433"
      decimals="INF"
      id="f-1221"
      unitRef="preclinicalmolecule">2</inpha:NumberOfPreclinicalMolecules>
    <inpha:RevenuesFromContractLiabilitiesRecognitionPeriodMaximum contextRef="c-431" id="f-1222">P3Y</inpha:RevenuesFromContractLiabilitiesRecognitionPeriodMaximum>
    <inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch contextRef="c-431" decimals="-3" id="f-1223" unitRef="eur">1500000</inpha:RevenueFromContractsWithCustomersAdvancePaymentReceivedResearch>
    <inpha:DisclosureOfVarianceOfDeferredRevenueTableTextBlock contextRef="c-1" id="f-1224">Schedule of variance of deferred revenue &lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Recognition in P&amp;amp;L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transfer from / (to) collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Monalizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2,994)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,990&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,826&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,424&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;10,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,396)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;6,915&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.738%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Recognition in P&amp;amp;L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transfer from / (to) collaboration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Monalizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(9,503)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,696&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Sanofi (2022) services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,328&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;14,481&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,675)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;5,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(283)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;11,024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inpha:DisclosureOfVarianceOfDeferredRevenueTableTextBlock>
    <ifrs-full:ContractLiabilities contextRef="c-434" decimals="-3" id="f-1225" unitRef="eur">5155000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-435" decimals="-3" id="f-1226" unitRef="eur">2994000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-435" decimals="-3" id="f-1227" unitRef="eur">0</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-435" decimals="-3" id="f-1228" unitRef="eur">-172000</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-436" decimals="-3" id="f-1229" unitRef="eur">1990000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-437" decimals="-3" id="f-1230" unitRef="eur">2500000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-438" decimals="-3" id="f-1231" unitRef="eur">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-438" decimals="-3" id="f-1232" unitRef="eur">0</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-438" decimals="-3" id="f-1233" unitRef="eur">0</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-439" decimals="-3" id="f-1234" unitRef="eur">2500000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-440" decimals="-3" id="f-1235" unitRef="eur">2826000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-441" decimals="-3" id="f-1236" unitRef="eur">402000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-441" decimals="-3" id="f-1237" unitRef="eur">0</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-441" decimals="-3" id="f-1238" unitRef="eur">0</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-442" decimals="-3" id="f-1239" unitRef="eur">2424000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-443" decimals="-3" id="f-1240" unitRef="eur">10481000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-444" decimals="-3" id="f-1241" unitRef="eur">3396000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-444" decimals="-3" id="f-1242" unitRef="eur">0</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-444" decimals="-3" id="f-1243" unitRef="eur">-172000</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-445" decimals="-3" id="f-1244" unitRef="eur">6915000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-446" decimals="-3" id="f-1245" unitRef="eur">14481000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-447" decimals="-3" id="f-1246" unitRef="eur">9503000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-447" decimals="-3" id="f-1247" unitRef="eur">0</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-447" decimals="-3" id="f-1248" unitRef="eur">-283000</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-448" decimals="-3" id="f-1249" unitRef="eur">4696000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-449" decimals="-3" id="f-1250" unitRef="eur">0</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-450" decimals="-3" id="f-1251" unitRef="eur">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-450" decimals="-3" id="f-1252" unitRef="eur">5000000</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-450" decimals="-3" id="f-1253" unitRef="eur">0</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-451" decimals="-3" id="f-1254" unitRef="eur">5000000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-452" decimals="-3" id="f-1255" unitRef="eur">0</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-453" decimals="-3" id="f-1256" unitRef="eur">172000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-453" decimals="-3" id="f-1257" unitRef="eur">1500000</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-453" decimals="-3" id="f-1258" unitRef="eur">0</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-454" decimals="-3" id="f-1259" unitRef="eur">1328000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-455" decimals="-3" id="f-1260" unitRef="eur">14481000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-456" decimals="-3" id="f-1261" unitRef="eur">9675000</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <inpha:IncreaseThroughUpfrontPaymentContractLiabilities contextRef="c-456" decimals="-3" id="f-1262" unitRef="eur">5000000</inpha:IncreaseThroughUpfrontPaymentContractLiabilities>
    <inpha:TransferFromToCollaborationLiabilities contextRef="c-456" decimals="-3" id="f-1263" unitRef="eur">-283000</inpha:TransferFromToCollaborationLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-457" decimals="-3" id="f-1264" unitRef="eur">11024000</ifrs-full:ContractLiabilities>
    <inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock contextRef="c-1" id="f-1265">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The total amount for government financing for research expenditures recorded as other income in the income statement can be analysed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,050 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4,854&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Government financing for research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;4,854&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inpha:DisclosureOfGovernmentFinancingForResearchExpendituresTableTextBlock>
    <inpha:IncomeFromResearchTaxCredit contextRef="c-1" decimals="-3" id="f-1266" unitRef="eur">4050000</inpha:IncomeFromResearchTaxCredit>
    <inpha:IncomeFromResearchTaxCredit contextRef="c-4" decimals="-3" id="f-1267" unitRef="eur">4854000</inpha:IncomeFromResearchTaxCredit>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-1" decimals="-3" id="f-1268" unitRef="eur">2000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c-4" decimals="-3" id="f-1269" unitRef="eur">0</ifrs-full:RevenueFromGovernmentGrants>
    <inpha:GovernmentFinancingForResearchExpenditures contextRef="c-1" decimals="-3" id="f-1270" unitRef="eur">4052000</inpha:GovernmentFinancingForResearchExpenditures>
    <inpha:GovernmentFinancingForResearchExpenditures contextRef="c-4" decimals="-3" id="f-1271" unitRef="eur">4854000</inpha:GovernmentFinancingForResearchExpenditures>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c-1" id="f-1273">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Operating expenses&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Subcontracting costs(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(15,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,857)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(15,857)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of supplies and consumable materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,510)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Personnel expenses other than share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,532)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,470)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(11,002)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,781)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(11,652)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,706)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(905)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(496)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(8,707)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4,001)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;(12,708)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(8,686)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;(13,053)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-scientific advisory and consulting(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Leasing and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Travel expenses and meeting attendance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Marketing, communication and public relations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Scientific advisory and consulting(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(933)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(933)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other purchases and external expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,166)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,146)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,645)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other income and (expenses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(956)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(464)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(29,076)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,582)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(38,657)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(31,453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,144)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(40,597)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26pt"&gt;The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt"&gt;Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt"&gt;Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <ifrs-full:DisclosureOfExpensesExplanatory contextRef="c-1" id="f-1272">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Operating expenses&lt;/span&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Subcontracting costs(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(15,585)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(15,857)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(15,857)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cost of supplies and consumable materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,510)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Personnel expenses other than share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,532)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,470)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(11,002)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,781)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,871)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(11,652)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,175)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,706)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(905)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(496)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(8,707)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4,001)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;(12,708)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(8,686)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4,367)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;(13,053)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-scientific advisory and consulting(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,934)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,194)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Leasing and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(490)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,200)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(470)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(915)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Travel expenses and meeting attendance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Marketing, communication and public relations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Scientific advisory and consulting(3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(933)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(933)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other purchases and external expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,166)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(503)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,146)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,645)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(568)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(570)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(638)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other income and (expenses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(956)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(464)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(562)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(29,076)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,582)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(38,657)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(31,453)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(9,144)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(40,597)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:26pt"&gt;The Company subcontracts a significant part of its pre-clinical (pharmaceutical development, tolerance studies and other model experiments, etc.) and clinical operations (coordination of trials, hospital costs, etc.) to third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt"&gt;Non-scientific advisory and consulting are services performed to support the general and administration activities of the Company, such as legal, accounting and audit fees as well as business development support. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:133%;padding-left:26pt"&gt;Scientific advisory and consulting expenses relate to consulting services performed by third parties to support the research and development activities of the Company.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Personnel expenses other than share-based compensation&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The line item amounted to &#x20ac;11,002&#160;thousand and &#x20ac;11,652&#160;thousand for the six months ended June&#160;30, 2024 and 2023 respectively. The Company had 168 full time equivalent employees as of June&#160;30, 2024, compared to 191 as of June&#160;30, 2023. June 30, 2024, we had 135 employees, in research and development functions, compared to 151 employees as of June 30, 2023. Meanwhile, the administrative staff, totaled 39 people, compared to 45.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Depreciation and amortization&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt; As of June 30, 2023, this amount includes the amortization of the additional payment made to Orega Biotech in 2023 for and amount of &#x20ac;2,000&#160;thousand and the amortization of rights related to the monalizumab for an amount of &#x20ac;651&#160;thousand. As of June 30, 2024, this amount included the amortization of rights related to the monalizumab for an amount of  &#x20ac;294&#160;thousand .  (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Cost of suppliers and consumable materials&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of supplies and consumable materials consists mainly of the cost of procurement of the Company&#x2019;s drug substance and/or drug product that is manufactured by third-parties, respectively.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfExpensesExplanatory>
    <inpha:SubcontractingCosts contextRef="c-458" decimals="-3" id="f-1274" unitRef="eur">15585000</inpha:SubcontractingCosts>
    <inpha:SubcontractingCosts contextRef="c-459" decimals="-3" id="f-1275" unitRef="eur">0</inpha:SubcontractingCosts>
    <inpha:SubcontractingCosts contextRef="c-1" decimals="-3" id="f-1276" unitRef="eur">15585000</inpha:SubcontractingCosts>
    <inpha:SubcontractingCosts contextRef="c-460" decimals="-3" id="f-1277" unitRef="eur">15857000</inpha:SubcontractingCosts>
    <inpha:SubcontractingCosts contextRef="c-461" decimals="-3" id="f-1278" unitRef="eur">0</inpha:SubcontractingCosts>
    <inpha:SubcontractingCosts contextRef="c-4" decimals="-3" id="f-1279" unitRef="eur">15857000</inpha:SubcontractingCosts>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-458" decimals="-3" id="f-1280" unitRef="eur">1485000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-459" decimals="-3" id="f-1281" unitRef="eur">153000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-1" decimals="-3" id="f-1282" unitRef="eur">1638000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-460" decimals="-3" id="f-1283" unitRef="eur">1410000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-461" decimals="-3" id="f-1284" unitRef="eur">100000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed contextRef="c-4" decimals="-3" id="f-1285" unitRef="eur">1510000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-458" decimals="-3" id="f-1286" unitRef="eur">7532000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-459" decimals="-3" id="f-1287" unitRef="eur">3470000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-1288" unitRef="eur">11002000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-460" decimals="-3" id="f-1289" unitRef="eur">7781000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-461" decimals="-3" id="f-1290" unitRef="eur">3871000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-4" decimals="-3" id="f-1291" unitRef="eur">11652000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-458" decimals="-3" id="f-1292" unitRef="eur">1175000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-459" decimals="-3" id="f-1293" unitRef="eur">531000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-1294" unitRef="eur">1706000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-460" decimals="-3" id="f-1295" unitRef="eur">905000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-461" decimals="-3" id="f-1296" unitRef="eur">496000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-4" decimals="-3" id="f-1297" unitRef="eur">1401000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-458" decimals="-3" id="f-1298" unitRef="eur">8707000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-459" decimals="-3" id="f-1299" unitRef="eur">4001000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-1300" unitRef="eur">12708000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-460" decimals="-3" id="f-1301" unitRef="eur">8686000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-461" decimals="-3" id="f-1302" unitRef="eur">4367000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-4" decimals="-3" id="f-1303" unitRef="eur">13053000</ifrs-full:EmployeeBenefitsExpense>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-458" decimals="-3" id="f-1304" unitRef="eur">124000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-459" decimals="-3" id="f-1305" unitRef="eur">1934000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-1" decimals="-3" id="f-1306" unitRef="eur">2058000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-460" decimals="-3" id="f-1307" unitRef="eur">532000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-461" decimals="-3" id="f-1308" unitRef="eur">1662000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:NonScientificAdvisoryAndConsulting contextRef="c-4" decimals="-3" id="f-1309" unitRef="eur">2194000</inpha:NonScientificAdvisoryAndConsulting>
    <inpha:LeasingAndMaintenance contextRef="c-458" decimals="-3" id="f-1310" unitRef="eur">490000</inpha:LeasingAndMaintenance>
    <inpha:LeasingAndMaintenance contextRef="c-459" decimals="-3" id="f-1311" unitRef="eur">710000</inpha:LeasingAndMaintenance>
    <inpha:LeasingAndMaintenance contextRef="c-1" decimals="-3" id="f-1312" unitRef="eur">1200000</inpha:LeasingAndMaintenance>
    <inpha:LeasingAndMaintenance contextRef="c-460" decimals="-3" id="f-1313" unitRef="eur">470000</inpha:LeasingAndMaintenance>
    <inpha:LeasingAndMaintenance contextRef="c-461" decimals="-3" id="f-1314" unitRef="eur">445000</inpha:LeasingAndMaintenance>
    <inpha:LeasingAndMaintenance contextRef="c-4" decimals="-3" id="f-1315" unitRef="eur">915000</inpha:LeasingAndMaintenance>
    <ifrs-full:TravelExpense contextRef="c-458" decimals="-3" id="f-1316" unitRef="eur">272000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c-459" decimals="-3" id="f-1317" unitRef="eur">151000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c-1" decimals="-3" id="f-1318" unitRef="eur">423000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c-460" decimals="-3" id="f-1319" unitRef="eur">180000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c-461" decimals="-3" id="f-1320" unitRef="eur">143000</ifrs-full:TravelExpense>
    <ifrs-full:TravelExpense contextRef="c-4" decimals="-3" id="f-1321" unitRef="eur">323000</ifrs-full:TravelExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-458" decimals="-3" id="f-1322" unitRef="eur">16000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-459" decimals="-3" id="f-1323" unitRef="eur">164000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-1" decimals="-3" id="f-1324" unitRef="eur">180000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-460" decimals="-3" id="f-1325" unitRef="eur">34000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-461" decimals="-3" id="f-1326" unitRef="eur">142000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-4" decimals="-3" id="f-1327" unitRef="eur">176000</ifrs-full:SalesAndMarketingExpense>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-458" decimals="-3" id="f-1328" unitRef="eur">933000</inpha:ScientificAdvisoryAndConsulting>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-459" decimals="-3" id="f-1329" unitRef="eur">0</inpha:ScientificAdvisoryAndConsulting>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-1" decimals="-3" id="f-1330" unitRef="eur">933000</inpha:ScientificAdvisoryAndConsulting>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-460" decimals="-3" id="f-1331" unitRef="eur">561000</inpha:ScientificAdvisoryAndConsulting>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-461" decimals="-3" id="f-1332" unitRef="eur">0</inpha:ScientificAdvisoryAndConsulting>
    <inpha:ScientificAdvisoryAndConsulting contextRef="c-4" decimals="-3" id="f-1333" unitRef="eur">561000</inpha:ScientificAdvisoryAndConsulting>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-458" decimals="-3" id="f-1334" unitRef="eur">10000</inpha:OtherPurchasesAndExternalExpenses>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-459" decimals="-3" id="f-1335" unitRef="eur">1125000</inpha:OtherPurchasesAndExternalExpenses>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-1" decimals="-3" id="f-1336" unitRef="eur">1135000</inpha:OtherPurchasesAndExternalExpenses>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-460" decimals="-3" id="f-1337" unitRef="eur">13000</inpha:OtherPurchasesAndExternalExpenses>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-461" decimals="-3" id="f-1338" unitRef="eur">1153000</inpha:OtherPurchasesAndExternalExpenses>
    <inpha:OtherPurchasesAndExternalExpenses contextRef="c-4" decimals="-3" id="f-1339" unitRef="eur">1166000</inpha:OtherPurchasesAndExternalExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-458" decimals="-3" id="f-1340" unitRef="eur">643000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-459" decimals="-3" id="f-1341" unitRef="eur">503000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-1342" unitRef="eur">1146000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-460" decimals="-3" id="f-1343" unitRef="eur">3044000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-461" decimals="-3" id="f-1344" unitRef="eur">601000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense contextRef="c-4" decimals="-3" id="f-1345" unitRef="eur">3645000</ifrs-full:DepreciationAndAmortisationExpense>
    <inpha:IntellectualPropertyExpenses contextRef="c-458" decimals="-3" id="f-1346" unitRef="eur">568000</inpha:IntellectualPropertyExpenses>
    <inpha:IntellectualPropertyExpenses contextRef="c-459" decimals="-3" id="f-1347" unitRef="eur">128000</inpha:IntellectualPropertyExpenses>
    <inpha:IntellectualPropertyExpenses contextRef="c-1" decimals="-3" id="f-1348" unitRef="eur">696000</inpha:IntellectualPropertyExpenses>
    <inpha:IntellectualPropertyExpenses contextRef="c-460" decimals="-3" id="f-1349" unitRef="eur">570000</inpha:IntellectualPropertyExpenses>
    <inpha:IntellectualPropertyExpenses contextRef="c-461" decimals="-3" id="f-1350" unitRef="eur">68000</inpha:IntellectualPropertyExpenses>
    <inpha:IntellectualPropertyExpenses contextRef="c-4" decimals="-3" id="f-1351" unitRef="eur">638000</inpha:IntellectualPropertyExpenses>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-458" decimals="-3" id="f-1352" unitRef="eur">-242000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-459" decimals="-3" id="f-1353" unitRef="eur">-714000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1354" unitRef="eur">-956000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-460" decimals="-3" id="f-1355" unitRef="eur">-98000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-461" decimals="-3" id="f-1356" unitRef="eur">-464000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-4" decimals="-3" id="f-1357" unitRef="eur">-562000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OperatingExpense contextRef="c-458" decimals="-3" id="f-1358" unitRef="eur">29076000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-459" decimals="-3" id="f-1359" unitRef="eur">9582000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-1" decimals="-3" id="f-1360" unitRef="eur">38657000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-460" decimals="-3" id="f-1361" unitRef="eur">31453000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-461" decimals="-3" id="f-1362" unitRef="eur">9144000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-4" decimals="-3" id="f-1363" unitRef="eur">40597000</ifrs-full:OperatingExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-1364" unitRef="eur">11002000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="c-4" decimals="-3" id="f-1365" unitRef="eur">11652000</ifrs-full:ShorttermEmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="c-2"
      decimals="2"
      id="f-1366"
      unitRef="employee">168</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-6"
      decimals="2"
      id="f-1367"
      unitRef="employee">191</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-462"
      decimals="INF"
      id="f-1368"
      unitRef="employee">135</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-463"
      decimals="INF"
      id="f-1369"
      unitRef="employee">151</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-464"
      decimals="INF"
      id="f-1370"
      unitRef="employee">39</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="c-465"
      decimals="INF"
      id="f-1371"
      unitRef="employee">45</ifrs-full:NumberOfEmployees>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-87" decimals="-3" id="f-1372" unitRef="eur">2000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-88" decimals="-3" id="f-1373" unitRef="eur">651000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-86" decimals="-3" id="f-1374" unitRef="eur">294000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="c-1" id="f-1375">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Net financial income / (loss)&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Net financial income (loss) can be analyzed as follows :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Interests on financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;965&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,471&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,044&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,083&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(642)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Unrealized losses on financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Interest on financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,064)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;For the six months ended June&#160;30, 2024 and 2023, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the US dollar on US dollars denominated cash and cash equivalent and financial assets accounts.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock contextRef="c-1" id="f-1376">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Net financial income (loss) can be analyzed as follows :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Interests on financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,269&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;965&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance on financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,471&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,044&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;873&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,073&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,613&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;3,083&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Foreign exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1,763)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(642)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Unrealized losses on financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Interest on financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(2,064)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(966)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net financial income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;1,549&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,116&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inpha:DisclosureOfNetFinancialIncomeLossTableTextBlock>
    <inpha:InterestsAndGainsOnFinancialAssets contextRef="c-1" decimals="-3" id="f-1377" unitRef="eur">1269000</inpha:InterestsAndGainsOnFinancialAssets>
    <inpha:InterestsAndGainsOnFinancialAssets contextRef="c-4" decimals="-3" id="f-1378" unitRef="eur">965000</inpha:InterestsAndGainsOnFinancialAssets>
    <inpha:ChangeInValuationAllowanceOfFinancialInstruments contextRef="c-1" decimals="-3" id="f-1379" unitRef="eur">1471000</inpha:ChangeInValuationAllowanceOfFinancialInstruments>
    <inpha:ChangeInValuationAllowanceOfFinancialInstruments contextRef="c-4" decimals="-3" id="f-1380" unitRef="eur">1044000</inpha:ChangeInValuationAllowanceOfFinancialInstruments>
    <ifrs-full:NetForeignExchangeGain contextRef="c-1" decimals="-3" id="f-1381" unitRef="eur">873000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain contextRef="c-4" decimals="-3" id="f-1382" unitRef="eur">1073000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-1383" unitRef="eur">3613000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-4" decimals="-3" id="f-1384" unitRef="eur">3083000</ifrs-full:FinanceIncome>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-1" decimals="-3" id="f-1385" unitRef="eur">1763000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-4" decimals="-3" id="f-1386" unitRef="eur">642000</ifrs-full:NetForeignExchangeLoss>
    <inpha:UnrealizedLossesOnFinancialAssets contextRef="c-1" decimals="-3" id="f-1387" unitRef="eur">0</inpha:UnrealizedLossesOnFinancialAssets>
    <inpha:UnrealizedLossesOnFinancialAssets contextRef="c-4" decimals="-3" id="f-1388" unitRef="eur">0</inpha:UnrealizedLossesOnFinancialAssets>
    <ifrs-full:InterestExpense contextRef="c-1" decimals="-3" id="f-1389" unitRef="eur">300000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c-4" decimals="-3" id="f-1390" unitRef="eur">324000</ifrs-full:InterestExpense>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-1391" unitRef="eur">2064000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-4" decimals="-3" id="f-1392" unitRef="eur">966000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost contextRef="c-1" decimals="-3" id="f-1393" unitRef="eur">1549000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c-4" decimals="-3" id="f-1394" unitRef="eur">2116000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-1395">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Income tax / (expense)&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Due to the Company&#x2019;s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, deferred tax assets are recognized up to deferred tax liabilities. The main temporary differences are related to the application of the IFRS 15 standard for fiscal years beginning on or after January 1, 2018, finance leases, provisions for pension commitments and tax loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company did not recognize a current tax expense as of June&#160;30, 2024 regarding a projected tax rate of nil as of December 31, 2024.  As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma SA were &#x20ac;483,570 thousand with no expiration date (same amount as of December 31, 2023). As of June&#160;30, 2024, the accumulated tax losses carryforwards of Innate Pharma Inc was &#x20ac;15,181 thousand or $16,775 thousand (same amount as of December 31, 2023).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-1396" unitRef="eur">0</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:ApplicableTaxRate
      contextRef="c-466"
      decimals="2"
      id="f-1397"
      unitRef="number">0</ifrs-full:ApplicableTaxRate>
    <inpha:UnusedTaxLossesWithNoExpirationDate contextRef="c-2" decimals="-3" id="f-1398" unitRef="eur">483570000</inpha:UnusedTaxLossesWithNoExpirationDate>
    <inpha:UnusedTaxLossesWithNoExpirationDate contextRef="c-3" decimals="-3" id="f-1399" unitRef="eur">483570000</inpha:UnusedTaxLossesWithNoExpirationDate>
    <inpha:UnusedTaxLossesSubjectToExpiration contextRef="c-3" decimals="-3" id="f-1400" unitRef="eur">15181000</inpha:UnusedTaxLossesSubjectToExpiration>
    <inpha:UnusedTaxLossesSubjectToExpiration contextRef="c-2" decimals="-3" id="f-1401" unitRef="eur">15181000</inpha:UnusedTaxLossesSubjectToExpiration>
    <inpha:UnusedTaxLossesSubjectToExpiration contextRef="c-2" decimals="-3" id="f-1402" unitRef="usd">16775000</inpha:UnusedTaxLossesSubjectToExpiration>
    <inpha:UnusedTaxLossesSubjectToExpiration contextRef="c-3" decimals="-3" id="f-1403" unitRef="usd">16775000</inpha:UnusedTaxLossesSubjectToExpiration>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c-1" id="f-1404">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Commitments, contingencies and litigation&lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Commitments&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company has identified the following changes in off-balance sheet commitments since December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt"&gt;non-cancellable purchase commitments as of June&#160;30, 2024 for a total of &#x20ac;6,612 thousand with various CMOs. These commitments are comprised of non-cancellable purchase orders placed during the first half of 2024 with contract manufacturing organizations (CMOs) for the supply of various services in relation with preclinical work for an amount of &#x20ac;3,020&#160;thousand and clinical work for an amount of &#x20ac;3,592&#160;thousand. The execution and billing of these services has not yet started at the date of this report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%;padding-left:31.02pt"&gt;financial commitments with Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale in connection with the Company&#x2019;s subscription of a loan in order to finance the construction of its future headquarters. As security for the loan, the Company pledged collateral in the form of financial instruments held at Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale amounting to &#x20ac;15.2 million. The security interest on the pledged financial instruments will be released in accordance with the following schedule: &#x20ac;4,200 thousand in July 2024, &#x20ac;5,000 thousand in August 2027 and &#x20ac;6,000 thousand in August 2031. At the date of this report, the first investment of &#x20ac;4,200 thousand had matured and the Company obtained its restitution in July 2024 for a total amount of &#x20ac;4,427 thousand, including interest. As of June 30, 2024, the remaining capital of this loan amounted to &#x20ac;9,617 thousand.  Furthermore, under the loan, Innate is subject to a covenant that its total cash, cash equivalents and current and non-current financial assets as of each fiscal year end will be at least equal to the amount of outstanding principal under the loan. The Company was in compliance with this covenant as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Contingencies and litigations&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company is exposed to contingent liabilities happening in the ordinary course of its activities. Each pre-litigation, known litigation or procedure in course the Company is involved in is analyzed at each closing date after consultation of legal counsel. There is no acknowledged litigation as of June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Provisions&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Provisions amounted to &#x20ac;669 thousand and &#x20ac;774 thousand as of June&#160;30, 2024 and December 31, 2023, respectively. As of June&#160;30, 2024, they mainly consist of provision for charges amounting &#x20ac;586 thousand relating to the employer contribution in respect of the grants of employee equity instruments. In accordance with French &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;social legislation, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan.&lt;/span&gt;&lt;/div&gt;As a reminder, on March 16, 2022, the Company received a notice of a tax inspection by the French tax authorities and relating to the 2019 and 2020 financial years as well as to the research tax credit and the accuracy of its calculation for the 2018 to 2018 financial years 2020. On February 13, 2024, the Company was informed of the tax authorities conclusions regarding the tax inspection. A definitive amount of &#x20ac;1,367&#160;thousand was determined and classified as short-term tax liabilities as of December 31, 2023. During the first half of 2024, the Company made a payment of &#x20ac;693&#160;thousand.</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <inpha:NonCancellableOffBalanceSheetPurchasedCommitments contextRef="c-2" decimals="-3" id="f-1405" unitRef="eur">6612000</inpha:NonCancellableOffBalanceSheetPurchasedCommitments>
    <inpha:NonCancellableOffBalanceSheetPurchasedCommitments contextRef="c-467" decimals="-3" id="f-1406" unitRef="eur">3020000</inpha:NonCancellableOffBalanceSheetPurchasedCommitments>
    <inpha:NonCancellableOffBalanceSheetPurchasedCommitments contextRef="c-468" decimals="-3" id="f-1407" unitRef="eur">3592000</inpha:NonCancellableOffBalanceSheetPurchasedCommitments>
    <inpha:LoanAgreementCollateral contextRef="c-201" decimals="-5" id="f-1408" unitRef="eur">15200000</inpha:LoanAgreementCollateral>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024 contextRef="c-206" decimals="-3" id="f-1409" unitRef="eur">4200000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027 contextRef="c-206" decimals="-3" id="f-1410" unitRef="eur">5000000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2027>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031 contextRef="c-206" decimals="-3" id="f-1411" unitRef="eur">6000000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2031>
    <inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024 contextRef="c-206" decimals="-3" id="f-1412" unitRef="eur">4200000</inpha:SecurityInterestOnPledgeOfFinancialInstrumentsWillBeReleasedIn2024>
    <inpha:SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest contextRef="c-469" decimals="-3" id="f-1413" unitRef="eur">4427000</inpha:SecurityInterestOnPledgedFinancialInstrumentsReleasedIncludingInterest>
    <ifrs-full:FinancialLiabilities contextRef="c-205" decimals="-3" id="f-1414" unitRef="eur">9617000</ifrs-full:FinancialLiabilities>
    <ifrs-full:Provisions contextRef="c-2" decimals="-3" id="f-1415" unitRef="eur">669000</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c-3" decimals="-3" id="f-1416" unitRef="eur">774000</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c-470" decimals="-3" id="f-1417" unitRef="eur">586000</ifrs-full:Provisions>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-471" decimals="-3" id="f-1418" unitRef="eur">1367000</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <inpha:PaymentOfTaxesOtherThanIncomeTax contextRef="c-1" decimals="-3" id="f-1419" unitRef="eur">693000</inpha:PaymentOfTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-1420">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Related party transactions&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:underline"&gt;Members of the Executive Board and Other Executive Members &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Personnel and other short-term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,386&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Extra pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;408&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Advisory fees &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Executive Board Members and other Executive Members compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,253&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Personnel and other short-term employee benefits correspond to amounts included in personnel expenses for the six-month periods ended June&#160;30, 2024 and 2023 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;As of June 30, 2024, the Company has also recognized expenses totaling &#x20ac;184 thousand with companies in which a mandate is held by the identified related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Members of the Supervisory Board&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The Company recognized a provision of  &#x20ac;163 thousand for attendance fees (jetons de presence) relating to the six months ended June&#160;30, 2024. This amount includes the compensation for the Chairman of the Supervisory Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Novo Nordisk A/S is a shareholder, Supervisory Board member and is related to the Company by three licensing agreements related to the drug candidates lirilumab, monalizumab and avdoralimab. Under the terms of the agreements, Novo Nordisk A/S is eligible to receive milestone payments as well as royalties on future sales. As of June&#160;30, 2024, the Company has no liability to Novo Nordisk A/S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;AstraZeneca is a shareholder and is related to the Company through several collaboration and option licensing or license agreements for different drug candidates (monalizumab, avdoralimab and IPH5201). The payments between the two companies as well as the liabilities and receivables as of June&#160;30, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30,2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collection (AstraZeneca to the Company) / Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,657&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;394&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (the Company to AstraZeneca) / Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,342)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,926) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,532)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;The business relationships between the Company and its subsidiary are governed by intra-group and commercial agreements, concluded at market standard conditions on an arm&#x2019;s length basis.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock contextRef="c-1" id="f-1421">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;For each of the period presented, the following compensation was granted to the members of the Executive Committee of the Company and were recognized as expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Personnel and other short-term employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,713&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,386&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Extra pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;519&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;408&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Advisory fees &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;318&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Executive Board Members and other Executive Members compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,253&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2,123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</inpha:DisclosureOfKeyManagementPersonnelCompensationTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-1422" unitRef="eur">1713000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-4" decimals="-3" id="f-1423" unitRef="eur">1386000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-1" decimals="-3" id="f-1424" unitRef="eur">21000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="c-4" decimals="-3" id="f-1425" unitRef="eur">11000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-1" decimals="-3" id="f-1426" unitRef="eur">519000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-4" decimals="-3" id="f-1427" unitRef="eur">408000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <inpha:KeyManagementPersonnelCompensationAdvisoryFees contextRef="c-1" decimals="-3" id="f-1428" unitRef="eur">0</inpha:KeyManagementPersonnelCompensationAdvisoryFees>
    <inpha:KeyManagementPersonnelCompensationAdvisoryFees contextRef="c-4" decimals="-3" id="f-1429" unitRef="eur">318000</inpha:KeyManagementPersonnelCompensationAdvisoryFees>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-3" id="f-1430" unitRef="eur">2253000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-4" decimals="-3" id="f-1431" unitRef="eur">2123000</ifrs-full:KeyManagementPersonnelCompensation>
    <inpha:ProvisionForExpensesWithRelatedParties contextRef="c-2" decimals="-3" id="f-1432" unitRef="eur">184000</inpha:ProvisionForExpensesWithRelatedParties>
    <inpha:ProvisionForAttendanceFees contextRef="c-2" decimals="-3" id="f-1433" unitRef="eur">163000</inpha:ProvisionForAttendanceFees>
    <inpha:NumberOfLicensingAgreementsWithRelatedParties
      contextRef="c-472"
      decimals="INF"
      id="f-1434"
      unitRef="licensing_agreement">3</inpha:NumberOfLicensingAgreementsWithRelatedParties>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-472" decimals="-3" id="f-1435" unitRef="eur">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-1436">The payments between the two companies as well as the liabilities and receivables as of June&#160;30, 2024 are as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30,2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands of euro)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets/Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collection (AstraZeneca to the Company) / Receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,657&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;394&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments (the Company to AstraZeneca) / Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,342)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3,926) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(3,532)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties contextRef="c-1" decimals="-3" id="f-1437" unitRef="eur">1657000</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1438" unitRef="eur">394000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties contextRef="c-1" decimals="-3" id="f-1439" unitRef="eur">3342000</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1440" unitRef="eur">3926000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties contextRef="c-1" decimals="-3" id="f-1441" unitRef="eur">1685000</ifrs-full:CashRepaymentsOfAdvancesAndLoansFromRelatedParties>
    <inpha:NetAmountsReceivablePayableRelatedPartyTransactions contextRef="c-2" decimals="-3" id="f-1442" unitRef="eur">-3532000</inpha:NetAmountsReceivablePayableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-1443">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Income / (loss) per share &lt;/span&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Basic income / (loss) per share&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,764)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares in circulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,872,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,319,897&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Basic income/(loss) per share (&#x20ac; per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#b3b735;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:34.52pt"&gt;Diluted income / (loss) per share&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;In thousands of euro, except for data share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net income/(loss) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,764)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares in circulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,872,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,319,897&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Adjustment for share instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,026,389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,461,439&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Diluted income/(loss) per share (&#x20ac; per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-1444">&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Basic income / (loss) per share are calculated by dividing the net earnings attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,764)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares in circulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,872,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,319,897&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Basic income/(loss) per share (&#x20ac; per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;Diluted income (loss) per share is calculated by dividing the net income (loss) attributable to equity holders of the Company by the weighted average number of ordinary shares in circulation during the corresponding period, increased by all dilutive potential common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.773%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;In thousands of euro, except for data share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#b3b735;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Net income/(loss) for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(24,764)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,718&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares in circulation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,872,369&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,319,897&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Adjustment for share instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5,026,389&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,461,439&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Diluted income/(loss) per share (&#x20ac; per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(0.31)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #b3b735;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-1445" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-1446" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-1447" unitRef="shares">80872369</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="0" id="f-1448" unitRef="shares">80319897</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1449"
      unitRef="eurPerShare">-0.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-1450"
      unitRef="eurPerShare">0.02</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-1451" unitRef="eur">-24764000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-4" decimals="-3" id="f-1452" unitRef="eur">1718000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-1453" unitRef="shares">80872369</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-4" decimals="0" id="f-1454" unitRef="shares">80319897</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares contextRef="c-1" decimals="0" id="f-1455" unitRef="shares">5026389</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares contextRef="c-4" decimals="0" id="f-1456" unitRef="shares">3461439</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1457"
      unitRef="eurPerShare">-0.31</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-4"
      decimals="2"
      id="f-1458"
      unitRef="eurPerShare">0.02</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1459">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:140%;padding-left:7.19pt"&gt;Events after the reporting date&lt;/span&gt;&lt;div style="margin-bottom:7pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:140%"&gt;On July 25, 2024, the Company received from Takeda a notice of termination of the Exclusive License agreement signed on March 31, 2023. This termination will be effective upon expiry of a 90-day notice period, i.e. on October 24, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
